Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - IMMUNOCLIN CORPORATION

0001517126-14-000195.txt : 20140702 0001517126-14-000195.hdr.sgml : 20140702 20140702135900 ACCESSION NUMBER: 0001517126-14-000195 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20140131 FILED AS OF DATE: 20140702 DATE AS OF CHANGE: 20140702 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immunoclin Corp CENTRAL INDEX KEY: 0001520047 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 320337695 STATE OF INCORPORATION: NV FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54738 FILM NUMBER: 14955617 BUSINESS ADDRESS: STREET 1: 9107 WILSHIRE BLVD., STREET 2: SUITE 450 CITY: BEVERLY HILLS STATE: CA ZIP: 90210 BUSINESS PHONE: 1-888-267-1175 MAIL ADDRESS: STREET 1: 9107 WILSHIRE BLVD., STREET 2: SUITE 450 CITY: BEVERLY HILLS STATE: CA ZIP: 90210 FORMER COMPANY: FORMER CONFORMED NAME: PHARMA INVESTING NEWS, INC. DATE OF NAME CHANGE: 20110505 10-K 1 form10k.htm FORM 10-K Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - IMMUNOCLIN CORPORATION - Form 10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

þ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended January 31, 2014

o TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT

For the transition year from _______________

Commission File Number: 333-174271

IMMUNOCLIN CORPORATION

(Exact name of registrant as specified in its charter)

Nevada

32-0337695

(state or other jurisdiction of incorporation or organization)

(I.R.S. Employer I.D. No.)

9107 Wilshire Blvd, Suite 450

Beverly Hills, California

90210

(Address of principal executive offices)

(Zip Code)

1-888-267-1175

(Registrant’s telephone number, including area code)

Securities registered pursuant to section 12(g) of the Act: Common stock, Preferred stock

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No þ

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No þ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter year that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter year that the registrant was required to submit and post such files). Yes þ No ☐ (Not required)

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer o Accelerated filer o Non-accelerated filer o Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of July 31, 2013 was $722,030 based upon the price $2.00 per share at which the common stock was last sold as of the last business day of the most recently completed second fiscal quarter, multiplied by the approximate number of shares of common stock held by persons other than executive officers, directors and five percent stockholders of the registrant without conceding that any such person is an “affiliate” of the registrant for purposes of the federal securities laws.

As of June 30, 2014, there were 26,471,154 shares of the registrant’s $0.001 par value common stock issued and outstanding.

Documents incorporated by reference: Amended Articles of Incorporation, Certificate of Designation-Series A preferred shares, and management agreements.

Table of Contents


		Page
	PART I

Item 1	Business	4
Item 1A	Risk Factors	6
Item 1B	Unresolved Staff Comments	6
Item 2	Properties	6
Item 3	Legal Proceedings	6
Item 4	Not applicable	6

	PART II

Item 5	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	7
Item 6	Selected Financial Data	8
Item 7	Management's Discussion and Analysis of Financial Condition and Results of Operations	9
Item 7A	Quantitative and Qualitative Disclosures about Market Risk	12
Item 8	Financial Statements and Supplementary Data	13
Item 9	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	14
Item 9A	Controls and Procedures	14
Item 9B	Other Information	15

	PART III

Item 10	Directors and Executive Officers and Corporate Governance	16
Item 11	Executive Compensation	20
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	21
Item 13	Certain Relationships and Related Transactions	22
Item 14	Principal Accountant Fees and Services	23

	PART IV

Item 15	Exhibits	25

FORWARD-LOOKING STATEMENTS

The availability and adequacy of our cash flow to meet our requirements;

Economic, competitive, demographic, business and other conditions in our local and regional markets;

Changes or developments in laws, regulations or taxes in our industry;

Actions taken or omitted to be taken by third parties including our suppliers and competitors, as well as legislative, regulatory, judicial and other governmental authorities;

Competition in our industry;

The loss of or failure to obtain any license or permit necessary or desirable in the operation of our business;

Changes in our business strategy, capital improvements or development plans;

The availability of additional capital to support capital improvements and development; and

Other risks identified in this report and in our other filings with the Securities and Exchange Commission or the SEC.

This report should be read completely and with the understanding that actual future results may be materially different from what we expect. The forward-looking statements included in this report are made as of the date of this report and should be evaluated with consideration of any changes occurring after the date of this Report. We will not update forward-looking statements even though our situation may change in the future and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Use of Term

Except as otherwise indicated by the context, references in this report to “Company”, “IMCL”, “Immunoclin”, “Immunoclin.com”, “we”, “us” and “our” are references to Immunoclin Corporation. All references to “USD” or United States Dollars refer to the legal currency of the United States of America.

PART I

ITEM 1. BUSINESS

Overview

Immunoclin Corporation (formerly Pharma Investing News, Inc.) was incorporated in the State of Nevada on February 8, 2011.

On December 13, 2013, the Company acquired Immunoclin Limited (“IML”), an England and Wales incorporated company, which is now a wholly-owned subsidiary. The Company changed both its name to Immunoclin Corporation and its stock symbol to IMCL in conjunction with this acquisition. The Company works on advanced immunology research and development skill to serve the pharmaceutical, biotechnology and food industries, providing comprehensive, clinical and basic science research expertise at a commercial scale and quality.

We have a laboratory in Paris, France, corporate headquarters in Beverly Hills, California and our telephone number is +1 (888) 267-1175.

Research and Development

The Company continues research and development on several products including:

MIRA™—an intelligent algorithm to analyze the complex multi-variant data (cytokines and cellular markers) to identify people who are at risk of having heart attack. MIRA™ detects inflammatory factors that contribute to causing or enhancing processes leading to the obstruction of blood flow and ultimately to a cardiovascular event such as a heart attack.

GARD™—a genetic test for multiple genetic polymorphisms (variants) associated with increased risk of the most common form of dementia: late-onset Alzheimer’s disease.

PRIMALEUKIN™—commonly known as interleukin-22 (IL-22), has a unique position as a combined antibacterial, anti-fungal and antiviral agent, harnessing and amplifying the body’s own natural defense against, and recovery from, infection.

DACTELLIGENCE™—a technology and newly patented concept in bio-sensing with a potential to challenge state-of-the-art detection platforms in multiple diagnostic fields. This technology targets the delivery of pure electronic point-of-care devices capable of rapid detection while simultaneously processing data.

GastroWellBeing™ (GWB™) -an immunological food supplement.

Summaries of the Company’s product are located on our website at: http://immunoclin.com/index.php/products/products-overview

Intellectual Property

The Company has registered patents important to the Company’s business. From time to time, the Company may become involved in litigation to protect its intellectual property and defend against the alleged use of third-party intellectual property.

Products

Immunoclin currently has several prototypes, concepts, and formulations for development of products MIRA™, GARD™, PRIMALEUKIN™, DACTELLIGENCE™, and GastroWellBeing™. However, no products are currently in production. The Company anticipates completing development of GastroWellBeing™ by Q3 and commencing sales by Q4 of the fiscal year ending January 31, 2015.

Employees/Consultants

As of the date of this filing, the Company has four executive officers, and one managing consultant, for a total of five staff under management contracts. The Company has seven consultants under scientific advisor contracts. The Company plans to hire additional laboratory and support staff during fiscal 2015.

Scientific Advisors

Mr. Railton Frith

Mr. Frith, as an inventor, led the team of professionals that designed ImmunoClin's DACTELLIGENCE™ bio-sensing technology. He was a founding member of the pioneering Silicon Valley network company Zynar/Nestar Systems. As an independent technology expert, Mr. Firth has worked for a number of noted banks and financial institutes and has created large-scale high volume information systems for diverse industry leaders in such markets as publishing and clinical institutions.

Professor Antony Bayer, MB, FRCP

Professor Bayer is the Personal Chair, Institute of Primary Care & Public Health, Cardiff University School of Medicine in Cardiff, Wales, UK. He is also the Head of the Geriatric Medicine Section as well as the Director of the Memory team. He is a leading researcher in the area of dementia and has focused research on the clinical care of people with cognitive disorders, with special interest in Alzheimer’s disease. Prof. Bayer is Editor of the journal 'Reviews in Clinical Gerontology' and holds various Alzheimer's and Aging appointments.

Professor Jean Mariani, MD, PhD

Professor Mariani is a neurobiologist and physician, leading researcher in the area of central nervous system diseases and aging. He is a professor at the Pierre and Marie Curie University (UPMC) in Paris, France, one of the largest and most respected European universities specializing in science and medicine, where he teaches neuroscience and the biology of aging. Prof. Mariani, among many honors, is the director of DHU FAST, a new multi-unit network of excellence conducting research into age related diseases, and of the newly built Charles Foix Institute of Longevity.

Marco Kaiser, PhD

Dr. Kaiser is a key member of GenExpress GmbH, a known German molecular biology company. He studied at the Technical University Berlin in the field of medical biotechnology and completed his doctoral thesis in "Ultra sensitive multiplex diagnostics for emerging pathogens" at the Centre for Biological Threats and Specific Pathogens at the renowned Robert Koch Institute in Berlin, Germany. Dr. Kaiser has a strong background in developing technologies for use in virology and dermatological research, and has authored numerous scientific publications and oral presentations.

Gundula Piechotta, PhD

Dr. Piechotta is biochemist and researcher for the Fraunhofer Institute for Silicon Technology (ISIT), Germany, one of Europe's most modern research facilities for microelectronics and microsystems technology. Dr. Piechotta is an expert in biotechnical microsystems, including bio-MEMS, microarrays, and other miniaturized and integrated devices for biological and biochemical diagnostics.

Heinz Ellerbrok, PhD

Heinz Ellerbrok, PhD is the deputy head of the Centre for Biological Safety, Robert Koch Institute (RKI), Germany, the central federal institution responsible for disease control and prevention and therefore the central federal reference institution for both applied and response-orientated research as well as for the Public Health Sector. Dr Ellerbrok has long standing experience in virology including development and application of molecular diagnostics as well as applied and basic research on various pathogens, molecular biology and management of national and international research networks.

Professor Iwona Wybrańska, PhD

Professor Wybrańska is the head of the Department of Genetic Diagnostic and Nutrigenomics, and Chair of Clinical Biochemistry, The Jagiellonian University, Medical College, Kraków, Poland. She is an expert in genotype-based personalized nutrition, a concept that links genotyping with specific nutritional advice in order to improve prevention and therapy of nutrition associated chronic diseases.

WHERE YOU CAN GET ADDITIONAL INFORMATION

We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy our reports or other filings made with the SEC at the SEC’s Public Reference Room, located at 100 F Street, N.E., Washington, DC 20549. You can obtain information on the operations of the Public Reference Room by calling the SEC at 1-800-SEC-0330. You can also access these reports and other filings electronically on the SEC’s web site, www.sec.gov.

ITEM 1A. RISK FACTORS

Not applicable. We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES

Our corporate headquarters are located at 9107 Wilshire Blvd, Suite 450, Beverly Hills, CA 90210 where we rent an office and services on a monthly basis. As of the date of this filing, we are seeking to relocate our corporate head office to Washington, DC.

Our laboratory facility in located in Paris, France at the Centre de Recherche des Cordeliers (CRC). The Company has a lease with the University of Pierre and Marie Currie (UPMC) under a contract with Immunoclin Limited since 2001 for the facility. The Company is currently under negotiations with UPMC to renew and extend the lease.

Additional space and facilities may be required as we expand our operations. We do not foresee any significant difficulties in obtaining any required additional space. We currently do not own any real property.

ITEM 3. LEGAL PROCEEDINGS

We know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our director, officer or any affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

PART II

ITEM 5.

MARKET FOR THE COMPANY’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Common Stock

As of June 30, 2014, there is limited trading of our Common Stock on the OTC Markets under the symbol “IMCL”.

The following table shows the high and low prices of our common shares on the OTC Bulletin Board for each quarter within the two most recent fiscal years. The following quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions:



Fiscal Year Ending January 31, 2013	HIGH	LOW
Quarter Ending April 30, 2012	0.07	0.07
Quarter Ending July 31, 2012	0.07	0.07
Quarter Ending October 31, 2012	0.07	0.07
Quarter Ending January 31, 2013	0.07	0.07


Fiscal Year Ending January 31, 2014	HIGH	LOW
Quarter Ending April 30, 2013	2.00	0.07
Quarter Ending July 31, 2013	2.00	2.00
Quarter Ending October 31, 2013	2.00	2.00
Quarter Ending January 31, 2014	2.00	2.00

Record Holders

As of June 30, 2014, an aggregate of 26,471,154 shares of our Common Stock were issued and outstanding and owned by approximately 20 holders of record.

Recent Sales of Unregistered Securities

As set out below, we have issued securities in exchange for services and properties using exemptions available under the Securities Act of 1933.

During the year ended January 31, 2014, the Company issued stock pursuant to agreements with several parties as follows:

On December 13, 2013, the Company acquired Immunoclin Limited, an England and Wales company, through a Take Over Agreement. In consideration for the acquisition, the Company issued 10,000,000 shares of common stock, with a fair market value of $20,000,000, or $2.00 per share, to Dr. Dorothy Bray in exchange for all issued and outstanding shares in Immunoclin Limited. An independent valuation firm validated the purchase price for IML to be $20,000,000 consisting of $19,800,000 in intangibles-R&D, 654,992 in goodwill, and ($454,992) in net tangible assets acquired, which was confirmed by a third-party valuator assessment and opinion contracted by the Company’s auditor. A total of $654,992 in unimpaired goodwill remains at January 31, 2014.

On December 13, 2013, the Company issued 6,000,000 shares of common stock, with a fair market value of $12,000,000 or $2.00 per share, pursuant to management agreements with executive officers, directors, and a management consultant of the Company.

On December 13, 2013, the Company issued 1,000,000 shares of Series A preferred stock, with a fair market value of $180,000 or $0.18 per share, to executive officers, management consultant, and consultant.

On December 13, 2013, the Company issued 100,000 shares of common stock, with a fair market value of $200,000 or $2.00 per share to the co-inventor of the of the DACTELLIGENCE™ patent to acquire the remaining 50% ownership pursuant to a License and Royalty Agreement dated October 1, 2013 with Immunoclin Limited.

On December 13, 2013, the Company issued 42,500 shares of common stock with a fair market value of $85,000 or $2.00 per share to a consultant for settlement of $85,000 in fees due pursuant to a settlement agreement.

Cancellation of Equity Securities

On July 11, 2013, Robert Lawrence, the former CEO/President and director of the Company cancelled 5,000,000 shares of common stock into the Company treasury. The Company recorded $5,000 in additional paid-in capital and ($5,000) to common stock for the cancellation.

Dividends

We have not paid any cash dividends on our Common Stock since inception and presently anticipate that all earnings, if any, will be retained for development of our business and that no dividends on our Common Stock will be declared in the foreseeable future. Any future dividends will be subject to the discretion of our Board of Directors and will depend upon, among other things, future earnings, operating and financial condition, capital requirements, general business conditions and other pertinent facts. Therefore, there can be no assurance that any dividends on our Common Stock will be paid in the future.

Securities Authorized for Issuance Under Equity Compensation Plans

None.

ITEM 6. SELECTED FINANCIAL DATA

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements are not historical facts but rather are based on current expectations, estimates and projections. We may use words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “foresee,” “estimate” and variations of these words and similar expressions to identify forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted. You should read this report completely and with the understanding that actual future results may be materially different from what we expect. The forward-looking statements included in this report are made as of the date of this report and should be evaluated with consideration of any changes occurring after the date of this Report. We will not update forward-looking statements even though our situation may change in the future and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Recent Developments

On December 13, 2013, the Company acquired Immunoclin Limited, an England and Wales company, through a Take Over Agreement. In consideration for the acquisition, the Company issued 10,000,000 shares of common stock, with a fair market value of $20,000,000, or $2.00 per share, to Dr. Dorothy Bray in exchange for all issued and outstanding shares in Immunoclin Limited. An independent valuation firm validated the purchase price for IML to be $20,000,000 consisting of $19,800,000 in intangibles-R&D, 654,992 in goodwill, and ($454,992) in net tangible assets acquired, which was confirmed by a third-party valuator assessment and opinion. A total of $654,992 in unimpaired goodwill remains at January 31, 2014. Immunoclin Limited works on advanced immunology research and development skill to serve the pharmaceutical, biotechnology and food industries, providing comprehensive, clinical and basic science research expertise at a commercial scale and quality.

CONSOLIDATED RESULTS OF OPERATIONS

Working Capital



	January 31, 2014 $	January 31, 2013 $
Current Assets	584,339	201,545
Current Liabilities	725,468	513,195
Working Capital Deficit	(141,129)	(311,650)

Cash Flows



	Year Ended	Year Ended
	January 31, 2014 $	January 31, 2013 $
Cash Flows used in Operating Activities	(110,629)		156,000
Cash Flows from Investing Activities	(6,590)		─
Cash Flows from Financing Activities	2,029		(42,947)
Net increase (decrease) in Cash During Year	(115,190)		113,053

Operating Revenues

We generated no revenues for the year ended January 31, 2014 and minimal revenues of $182,621 for the year ended 2013.

For the Year Ended January 31, 2014 (“2014”) as Compared to the Year Ended January 31, 2013 (“2013”)

For 2014, the Company earned $0 revenues compared to $182,621 for 2013. The reduced revenues are the result of the Company stopping contracted clinical services for 3^rd parties in order to focus on internal research and development of its own patents and products.

For 2014, the Company incurred $12,982,473 of operating expenses compared to $144,185 for 2013. This increase is due to the following major changes in operating expenses:

(i)

Amortization increased to $206,534 in 2014 from $0 in 2013. This increase is the result of amortization on R&D and patent intangibles acquired with Immunoclin Limited on December 13, 2013 for 2014. There were no intangibles to amortize in 2013.

(ii)

Management and consulting fees increased to $12,453,670 for 2014 compared to $0 for 2013, which was the result management and consulting contracts entered into in 2014 and relating stock-based compensation and management fees. $12,369,671 was non-cash stock-based compensation.

(iii)

General and administrative expenses increased from $143,416 in 2013 to $167,464, representing an increase of $24,048 or 16.8%, in 2014. This increase was due to increased operating activity and related G&A expenses in 2014 as compared to 2013.

(iv)

Research and development expenses increased to $98,276 in 2014 as compared to $93,124 for 2013, representing an increase of $5,152 of 5.5%. This increase was due to increased laboratory and clinical work and related expenses on development of patents and products in 2014 as compared to 2013.

For the years ended January 31, 2014 and January 31, 2013, the Company had a loss per share of $1.21 and $0.01, respectively.

LIQUIDITY AND CAPITAL RESOURCES

As at January 31, 2014, the Company had cash of $51,956 and total assets of $21,039,038 compared with $167,146 in cash and $202,807 in total assets at January 31, 2013. The increase in assets resulted from the acquisition of Immunoclin Limited on December 13, 2013. The Company had total liabilities of $725,468 at January 31, 2014 compared with $513,195 at January 31, 2013. The increase in total liabilities is attributed to accrued management fees and notes payable.

Cash flows from Operating Activities

During the year ended January 31, 2014, the Company used cash of $110,629 in operating activities compared with cash provided by operating activities of $156,000 for the year ended January 31, 2013. The increase in cash used for operating activities is a result of increased operating activity and expenses during the year.

Cash flows from Investing Activities

During the year ended January 31, 2014, the Company used $6,590 in cash for investing activities, net of acquisition adjustments, compared to $0 for the year ended January 31, 2013.

Cash flows from Financing Activities

During the year ended January 31, 2014, the Company had cash provided by financing activities of $2,029 compared to $42,947 in cash used by financing activities for the year ended January 31, 2013.

Critical Accounting Policies

Our consolidated financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting years.

We regularly evaluate the accounting policies and estimates that we use to prepare our consolidated financial statements. A complete summary of these policies is included in the notes to our consolidated financial statements. In general, management’s estimates are based on historical experience, on information from third-party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.

Going Concern

We have not attained profitable operations and are dependent upon obtaining financing to complete research and development of the Companies products to bring them to market. For these reasons, our auditors stated in their report on our audited consolidated financial statements that they have substantial doubt that we will be able to continue as a going concern without further financing.

Future Financings

Management intends to raise required working capital through private stock subscriptions, debt and/or equity financing. Issuances of additional shares will result in dilution to existing stockholders. There is no assurance that we will achieve any additional sales of the equity securities or arrange for debt or other financing, including on favorable terms, to fund planned R&D, production, acquisitions, and other operating activities.

Off-Balance Sheet Arrangements

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Contractual Obligations

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

Long-lived Assets

Under ASC Topic 360, “Property, Plant, and Equipment”, the Company is required to periodically evaluate the carrying value of long-lived assets to be held and used. ASC Topic 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.

Goodwill

Under ASC Topic 350 “Intangibles-Goodwill and Other”, goodwill is not amortized to expense, but rather that it is assessed or tested for impairment at least annually. Impairment write-downs are charged to results of operations in the period in which the impairment is determined. The Company did not identify any impairment on its outstanding goodwill from its most recent testing, which was performed as of January 31, 2014. If certain events occur which might indicate goodwill has been impaired, the goodwill is tested for impairment when such events occur. Other acquired intangible assets with finite lives, such as acquired R&D and patents, are required to be amortized over the estimated lives. These intangibles are generally amortized using the straight-line method over estimated useful lives.

The Company tests the carrying value of goodwill and indefinite life intangible assets for impairment at least once a year and more frequently if an event or circumstance indicates the asset may be impaired. An impairment loss is recognized if the amount of the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less selling expenses or its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows (cash generating units).

The Company is adopting ASU update number 2012-02—Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment whereby the Company will first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, we conclude that it is not more than likely than not that the indefinite-lived intangible asset is impaired, then we are not required to take further action. If the Company concludes otherwise, then we will determine the fair value of the indefinite-lived intangible asset and perform the required quantitative impairment test by comparing the fair value with the carrying amount.

The Company did not record an impairment loss on goodwill for 2014.

Revenue Recognition

Revenues are recognized at the time clinical and laboratory services are completed and delivered pursuant to percentage of completion and/or milestone payments as per contracts with the Company’s customers.

Stock-based Compensation

Under ASC Topic 718, ‘‘Compensation-Stock Compensation’’, the Company is required to measure all employee share-based payments, including grants of employee stock options, using a fair-value-based method and the recording of such expense in the statements of operations. The Company has adopted ASC Topic 718 (SFAS 123R) and recognizes stock-based compensation expense using the modified prospective method.

Research and Development Expense

Under ASC Topic 730 “Research and Development”, costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a product receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a product receives regulatory approval, any milestone payments will be recorded as Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, amortization of the payments will be on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.

Recently Issued Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect as of the date of this filing. These pronouncements did not have any material impact on the consolidated financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

IMMUNOCLIN CORPORATION

Consolidated Financial Statements

For the Years Ended January 31, 2014 and January 31, 2013

Report of Independent Registered Public Accounting Firm F-1

Consolidated Balance Sheets F-2

Consolidated Statements of Operations F-3

Consolidated Statements of Cash Flows F-4

Consolidated Statements of Stockholders’ Equity F-5

Notes to the Consolidated Financial Statements F-6

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors

ImmunoClin Corp.

We have audited the accompanying consolidated balance sheets of ImmunoClin Corp. (the Company) as of January 31, 2014 and 2013 and the related consolidated statements of operations, stockholders’ deficit and cash flows for the years then ended. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion the consolidated financial statements referred to above present fairly, in all material respects, the financial position of ImmunoClin Corp. as of January 31, 2014 and 2013, and the results of their operations and cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has an accumulated deficit of $12,862,769 which raises substantial doubt about its ability to continue as a going concern. Management’s plans concerning these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ Sadler, Gibb & Associates, LLC

Salt Lake City, UT

July 1, 2013

F-1

IMMUNOCLIN CORPORATION

Consolidated Balance Sheets

As of January 31, 2014 and 2013


	2014 $	2013 $

ASSETS

Cash	51,956	167,146
Accounts receivable	14,309	34,399
Other receivable	7,745	–
Prepaid expenses	510,329	–
	584,339	201,545

Property and equipment, net (Note 8)	6,241	1,262
Intangibles, net (Note 9)	19,793,466	–
Goodwill	654,992	–

Total Assets	21,039,038	202,807

LIABILITIES

Current Liabilities
Accounts payable	177,817	456,510
Accrued expenses, primarily management fees	469,888	–
Due to related parties (Note 4)	2,704	56,685
Notes payable, related parties (Note 5)	2,062	–
Notes payable, stockholders (Note 5)	72,997	–
Total Liabilities	725,468	513,195

Commitments and contingencies – Note 10	–	–

STOCKHOLDERS’ EQUITY (DEFICIT)

Preferred stock, $0.001 par value, 9,000,000 shares authorized,
0 shares issued and outstanding at January 31, 2014 and January 31, 2013	–	–
Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at
January 31, 2014 and 0 at January 31, 2013	1,000	–
Common Stock, $0.001 par value, 290,000,000 shares authorized,
26,503,515 issued and outstanding January 31, 2014 and 5,361,015 at January 31, 2013	26,504	5,361
Additional paid-in capital	33,164,274	72,094
Accumulated deficit	(12,862,769)	(389,628)
Accumulated other comprehensive income	(15,439)	1,785

Total Stockholders’ Equity (Deficit)	20,313,570	(310,388)

Total Liabilities and Stockholders’ Equity (Deficit)	21,039,038	202,807

F-2

IMMUNOCLIN CORPORATION

Consolidated Statements of Operations

For the years ended January 31, 2014 and 2013


	2014 $	2013 $

Revenues	–	182,621

Operating Expenses
Amortization	206,534	–
Depreciation	1,611	1,508
Management and consulting fees	12,453,670	–
General and administrative	167,464	143,416
Professional fees	54,918	88,758
Research and development	98,276	93,124

Total operating expenses	12,982,473	326,806

Net Operating Loss	(12,982,473)	(144,185)

Other income (expenses)
Interest expense, net	(89)	(47)
Tax credits, research and development	2,245	75,794
	2,156	75,747
Net Loss	(12,980,317)	(68,438)
Other Comprehensive Income
Foreign exchange translation adjustment	(17,224)	(10,094)
	(17,224)	(10,094)
Net Comprehensive Loss	(12,997,541)	(78,532)

Net loss per share – basic and diluted	(1.21)	(0.01)
Weighted average shares outstanding – basic and diluted	10,774,666	5,315,824

F-3

IMMUNOCLIN CORPORATION

Consolidated Statements of Cash Flows

For the Years Ended January 31, 2014 and 2013


	2014 $	2013 $

Operating Activities
Net loss for the year	(12,980,371)	(68,438)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization	206,534	–
Depreciation	1,611	2,396
Common stock issued for services	12,369,671	–
Expenses paid by related parties	20,555	39,000
Foreign exchange translation	(17,224)	(10,094)
Changes in operating assets and liabilities:
Accounts receivable	20,090	117,715
Other receivable	(7,746)	–
Accounts payable	(193,691)	312,005
Accrued expenses, primarily management fees	469,888	(236,584)
Net Cash Provided by (Used In) Operating Activities	(110,629)	156,000

Investing Activities
Purchase of property and equipment	(6,590)	–
Net Cash Used in Investing Activities	(6,590)	–

Financing Activities
Proceeds from the sale of common stock	–	12,550
Related party loans forgiven to share capital	–	–
Proceeds from related party notes payable	2,029	880
Repayment of related party loans	–	(56,377)
Net Cash Provided by Financing Activities	2,029	(42,947)
Change in Cash	(115,190)	113,053
Cash – Beginning of Year	167,146	54,093
Cash – End of Year	51,956	167,146

Supplemental Disclosures
Cancellation of common stock	5,000	–
Common stock issued for prepaid services	700,000	–
Common stock issued to acquire IML	20,000,000	–
Common stock issued to acquire patent	200,000	–
Common stock issued to extinguish debt	86,507	36,433

Interest paid	–	–
Income tax paid	–	–

F-4

IMMUNOCLIN CORPORATION

Consolidated Statements of Stockholders’ Equity (Deficit)

For the Years Ended January 31, 2014 and 2013



	Preferred Stock		Common Stock			Additional	Cumulative
	Shares	Par Value	Shares	Par Value	Paid-In Capital			Translation Adjustments	Deficit	Total
	#	$	#	$	$			$	$	$

Balance – January 31, 2012	–	–	5,181,698	5,182	23,290			11,879	(321,190)	(280,839)

Common stock issued for cash	–	–	179,317	179	12,371			–	–	12,550
Director loan forgiven to additional paid-in capital	–	–	–	–	36,433			–	–	36,433
Net loss for the year	–	–	–	–	–			(10,094)	(68,438)	(78,532)
			–	–
Balance – January 31, 2013	–	–	5,361,015	5,361	72,094			1,785	(389,628)	(310,388)

Preferred stock issued for services	1,000,000	1,000	–	–	179,000			–	–	180,000
Common stock issued for acquisition	–	–	10,000,000	10,000	19,990,000			–	–	20,000,000
Common stock issued for prepaid services	–	–	10,000,000	10,000	690,000			–	–	700,000
Common stock issued for services	–	–	6,000,000	6,000	11,994,000			–	–	12,000,000
Common stock issued to acquire patent	–	–	100,000	100	199,900			–	–	200,000
Common stock issued to extinguish debt	–	–	42,500	43	86,464			–	–	86,507

Cancellation of common stock	–	–	(5,000,000)	(5,000)	5,000			–	–	–
Adjustments to reconcile additional paid-in capital and retained earnings from IML acquisition	–	–	–	–	(52,184)			–	507,176	454,992
Net loss for the year	–	–	–	–	–			(17,224)	(12,980,317)	(12,997,541)
Balance – January 31, 2014	1,000,000	1,000	26,503,515	26,504	33,164,274			(15,439)	(12,862,769)	20,313,570

F-5

Nature of Operations and Continuance of Business

Immunoclin Corporation (the “Company”), formerly Pharma Investing News, Inc., was incorporated in the State of Nevada on February 8, 2011.

On December 13, 2013, the Company acquired through a share for share takeover transaction Immunoclin Limited (“IML”), an England and Wales corporation, which is now a wholly-owned subsidiary. The Company changed both its name to Immunoclin Corporation and its stock symbol to IMCL in conjunction with this acquisition. The Company works on advanced immunology research and development skill to serve the pharmaceutical, biotechnology and food industries, providing comprehensive, clinical and basic science research expertise at a commercial scale and quality.

Going Concern

These consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of January 31, 2014, the Company has not recognized any revenue, and has a working capital deficit of $141,129 and an accumulated deficit of $12,862,769. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounting Policies

A. Basis of Presentation

The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and are expressed in U.S. dollars.

The operating results of Immunoclin Limited (“IML”), acquired on December 13, 2013, were consolidated with the financial statements of the Company for the years ended January 31, 2014 and 2013. An independent valuation firm validated the purchase price for IML to be $20,000,000 consisting of $19,800,000 in intangibles-R&D, 654,992 in goodwill, and ($454,992) in net tangible assets acquired, which was confirmed by a third-party valuator assessment. A total of $654,992 in unimpaired goodwill remains at January 31, 2014.

The Company recorded adjustments of ($52,184) to additional paid-in capital and $507,176 to deficit for the year ended January 31, 2014 to reconcile the consolidated statement of stockholder’s equity (deficit) as a result of the acquisition of IML.

The Company’s fiscal year end was changed from February 28 to January 31 during 2014.

F-6

B. Use of Estimates

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the consolidated financial statements in the period they are determined.

C. Basic and Diluted Net Income (Loss) Per Share

Under ASC 260, "Earnings Per Share" ("EPS"), the Company provides for the calculation of basic and diluted earnings per share. Basic EPS includes no dilution and is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the years ended January 31, 2014 and 2013, basic and diluted loss per share are the same since the calculation of diluted per share amounts would result in an anti-dilutive calculation.

D. Cash and Cash Equivalents

The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

E. Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable consists principally of trade receivables, which are recorded at the invoiced amount, net of allowances for doubtful accounts and prompt payment discounts. Trade receivables do not bear interest. The allowance for doubtful accounts represents management’s estimate of the amount of probable credit losses in existing accounts receivable, as determined from a review of past due balances and other specific account data. Account balances are written off against the allowance when management determines the receivable is uncollectible. The Company does not have off-balance sheet credit exposure related to its customers.

F. Prepaid Expense

Prepaid expenses consist of $510,329 in prepaid stock-based compensation under management contracts. Prepaid stock-based compensation expense is amortized over the service periods pursuant to the agreements.

G. Long-Lived Assets

F-7

H. Fair Value Measurements

Under ASC Topic 820, the Company discloses the estimated fair values of financial instruments. The carrying amounts reported in the balance sheet for current assets and current liabilities qualifying as financial instruments are a reasonable estimate of fair value.

In accordance with the reporting requirements of ASC Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of those financial instruments (see Note 4). The estimated fair value of other current assets and current liabilities approximate their carrying amounts due to the relatively short maturity of these instruments. None of these instruments are held for trading purposes.

I. Goodwill and Intangible Assets

Under ASC Topic 350 “Intangibles-Goodwill and Other”, goodwill is not amortized to expense, but rather that it is assessed or tested for impairment at least annually. Impairment write-downs are charged to results of operations in the period in which the impairment is determined. If certain events occur which might indicate goodwill has been impaired, the goodwill is tested for impairment when such events occur. Other acquired intangible assets with finite lives, such as acquired R&D and patents, are required to be amortized over the estimated lives. These intangibles are generally amortized using the straight-line method over estimated useful lives.

The Company did not record an impairment loss on goodwill for 2014.

J. Revenue Recognition

F-8

K. Research and Development Expenses

L. Income Taxes

Under ASC Topic 740, “Income Taxes”, the Company in required to account for its income taxes through the establishment of a deferred tax asset or liability for the recognition of future deductible or taxable amounts and operating loss and tax credit carry forwards. Deferred tax expense or benefit is recognized as a result of timing differences between the recognition of assets and liabilities for book and tax purposes during the year.

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

Deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carry forwards. A valuation allowance is established to reduce that deferred tax asset if it is "more likely than not" that the related tax benefits will not be realized.

Unfiled Federal Tax Returns: For the years ending January 31, 2014 and 2013, the Company has not filed federal tax returns and may be subject to penalties. The Company estimates that the amount of penalties, if any, will not have a material effect on the results of operations, cash flows or financial position. No provisions have been made in the financial statements for such penalties, if any.

The Company is planning to have its accountants prepare and file overdue federal tax returns for the years ended January 31, 2014 and 2013 by Q4 of fiscal 2015.

M. Stock-Based Compensation

N. Comprehensive Loss

ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As of January 31, 2014 and 2013, the Company had foreign exchange translation adjustments of ($17,224) and ($10,094), respectively, which are included in other comprehensive income in the consolidated financial statements.

O. Recent Accounting Pronouncements

During the year ended January 31, 2014 and through June 30, 2014, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.

P. Reclassifications

For comparative purposes, certain prior period consolidated financial statements have been reclassified to conform with report classifications of the current year.

F-9

3. Fair Value Measurements and Disclosures

ASC Topic 820, Fair Value Measurement, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows:

Level 1

Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities that the Company can access at the measurement date.

Level 2

Inputs to the valuation methodology are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3

Inputs to the valuation methodology are unobservable inputs for the asset of liability.

The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

Following is a description of the valuation methodologies used for the Company’s liabilities measured at fair value. There have been no changes in the methodologies used at January 31, 2014.

Intangibles from IML acquisition: Valued at replacement cost. The replacement cost is determined as the cost of replacing the asset with a modern unit of the near equivalent utility.

The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. The following tables set forth by level, within the fair value hierarchy, the Company’s assets at fair value as of January 31, 2014. The Company had no assets as of January 31, 2013.



	Level 1	Level 2	Level 3	Total
Intangibles from acquisition of IML, net of accumulated
amortization	–	–	$19,793,466	$19,793,466
Total assets as of January 31, 2014	–	–	$19,793,466	$19,793,466

F-10

Related Party Transactions

During the years ended January 31, 2014 the Company’s former President and CEO, Robert Lawrence, advanced $0 (2013; $56,685) to the Company and paid expenses of $0 (2013; $0) on behalf of the Company. The $56,685 owing at January 31, 2013 to Mr. Lawrence was unsecured, non-interest bearing, and due on demand. On April 25, 2013, Mr. Lawrence assigned his loans payable of $55,145 to Jagpal Holdings Ltd., a non-related party that was secured by the Company under a non-interest bearing demand promissory note due and payable on April 25, 2014. In addition, Mr. Lawrence was paid $33 and he forgave $1,507, which has been recorded in additional paid-in capital as of January 31, 2014.

On October 21, 2013, Intrinsic Venture Corp. loaned the Company $2,062 that was secured by a non-interest bearing demand promissory note due in 12 months. Intrinsic Venture Corp. is owned and controlled by J. Scott Munro, the Company’s CFO.

On December 13, 2013, the Company issued 1,000,000 shares of Series A preferred stock, with a fair market value of $180,000 or $0.18 per share, to executive officers and directors and a management consultant pursuant to a Control Shareholder Agreement.

On December 13, 2013, Dr. Dorothy Bray was appointed a director and CEO/President under pursuant to a five-year management agreement with the Company. Under the agreement, Dr. Bray is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Dr. Bray shall also receive 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payments one year following the signing of the Agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock. The estimated fair value of the initial stock compensation package to Dr. Bray is $4,000,000, based on the closing price of $2.00 per share for the Company’s stock on December 12, 2013.

On December 13, 2013, Chad S. Johnson entered into a five-year management agreement with the Company for acting in the capacities of Chief Operating Officer, General Counsel, Secretary and Director. Under the agreement, Mr. Johnson is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $15,000 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Mr. Johnson shall also receive 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payment one year following the signing of the agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Rule 144 restricted common shares of the Company common stock. The estimated fair value of the initial stock compensation package to Mr. Johnson is $2,000,000, based on the closing price of $2.00 per share for the Company’s stock on December 12, 2013.

On December 13, 2013, J. Scott Munro entered into a five-year management agreement with the Company for acting in the capacity of Chief Financial Officer (Principal Accounting Officer). Under the agreement, Mr. Munro is to be paid $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under this Agreement, considered to be November 30, 2014. Mr. Munro shall also receive 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payments one year following the signing of the Agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock. The estimated fair value of the initial stock compensation package to Mr. Munro is $4,000,000, based on the closing price of $2.00 per share for the Company’s stock on December 12, 2013.

On December 13, 2013, Raymond Dabney entered into a five-year management agreement with the Company for services as Managing Consultant. Under the agreement, Mr. Dabney is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Mr. Dabney shall also receive 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payment one year following the signing of the agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Rule 144 restricted common shares of the Company common stock. The estimated fair value of the initial stock compensation package to Mr. Johnson is $2,000,000, based on the closing price of $2.00 per share for the Company’s stock on December 12, 2013.

The aforementioned management agreements are incorporated by reference to this Form 10-K as filed on Form 8-K filed with the SEC on December 20, 2013.

On January 23, 2014, Khadija Benlhassan, PhD entered into a five-year management agreement (the “Agreement”) for acting as Director and Chief Scientific Officer for the Company and undertake the duties and responsibilities of these appointments as of March 1, 2014. Under the Agreement, Dr. Benlhassan is to receive compensation of $16,667 per month for the first three months (March through May 2014) and $17,778 per month for the nine months thereafter through to the end of her first year of service under the Agreement. Dr. Benlhassan will earn 2,000,000 Rule 144 restricted common shares of the Company on November 30, 2014 pursuant to the Agreement and May 30, 2014 Addendum Agreement.

During the year ended January 31, 2014, the Company recorded the following related party stock-based compensation:


Related Party	Position	Amount
Dr. Dorothy Bray	CEO/President	$ 4,000,000
J. Scott Munro	CFO	4,000,000
Chad S. Johnson, Esq.	COO and General Counsel	2,000,000
Raymond Dabney	Managing Consultant	2,000,000
		$12,000,000

The above table includes stock-based compensation paid to companies beneficially owned by the related parties.

F-11

Notes Payable

The Company has two non-interest bearing promissory notes due upon demand in 12 months to Jagpal Holdings Ltd.; one for $55,145 dated April 25, 2013 and one for $17,852 dated June 1, 2013.

On October 21, 2013, Intrinsic Venture Corp. loaned the Company $2,062 secured by a non-interest bearing promissory note due on demand in 12 months. (see Note 4)

Equity

The Company is authorized to issue 290,000,000 shares of common stock with a par value of $0.001 per share. These shares have full voting rights. There were 26,503,515 and 5,361,015 shares of common stock issued and outstanding as of January 31, 2014 and 2013, respectively.

The Company is also authorized to issue 1,000,000 shares of Series A preferred stock, with a par value of $0.001 per share. The shares of Series A preferred stock have 51% of the total vote on all shareholder matters and 66-2/3% of the Series A preferred stockholders may make any affirmative vote to amend, alter or repeal and provision of the Articles of Incorporation or the Bylaws of the Company. There were 1,000,000 and 0 shares of Series A preferred stock issued and outstanding as of January 31, 2014 and 2013, respectively.

The Company is also authorized to issue 9,000,000 shares of preferred stock. These shares have full voting rights. There were 0 and 0 issued and outstanding as of January 31, 2014 and 2013, respectively.

During the year ended January 31, 2014, the Company issued the following common stock:

On December 13, 2013, the Company acquired Immunoclin Limited, an England and Wales corporation, pursuant to a Take Over Agreement. In consideration for the acquisition, the Company issued 10,000,000 shares of common stock, with a fair market value of $20,000,000, or $2.00 per share, to Dr. Dorothy Bray in exchange for all issued and outstanding shares in Immunoclin Limited. An independent valuation firm validated the purchase price for IML to be $20,000,000 consisting of $19,800,000 in intangibles-R&D, 654,992 in goodwill, and ($454,992) in net tangible assets acquired, which was confirmed by a third-party valuator assessment and opinion contracted by the Company’s auditor. A total of $654,992 in unimpaired goodwill remains at January 31, 2014.

Stock Options and Warrants:

The Company has no stock options or warrants outstanding.

F-12

Income Taxes

The Company has $4,544,793 of net operating losses carried forward to offset taxable income in future years that expire commencing in fiscal 2034. The income tax benefit differs from the amount, computed by applying the US federal income tax rate of 34% to net loss before income taxes. As at January 31, 2014, the Company had no uncertain tax positions.


	January 31, 2014 $	January 31, 2013 $

Net loss before taxes	(12,980,317)	(68,438)
Statutory rate	34%	34%

Deferred tax assets:
NOL expense (benefit)	(136,850)	(22,454)
Valuation allowance	136,850	22,454

Net deferred tax assets	–	–

The significant components of deferred income tax assets and liabilities at January 31, 2014 and January 31, 2013 are as follows:


	January 31, 2014 $	January 31, 2013 $

Net operating loss carried forward	(4,413,308)	(23,269)

Stock issued for services	4,205,688	–
Depreciation and amortization	70,769	815

Net deferred income tax asset	(136,850)	(22,454)

F-13

Equipment

Accumulated

Net Book Value

Cost

Depreciation

January 31, 2014

January 31, 2013

Computers

$ 11,327

$ 5,086

$ 6,241

$ 1,262

All equipment is stated at cost. Maintenance and repairs are charged to expense as incurred and the cost of renewals and betterments are capitalized. Depreciation is computed using the straight-line method over the 5 year estimated lives of the related computer equipment.

Intangible Assets


	January 31, 2014	January 31, 2013

Patents

$ 200,000

Research and development

19,800,000

–

Less accumulated amortization

(206,534)

–

$19,793,466

$ –

Intangible assets are stated at fair value on the date of purchase less accumulated amortization. Amortization is computed using the straight-line method over the estimated lives of the related assets (13 years for intellectual assets).

On December 13, 2013, the Company acquired the remaining 50% interest in the DACTELLIGENCE™ patent from one of the inventors for consideration of 100,000 shares of common stock with a fair market value of $200,000 or $2.00 per share.

On December 13, 2013, the Company acquired R&D intangibles in the IML acquisition. An independent valuation firm validated the purchase price for IML to be $20,000,000 consisting of $19,800,000 in intangibles-R&D, 654,992 in goodwill, and ($454,992) in net tangible assets acquired, which was confirmed by a third-party valuator assessment.

The Company will recognize approximately $1,538,462 in intangible amortization expense per year over the next 13 years with intangibles being fully amortized by fiscal 2028.

10.

Commitments and Contingencies

The Company has a 1,668 sq. ft. laboratory facility in located in Paris, France at the Centre de Recherche des Cordeliers (CRC). The laboratory has operated under a lease with University of Pierre and Marie Currie (UPMC) in Immunoclin Limited since 2001. The Company is currently under negotiations with UPMC to extend the lease. Lease commitments are approximately $38 per square foot or $63,000 per year, plus charges of approximately $4,000. The lease is paid semi-annually on January 1^st and June 1^st.

The Company’s corporate headquarters is currently on a month-to-month lease with no commitments.

The Company has no other commitments or contingencies.

F-14

11.

Subsequent Events

Appointment of director and officer

On March 1, 2014, Dr. Khadija Benlhassan was appointed director and Chief Scientific Officer pursuant to her management agreement dated January 23, 2014.

Loans

On February 7, 2014, Intrinsic Venture Corp. loaned the Company $10,000 via a third-party payment to the Company’s attorney Dean Law Corp. in trust.

On February 18, 2014, Intrinsic Capital Corp. loaned Immunoclin Limited, the Company’s wholly owned subsidiary, $100,000.

On March 10, 2014, Intrinsic Capital Corp. loaned the Company $15,000 via a third-party payment to the Company’s auditors Sadler, Gibb & Associates, LLC.

On April 7, 2014, Intrinsic Capital Corp. loaned the Company $25,000.

On June 30, 2014, the $240,000 loaned to the Company by Intrinsic Capital Corp. was secured by a non-interest bearing promissory note due upon demand in 12 months.

Intrinsic Venture Corp. and Intrinsic Capital Corp. are owned and controlled by the Company’s CFO, J. Scott Munro.

Agreements and Equity

On March 20, 2014, Prestige Performance Corp. cancelled 92,361 shares of common stock.

On June 18, 2018, a meeting of the Board of Directors with the unanimous consent approved the issuance of 2,000,000 stock options to each management staff of the Company. Each unregistered stock option is exercisable at a price of $5.60 per share and converted into one common share with expiry five-years from vesting. On June 30, 2014, the Board of Directors signed the resolution to ratify the issuance of the previously approved unregistered stock options. Dr. Dorothy Bray, Chad Johnson, Dr. Khadija Benlhassan, J. Scott Munro, and Raymond Dabney each received 2,000,000 stock options at an exercise price of $5.60 (current market) that expire five-years from vesting. 1,000,000 options vest on each of November 1, 2014 and November 1, 2015. The Black-Scholes fair market value of stock options granted to each management staff was calculated to be $3,161,900 with a total expense of $31,600,000, or $3.16 per option.

Subsequent to the year ended January 31, 2014, the Company entered into the following agreements with scientific advisors:

On April 23, 2014, the Company signed a two-year management consulting agreement with Dr. Marco Kaiser to act as an advisor for molecular biology, genetics, infectious diseases, and DACTELLIGENCE™. Dr. Kaiser was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $42,500, or $4.25 per share, in addition to performance bonuses for services rendered under the agreement.

On May 1, 2014, the Company signed a two-year management consulting agreement with Railton Frith and his affiliates to act as advisors for DACTELLIGENCE™. Mr. Frith was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $37,500, or $3.75 per share, in addition to performance bonuses for services rendered under the agreement.

On May 7, 2014, the Company signed a two-year management consulting agreement with Professor Antony Bayer and his affiliates to act as advisors for neurology and aging. Prof. Bayer was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $37,500, or $3.75 per share, in addition to performance bonuses for services rendered under the agreement.

On May 27, 2014, the Company signed a two-year management consulting agreement with Professor Jean Mariani to act as an advisor for treatments targeting central nervous system diseases and aging. Prof. Mariani was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $50,000, or $5.00 per share, in addition to performance bonuses for services rendered under the agreement.

On June 4, 2014, the Company signed a two-year management consulting agreement with Professor Iwona Wybrańska and her affiliates to act as advisors for nutrigenomics, metabolomics and functional food. Prof. Wybrańska was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $56,000, or $5.60 per share, in addition to performance bonuses for services rendered under the agreement.

On June 21, 2014, the Company signed a two-year management consulting agreement with Dr. Gundula Piechotta and her affiliates to act as advisors for infectious diseases and DACTELLIGENCE™. Dr. Piechotta was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $56,000, or $5.60 per share, in addition to performance bonuses for services rendered under the agreement.

On June 30, 2014, the Company signed a two-year management consulting agreement with Dr. Heinz Ellerbrok and his affiliates to act as advisors for infectious diseases and DACTELLIGENCE™. Dr. Ellerbrok was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $56,000, or $5.60 per share, in addition to performance bonuses for services rendered under the agreement.

Common shares reconciliation table:

Issued and outstanding as of January 31, 2014 26,503,515

Subsequent event issuances and cancellation (32,361)

Unissued and outstanding as of June 30, 2014 26,471,154

In accordance with ASC 855-10 the Company has analyzed its operations subsequent from January 31, 2014 through the date these consolidated financial statements were issued, and has determined there are no other material subsequent events to disclose in these consolidated financial statements.

F-15

ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

ITEM 9A. CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934 (the "Exchange Act"), that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time years specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of January 31, 2014. Based on the evaluation of these disclosure controls and procedures, and in light of the material weaknesses found in our internal controls over financial reporting, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective.

Management’s Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rule 13a-15(f). The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future years are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, the Company conducted an evaluation of the effectiveness of the Company’s internal control over financial reporting as of January 31, 2014, using the criteria established in “Internal Control - Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO").

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim consolidated financial statements will not be prevented or detected on a timely basis. In its assessment of the effectiveness of internal control over financial reporting as of January 31, 2014, the Company determined that there were control deficiencies that constituted material weaknesses, as described below.


	1.	We do not have an Audit Committee – While not being legally obligated to have an audit committee, it is the management’s view that such a committee, including a financial expert member, is an utmost important entity level control over the Company’s financial statements. Currently the Board of Directors acts in the capacity of the Audit Committee, and does not include a member that is considered to be independent of management to provide the necessary oversight over management’s activities.

	2.	We did not maintain appropriate cash controls – As of January 31, 2014, the Company has not maintained sufficient internal controls over financial reporting for the cash process, including failure to segregate cash handling and accounting functions, and did not require dual signature on the Company’s bank accounts. Alternatively, the effects of poor cash controls were mitigated by the fact that the Company had limited transactions in their bank accounts.

Accordingly, the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls.

As a result of the material weaknesses described above, management has concluded that the Company was not effective in maintaining adequate internal control over financial reporting as of January 31, 2014 based on criteria established in Internal Control—Integrated Framework issued by COSO.

Changes in Internal Control over Financial Reporting

There have been changes in our internal control over financial reporting identified in connection with our evaluation we conducted of the effectiveness of our internal control over financial reporting as of January 31, 2014, that occurred during our year end audit that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. The Company has implemented regular backup protocol for its financial data to ensure integrity and preservation of records. The Company has also implemented monthly review and analysis of the financial statements by the CEO/President and CFO to assess all transactions that indicate possible material errors or potential misstatement of the Company’s financial reporting.

This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the SEC that permit the Company to provide only management’s report in this annual report.

Continuing Remediation Efforts to address deficiencies in Company’s Internal Control over Financial Reporting

The Company will continue to add additional systems and personnel to address the aforementioned deficiencies. In addition, we will establish the following remediation measures:



	1.	Our Board of Directors will nominate an audit committee or a financial expert on our Board of Directors in the next fiscal year.

	2.	We will appoint additional personnel to assist with the preparation of the Company’s monthly financial reporting, financial analysis, including preparation of the monthly bank reconciliations.

ITEM 9B.

OTHER INFORMATION.

None.

PART III

ITEM 10.

DIRECTORS AND EXECUTIVE OFFICERS.

Identification of Directors and Executive Officers

The following table sets forth the names and ages of our current director(s) and executive officer(s):


Name	Age	Position with the Company	Appointed Since
Dr. Dorothy Bray	58	CEO, President, Director	December 2013
Chad S. Johnson	46	COO, Secretary, Director	November 2013
J. Scott Munro	45	CFO, Treasurer	December 2013
Dr. Khadija Benlhassan	39	CSO, Director	March 2014

The board of directors has no nominating, audit or compensation committee at this time.

Term of Office

Each of our officers is elected by the Company’s Board of Directors to serve until the next annual meeting of Directors or until his or her successors are duly elected and qualified. Each of our directors is elected by the Company’s Board of Directors and shall hold office until the next annual meeting of stockholders and until his/her successor shall have been duly elected and qualified.

16

Background and Business Experience

The business experience during the past five years of the person presently listed above as an Officer or Director of the Company is as follows:

On December 13, 2013, Dorothy Bray, PhD was appointed as director and CEO/President under a five-year management agreement. Dr. Bray is British, a 1978 graduate of one of the oldest universities in the world, the Jagiellonian University in Cracow, Poland. She holds a PhD degree from The University of London, United Kingdom. After her Fellowship at the Polish Academy of Sciences, in 1981 Dr. Bray received a position at the ARC Institute of Animal Physiology, Babraham, Cambridge, in the United Kingdom working in neuropharmacology. In 1985 she received Churchill Fellowship to study medicinal plants in Africa and subsequently continued the research on medicinal plants at the School of Pharmacy and The London School of Hygiene and Tropical Medicine until 1989 when she received the Royal Society grant to study immunology at the Orsay University in Paris, France. She became a Research Fellow at the Royal Free Hospital School of Medicine in London, UK in 1990 and joined pharmaceutical industry in 1993 to work in key developed and emerging markets in infectious diseases and to develop collaborations with academia governmental and non-government organizations worldwide. Since 1993 Dr. Bray served as a Principal Clinical Research Scientist at Antivirals Wellcome Foundation, Senior Medical Strategy Head, International Medical Affairs, Glaxo Wellcome Inc., USA and UK a Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline and also as Global Director of HIV Research for GlaxoSmithKline. Since 2000 she has been participating as a scientific advisor in multiple projects to enhance health systems in emerging economies in Africa and Latin America. In 2002, she founded IMMUNOCLIN which now has a diverse R&D portfolio and is working on personalized approach to medicine and nutrition to develop novel solutions to manage ageing society. In addition to her industrial activities, between 2004 and 2011, Dr. Bray served as a Member of the Scientific Staff and the Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit in the UK. She currently holds the honorary Senior Lecturer position at the Royal Free School of Medicine, University of London in London and continues to serve as the European Commission's Scientific Expert.

On December 13, 2013, Mr. Chad S. Johnson, Esq., entered into a five-year management agreement with the Company for acting in the capacities of Chief Operating Officer, General Counsel, Secretary and Director. Mr. Chad S. Johnson, a native Kansan, is a June 1989 graduate of Harvard with a concentration in economics and a June 1992 graduate of Harvard Law School. After a federal clerkship, Mr. Johnson worked as a financial institutions mergers, acquisitions and regulatory attorney for Skadden Arps Slate Meagher & Flom LLP from November 1993 through October 2000, and has sound background and experience in corporate, regulatory, advocacy, and non-profit law. In May 2000, he began full-time with the Gore/Lieberman campaign and subsequent recount effort. Mr. Johnson served as founder, pro bono general counsel, and/or director for several gay and lesbian civil rights, AIDS, and political organizations during his time at Skadden Arps. He then served as executive director of the national LGBT democrats’ organization for two years before pursuing various private entrepreneurial ventures while also serving as chief of staff and general counsel for a premier cosmetic surgery center from September 2003 to February 2013, gaining key insight into law and medicine through interaction with patients, physicians, and industry partners. In June 3010, Mr. Johnson co-founded and joined the board of directors of the non-profit World AIDS Institute and thereafter the Timothy Ray Brown Foundation of the World AIDS Institute. He has founded or served on the boards of directors for several political action committees (PACs) and issue-advocacy or lobbying organizations in Washington, DC. Currently, Mr. Johnson holds executive positions on the boards of multiple corporations and non-profit organizations.

On December 13, 2013, Mr. James Scott Munro was appointed Chief Financial Officer (Principal Accounting Officer) and Treasurer. Mr. Munro is Canadian and studied through the Certified General Accountants Association of BC and Thompson River University majoring in Accounting. Prior to joining the Company from May 1999 to March 2010, Mr. Munro was principal financial officer for Most Home Corp., a U.S. public company in the business of real estate referral and wireless technology. Mr. Munro has been president and principal of Intrinsic Venture Corp., a private venture capital company, since July 2010. Intrinsic Venture Corp. provides business and financial consulting services to U.S. public companies, including mergers, acquisitions, and structuring, along with direct investment and financing.

On January 23, 2014, Khadija Benlhassan, PhD entered into a five-year management agreement for acting as Director and Chief Scientific Officer for the Company and undertake the duties and responsibilities of these appointments as of March 1, 2014. Dr. Benlhassan is French; she holds a Master’s Degree with thesis of “Genetic and Molecular Basis of Normal and Pathologic Immune System”, at University Paris 5 René Descartes, France / Pasteur Institute, Paris and the “cytokine and Immunology of human tumours” Laboratory at Gustave Roussy Institute; Villejuif, France. Dr. Benlhassan received a PhD degree in Immunology in December 2003 with the highest honours and distinction awarded by the jury from the University Paris 5 René Descartes, France. During her PhD studies, Dr. Benlhassan carried out a research project involving the evaluation of antiviral drug efficacy and study of immune response enhancement in post-exposure prophylaxis of Human Immunodeficiency Virus (HIV) transmission at the Neurovirology Laboratory, Medical Research Department, French National Nuclear Agency (CEA), France in collaboration with GlaxoSmithKline Laboratories France, the French National Institute of Health and Medical Research (INSERM) in Necker medical faculty and with the Laboratory of viral immunopathology of Pasteur Institute, Paris, France. In March 2003, Dr. Benlhassan joined Biopharm Centre of Excellence in Drug Discovery as a senior research scientist at GlaxoSmithKline R&D, Stevenage, UK, where she carried out research on the evaluation of molecular adjuvants to enhance the potency of DNA vaccines. In September 2005, Dr. Benlhassan became a Research Manager, Immunity, at Danone Research, Palaiseau, France, responsible for design and conduct of clinical trials as well as pre-clinical research projects to evidence health benefits and immunity of nutritional interventions. Within dynamic and highly skilled research teams, widely connected to the top international experts, she was in charge of demonstrating the relationship between probiotics and immunity in humans. In May 2006, Dr. Benlhassan joined MERCURIA, Paris, France as manager responsible for pre-clinical and clinical research projects in anti-infectives, neurology, cardiovascular diseases and functional food. In April 2009, she joined ImmunoClin Sarl and took responsibility for the conduct of international clinical research projects in infectious diseases, cancer, Alzheimer’s, diagnostics, innate immunity, cardiovascular diseases and functional food as well as for directing pre-clinical laboratory research in Paris.

Identification of Significant Employees

See Background and Business Experience.

Family Relationship

We currently do not have any officers or directors of our Company who are related to each other.

Involvement in Certain Legal Proceedings

During the past ten years no director or executive officer of the Company has been involved in the following:

(1)

A petition under the Federal bankruptcy laws or any state insolvency law which was filed by or against, or a receiver, fiscal agent or similar officer was appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing;

(2)

Such person was convicted in a criminal proceeding or is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses);

(3)

Such person was the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities:

Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity;

ii.

Engaging in any type of business practice; or

iii.

Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal or State securities laws or Federal commodities laws;

(4)

Such person was the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described in paragraph (f)(3)(i) of this section, or to be associated with persons engaged in any such activity;

(5)

Such person was found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;

(6)

Such person was found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated;

(7)

Such person was the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:

Any Federal or State securities or commodities law or regulation; or

ii.

Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or

iii.

Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

(8)

Such person was the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

Audit Committee and Audit Committee Financial Expert

The Company does not have an audit committee or an audit committee financial expert (as defined in Item 407 of Regulation S-K) serving on its Board of Directors. All current members of the Board of Directors lack sufficient financial expertise for overseeing financial reporting responsibilities. The Company has not yet employed an audit committee financial expert on its Board due to the inability to attract such a person.

The Company intends to establish an audit committee of the board of directors, which will consist of independent directors. The audit committee’s duties will be to recommend to the Company’s board of directors the engagement of an independent registered public accounting firm to audit the Company’s consolidated financial statements and to review the Company’s accounting and auditing principles. The audit committee will review the scope, timing and fees for the annual audit and the results of audit examinations performed by the internal auditors and independent registered public accounting firm, including their recommendations to improve the system of accounting and internal controls. The audit committee will at all times be composed exclusively of directors who are, in the opinion of the Company’s board of directors, free from any relationship which would interfere with the exercise of independent judgment as a committee member and who possess an understanding of financial statements and generally accepted accounting principles.

Code of Ethics

We have adopted a Code of Ethics (the “Code”) that applies to our directors, officers and employees, including our Chief Executive Officer and Chief Financial Officer. A written copy of the Code is available on written request to the Company and was filed with the SEC on May 17, 2011, as part of the Company’s Registration Statement on Form S-1.

Section 16(a) Beneficial Ownership Reporting Compliance

The Company filed a Form 8-A12G on June 15, 2012. Therefore, we have a class of shares registered pursuant to Section 12(g) where ownership forms are required. All directors, officers and 10% shareholders are filing the necessary Form ID form to obtain EDGAR codes to file required forms.

ITEM 11. EXECUTIVE COMPENSATION

The following table sets forth the compensation paid to our executive officers during the years ended January 31, 2014 and January 31, 2013:

Summary Compensation Table⁽¹⁾


Name and Principal Position	Fiscal Year Ended	Salary $	Other $	Stock Awards $	Total $
Dr. Dorothy Bray President, CEO, Chairman and Director	1/31/2014	20,000	1,000	4,000,000	4,021,000
Dr. Dorothy Bray President, CEO, Chairman and Director	1/31/2013	–	–	–	–
Dr. Khadija Benlhassan CSO and Director	1/31/2014 1/31/2013	– –	1,000 –	– –	1,000 –
Chad S. Johnson	1/31/2014	20,000	1,000	2,000,000	2,021,000
COO, General Counsel, Secretary	1/31/2013	–	–	–	–
J. Scott Munro	1/31/2014	20,000	–	4,000,000	4,020,000
CFO	1/31/2013	–	–	–	–
Raymond Dabney	1/31/2014	20,000	1,000	2,000,000	2,021,000
Managing Consultant	1/31/2013	–	–	–	–


⁽¹⁾The table includes compensation through beneficially owned entities.

Narrative Disclosure to Summary Compensation Table

There are management agreements with all executive officers. There are no provisions that would result in payments to such person because of his or her resignation, retirement or other termination of management agreement with the Company, or its subsidiaries, any change in control, or a change in the person’s responsibilities following a change in control of the Company.

Outstanding Equity Awards at Fiscal Year-End

All executive officers had pending stock to be issued pursuant to December 13, 2013 management agreements. All stock was deemed issued and outstanding at the year ended January 31, 2014. There were no other equity awards, or holds exercisable or unexercisable options, as of the year ended January 31, 2014.

Long-Term Incentive Plans

There are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers.

Compensation Committee

We currently do not have a compensation committee of the Board of Directors. The Board of Directors as a whole determines executive compensation.

Compensation of Directors

Our directors receive no extra compensation for their service on our Board of Directors.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

Security Ownership of Management

The following table sets forth certain information concerning the number of shares of our Common Stock owned beneficially as of January 31, 2014, by: (i) our directors; (ii) our named executive officer; and (iii) each person or group known by us to beneficially own more than 5% of our outstanding shares of common stock. Unless otherwise indicated, the shareholders listed below possess sole voting and investment power with respect to the shares they own.


Name and Address of Beneficial Owner	Title of Class	Amount and Nature of Beneficial Ownership⁽¹⁾ (#)	Percent of Class⁽²⁾ (%)

Dorothy Bray, PhD⁽³⁾ Tanglewood, North Dean, High Wycombe, United Kingdom	Common	12,000,000	45.3%
Raymond Dabney⁽⁴⁾ 900 – 555 Burrard St. Vancouver, BC V7X 1M8		11,000,000	41.5%
Chad S. Johnson⁽⁵⁾ 1754 Willard Street, NW #3 Washington, DC 20009	Common	1,000,000	3.8%
J. Scott Munro⁽⁶⁾ 1060 – 1055 Hastings St. W. Vancouver, BC V6E 2E9	Common	2,000,000	7.5%
All Officers and Directors as a Group (3 Persons)	Common	15,000,000	56.6%



1.	The number and percentage of shares beneficially owned is determined under rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares as to which the individual has sole or shared voting power or investment power and also any shares which the individual has the right to acquire within 60 days through the exercise of any stock option or other right. The persons named in the table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them, subject to community property laws where applicable and the information contained in the footnotes to this table.
2.	Based on 26,503,515 issued and outstanding shares of Common Stock as of January 31, 2014.
3.	Dorothy Bray, PhD is the Company’s President, CEO, Chairman and Director. Dr. Bray’s beneficial ownership includes 10,000,000 common shares..
4.	Raymond Dabney is Managing Consultant of the Company. Mr. Dabney’s beneficial ownership includes 10,000,000 common shares beneficially held through Castor Management Services, Inc.

5.	Chad S. Johnson, Esq. is the Company’s COO, Secretary, General Counsel, and Director. His beneficial ownership includes 1,000,000 common shares beneficially held through CSJ Group LLC.
6.	J. Scott Munro is the Company’s CFO.

Changes in Control

There are no present arrangements or pledges of the Company’s securities that may result in a change in control of the Company.

ITEM 13.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

Related Party Transactions

On December 13, 2013, Dr. Dorothy Bray was appointed a director and CEO/President under pursuant to a five-year management agreement with the Company. Under the agreement, Dr. Bray is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Dr. Bray shall also receive 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payments one year following the signing of the Agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock. The fair value of the initial stock compensation package to Dr. Bray is $4,000,000, based on the closing price of $2.00 per share for the Company’s stock on December 12, 2013.

On December 13, 2013, Chad S. Johnson entered into a five-year management agreement with the Company for acting in the capacities of Chief Operating Officer, General Counsel, Secretary and Director. Under the agreement, Mr. Johnson is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $15,000 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Mr. Johnson shall also receive 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payment one year following the signing of the agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Rule 144 restricted common shares of the Company common stock. The fair value of the initial stock compensation package to Mr. Johnson is $2,000,000, based on the closing price of $2.00 per share for the Company’s stock on December 12, 2013.

On December 13, 2013, J. Scott Munro entered into a five-year management agreement with the Company for acting in the capacity of Chief Financial Officer (Principal Accounting Officer). Under the agreement, Mr. Munro is to be paid $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under this Agreement, considered to be November 30, 2014. Mr. Munro shall also receive 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payments one year following the signing of the Agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock. The fair value of the initial stock compensation package to Mr. Munro is $4,000,000, based on the closing price of $2.00 per share for the Company’s stock on December 12, 2013.

The aforementioned management agreements are incorporated by reference to this Form 10-K as filed on Form 8-K filed with the SEC on December 20, 2013.

Other than the foregoing, none of the directors or executive officers of the Company, nor any person who owned of record or was known to own beneficially more than 5% of the Company’s outstanding shares of its Common Stock, nor any associate or affiliate of such persons or companies, has any material interest, direct or indirect, in any transaction that has occurred during the past fiscal year, or in any proposed transaction, which has materially affected or will affect the Company.

Director Independence

For purposes of determining director independence, we have applied the definitions set out in NASDAQ Rule 5605(a)(2). The NASDAQ definition of “Independent Officer” means a person other than an Executive Officer or employee of the Company or any other individual having a relationship which, in the opinion of the Company's Board of Directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

According to the NASDAQ definition, none of our directors are independent because they are also executive officers of the Company.

Review, Approval or Ratification of Transactions with Related Persons

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 14.

PRINCIPAL ACCOUNTANT FEES AND SERVICES.


		Year Ended January 31, 2014		Year Ended January 31, 2013
Audit fees	$	61,248	$	10,000
Audit-related fees	$	0	$	0
Tax fees	$	0	$	0
All other fees	$	6,000	$	880
Total	$	67,248	$	10,880

Audit Fees

During the fiscal year ended January 31, 2014, we incurred approximately $61,248 (2013; $10,000) in fees to our principal independent accountants for professional services rendered in connection with the audit and reviews of our financial statements.

Audit-Related Fees

The aggregate fees billed during the fiscal years ended January 31, 2014 and 2013 for assurance and related services was $0 and $0, respectively, by our principal independent accountants that are reasonably related to the performance of the audit or review of our financial statements (and are not reported under Item 9(e)(1) of Schedule 14A).

Tax Fees

The aggregate fees billed during the fiscal years ended January 31, 2014 and 2013 for professional services rendered by our principal accountant tax compliance, tax advice and tax planning were $0 and $0, respectively.

All Other Fees

The aggregate fees billed during the fiscal years ended January 31, 2014 and 2013 for products and services provided by our principal independent accountants (other than the services reported in Items 9(e)(1) through 9(e)(3) of Schedule 14A) was $6,000 and $880, respectively.

PART IV

ITEM 15.

EXHIBITS.

(a)

Exhibits


Exhibit Number	Description of Exhibit	Filing
10.01	Management agreement between the Company and Dr. Dorothy Bray dated December 13, 2013	(1)
10.02	Management agreement between the Company and Chad S. Johnson dated December 13, 2013	(1)
10.03	Management agreement between the Company and J. Scott Munro dated December 13, 2013	(1)
10.04	Management agreement between the Company and Raymond Dabney dated December 13, 2013	(1)
10.05	Control Shareholder Agreement dated December 13, 2013	(1)
10.06	Management agreement between the Company and Dr. Khadija Benlhassan dated January 23, 2014	(1)
10.07	Promissory Note between the Company and Intrinsic Capital Corp. dated June 20, 2014	Filed herewith.
31.01	Certification of the Chief Executive Officer Pursuant to Rule 13a-14 or 15d-14 of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith.
31.02	Certification of the Chief Financial Officer Pursuant to Rule 13a-14 or 15d-14 of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith.
32.01	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed herewith.
32.02	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed herewith.
101.INS*	XBRL Instance Document	Filed herewith.
101.SCH*	XBRL Taxonomy Extension Schema Document	Filed herewith.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document	Filed herewith.
101.LAB*	XBRL Taxonomy Extension Labels Linkbase Document	Filed herewith.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document	Filed herewith.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document	Filed herewith.

(1)

Incorporated by reference as filed on Form 8-K with the SEC on December 20, 2013.

*Pursuant to Regulation S-T, this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

IMMUNOCLIN CORPORATION

Date: July 2, 2014

/s/Dr. Dorothy Bray

By:

Dorothy Bray, PhD

Its:

CEO, President, Principal Executive Officer

Date: July 2, 2014

/s/J. Scott Munro

By:

J. Scott Munro

Its:

CFO, Principal Accounting Officer

EX-10.7 2 exhibit107.htm EXHIBIT 10.7 Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - IMMUNOCLIN CORPORATION - Exhibit 10.7

EX-31.1 3 exhibit311.htm EXHIBIT 31.1 Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - IMMUNOCLIN CORPORATION - Exhibit 31.1

Exhibit 31.1

Certification of the Chief Executive Officer Pursuant to Rule 13a-14 or 15d-14 of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Dorothy Bray, certify that:


1.	I have reviewed this Annual Report on Form 10-K of Immunoclin Corporation

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report.

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the Registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

By: /s/ Dorothy Bray

Dorothy Bray

President and Chief Executive Officer

July 2, 2014

EX-31.2 4 exhibit312.htm EXHIBIT 31.2 Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - IMMUNOCLIN CORPORATION - Exhibit 31.2

Exhibit 31.2

Certification of the Chief Financial Officer Pursuant to Rule 13a-14 or 15d-14 of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, J. Scott Munro, certify that:

1.

I have reviewed this Annual Report on Form 10-K of Immunoclin Corporation

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report.

4.

I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the Registrant and have:

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.

Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.

I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

By: /s/ J. Scott Munro

J. Scott Munro

Chief Financial Officer, Principal Accounting Officer

July 2, 2014

EX-32.1 5 exhibit321.htm EXHIBIT 32.1 Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - IMMUNOCLIN CORPORATION - Exhibit 32.1

Exhibit 32.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Annual Report of Immunoclin Corporation, (the “Company”) on Form 10-K for the year ended January 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dorothy Bray, Chief Executive Officer of the Company certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:


1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By: /s/ Dorothy Bray

Dorothy Bray

President and Chief Executive Officer

July 2, 2014

EX-32.2 6 exhibit322.htm EXHIBIT 32.2 Filed by OTC Filings Inc. - www.otcedgar.com - 1-866-832-FILE (3453) - IMMUNOCLIN CORPORATION - Exhibit 32.2

Exhibit 32.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Annual Report of Immunoclin Corporation, (the “Company”) on Form 10-K for the year ended January 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, J. Scott Munro, Chief Financial Officer of the Company certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:


1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By: /s/ J. Scott Munro

J. Scott Munro

Chief Financial Officer, Principal Accounting Officer

July 2, 2014

GRAPHIC 7 image1.jpg IMAGE begin 644 image1.jpg M_]C_X``02D9)1@`!`0$!+`$L``#_X0!817AI9@``34T`*@````@`!`$Q``(` M```1````/E$0``$````!`0```%$1``0````!```N(U$2``0````!```N(P`` M``!!9&]B92!);6%G95)E861Y``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"L#QK_R*-]_VS_\`1BUOU@>-?^11OO\`MG_Z,6@#S'0O^1AT MW_KZB_\`0Q7MM>):%_R,.F_]?47_`*&*]MIL`HHHI`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%8'C7_`)%&^_[9_P#HQ:WZ MP/&O_(HWW_;/_P!&+0!YCH7_`",.F_\`7U%_Z&*]MKQ+0O\`D8=-_P"OJ+_T M,5[;38!1112`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH` M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**** M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH` M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB MB@`HHHH`*P/&O_(HWW_;/_T8M;]8'C7_`)%&^_[9_P#HQ:`/,="_Y&'3?^OJ M+_T,5[;7B6A?\C#IO_7U%_Z&*]MIL`HHHI`%%%%`!1110`4444`%%%%`!111 M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111 M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%8'C7_D4;[_MG_P"C%K?K`\:_\BC? M?]L__1BT`>8Z%_R,.F_]?47_`*&*]MKQ+0O^1ATW_KZB_P#0Q7MM-@%%%%(` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`K`\: M_P#(HWW_`&S_`/1BUOU@>-?^11OO^V?_`*,6@#S'0O\`D8=-_P"OJ+_T,5[; M7B6A?\C#IO\`U]1?^ABO;:;`****0!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11 M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%5-1U2QTBT:ZU"ZBMH%S\TC8R<$X`ZDX!X')KRKQ+\6 M[J6:6V\/QK#"K8%Y(NYW`QRJD84<$<@D@C[IJ)3C'N,D]>#^5<7J/Q:\.VFY;1;J^?RRRM''L3=SA26P M1VY"GKWZ5XI>7]YJ,PFOKN>ZE5=H>>0NP'7&2>G)_.J]82KOH>]0R*E'6K)M M_7]@TFU@QG?Y\C2YZ8QC;COZ_A6->?%/Q3=3!X;J"T4+@QP0* M5)]?GW'/XXXKBZ*S=2;ZGH0R["PV@OGK^9UG_"R_%W_07_\`):+_`.)J6V^* M/BN"X262^BN47.8I;=`K<=]H!]^#7'44N>7"PS5O9K[D>B1?&/71,AFL- M.>(,-ZHCJQ'<`EC@^^#]*W+/XSV;S$7VCSPQ;>&@F$K$^F"%XZ\Y_"O'Z*I5 M9KJ83RK"3^Q;TN?1.G?$'PQJ6U4U6*"0QAV2Y!BV]."S?*2,]`3WQD5TU?*% M:>D^(M8T-@=-U&>W4,6\M6S&21@DHE:1K]T>=6R&+UHR^_\`S7^1 M].45Y5H/QA6281:]9+$K-Q<6@.U1P/F0DG`Y)()/0;:]*T[5+'5[1;K3[J*Y M@;'S1MG!P#@CJ#@C@\BMXSC+8\3$8.MAW^\C\^A;HHHJCE"BBB@`HHHH`*** M*`"BBB@`HHHH`*P/&O\`R*-]_P!L_P#T8M;]8'C7_D4;[_MG_P"C%H`\QT+_ M`)&'3?\`KZB_]#%>VUXEH7_(PZ;_`-?47_H8KVVFP"BBBD`4444`%%%%`!11 M10`4444`%%%%`!1110`4444`%%%%`!17)^(_B'H?A_S(?.^V7JY'V>W(.UAD M8=NB\C!'+#/2O,-<^)_B#5U:&"1=.@+'`MN,D]>#^59YII&DED8L[N_&;3X_+^P:3=3YSO\`/D6+'3&,;L]_3\:J?\+J_P"I M?_\`)S_[77D]%3[:?*X$C#CC"E5!YQW%>144O;3[@\HP=O@_%_YGNUG\6?#-U,4F-Y M:*%R))XY)I_?_`%]Y]7T5\YZ'XZ\0:"RB"^:>!5"BWNB9(P`"`!SE M0,_PD=!G.*]*\.?%?2]2\NWU=/[/N3A?,SNA8\#KU3))//``Y:M8UHL\G$Y1 MB*.L5S+R_P`CT*BF12QSPI-#(LD4BAD=#E6!Y!!'44^M3R@HHHH`****`"BB MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**** M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH` M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB MB@`HHHH`*Y[Q1XQTOPM;G[5)YEX\9>&U3[S\X&3T49[GT.,D8IOC3Q7'X3T8 M7`19;N9O+MXF;`)QDL1G)4<9QW('&QEN6?6?WE3X?S_X!>U_Q)JGB6[6XU*XW[,B*-1M2,$YPH_(9 M.2<#).*R:**Y6V]6?60A&$5&*LD%%%%(H****`"BBB@`HHHH`****`"K>G:I M?:1=K=:?=2VTZX^:-L9&0<$=",@<'@U4HH$XJ2LUH?4.C7DFHZ%I]],JK+8Z%_P`C#IO_`%]1?^ABO;:\2T+_`)&'3?\`KZB_]#%>VTV`4444@"BBB@`H MHHH`****`"BBB@`HHHH`****`"BBN6\:>-+7PI8A5"S:E,N8+!W(3:2NS2E2G5FH05VS6USQ!IOAZQ:ZU&Y6,!24B!'F2D8X1>YY'L,\X'-> M+^+?B+J7B%I+6T9K+3=S`(C$22J1C$A!Y'7Y1QSSG`-MWWB#5)-0U"7? M,_`4<+&O95'8#_$G))-9]G^84445B>L%%%%`! M1110`4444`%%%%`!1110!]!_#3_DGVE_]M?_`$:]=97)_#3_`))]I?\`VU_] M&O765WP^%'P6,_WFI_B?YA1115',%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11 M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`54U34;?2-+N=0NFVP6\9= MN0"<=`,D#).`!W)%6Z\7^*_BA=1U!-"M3F"RDW3N"I#RXP`,(=9N-1NF8F1B(XV;(B3/RH.!P,^G)R>I- M9E%%<3=S[B$(PBHQ5D@HHHI%!1176>%/`.J>*-MQ_P`>FG'U@EGG?.V.)"S-@9.`.>@)K MW[1OAQX;T?>WV/[=(V1OO<2X''`7`7MUQGD\XKJ8HHX(4AAC6.*-0J(@PJ@< M``#H*W5!]6>)5SZFG:G&_KH?-/\`PBWB'_H!:G_X!R?X4R7PYKL$+S3:+J,< M4:EG=[5PJ@VE(SG/`5LJ!ST`&,#'%0Z#Z,ZJ6? M4I?Q(M?C_D>`T5W^O?"?6-,A,^G3+J<2KEU1/+E'4G"DG<.!T.23TKA;FUN+ M*X>WNH)8)TQNCE0JRY&1D'GH0:RE%QW/6HXFE75ZA'9'Y[6_B2]6%%%%,S"BBB@`HHHH M`****`"BBB@`K`\:_P#(HWW_`&S_`/1BUOU@>-?^11OO^V?_`*,6@#S'0O\` MD8=-_P"OJ+_T,5[;7B6A?\C#IO\`U]1?^ABO;:;`****0!1110`4444`%%%% M`!1110`4444`%%%8WB?Q':^%]&?4+E&D)81Q1+UD<@D#/8<$D^@[G`*;25V5 M"$JDE"*NV9_C3QI:^%+$*H6;4IES!;D\`=-[^B_J3P.Y'@-]?W6IWTU[>S-- M1NI/]!V`'`'%%]?W6IWTU[>S--1NI/]!V`'`'%5ZXZE1S9]K@, M!#"0[R>[_KH%%%%9G>%%%%`!15O3M+OM7NUM=/M9;F=L?+&N<#(&2>@&2.3P M*]"TCX.WTVR35[^*V0[&,,`\Q\?Q*6.`I'3(W#\N:C"4MCFKXNA0_B2M^?W' MF5%?0-C\,_"UDL.ZP:ZEB;=YEQ*S%CG(W*"%([8Q@CKFMC_A%O#W_0"TS_P# MC_PK54)=SS)Y]13]V+9\S45],_\`"+>'O^@%IG_@''_A52]\"^&-0\OSM%M5 MV9QY`,.`1@_7$2I270[ MJ.9X6MHI6?GH:G^)_F%%%%4%7(!QEB!G'&:^8Y99)YGFFD:261BSNYRS$\DDGJ:]@^,6K^3I=EI$;X>X MD,TH63!V+P`R]P6.1GNGY>.5R5Y7E8^LR2AR4'4>\OR7],****Q/:"BBNQ^' M/A=?$6OF6Y&;*QVRRKA2)&S\J$'L<'/!X!'&0:<4V[(RKUHT:;J3V1N?#SX> M_;_*UK6H?]$X>VMG'^N]'8?W/0?Q=>GWO8J**[H0459'Q&+Q=3%5.>?R78** M**HY0HHHH`****`"L_5]"TO7;<0:G917*+]TL,,G()VL.5S@9P>:T**&KE1E M*+YHNS/%_%'PHO-.0W6A/+?0#)>!P/-0!=RQ203/#-& MT$'_`*+6M:JFEV7]FZ196'F>9]F@ M2'?MQNVJ!G';.*MUNMCPJK4IMKN%%%%,@****`"BBB@`HHHH`****`"L#QK_ M`,BC??\`;/\`]&+6_6!XU_Y%&^_[9_\`HQ:`/,="_P"1ATW_`*^HO_0Q7MM> M):%_R,.F_P#7U%_Z&*]MIL`HHHI`%%%%`!1110`4444`%%%%`!1110`R66." M%YII%CBC4L[N<*H')))Z"OG3QCXHF\4ZX]UF5+./Y;:!R/D7C)P.,L1D]>PR M0!7;_%CQ7_S+=H_]U[TE/]UD4$_@QP/[O/45Y/7+6G=\J/JCL/[GH/XNO3[WL5=%.E?61X&99M[-NE0 M>O5]O3S*FG:78Z1:+:Z?:Q6T"X^6-<9.`,D]2<` M"?%.\DNO'5Q"ZJ%M88X4*CD@KOY]\N?PQ7%UK>*?^1NUK_K_`)__`$8U9-<$ MG>39]_A8*%"$5T2"BBBI-PKZ,\"Z&N@^$K.`HRSS*+BX#J58.P'!!/!`PO;[ MN<VUXEH7_(PZ;_U]1?^ABO;:;`****0!1110`4444`%%%%`!1110`5GZ[J\ M.A:'=ZG.-R6\>X+R-['A5R`<98@9QQFM"O'?B]X@^T:A!H,+?N[7$T_'60CY M1R.RG/!P=_J*B)KJGTW?I_6AYO=7,U[=S75P^^>>1I)&P!N9CD MG`XZFHJ**X3[I))604444`%>B?#3P3'K,S:OJD#-8PL/(C=?DN'&"#RWA/P[-XGU^&PCXA'[RX?<%*Q`@,1D'GD`<'DCMDU]'VMM#96D-K;I ML@@C6.->@K>C"[NSQ>_[S'_"OS84 M445L>*%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`5@>-?\`D4;[_MG_`.C%K?K`\:_\BC??]L__`$8M`'F.A?\`(PZ;_P!? M47_H8KVVO$M"_P"1ATW_`*^HO_0Q7MM-@%%%%(`HHHH`****`"BBB@`HHHH` MJ:IJ-OI&EW.H73;8+>,NW(!..@&2!DG``[DBOF"ZN9KV[FNKA]\\\C22-@#< MS').!QU->Q_%[6UMM#@T>*7$]W())4&T_NEYY[C+;<$==K<]CXO7+7E=V/J\ MCP_)1=5[R_)!1116![8445UGP\\.?\)!XGB\Z/=96F)Y\KE6P?E0Y!!R>H/5 M0U-*[LC.M5C2INI+9'JOP[\,+X=\/)+,C+?WJK+RL`PP<%R0?H001[&L:O/:LS]#IRYX*7=!1112+-OP=-?^11OO\`MG_Z,6@#S'0O M^1ATW_KZB_\`0Q7MM>):%_R,.F_]?47_`*&*]MIL`HHHI`%%%%`!1110`444 M4`%%%4=9U*/1]&O-1EVE;:%I`K/L#D#A<]B3@#W-`XQ0"#QS6 M)=?$F\?9]DT^"+&=WFN9,^F,;<=_6BP'HU%>?Q_$MQ&HDTI6<`;BL^`3WP-I MQ^9K=T_QQHM_,8C*]JW\)N0%5NO<$@=.^.M`'1T444`%%%%`!117.:IXTT[2 M=1EL9X+II8L;C&BE>0#QEAZT`='17(?\+&TC_GVOO^^$_P#BJZFTN4O+."ZC M#!)HUD4-U`(R,_G0!-1110`4444`%%UDM[PO#(T;%47!(.#CY MO:H?^%C:1_S[7W_?"?\`Q5`'7T5R'_"QM(_Y]K[_`+X3_P"*K2M?&.A7;1H+ MY8G<9VS*4V\9P6(V_K0!NT4V.1)8UDC=71P&5E.00>A!IU`!1110`4453U34 MH=)TZ6^G5VBBQN$8!;D@<9(]:`+E%H` M****`"BBB@`HHHH`**R=9\3:-H&P:GJ$4#OC;'RSD'/.U03C@\XQ7$WOQFT^ M/R_L&DW4^<[_`#Y%BQTQC&[/?T_&I4?\+J_ MZE__`,G/_M=;>G?%KP[=[5NUNK%_+#,TD>]-W&5!7)/?DJ.G;I4JK!]36>68 MN"NX/Y6?Y'>45%;75O>VZ7%K/%/`^=LD3AE;!P<$<=014M:'"TT[,***\]_X M7%X>_P"?/4_^_4?_`,74N2CN;4<-5K7]G&]CT*BN6\->/=+\4ZC)8V-O>1RQ MPF8F=%"X!`[,>?F%=33335T15I3I2Y:BLPHHKAK_`.*VA:=J-U8S6FHM+;3/ M"Y2-"I*D@XR_3BAR2W*HX>K6;5.-['I_]^H__BZ/^%Q> M'O\`GSU/_OU'_P#%U/M(=S?^SL5_(ST*BN1L?B9X6O5AW7[6LLK;?+N(F4J< MX&Y@"H'?.<`=<5TUG?V>HPF:QNX+J)6VEX)`Z@]<9!Z\C\ZI23V9SU*%6E\< M6O5%BBBBF9!1110`45PU_P#%;0M.U&ZL9K346EMIGA MHPF:QNX+J)6VEX)`Z@]<9!Z\C\ZL59RM-.S"BBB@1X/\5K+[+XWEF\S=]K@C MFQMQLP-F/?[F?QKB*]C^,6D>=I=EJ\:9>WD,,I6/)V-R"S=@&&!GN_Y^.5Q5 M5:3/M\LJJIA8/MI]P4445F=X5[7\)->CO-!DT9RJSV+%D'0O&Q)SUR2&)!X` M`*^M>*5T/@KQ!_PC?B>VO';%L_[FYX_Y9L1D]">"`W')VX[U=.7+*YPYCAOK M&'E%;K5>J/HZBBBNX^'"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`*P/&O_`"*-]_VS_P#1BUOU@>-?^11OO^V?_HQ:`/,= M"_Y&'3?^OJ+_`-#%>VUXEH7_`",.F_\`7U%_Z&*]MIL`HHHI`%%%%`!1110` M4444`%<'\6M1^R>$!:*T6^]G5"C'YMB_.2HSV94!//WO<5WE>._&:]\S5],L M/+QY,#3;]W7>V,8]O+_7VK.J[09Z&5T_:8N"[:_=_P`$\RHHHKB/M@HHHH`] M"^$.F?:O$\]^\.Z.S@.U]V-DCG`XSSE?,]OQQ7MM<'\)=.^R>$#=LL6^]G9P MZCYMB_(`QQV97('/WO> MN.@X[C-=3\0-7-IIL5A!,R37)S(%(_U0&"#W&3CZX(KS.F@"BNI\)^$WUF07 MEXK)IZ'@=#,1V'MZG\!SDCT2RT/2].\LVEA!&\>=LFS+C.<_,>>Y[T7$>)45 M[7=:!I%ZL@GTZV8R'<[K&%N3UGX>??FTB;U/V>8_4X5OR`!_$T M7`T?AW([^'959V8)6\<3>6VW.'/"\?[Q%>)4T`5ZYX(NA=>%K8>:TCPEHGW9^7!R!SZ*5KR.O M1/AM):[_P`C#J7_`%]2 M_P#H9K/K0UW_`)&'4O\`KZE_]#--T:-)==T^.1%='N8U96&006&015"*-%>U M3^'-%N(6B?2[4*W4QQ!&_`K@BN?U/X>6,ZN^G3/;2]5C<[X^G3^\,G'.3WXI M7`X/2]7O='NEGLYF0Y!9,G9)CLP[]3],\8KTSPYXNM=V1>01RKCLP/*19(W9'0AE93@@CH0 M:`/>Z*P/"6O_`-N:7^^;-Y!A9\+@'.=K#MR!^8/`&*WZ0PK`\:_\BC??]L__ M`$8M;]8'C7_D4;[_`+9_^C%H`\AKT[X<_P#(O7'_`%]-_P"@)7F->G?#G_D7 MKC_KZ;_T!*;$=?1112&%%%%`'(?$;_D7K?\`Z^E_]`>O,:].^(W_`"+UO_U] M+_Z`]>8TT(**]&\+^%]&U'PY:7=W9^9/)OW-YKC.'8#@''0"MC_A"O#W_0/_ M`/(TG_Q5%P/(:*]>_P"$*\/?]`__`,C2?_%4?$5X>_Z!_\`Y&D_^*HN!@?# M/_F*?]LO_9Z[ZL_3-$T_1_-^P6_D^;C?\[-G&<=2?4UH4AGD/C7_`)&Z^_[9 M_P#HM:P*W_&O_(W7W_;/_P!%K6!5""BO7O\`A"O#W_0/_P#(TG_Q50W/@/0I MXPL<$MN0<[XI22?;YLC]*5P/)ZZO0O'-]IS"*_+WML<#+-^\3GD@G[W4\'VY M%0ZUX*U'28WN(BMW:H-S2(,,HXR2OXGIG@9.*YJF![O:W4%]:QW-M*LL,@RK MKW_SZ5-7DO@_7Y-(U2."67%CB@1KNDFE)$<8[9(!Y.,``9_`$CV71/AG MX=TE(VGMO[0N5Y,MSRI)7!`C^[CJ1D$C/7@5E"G*1[&+S&AA?=EJ^R_K0\!H MKZ6E$>'9H7B;0M."NI4E+9%;!]"`"#[CFN4U[X2:5>0E]&D:PG5>(W9I(G/ M/7)+`DD<@D`#[IJG0DMCDI9YAYNTTT9GP5_YCG_;#_VI7J]DFH),\+,YQJ8J4H.ZT_)!7RA7U?7 MRA6>(Z'JA?!W_`)&Z[_Z\'_\`1D=>VUXE\'?^1NN_^O!__1D= M>VU='X#BSK_>GZ(*^9O%/_(W:U_U_P`__HQJ^F:^9O%/_(W:U_U_S_\`HQJF MOLCIR#^)/T,FBNA\#Z99ZQXQL+"_A\ZVE\S>FXKG$;$<@@]0*]B_X5IX1_Z! M'_DS+_\`%5C"FY*Z/7Q>94L+-0FG>U]+?YGSY5BSO[S3IC-8W<]K*R[2\$A1 MB.N,@].!^5>T:M\)-!O%+:?)/I\NT!0K&6/.>20QW$XXX8#I^/EOB/P?K'A= ME-_"K0.VU+B%MT;'&<=B#UZ@9P<9Q1*G*.H\/F&&Q7NQ>O9G>>#_`(J---#I M_B(J&=B%O^%7)Z!U```ZC<..F1U:O5:^4*]=^%'BR:YW^'[^?>8X]UFSD9VC M[T>2I4445T'SI\S>*?^1NUK M_K_G_P#1C5DUK>*?^1NUK_K_`)__`$8U6_`^F6>L>,;"POX?.MI?,WIN*YQ& MQ'((/4"N"UY6/OHU%3PZF]DK_8:3LTU\O\FSQ>SO[S3IC- M8W<]K*R[2\$A1B.N,@].!^5>L>$OBM'=-'8^(0L4S,J)=HNV,\=9.?E.1U'' M/10,UY[XC\'ZQX793?PJT#MM2XA;=&QQG'8@]>H&<'&<5@U"E*#.NMA\/C:= M]^S1]7T5YA\*?%K74)\/7TK--$I>TD=QR@Q^[',]`HKT^NR,E)71\= MBL-/#U73D9GB+25USP]?Z:0I:>$B/>Q"AQRA)'.`P!_#O7S-+%)!,\,T;1RQ ML5='&&4C@@@]#7U97A/Q4T-M,\4F^1%6VU!?,7:H4!U`#C`/)Z,3@9+]\&LJ M\=.8]?(L1RS=%]=5Z_\`#?D<-1117*?3A1110![7\*?$ZZAI)T2X=FN[-2T1 M()W0Y&.O/&* M^D]'U:UUS2;?4K,L8)URN]<,""001Z@@CTXXS771G=69\CG&#]C5]K'X9?G_ M`%^I>HHHK8\<****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH` M****`"L#QK_R*-]_VS_]&+6_6!XU_P"11OO^V?\`Z,6@#S'0O^1ATW_KZB_] M#%>VUXEH7_(PZ;_U]1?^ABO;:;`****0!1110`4444`%%%%`!7SM\0KF&[\> M:K)`^]%D6,G!'S(BJPY]&4BOHFOEB_O)-1U&ZOIE59;F9YG"#"@L23C/;FL* M[T2/>R"%ZLY]E;[_`/ABO1117*?4!115[1K./4==T^QF9EBN;F.%RAPP#,`< M9[\T"E)13;Z'T=X3DY2?XG>/9M^SQ)'G.=V1NS[?>Q^ M%01^%<]5"/=;&SAT^QAM(%Q%"@5>!D^ MYQW/4^YJQ38Y$EC62-U='`964Y!!Z$&G5(PHHHH`****`"BBB@#EOB!6%J`V^.-Y">V&(`_]`/Z5QEI;/>7D%K& M5#S2+&I;H"3@9_.FA$;QO&P5T920&`88X(R#^((-=+X!NO(\3I'LW?:(GCSG M&W`W9]_NX_&CQ];?9_$[R;]WVB)),8QMP-N/?[N?QK&T:Z%CK5E):[_R,.I?]?4O_H9HT+_D8=-_Z^HO_0Q1 MKO\`R,.I?]?4O_H9HT+_`)&'3?\`KZB_]#%4(]MHHHJ1F9KNA6NO6)@G&V1< MF*8#YHS_`%'J._UP1XS/!);7$L$R[98G*.NA!KP2O7/!5^;_PS`'+%[-?\` MD4;[_MG_`.C%K?K`\:_\BC??]L__`$8M(#R&O3OAS_R+UQ_U]-_Z`E>8UZ=\ M.?\`D7KC_KZ;_P!`2FQ'7T444AA1110!R'Q&_P"1>M_^OI?_`$!Z\QKT[XC? M\B];_P#7TO\`Z`]>8TT(]>\%?\BC8_\`;3_T8U;]8'@K_D4;'_MI_P"C&K?I M#"BBB@`HHHH`\A\:_P#(W7W_`&S_`/1:U@5O^-?^1NOO^V?_`*+6L"J$>^T4 M45(PKRWQOH$>E7T=W:1;+2XSE5^ZDG<#C`!'(&>QZ`5ZE6%XPL!J'AFZ&%WP M#ST+$C&WD]/]G M@_#21S'J49=BBF-@N>`3NR<>^!^0IL1WE175S#96DUU@J6N`^+>K+9^%H]/4KYM_,`5923L0AB0>@.[8.>Q/X1*7*KG1AJ+KUHTUU M?_#GC^NZO-KNN7>ISC:]Q)N"\'8HX5<@#.%`&<ZU-%CSL6]NQW`E0.$P[E%;:)?D>A:)HECX?TN/3]/BV0IR6/+2-W9CW)_P`P`!6A1 M17#_P#HR.O;:\2^#O\`R-UW_P!>#_\`HR.O;:NC\!Q9U_O3]$%?,WBG M_D;M:_Z_Y_\`T8U?3-?,WBG_`)&[6O\`K_G_`/1C5-?9'3D'\2?H:WPT_P"2 M@Z7_`-M?_13U]!U\^?#3_DH.E_\`;7_T4]?0=.A\)EGO^\Q_PK\V%5[ZQM=3 ML9K*]@6:VF7:\;="/Z'N".0>:L45L>,FT[H^8-=TB;0M3:&P!O4 M\JV`3C*D'&>,TW1M2DT?6;/48MQ:VF60JK["X!Y7/8$9!]C7>?&6SD37=.OB MR^5-;&%0#\P*,2<^W[P?K7FM<,ERRLC[O"U?K.&C*75:_DSZOHK)\+?\BCHO M_7A!_P"BUK6KM3NCX6<>63CV/F;Q3_R-VM?]?\__`*,:M;X:?\E!TO\`[:_^ MBGK)\4_\C=K7_7_/_P"C&K6^&G_)0=+_`.VO_HIZXH_&O4^WK?[E+_"_R/H. MBBBNX^&*FJ:=;ZOI=SI]TNZ"XC*-P"1GH1D$9!P0>Q`KYKUW2)M"UR[TR<[G MMY-H;`&]3RK8!.,J0<9XS7T_7BGQAL6@\2VEZL"I%Z.C/Z:M"?75&M6)XL\.P^)]`FL).)A M^\MWW%0LH!"DX!XY(/!X)[X-;=%=#5U9GSU.;B[\M>$DSPYY_BSCH!D%Q$<1252/7\PHHHJ3H"NW^'/C#_`(1W5#8W7.GWLBAF9\"!^@?DXQR- MWL`<\8/$44XR<7=&5>C"O3=.>S/J^BO./A?XQ_M*T70K^2);FVC5;4]#+&!] MW'3*@#W([<$GT>NZ,E)71\+B-?^11OO M^V?_`*,6@#S'0O\`D8=-_P"OJ+_T,5[;7B6A?\C#IO\`U]1?^ABO;:;`**** M0!1110`4444`%%%%`&?KUS-9>'=3NK=]D\%I+)&V`=K*A(.#QU%?,%?0WQ'E MDA\`ZJT4C(Q6-25.#@R*"/H02#[&OGFN6N]4CZG(86HSEW?Y+_@A1116![H5 MUGPVM?M7CS3MT'G1Q;Y7RFX)A#M8^F&VX/KCO7)UZ)\'(I#XHO9A&QB6R96< M#Y02Z$`GU.T_D?2KIJ\DF<]J\;DC>*1HY$9'0E65A@@CJ"*:$>J>!M7_`+1T,6TAS/9XC/'5 M/X#TQT!'_`,L0'4]0%)6=(R(ESGY=H`8#/^ MUNH\'6HN_%-F'B9TC)E;&?EV@E2ZD"AYI&D8+T!)R_'E1+'MQUW'.<^VS]:8BU\2;4F.PO%B7`+Q/)QGG!4>IZ-].?6 MO/J]8\>6R3^%II&+`P2)(N.YSMY_!C7D]"`]QTJ\_M#2;2[+(6FB5G\L_*&Q M\P'T.1^%7*YCP#=>?X82/9M^SRO'G.=V3NS[?>Q^%=/2&%%%%`'B6N_\C#J7 M_7U+_P"AFC0O^1ATW_KZB_\`0Q1KO_(PZE_U]2_^AFC0O^1ATW_KZB_]#%4( M]MHHHJ1A6-XKLDOO#-\C;08HS,K%!5V_PVNMFH7UIL MSYD2R;L]-IQC'OO_`$KC)X)+:XE@F7;+$Y1USG!!P1Q6[X'D=/%MHJNRAQ(K M`'&X;"<'UY`/X4Q'KE8'C7_D4;[_`+9_^C%K?K`\:_\`(HWW_;/_`-&+2&>0 MUZ=\.?\`D7KC_KZ;_P!`2O,:].^'/_(O7'_7TW_H"4V(Z^BBBD,****`.0^( MW_(O6_\`U]+_`.@/7F->G?$;_D7K?_KZ7_T!Z\QIH1Z]X*_Y%&Q_[:?^C&K? MK`\%?\BC8_\`;3_T8U;](84444`%%%%`'D/C7_D;K[_MG_Z+6L"M_P`:_P#( MW7W_`&S_`/1:U@50CWVBBBI&%9^N_P#(O:E_UZR_^@&M"LWQ!(D?AW4F=U4& MVD4%CCDJ0!^)(%`'BE=?\.?^1AN/^O5O_0TKD*[?X;6V_4+Z[WX\J)8]N.NX MYSGVV?K3$>C5XI\8;]I_$MI9+,KQ6UL&,:X)1W8YSWR55#@]L'O7M=?.?CZ\ MCOO'6K31*P59A"0PYS&H0_AE3CVK"N_=/:R.GS8ER[+_`(!SE?3/AC3/['\, M:;8&'R9(H%\U-V[$A&7YR?XBW3CTXKYTT:SCU'7=/L9F98KFYCA_-?4-106[.O/ZFD*?J_Z_$****Z3YL****`"BBB@`KY0KZOKY0KGQ'0^CX? M_P"7GR_4]"^#O_(W7?\`UX/_`.C(Z]MKQ+X._P#(W7?_`%X/_P"C(Z]MJZ/P M'%G7^]/T05\S>*?^1NUK_K_G_P#1C5],U\S>*?\`D;M:_P"O^?\`]&-4U]D= M.0?Q)^AK?#3_`)*#I?\`VU_]%/7T'7SY\-/^2@Z7_P!M?_13U]!TZ'PF6>_[ MS'_"OS84445L>*>/_&>\C?4=*L0K>;##),Q(^4AR`,>_[L_I7F%=#XU\0?\` M"2>)[F\1LVR?N;;C_EFI.#T!Y)+<\C=CM6=H6D3:[KEIID!VO<2;2V`=BCEF MP2,X4$XSSBN&;YIZ'W.#A]7PL5/2RN_+JSZ)\+?\BCHO_7A!_P"BUK6HHKM6 MB/B)RYI.7<^9O%/_`"-VM?\`7_/_`.C&K6^&G_)0=+_[:_\`HIZR?%/_`"-V MM?\`7_/_`.C&K6^&G_)0=+_[:_\`HIZXH_&O4^WK?[E+_"_R/H.BBBNX^&"O M'?C->^9J^F6'EX\F!IM^[KO;&,>WE_K[5[%7S=XRUQ?$/BF]OHF9K;<(X-S$ MC8HP"`0,`\MC'!8UC6=HV/8R2DYXCGZ17YZ?YF#7TYXAKYV\.Z2VN>(;#30&*SS`2;&`8(.7()XR%!/X=Z^G*F@MV=>? MU%[E/KJPHHHKH/G"IJFG6^KZ7`0?4=QD'2G/E?D>=F M6!6*I^[\2V_R/I:BJFEZC;ZOI=MJ%JVZ"XC#KR"1GJ#@D9!R".Q!JW7:?%R3 MBVGN%%%%`@HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"L#QK_R* M-]_VS_\`1BUOU@>-?^11OO\`MG_Z,6@#S'0O^1ATW_KZB_\`0Q7MM>):%_R, M.F_]?47_`*&*]MIL`HHHI`%%%%`!1110`4444`<-\6;R2U\%&%%4K=7,<+EA MR`,OQ[Y0?AFO":]M^,7_`"*-I_U_I_Z+DKQ*N2M\1]?DB2POS84445B>N%>L M?!7_`)CG_;#_`-J5Y/7M?P]F$:B5KUE9P/F("(0"?0;C^9]:UH_&>9 MG$K822[V_,]$HHHKL/C`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KSOQ[X?$$@U>U15CD(6X M15/#'/SGMSP#TYQU)KT2HYX([FWE@F7=%*A1USC((P1Q0!X-75^"O$?]E7@L M;ET6RG?)=N/+?&,Y]#@`YZ=>.VIA\/R3M$JF>=BK\990`!^1#<'W]:\OKVCPS;):^&=.C0L08%D.[U? MYC^I--B+>I6SWFEWEK&5#S0/&I;H"5(&?SKPRO?:\2URR_L[7+VT$?EI'*WE MKNSA#RO/^Z10AG6_#:Z`DO[-I6R0DJ1\XXR&/H.J_IZ5Z!7D?@BZ-KXIMAYJ MQI,&B?=CYLC('/JP6O7*&`4444@/$M=_Y&'4O^OJ7_T,T:%_R,.F_P#7U%_Z M&*-=_P"1AU+_`*^I?_0S1H7_`",.F_\`7U%_Z&*H1[;1114C"BBB@#Q+7?\` MD8=2_P"OJ7_T,T[P_(\?B+361V4FYC4E3C@L`1^()%6?%\$=OXKOTB7:I=7( MSGEE#$_F3530O^1ATW_KZB_]#%4(]MK`\:_\BC??]L__`$8M;]8'C7_D4;[_ M`+9_^C%J1GD->G?#G_D7KC_KZ;_T!*\QKT[X<_\`(O7'_7TW_H"4V(Z^BBBD M,****`.0^(W_`"+UO_U]+_Z`]>8UZ=\1O^1>M_\`KZ7_`-`>O,::$>O>"O\` MD4;'_MI_Z,:M^O#H-6U*VA6+J*)?NI',RJ._`!J3^W=7_`.@K??\`@0_^ M-%AGMM%>)?V[J_\`T%;[_P`"'_QH_MW5_P#H*WW_`($/_C18#VVBJ.C2/+H6 MGR2.SN]M&S,QR22HR2:O4@/(?&O_`"-U]_VS_P#1:U@5O^-?^1NOO^V?_HM: MP*H1[[1114C"N.^(.JI;Z4FFKM,MT0S#KM13G/7C)`QQV:NAU;6K'1;<37LV MW=G8BC+.0,X`_J>.1S7D&KZI/K&I2WD[-ER=B$Y\M<\*/I^O7O30%&O3/AW8 M&WT>>]8,#=287D$%4R`?;DL.?05YW8VVV- MG#I]C#:0+B*%`J\#)]SCN>I]S0Q%BOF;Q3_R-VM?]?\`/_Z,:OIFOE6ZN9KV M[FNKA]\\\C22-@#\`V<=]XZTF&5F"K,9@5/ M.8U+C\,J,^U?1E?/GPT_Y*#I?_;7_P!%/7T'3H?"99\W]8BO+]6%%5-4O?[- MTB]O_+\S[-`\VS=C=M4G&>V<5YG_`,+J_P"I?_\`)S_[76LIQCN>=A\%7Q"; MI1O;S7ZGJ]%>4?\`"ZO^I?\`_)S_`.UT?\+J_P"I?_\`)S_[74^UAW.C^R<9 M_)^*_P`SU>BN(\'?$+_A+-7EL/[+^R^7`9M_VC?G#*,8VC^]^E=O5QDI*Z.* MM0J4)\E1685\H5]7U\H5AB.A[W#_`/R\^7ZGH7P=_P"1NN_^O!__`$9'7MM> M)?!W_D;KO_KP?_T9'7MM71^`XLZ_WI^B"OF;Q3_R-VM?]?\`/_Z,:OIFOF;Q M3_R-VM?]?\__`*,:IK[(Z<@_B3]#6^&G_)0=+_[:_P#HIZ^@Z^5;:ZN+*X2X MM9Y8)TSMDBXNIXH($QNDE<*JY.!DGCJ0*\?\>_$==5A;2M#E863K MBXN=I5I0?X`#@A?7N>G3[WG5S=7%[HBQTZ-7E"[W+N%5$R`6.>PW#ID^U.55RT1&&RFCAG[6M*]ODD9E>V_#'P M=<:%;RZKJ,?EWEU&$CA.0T4>$_AC8Z#<0ZA?S?;;^/Y MD7;B*)L#D`\L0:1JQ]C1VZL****W/!/F;Q3_R- MVM?]?\__`*,:M;X:?\E!TO\`[:_^BGK)\4_\C=K7_7_/_P"C&K.MKJXLKA+B MUGE@G3.V2)RK+D8.".>A(K@O:5S[UTW4PW(NL;?>CZJJO>7]GIT(FOKN"UB9 MMH>>0(I/7&2>O!_*OF[_`(2GQ#_T'=3_`/`N3_&LZYNKB]N'N+J>6>=\;I)7 M+,V!@9)YZ`"MW7[(\.&02O[\]/)'HOCWXCKJL+:5HHBQTZ-7E"[W+N%5$R`6.>PW#ID^U>P>$_AC8Z#< M0ZA?S?;;^/YD7;B*)L#D`\L0A*OA["BBBJ,`HHHH`\=^*?@_['-HY%R1N5A@C(YZ&OG;QCX7F\+:X]KB5[.3YK:=P/G M7C(R.,J3@].QP`17+6A9\R/JLGQWM8^PF_>6WFO^`<]1116![@4444`=C\/_ M`!C_`,(QJC0WDDITNXXD5>1$_&),=3P,$#J/7`%>]Q2QSPI-#(LD4BAD=#E6 M!Y!!'45\IUZK\,/&TGG1^']4G4Q%=ME+(WS`\`19[C^[GIC'.0!O1J6]UG@9 MOE_.G7IK5;_YGK5%%%=1\P%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`5@>-?\`D4;[_MG_`.C%K?K`\:_\BC??]L__`$8M`'F.A?\`(PZ;_P!? M47_H8KVVO$M"_P"1ATW_`*^HO_0Q7MM-@%%%%(`HHHH`****`"BBB@#RCXU? M\P/_`+;_`/M.O)Z]8^-7_,#_`.V__M.O)ZXJOQL^URG_`'.'S_-A11169Z(5 M[;\'?^11N_\`K_?_`-%QUXE7O?PLLX[7P+;S(S%KJ:29PQX!#;./;"#\_;K7CE]9S:??36DZXEA,O#O M]L6(NH.+NV1BJANW@9SZ>Y/KD-`>5QR/%(LD;LCH0RLIP01T(->P>%M= M77-)61SBYAQ'."1DG'WL#H#].N1VKQVM+0M5?1M8@O%W%%.V51_$AZC&1GU& M>X%`CVNBHX)X[FWBGA;=%*@=&QC((R#S4E(85YO\2+EVU2SM2%V1P&0'OEF( M/_H`_6O2*\;\67*77BG4)$#`"01G=ZH`I_4&F@,RTMGO+R"UC*AYI%C4MT!) MP,_G7N]>/^#K47?BFS#Q,Z1DRMC/R[02I./]K;7L%#`*\K^(%LD'B8R*6)G@ M21L]CRO'X**]4KAOB3;.UG870*[(Y'C([Y8`C_T`_I0@.#L+K[%J%M=[-_D2 MK)MSC=M(.,]NE>ZUX%7M7AR\^W^';"X+.S&(*[2'+,R_*Q/KD@FA@:=%%%(# MQ+7?^1AU+_KZE_\`0S1H7_(PZ;_U]1?^ABC7?^1AU+_KZE_]#-&A?\C#IO\` MU]1?^ABJ$>VT445(PHHHH`\?\92))XMOV1U8`HI*G/(101^!!%4M"_Y&'3?^ MOJ+_`-#%&N_\C#J7_7U+_P"AFC0O^1ATW_KZB_\`0Q5"/;:P/&O_`"*-]_VS M_P#1BUOU@>-?^11OO^V?_HQ:D9Y#7IWPY_Y%ZX_Z^F_]`2O,:].^'/\`R+UQ M_P!?3?\`H"4V(Z^BBBD,****`.0^(W_(O6__`%]+_P"@/7F->G?$;_D7K?\` MZ^E_]`>O,::$;%EX7UG4;..[M+/S(),[6\U!G!(/!.>H-3_\(5XA_P"@?_Y& MC_\`BJ[_`,%?\BC8_P#;3_T8U;]%QGD/_"%>(?\`H'_^1H__`(JC_A"O$/\` MT#__`"-'_P#%5Z]11<"GI,$EMH]C!,NV6*WC1USG!"@$<50^-?^1NO MO^V?_HM:P*W_`!K_`,C=??\`;/\`]%K6!5".O_X6-J__`#[6/_?#_P#Q50W/ MQ`UN>,+&;:W(.=\462?;YB1^E8W]A:O_`-`J^_\``=_\*JW-I6!R M-P65"I(]<'Z&D`V>>:YF::>5Y96^\\C%F/;DFFQQO+(L<:,[N0JJHR23T`%- MKUSPEINE6^E0WVGQ-ON(_GDD;<_4Y7.`.#QP!G`/-`$/A'PO_8<)NKDYOIDV MLH/RQKP=ON>!D^W'J>GHHI#"OE6ZMIK*[FM;A-D\$C1R+D':RG!&1QU%?55? M,WBG_D;M:_Z_Y_\`T8U<]?9'T&02?/./DC6^&G_)0=+_`.VO_HIZ^@Z^=OA[ M*?^1NUK_K_G_P#1 MC5A4I\BW/>P&9?6Y./+:WG?]$=9\'?\`D;KO_KP?_P!&1U[;7B7P=_Y&Z[_Z M\'_]&1U[;6]'X#P\Z_WI^B"OE"OJ^OE"HQ'0[>'_`/EY\OU/0O@[_P`C==_] M>#_^C(Z]MKQ+X._\C==_]>#_`/HR.O;:NC\!Q9U_O3]$%?,WBG_D;M:_Z_Y_ M_1C5],U\S>*?^1NUK_K_`)__`$8U37V1TY!_$GZ$.AZ/<:_K$&F6KQ)//NVM M*2%&U2QS@$]`>U=#<_"[Q7!>&SU2ERUXV\U_D0>*^6Y8I()GAFC:.6-BKHXPRD<$$'H M:Z[X>>+)O#^N16L\^-+NY`LRN1MC8\"0$D!<'&3_`'>QP,*G5:=F:9CE<*D' M5HJTM_7_`(/YGOU%%%=1\J?,WBG_`)&[6O\`K_G_`/1C5#H>CW&OZQ!IEJ\2 M3S[MK2DA1M4L0>*L5X#\//%DWA_ M7(K6>?&EW<@697(VQL>!("2`N#C)_N]C@8]^KIISYU<^8Q^"EA*O+NGL%%%% M6<04444`%8WB?PY:^*-&?3[EVC(8212KUC<`@''<A['!&S12:35F5"P-#-NH/]1W!'!'-5Z]S^)7@[^W=/.J641@Y&/#*XIP<78^XP.,CBJ7.M^J"BBBH.P****`/= MOAUXT7Q#8C3+L,-2M(02Y)83(,+O)/\`%R,YZDY'4@=S7RQ8W]UIE]#>V4S0 MW,+;DD7J#_4=B#P1Q7T9X7\46/BG2Q=6IV3)A9[=CEHF_J#S@]_8@@==*IS* MSW/DLVR_V$O:TU[K_!_\$VZ***V/&"BBB@`HHHH`****`"BBB@`HHHH`**** M`"BBB@`K`\:_\BC??]L__1BUOU@>-?\`D4;[_MG_`.C%H`\QT+_D8=-_Z^HO M_0Q7MM>):%_R,.F_]?47_H8KVVFP"BBBD`4444`%%%%`!1110!Y1\:O^8'_V MW_\`:=>3UZQ\:O\`F!_]M_\`VG7D]<57XV?:Y3_NOGROH/X:?\D^TO_MK_`.C7K:A\1XN>_P"[1_Q+\F=91117 M6?)A1110`4444`>)?\+B\0_\^>F?]^I/_BZ/^%Q>(?\`GSTS_OU)_P#%UY[1 M7#[2?<^Y_L["_P`B/0O^%Q>(?^?/3/\`OU)_\71_PN+Q#_SYZ9_WZD_^+KSV MBCVD^X?V=A?Y$>A?\+B\0_\`/GIG_?J3_P"+H_X7%XA_Y\],_P"_4G_Q=>>T M4>TGW#^SL+_(CT+_`(7%XA_Y\],_[]2?_%T?\+B\0_\`/GIG_?J3_P"+KSVB MCVD^X?V=A?Y$>A?\+B\0_P#/GIG_`'ZD_P#BZ/\`A<7B'_GSTS_OU)_\77GM M%'M)]P_L["_R(]"_X7%XA_Y\],_[]2?_`!=>VU\H5]7UO1DY7N>'G6&I4>3V M<;7O^@4445N>$%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!YCXZ MT#[!??VE`N+:Y?\`>9;)64Y)X]#U[\YZ<5R%>WZQ8#5-'NK(A298R$W$@!NJ MDX]"`:\2DC>*1HY$9'0E65A@@CJ"*:$>C?#O5#/I\^FR,N;<[XAD9*L3D8]C MW_VA[5VM>2^!9Y(O%=LB-A9D='&.HVEL?FH_*O6J&,CGGCMK>6>9ML42%W;& M<`#)/%>$22/+(TDCL[N2S,QR23U)->Q>++E[7PMJ$B!23&(SN]'(4_H37C=" M`V/#FN?\(_J$EW]F\_?$8]N_;C)!SG!]*Z?_`(69_P!0C_R9_P#L*X"B@1W_ M`/PLS_J$?^3/_P!A67K_`(RCU[2VLWTSRV#ATD\_=M([XVC/!(_&N4HH`*]0 M^'MT9O#\D#2JQ@G8*G&54@$?F2W)]_2O+Z[?X;76S4+ZTV9\R)9-V>FTXQCW MW_I0P/1J***0SQ+7?^1AU+_KZE_]#-&A?\C#IO\`U]1?^ABC7?\`D8=2_P"O MJ7_T,T:%_P`C#IO_`%]1?^ABJ$>VT445(PHHK*\37*6OAG49'#$&!HQM]7^4 M?J10!X[=W+WEY/=2!0\TC2,%Z`DY./SK;\#QN_BVT949@@D9B!G:-A&3Z0UZ=\.?\`D7KC_KZ;_P!`2O,:].^'/_(O7'_7TW_H M"4V(Z^BBBD,****`.0^(W_(O6_\`U]+_`.@/7F->G?$;_D7K?_KZ7_T!Z\QI MH1Z]X*_Y%&Q_[:?^C&K?K`\%?\BC8_\`;3_T8U;](84444`%%%%`'D/C7_D; MK[_MG_Z+6L"M_P`:_P#(W7W_`&S_`/1:U@50CWVN,^(>F+/I<6HI'^]MW".P MP/W;>O#5Z#\.M5=UN-*DW,$ M'G1'KM&0&'7CD@@`=VKAKZSFT^^FM)UQ+"Y5N#@^XSV/4>QJ;1[\Z7K%K>@L M!%("^T`DKT8#/J"13$>WT4V.1)8UDC=71P&5E.00>A!IU(85\X^.K+^S_&^K MP^9YFZUD=3EQ#CW1R&@W,-EXBTRZN'V007<4DC8)VJK@DX'/05]/U\H M5]/Z#J/]KZ!8:@6B9[B!'?RCE0Y'S`VUXE\'?^1NN_P#KP?\` M]&1U[;5T?@.+.O\`>GZ(*^9O%/\`R-VM?]?\_P#Z,:OIFOF;Q3_R-VM?]?\` M/_Z,:IK[(Z<@_B3]#6^&G_)0=+_[:_\`HIZ^@Z^?/AI_R4'2_P#MK_Z*>OH. MG0^$RSW_`'F/^%?FPHHHK8\4\:^+^AK:ZM:ZS"C;;Q?+G(4E0Z`;23G`)7C' M'W">>:\UKW#XOQL_@^!@5`CO48[G`)&QQP#U/(X'.,GH#7A]<=56F?:914=3 M"QOTT/I'P5J4FK^#M+O)MWFF'RW9WWLY0E"Q)[G;G\>];UNJ!CD*-B'`]!DD_4FN_KJ@[Q3/E,;35/$3BMKL^9O%/\`R-VM?]?\_P#Z M,:M;X:?\E!TO_MK_`.BGK)\4_P#(W:U_U_S_`/HQJUOAI_R4'2_^VO\`Z*>N M./QKU/L*W^Y2_P`+_(^@Z***[CX8*\:^+^AK:ZM:ZS"C;;Q?+G(4E0Z`;23G M`)7C''W">>:]EKSWXQ?\BC:?]?Z?^BY*SJJ\&>CE524,7&W70\2KT^P^,4EI MIUK;3:.UQ+#"D;S/>?-(0`"QRAY/7J:\PHKDC)QV/K<1A:.(2557MZ_H?5]% M%%=Y\"%%%%`!1110`5X[\4_!_P!CN'\16?\`J)Y`+F)4_P!6Y'W^!C#$%M9.S:;"Z9WM2IY4`C*$$DY7(&>XP>N0.6KA::=F?<4JL*L%4@]&%%% M%(T"M[PEXGNO"^LQW,3L;61E6ZA`R)$SS@9'S#)(.>OL2#@T4TVG=$5*<:D' M":NF?4]C?VNIV,-[93+-;3+N21>A']#V(/(/%6*\4^&'C"33M1CT.^F9K&Y; M;;@KN\J5B,`'LK9/KR0>,L:]KKMA/F5SXC&X26%JN#VZ>@44459QA1110`44 M44`%%%%`!1110`4444`%%%%`!6!XU_Y%&^_[9_\`HQ:WZP/&O_(HWW_;/_T8 MM`'F.A?\C#IO_7U%_P"ABO;:\2T+_D8=-_Z^HO\`T,5[;38!1112`****`"B MBB@`HHHH`\H^-7_,#_[;_P#M.O)Z]8^-7_,#_P"V_P#[3KR>N*K\;/MVUXUX6MOM?B?3X]^S;*),XS]P;L?C MMQ^->RT,#B/B3=;-/L;39GS)6DW9Z;1C&/??^E>'+%KNPLYIGC\P MNT*L2&)89)&>`0*U?["TC_H%6/\`X#I_A5R"".VMXH(5VQ1($1J7EK&6*0SO& MI;J0&(&?RJ_X3N4M?%.GR.&(,AC&WU<%1^I%7/'EL\'BF:1BI$\:2+CL,;>? MQ4UST$\EM<13PMMEB<.C8S@@Y!YJA'O-%-CD26-9(W5TS#=MP$C#`%V/0#/Y_0$UXU?7DVH7TUW.V99G+-R<#V&>PZ#V%-`5Z]<\% M6!L/#,!<,'N"9V!(/7`7&/50I_&O-="TI]9UB"S7<$8[I6'\*#JO M=1C@?P^]<17M7B'3%U;0[JU\O?+L+PXP#Y@Y7!/3/3Z$UXK30CU3P'J@OM!% MJS,9K,[#N).5.2I_F,?[-=37D/@W4O[.\26^5W)<_P"CM@9(W$8(Y_O`?AFO M7J3&%>>_%[3/M7AB"_2'=)9SC<^[&R-Q@\9YRWE^_P"&:]"JO?V<>HZ==6,S M,L5S"\+E#A@&!!QGOS4R7,FC?"UO85HU.S/EBO:/A#K:W.ASZ/++F>TD,D2' M:/W3<\=SAMV2>FY>>P\BU33KC2-4N=/NEVSV\A1N"`<=",@'!&"#W!%6_#>O MW'AK7(-2MUW[,K)$6*B1#U4X_,=<$`X.*XX2Y9:GV6.PZQ6'<8[[H^F:*KV- M_:ZG8PWME,LUM,NY)%Z$?T/8@\@\58KN/AVFG9A7S-XI_P"1NUK_`*_Y_P#T M8U?3-?,WBG_D;M:_Z_Y__1C5A7V1[V0?Q)^AUGP=_P"1NN_^O!__`$9'7MM> M)?!W_D;KO_KP?_T9'7MM51^`YLZ_WI^B"OE"OJ^OE"HQ'0[>'_\`EY\OU/0O M@[_R-UW_`->#_P#HR.O;:\2^#O\`R-UW_P!>#_\`HR.O;:NC\!Q9U_O3]$%? M,WBG_D;M:_Z_Y_\`T8U?3-?,WBG_`)&[6O\`K_G_`/1C5-?9'3D'\2?H:WPT M_P"2@Z7_`-M?_13U]!U\^?#3_DH.E_\`;7_T4]?0=.A\)EGO^\Q_PK\V%%%, MEEC@A>::18XHU+.[G"J!R22>@K8\4\[^,ES"GAVPM6?$\EWYB+@\JJ,&.>G! M=?SKQ>NF\<^*&\4:^\L9Q96^8K906PRY^_@]"W'8<`#MFNY_":SDM?!0F=E*W5S),@4\@#"< M^^4/X8KN:S/#NDKH?AZPTT!0T$($FQB5+GER"><%B3^/:M.NN*M%(^/Q555: M\YK9MGS-XI_Y&[6O^O\`G_\`1C5K?#3_`)*#I?\`VU_]%/63XI_Y&[6O^O\` MG_\`1C5K?#3_`)*#I?\`VU_]%/7''XUZGV-;_53$*?2.O^1S- M%/BBDGF2&&-I)9&"HB#+,3P``.IKWBP^&/AN/3K5+[35ENUA03R)<2[6?`W$ M?,."<]A7-"#GL?2XS'4L(E[2^O8[2BBBNX^%"BBB@`HHHH`****`,SQ!H=KX MAT:XTZZ12)%)CD9K7&FW@43P-AMC94@@$ M$'T((/KSSBOJ&N.^('@[_A)]+6:SCB&J6_,;-P94YS'GIU.03T/IDFL:M/F5 MUN>OE6/^KS]G-^Z_P??_`#/`:***Y#Z\****`"O=OAIXM;7M):PO)6?4;-1N MDD<%ID).&]21P">>Q)):O":O:/JUUH>K6^I6943P-E=ZY4@@@@CT()'KSQBK MISY7G'& M:O5W;GP\HN+<9;H****!!1110`4444`%%%%`!1110`4444`%8'C7_D4;[_MG M_P"C%K?K`\:_\BC??]L__1BT`>8Z%_R,.F_]?47_`*&*]MKQ+0O^1ATW_KZB M_P#0Q7MM-@%%%%(`HHHH`****`"BBB@#RCXU?\P/_MO_`.TZ\GKV#XSV%%%%`!1110!XE_PIWQ#_`,_FF?\`?V3_`.(H_P"%.^(?^?S3 M/^_LG_Q%>VT5E[&!ZW]M8KNON/$O^%.^(?\`G\TS_O[)_P#$4?\`"G?$/_/Y MIG_?V3_XBO;:*/8P#^VL5W7W'B7_``IWQ#_S^:9_W]D_^(H_X4[XA_Y_-,_[ M^R?_`!%>VT4>Q@']M8KNON/GGQ+X"U3PMIT=]?7%G)%),(0('8MD@GNHX^4U MRU>V_&+_`)%&T_Z_T_\`1)5SU(J,K(^ARW$3Q%#VE3>["BBBLSO"OJ^OE M"OJ^NG#]3YSB#_EW\_T"BBBN@^<"BBB@`HHHH`****`"BBB@`HHHH`****`/ M*_$VHW>E^.+VYLIVAE`1<@`Y!C7@@\'\:V]+^(L$BJFJ6S1.2!YL`RG)ZD$Y M&!CIG//TK"\=6-U%XCN;MX'%M-LV2X^4G8!C/K\IXZ\5S%,1[;9:YI>H^6+2 M_@D>3.V/?ASC.?E//8]JL75_9V6S[7=00;\[?-D"[L=<9Z]17A5%%AG;^*_& M<=_;OI^EL_DOCS+@?+O&#E`",XZ<\=",8Z\116QH7AR^UZ8>0FRV5PLD[?=7 MOP.Y]AZC.,YIB.E^'>D$R3ZK/"P`'EV[L!@]=Q'?C`&?@5#:VL%C:QVU MM$L4,8PJ+V_SZTV_NOL6GW-WLW^1$TFW.-VT$XSVZ5(SR#Q-)M1D<*") MVC&WT3Y1^@%.\+6WVOQ/I\>_9ME$F<9^X-V/QVX_&L>NQ^'5J9=:N+DQ*R0P M8#G'RLQ&,=^0&Y_QIB/3****0PHHHH`X'XDV7_'C?K'_`'H9'W?BHQ_WW_G% M/@$$#8G7D$GGIST->7T4K`7M4U>]UBZ: M>\F9SDE4R=D>>RCMT'UQSFJ<<;RR+'&C.[D*JJ,DD]`!5K3]*OM5F,5C;/,P M^\5&%7KU)X'0]:],\->$(-#;[3.ZW%Z1@/MPL?'(7]>?3L.<@$WA+0/[#TO] M\N+R?#3X;(&,[5';@'\R>2,5OT44AA6!XU_Y%&^_[9_^C%K?K`\:_P#(HWW_ M`&S_`/1BT`>0UW?@OQ#I6DZ/-!?77E2M<,X7RV;C:HSP#Z&N$HJA'KW_``FO MA[_H(?\`D&3_`.)H_P"$U\/?]!#_`,@R?_$UY#12L!Z]_P`)KX>_Z"'_`)!D M_P#B:U[*]M]1LX[NTD\R"3.UMI&<$@\'GJ#7A5>O>"O^11L?^VG_`*,:@9G_ M`!&_Y%ZW_P"OI?\`T!Z\QKT[XC?\B];_`/7TO_H#UYC0A'HWA?Q1HVG>'+2T MN[SRYX]^Y?*_Z"'_D&3_XFO(:*+`>O?\)KX>_Z"'_D M&3_XFC_A-?#W_00_\@R?_$UY#118#VK3?$.E:M<-!8W7FRJA0^-?\`D;K[_MG_`.BUK`K?\:_\C=??]L__ M`$6M8%4(]]HHHJ1A7DOC;3&T_P`132K'M@NOWJ$9()/WN3WW9.!T!%>M5S'C MG2/[1T,W,8S/9YD'NG\8ZXZ`'_@.!UH0'E->T>&]4.KZ#;73LIFQLEP0?F'! M)QTSP<>]>+UV?P\U-H-4ETYY/W5PA=%.3^\7T[#*YS_NBFQ'I5%%%(9YG\4_ M!_VRW?Q%9_Z^","YB5/]8@/W^!G*@\Y_A'4;>?'*^KZ\B\<_#.9+A]2\.VV^ M%\M-9I@&,XR3&.X/]T<@]`0<#GJT_M(^CRG,HQ2H5G;L_P!#EO!?C2Z\*7Q5 M@TVFS-F>W!Y!Z;T]&_0C@]B/:-)\9^']9AB:VU.!)9&"""=Q'+O./EVGJ><< M9!/0FOFZBLX57'0]'&971Q,N?:7='U5A?! MW_D;KO\`Z\'_`/1D=>VUXE\'?^1NN_\`KP?_`-&1U[;6]'X#PLZ_WI^B"OE" MOJ^OE"HQ'0[>'_\`EY\OU/0O@[_R-UW_`->#_P#HR.O;:\2^#O\`R-UW_P!> M#_\`HR.O;:NC\!Q9U_O3]$%?,WBG_D;M:_Z_Y_\`T8U?3-?,WBG_`)&[6O\` MK_G_`/1C5-?9'3D'\2?H:'P^NK>R\;NDE<*JYB<#)/'4@5[1> M^.O#&G^7YVM6K;\X\@F;&,==@..O?K7SC16,*KBK(]7%Y93Q555)R:LK:?,] MPU;XMZ#9J5T^.?4)=H*E5,4><\@EAN!QSPI'3\/-?%'CG5O%#F.5_LUD,@6L M+$*PW9!?^^1@>W&0!DUS-6+.PO-1F,-C:3W4JKN*01EV`Z9P!TY'YT2J2EH5 MA\NPV&]]+5=7_5BO7I7PK\)->WPU^]B86ULW^BAD!65^06Y[+V('WN_RD5>\ M*?"?[MWXD_V@+%&_`%G4_4X'MSU%>J111P0I##&L<4:A41!A5`X``'05I3I. M]Y'G9EFL'!T:#O?=_P"0^BBBND^:/F;Q3_R-VM?]?\__`*,:M#X?75O9>.=. MN+J>*"!/-W22N%5CZ.O?'7AC3_+\[6K5M^<>03-C&.NP''7OUK!U;XMZ#9J5T^.?4)=H*E5 M,4><\@EAN!QSPI'3\/#Z*T=>70\ZGD>'CK)M_P!?UU.F\4>.=6\4.8Y7^S60 MR!:PL0K#=D%_[Y&![<9`&37,U8L["\U&8PV-I/=2JNXI!&78#IG`'3D?G7J' MA3X3_=N_$G^T!8HWX`LZGZG`]N>HJ%&4V=E2OAL#3MLNRW_KS*GPL\'_`&RX M3Q%>?ZB"0BVB9/\`6.!]_D8PI/&/XAU&WGV*F111P0I##&L<4:A41!A5`X`` M'04^NR$5%6/D,9BI8FJZDODNR"BBBJ.4****`"BBB@`HHHH`****`/'_`(K> M$EM9AXAL8E6&5@EW&B'ASG]X>P!X!Z""#U%?.GC'PO-X6UQ[7$KVHHHK`]P****`/1/A3XG;3]6.B7#JMI>,6B)`&V;`QSD<,! MC'/.W&,FO:Z^4*^CO!7B#_A)/#%M>.V;E/W-SQ_RT4#)Z`<@AN.!NQVKIH3O M[K/F<[PG+)5X[/1^O-?^11OO^V?_HQ:`/,="_Y&'3?^OJ+_`-#%>VUXEH7_ M`",.F_\`7U%_Z&*]MIL`HHHI`%%%%`!1110`4444`>>_&+_D4;3_`*_T_P#1 M)5[W\4[..Z\"W$SLP:UFCF0*>"2VSGVPY_'%>"5R5OB/K\DDGA;=FPHHH MK$]<*]E^#5Y&^A:C8A6\V&Y$S$CY2'4`8]_W9_2O&J]8^"O_`#'/^V'_`+4K M6C\:/,SB*>#D^UOS1ZO11178?&!1110`4444`%%%%`!1110`4444`>>_&+_D M4;3_`*_T_P#1)5[;\8O\`D4;3_K_3_P!%R5XE7'6^,^PR7_=5ZL****R/ M6"OJ^OE"OJ^NG#]3YSB#_EW\_P!`HHHKH/G`HHHH`****`"BBB@`HHHH`*** M*`"BBB@!LD:2QM'(BNC@JRL,@@]017.7O@31+R3>D MO2**+@<=8?#O3K=@U[<2W9!/R@>6A&.X!)Z\\$5UL$$-M"L,$211+]U(U"J. M_`%244`%5=1L4U+3YK.266))1M9HFVMC/(S[]#[$U:HH`Y#_`(5SI'_/S??] M]I_\36QH?ARS\/\`VC[))._G[=WFL#C;G&,`>IK7HH`****`"BBB@"&[MDO+ M.>UD+!)HVC8KU`(P%![GOWK9HHH`Y:[\!:7>7D]U)<7@>:1I&"NN`2#-#LO+;[)Y\B9^ M>=B^[.>J_=/7T_6M^B@".""&VA6&")(HE^ZD:A5'?@"I***`"BBB@`JGJFFP MZMITMC.SK%+C<8R`W!!XR#Z5EZ;#I.G16,#.T46=ID(+5$202`Q$`Y`([@^IK"_X5SI'_`#\WW_?:?_$UU]%`'(?\*YTC_GYO MO^^T_P#B:/\`A7.D?\_-]_WVG_Q-=?10!R'_``KG2/\`GYOO^^T_^)H_X5SI M'_/S??\`?:?_`!-=?10!A:+X3L-"O'NK66Y=WC,9$K*1@D'L!Z"MVBB@#G-4 M\%Z=JVHRWT\]TLLN-PC=0O``XRI]*I_\*YTC_GYOO^^T_P#B:Z^B@`HHHH`* M;)&DL;1R(KHX*LK#((/4$4ZB@#D/^%Z.NCCL M315H3=OO_,\H_P"%*_\`4P?^2?\`]LK5TSX0Z':^4]_<75](N=ZY$4;]<<#Y MACC^+J/3BO0J*2I070TGFF+DK.?Y+\D5-.TNQTBT6UT^UBMH%Q\L:XR<`9)Z MDX`Y/)JW116APN3D[O<*\]_X4[X>_P"?S4_^_L?_`,17H5%2XJ6YM1Q-6C?V M`M+\+:C)?6-Q>22R0F$B=U*X)![*.?E%=3113225D15JSJRYJCNP MKAK_`.%.A:CJ-U?37>HK+U@B@@3.V.)`JKD MY.`..I)J6BJ44MD<]2O5J_Q)-^K"BBBF9!1110!PU_\`"G0M1U&ZOIKO45EN M9GF<)(@4%B2<93IS5;_A3OA[_G\U/_O['_\`$5Z%14>SCV.Q9ABDK*;//?\` MA3OA[_G\U/\`[^Q__$5K6OPV\*6ODM_9GG21;3OFF=MY'=ESM.>XQCVQ7644 M*G%=!2Q^)DK.H_O(K:UM[*W2WM8(H($SMCB0*JY.3@#CJ2:EHHJSE;;=V%%% M%`@HHHH`****`"BBB@`HHHH`****`"L'Q;X8M?%&C26TJ*+J-6:UF)P8WQQD MX/RG`!&.GN`1O44FDU9ETZDJ%/^9DM$_NI>@O\`[JHP!_!3@_W>.IKR>N&<7%V/NL)B8XFDJD?GY,** M**DZ0KM_A?X@_L?Q.MG*V+;4=L+<=),_NST)ZDKV'S9/2N(HIQ?*[F5>C&M3 ME3ELSZOHK!\&ZXWB'PM97TK*USM,<^U@3O4X)(`&">&QC@,*WJ[T[JY\#4IR MIS<);K0****9`4444`%%%%`!1110`4444`%8'C7_`)%&^_[9_P#HQ:WZP/&O M_(HWW_;/_P!&+0!YCH7_`",.F_\`7U%_Z&*]MKQ+0O\`D8=-_P"OJ+_T,5[; M38!1112`****`"BBB@`HHHH`YSQ]9R7W@75H8F4,L(F)8\8C8.?QPIQ[U\YU M]2:I9?VEI%[8>9Y?VF!X=^W.W?:;HFK^)IWGC+2#.V2 MYN'.,XX!/)/``XSC(Z4P/9**Y#P-I>I:3]O@OX7B5O+>-2P9<_,"1@D9X&>_ M3VKA]2MGO/%MY:QE0\U\\:EN@)D(&?SH`]GHKS'_`(5SJ_\`S\V/_?;_`/Q- M=/X0\.7GA_[9]KD@?S]FWRF)QMW9SD#U%(#IZ*\8U*V>\\6WEK&5#S7SQJ6Z M`F0@9_.K=UX=\0^'FDN(A*J*,-/:2'[N,G.,,`,N45QGA#Q?)J M`M4O-4O+J.XLPDT[R*&=L@%B1G MY?>D!Z)17AW]FS?VQ_9>Y//^T?9]V3MW;MN>F<9]J[;P]X+U+2==MKZ>>U:* M+=N$;L6Y4CC*CUI@=W17D/C7_D;K[_MG_P"BUKT[7?\`D7M2_P"O67_T`T@- M"BO%-%T6YUV\>UM7B1TC,A,I(&`0.P/J*W?^%-+9[/P5IEK(5+PR11L5Z$B-@>+;RUC*AYKYXU+=`3(0,_G0![/17D-[H.O>&O,N@7CB M&$-Q:RD`@X.#C#`9P.1C./:NQ\(>+'UAGL[]HENU`,97CS1CGCID8SQZ].#2 M`ZVBBB@`HKR'QK_R-U]_VS_]%K4USX1\0Z/(+BW1I"@R);.0EESQ@#AOR'0_ M6G8#UBBO/_"?C.=[J/3M4D:42E4AGQE@W0*V.N?7KGKUR-'XC?\`(O6__7TO M_H#T@.OHKD/AS_R+UQ_U]-_Z`E;^N_\`(O:E_P!>LO\`Z`:`-"BO,?AS_P`C M#K?^AI1\1O\`D8;?_KU7_P!#>G8#TZBO*;KP1KVG;)X%2=DR^ZVD.Y". M01D`D^F,GBK7ACQG=VUY%::G.T]K(0@DD8;HB3U+'J.>@#T MZBL_0O\`D7M-_P"O6+_T`5R?CCQ/&&'Y)70;6:0'D!N MH`QCC&>>HQ0!Z-17DL/@;7)K'[2($1CC;`[A9&!QSCH.O0D'@\5WOAIY;'PA M;OJ(EB,$;F02J=R*K-CCKPH&!Z8H`W:*\CU37-5\3ZDUG;M*T$LA$-L@VY7/ M&['7H"220.>@IUSX-U[388KN.+S'&'Q;.6DB/&.!R3D_PYZ4[`>M5#DM(ASA: MMXGFFG23=MP'N+EVPQXPN<$DX_(?A2`]@CD26-9(W5T-K-(WE1R`3PJVY'4X^8#(YQ@@\'H#W%>M1R)+&LD;JZ.`RLIR"#T(- M`#J*\A\%?\C=8_\`;3_T6U>O4`%%>0^-?^1NOO\`MG_Z+6N_\:_\BC??]L__ M`$8M`&_17E?@/5#8Z\+5F40W@V'<0,,,E3_,8_VJ]4H`**\QT;_DI\G_`%]7 M/\GK3\0^"]2U;7;F^@GM5BEV[1([!N%`YPI]*`.[HKQ2YT6YM=>71W>(W!D2 M,,I.S+XQSC/<=JZ?3?`6J6>J6=U)<692&=)&"NV2`P)Q\OM3L!Z)15'6;HV. MBWMRLJQ/'`Y1VQPV/EZ\=<<5Y%H%T;+Q!83B58@)U#NV,!2<-G/3@GFD![71 M17(?$;_D7K?_`*^E_P#0'H`Z^BO/_AO?D27FG,6(($Z#`P.BMSUYROY'\?0* M`"BO,?AS_P`C#K?^AI5K4O`6J7FJ7EU'<682:=Y%#.V0"Q(S\OO3`]$H MKP[2]-FU;48K&!D667.TR$A>`3S@'TKMO#W@O4M)UVVOIY[5HHMVX1NQ;E2. M,J/6@#NZJVVI6%Y(8[6]MIW`W%8I58@>N`?<5Y;K.LW_`(KU5;6U65H&D_T> MVXXXQDX^A/).,GG%6I_A[K44+.CVLS#I''(0Q^FX`?K18#U*BN6\!27+:%/' M=/*7AN6B"RDY0!5^7!Z8YXKJ:0!1110`4444`%%%%`!1110`4444`%%%%`$5 MU;0WMI-:W";X)XVCD7)&Y6&",CGH:^:_$F@7'AK7)]-N&W[,-'*%*B1#T89_ M(]<$$9.*^F:\[^+>@QWF@QZR@59[%@KGH7C8@8Z9)#$$<@`%O6LJT;QOV/7R M?%.C7]F]I?GT_P`CQ2BBBN,^O"BBB@#TWX.ZOY.J7ND2/A+B,31!I,#>O!"K MW)4Y..R?E[%7S3X4U9=$\4Z=J#E5BBF`E9E+!48;6.!SD*Q(]_6OI:NN@[QL M?)9W1Y,0IK:2_%?T@HHHK8\8****`"BBB@`HHHH`****`"L#QK_R*-]_VS_] M&+6_6!XU_P"11OO^V?\`Z,6@#S'0O^1ATW_KZB_]#%>VUXEH7_(PZ;_U]1?^ MABO;:;`****0!1110`4444`%%%%`!7R]K-G'IVNZA8PLS16US)"A.KUO(6**Y5)X]N`&!4!FP.Y=7SGDGGO6%=:)GNY#4M6E# MNOR_XG:[I]],K-%;7,>_&+_D4;3_K_3_T7)7B5>V_&+_D4;3_ M`*_T_P#1)5QUOC/L,E_W5>K"BBBLCU@KZOKY0KZOKIP_4^!D^YQW/4^YKROPTPU3QO;SW**3+ M.\Y5<@!L,XQSV(%>N4V`5Y#_`,U!_P"XK_[5KUZO'Y)$B\>M)(ZHB:H69F.` M`)>230@/8**S_P"W=(_Z"MC_`.!"?XU:MKNVO(S):W$4Z`[2T3A@#Z9'U%(# MR?\`YJ#_`-Q7_P!JUZ]7D/\`S4'_`+BO_M6O7J;`\=U2"/P[XP<0KYD5K<), MB9QQPX7)STSC/XU[%7C^H./$WC%_LP8),GZ&O1/[=TC_H*V/_@0 MG^-#`P/B-_R+UO\`]?2_^@/1\.?^1>N/^OIO_0$H^(W_`"+UO_U]+_Z`]'PY M_P"1>N/^OIO_`$!*.@'(>-?^1NOO^V?_`*+6O7J\A\:_\C=??]L__1:UZ=_; MND?]!6Q_\"$_QH`T*\A_YJ#_`-Q7_P!JUZQ;7=M>1F2UN(IT!VEHG#`'TR/J M*\G_`.:@_P#<5_\`:M"`]><&O8*\Y^)-MLU"QN]^?-B:/;CIM.*>%MT4J!T;&,@C(/-25F>')X[CPWISQ-N46Z(3C'*C:1^8-:=(#R'QK_R- MU]_VS_\`1:UZ]7D/C7_D;K[_`+9_^BUKUZF!Y+XXT^.P\22&(_+>"M,NI`H>:2*1@O0$QL3C\ZQOB%/'+XD5$;+0VZHXQT M.6;'Y,/SK7\8026W@;2H)EVRQ/"CKG."(F!'%`BY\.?^1>N/^OIO_0$K?UW_ M`)%[4O\`KUE_]`-8'PY_Y%ZX_P"OIO\`T!*W]=_Y%[4O^O67_P!`-(9P/PY_ MY&&X_P"O5O\`T-*/B-_R,-O_`->J_P#H;T?#G_D8;C_KU;_T-*/B-_R,-O\` M]>J_^AO3ZB/3J\I\>V<-IXD+0KM^T1+,X``&XD@XQZ[<_4FN_O/%&BV5N9FU M""7'1('$C,<9Q@=.G4X'O7FSM>^,O$P(1E,I`PN6$$0XSR>W7MDGWH0SM?$$ M\ES\.//F;=++;P.[8QDED)/%9GPS_P"8I_VR_P#9ZW?&4:1>#;R.-%1$$:JJ MC``#K@`5A?#/_F*?]LO_`&>CH!WU>8_$;_D8;?\`Z]5_]#>O3J\Q^(W_`",- MO_UZK_Z&]"`[G3;E+/PE9W4@8I#8I(P7J0(P3C\J\V\,V;:]XJ1KI?-7>US< M'"@'G/(Z$%B`0!T-=O>77V3X;K)LW[M/CCQG'WU5<_ANS^%87PVMD:\O[HEM M\<:1@=L,23_Z`/UH`]$HHHI`%%%5[^Z^Q:?S?Y$32;CW5Z2H,49*;@2"W10<>I(%>=^`=,6]UQKJ6/=%:)O M&<8\P\+D'_@1XZ$"NS\:_P#(HWW_`&S_`/1BUB_#:V=;._NB5V22)&!WRH)/ M_H8_6@9W-NKK@?B9_S"_\`MK_[ M)2`G^'.G>58W6H.OS3.(XRR8.U>I![@DX^J_EV]8WA.V>U\+:?&Y4DQF0;?1 MR6'Z$5LT`>8_$.]\_7(K19-R6T0RNW&UVY//?Y=G^6Y_WB:\U\7027/C:Z@A7=+*\2(N<9)10!S7K5,#@_B18`QV>HJ%! M!,#G)R>K+QTXPWYC\-GP->?:_#$"EG9[=VA8N<]#D8]@K`?A3?'ELD_A::1B MP,$B2+CN<[>?P8U5^'/_`"+UQ_U]-_Z`E'0#D/!7_(W6/_;3_P!%M7KU>0^" MO^1NL?\`MI_Z+:O7J&!Y#XU_Y&Z^_P"V?_HM:[_QK_R*-]_VS_\`1BUP'C7_ M`)&Z^_[9_P#HM:[_`,:_\BC??]L__1BT`>2P3R6UQ%/"VV6)PZ-C."#D'FO< M;&\AU"QANX&S%,@9>1D>QQW'0^XKR#3]+%]H.JW2JQFLS$XV@G*G<&'\CG_9 MKM/AYJ:SZ7+ISR?O;=RZ*<#]VWIW.&SG_>%#`Q-&_P"2GR?]?5S_`">O3J\Q MT;_DI\G_`%]7/\GKTZA@>8ZS_P`E/C_Z^K;^25Z=7F.L_P#)3X_^OJV_DE>G M4` M.HY]:[/XDWF;BQL59QM1IG&?E.3A?Q&UOS]ZK^(M-AM_`NA3(SEDQ@$C'[U2 M[=O4<>WK0(]`TVY>\TNSNI`H>:!)&"]`2H)Q^=M_^OI?_0'JUX#N M4G\+0QJ&!@D>-L]SG=Q^#"JOQ&_Y%ZW_`.OI?_0'H&<'HU\^C:Q97[Q,44[N M5^\ARK%>F?XL>XKVNO(]3L`?!NBZBH4$&6!SDY/SNR\=.,-^8_#O?!NI?VCX M;M\KM>V_T=L#`.T#!'/]TC\G5YC\.?^1AN M/^O5O_0TKTZA@>0^"O\`D;K'_MI_Z+:O5-22>32[Q+4L+AH'$15MIW;3C![< MXYKROP5_R-UC_P!M/_1;5Z]0P/)_`ES;6_B:,7`7,L;1Q,V/EF0"./7 M'>O6*\E\6Z/)H6N>?;_N[>=S+;LC8*$8)`QC&">/;'/6N_\`#/B*/Q!8LY3R M[F'`F0#YVDUK<)O@GC:.1AJ6B@:;3NCY8O[.33M1NK&9E:6VF> M%RARI*D@XSVXJO7>?%K3OLGB\7:K+LO8%OR$*<=E5"1S][W%<'7!)6 M;1]]AJWMJ,:G=!1114FX5]0Z->2:CH6GWTRJLMS;1S.$&%!903C/;FOEZOH' MX8RQR>`=/5)%9HVE5PIR5/F,<'T."#]"*WH/5H\+/H7HQGV?YK_@'74445U' MRP4444`%%%%`!1110`4444`%8'C7_D4;[_MG_P"C%K?K`\:_\BC??]L__1BT M`>8Z%_R,.F_]?47_`*&*]MKQ+0O^1ATW_KZB_P#0Q7MM-@%%%%(`HHHH`*** M*`"BBB@`KR+XS:=MN],U-5E.^-K>1L?(NT[E'3@G<_?G;[&O7:X[XGZ=_:'@ MBY=5E:2TD2X18QG.#M8GCH%9C[8STJ*BO%G=EM7V6*@^[M]^AX#1117"?)?"'4_LOB>>P> M;;'>0':FW.^1#DWXXKVVNVD[Q1\5FM'V6*EYZ_?\`\$****T/."BB MB@`HHHH`****`"BBB@#SWXQ?\BC:?]?Z?^BY*\2KVWXQ?\BC:?\`7^G_`*+D MKQ*N.M\9]ADO^ZKU84445D>L%?5]?*%?5]=.'ZGSG$'_`"[^?Z!11170?.!1 M110`4444`%%%%`!1110`4444`%%%%`'D/@K_`)&ZQ_[:?^BVKUZO(9YVTWQ[ M+/,SP+'J!=VP0?++Y)XY(*G\0:]>IL`KQJ_MOMOC&YM-^SS]0:/=C.W=(1G' M?K7LM>0_\U!_[BO_`+5H0'0?\*S_`.HO_P"2W_V==/X>"2*D_YJ#_W%?\`VK70?$?3?^/35%;_`*=W4GZLI''^ M]GGTIB+O@WPJ=,8:G=212321CR5C(=45@#G=Z]N.,9Y.>.QKEO`>J"^T$6K, MQFLSL.XDY4Y*G^8Q_LUU-(9Y#_S4'_N*_P#M6O7J\A_YJ#_W%?\`VK7KU-@> M0^-?^1NOO^V?_HM:].UW_D7M2_Z]9?\`T`UYCXU_Y&Z^_P"V?_HM:].UW_D7 MM2_Z]9?_`$`T`>2:+HMSKMX]K:O$CI&9"920,`@=@?45N_\`"N=7_P"?FQ_[ M[?\`^)H^'/\`R,-Q_P!>K?\`H:5Z=0!R'Q&_Y%ZW_P"OI?\`T!Z/AS_R+UQ_ MU]-_Z`E'Q&_Y%ZW_`.OI?_0'H^'/_(O7'_7TW_H"4=`.0\:_\C=??]L__1:U MT'_"L_\`J+_^2W_V=<_XU_Y&Z^_[9_\`HM:]>H`R/#FA_P#"/Z?):?:?/WRF M3=LVXR`,8R?2O./^:@_]Q7_VK7KU>0_\U!_[BO\`[5H0'KU<#\3/^87_`-M? M_9*[ZO*_B!A(4`X_*K5(#R'QK_`,C=??\`;/\`]%K6U=?$ MB>6UD2VT]8)F&%E:7?M]\;1G_/7I6+XU_P"1NOO^V?\`Z+6O1[7PMH=IO\O3 M(&W8SYH,G3TW9Q^%,#@/"N@76LZM'>W<3M9J_FR2R])CD\#(.[+#GVSSG%=/ M\1O^1>M_^OI?_0'KKZY#XC?\B];_`/7TO_H#T`'PY_Y%ZX_Z^F_]`2M_7?\` MD7M2_P"O67_T`U@?#G_D7KC_`*^F_P#0$K?UW_D7M2_Z]9?_`$`T@.!^'/\` MR,-Q_P!>K?\`H:4?$;_D8;?_`*]5_P#0WH^'/_(PW'_7JW_H:4?$;_D8;?\` MZ]5_]#>GU$6+SX<745N7M+Y+B4<^6\?EY&.QR>>G7`]ZK^'?$-QX8OGTK5(? M+M@^'`0!HF/\61]X'CUXQCI@^G5YO\1[:VCU*TGC*BXEC(E48Z`C:Q'7G)&3 M_=]J!G4^-?\`D4;[_MG_`.C%K`^&?_,4_P"V7_L]7]9_Y)A'_P!>MM_-*H?# M/_F*?]LO_9Z.@'?5YC\1O^1AM_\`KU7_`-#>O3J\Q^(W_(PV_P#UZK_Z&]"` MZ'5HWD^&4:HC,19V[$*,\#82?P`)K.^&?_,4_P"V7_L]='!!)<^!HH(5W2RZ M:$1Z% MKX6N1YK1O,5B3;GYLG)''JH:NAK@_B3=$1V%FLJX)>5X^,\8"GU'5OU]*`)_ MAO;(NEWET"V^2<1D=L*H(_\`0S^E<]XL632?&K7<<*+\\=S$,?*Q&,D@>K*V M>]%CHWB[[#"UDUTELZ!XQ'>!%PW.0-W&D>-?^11OO^V?_`*,6LWX<2(="N8PZEUN2Q7/(!5<''O@_D:;, M\FI_"T&*+#);J"N[M$X!/;LA./PYK.^&URBWE_:D-ODC20'MA20?_0Q^M`ST M2N!^)G_,+_[:_P#LE=]7#?$FV=K.PN@5V1R/&1WRP!'_`*`?TI(#IO#D\=QX M;TYXFW*+=$)QCE1M(_,&M.N:\!W*3^%H8U#`P2/&V>YSNX_!A72T`>5^([E+ M/XAO=2!BD,\$C!>I`5"3^/+9X/%,TC%2)XTD7'88V\_BIKU2">.YM MXIX6W12H'1L8R",@\TP,3QK_`,BC??\`;/\`]&+6?\.?^1>N/^OIO_0$IOQ' MD0:%;1EU#M2`K9./;(_,5-\/8)(O#;.ZX6:X9T.>HPJY_-3^5'0#C/! M7_(W6/\`VT_]%M7KU>0^"O\`D;K'_MI_Z+:O7J&!Y#XU_P"1NOO^V?\`Z+6N M_P#&O_(HWW_;/_T8MC?\`)3Y/ M^OJY_D]>G5Y+X1GDN?&UK/,VZ65Y7=L8R2C$GBO6J&!YCK/_`"4^/_KZMOY) M7IU>8ZS_`,E/C_Z^K;^25Z=0!Y3XL:35O&K6DC,V>]= M[XLMGNO"VH1H5!$8D.[T0AC^@->7Q1WVN:]--IT#_:997N%5'P8_FW9W<8QD M<\N8\#RS6?BV.W:/:TJ20R*ZD,N!N_`Y4#GWKI_ MB-_R+UO_`-?2_P#H#T=1CM"L!JGPYCLB%)ECE";B0`WF,5)QZ$`U@?#N_%OK M$]DQ4"ZCRO!)+)D@>W!8\^@KK?!7_(HV/_;3_P!&-7#>*+9]"\8&ZB*N7D6\ MC#\\ELD'I_$#^&.:`+7PY_Y&&X_Z]6_]#2O3J\Q^'/\`R,-Q_P!>K?\`H:5Z M=0P/(?!7_(W6/_;3_P!%M7KU>0^"O^1NL?\`MI_Z+:O7J&!1U?2X-8TV6SG5 M<.#L9I&F7_F8\F=H=FWKO7.<^WE_K[5XY7MOQB_Y M%&T_Z_T_]%R5XE7'6^,^QR9MX1)]&PHHHK(]4*]M^#O_`"*-W_U_O_Z+CKQ* MO;?@[_R*-W_U_O\`^BXZUH_&>3G7^ZOU1Z%11178?'A1110`4444`%%%%`!1 M110`5@>-?^11OO\`MG_Z,6M^L#QK_P`BC??]L_\`T8M`'F.A?\C#IO\`U]1? M^ABO;:\2T+_D8=-_Z^HO_0Q7MM-@%%%%(`HHHH`****`"BBB@`JO?V<>HZ== M6,S,L5S"\+E#A@&!!QGOS5BB@:;3NCY5NK::RNYK6X39/!(T]S&FV"^C$PVQ[5#CY7&>A.0&/^_P#B>(K@DK.Q]_AZRK4H MU%U04445)L7M&U*31]9L]1BW%K:99"JOL+@'E<]@1D'V-?3T4L<\*30R+)%( MH9'0Y5@>001U%?*=>]_##7&U?PE'!,RF>P;[.0&&XH`-A(`&!CY??83GK710 MEK8\#/:'-"-9=-'\_P"OQ.THHHKI/F`HHHH`****`"BBB@`HHHH`\]^,7_(H MVG_7^G_HN2O$J]M^,7_(HVG_`%_I_P"BY*\2KCK?&?89+_NJ]6%%%%9'K!7U M?7RA7U?73A^I\YQ!_P`N_G^@4445T'S@4444`%%%%`!1110`4444`%%%%`!1 M110!YS\0](\F\BU6,?)/B.7_`'P.#U[J,<#^'WK1\/\`CFQ.FI#JTS0W$("> M859_-&.O`)SZY^O?`Z^ZM8+ZUDMKF)989!AD;O\`Y]:XZ\^'%K+<%[2^>WB/ M/EO'YF#GLF!TFDZ_8ZU-F>>QZ@5YA//';>. M99YFVQ1:D7=L9P!+DGBO1_#GAN'P[#,$N'GEFV^8S`*O&<8';KZFL._^'OVW M4+F[_M39Y\K2;?L^=NXDXSNYZT`;'_":^'O^@A_Y!D_^)J_IFMZ?K'F_8+CS MO*QO^1EQG..H'H:Y'_A6?_47_P#);_[.M_PSX9_X1W[5_I?VCS]G_+/9MVY] MSGK0!P'_`#4'_N*_^U:]2U73X]5TNXL93A9DP&_NGJ#U&<$`X]JYS_A!O^*A M_M7^T?\`EZ^T^5Y'^WNVYW?AG%=?0!Y+X/U*;2/$D=O(KJEP_P!GEC(((8G` M.,CD-QST!->M5QVL>`TU35;B]2^6W$Q#&-;?.#@`G.X=3D_C76P))';Q)-+Y MLJH`\FW;O..3@=,^E(#R7_FH/_<5_P#:M>O5R'_"#?\`%0_VK_:/_+U]I\KR M/]O=MSN_#.*Z^F!Y#XU_Y&Z^_P"V?_HM:].UW_D7M2_Z]9?_`$`U@:WX&_MC M5Y[_`/M'R?-V_)Y&[&%`Z[AZ5T]_;?;=/N;3?L\^)H]V,[=P(SCOUH`\Y^'/ M_(PW'_7JW_H:5Z=7,>'/"'_"/ZA)=_;O/WQ&/;Y.W&2#G.X^E=/2`Y#XC?\` M(O6__7TO_H#T?#G_`)%ZX_Z^F_\`0$K8\1Z'_P`)!I\=I]I\C9*)-VS=G`(Q MC(]:/#FA_P#"/Z?):?:?/WRF3=LVXR`,8R?2F!YQXU_Y&Z^_[9_^BUKO_P#A M-?#W_00_\@R?_$UGZWX&_MC5Y[_^T?)\W;\GD;L84#KN'I5#_A6?_47_`/); M_P"SH`ZO3?$.E:M<-!8W7FRJAU;^SV:ZN&!V#8RHI_VLX/Y>G;K7+>#]'NM7 MUR/4)=YM[>7S9)F;EY!\P&3G)S@GV[\BNEM?AUID2QFYN;F=U.6"D(C<],8) M'''7\JZNUM8+&UCMK:)8H8QA47M_GUH`FHHHI`>0^-?^1NOO^V?_`*+6O7JY M#6_`W]L:O/?_`-H^3YNWY/(W8PH'7(K338Y["^D6%))!)%(0<;CA2&/;H.>G7)Z5H^,?%5B MVES:=8W'G3S85Y(6^5%X)^8<-D<8'OGT,VJ?#VRO+II[.Y:S#DEH_+#H/]T9 M&._'/7C%0V?PXM8K@/=WSW$0Y\M(_+R<]SD\=>F#[TP&_#C3WCM;N_DC4"4B M.)BOS8&=V#CH21T[K[5E?$;_`)&&W_Z]5_\`0WKTBUM8+&UCMK:)8H8QA47M M_GUKGO$?A#_A(-0CN_MWD;(A'M\G=G!)SG M#$%08^A#>_>NGTW1[#2(W2PMEA$ARYR6)].22?P]SZT`9'BNV2S\"SVL98I# M'#&I;J0'4#/Y5RW@;6]/T?[?]ON/)\WR]GR,V<;L]`?45WVMZ9_;&D3V'G>3 MYNWY]N[&&!Z9'I7(_P#"L_\`J+_^2W_V=`'1P>+]"N;B*"&^W2RN$1?)<9). M`.5KC/B-_P`C#;_]>J_^AO6O8?#W[%J%M=_VIO\`(E63;]GQNVD'&=W'2M#Q M'X0_X2#4([O[=Y&R(1[?)W9P2[&-VT`9QVZ57U; M1;'6K<0WL.[;G8ZG#(2,9!_H>.!Q2`RK7QUHG2M/1=:MM=LWNK5)41)#&1*`#D`'L3ZBN5D^&B&1C'JK*A)VAH,D#MD[AG\ MA76:/H]KH=C]DM-Y0N79I&RS$]SVZ`#@=J`-"O*?'UUY_B=X]FW[/$D>3Q$-7?5&8BY$XC:'/`;(7.[L`!TH0'3VELEG9P6L98I M#&L:ENI`&!G\JYCXA6IF\/QSK$K&"=2S\952"#^9*\#V]*ZVJ.L::FKZ5<6# MR-&)0,.HS@@@CCOR!0!S7P]GCNM!NK*5O-\N4[HG&5$;*..>,$A^/KZUQS1W M?A+Q,C,C%[>3B^&?#/\`PCOVK_2_M'G[/^6>S;MS M[G/6KNLZ'9:[:K!>*V4.4D0@.GK@^_5'P3Y+1'?QVR/ MEY^O?M4FH+%XN\(226D;`R@O`)5&X,C$8ZX&<$9ST-8O_"M8?M&[^TW\C?G9 MY(W;<]-V<9QWQ^%=?I>FPZ3IT5C`SM%%G:9""W))YP!ZT`>7^&->/AK4IUNH M93#(-DL:J`ZLIX.#ZY\>:%!&&CGEN"3C9%$01[_`#8'ZU-KOA'3 M]"YV%?,CQACV+`]S''`_B]J=X,\3V7]E)I]]?#BUEN"]I?/;Q'GRWC\S!SV M.1QTZY/O0!SGBO7/^$BU:*.S1WMXOW<*[?FD8GD@8SSP`/;MG%>F:/8#2]'M M;(!08HP'VDD%NK$9]22:S/#_`(0LM"D^T;VN;O!`E=0`O7[H[<<9R?PR170T M@/(]7-SH'C:6Z96RMR;A=K%=Z,V<9QW!*G\1S7H,/B[0Y;'[6;](U&-T;@B0 M$XXV]3UZC(Z\\5-K/AW3M=53=QL)5&U9HSAU&0^"O\`D;K'_MI_Z+:O7JY32_!,>EZ^FI0W MG[I'F"0:R[SPA]K\3KK7V[9MECD\GR<_<"\;MW?;Z=ZU-?TF36M M+:Q2[^S*[@NWE[]P'..HQS@Y]J8'&?#:VWZA?7>_'E1+'MQUW'.<^VS]:]&K M&\-^'T\/61ZN$TCQY++(S2)%>)<-M7 M!P2'(`SVSBNM^(W_`"+UO_U]+_Z`]3>(?!B:[J0O%O%MCY81@(-VX@GDG([8 M'X5M,!O@K_`)%&Q_[:?^C&K/\` MB%IOVG1H[X-AK1^03P5<@'MUSM_#-;^B:9_8^D06'G>=Y6[Y]NW.6)Z9/K5J M[MDO+.>UD+!)HVC8KU`(PG5S'ASPA_PC^H2 M7?V[S]\1CV^3MQD@YSN/I73T`>0^"O\`D;K'_MI_Z+:O5K^Z^Q:?S?Y$3 M2;:5?*JW1:RF)`VO\R')[,!],D@=:S?&/BK3;K2)M-LY M?M$LKA7900J!6!SDCYLXP,<=\],S7OPXLII-UG>RVX))*.HD`]`.01CW)IMG M\.+6*X#W=\]Q$.?+2/R\G/';"U9\3R7?F(N#RJHP8 MYZ<%U_.O%ZXZWQGV.2I_5%ZL****R/5"O;?@[_R*-W_U_O\`^BXZ\2KVWX._ M\BC=_P#7^_\`Z+CK6C\9Y.=?[J_5'H5%%%=A\>%%%%`!1110`4444`%%%%`! M6!XU_P"11OO^V?\`Z,6M^L#QK_R*-]_VS_\`1BT`>8Z%_P`C#IO_`%]1?^AB MO;:\2T+_`)&'3?\`KZB_]#%>VTV`4444@"BBB@`HHHH`****`"BBB@#@_BOH MC:EX82^ABWSV$GF$C<2(F&'P!QU"DD]`IY]?#*^JKJVAO;2:UN$WP3QM'(N2 M-RL,$9'/0U\QZSILFCZS>:=+N+6TS1AF387`/#8[`C!'L:Y:\=;GU&18CFIN MB^FJ]'_P?S*-%%%8'O!76?#SQ'_PC_B>+SI-ME=X@GRV%7)^5SD@#!ZD]%+5 MR=%-.SNC.M2C5ING+9GU?17)_#SQ'_PD'AB+SI-U[:8@GRV6;`^5SDDG(ZD] M6#5UE=Z=U='P-:E*E4=.6Z"BBBF9A1110`4444`%%%%`'GOQB_Y%&T_Z_P!/ M_1)5[;\8O^11M/^O]/_1)5QUOC/L,E_P!U7JPHHHK(]8*^KZ^4*^KZ MZQX/L<<9'-:="=]BIPE"3C)6:"BBB@D****`"BBB@`HHHH`****`"BB MJFJ:C;Z1I=SJ%TVV"WC+MR`3CH!D@9)P`.Y(H'%.326YX_\`%_5EN_$-KIJ% M2MC#E\*0P>3!()/!&T(>/4_AYW5O5-1N-7U2YU"Z;=/<2%VY)`ST`R2<`8`' M8`54K@G+FDV?>X2C["C&GV7X]?Q"BBBI.@*^B?A[;36G@/2HYTV.T;2`9!^5 MW9E/'JK`U\]VMM->W<-K;IOGGD6.-<@;F8X`R>.IKZEM;:&RM(;6W39!!&L< M:Y)VJHP!D\]!7106K9X&?5$J<*?=W^[_`(VUXEH7_(PZ;_`-?47_H8KVVFP"BBBD`4444`%%%%`!1110`4444` M%>4?%[PY_J/$%M'Z076U?^^'.!_P$DG^X!7J]5-4TZWU?2[G3[I=T%Q&4;@$ MC/0C((R#@@]B!4SCS1L=6#Q+P]:-3IU]#Y;HJWJFG7&D:I M,J3D=.XR`37T7%+'/"DT,BR12*&1T.58'D$$=17RG7H_PU\L%?5]?*%?5]=.'ZGSG$'_+OY_H%%%%=!\X%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110!\JVUU<65PEQ:SRP3IG;)$Y5ER,'!'/0D5ZGX<^+W^KMO$%OZ+]KMQ]! MET_[Z)*_0+7D]%<$9N.Q][B<'1Q*M47SZGU)IVJ6.KVBW6GW45S`V/FC;.#@ M'!'4'!'!Y%6Z^6].U2^TB[6ZT^ZEMIUQ\T;8R,@X(Z$9`X/!KTK0?C"T<(BU MZR:5E7BXM`-S'@?,A(&3R200.@VUTQK)[GSN*R6K3UI>\OQ/6J*S-)\1:/KB M@Z;J,%PQ4MY:MB0`'!)0X8#/J.X]:TZV3OL>-*$H/EDK,****"0HHHH`***K MWU_:Z98S7M[,L-M"NYY&Z`?U/8`<<`E_CGXE?VQ;OI>BF6*S?*SSL-K3#.-JCJ$(Y.<$YP M0!D'SBN:K5O[J/ILKRMTVJU9:]%V\V%%%%ES(FZ" MQC,QW1[E+GY4&>@.26'^Y^(]XKD_AYX<_P"$?\,1>='MO;O$\^5PRY'RH<@$ M8'4'HQ:NLKMI1Y8GQ.:8E5\0VMEH@HHHK0\\****`"BBB@`HHHH`****`"L# MQK_R*-]_VS_]&+6_6!XU_P"11OO^V?\`Z,6@#S'0O^1ATW_KZB_]#%>VUXEH M7_(PZ;_U]1?^ABO;:;`****0!1110`4444`%%%%`!1110`4444`>FNVHS/91[9T`8EXLY!&.!M)8GCH22>`*\7KZOKP'X@>#O^$8U19K..4Z7< M>O09!/4>N":YJT/M(^ER7')KZO-Z]/\CCJ***YSZ$****`/6/! M7Q0_X]M*U]O]A-09_IM$GZC?GTSW:O5Z^4*[GPE\2]0T%8[._5K[3D541<@2 M0@'^$X^88)^4GL`"`*Z*=:VDCY_,,HY_WF'6O5?Y?Y'NU%9^D:[I>NVYGTR] MBN47[P4X9.2!N4\KG!QD)5[;\8O^11M/^O]/_1)5QUOC/L,E_P!U7JPHHHK(]8*^KZ^4 M*^KZZ?O0Q(Q]X_,!T.`0,_4YY:BFFUL9U*-.JK5(IKS/5;'XS MR!84U#1U9MW[V6WFVC&>JH0>0.Q;D]Q6W%\7_#LDR(UOJ,2LP!D>)-JCU.') MP/8$UX?16BK31Y\\GPDG=1MZ,^@_^%E^$?\`H+_^2TO_`,363_PN+P]_SYZG M_P!^H_\`XNO$J*?MY&<%`(YZ@@\?CP>I:SJ6L3>;J-]/%%%%2=(4444`%==\._##>(O$*2S(K6%DRRW`8CYCSL3!!R"1S MVP#R#BL'1-$OO$&J1Z?I\6^9^2QX6->[,>P'^`&20*^C/#^AVOA[1K?3K5%` MC4&215P97Q\SGD\G'KP,#H!6M*',[O8\G-<HHW'&3BU*.Z/FOQ1X7OO"NJ&UNAOA?+07"C"RK_0CC([>X()Q*^EO$_ARU M\4:,^GW+M&0PDBE7K&X!`..XY((]#V."/`O$?AC4O"]\MMJ"*1(NZ.:(DQR# MO@D#D9P01G\"">.I3Y7=;'V.79C'$QY9OWU^/F8U%%%9'J!1110!+;75Q97" M7%K/+!.F=LD3E67(P<$<]"17=:3\6]>LV"ZA'!J$6XEBRB*3&.`"HV@9YY4G MK^'`452DX[&%;#4:ZM4BG_7<]KL?C#HLZPK>V5Y:RNV'*A9(T&>N1YT\DPLG=77S_P`TSZ#_`.%E^$?^ M@O\`^2TO_P`363J?Q>T.U\U+"WNKZ1<;&P(HWZ9Y/S#'/\/4>G->)44.O((9 M'A8N[N_G_DD=3XK\=ZEXKA2VN(8+>TCF,J1Q@EB>0NYCU(!(X`!R>.F.6HHK M)MMW9ZE*E"E'DIJR"BBBD:!7U?7RA7U?73A^I\YQ!_R[^?Z!11170?.!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`?*^$FJVLFF MKH****`"BBB@`HHHH`****`"BBB@`K0T31+[Q!JD>GZ?%OF?DL>%C7NS'L!_ M@!DD"ND\)?#K4O$+1W5VK66F[E)=U(DE4C.8P1R.GS'CGC."*]HT/P_IOAZQ M6UTZV6,!0'E('F2D9Y=NYY/L,\8'%;0I.6KV/)QV:TZ"<*>LOP7K_D5_"_A> MQ\*Z6+6U&^9\-/<,,-*W]`.<#M[DDG;HHKJ225D?)5*DJDG.;NV%%%%,@*** M*`"BBB@`HHHH`****`"BBB@`K`\:_P#(HWW_`&S_`/1BUOU@>-?^11OO^V?_ M`*,6@#S'0O\`D8=-_P"OJ+_T,5[;7B6A?\C#IO\`U]1?^ABO;:;`****0!11 M10`4444`%%%%`!1110`4444`%%%%`!6?K>B6/B#2Y-/U"+?"_(8<-&W9E/8C M_$'()%:%%#5RHRE&2E%V:/GGQ9X%U+PM-OPUW8%01=QQD*IX&''.TY(QDX.1 MCG('+5]62Q1SPO#-&LD4BE71QE6!X((/45YQXE^$MK?32W>B7"VOJ^O'?#_P`(;RXVS:]< M?9(_^?>`AI#U'+Y\KG6*I5I0C3=[7O\[!1116YX@4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11 M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110!1U+1M-UB'RM1L8+E0K*ID0%D#==IZJ>!R,'@5P>N?"#3[ MIFFT:[:R;:<02@R1DX&`&SN49!R3NZ\#C%>E45,H1ENCIH8NO0?[N37Y?`1@_7',WEA>:=,(;ZTGM967<$GC M*,1TS@CIP?RKZGIDL4<\+PS1K)%(I5T<95@>""#U%9.@NC/5I9]56E2*?II_ MF?*=%?2ESX.\-W=N\$FAV"HV,F*$1MP<\,N"/P-9W_"M/"/_`$"/_)F7_P"* MJ/82[G9'/J%O>B_P_P`SY\HKZ#_X5IX1_P"@1_Y,R_\`Q5'_``K3PC_T"/\` MR9E_^*I>PD5_;N&_EE]R_P`SY\JQ9V%YJ,QAL;2>ZE5=Q2",NP'3.`.G(_.O MHFS\%>&;&$Q0Z)9LI;<3/'YS9^KY...G2MN**."%(88UCBC4*B(,*H'```Z" MJ5!]68U,_C_R[A]YX9H?PKU[4V5[X+IML5#;IF0Q4C/?&*]*\ M.?#W0_#_`)1D'EAGK7645K&E&)Y.)S/$5]&[+L MOZN%%%%:'GA1110`4444`%%%%`!1110`4444`%%%%`!1110`5@>-?^11OO\` MMG_Z,6M^L#QK_P`BC??]L_\`T8M`'F.A?\C#IO\`U]1?^ABO;:\2T+_D8=-_ MZ^HO_0Q7MM-@%%%%(`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M(KFUM[VW>WNH(IX'QNCE0,K8.1D'CJ`:X+6?A'HU[L;3)Y=-<8#+S,C#GG#' M.>1_%CCIWKT*BIE%2W-Z&)K4'>G)K^NQX3J7PH\1V*M.*?X'RA17U9+%'/"\,T:R12*5='&58'@@@]169_PBWA[_`*`6F?\`@''_ M`(5/L'W.J.?Q^U#\?^`?,U%?3D7AS0H)DFAT73HY8V#(Z6J!E(Y!!`X-:='U M=]Q2S^/V:?X_\`^8['PYK6IK"]EI5Y-%,VU)5A;RR?.#OSGILW=/?'6O>**I4(]3FJ9[7E\$4OQ/.])^$&CVC!]2 MNY[]@Q^11Y,9&,`$`EL@\Y##MQZ]Y9V%GIT)AL;2"UB9MQ2",(I/3.`.O`_* MK%%:QC&.R/+KXJM7?[R3?]=@HHHJCG"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"L#QK_`,BC??\`;/\`]&+6_6!XU_Y%&^_[9_\`HQ:`/,="_P"1ATW_ M`*^HO_0Q7MM>):%_R,.F_P#7U%_Z&*]MIL`HHHI`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11 M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%8'C7_D4;[_MG_Z,6M^L#QK_ M`,BC??\`;/\`]&+0!YCH7_(PZ;_U]1?^ABO;:\2T+_D8=-_Z^HO_`$,5[;38 M!1112`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@ M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH MH`*P/&O_`"*-]_VS_P#1BUOU@>-?^11OO^V?_HQ:`/,="_Y&'3?^OJ+_`-#% M>VUXEH7_`",.F_\`7U%_Z&*]MIL`HHHI`%%%%`!1110`4444`%%%%`!1110` M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110` M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%%`!1110`4444`%8'C7_D4;[_`+9_^C%HHH`\QT+_`)&' M3?\`KZB_]#%>VT44V`4444@"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@ M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@ M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/ "_]D_ ` end GRAPHIC 8 exhibit107image.jpg IMAGE begin 644 exhibit107image.jpg M_]C_X``02D9)1@`!`0$`E@"6``#_X@H@24-#7U!23T9)3$4``0$```H0```` M``(0``!M;G1R4D="(%A96B````````````````!A8W-P05!03``````````` M````````````````````````]M4``0````#3+``````````````````````` M``````````````````````````````````````````````ID97-C````_``` M`'QC<')T```!>````"AW='!T```!H````!1B:W!T```!M````!1R6%E:```! MR````!1G6%E:```!W````!1B6%E:```!\````!1R5%)#```"!```"`QG5%)# M```"!```"`QB5%)#```"!```"`QD97-C`````````")!"!3;V9T=V%R92`R M,#$Q`%A96B````````#S40`!`````1;,6%E:(`````````````````````!8 M65H@````````;Z(``#CU```#D%A96B````````!BF0``MX4``!C:6%E:(``` M`````"2@```/A```ML]C=7)V````````!``````%``H`#P`4`!D`'@`C`"@` M+0`R`#<`.P!``$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0": M`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T! M$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I M`;$!N0'!`$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<" M<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-: M`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$ M?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07% M!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&09!ZP'OP?2!^4'^`@+"!$,@A&"%H(;@B"")8(J@B^"-((YPC[ M"1`))0DZ"4$9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP* M\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT- M#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/ M>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$)%ZX7TA?W M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL; M8QN*&[(;VAP"'"H<4AQ['*,0!YJ'I0>OA[I M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B--@U M$S5--8Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546: M1=Y&(D9G1JM&\$25^!8+UA]6,M9 M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9O5\/7V%?LV`% M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\> M;WAOT7`K<(9PX'$Z<95Q\')+%V/G:;=OAW M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$ M?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2( M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_ MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB: MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16 MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:QK_UP'#`[,%GP>/"7\+;PUC# MU,11Q,[%2\7(QD;&P\=!Q[_(/%$XIZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[< M_VW____;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>'1H<'"`D M+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,&`T-&#(A M'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R M,C(R,C(R,O_``!$(!G($^P,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0`````` M`````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q M008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4 ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+C MY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4& M!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R M@0@40I&AL<$)(S-2\!5B7J"@X2%AH>(B8J2DY25EI>8F9JB MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(RKR M\_3U]O?X^?K_V@`,`P$``A$#$0`_`/?Z***`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHJO?7]GIEG)>7]W!:6L>-\T\@C1$I'")XIT1F/0+J$1)_P#'JN7_`(AT32HX)-1UC3[-+@$PM<7* M1B4#&2I8C/4=/44`:5%8O:7;W6<>3->1H^?]TG-7+O4K&PL&O[R]MK>S4`FXFE5(P"0`=Q.. M20!]10!:HJAIFNZ1K0E.E:K8WXBQYAM;A)=F"^L[J1H[>Z@F=461ECD#$*V=K$#L=K8/?!]*J:AXDT+2)Q!J6M:= M92D9$=S=)&Q_!B*`-.BHX+B&Z@2>WFCFA<962-@RL/8CK6'_`,)WX/\`^AKT M/_P8P_\`Q5`'0453T[5]-U>%IM,U"TO8E."]M,L@!^JDU1@\8>&;J[2TM_$> MD37+OL2&.^C9V;T"ALD^U`&U169/XCT.UU--,N-9TZ'4'956UDND65F;[H"$ MY).1CCG-:$LL=O"\TTB1Q1J6=W8!54)=&AGB)RDD,58TWQ+H.LW#6^EZWIM].J%VCM;I)6"Y`R0I)QD@9]Q0!J4444`%%% M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110` M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!39(TEC:.1%=&&&5AD$>A% M.JKJ-S/9V$L]K8S7TZ#Y+:%T5G.<=795'J/'][%=;\%/#_B#PEH%[HVNZ+-:-)=-=)<>?#)&05C79A'+! MOE)Z8QW]=CXLZ;K&O>!;O0]%TF:^N;TIEUFBC2$)(C_-O8$YP0,`]\XXR`<- MJ/BSP_J7PITGP@MA=:CX@N=&@BM;,V,BLLGE+B16=0"H(W;E)!"^E3^*]2\1 M?#_X`Z79W5PZ:S*RV3S*^6A5M[X##N$4)D?A5_5/`&I^(_AOHBBPFTCQ7X?M MXH[1WEC)D:-%&`Z,1M8CC)!!'0#KM7>@ZK\1/A_)HGBW29=(U-%1A<"6*2-I MAGYT".3CU4@<-@$]0`;_`(4\,:9HOA"STN.S@:-X$-QN0-Y[D99GR/FR2>M> M??#"^.F_$+Q;X"7,ND6S27%I%+\PA3>JM&,_PGS!Q['U-=CHU_XKT;0K?3=0 M\-2ZA>VL8A6ZL[J`0S!1A6/F.KKD`9^4_P!*S?"7A'4_"JZ[XHO[7^T_$NJR M&1K6TD55C4MD1JSE1@9!))Z*,9QR`<#X-3_A`?'/A.Z!V:3XJT:VC?/W5N/* M3]2VT_\`;0UU/QF8ZGX'\1S9S:Z8(($]&G>:(N?^`H54'U=QVI^L>"]7\3?! MW3-(DTN33_$&CQP+:K+-$=SQ(JEE=&("L,]2#D#(X!-[X@>'-9N?A>WA?1]. MFU2^N]C3W(EBC42"597=M[+R[;B`H/?IQD`Q?&4,7_#+]I^[3Y=,TYU^4<,6 MAR1[G)_,T[Q-X>UG7OV>]`L?#Z%IELK.::WC.TSQB(%E'J=Q#8[[>YJ;Q#I' MB?5/@G:>%+?PO>#4Q;6]I('NK8(GD^42^[S>0VT@#KP<@<9N2Z3XNE\"^#;7 M3M)^QZQHEY;"6.\N(O+:..W>-FW(S?*V[;_>YZ8YH`YC1O&GAGQ[?Z'INN6* M:!XDTN^MY+=S#\CF-P3$#P4W8(VG@$C&2,&7QY?>(/`GQ8;QI-I1U70Y;5;9 M".1;+A=P!P=C;E)R1@AR,]<;/CKP;J/Q#O\`28_^$>.C36\ZO=:M+/"7\L`_ M)'Y;%FY.06"X([9-;MO;>)])\<^)[W^R!?Z#J#P-%%%/&)BZP(C,JN0NT[=I M#,#\HQQU`.-B\4>'=/\`!_C3QMX,F6&XNH+9);'R0C6LVYD$F,X(/F@\#&4/ M)R0.Q^$^AVMGX`L+Z2-9K[5(OM-YNCZ;K-O]E@TN"16,*Y5O,.W*!MR!@!D#)'3KO^$K?Q-X+T&/0+O19=8ALR M4M+RPFA3?&3D!TE="I&<<;OZD`YC1;W_`(1/]H&]\,:>"FDZQ%]H^RC[D,WE MERRCMG:W`]1Z"J-KK.F>&/VC?%]]?F2"S33$+O#;22A,K;,681J2!U)8\9/7 M)KLO#'@S4'\=ZCXX\1)%%J%PODV=E')Y@M8@`O+="Q`[<%+I-(U6U6SVO%HW\3_&)/&'AFPEL M_#0M&@N;AD\I;V3##A>IPVSG'_+/U-,^)VGR>!O&ND?$72HMMN95M]4BB7&] M3_$?=ER,^H7N:TM`\,^)?ASXQOH-#TN;5O"-]^^$$5Q$DEK(>RB1USTQUY&W MG(K=^+.FZSKW@:ZT/1=)EOKB]*9=9HHTB"2(_P`V]U)SC`P#WSCC(!?T""+Q M#K+^+I4#P&/[/I.Y,$09RTO(R#(>G^R%]375USW@>*_M?!FE6&I:=-875C:Q M6KQRR1OO*1JI92C,-I(/7!XZ=,[L\C0V\LJ0R3NB%EBC*AG('W1N(&3TY('J M10!X1KFA:AX;9OB3X<3==6NJ:BFIVXZ3PB\F&X_0``^@`/\`#79:?XHTJ\N? M$?C+2XHI53PY;78^4;]RM=ED8^OR`'_='H*W_!2:G_8U[9ZWH4NGLUY>27`V,W0/@@@>V><8_@WX;P>%-:\66Z()-#U>.'R(RW*+^]$D1[X&\ M8/H1W!H`SO@E9#4/#<_BS4B+K6=3N9#)=2?,ZHIVA5_NCKP/4>@K,\272^"/ MCGH$FE)Y%MKZI;WUM&,1R,7V*^.@897GV/J<]!X/T'7OAS#=Z-#ITNMZ*TS3 MVF<@^O'8+!X0U/Q+\1K;Q=XAMEL;;38A'I^G^:LC[N3Y MDA4E0!KK0 M]%TF6^N+TIEUFBC2()(C_-O=2!I7;Y;D? M=4$GMSV`YP!75?#R"/Q+]B^(#;8KN\M[RUDC$*J7C-V3%DCNBQ[>A)SR>.T)6YM@\W$PWJIE''[P$9P<#D`\5T?AV+6;34 M[/2[;P[>:5H,$ES=237=U`[N\CLPC"1.V%!D8C.?NK^(!V]%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`%35=1ATC1[W4[@,8;.WDN)`O7:BECC\!7G6C^-?%.K:K9WUG!I][I M5W!I\LUI;JS26B7$LR,V\?>9-@WY`''&W!+>BZK<65II%[397%]8LV_?'/+*BB/UP4.#G M(W]QF@#H/%GQ5\7:%*=6M/"2'PO'.83=7#D23X;;N`!S&"78J#_L@9/49V?$'B5++P79W?ANRO]1M)Y5M8VTFV,TD40W`R(O&0 M-F`W3)4\CJ`5+SXB_P#%U](\&V,$>OF;=QR@WY9L_PN><5=^'L$NG_``.^(%E>';=V M\NH1S!CR&^S*O?W!H`]IT/6+;7]"LM6L]WV>[A65`W49'0^XZ?A7,'Q9JNM^ M)]$MI&H#]FM;G:_DG7OM1SD?N?+\K\O,K MU7XF6\NI?$KX9QVC%F6]EG.SG]VIA=CQVVJ:`-`^/]6U/2O$6OZ)!9-I.A3R MPO%<(QEN_*4-(RN&`C&#QE6S[=*[?0]8MM?T*RU:SW?9[N%94#=1D=#[CI^% M>+?#V"73_@=\0+*\.V[MY=0CF#'D-]F5>_N#7>?"IX]&^&/AFSU*ZB@N;J-V M@CFD"-)O=G55!.2=K#@=J`)CXLU76_$^N:/X;6R7^Q$C^T27D32>?*X8B-`K MKM^Z06.>>W>JI^*VG#X5CQK]E?)_=?9-W/GYV[-WIGG/IVSQ6/\`"^"6P^)? MQ+BO#MD:^BG7[#Q7JVB>+=&T/Q&MDXUE)/LT]G$T8BE0`F-@SMN^\,,,A!KF[+X=^&[#4Q>Q6L[[$B2*WFN9)88?+9V M4JC$@$%SCLO50"6)ZFB@#A;KX.>`[VZENKK1'FGE8O)))?7!9F/4D^9UKL=. MT^UTG3;;3[&$0VEM&L448).U5&`,GD_4\FK-%`&/<>%M&N_%%IXEGL]^KVD1 MA@N/-<;$(8$;0=I^^W4=_I45]X-T#4;V:ZN;`L]P5:X1)I$CN"O0RQJP23'^ MT#6[10!S'B;PS#KNJ^'Y?L2%].NA<)=^85-NJLC%54'YBY15Y&``W0XS>U3P MKHVL79N[RU?[0T?DO+!<20M)'G.QS&PWK_LMD5LT4`5#I5@VDG2C9P'3S%Y/ MV;8/+V8QMV],8JEI?A;1]'NOM5G;2?:!'Y2R3W$DS1Q_W$,C'8O`^5<#CI6Q M10!A7W@W0-1O9KJYL"SW!5KA$FD2.X*]#+&K!),?[0-3ZGX:T?6;W3+S4+&. M>XTR7SK-R2/)?CD`$`_=7@Y'`K6HH`QM4\*Z-K%V;N\M7^T-'Y+RP7$D+21Y MSL>_&^-'^$>M,R*S(8"I(R M5/GQC(]."1^-`'1?\)WX/_Z&O0__``8P_P#Q5;D]Q#:P//<31PPH,M)(P55' MN3TKDI=>T7Q?K,GA*XTN[FMY]/EN)VO;2:VX#1IM42*K$GS"=PQC`]>*=LR> M)_BMK=I?H);/P[!;+;VSC,9FF4N92.[!0%&>G..3F@#K=-U[1]99UTO5K&^, M?WQ:W"2[?KM)Q5.?QIX5M;B6WN/$NC0SQ.4DCDOXE9&!P006R"#QBLWXAZ;& MWA6_UJV5(=6TJ![VUNU4"1#&-Q7/4JP!4KT(-<=;^)K&/XM6'B&ZAGBAO_!L M5RXM[62=E+S!LL(U8X"C&X\<#GI0!ZM8ZC8ZI;BXT^]M[N`G`EMY5D7\P2*L MUYOX(3^V?'.I^+=(LVLO#M[8I`FX!/MLX3Q9X;BOS8 M2>(-*2]$GE&W:]C$@?.-NW.HKD/'L$&@Z[H'C58(E%E(M.T MZ:".:.R']H2AT#;6Y2(<],G>W_;.@# MX@NH1-;S1S1$D!XV#*2#@\CT((_"J.OWLMEI,GV9@MY<,MO;9[2N=JGZ#.X^ MRFN/\$+_`,(GXMU?P3([FT(_M+2C(V28G.)$R>I5\GUY)H`ZN^\6>&],O)+. M_P#$&E6EU'C?#/>QQNN0",J3D9!!_&MBO//%\,3_`!A^';-$A8_VCDE1D[8` M5_(G(]*]#H`Q['Q9X;U.\CL[#Q!I5W=29V0P7LZ192S8VC83G)R,#'.17(>#X8H_B_\12D2*0=..54#[T+ M%OS/)]3707L,1^)&BRF)#(-*OL.5&>);7'/_``)OS/K0`_\`X3OP?_T->A_^ M#&'_`.*K0TS7='UOS?[)U6QO_)QYGV2X279G.,[2<9P>OH:\]T/5[+0_BY\0 M1/!>;93I[#['837`!\@EBWE(VW).><9YZX-=;X-NM,UVRF\4V.G?8YM2=XI2 M(L4=C))$P M)153?M\L'C[I8?RH`];N=3L++3SJ%U?6T%D`&-S+*JQ@$@`[B<>WT]R'^RV[GY83C MCCDX_P!JN)\`>.-.\+_`ZSEN++4+F2VBN&\M;"?R9"9I"%\[RS&`"O"O@33XV>XAL?%4#QNL):01O)+)M"KEF(!`P.6*CCM77G7M#\5>*K30)- M+NI7MX?[42:\M9K9HI(I8PFT2*K'ELDCC`PQQNN0",J3D9!!_&B3Q9X;BOS82>(-*2]$GE&W:]C$@?.-NW.+H8F^,/P[I6)6;&%QDC'09Z4`=M:^+/#=]Y_P!C M\0:5<>1$T\WDWL;^7&OWG;!X49&2>!4`\<^$68*OBK0R2<`#4(N?_'JJ>&=1 MTCQ3JVHZ[:Z:\%U832:6MQ*C1R2Q[8I&W(P!'S$`!AD;<\;B*Q?A7;P"+QK$ M(8Q'_P`)1>IL"C&T;,#'I[4`=_;7-O>0)/:SQSPN,K)$X96^A'!J6O.?LD'@ M_P"+FE6VEH(-/\26]P)K2/B-9X5#^:%Z`E3@XZUZ-0!'//%:V\MQ<2)%#$A> M21SA54#))/8`5GZ%XCTCQ-:376C7J7<$,Q@>1%8`.`&(&0,\,.1QS7%?"]]: MN;_Q9->:A:S0IXANH95^R,LCNBQJ"K>9A5P%&TJ3Q]ZL7PWJ.M:-X?\`B)J6 MD)8!;#Q#J%RPNE9O,"!2R`*5VG:.#SR<8[T`>QT5P&I?$>`2Z':VM[I>F2ZG MIRZDUSJLN(H8F`VJ!N0NY)Z9'"D\UM^!_%*^+=!DO#]G^T6]S+:7!MI-\1=# M]Y&[JP*L/9N_6@#I**P?&>H:KI'A34-4T=[(7%C"]RZWD3.DB(A9E&UE(8XX M/([8YR.7U#QGXAM=+\"ZM&NEFTU^:QMKN%H)/,C>==S-&V_&W&0`02#W.>`# MT:BO/])\3>+]8\1^*-"^RZ+:76DK`8Y,RS(3(C.`W*%L@*,C;CGAN!1IOQ#N M-:\)^&;JQM(!K.ON\,,,C'RHS'N\USW*J$)`ZG(&>]`'46?BK0]0\07&A6>I M13ZG;HTDT$>3Y85@K9.,`@L!C.?R-;%>8Z5_::_'Z5-5^RM.OADA9;5&1)5^ MTC#;6+%3U&-QZ=>:K2_%Z(6_]LIJ&A#3!>_9SI[7'^G&'S/+,V-_'/S;-A^7 MG=0!ZO17!3^)_%3?$2[\*V]II$0.EO?VL[O))QYH1#(/EZX.5'3(PQQS+-XI MUB36+K2+2XT1-6L(HS+IT^\/>,8E=FA?<-J9;:#M;E3G%`'67.JV5IJ5EIT\ M^R[OO,^SQ[2=^P;FY`P,#UQ5RO/[?QCXD3Q-X,TS4M-L;>'7;1Y9L>8)HY$M MQ)(I1L;,.P&"6.`';F:WEM)PXGN?)4-(PD# M;8QR=ORMG':@#T.BO.M9\=>(;/3/"6IVFE:8;77;JUMV5KJ1V4S$LH'R+_`/ MO'H3]T@9.QIGB+5%^(-YX6U5;.0_V>NHVLUJCIB/S#&R.&9LD'&",9';T`.M MJ.>>*UMY;BXD2*&)"\DCG"JH&22>P`KRR7XO1"W_`+934-"&F"]^SG3VN/\` M3C#YGEF;&_CGYMFP_+SNKK[S7=4O_%%UH.@_8HY+"".:]N;Q&D56DSY<:HK* M&'(XYK4KSGX0- M,UEXN:XB2*<^)KPR1HV51L1Y`/&0#7HU`&?J>NZ/HGE?VMJMC8>=GR_M=PD6 M_&,XW$9QD=/45)INK:;K-NUQI>H6E]`KE&DM9EE4-@'!*DC."#CW%<3\;T1_ MA%K3,BL4,#*2,[3Y\8R/3@D?C5.\U_4?!_P$T76]'CLC+:Z=9,\=S$S*ZNJ* M<;67#;G!SST/'.0`>G45Y%J7Q+\5:6O@J5M.TFY_X2:W7R[=#(ACF81[?G)( MVDRJ<;ZT^WCN([BRC>-74A"059F/'F+SG ML:`.^HKQ_3/B-XOOXO':-%H?F>%]Y$H@E"S;#+D;/,/41D@[N.F#G(KS_%OQ M+:^#M%\8W&G:5'I%[>+:/;#S&F.`^^0/G"C,;`*58].3F@#VBBO/O'7C36?" M_C3PEIEI'826&MW2VTHFB"#US@1Z7XS\07WQ6\1^#7& MF+%8V37%I<+;R;@S>44$@\SY@!+SC;G'&*`/1:*\2TSXL>++[X7:GXR:VT5? M[/OEMW@$,O[U"8P<'S/E(,@YYSZ#'/9^(OB&--T+PW<:?:I+J'B-X4LHI6.Q M/,"G*?%-AJNJ>#-/TVYM+"^-G%;W6X2W>T*6<^@QS[!H^HIK M&B6&IQ+LCO+:.X529G_=SFO._ MCAK]]9:=HOAZPN'MFURZ,,LL9PWE`J&4'MDR+^`([UZ!#X6T*#0%T-=*M3IH M39]G:(%3QC)]6]^M`&E;W-O=P^=;3QS1;F7?&X8;E)5AD=P00?0@BI:\VO;^ M/X4>&-!\,:6JWM[?W[VM@)\JJB28ME\')"^8J\8SUXS6II_B^_M/B`/!NO+: M27<]H+NSN[.-HTE7+!E9&9BI&UOXCG':@#M:*\F\/^//&VOW_B[2[2PT>XOM M#N5AB*QO$DV)'1@=TAP2$R.<#!SG(K1UWQKXDL/B]IO@^RCTI[34;7[1')-% M()(@%DSDA\-@Q$XP,@@9'WJ`/2**\S@^*,VDW?BO3O$UO;_;=`B6@#TZBO.-;\;^(--^+^F>$+:'3IK+4;4SH[0N)8OEDZG?A@&CW=!P<=> M:O7OBKQ+I5IXVGFMHWFM[0!L*Y"G)W*0<;AC#<\4`=S43W M$$9D#S1KY2>9)N8#8O/S'T'RGGV/I7!^#O'UUK/CC6?"E^^G74UA$)XK[3MP MBE7Y-PVEFP07`/S'D'TK@]*U?Q'?ZC\6+N:\TZY73XV@G@N[.1DFAB^T`1IM ME4Q@@-UW?>^I(![O:W=M?6L=U9W$5Q;RC='+"X=''J"."*FKS3P/XILM%^!5 MIXBFL(+2UMH9F%K:E@F1,ZJJEV8Y8XY)/+&F2_$/6M%T7P[XCUVWT\Z/K4D: M&.V1UEM!(I="69B)!@9/"X]Z`/3J*\TL_&?BF^^*VO>#81HRQ6-J;F"X>WEW M8(C*A@)/FXD`.,=,_P"R=CX8>-9O'GA$:K=6\4%U%.]O,L.=A8!6R`(-2UFVU'2M.T>R1FOGD\Z^GB:2&T1%W9=5*DECP!N'/>@#?JG MJ6K:;HUNMQJFH6EC`SA%DNIEB4M@G`+$#.`3CV-2UNI#_QY7,D89HF/9&))4]N1ZFNUTF>T MTF\\;W\J+'#!J`FF95`.U;*W=C^K'ZDT`=717F&E?%$W5_H+W%]H,EMK4P@% ME:7&^ZLF<$Q^9\QW9.%;Y5VD@I16<)9&.XJ>QVJ1GWH`Z!O$FA)J'] MGOK6G+>YQ]F-T@DSZ;6[3Z7=(9+>&8H1O1 MU/F,K!76'CSQ9J'PPC\;166DF.)999[/;)NEB21U)5]WR$!>X;.">,@5 MOVWBV\\3:B]CX9:SB$-C;WDUU>QM*J^>I:.,(K*=_P#" M>:V?#'B*0:=IZZ]X=9_M\#S.(FC6,N)(\*2=P'"G'?)]7P^)O&<^@Z'JMOI6 MGW*:O!:J$B24FUDE`+2R8)S"%R<<$$@9/6@#T&H;NZ@L+*>\N7\NW@C:65\$ M[549)P.>@KC=(\5:G<^--3\)7=WI5Q>16'VR"\LHF"(=^PK)&9&(8$J<;QD> MF:Y;P-K/B?3_`()CQ#!+IM$X[N[,5Q')&XVRRO(Q<,PMVE MU!?V4%Y;/YEO/&LL3X(W*PR#@\]#4U<8OC*[DT+PCY4%N^L^(H8WC0DK%'^Y M$LKXR254=%SDY`SWI(/$VN:?XL_X1K68M.FNKRUDN-+NK_%`':45YA9>-_%M]X4\5:K]ET:"X\/WES"Z$22),L"!G4'VT=PJDY*AU#`?K0!=HHHH`****`"BBB@`HHHH` M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"N%^+.FZSKW@:ZT+1=( MEOKB]*9=9HHTA"2(_P`V]@3G&!@'OG'&>ZHH`I6!-[#;W]WIC65Z(V3RY_+> M6($C_B?18TN6NK=;;4+%G"&4+G9(C'C>N< M8.`0>H(YZRB@#C=;@UOQCIDVBG2I]&L+H!+NYNYHFE,61N2-(G<98<98C`SP M>*R;73=:L_BY%JD/AB[CT2'2%T:*47-OP!,&$NWS-VS';[V.V>*](HH`\_M- M)UOP1XDNET+2)=4\-ZBQN&M89XHWL9R?FV"1E!1NN,\'T[]^I+*"5*DC.#U% M+10!G:_I$&O^'[_2;G_57D#PDX^[D<'Z@X/X5B?#[1]7TKPVC>(2C:Q+M6?: MP8*D:B.,9'7Y5W'W=JZRB@#C-6MKW7O%UK9:IX4DNO#MLK$2S/;21R3G`#M& MSYV*N_'!;+=!BL?Q?X2DTK4="U3P/X3MUU&RN_-E:S%O;($!5XW)9220>.# MCGI7I=%`'FVO)XDU'Q]X4UN#PCJ/V32%N3.#=6@=C-$%PH\[!VD_1V M^I>)-1\26UMK6259)"'=6=V*$J,^6@`!/0\UT5%`'FN@+XCTWQUXLURY\'ZF;;5S: M_9TBN;,NHAC*'>#.`,Y!X)KI/#\NMW&M7K7&BG1='CC_`-'MG:%GGF=R\DK> M6S!>>V>2[$Y/3IJ*`(YY&AMY94ADG=$++%&5#.0/NC<0,GIR0/4BO./!?AW4 M+BP\5Z/XH\-SVUGK6I7-^&>XAD39+LPGR.6#C&0<8XZYQ7I=%`'!>'[CQ?X: ML9=$O=`N]9@LLQV.HV]U;J9XA]P2+)(I#`<$\]._4Y_@2UUOPY\.K/PWJ_@K M4;N2))DF5)K)X9%>1VP=TXR,-@Y'KUKTVB@#B+GP]K/B_P`'E-=(TW5Q>_;; M*-2L@LFC;]TI*\/P,DYS\YQC`QI)K7B7R%@?PI)]NQM,PO8?LF[UW;O-V]_] M7FNEHH`\X\;:7XFO8_"MK!IMQK$NFZK;ZG>7D;V\*ML+;D1&=3GGC/&,98G- M:NJ:CXBOI+9=+\)7EE>.X@;4KR2T/V6%F4R,H65RQPH.W&"0">> M*[;7[CXD^&-5L?#=W=Z?HOVGS9H[FW4R^=$%^17D!^7ONQGG'')[+7](@U_P M_?Z3<_ZJ\@>$G'W^()O$#31>&;C3-,2&2YN=\EJ9[^?:J(F%D('`'S,P^ZH)`%87@D M>)O#L?B#[;X.U%I-2UBXU&(0W=HRJLFW"L3,#D;>P->ET4`<;I'A_5]1\8?\ M)5XB2"WDMX&MM.T^&3S!`C'YW=\`%VZ<<`>M=E110!P?A'3=<\-7_B>&;1VG MMKS5[K4XIX[B,>8DB@K&BDYWY7!W;5YSNK$T?1/$T7@3Q]97/AV>&_UF\N[B MU@^TP,'%PH0#<),`KC)SCCID\5ZO10!XS::'XXT:^\->(-,\.^;=:?HT>BWV MG3WD*&5$PWF(X8K@GUY&W[N.:]/\.-K;W^A^+KWP?X M*TZ'P]LN=`O[.6=9KR("40(PW*59OE.!U^;+#Y2`37K=%`'G'A&W\2VWC'QA MKVI^&+BS75(+:2WB%W!(2\,90QY#]6)X)P.#DBN;\-^#_%FF>'?"4W]B/%JW MA>XN";>6YA*7D-PS;Q&RN=K!2/O8'/!->UT4`>>16'B:?XM0>)1H"P:<^D+I M\GVF\C$D>9C(Q(3?EACH#@Y'S#D#&\*:3\1/">EOX0M=*M7L$F<6NM_:T_<1 M,Q8L8B"689)`(`R>1R MQSGY2-M>D44`>8:MIWBI/&7@N\&AW>J1:!;RQWEY'<6ZFZDE@5&9%>0'@@D[ MMO?ZG"EM-;U/7_$5TG@6/Q!8W.HLJ7%KK@LX98XP$5)(\@2D%3DL#R6'05[9 M7*Z9X&AT*(VNBZYJ^GZ?O9Q91O%)&F220IDC9E&2>C"@#C=;OO$/C"U\/QV7 M@N]MI=#URWN;Z`W-NJQ>4N[RT+.NXE)%(.`O(&>N-Z>QUR+XTC7$T*YFTDZ2 MNF&Z2>`88RB0OM9PVT9P>,\'`/&>WM+.&Q@\F!2%R6)9BS,QZDD\D^YJ>@#R M/PII/Q$\)Z6_A"UTJU>P29Q:ZW]K3]Q$S%BQB()9ADD`@#)YR*Z,Z3K/A_XB MZKKUAI[ZGIVM0PKU=S10!YIX6M_%GA2Q\675 MUX>MI?M6J7&I0(-212^]E&,D850JEMQ(/;;GIZ!I=[_:6DV=_P"3)!]I@2;R MI!ADW*#M/N,XJQ-#%<1&*:))8R02KJ&!PE,NLT4:1!)$?YM[J3G&!@'OG'&<37M#\1ZK\"8?#$/AZY35D@M;,PO<6 M^/W7EL9-PDQM.P@#.[)Z8YKU6B@#Q+6_"WBN\3X9-!X:N6_X1Q(FOE^U6P.4 M:(%5S+@G$)8_!30/"<7AV;^TK+4))ILW5N$"9D((/F:_$7PSK7B'4O!FOZ;I[RR:/>K61]['/!-4=&T M/Q/8_&G7O%EUX=F-A?6!AA\FZ@9MRI$54@N,$^5M]`Q'.WYJ]8HH`^?M)\"> M,;+X)Z]X3E\.S?VE>ZA'-%BZM]A3]V2<^9V\G!'^VN,\XZK4_`VL:GX2\!W< M5GY.M>&#`S6,\J?O0GEAP&5BN28E(YZ'G!XKU>B@#SNT\+ZGK?Q9A\::E92: M=:V%E]FM+:>2-Y78[P6/ELR@8D;^(GD5E^"?#OB?X;R:YI%IHKZOIEQ,;C3Y MX;J*,*Q`&V178,!@+D@-]WH:]8HH`\ET+0_%5A\9-<\57WA^5[2[T_[.KP7$ M&'E1(N0IDR%8Q$+GD;EW8Y(M?!OP_K_@WP9JEAK&BS170NGNH8TGA?SP8U&U M2'P&RG\6!\PYZX]0HH`^?M)\">,;+X)Z]X3E\.S?VE>ZA'-%BZM]A3]V2<^9 MV\G!'^VN,\X]E\&6UW8^"=$LK^T>UN[6RBMY87=&(9%"$Y0D$';D<]",X/%; ME%`'%?$KP(?'.AP16MPEKJEE+YUG.^=JMW!QS@X'.#@@5=L]<\3"SABOO"-P MU_@+))!=V_V8M_>!:3>!WQL)'O7444`>=>-?!VM^((O#6LJ;6;6M#OA=FWC8 MK'*A=6,:LW,XI;3POJ>M_%F'QIJ5E)IUK867V:TMIY(WE=CO!8^ M6S*!B1OXB>17HE%`'E_PQ\/Z_HOC'QE?ZOHLUE;:S=?:K=WGA?`$DAVL$=B& MQ(.Q'RGGIG(\72W$'[2WA:2UMOM,JZ4Q$.\(6&+G.">,XSC.`3@9'6O9ZY*^ M\`65_P"/;3QA)JFI)J-HJQPQHT7E+&`04P8R2&W/GG/S'!'&`#BI?AEJ?BW5 M/&FLZQ%_9$O$&E_&34_$-[I-M;:;>Z:L$9LYD,<# M`0X3!PW'ED9"X/'3/&4/"'BO0[OXD0VFA-J4?B7>;6:*[AC5`_G9W!V!R/-' M&,':>>F?::*`/+/#W@34[[X%OX+UBV?3;X"1`7D212WG&9&!1F^7)`/0\'CH M32U7P7XA\5^$_"OA&_TMK"UTMX?MUXT\31RK%&8QY05BY)!/W@N,U[!10!Y5 MIFA^([#XW>(O%3^'KE],N[)K>W9;BWW.R+%@X,F0&,)`STW+G'.(/A=I'B?P M!\/=9@U#P\S7T=V;J&%KV!4F1E13\X8A=H0D[@.,8SSCURF30Q7$1BFB26,D M$JZA@<'(X/N*`*^EWO\`:6DV=_Y,D'VF!)O*D&&3)M0G MT6.TT[5%LS`T<\96,11,I7:.=V2.,8Z\G`SVFHW-Q9Z?-/:V,M].@^2VA=$: M0YQU=@H]3D]`<9/%6J*`.0T#0CJOPTL_#?B31Y;81645E/!-)&^_8BCS$9&8 M`9&03@@CIT)S?#/@O5;/P=XJ\.ZK?-,1K%@D%@`NXXP,G@UI> M./"^K:CKND:QX?D6&]4/I][)N`(M)0=SI]J[JB@#B/%^B:G+<>&H M-,T\WOA^RD9=0TN*98S,@0+$/G*JRJJR^(_&\=WI"6.E^( M;."WBDBGC9856W>-AM'.[+#C&.O)P,^F44`>1:QH'C'4?A#)X);0@]]!'!;) M=K=1"&:*.1-K+EMP.U1D,HZ'DG`.Q:Z?XGG\;76J:]X>BO;>2"$:;&M\DD.G MN!\^X,%.YCSO5&(Q@9%>BT4`<5\*]'U;P[X#L=%U>P^RW%F9`3YR/YFZ5WR- MI/&&7J.ZM)\9\J9#E21W'4'V)K?HH`YI- M:\2^0L#^%)/MV-IF%[#]DW>N[=YNWO\`ZO-9/B7PQKL[^&=6179ESOW#+84*0>#D=!U&G^%]3\$>+)-0T:Q MEU72;S3[>TN+>*6-)HW@01QN/,958;`1C(.372>#_"-OX+TG^RK+4;^ZLE.8 M8KLQMY.26;:513R6R("VB M$)B0N[,`2!DG:3RP`R`33;G2O%4_POT#2K73+FVN[![2#4+,W<2/=V\:`2+' M(CD`,<#DJ<`_CZ710!YUIVA:K:?%&WUNV\-I8Z0VB_V>(TFA7R6\_P`PEU4\ M';GA=PSCD9.,K2=$\5:+\'[OPA_PC>+%U$8DCEV.C,HR%XW8[ MY[9WWT_4=:\5:=XDO='N+./1;:X^RV;RPM//-*H#?=&/#6I^&;FS`LEM6NGNX7`DBBY(1&8["%^\<8+`8Y!KNZ9Y,7GF?RD\XK ML,FT;MNZ=J%U:*VV62S1&\K)`!;^.+?3O$>D:)=:1J M<FK8>((-2T76&T^Q+6MW+'`'20-' MN;:8W+`;#DL=H&1D@\5YW<0ZMJ/PWTOQC=6\BZEX'OA!K/]KW,-O>7]E<^9YC@&2ZF1V\M?[QR2`!V7T%`%6[\9SV M&I>`+#0=)O)-*U6T>=(5:+S9(EM\I%^\<`%=R,Q+#I@%N155/*T?X\RRPVU] M(]YX<:X-MYAE"C'':L2RUG3?.^$6J"^@-C865Q:7:"X0+)#*APR,`2,CV)ZUKUYC\(M:TR]N? M&%M;7]M+/+XAO+R.))`6>!B@$@'=2>,CCIZUZ=0!S&J>.M-TGQ19^'I[34GO M;L-Y)CM3Y;E4WD*QP&[#C(!(SCDA+77-+\7OJOAVZMM0LKNW51=6D[&&78Q^ M5E>-B"IQU5O8]:Y[QY?VVF?%+X>WEY*(K=#J(>0]%S"@R?0#/)Z`9)X%-L]2 MTV?XE:OXU6\@C\/V6CII\E^S@0S3&7>2C=&P-JY&*;73O@AX>2V^PW%U;:DL5U+-&)O[+$D\K"Y9.HPOW M3QR>O45=O4@N?B3JEM8:O<7TNI>$)[6VNYWW>=.\V`(R`%VC@_(-HPQ[$T`> MB)X]TQ[K3Q]CU`6&HSBVL]1,2_9YI#D*!\V\`XX8J`>H)%.U7QUINE3WRFUO MKJ#3BHO[JVB#16N1GYLL"2`02$#$`\XKFO`7C_3FT+0O#`MKUM?M(8;*ZL?L MLBM;A`$:1V(VA0!GKGMUKD8-1\/Z+XE\8Z)XR36DFOM3GN+2&WN;M8[V&7A4 M"1,%8D`#)'.<$\8H`]Y1TEC62-@R,`RL#D$'O3JHZ)#]GT'3H/LAM/+M8D^S M&4R&'"@;-YY;'3)Y.,U>H`Y[4/%UO:75Y;6>FZCJLMB%-VMA&C>3D9`.YEW- MCG:NX\CCFN6^(?C=F^$MUKGAO[3+#=1!5OH2J"VS(J'<&8.&^9E&T'!'..M- M\+ZQ;^$/$OBW2_$EU%8&[U234K*XN7")<12``*C'@E=@&.O/2N.\5)#H?P3\ M20WDHM9-=U>2\TVRF.R7R3<1L`$/(PJ[B.VX9P30!ZCX7\,Z?I^IW.L66CW^ MAR31BWEL998C')C!$VV-W&[^'.[/!R.3^%Y4\-?$CX@6ME8:GJ"Q"P=(8I/.DP8G=OGE<9Y&()`P.<]!7/:UH6II\#?&$SV-@"O8[4+$=L^M`'I=UXPM[+QI8>&+C3=0CGU`2&UNRL9@ MDV1[WP0^X8Z8*]<=CFJ\OCRRA>R:33-46TU"XA@LKP0HT,YE<*I!#$JO.[+A MUB:9HCSGM07#>;!D!E2/[ZM@*0H.3Y'\L)$3NSM4\!03D=&\`ME5X=H!9B&8<#/(^\,'Y<E8^A:YIDWPU^*L\=]`T1RQ')`ZTVV\7Z?>Z);ZE M9Q7,[7,S6T5HJ!9S,N[=&0Q`#+L#PS-X/M1;V.K6.EZGKQ>VU".YG M:Y63R78W@\P,X!*,"#_"2^>30!V]IXXT^Y?4HI;+4;2YTY8#/!<0A7+S,RQQ MKAB&8E0,@[?F'/7$^F^+(+_Q!_8Z,=U&@7RU=%R'1F5LEQC:3 MT.<<9X#SPO@_Q!'K5Y%XHT[?96\>KZ>@6>97GVA-R!M\D)8.,9R6QU)K:\"? M:8O$,MJGB&#Q-IT5H_DW[J&N;(ET_<22#J6QNP>BUCZWXDM-#N+" MT>&XNK_4'9+2TME4R2E5W,1N*J`!R22!6Q7#>/=:_LK6_#,+_9[**[GFCDUJ M:%7-B-@^5&8;4:0D+D\<'(-`%BY\>12>&?$E[9:?=IJ6B1.UQ87(1)(VV;@2 M0Q4KC+9!.0#C)P#?\$:Q?ZYX1TN]U&SN8;B2S@=YIO*Q<,T8)D41L<`GG!"G MGH*\RM#;_P!K?%BPM+BZNY;W2X1:^=O>6X_T27+#(R1DX!^[RH'4"O1/AQJE MGJ'@/0X;2<2O:Z=;13%5.U'$8!7=C!8$$$`Y'?&10!U=<&+J3Q1\0_$&@W5] M?6=MI%O;&WCL[EX&E:52S2DJ06V_*H!^7KD'-=Y7!^+9_#(UII(;634/%D47 MDQ6VG7$DP'0>E;7 M@3PPWA/PQ'8SNDE[-(]U=O&,*9G.6Q[#@#V%*9;?4[VSCTNY;3M.%K.8U6>-07=P M.)/F8#:V5P.F,K/4)!'+>7\FJ:#I=)\5CQ[-\\G_;3\*Z"@#/UK M2AK6E361O+RS9Q\L]G.\,D;=B"I'Y'@UYMI&G7>L?"O4K*37=9M?$&DS7,=Q M=_VG-N%Q'T));_5E0AQT&21SDGUFO)_&&FZA9>/3I^GQN;#QE$EM=E(C MS'X]8"P[9//:@"UI.KQ:M\#+>^@NM1:[E@6$/_:$HG:\+B,#S=VX`R$<=,'` M&.*T;:?0M%\6>'/#=XNM7VM(LWV34+QI71F,.Z4^8[8;*@#`W!20..:P]%T2 MZT[XH7_AA(`NA)=+X@AP,*I*E/+`Z`>;A@!_SSJ;QMXCT6R^,7@=+K5+2$V` MOC=F250(/-@41[S_``Y[9]0>]`%NSLH;']H6X$+38N/#C7#B29G&]KE02-Q. MT85>!@#'2MZ7QY90O9-)IFJ+::A<0P65X(4:&BG]H@K_:EID:#_`&?_`*U$]1'G/:@N&\V#(#*D?WU;`4A04CRG=OFD;U<\%LG/&:V]2\:^%M3M_"T]S::CV\FGRI`ZI'.6*I MO?(7(.[*Y/`)P>,Y/@OQ'HUS\3_B+?PZI:/:F*RF$JS+M:.*%ED<'/*J<`MT MY'K7GVE>)=%@^%_PYL9-4M5NK+Q)'<74)D&Z&)9I6+L.H&'4Y]Z`/;M3\WFX0,EJ1$Y5-Y"NV`W8<9`+#..<1-X\M?+01Z-K,MX+IZ5X:^+WB"7Q9+JMGIVIP6SV-U:7-U$A,<>UD/D, M"QR6ZYQ[;J`/8=,U&UU?3+;4;&42VMS&LL3@8RI&1QV^E6JP/!=O:6OA&PBL M--ETVS`=H+661W=(R[%22_S`D$-@_=SCM6_0!YC-IAN/C=/I,FJZW_9TVAG4 M3;)JUS&BS&XV$KM<$+C^$<#L.E:'AN^N[+XEZIX:@U*YU+28=.CNM]S+YSVL MQ*],U&_L=(U.)+ M&1H6BN%B1Y)5&6C4>8<,.!\VT?,.>N.3\#^(]%OOB_XY%KJEI+]N-D+39*I^ MT>5"PDV?WL=\=N:35K._T/X@W^D:?'(++QC$&$D?2VF3"SO[9B);/=L"@#JK M?QW9W.E:9=QZ7J9N-4W&RL=D?GS(!DO]_8J8P=S,!R/45R_PR^SCX@^/4M([ MR*!38!8KUW>6-O+D+JQ8DGYBW(]+M_BIX_NI)I!:SQV:EX-FUW7+N;5 M=>\/_9K:2T,,D4K0(HF,IP67$M$':212DK'**"$!&['1N3Q7"VNGH&\3M.`2!Z4`=U=?$&QM$\.32:7JAM/$!MTM;E4C,:/-RJ2?/D,!R<`C' M0G!IL6OZ+P4Y<\-C!P?FQ7GFJ^(-- MF^'_`,-%@N//;3]4TPWBPH9#`8HF#JP4$AAM;Y>I`/%;EOXIT.Y_:`22/5+8 M*_A\62[WV'[0;D,(B#@B3!^Z>0>,9XH`Z'X:^+=0\4>$(-4U6SFA\PSR?:W: M(0LHFL/'>FW]]80K:W\-MJ+,MA>S1!8;HJ"<+\VX M9`)&Y5R.F:XGX?2&[^!ESX;M&?\`MN*POXGMPK!H9&>4*K'&%8[E(!Y(YQ67 MX'U7PMJMCX:TEK+6;KQ)I\T`>QGO;SR[5XL!I]I8QJ`N2%P.NW`!H`]RIDLL M<$+RRNJ1HI9W8X"@:QIR6MG>6]M^^5Y1<6S3)*@YV%0Z'!. MW//(!!!!-`'&Z+KFKZC\96AN9IHM,G\/F[M;(DJ%4W"JKNO]\@$\C*AMO8Y3 MXG>((+.^L-,U"[\1Z5I;(T]QJ>D1LNUL@(AD`.%QO+`9/"^M58(->7X^Q+<: MEILDX\.!I'CT]T5H?M7*!3,2'S_'D@?W37;7OBWPU!J=SHM_J=K%=H@\RUN/ ME,BL,@*&&),@]%SZ4`Z\(7&F^"!>6%K,+>P\2KKMI8&-M\=NK`;`G4<;G"]<''6M\RV_B_XH:'J M>E7$=WINAVMP\EU$=T9FF4((PPX+!1DCMQG!-`'H-%9FF>(-*UF\U"TT^\6> MXT^7R;J,*08WY&.0,\@C(R.#Z5IT`><_%*":.[\*7-MJ6J6C7>N6NG7"6E_+ M"DD+EBP*JP&[C[PY]^!@U\S>$?%'AF/1M5U"8ZCJ*VMSIUU>R70:%E.Z4>:S M,NS`/!Q5+XRZGHRMX3TS4KJTYUZUN;BWG92/LPWJ[NI_@Y(R>#SZ&LSQ4OA2 M!K.Z^'+V`\5FXC2V31&4HZ%AO$ZQ_*(]N&SM%4R,B_>8EF5549`R2.2`,UA:I\3=)TOPU;:__`&=JES832M!(8(DW M6TH;;LE5W4J=V1QD<=>1GE?B!>6F@_%?3-8U_P#M&'09])-F;JSGGB\J7S2_ MS&$AB"-O'.>N#BNCT'1-"\2>!=9L=/L+FVTG59IFCFN999)+@LJ_Z1^].X$N M"0">=H;^*@#H-4\2'2O[(631M1FEU.40K%#Y):&0KNVOF0#@!B2I8#8>>F:> MJ^.M-TJ>^4VM]=0:<5%_=6T0:*UR,_-E@20""0@8@'G%87PYN-3UQ()-9@>. M?P_&^EL7Z2W`.UY!ZX18P#ZN]<3!J/A_1?$OC'1/&2:TDU]J<]Q:0V]S=K'> MPR\*@2)@K$@`9(YS@GC%`'J>H>/-*T[Q)8Z$]MJ$MU?!C;R1VQ\J3";\*YP& MXP,KD`L,D^&WN9+:_9O,CD-V%/RLQVC"#`4XQC%4 MM:US1M-^(OPWM+BYM=..F6ERMW;RW6_[%OME"([MWXQEL$\'O5X>(]%/[1!7 M^U+3(T'^S_\`6KC[3]ISY6?[_P#L]<\=:`.L\-^-8/$NKZEIL>D:G93Z<0MS M]L$2[&/W5PLC$Y&2#C;@=>F='0==&O6]Q.FG7MG'#.\`-SY?[QD8JQ78[9`( M(SQ7&^.(M3\.>+=/\3:%!YLNHQG2;F(#AI&!-O(?]U^"?3BN]TO3XM)TJUT^ M$DQV\2QAFY+8'4^I/4^YH`MUYH+&0?'?[!_:VLFP_L?^U/LG]I3>5Y_VC;]W M=C9C^#[O;&.*]+KR#4;SPGK/[0`M-4DTF^A31!9".Z"2(+O[23Y8W9'F8)&. MO)'7B@#4\8V,C_%7PA:IJVLP6FK?:_M=O;ZE-%&_DPJR856&WGKMQGZY-;UG MKFA7OQ*N-/CL;^/78-.;=/-$\<;6ZR@84,0&!<\,%P<'FN)\1R^#?#'QA\&+ M9C1=*-M]L^W^0D<(CWP`1>:0!C.3C/KGO6@/$>BG]H@K_:EID:#_`&?_`*U< M?:?M.?*S_?\`]GKGCK0`OA30K)_B!\1]%8W1LB-/&#=R^8`T3N?WF[?]XGOW MQTJ;X4:LNG_!WP_++'/=7%Q+<1PPQ8,DTAFE8@;B!G"LQ)(&`3FL[PSXU\,V MWQ/\?WT^O:?':W`L3!*UPH6;RX65]AS\V#QQFN?\*ZCH-[\%_#.DWEU.)DU) MXI)M/F(N=-D)N9$FPH)`VJ1T`VLQS\IH`]AT/Q1;:YJ-_IZ65]9W=@D3W$5W M$$*^9OV@$$AON$Y!(Y&"><;E>=>%-:71+#6K_6]>LM7TVT6!4U^"'+3*6<") MRF=Y0L.F?];ZYKT"UN8+VTAN[:598)XUDCD7HRL,@CV(-`$M<197-WXT\1ZU M#]NN;70])N?L(CLY3%)>Z'+%X#\0^(K7695 MM=-U74'U.TOY>(=T@'F1N_1&!7@-C(Z>E`%Z3PUK6G^,-"N=,UC49M"22;[= M9W-T9=N87"-O,+6W<#)1WXWX[[1N? MZ*:AL/$MKK.I)!H^V_LU5C<7T3YAC/\`"JL`1(Q/4`\`9)'`/.2:SIGC#QO_ M`&;IGB?[+)I$98&S>%GEF?(;:)$<,$0$$@<&0C/6@#0^'6N76K>&S9ZHQ.L: M3,UA?;FR6=.`Y/?1WNHV/PY^*MO-?>(CO/%>M1R)+ⅅJ\;@,K*A!]*`*.NZ@^D>'M2U*.+S7L[ M66X6/^^40L!^.*\UN]4O='^'.D?$"+6;ZXN<6UQJ,4EPSP3)*RK)&L7W4VE\ M`J`1MYS7JMS+;V]I--=21QVT:,TKRL`BH!DEB>`,9SFO*)?#.A^*KNST?PO: M3+X=BNA=7]T)I3:G:=PBMT9MF6;EF08`[DG%`'237$_BCX@ZKH7VR[M=.T:T MA:46=PT+O<399264@X5!PO0D\@\"HO#NIZYXD\)3Z>E_Y.IV6I3:7>Z@BJ64 M1$YD53QO9=H]`6SC`Q48GM?!_P`3?$&IZM<16NG:W:6\L=S,=J>;`I0QYZ;B MI!`ZGMT-0>%;^V\$>!]3\1>))#8KJFJ7&HF.52)!YK?(FWKN*J#C''?�`S M2[#6_"7Q+TS2(?$.IZWI6I6L\MQ%J4OFR6OE[=KAL#@LP7'`Y/M5SXD3ZAI^ MI>$;NSU6]MX[C7K.RFMHI`L;6KIUEFB;:ZP1)ODVGLQ&! MGJ,G'."(]!OI]*\?:GX3FNI[FV-E'J5BUS,99(T+&-T+L2S#<`1N)(SUZ57\ M8HG]M^#O&$$B3Z?IT\@FFC.]!!<1[/-R."@^4YZ8.>F:;H"+K_Q0U3Q3:.LV MEP:;'IEM!= M-T"#38KF]N-3UFW@N[DM&9)F8@N,.0-SJI4=%4#&5PM9GB4QVOQ:\!ZO):W] MO/>"^\ZUDE,K`K`%0!%9D4_.?NG'.2>IK3^+!$-EX5O)#LMK3Q+93W$I^[%& M-^78]@,CGWK*\0^)M%O_`(P?#];?48&:$WHD5CL*&6$+$"#@@N1\O]X%2,@C M(!W6B>*;/6Y-3A\BYL;G3)?+NX+Q55H\KN#95BI4CD'-4[#QWIM_?6$*VM_# M;:BS+87LT06&Z*@G"_-N&0"1N5Y4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%%`!116%K?B2#1M-)6C=U+C:%C&WHS;L@ MGC"-0!NT5SVC>(UU^77+2SFCAOM/N'MC'+`Y\E@65&?E0X;;O`4CY2!G/-<9 MX1\8>-_%6L^)M+6;P];S:'T:_O9+*SU:PN+N/_600W*.Z?50E9S:W?3^)=*337TV M]T*\B]\1:QH&H+<26%KJ<%RT4% MS;(TEO*%VL#A\$C)9&]U8@]*T/#>O)K^F/,T7D7=O,]K>6^[=Y,R'#+GN.A! M[@B@#8HHJO?:A9:9:M=7]W;VENOWI;B01H/J2<4`6**X+P-K^KZGXQ\6:;J. MJVVHVVGBS:TEM8%CC*RQNY(P6)_A'+'I[UUIU[1QJ@TPZM8C4#TM#<)YI_X! MG/Z4`:%%4]0U?3-)6-M2U&TLEE;;&;F=8PY]!N(R:6^U33]+M!=ZA?VMI;$@ M":XF6-,GI\Q(%`%NBH+6]M+Y7:TNH;A48*YBD#A25#`''0[64_0@]ZXWXKZQ MKOAWP/=:UH>H0VCVA7S`]L)6?>ZH-I)PN-Q/*G/MW`.YHJI#JNG7&H3:?!?V MLM["NZ6V296DC'JR@Y`^M-N]9TNPNX;2\U*SM[F?_4PS3JCR?[JDY/X4`7:* MJ7&JZ=:7*6US?VL,[@LD4DRJS``L2`3D@`$GV!-5Y?$>AP65O>3:SIT=KOH?2K.GZG8:M:BZTV^MKRW)*B6VE61,CJ,J M2,T`6J*X7Q)K_B?3O'V@Z%87&D+9ZT)_+DN+.622`PQAVSB50^<\?=QGOC)F M7Q'KFG^*+;PUK"V'VG4[>9]-U"VA<1&2-'X)M+U2;3C'_9\Q64Q[#_`!2?$FC7=S>6 MZ6=WI]W+97J!]T:2QXW%6.,K@@Y_PH`Z2BN3TW6M=\4V9U+1#86&F.2+6:^M MWGDN5!QOV*Z;%/;))(YP,U-8:_J,FJ77A[48[6TUI;8W%K,FZ2WN$SMWA25; M*MC;>!_'^LZKXQU+PUXDM["&XC$K64UHCHMPL4SPR'#,W\ M2''L#6O\3/&5SX)\)3:E86\5Q>[E$:3`E%7SE"2;Y%1?+`ERN-W.2<]?EZ5=\3>)K_`,(^&].E MOOL5UJE[>Q6*R*K06RR2$X9LLQ"*H.>><=L\`'745R,FK^)],\3:#IE_%IMU M9ZC-+')>V\;Q%"L,D@3RV9L$E/O;CP#P,@UEZ-K?C+5?%WB/07O]!A.C&W_? M+IDS^<)D+CC[0-N`!W/6@#T*BL+0V\3KJ>HP:]_9TMHBQ-97-E$T7F$[]X=& MD<@C">WS=3SB_K5Q>VNA:C<:;`MQ?Q6TCVT+`D22A254@$$Y.!U%`%ZBO.[_ M`%WQKIOB?PQH5Q>Z`9M:6X+R)ILQ6W:&,.0/](^<'.,_+Z^U:L7B35=!T#5[ M_P`70VWF6EYY-K]@B91=HRIY>Q69CN9F*XSP1[9H`Z^BN;'_``FDT"W*OH=L MY&[[#)%+(1_LF<.!GU(C(^M7/#GB"/Q!93N8&M;RTG:VN[5VW&&5>HSW!!!! M[@CZ4`;%%<;\3/$.M^$O",^O:.=/86A7SX;R!WWAW5!M*NN,%N<@Y]L:`.XHJ&ZN8K*SGNI MVV0P1M)(WHJC)/Y"N>\$>*9O$^FW?VZU%GJEC=26UW:C_EF0TE:2W9@=H?$H!#$8W<`9Y'KK^*= M0\0PWNF6/AI],-W<,YFCOH9'"1`#,F49<`'`P:>X6,*Y=52+!Z MLP8MC.<`<'/`!U-%4-1US2=(,8U/5+*R,IQ&+FX2/>?;<1FKRLKHKHP96&00 M<@B@!:;(I>-T5VC9@0'7&5]QD$9^HK#\9:AJND>%-0U32'LUN+&![EENX6D2 M1$0L5&UE()QP>?3'.1B>`?&%]K7@5/%7B>\TBRM)R=GEHT"0A9&C.]Y)"#E@ M,=,>^>`#L+"P@TVS2UME*QJ6;DY+,S%F8GN2Q))]2:LUDP>*/#]R]LD&NZ9* M]T<6ZQW<;&8Y(^3!^;D$<>AK%\0?$31=!\7Z3X?N+VUBEN2[W'+31;S0;JWU&<"Y,VH1K((BVU6A7<"Y+!AP&R5QCG(`.SHK.O M-?T;3KZ*QOM7L+6\F`,5O/-[$@\!=RY/;(SU MK(\!>(=1\2Z%/>:H-*$Z74D2_P!F7:W$>P`%:C;6DMW;I)";=9) M`I)B+-G.<`[^#C(/2@#MZ*SM0U_1M)D2/4M6L+*1_NKHZE9V=M(P5)KB=8T8D$@!F(!)`)_"@!UMIT-M>W5X"\ES<[1)(Y&=JY MVH,=%&YL?4DY)JW6;;>(=$O+N.TM=8T^>YDC$J0Q7*,[(1D,%!R01SGTK$\' M^*+OQ'JFO1RR:/+96EPJV,NG7J3M)$=V&D"L=I.WOCN,<9(!UM%YZ8K>7Q#HCZD--76-/:_)P+4 M7*&7/^YG/Z4`:5%>?:AXTUFP^-.E>#S'8/I>H6K7(?RG$R827C=OVGYHL_=Z M''49KT&@`HKBM3\;W,_C/_A$?#=K!=:E%%YUY<7+$0VB<8R%Y=CN'`(ZCGKA MNLZYXO\`#L^E+<6VE:A:7FHVUI+=VZ20FW620*28BS9SG`._@XR#TH`[>BJ> MHZOIFCPK-JFHVEC$QVJ]U.L2D^@+$5'=Z[H]A817]YJMC;VP MKIJSTU[1Y%D9-6L66.W%TY%PA"PD9$AYX3!!W=,553QAX9DB25/$>D-')(8D M<7T9#.`"5!W&Z1Y! MCKE04^,'M M[\`'<74'VJUD@\Z6'>,%XB`P'?!(./3/7TP>:6UMH+*TAM+:)8H((UCCC7HJ MJ,`#V`%<[XEO?$=IK.BV^D7.E1VVH7!MG^UVDDKQL(I9=P*RJ",1XQ@<\YYX MV]0U?3-)6-M2U&TLEE;;&;F=8PY]!N(R:`+E%96H>)M`TB=(-2US3;*5T$B1 MW-W'&S(20&`8C(R#S[&I[C6M*M=2ATVXU.RAOYP&BM9)U660$D`JA.3R#T'8 MT`7J*S3XBT1=3&F'6=/&H%MOV4W2>;GTV9SG\*=J^J6>EV3-=:I9:<\@*0S7 MCJJ;R.."R[N<<`C-`&A17"_#[Q)?WVE>(Y_$6IV\O]F:S<60N=BPQB.-4`/H M`22>2>O6NLTW6=+UF-Y-+U*SOHT.':UG64*?HZMIVD0"?4]0M;*$G`DN9EC4GTRQ`ILVLZ7;Z> MNH3:E9QV3CT>PO8[*\U:QMKJ M7_5P37"([_12K$@`KDYZ5?U'5M.TB`3ZGJ%K90DX$ES,L:D^F6(%`%RB MJ,VLZ7;Z>NH3:E9QV3CN3PKOJ:`. M&M8GU?\`:@N+S3VWVVF6FR]=!\NXQ%-A/KN8K$\L?DB*P1QZA@<]Z`/,]0A# M?M#>!8[BZCU$KH8S=;1MG8)<$2`9(Y(W#D_6M3P8)8?C[XW@L5VZ7Y$3S*HP MHG(CP?3))E_6N^U7P?H.M:DFI7U@'OHXUCCN4E>.6)5+,-C*05.6;D8/-6M& MT#3-`@EATRU$(FD,LKEV=Y7/5G=B68^Y)H`\`\#W=]9?LV^+9].+BX%\Z[DZ MJA2`.1]$+&M7QD1I?PA^'-[HT8758YK0VS1<,6:%BZY']Y\9'>O6].\#^&]* MO+BYLM+2-IW=Y(S([1;G&'(C)**2.#@#CCI19>!O#NGW=KL:7I5CHNG1V& MG6ZV]K&6*1*20"S%CU]22?QK*NO!&@7OBB'Q+/:3-J\)7RK@7DR[`HP`%#[0 MO7*XP!R>IP`,D\"N6M?!8D\*ZK9ZG#;W5]K,YNKU3(Z1[RP(4, MN&*H%4#INP>FXT`=E7!:EJC3HFBLS#(\1MU;;G84(*GY M%Y'(YP>3D`R?AVEJNF:H\.D3:/=2:B[WVGR%2L$YCCR$*@`H5V,#_M&J'QM/ M_%H=<_[=_P#T?'7;:?IUKI=J+:TC94W%F+NSN['JS.Q+,3ZDDUG^(_">C>+; M6.UUNVEN;>,EA$MS+$A/'+!&`8C'&QVD4<*O%J$+ MA%`RBPJRJ?8'G\ZYC3+2?Q;<_$6PN=6TJU+:E/#D@M)O=0Y'32,;<($6(OLI0>7L'08]L#\JK:3X5T?1)Q/96T MGG+'Y223W,L[1Q]=B&1FVKP.!@4`N>%K)/+AUD"[T/CY8YY&$< MB8]%9@^.,*#7IVFZ?;Z5IEMI]JFR"WC6-![`8Y]ZY?2YY/%WB2TU:XT"_P!- MM=)658#J4`CEDF?"DHN20@4-SW+#'2NRH`\V\>Q7LWQ1^'J:?=0VUT3J)26: M`S(,0H2"@92HW$1BXP=@20!,CKM`SR3UK?GA6Y MMY8',@21"C&.1D8`C'#*05/N"".U`'BVCZ5XCO=%\?7'AS6KNVNX_$UZ5LHU MB"3X*%@'*;U\/^#-"\+3SRZ/;W%N;@DRJU[-(CL2"6*NY7=P/FQGWYIUMX.T. MRU^?7+2UEM[^X?S)VANI425L8RT8;8WXKUYZT`4OAM>PWGP\T18QMDM;5+2> M,C#1RQ*$=6'8Y'3WK,UA&U/XR^&DL^?['L[J>^=>BK,H2-&/J2"P'H,UTE[X M5TB^O);MH;B"YEQYLME=S6K2X&!O,3+NX]<]*L6>A:;I^G36-E;?9H)@WF&% MV21BPP6,@.[=_M9R/6@#RSQ%IUQ:>&K7QIIL9;4/#^N:C-(J]9;8WLPE3\N? M8;O6G_$N\B\0?"GQ)XA@;?9RK;6]BWK&MQ&7?_@3Y'TC4UZ-I'A+1M#L+JQL M;>86ET")H9KN6=#G.[`D9L9W'.,9[YJ#4_`OAW6-$LM&O;&1]-LT"0VR74T: M```#<%8;R,#!;)'/J:`,'XV_\DAUW_MW_P#2B.NB\5R:))9V6E:_:KF7MF;RSLY/-@CNYI)BK8902SL2V`[8R3CC&,#`!Q MLD>J_#?7M"L[75)]2\.:I>K8+9WA\R:T=@=IC?J4&.0>@'OFH]&T^ZU#XN_$ M'[)K5[II3^SLFU2!M^8#C=YL;],=L=3G/&.UM/">C6>IQZBEO-+=Q`K#+=74 MMP80>HC$C,$]/EQQ5"W^'?AVTN[F[MDU2&YNB#<31ZQ>*\Q'3>PERV,GKZT` M/\'VO_"/:?%X:O=16\U1#<7CN`27CDN'8.W&`QWC(]0V,@9KIZQ]&\,:3H-U M>75A!,+F\V?:)I[J6=Y-N=N6D9CQDUL4`>?^+?\`DKWPZ_[B?_I.M2_%:&5= M!TC4U5WMM)UFUU"[51DF%&(8X]!N!/TK8U3P+H&LZW'K-]!>/J$0Q%-'J%Q$ M8N,?($D`3(Z[0,\D]:Z(@,I5@"",$'O0`V*6.>%)8G5XW4,CJ00?2N%\ M"HUYXS\;:Y!_R#;V\@@MF'W9&ACV2.OJ"W&1UQ6V?`_A\J8UM;B.V/6TBO9T MMS[>2KB/'MMK>@@AM8(X+>*.&&-0J1QJ%50.@`'`%`'!_&W_`))#KO\`V[_^ ME$=7=3\&ZMXDBMK/Q'K\%UID4B2RVMG8&W^TE3D"1C(_&<'``K:\1^%-'\66 ML=KK5O-<6R$D0K=2Q(QXY8(P#8P,9SCG&,FM#3[+&*SMC,88@0OG3O,^, MYY=R6/7N>!QT%`&'XMFN[@V.C:=!;W%U=2B>6*>8Q(8(B&;%_B=9ZWJEE966G^(`FG7/V6\>=?M"@F%V+11X)'R=Z[0>$M'7Q$VO MB.[&IL-K2B_GP5SG;LW[=N>=N,>U+XB\(Z+XKBABUJVFN8H6W)&MU+$N[U*H MP!([$\CM0!(8Y9WZE(G>-%^@`)]RS'O762Z)93:&='D-T;,H(SB\E$A4'.#*&W^W MWN1P>.*K^'?"ND>%+1[31H)K>V8@^2UU+*BG)/RJ[$+G)SC&>^<"@#9KS_\` MYN%_[E3_`-NZ]`K'U+PMHNKZG#J-]8B6[AC,*OYC+NC)SL<`@.N>=K`C-`'* M>!FM]9UWQY#JL$WECF0-FT"@0J0?X2`YQ[FK'PH2>W\-ZE8LQ>QLM7 MN[;3W)SNMT?"X/<;MX_"N@U#PEHNIZD=1GMI8[UD$;SVMU+;M(HZ*YC9=P]C MFM6TL[:PM(K2T@C@MX5"1Q1KM50.P%`&+X[./AYXE_[!5U_Z*:O/_!P#?LNW M((!']E:B>?\`?FKT[7-"T_Q'IK:=J<.G'`K, ML_`'AS3]`N]"M;2YCTN[4++;?;[@KC))"Y?*`Y.=N-W0Y%`'@FM*MK^S5X1N MX41+A=8=Q(%&[.ZXYS_P%?\`OD>E>@>(?^3H?"?_`&"I/_0;JNOF^%G@ZXT2 MVT:73)GTVVE>:&V-_<;$=L9(_>>W3H,L1C<=>*+>*X_:=\*1R+E3IC,1ZD"Y(S^0JO\` M$O2;#1/&GPNL=-MDM[:/5G*QKG`W3P,>O^TS'\:](D\!>&Y/$-KKQL95U*T5 M$MYDNYE$2H,!54.%"XR"N,')R#DY?KW@C0/$VHVFH:M:3375F!]FD2\FB\HY MW94(X`;./FZ\#G@4`>>_&.*.7X@?#1)(T=7U,JX900R^;;\'U')_.J<4,GO>)86MSH)\VXR%6',4`,A/`&-['/UKT[7O!&@>)M1M-0U:TFFNK,#[- M(EY-%Y1SNRH1P`VZC%+#=RF]G_`'L,K^H%>IP>"]`MKAIX;.1) M/(:VC(NI?W$;#!6(;L19_P!C::?X:\'Z'X0MY[?0K1[6&=@\D9N)9%+`8R`[ M$`XZD8S@9Z"@#SGX9Z'X9\5?"#37U^VBN/LEW//<32RM&1-YC'>S@@GY2F>%H;N:XATPQ>?,)YH8[F58)'!R&:(-Y9P>>5KIZ`/%_`2OHOQ MX\8V&IG9Y)`Q5#6/#6C:\T+ZE813S0',,W*2Q'_9=2&7\#4=EX6TBPO%O$AN)[E/\` M5RWMW-=-'V^4RLVWJ>F.M`'D6JSVBR?$^ST6[%U&T4D^IS:DRE(9-D@$4"C! M9LY4,2`NU1AN\$\KW/[(RR3'>RJJJ3V"WH4?H,5ZL_PZ$R:Q>:K)H5J][>! MQ/(^Y@V\$,=I.`2"R++)$MO:6R37+`^#M%?PWX9U*[TJX34;*SB`CN_.003!0'80N0 MJL64G<%!/7)SFMS0/!&@>&-0N[_2+2:"YO!_I#O>32^:`_#%QJEYJ4NE(UQ>X-R/,?RY MB`0"T>[83R>2,\GUJ@/A1X&72I-,'AZW%K+(LKCS)-Y89P=^[<,;CQG')H`Y M'Q#_`,G0^$_^P5)_Z#=5[!7.3>!?#UQXDM_$,UK/&-AJ9V7.H;KFT9SCS(S)N`7U^5A_WP?0U[%< M75O:(C7$T<2O(L2%VQN=CA5'N20,50UCPUHVO-"^I6$4\T!S#-RDL1_V74AE M_`U'9>%M(L+Q;Q(;B>Y3_5RWMW-=-'V^4RLVWJ>F.M`'`V4D]Y^TKJ<.H+N@ MM-&'V!7Z88Q;BH]>2"55/50\;*V#Z9Q5*Z\">&KOPX/#\NFXT MKS?.:WBGDCWOUR[*P9^>?F)Y`/84`4?`&A:9%X1\-ZHMHGVYM$@@,Q)),;JK MLI[8W0#MOA=JX'PS\,+JUW'#=W$30VZ3R@/,%9@@4$ MY8[`IP.U=W6/?>%=#U*XTF>[TV)WTAP]AC*B`C&,`$#`VKP>.!Z5#;>&XH/& MEYXB0>5)<6PMW"RNWG?=PS*?E4J$P`H_B8D\\`%WQ`;0>&]4-_-)!9?8Y?M$ ML1P\<>P[F7KR!DBO)-6\X:/\-;NRL8;'24UFPAL/,.^[>%U;YG*X5=RC)49R M2"2.17L]Q;PW=M+;7$22P3(8Y(W&5=2,$$=P17.#X=^%OL=M:?V=(8;299K8 M&\F)MW4DCRVWY09.<*0/:@#J*X_4=$L/$7BGQ%I6I0^;:W&CV"L.A!\Z[(8' ML0<$'U%=;%%'!"D,2!(XU"HHZ`#@"L>V$Z19^()M=A2\&HS$^;(U_.RN.<` MH7*%1N.%QA>P&*`."TO5]5L?&'ASP7XA+SZA8W\D]I?[?EO;7[)Z0)B5,#<_P`W7/'3'/IEUI=E M>WUC>W%NKW-B[O;2_P`499"C8/H58\=.A["L;Q%\/_"OBN\CN]:T>*ZN8UVK M*)'C8CL"4(R/KF@#B]6\-E/A1I-[I=\NK:EX8D^TV=YY!C\U8)"&3:23MVKC MJ0VP$<$5U?A^_M/&&M)XCM<26-I:K#:.<9\R4*\I^H7RU]CO'K73VEG;6-E% M96L$<-M"@CCB1<*J@8``]*@T?1]/T#2X=-TNU2VLX<[(D)(&22>O/4F@#Q#Q M(8F^!MW<>';=5T*TNA+;WUZV^[N9/M0!D7:`%&XL-S9)`QM'6N_TB:/4?C'X MHM]0C1Y;&RM8[!9!G$+J6F*CW8J"?8"M1_AQX3?3KG3VTD&QN&+O;?:)?*5B M0247=B,Y`Y4"KMSX-T*ZFM9Y+21;FU4K%<0W,L4P4G)!D5@S`DDG<3DD^M`' MD^C1:)9:!K5O>07$D@H`L^)KFZL M_"FL75CG[7#8SR08Z[PA*_J!7)^$[3PUJ'P\\(7M\D#/$;>6&9G(;[:@D9+Z;\.?".D:XVLV&A6T%^26$@+$(3W5"=JG_`'0*`,C1 M[E+OXT>*+74$5I;>PM5T\.,_N""9BOU=E!^@KSCQGH]K9^&/B5;16=N=/TZ_ MM'TU_+!^SRS&)ITC/\(Y4$#%>WZMX9TG6[J"[O;>3[7;@K%EV:WD(MUCN!`OF*/.C7&_&?N\=>E6O'UA;VNN>`KC3(HX[Z/6HH M(_*4`_9BK&4?[NT?K3/BQ8M#\+;KP]I5CJM]<7)C$"113WC`+,CMOD.X@8SC M>)+=,X*)',K80+@FO6KGP3X?N[ZYO)+)UDNCFY2*YECCN#_TTC5@ MC^^X'/>H]0\!^'M3UF'5[FVNOMT"A8)8K^XB\E=NW$81P$&/[H&>?6@#%O[? M3+#XBV5KHFG))K@TF01V[,L5G:VQERTI`4G>SG&%Z\YQUKSFU66'3K.UE,?^ MC?$Y8E6%-L:@7ESMW==N><=,U8T>Y2[^-'BBUU!%:6WL+5=/#C M/[@@F8K]790?H*V=3^'_`(:UA;-;VQF9++FW2.]GC6-LEMX".!OR22_WCW-6 M[[PGHVI-9R7,$YN+./RH+J.[FCG5?0RJP=L]\L*>--'M;/PO\2K6* MSMSIVG7]H^FOY8_T>68Q&=(S_".5!`KT+Q%!#8_%OX>QVD20J\6HPL$4#*+" M&53[`Y/US70:EX!\-:MI,.EWEA(]C$[2>0EU-&KNQ!+/M<>8V1G['YCQDG%`'1T444`%%%%`!11 M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!2$A5+,0`!D MD]J6N*^)]X\7AVPTN-]G]M:I;:8[#/W)&^;"+.20%*9/(9CM7^\>F0030NO&.GVGC&P\,2V]\+Z]#F&3[.1"=D9=L. MWE\GP9%;7D]FC>([.#;`$`&6TAN M)[G1);1+2=0",,T2#8PW``[CD#GF@#T"H)KN"WG@ADDQ+.Q6-`"2V!DG`[#N M>@R/6IZR-5\/P:KJNEZDUY?6UQISL4^RS;!*C%2T<@Q\R$HI(]J`-&"[@N7F M2%]YA?8Y`.`W<9Z$COCH>#7-67Q(\+ZCKG]BVMY=OJ>X*UL=-N5=.0,N#&-H M&1DM@#O6IHWA^#1+K4IK>\OI4OIVN#!/-OC@9F9F\L8^4,S$GKS7FWA[_DZ' MQ9_V"H__`$&UH`]@HK/UG6+30]+N+Z\E15BBDE"%@&DV(SL%'<[58\=@37D5 MA\1O%5_HVD>)+*WU34#1&B1% MX9&4(5`.`IP=V[)YR._=Z_XZNY_B/=>$K.[O=/ALK+SYKJQT]KR9Y6"%5V"- M]J`."3MYZ9&10!Z=5'5]7L-!TJ?4]3N!;V<`!DD*EMN2`.`"3R0.!7EVI^,_ M%W_"D+KQ#A^(-/G2.02V803@NBYV2J?E(D!R/XEX.,BNJ\)#Q-K&EZ7J MFHZPILK_`$:)I(HHD21;A@I\Q6"\`KG([$\`4`;R>*-%DU:QTM-0C:\OK;[7 M:Q@'][%@G<#C'0$XSG`-3V&LVFH7EY91EX[NS?;-!*NU@#]UP.Z,!D$>XX(( M")HEE$^F^6C)#IJ;;6!3\D?R%`<=IJY7#ZWK&NZ=\5/"VF+J$)TC5?M6^V6V`<>5#NY`N,8YYK/T.]\6 M:MXO\8>'[KQ%'&-,6U^SW%K8QJ4:5&?A7W#'0$-G[HP1DT`>D45R_P`.O$-U MXJ\`:3K-Z%^U3QLLI48#,CLA;';.W/XUU%`'/V?C'3[WQC<>%X[>^2_M[9KE MFFMS'&R!U3*EL%@2W!`P<'FN@KS_`/YN%_[E3_V[KG_$/B_Q'X:\.-K6I:VD M6MPSK)/H$4,4T*0&4*`SJI=25(.XN`3P!F@#V"BN`N[W7=/^*MII5SKUR='U M>RN'LXQ!`#%.G)7=Y>6"J=PR>N,Y&<\_X?\`%NOWND^+K*77;B75(+F&+29Y M+:!&9)CB!]H3!#9!)(/R\\4`>GZQK-IH=B+J\9\/(D,4<:[GED<[511W))Q_ M]:JF@^)[;7KG4+1;.]LKW3Y%2XMKR,*Z[@2I!4LK`@'!!-W66&4S",,"L8!(`)&01SR#B@#KO$.OVOAK1YM4O8KJ2WA&7%M`TK*,$ MDD#H``>&O^P5:_P#HI:`. M@HHKSC0[WQ7JOB[QCH%UXAC3^S%M?L\]M8HA1I8V?(#;N.@(;=G;P1S0!Z/1 M7CB^-O$[?!VS\>R:FBS02)YMG';)Y=P@G\EMY(+!CURI4#ICO7<:OK-Y=>-K M3PGI]W]B=K!]0NKE45Y%C#B-5C#`J"6)))!X'3F@#JZ*\JU7Q+XJT:3Q+H+Z MM!)?Z;IC:Q9W\MDI:>W4,&1E4A0P8`!@,8S\OI,?$GB'3]&\`:W?'D2`@;@P(R<':<\`"@#T^BO.M;\6WMUXPU;0K*_OM/32[>(F M2RTJ2]:6:52RA]L;A4"@<8!.3@\<9VNZ_P"+5\'Z#XK>]O\`1K<&./6[`648 MDB7>5>91+&S#G!P-+>*QU:6/3K6T$]W#$D3),SL?+ M&XJ6&0KDX8<;>F*-=NK+6-`T'3Y$AO=9GD43NF[RHHD+R,!T+8 MP!GCG)!Z5E+J>M:+XXMO#&I:O->6FM6LS:??&")+B"6,993M41MA3N!*=<`@ MT`:.J^/]+TF6Y+VFH7%I9W"VUY>VT(>&VD(!VO\`,&.-RY*J0,@'FNKKS#X4 MZ?=+>>*YVUJ^>.#Q+>QR0,D&RX8!1O.P)K#L_&.GWWC&Y\+QV]\E_;V[7+--;F.-D5U3* MEL%@2W!`P<'FN6\X**TF/M/4#&W=G'4$=>*`/2Z*\RL_'^H:7\.O% M.JZDZ7U[H&I7&G+,T8C%PRNJQLRKP.9%SC'3\:NZ#KNMCQ786,TVK:G87EM( M;B>YT26T2TG4`C#-$@V,-P`.XY`YYH`]`K`U_P`::%X7NK:VUBYN()+G`@VV M?_%/_F2O^QKL?_9Z`.JU7Q)IFB:(NL:@]S#8 ML%8O]CF9HP1G+HJED'KN`P>#@\5J'/#=\&N1U/5- M?TCQ_H.E'54FAUVVNU$;VR^7:S11APZXPS+S@JS'ZC/&):ZSKFL?#+XAC5-4 M9[S3+J_M(KBWB6'Y(8E(`&#@$[L\DX8X/`(`/4H)X;JWBN+>6.:"5`\>#_A+X9GCU"YNKG5(["SM?/@606IDC'W$B0,X50V% M.YB0!D]]31O%.H66HZTFHOJM[H]II_V^+4+W2GLV4KGS(CF-%8XPPP.A/)P: M`-[Q?XQT_P`%Z5_:.I6]]+!G!-K;F0+T'S-PJY)`&XC/:NAKQ/XA2:_JOP1N M=?O-54PZA%;7#Z>L"".*)Y8VC"MC>7&5R22#S@#BO;*`"L.[\7Z%8W\UE->D MS6^/M'E0R2);YY'FNJE8^/[Q%;E>;_8O$7@#6-8U"QL#KN@:G>/?W$$)`N[9 MWQN*@\2+P,+UX'OD`[;3M?TG5K.UN['4()H+N22*W<-CSF0L&"9^]C8YXZ@$ MCCFM*O$433+_`,5?#I/"NM7UOIEQ)JKQB-8]UN^UI&`5T(!!D9,,#A0,<_,> M^\0W.L6NKP12ZR-(T".SW2:D/(,\USNPL85U(^[\W"Y@M45[B:. M%6=8U,CA078A549[DD`#N34M>#ZEK^J>*-"T#[3J=PLUGXWCTLW$4*Q&8*=R M2M&RG#CC"D8SG*GMW'B#Q)=Z=XGT[PI'JFHHWV!KVZO[?3OM=RZ[]B`)'$RK MDY);9C@#@GD`]`HKS4^--6M/`Z7^M)?V(AU-K.\U$:#+[4]1NK^X?7+?6M$,4`T^\B2-69\R>:)`G\8_=YX48Q@`[J` M.NHHHH`H7FL6EG97ET#)="S;9-%:(9I%;`.W8N3G#*<>ASTYJOX9\167BSP] M;:WIZS+:7)<1B90K?*[(20">ZG'M7%?"JTN_MGBV>76+Z9(O$=Y"T,@B*RE0 M@#L=F[=C`P&"\#Y:Y3PUJVL^&?V?M*\1V6H^7%83%FLQ`C+/&UVR,KEAN!^8 MD%2O3\:`/=Z*\ZUOQ;>W7C#5M"LK^^T]-+MXB9++2I+UI9I5+*'VQN%0*!Q@ M$Y.#QQUGA/4[[6?"NG7^IV,MC?RQ?Z1;RQ-&R."5;Y6Y`)&1GL10!LT45Y7J MGBS5;W4-:TO2O$/]G>)[>2:*TT>[MHA%.H)$31NX!9V7##+$9."N!0!ZI17` MQ7VN)\7;_P`.2:]<2:=<:&]_`OD0AK61IQ&-K!/FVC.-V>O.:Q],\0>*Y/`/ MC2[.N1RZAH.IWL,=S/9(?,A@C!"[4VJ"3_$0<9/!XP`>K45Y7>>(_%-CX=\! MZRNKQS2ZU/9VES;RVJ")C/'D2?*`P(()(#`'/`%;^EZMJMG\4+OPQ>ZB^H6L MFDIJ4+RPQHT)$OELF4`R#UYR1Z^H!VM%%11.Z; MO*BB0O(P'0MC`&>.[A%E?W\EE"L]XMC$K_`&:-L[6? M+#KM8X7)P"<8K+MM7UCP_P#$"Q\.:KJ+:G8ZO!+)8W,L*1S1R1`,\;>6%5AM MYSM![5B>$-+O1\6_'"GQ!J3&V;3FD8QV^;H&$G;)^ZP`!Q\FPX/4GF@#TRRN MX=0L;>]MFWP7$2RQL01E6&0<'IP:SM9\4:3H%U96NH33BYO=_P!FA@M)9WDV M8W8$:L>-P_.MBHFMH'N8[EX8VGB5DCE*`LBMC<`>H!VKGUP/2@#DT^*/A*3[ M;Y=[>M]@.V[VZ5='[.G6U_9R>9:W4230OM(W M(P!4X/(R".M>3?")5?X@?$]6`93JN"",@CS;BM/XM7WB/PAX;L]6\+ZA]BT^ MS9+>XLH;:$JL9X4J61MN.%QTY'''(!Z=17BCP0:K)N45Y]9^)]2T3XJ0^"]3OVU*"_L?M=I=2QHDJ,-^Y M&V*JL,1L00!CCK7H-`&+XC\5Z-X3M8[K6KB6VMY"5$JVLLJ`\<,44AC^++62ZT6XFN+9"`9FM98D8\\*74!L8.<9QQG&16S7D?@:YO+ M']FM;W3[M[2[M;*]N(ID1'(9)97QA@00=N#QT)Q@\US^M_$#Q=;?!#PUXJM] M<>/4[F]EM[AA;0E95W3;204P"!$`,8ZG.:`/?**\O^)?B+Q#H7C7P99Z1J[6 MMMJ]V+:XA:WBD7B2,;LE=V2)"#AA]T8PK:K9Z)I5QJ>H2/':6Z[Y72)Y"J]SM0$X'4G' M`R3P*CT36].\1Z/!JVDW'VBQGW>7+L9-VUBIX8`CD$/O`'CC7A MJ?V33+>*[MK:PC@1E>-8-Q+L1OW$,,88`'/!Z5S8\2:[X3_9X\)ZIH6IO9S- M>SV\BB&*175I)VR=ZD@@IQC'WCG/&`#Z,HKFUGUC0H==U?6[Z*YTZ&V%S!!' M&%:#8C-*N0!N&0,9R>.:\VL/B-XJO]&TCQ)96^J:@;F]9;O2+;1Y'@BM@S+N M2<1_,XVC/SD9;&T8-`'M%Q.EK;2W$HU9GAOQ3H MWB[3I+_0[S[7:QRF%G\IX\.`"1AP#T8?G7'Z)XDUKQEX^\2V%CJ?]FZ;H+I; MJD<"2&>4LX)G-8_[./_)/-0_["LG_`**BH`]@KF=9\?\`ASP_ MK$6DZG=W,-],56&(6%P_G%L8"%4(*Z:O&_C-(T/CKX;2I#).Z: MFS+%&5#.1+;_`"C<0,GIR0/4B@#NW^(GAJ'4K/3KBYO;:[O)5@MX[K3+F'S' M8@``O&!U(_.NIKSSPH9?'%MKDFN6]U;26/B59;:WD<%[8P+`R*.H`.#G'!WM M@\YK#T[QIXA\5>%/%'B_3=5%C:Z5+,+.R%O&\\8>'[YM.FO;GR)H5BCE0DJ^[[ZD_*T1`QC@G.>,=GK\? MB6Q\*^+[VZU@+&-.:>Q%NBK);.L3M(N=O*DA0#R<9Y!P:`.OM+VVOX#/:S++ M$)'CW+TW(Q1A^#*1^%3U\^:,_C#2?@'IWB'PWX@N8S;F>2>S>W@D01^?(&9" M8]V1]X[F/?&,`5Z#H.M:AXJF\+7.E^(+H6CV/VK4HS#`WF$,%"L?+RK,X<'; M@8C;&#@T`>A4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11 M10`4444`%%%%`!7'?$K2+G4O#=M>62/)=Z/?P:I%$B[FD,1)*@=SM+8'BZ%?:'=6KM9ZC;:K;F9RLUL]/M=/$RVD*PK-*9 MG5>AI-6:`/*]5^'>O:WJWC1;MM,CTWQ&(`LD=Q(TT'V6`V2%W#<,9."<<[WA?1_',-U9#Q1J^FR6E@A$:Z?YH>Y8J5!F+8!`!)P!U MP>HKMJ*`"BBB@`KRW3/"'C/3_BAJWC1K;093J%L+O4J*`."N?#'B/Q-XE%QXD_LRWT5+"XM8[2QN9)9-\RA&8LT:C[F0../3DU M#X+$>*?"&E2^'H]0T]]*$[26]\I;[3$A.67RBI0D\X.[`))PW2O0Z*`/-K# MP;XFL/BUKOC%4TB2WO[1K:&`W<@==JH(V;]UCDQ+D#IN.-V,'.\(_"C4;'X: MZYX-UZXL_+OY_/BN;*5W*MA,95D7HT:GJ)/`&C>% M;N_TF!-+EC`GC,CF9$1D4X*C:0"!MY!ZY&,'7O?`>N6?Q`MO&NC7=A-J$MNL M&IVUR7ABGPBJ6C*ARGW1P=V,#DUZ/10!P_C?PQX@\4?#^]T..ZL7O[Z9&=IF M:.*!%=7VIM0LV-@&6QG)/'"UT'A/3[S2/"6DZ9J`@%U96L=LYMY"Z-L4*""5 M4\@`XQP3CG&3L44`%<3XLM#X@\9^&-)BRT>G70U>[('$80$1`^[,3@>BL>U= MM5:TT^TL6N&MH%C>XE,TS#EI'/^`>'=`\4Z;XL\5Z]>PZ/NUB*$P0PWDC>7)"A1%8 MF(?*0>6`R,?=.>.[HH`X[X:>'M:$^$8-!U=;!A:%O)FM)W?S`[LYW*R+MP6 MP,$Y]L<]C110!P@T#Q3_`,+6/BDP:.=/^P_V:(OMDOFB'S=_F?ZK&_\`V9=$S"3,HV_*W&-V7X`&.]>LT4`..TAL1`ULO&Z521&V,8P$=A[$+7744`<1X^\/>(O$5WH0TA-+%OIFH0ZDS7 M=S(C221EL(`L;`+@_>SGGIQS)>>'M='CNR\662Z<9VTK^SKNUFN'"I^\\S=& MXC);#<NWL.C[]8BA,$4-Y(PCDA0HBL3$/E(/+`9&/NG/'=T4`>3 M'X=>)O\`A2(\#!])%[YV#/\`:9/+,7G>=G_5YW;OEVXQCG/:NDU3PSK5SX@T MCQ99&Q@URUMVM;JT>9S;SPL2=OF!-PPQW`[>O;U[6B@#S[6_".OZK;ZYJ`32 M_P"VM5L/[*5&N)!#:6Q#EL.(]TCEFSRJCIZZ/#/J=M$ MFHV5^TKQ!T4*"C*H+8QP2%[\2XN+E5E,D@PWE[0L2D=L1J@QZYKL*,8&!10!RWC'PM<:[/I&J:;< MQV^KZ/<>?:M,#Y<@;`>-\<@,`!D4U=$U>_UZW\0:K!IZWFG6TT6GV<%P[1B2 M0#<[RF,$9"A\1>'9M;76$TMHM2U";4O,L[F1F223; ME-K1J-O!^;.?;G([>BHQ/"UP]NLL9G1%=XPPW*K$A21U`)5@#WVGTH`Y;Q3X MT,^CM\3?\`"TO^$GU` M:2;+^S#IN+>>3S-H?S!)M*8R6'W=W`/WFQSW5%`'E=I\.]>O/#/BW0-9;3(8 M-=OI=1CGM+B21H9F=&5"K1J"H*#G(/MSQO>%]'\D44`>:ZAX!U_6/AYIFA7%]86 M>HZ.;9]/FMR[KYD"%`SL0#\P/0+\I[M6OI>@>*-4M[Z/QI?V$D=Q9/8K;:7Y MBQ%7&'D??U?``'&`,XZFNSHH`\MU+P)XMO\`X:R^"&O-)>WC$44%\[R"1X4D M5E5H]N%("@9#-G&,#.1Z1IRWRV$0U*2WDO,?O6MHV2,G/8,2>F._Y=*M44`% M<;I.D^+/#Z:HELVDW\5WJ%S=P1SS20&W665G`+!'W]02,+@DC)̚QYHHI M(XY)41Y6*QJS`%R`20!W.`3]`:`/,[7X;:MI.I:)K-C=V-QJ5K?WU]=QS;XH M7>Z0*WEX#$!=HP._J,UN:EX)+:73KP6^GM9R6]R7B6.1FRTT6`^" M>%P?X1C=777%S;V<#3W,\<$2_>DE<*H^I-+!/#=6\5Q;RQS02H'CDC8,KJ1D M$$<$$(?"' MBRX\2Z7XKT/4=*AUNWM6M+F&X206\L1M=] MHEE=:=H]O;7UZ][=J&::=L_.[,6.`2<*"<`=@`.U:%%`!7GNH>"]9UFVN]/U M=-*OX9KVXFM+^6207.G1O*S((_E.YE4C'S(%P!\P'/H5%`'(:GX=U=/B';^* MM)-E+G33IL\%U*\>%\SS`ZE5;)SV.,^HKG8?!'C"PT#Q=I<%UHERNOW=W,#* M98C&)QM+$A6YV@?)CJ3\W&#ZC10!YKJ7@WQ-=>%/!&F0+I/VC0+JVN;C?=R! M)#;C:@1A$3\PR3D#:>/FZUK/X>UX?%K_`(2>---;3/[-&F[&N'68+Y@D+[?+ M*YW9&-W(YR.E=I10`5RWC'PM<:[/I&J:;?:M,#Y<@;`>-\<@,`! MD5U-%`',6NA:CJ/B>RU_74LX9=/@DBL[:TE:55:3`>0NR(22%``V\<\G/&7X M8T#Q1IOCO7]3&57`:)0^5K M>..2<(3&DCE%9L<`L`2!GO@X]#4E%`'FGP_\&^*/"_BOQ!J>I#2);;7+G[1- M]FNI"\!W2,`H:(!AF3')'KSTKN?$&CP^(/#VH:1?#;P_X=2[@BU#3KE9Y;I6;!W$^;M.,G@C;D#[B]*Z?QEX$37[ M?0YM-DBM+_0;F.>Q\P$QX4J?+;N`=B\\].AKLZ*`.'L/!M_>?$4>,]=-I%<6 M]H+6SM+69IEC'S;F+LB\X9A@*.IKN**8DT4LDD<WCNK.9Y"PF,A8LK(N"-_&"<^W?D-3^$WBV_\`ACI?@Y+O1473KUYU MF,LO[Y6,A!/[OY2/,(Q\V>N1C!]NHH`\V\=>#O$OBCQ#X2U:T328O[$E6ZEB MFNY!YDI>-F12(C\H\L`,1DY^Z,!YG$<2RRJID8G`503R22!@>M`'FFF?#;7?#WA[Q-X9TB\T]M(U82M; MS7#/YL!>/84*A<,"`HW;AC&=IZ5E:Q\)/$MW\+=(\&VU_I,ILKU[HW$ADBPI MWX0`*VXYE<[OEP`HP>37M-%`%&[L?[8T&?3]2C5/MEJT%RD,A8+O7:P5B`2. M3@D#Z#I7%>"_"'BGPAI4OAZ/4-/?2A.TEO?*6^TQ(3EE\HJ4)/.#NP"2<-TK MT.B@#S_3/!&L>&O&VO:MH=S9/8ZZ1+.ET7#V\N6.Y0`1(,NQVDKUZ\ET4`4M-L([1)Y_LT=O=7L@N+M8I&=3-L5"02!D811G"YQG M`)->=P?#G6M#\/>(O#.A3:>=(UB61TEN)726T610K*$5")!@`#YEKU&B@#RC MQI\*[_4OAUH?@_P]-9)!I\PFDGO)&0LP5APJHWWC(Y/(Q@=<\>B:IITNN>%[ MW3+LI;RWUD]O*8F,BQLZ%6VD@;@"3@D#/H*TZ*`.`\#Z)>>$/#-EX4\1W>B_ M966:W@1)V+W;.[.1APO\+$;0&/?/:CX2>%+?PSX9N6@E>9+VZDDAE?J;<,1% M^!&7_P"!FNFUWPIHGB6:QFU:Q%Q+82>;;.)'1HFR#D%2.ZK^0K7CC2*-(XT5 M(T`5548"@=`!Z4`.HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"L;Q%X7TOQ3!96^K0F>WM+I;I83C9(P5E`<$5&Q6WRRKC"GYFY'/)]: MC^-WA?2_#/PJT6QT^(^7::HRP/+AGC2432,@./NYV_\`?*YR1FM+P[-=#]H# M7->DT76XM+U"T2TM[F72[A5+X@'S93*K^[;EL`=\5?\`C]8:AJ_@[3M/TS3; M^^N3J"SE+2UDEVHL;J2Q4$#EUQGKSCH:`.FM_';K\08/"6I:0UG<7=G]KM91 M<"3.+B[\1:KHWA[2%U.;245KUY+GR`&;.(X_D;< M_!Z[1D=:Y#5UN[W]H3PSK<&DZL=,AL!!)='3IPB/(DQ4$E>/]:@.?NG.<8.+ M6@Z??^`?''C6[N=/O[NUUF1;RRFM+62X#/ND8QL$!VG,F,M@8'6@"QKWQDMM M.\#Z7XLTS2O[0LKR([+X"V^G+8RSZE_:PU*:TB&^ M2-#$8]H`ZG[I(&>IKJ-2-]J/[0'AC7XM$UA-*BL3`UR^GRA0S"<#<-N4^:0` M[L8ZGCF@#J[;XAOJ&N:AI^FZ.;R.QU./3IC'9HMN1$N6^8$Y*G(4 M!QVQE^,,L7A+0_%%[X>\C2M3NS:,RWP=X2&<; M@NP;A\C=P>#[$\[X`TC5M%^!_C'2M0T?4H=0E>Z2*V^QR,\ID@2-2@"_,-P/ M(R`!D\A$R8/?G'W3@` M]GU/QJ\7C.+PIH^G+J&IBW-U<&6?R8H(^,98*Q).1P!W'/IPGP1B2#QE\188 M[5;2./4$5;=<8B`DN`$&.,#IQQQ6A'8W^B?&RX\7-IU_G+$DD%I([P/ MMBPLD8&]/]7W`QNYQ@X/A5I>M:=XV\<7FI:)>V5OJEZ9X)9@H7Y993MZY)(D M!!`*D`\],@'JEQ/%:VTMQ.X2&)"[N>BJ!DG\J\3^(?BB7QM\'=5U:+0432%N M$^QWWY0O>(=-DUCPSJNEQ.(Y+RSFMT=NBET* M@G\Z\5;3=>3X!W?@D^'=4;6+>81E%MF*,IN1)O5_NN.B>%?`NAVEI]MUC5-,M_L]N9?+156%2SN^&V@`'H"3@\5'K_`(GM/$OA#QQH M&IZ>MKJVE:?+)/:._FH<1%XY$;`R,[2,@$''`K`M_#>L:9K_`,/?%=QI5Z(= M+TI=-U"U2/S9H"L MX+`'T)1<_P"Z*^@/%'C&T\,WNCZ?)$9;W5[C[/:*S;(]W`R[8.T991P"E_$[4?$+ M6'AYM`TO4;FRN;E9+U[2W(NH8_EP%##=$Q#.-Q`*D8.,T`:NB>.KC5/$6M^& M;C28[77M,A$PA%WYD,P*J5Q)L!`^=,_(<9[]*R_"'Q2O?&&E0W]IX6F$9U)+ M&X$=SYGDHP4^;]P9`W'(XP`#GGCG/!^D7>@_&?7-6D\-ZCIND3:1F`+`\W($ M)*EDW`R'8Y(R26R.21G3^`.GZAI'@[4=/U/3;ZQN1J#3!+NUDBW(T:*"I8`' ME&SCIQGJ,@&_;?$-]0US4-/TW1S>1V.IQZ=,8[D>(?#6C:QHWBM-0>&/RH'-M>QK*4,SN!MC#*-QW8W#LV M=U>XT`G1_$V6*_\)1:CH?V6V\31*]M,EV)&C<]#TSD#5U/QJ\7C.+PIH^G+J&IBW-U<&6?R8H(^,98*Q).1P!W' M/IY?K]MJ,Z?"1HM$UIQHR0/?[=,G)@"M"K`C9G(,+\=2,$<,">IDTK4O#?QU MO?$\MA=W6DZM8"W$MI`\QA<"(8=5!(!,77&/FZ\'`!E_!&)(/&7Q%ACM5M(X M]015MUQB("2X`08XP.G''%>@?$779_#7P_UG5K5]ES#"%B?&=KNP13CV+`UQ M_P`*M+UK3O&WCB\U+1+VRM]4O3/!+,%"_++*=O7))$@((!4@'GIGM_'7AUO% M?@G5=$C95EN8OW18X'F*P=,^VY10!Y7KLT/@OP!X&\96`\G4IY;0ZA<`9>\2 M6%GD$IZOR.,].U=%/=1>*_CI?>&M4BCN])TO2O-6SE0-$TS&([V4\,0LF!GI MVYS69J6@ZAXP\%^#?![Z5?6L^G36QU.2YMG2**.&)HVPY&V0MGC83[XK=NM% MG\-?&2Y\7FTNKC3-3TW[-.]K`\[PS*8\91`6P5C49`/.X MD>RE$?GS!"[%SC."^XX!'WC6'X2\):A!JU[>7EE-`NO:Y)JDT;IS%;PLTD*N M>@3X+U:QBLM0N[J_L;B""*SLI9\LR;1N**0OWA]XC.#C M.*`.<^&.J-IOP%MM6D8R-:VU[YZ5QI:0_`9?'WF$>*5N/M!U+ M`\TG[7Y>S/\`\^#X\+:G9:A8W(M[BWN4NK26'"S/+@J64 M!OE;^$G'?&17.KH&M'X-_P#"N3I5X-9^T^5YOD/]F\O[3YOF^=C9MQVSN]J` M+VEZW!\0OBLFFZE#'I92INB,THA?>RG[Q"R@#/3MSFM?X3ZS//=^ M+/#LT\DT>B:K)#;&0Y982[A5SW`V''IGTQ56T\+/X%^)D>O16MU M+1M4\)W5G%-!YR7T$QG@3C.R1MBA6XQ@$\XQD'-9?QD\*:AXN\!M::6OF7=K M<+=+"#@RA592H]\,2![5L>'_`!5=:PNG0/H>JV]P\):^>[M'MTMV`Z`LH#DM MTVD\9)QC%`&'??%6"#3]3UJRTIKS0-+O%L[N]%P%?>2H)CCVG>H+KR67.>,C MFI;WXD7$/Q"TSPM9Z-#=QZI:B[M+U;[:&C*.V67R^!E&Z$\8/)^6N(\!>$8O M"DFL:#XH\%C5[D3^;87O]F"XCG!`&SS2I$8X!^8@#)S@]=+4K"\B^/WA6]AT M.]ATVPTU;.62ULI6MH'9)@J*X0*4'F(-P``[XP<`'167Q*GU/PWXON8=+CMM M6\-^"?&U]I7P7D\5:[`D\49FF22.#](U6\N?BM`=)U*V;74G?3VO+.6!90QG`^9U M`!_>IP>>3QP<:O@PW%C\'(?#^I^$-5OYH-T5S92VS1!Q)=$84L!N(5]^1P-O M++U`!W_ASQ#=ZY-<+/IBV\$<$,L5W#<>?!<[]^1&^T9"A5SG!RW0<$[=S<16 MEK-7_#7P[>>&_&.JVFEMJH\*&V#I'J,#Q&.Z+C*H'` MW`*#E@,'(Y.,UZ!XFL)=5\*:QIT'^NNK&>"/_>9"H_4T`<-X8NM6\:>'-3\: M(&^WRI0_`Y%TVW$NJV,=XD=O*,!IP[NJ,, MCJ64'D=>U6VZ-2,^C''8?-T*0>)OB!X,M;B1G\)WGVX3QP2VGG MLL<>0JR))M!)?YP2!P%X[T`:KJU]^T/X2CO2\-FUE-CEDSNZ_A6+-X2 M\:0_'7PU=WVL7>J)%;[I-6725CBCC'FEH&V_("PRNXG(\T$=!72Z+IMQX"\> M>+[V73KZZL-;:.[M9+.W>-@H.P[G."V%QW[4`7/@MXDN_$OP[@EOYF MGNK.=[1Y7^\^T!E)/<[649]O6L^>ZB\5_'2^\-:I%'=Z3I>E>:MG*@:)IF,1 MWLIX8A9,#/3MSFHO!,%_\+O"WAW2+[1Y[B76+XF]GA.4LGD*)&'(!R3E!V'! MY.!F_=:+/X:^,ESXO-I=7&F:GIOV:=[6!YWAF4QXRB`M@K&HR`>@^!_&6A6M],LNGZX=.LYB29(H':7"AO80N`>V>.U=KXA^R?#_XC^"4T M6%;.TU>26RO88EPLYS&J.P'5]SYW'G]:P-1^%>JZWX+\5WPM3%JNJ:PVJ6EI M(=KB-6DVJW8,5E?@]"1G';J]6TVX\>>.O"-^FGWMK9:&TEU=O>6SP_O3Y92- M`X&\ADY897'?:`RDGN=K*,^WK5/1=-N/`7CSQ?>RZ=? M75AK;1W=K)9V[SDRYD+QL%!V'GZO\-_#/A[19-`N;ZXU:\> M2_EMCE+#<%`+G!SA0,]!\IY/&0!9[J+Q7\=+[PUJD4=WI.EZ5YJVRGAB%DP,].W.:X34O'NIZ#X'\9:%:WTRRZ?KATZSF))DB@=I<*&]A"X![9 MX[5Z+=:+/X:^,ESXO-I=7&F:GIOV:=[6!YWAF4QXRB`M@K&HR`>JZWX+\5WPM3%JNJ:PVJ6EI(=KB-6DVJW8,5E?@]"1G'8`W_$/V3X?_`!'\ M$IHL*V=IJ\DME>PQ+A9SF-4=@.K[GSN//ZUJ1:BW@CXD6'ASS&.@ZW$[64;L M6^R7"_>12?X&!&%Z`GC`JOJVFW'CSQUX1OTT^]M;+0VDNKM[RV>']Z?+*1H' M`WD,G+#*X[FJ?Q)@EU;XL_#S3[0$S6MQ)>RD?PQ!XV)/H"(V'XT`>LUQ7@^Z ME\1PZEXK\M)IY9Y[?3%F;:D<$;%``0#MWNI+$`GH.0H%=K7!_!^&33_`,>BW M"[;K2KRYM)US_$)6?]0X/TH`Y?2;O4?%GP$U/4/$-G9W:&QO[JWN9)FEE$H: M;!V,F(]O12'.`!TZ5N^'/%EQHGA;P);W>E;=.U*VM+".[-P-ZS&$;,QX^ZVT MX.[/M6!H;ZAHOP+O/#-UH&M'4UM+RTV16$C@RRO+L`('S*0V=XRHQ@G)`,FM M"\'@#X9Q)H^KRS:??V$]W#'ITS20K;IMDW+MR.3QG[W49'-`'>:GXHNX]9N] M)T32?[3N[*W6XNP]QY*QAL[$!VMN=@K$#`'')%:N@:U:^(M!LM8LBWV>[B$B M!NJYZ@^X.0?I7E&KVG]F_$O5=)-&UJVMI+=X],$\MLZ1A=I20`IGN M#M/3TQ7J'A:"2W\.6DG M7$ZI:*QABE2-RC1[_F!`QS[GL:[NN:^(,[1^`]:@BM;RZGO+.:UABM+9YW9W MC8#(0'`]2<#\2*`/$]#7P4WP.@,@LF\5^3<"W%D1]N\[S7\O.SY\?=Z\;:[: MV^('B#P;I/@G3/$NCM=WNK@0R3FY*S1L)`OS1[#N;8\9^\"3N!QC)VO@R+BT M^'-AI-[87]E>V1D$T=W:20_?E=E*EE`;@\XSCOC(K$^+-M>W/COP'<6FEZE= MP:9>_:KN6ULI9ECC,L1ZHIR<1L=HYZ<^(6NW<_PN\02:QX=N8((;M;2 M:)+[RGDBW)MEB?RR""S*,%<8W<]BNN?$-_!'PU\+ZW!HQO;.\MH(MDM^1)$6 MA#H"WEG?PK9;CD#CGC1^,EO=7WPPU.PL;*[O+NZ>%(H;6W>5B1*KDD*#@80\ MGCH.I%<'\1-/U/5/@AX.TJQT;5I[^+[/YMNFGS%XO*@:-]XV_+\S#&?O#D9' M-`'HT'CJ6/XA0>$-3TG[)<75I]KM9DN1*''S95AM&TC8W0L./3FF:EX\N/[5 MUG3O#NB-K,^BQ(]Z!<>5\S9(CC`5B[X!XP!P1G/%G7]QILA@$UX4V(5E+" M2`Q_>W(X'S&X7N[&(S+.=0Q&Z?(5+?N\KE9% MZ;L'CD%]?E\/:O;6<-B;>=VLY76)G$^P,X7;TECW'.%)()^4 MTS3]073/VF/%=Q);74\?]F1A_LT+2L@V6QSL7+$9`'R@GD<8R0`==8?%32Y_ M".LZY?6=Q:2Z-,;>^LP1(Z2;@H"G@$$G&3CHUUKP[::EI445EXA4' M3[NVO/.R2%(#J47;]]1P3UKD?#^D>*-'\+>/O$UKH\O]I:W=M-9Z=<19<1F1 MB6:,]\2L=IY.SIS6!=:)K=[J'P]UF3PQK:7%M?1OJMWVAL_'/Q(M;:)(8(=26..-!A442W```[``5[)7D?PEMKVV M\=>/+F[TO4K2#4[W[5:275E+"LD8EE/5E`!Q(ORGGD\<''J.IZ@FE:;/>R6] MU<+$,^5:0--*_.`%1023S^'4X`S0!Y=\9[W6391W6BR;4\.SP7]UC/S.Q(0< M?W1RP]'%>F:%K%OK^@V.K6A_<7<*RJ,\KD<@^X.1^%<3I.B3>(O#&HWE_JWB M&P&I&634-/.GQIM+(`8U66W,C@)M0%2<[>/2L;X*7>K:-:77A;5M)UB&"*X= M]/NY]/FCB=#DD%F7"<@L-V,EB.N!0!?L/BOJ5]%XL"^%HQ-X:W&Y`U+*/L+A ML-Y8.?W9(^7D`Y(.`8V^,K1Z%I?B*7PU+%H-]=):&YDNU$BR$-N*Q[?F0%6& M2RYVG@5RV@6VHP1?%N270]:0:RDSV`;3)P9P[3*,#9US,AQUQD]%.,C6](UF MY^`'AK0(=`UI]4M]2EDFMQILVY%!E.3\O0B9,'OSC[IP`>W>(_&$>B:SI6AV MEI]MUC5&;[/;F7RT55!+.[X;:``>@).#Q66WQ%9+'Q+$^DK'KGA^'S[FP>ZP MDD04/O279R-N2,J#G`(&)]'O!\3_``IX\MK2[N=-@M6M[F*.WKZ_XG^(/B1;6>VAU;2Y--T^*YC,+S$Q*N\HV&49 M0=<=3Q0!>U+XQS:?\.=%\8KX=26#49Y+=[N/@3H M'AN'PWK3ZE8ZE(]S&+"3Y!NG(QQ\P(<'3IV\J-I(2-P"9#8C;*?>&.1R*`.R\/\`CAM5\::SX4OM.%GJ.FHL MN8[CSDEC8*<@[5(/SKQCO7)^"MIQ:?=67V6&ZDLI5B>1%AS\Y7&/W3X M.<'`P3D9?X!L=3\,_$CQNE_I&H%-6U%)K6>*W9H6C+S,6,GW1@2+D9SZ`XH` MZB+P'#%IWAVV5L2:/=&>&83R9A0R;S$@S\ZXQ'E\_+[TSQO./#%S8>+;9=A2 MYBM=1`X$UL[;V2.AKM:X3XO0/J/@1M%A&;C5KVVM(AWR954KGTW[3C\O\:HZ5X@M]5U34].2TO;: MXT]U5Q^*]7CN].@TSP_'J?VJP^VRB*_5&C&5&!O4!L[N" M2N0K<<8//6'@JZN/$WBC1KV%AX;GG>_A9EXDFN(MC`>R?O#CU*GBK?P_M]2\ M.>"7U'Q#:W;WT4:6@@A@>67R828XP$4%CDEFSC&&!/&30!CZYXQGF_9^F\1^ M&["+1TEW1K%#)L-NAN#$638H^8GGMC<3DDLM)U:__9KN_#4>CZG'K%J`6M9[.2)G!NO-^3*)[GQA>>&M1TY;.[BM%O8&CN!*LT)8H2?E7:0W!'/U]=K4KFXL]/ MFN+6QEOIT&4MXG5620W,RQ#/EVT#S2,S\8/H!BTAY_*N6:[&^%#,8@ZKMPXSC()7!.!D#-=+?^([G^VY] M%T73X[^_MH%N+CSKCR(HE8D(I<*QW-M)`VXP.2*\G.GZI_PS$-!_L75O[5\[ MR?LGV";S,_:?.SMVYV[/XNF>,YXKK]/N;K1OB#JGB-M.U270_$%M"=R:?,TU MM-"-FUX0OF*"-QSMP>.W-`'5^%O%$7B6VNPUI)8W]C.;:\LY6#-%(.>".&4C MHW>L_P"(_B./PQX5FOKKP]_;-B,?:(W>,1I\RA-P;).6(QA3C&3CBCPAI$\? MB'Q-XDGMY+5=9GA\FWE7:XBBCV!V7^$L2QP>0,9YX&9\9_M-W\.K[2+'3]0O MKV^,8BCM+22;`25'8L5!"\#C.,]LX.`#6\7>,Y_"E]I$/]AW-Y!J-Y%9BXCF M15621B`H!.XM@$]`#P,^F9KOCC4[)/$VE'38+35K#1WU2T?[49$EA&06.$!5 ME(^[R"?X@.:SOB%JK:LG@]['2--(;ZZ^(^MB#2=4EBNO"R\=S3S:+/=Z,UII.MR>787;7`9RQ4M'YD>WY-Z@D89O?%"TI`X(S\QSDB@#T._\3WD=_J,&EZ2FHIIA47BK M=B.<%D$@$<94AOE9>K+DD@9P:Y33O%WB'6?B1I*VEK:BQNO#,>HBTEOG15$L MD>YB1&0SK@J!@<$G<,D5%XGT:'5O%NJ7ESIVN:7J-I)'%INM:/;RNUPOE(Q1 MPN00'9AN8*N!MW?*:M)%K>F_$[2]:U/3+NZ>;PPEC,]E#O7[7YP=U)'RH.I! M8@>]`'I=%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4452U35K#1;$WFHW*6\`8+N;)+,3@*`.6)[``F@"[161I/B;2= M;NKBTLKB3[5;`--;SV\D$J`]"4D56Q[XQ4"^,_#[ZG#IXU`>=/*T,+F)Q%+( M."BR[=C,#QM#9S0!O45B:OXMT30I7CU"\,;1J'E\N&240J3@-(44A%/JV!44 MWCCPS!JT&E-K%NU].F^*&+,A8;-X^Z#U7D>N1C.1D`Z"BN8T_P"(/AG5-5LM M,M+^5KN^5FMD>SGC$H4$MAF0+QM.>>"".O%/L_'OAF^AU.6/4C$FE[/MOVJW MEMS`7)"AA(JG)((Q_B*`.DHKC++QGX3T'P?8W\_B:2XT^4RB"\O69YI]KD-Q MM#-@\<#ICVKM?V1#>9OC$9D1HG594!P6C<@*X'^R30!KT5SK^.O# M,=Q)'+JT<21R-"US*CI;B1>J>>0(]P]-V:WX9HKF".>"5)895#QR(P974C(( M(X(([T`/HK+U3Q#IFC2+%>3OYSH9%@@@DGE*#JVR-6;:/7&*S+KXA^$;/1H- M7GUVU6RG+")P2S,5QN`0#=D9&1C(R/6@#IZ*SM.UW3=5N[RULKCS9K,J)U\M ME`W#*D$@!@0.",BL]O'/AL:Q<:0FJ)-J-NK-);01O*XVL%(`4'+`D?*,GKQP M<`'0T5C67BW0=0T6XUBWU.`V%L66>5\IY)'57#`%3R."`>:KVWC?0+N>2WCN MKA;A+=KD0RV4\1CD+DCCU%0)X\\.RVMM<17=S(+I6>"*.QG:61%ZN(@F_;_M M8Q[T`=)17&>*-7AUWX:ZKK'A[7+B$6UK/<)/:$*Q>-&.Q@RY7D#(X;W]6^$O M&6EMX;\+VE_J,C:A>V%NJRSQR%9YO+7?^")M0B^( MGCC2KS5K[4(+(V/D&Z<'9YD;NV`H"CD]@.`/2NDLO&&@ZAJ<>GVNH"2>4N(3 MY;B.8I]X1R$;'(P<[2<4`;E%%8OB/Q9HWA*VBN=;N9;:WD)42K;2RJ",<,44 MA>O&<9YQT-`&U16++XLT:'Q1!X;EN98]5G!:&%[:4+(`F\E9-NPX`/0]1CKQ M5*'XA>%;D7WV75DNC8J&N!:PR3%0<\@(IW`;3DKG'?&10!T]%>;>.-6EF?P3 MK>B:]=BPU#6[.V:*WD"PSQ.Q8DX&[)V@$$XQD$=:[+6/%&CZ#*L6H7925HS+ MY<4+RLL8."[!%)5!_>.![T`:]%4)]:T^WTR+46N0]K,%,+PJTIEWU/5;'1K%KS4+E(+ M=2%W-DY8G`4`G/HCW)M+I3$+>8W"K MM\HJI4A0,;ANPW4YKL9/&&@Q:J--?4`+@SBVR(W,8F/2,R8V!_\`9W9]J`-R MBO//&_BP6WC#P_X;W:K#:W?,*MS@@8H`[VBL/4O&& MA:3J.G6%[>/'-J3(EFRV\KQS,YPH$BJ4R3V)Z$'H3R[9XI(T#!2RM(FT@D@`C.06ME<>;-9E1.OEL MH&X94@D`,"!P1D5F6>M:'J'CFXL[/799]3M[-HYM.CD)AC"R#'(].\03ZIIMP;:.\8O?6@0&.>3&!(/[C],D<,!R,\UMUS5IX]\. MWT&J2V]U=/\`V5L^VQ_8+@20[R0,QE-QZ'.`<`9.!5FW\8:!=>&HO$46HH=* ME)6.=D==[!RFT*1N)W`@#&3VH`W**\RT#6I;WXUW=I;ZUJ-WISZ(]R;2Z4Q" MWF-PJ[?**J5(4#&X;L-U.:ZM_'7AF.XDCEU:.)(Y&A:YE1TMQ(O5//($>X>F M[-`'145S\WCGPQ!JUOI;:U:M>W"!XHHV+[E*;P'YK*^NS MJ*PQ6.W[5]IC>!H=WW2RN`P#=CCGMF@#=HKF8OB#X6GL[.\BU4-:W'7M+I$T\V\<4BV4S;I'#ER[`%4 M3`3:6V@\D$CH`=C116=JVN:=HB0M?W!C:=_+AB2-I))6QG"(@+,?H#0!HT5C M6/BO1-1T^[O;:^!ALVV7`DC>-XF_NLC`,">PQD]J33?%FBZMJ9TRTNG^WK$T MS6LUO)#*B*RJ6974%1EUQGKSC.#@`VJP]%\-Q:9?W6JW=PU]K%VH2:\=`N(Q MTC11]Q!Z9))Y))I?%NO#PUX8O]4\J:62&"1HEC@>4;PC,-VP':OR\L<*.Y%< M?X0N!<6&F>*KGQ)K$$<>GI+JT.I1S):SO(F0T9D"HH#9YBR"-H[Y(!Z764-$ MCA\0-J]I*;=YU"WD07*7(`(1CZ.O'S#J.#G@BK:^*=&UJ\FT>UU":WU!HBRQ MRV[P2[2,;XQ*@W`=<@$5S'P^&I:MH?BW3KO7=2>:WU^ZLX;TR*TR1H(P,;@5 M'?H,!/(!ECZ``#\!6_:>,M M"O;V:QBNI5O(HC,;::UEBE=!SN1'4%Q_N@T`;U%7G@=3C`R,XR*M'QIH0L-*OA@H`WZ*Y_5/&_A[17G&HW[0)!N\R8V\IB#`9*>8%VE_\`8!W9XQFM M3^U;+^VO[(\__3_L_P!J\G:?]5NV[LXQUXQG-`%RBBB@`HHHH`****`"N&TS MP#>:?\4-1\:/K4,OV^(P26@LBNV/"!`'\P_,/+3)VX//`R,=S10`4444`%%% M%`!1110`4444`%%%%`!1110`4444`%99T5)M?75KN8SO`I6SB*@+;Y`#L/5S MS\QZ#@`D37EA%= MW#:O;I8>?*8XH;D[MDKL/X5&XGK_`%'957O;&SU*U>UOK6"ZMW^]%/&'1OJ# MP:`/(-3.HQ?$_7XAJT=YJ;^#IDC:%%B5)S-B.-5!)!R1C<2WS=>@K=\$^*O" M-WX(\*:?-<6$]_$EM!'8_))-'<*`N_R_O*006W8X&3FNZBT'1H)[>>'2;".: MV3RX)$MD#1+UVJ0,J.3P/6EM]#TFTU&74;;2[*&^FSYES';HLCY]6`R:`/.? M"_B31='U;QWIOBF_LK6XDUB:;9?2*OGVSHH0`-]\;5Q@9Z^]3ZY/83_$WX7_ M`&6..&`P7LD4!0(8T-NOEC9_#TP!V(]J[^[T/2=0O(;R]TNRN;J#_5336Z.\ M??Y6(R/PJO>^%/#FI7KWE]H&E75U)C?//9QN[8&!EB,G@`?04`^. ME>A:AI6G:O`(-2L+6]A5MPCN85D4'UPP/-5YO#FA7"3I-HNG2K.%697M482! MFT>E`'AYEA_X9&52Z;]^T#(SN^VYQ]<9/TKT#Q7+%'\7/ATJN MJ*1J(P#@8,"[1^?2NC_X03P?_P!"IH?_`(+H?_B:-:$Z-J.G.L>@Z++>PVA MM[)KNRC=(<`^6OW20@)Z#WQ0!Y#I4^F:I\/5$Q^*O#UIHGV^1HKN[U`17R0 MK<%Q^Z(P&)&0VX?*PXKWN*6.>%)H9$DB=0R.C`JP/0@CJ*\VT7PO`FE066M? M#>SN=3V;;C4&6S>.:0_>D+EO,&22>$XZ#I7;^'-%B\/:%;Z9#@1Q%V"KG:F] MV?:N>=J[L#/8"@#D](O&M/C9XEM-0^1KZQM'TUWX#11@B15)ZG>Y.!Z9K@O& MT2P>$_BC<6\BC2;O4;(6F"-KW`:,W!7U.[@X_NGT->XZEHVEZS$D6J:;9WT: M'*I=0+*%/J`P.*@O/#6@ZA;VUO>Z)IMS#;`K!'-:(ZQ`XR%!&%!P.GH*`-)` M@C41[=F!MV],=L5YY++!%^T3"LKQH\OAC;$&(!9_M).!ZG:&_`&N^LK&TTVT M2TL;6"UMH\[(8(PB+DY.%'`Y)/XUYU?:+J6J?%UM4U'P?)=Z$VF#2RUQ):R* M3Y^_SC&9,[,>V[';/%`&#>SZ5:V_Q1UR]L#J?AN6YM$2!)"JSSH%#X8=O-9< MD>AZXQ6CJEQ=)\6/`5SJFL64TCQ7\DD5L%6*W3[."/F)+,#UW,<';D`G_8$L[=;+;L^SB)1'M]-N,8]JJ1^&=`BCMXX]$TU$MG,D"K:1@1,<991 MCY3P.1Z4`>>ZB+WPIXUU+0M/1TM/%B^;9/&.+>Z)"3L/3Y"9?JM:VH2V=E\1 M;#1-'M[2QU4:(UG6DU77]'ATE+ M))(K2U6Z6X9VJ20R:AIMG=O",$D'@8^:I]<9-2^!'AG3- M-=)=5NX-/BL1$0S+,GEER,=-H5\GMWKU6UTK3K*XN+BTL+6":Y;=/)%"J-*? M5B!EC]:ALM`T;3;N2[L=)L+6YE_UDT%LB._U8#)H`\U2>23Q;\818/ON_P"S M[80",Y8NMJXX]PV!]:S?!]YX=U?P]X+63Q9J-Q?V<]L(-)A-JKQ3*-C941"3 MR@I8DECE>F7D=Y8>']*M+J/.R:"RCC=<@@X8#(R"1^-3VOA_ M1;&_>^L](L+>\DSON(;9$D;/7+`9-`%F._LY;V6RCNX'NX5#2P+(#(@/0LO4 M`^]<3\:U9_A%KH52QQ`<`9X$\9/Z5U$6@6D?B>;7O+A%W)!]G#1Q!&*G:3O; MJY^10,]`,#N3I3P0W,#P3Q)+#(-KQR*&5AZ$'J*`/-O&>L:;;_%?X?3SW]M% M#&M^[R/*%55>!0A)/`R>E6/",D#?%SXCN&C*K_9X)&.,0L&_4KSIO7Q3"2&<9`6>;.?8`K^8KH;C5+6R^ M,WBJUU?Q+/H,=Q:VAM9?]'$DVLZ4Y*L/./V>0JQ`5HW^9AP=I';%>I3Z?974445Q:6\T<1S&DD88(=I M7@$DVE@+"VTNRALQ()1;QVZ+&'#!@VT#&0P!SZ@&@#C_"H MUN'Q>MOXE_L_4KQ=.D:RUFS.PR6YDCW++&.`2=I!`Q\K8/6CQY>?8/&W@2YO M#MTA;V=9W;[BS-%MA)[#DMSVKL]/TC3-)$HTW3K2S\YM\OV:!8][>K;0,GW- M37=G:W]J]K>6T-S;R##Q3('1A[@\&@#SF34=-M?VB<27EM$TOAQ8/FD52\S7 M(*I[L5Q@=2,5PWA2\T;4?AS)I>O^*]3MK^"\%_B)'I+VNCZ?:SWL=VK'S)[VZ\L[V^27E_P"']*N[J3&^:>RCD=L``98C)P`!^%6)-!T:6]EO9-)L'NYD,&O(W22A1YGVG.SG^+'..M=]_86D?V7_9?]E6/]G?\`/I]G3RO^ M^,8_2H)?"WAZ>%89=!TN2)8Q$J/9QE0@8L%QC[H))QTR2:`/%-%=3\(/AB0P MQ'XKAWG/W?W\YY].H_.O?+>X@NH1-;S1S1$D!XV#*2#@\CT((_"LR+PEX;@M M9[6'P]I,=M<;?.A2RC"2[<[=P`P<9.,],FM6**.")(HHUCC0!51!@*!T`'84 M`.--U(B/4!JSW8\S@O:LH$1&>JA4^@S7":U!]B^`'BM=X73[C6 M7?25)P#;&Z0KM]CM=A['/2O;=1T'1M7DCDU/2;"]DB_U;7-LDA3Z%@<4FHZ! MHVL+"NIZ187RP`B$7-LDHC!QG;N!QG`Z>@H`OH$$:B/;LP-NWICMBN!Q_P`9 M"_\`+M6TXZ7,=*33DLFF25@?-:1VW(2",[0.AZY`[@&;X;N8;+XM_$62YE6%#'I MT@+G&5$!!(]@3CZUY]X)UBUM]!^%XFNH6L+2]O5OEW@^1-(91;EQGYP_ZJYD@5I$_W6(R/PI$T+2(]-;3DTJQ6Q<8:V6W0 M1,/=<8_2@#@I-1TVU_:)Q)>6T32^'%@^:15+S-<@JGNQ7&!U(Q7&Z5/IFJ?# MU?"SN=3V;;C4&6S>. M:0_>D+EO,&22>$XZ#I0!-XHN;:X^+OPX:&:*4,FH2`HP8%3`-IX['!P:=X2: M$?%SXCR93:HT_+>G[AMWZCFMO0O`'AS1[:V)T33)+R&0S+<&U1GC8N74*Y&[ M"9"KSD!1Z5JIX:T&.XN[A-$TU9[U'2ZD6U0-.KG+ASC+!CR0&17LEK M^SWX+NS/,EM;ZVCWDL05FCB6>8YPP(X.S`((SC@BO1_#U=;:>'-#L+2>TL]&TZWMKC_70PVJ(D MO^\H&#^--C\,Z!#ILVFQ:'IJ6$Q#2VJVD8BD(((++C!((!Y':@#Q,,D?[(X* MD*Y;@CKN^W?SP*[OPO=VT/Q<\?O+<11K.=+6(NX`D)@(`7UR3@8KKO\`A$_# M?]G?V=_PC^E?8?-\_P"S?8H_+\S&W?MQC=CC/7%2V?AS0M/GAFLM%TZVE@4I M$\-JB-&I))"D#@$DG`]30!;MK^SO))X[6[@G>W?RYEBD#&-_[K`=#[&N1\9W M]K:^+/"=O':6[:W=2W$=A>73L(K4>6/-)4$;V8$*%XR3U%=!I>@6FEZIJ>HP MQPI<:@RF7R8A&I"EB,@?>;+L2QY)/8``6]0TK3M6A6'4K"UO8E;<$N85D4'U MPP/-`'B_VBQMM:^)*ZMK\GEF?2`NHV^Q6CG_`(7500,(X!(Z[4.F!CI4VGZ1IFDB4:;IUI9^]O5MH&3[F@ M#)\?2)%\._$K.P4'2[EH/A7=6YA\;3">/RQXGOI2^X8"'80WTX//M78V MOAO0K&"Y@M-%TZWBNE*7$<-JB+,I&"'`'S`@G@U7C\%^%84F2+PUHR),FR55 ML(@'7<&PWR\C$+U5,ME8ZTD^I(@W?N$N9&.1Z9V M&O0?'$::EXA\#R:7,DFH)JJSJ\3`_P"B;&\YLC^$C:,]"2!WKK-/\/:)I,<\ M>FZ/I]FEP`LRVULD8E`S@,%`SU/7U-.TW0M(T=I&TO2K&Q,O^L-K;I%O^NT# M-`'G$EG-9_$+Q)X2CCD6S\2K%?!X^/+C(*71SV+;<#T+K4GPLAO)DCTN_1MO MA22XL0[#`DE9R%8?[L7'TDKTXV\!N1"W M:5H88XS*_F2%%`WM@#<<=3@`9]A0!Y!J#7HMO$=QI=Y;:SX76^NHM6T&^/ES MP-YK>;Y+J9L MSG;NZ[<\XZ9H`FHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBLS6_$.F>';>WGU.:2-+F=;:$1P23-)(P)"A44 MDDA3VH`TZ*Y-OB3X922]C:;45>Q56NU.D78-N&&5,@\KY01R,XR*?%X_T:?Q M!H^CP1WTDFKPF>TN/LS)"Z>5YN0S8S\N.@."0#CG`!U-%%%`!1110`4444`% M%%%`!1110`45GZQK-IH=B+J\9\/(D,4<:[GED<[511W))Q_]:JF@^)[;7KG4 M+1;.]LKW3Y%2XMKR,*Z[@2I!4LK`@'!!-`&W16'J7B[1])UA=(N9+M]0:`7` M@MK&>X;RRQ7=^[1L#*D5C1_%GP9+ILFI1ZE=/81OY;W2Z;=&)6X.TOY>`>1Q MGN*`.UHHHH`****`"BJNHZA;Z5I\U]=>;Y$(W.887E8#.,[4!8^^!P,D\"L3 M0O'_`(<\3174NC7=S>1VL;22O'87&!C'R@E/F;GA!ECV!H`Z6BN8T/XA>&?$ MFJ/IND7MQ?,06,ZB/&?OLR`+T(Y(YXZUT]`!1110`445A^'_`!AH7BF> M^@TB\>>:P94NHWMY86B8E@`0ZJ.VK62L\]N]O+&44%03EE`(^9<$$Y!!&1S0!N445R,'Q,\+W6IS:;;W.H37\ M`+2VL>DW;2Q@8!+((L@T;QQX?U[69M(T^\F;4(8C/);S6DT+ M*@(&3YB+W9?SKH:`"BBH+V]MM.L9[V\F6&VMXVDED;HJ@9)H`GHHHH`**KW] M];Z9IUS?WDGEVMK$\TS[2=J*"6.!R<`'I7+R_$_PG`;(2W=]&;\XLP^E78^T M'@8C_=?/]Y>F>H]:`.PHKF8O'_AR6TU6Y6[N5CTE4:^62PN$>`/G:2A0,1P2 M<`X`R<"M;1-;T[Q'H\&K:34!UVE\A]NPC"MSGJ".HQ6Y M0`45%<3I:VTMQ*',<2%VV(SM@#)PJ@EC[`$GM69X;\4Z-XNTZ2_T.\^UVL/#@`D8<`]&'YT`;%%%<]H_CCP]KR:HVF7DTYTL9O(_LDRR1?>XV,@8M M\C<`$Y&,4`=#16/X;\4Z-XNTZ2_T.\^UVL/#@`D8<`]&'YUL4`%%% M%`!1110`4444`%%%8>K>,-"T/6M/TC4KQX+W465+1#;RLLK,VT`.%*YR1D$\ M9!.`10!N445F:MX@TS1&ACO9W$TV3%##`\TK@=2$C5F(&>3C`H`TZ*J:?JEC MJNGI?V-U'/:N#B13QQP0?0@@Y!Z5FV/C'0=2OHK2UOBTD^?(9H9$CGQU\N1E M"R8Q_"30!NT57FOK>WNK:UEDQ-WRJ6.=N=O"D\XH`V:*H:KK-AHMNDU_/Y:R.(XU5&D>1S_ M``HB@LQX/`!-&DZUI^N6[SZ?<>:L;F.161D>-QU5D8!E//0@&@"_16#_`,)G MH`U`67V_]X9OLXD\F3R?-SCR_-V^7OSQMW9]JWJ`"BBB@`HHHH`**@N[VVL8 MDDNIEB1Y4A4MW=V"*OU+,!^-3T`%%%!.!DT`%%9*^)M%?3)]2748?L,,AB:X MR=A<8&%/1^2`-NHZ=:WL?]HBKVIZU MIVCVT=Q?7&Q)6"1*B-(\K'D*B*"S''8`T`7Z*QHO%>B3:1<:JM[BSMFV7#-$ MZM"V0,.A&Y,9!.0,#D\5K0S17$*302)+%(H9'1@RL#T((ZB@!]%%<]XO\8Z? MX+TK^T=2M[Z6#.";6W,@7H/F;A5R2`-Q&>U`'0T444`%%%%`!1110`445SVO M^,=/\.:II>GWEO?-+J5Q';0216Y,0=VVJ&)9'MI/-A+?P/M9,CWVNP_&IZ*`//O"BJ_P`7/B.K`,I&F@@C((^SM57Q M79"S^)7PUL=,\NV2&/4(81MW+&BVZ#`&>RCC\*T/#&@>*-.\>:_KFI0:.+76 MC!O2VO)7>#R8RBX#1`/G(SROK[5+KGA_Q#J?Q(\.ZY!'I8TO1S,`'N9!-*)H MPCMM$94%>PSSCDC/`!B3^.]2\,0>/HM0N/[3?P^;9[6::-8RXN$&Q'V``A6( M&0`2/TT=!UW6QXKL+&:;5M3L+RVD-Q/UO5O&BW;:9'IOB,0!9([B1IH/LX_=,4\L!LD+N&X8R<$XYWO"^C^.8; MJR'BC5]-DM+!"(UT_P`T/J>+-5O=0UK2]*\ M0_V=XGMY)HK31[NVB$4Z@D1-&[@%G9<,,L1DX*X%>J5Y[J'@O6=9MKO3]732 MK^&:]N)K2_EDD%SIT;RLR"/Y3N95(Q\R!<`?,!R`217VN)\7;_PY)KUQ)IUQ MH;W\"^1"&M9&G$8VL$^;:,XW9Z\YKC[WQ=XSL?AUXKU1/$,N36`FEL8 M]\L8:*-<8PJD%V8Y5LYQQBN_U/P[JZ?$.W\5:2;*7.FG39X+J5X\+YGF!U*J MV3GL<9]17%:G\-O&L_AWQ)H5O>Z#+::YJ.2VUR*Y21'MDVV[1('+QX^;D'`#%AGGGI5WPAK.I3 M>*_%?A[4;UKX:3-;M!F);Z M3'+]IB-U)N+S)L<)^[PP4`$$[=W0A>M.\/\`A[7M,^(7B;6[M--;3]8:'9Y5 MPYEC$*%$RIC`)8')^;CWH`ZG5-0BTG2;W4;C/DVD#SR8Z[44L?T%4#8\P,$/WMQ!(Z"O0M0L8-3TVZL+E=UO=0 MO#*H[JP((_(UPMEX1\36_@]_!DEWI\FE&)[1=1\Q_M`MFR-OE;-N[:=H._`X M.#0!E_$>1M;L?`>K6>IWD%K?ZWIYBB1(L)O#LLHW(3O`(&"2OJIKTZQMY;2S MC@FO9[V10BJO'3@#IZ\UQ7C+PIKFIIX;LO#\.E1Z?HEY;WJB[N M9$9C#D+&`L;87!'S9S[<<]S`9FMXFN(XXYR@,B1N756QR`Q`)&>^!GT%`""V M@6Z>Z$,8N'18VE"#>R`DA2>N`68@>Y]:\?\`V>K:WO?AGJEM=01SV\NIRK)% M*@974PQ9!!X(KUO46ODT^8Z9%;RWN/W27,K1QYSU+*K'@9/3G&.,Y'"?";P9 MK_@/2+O2-4_LR:VEG:Y6>UN)&<.51=I1HP,87.=WMCN`#+\1^(?$GAOXMZ1I MM[K\Z^'-8++!MMX`89#P$+&,D@,4[YPPR>.*]/U77+Q[J"T M2;2?]&MXV<2,HB;;Y>-S>9",'CYSQW'H/Q)\"KX[T:SM$E2&>VNTF65R1A,X MD`QW*G(]P.15:]^'$-S\4M,\5QM%':6EIYJ+Q0!3UG MQ'K-CXN\+^`X-5ZH88_,V*'/R+MV`DQL.5.`!P>M7/"?BN_?Q]K_ M`(*U6X%Y/IJ)<6]YL5'DB94.'50%W#S%Y``.>E6O$W@VXO\`QAHOB[29(!JN MF*T1AN6*QSQ,&&TL%8J1O;!VGKTI/"W@RYT[Q=K?BS5I(&U75`L8BMV9XX(@ M%&T.P!8G:O8?='%`':5X7\`M5O+'P+?16_A_4M00ZG(QEM9+=5!\J+Y3YDJ' M/&>F.1SUQ[5J+7R:?,=,BMY;W'[I+F5HX\YZEE5CP,GISC'&&2/[IH`Q/@S(TWCKXDRO#)`[ZF MK-%(5+(3+'=_V"X^S0!E\LSGD! M-IW")0^'_`(-\4>%_%?B#4]2&D2VVN7/VB;[-=2%X#ND8!0T0##,F M.2/7GI57_A6^OZ?>^.UTRZTU[7Q0CD27#N'@9O,RI4*00?-(W;N.N#TH`H2^ M,O$LG[.T'BU-7>/68W+/.MO$1*/M)BVE2FT#:0>`#E1SURZ7QGXDTB_^&LUS MJWVR#Q)%&MY`]M&JAG$6&4J`P.9?7&1TP<"U_P`*Z\2_\*1_X07=I/VWSL>? M]ID\ORO.\[=_JL[MWR[<8QSGM46K?#SQ9?IX!,8T56\+I&9%:\EQ.Z-'P#Y/ M`*PJ65CLPHWJR@?O%/ M3/7GI7">#9]0TZ;XRW=K?M!J%G,\ZW,<2>,/3?AIXDTNW\=$:CI= MS-XF250C+)$J,[/ARPW8PLKG;M.3@;@`20#0^&VI>+O$WAOP[KU]J\,ENYN5 MOH6@16G4,ZQL-JC:P8`'&`0/6L?4OB%K&KZ[XLL=%GO[5M"'E6D-EI;79N[@ M;P1*1&P124VCE>N<\$5VGPV\.ZEX2\$6>A:H;1I[1Y`LEK*SJZLY?)W*I!RQ M&.>@.><#%LO`NM>&/'^K:_X=FL+BQUC+W=I?2O&R2%BVY&5&R,DG!`ZD9[T` M9DGC[Q!K.M^#O#44,NA:EJUNUSJ#2V_[V%4\P%4212!N,3D%@>"OXT?",,\' M[2WBF*YN3XUO3$ M,,ZW0,,5Q&=^0"BL4QYC@<-P1DDC);H?@77+'XK:EXRO-0L#%?0"![:*)RVW M9&``Q(P0T:\X.0#P">`#T.O!;O5[S0OCYXYU"PTVXU"XBT4,L<)0;<1VYW-N M(RH(&=N3SP#7O5>7Z1X,\66GQ5U+QA>0Z&UOJ<`M9K:.]E+11_NP2"80&.(^ MAP#GJ*`)VU�/AOI7Q!NO-N=5M?#L,!:1\^>9?)(WGJ3Y@'.?XFZYXRM0\9 M^(?"OA3PMXNU+5!?6FK20B]LF@C1(5EC,@,3*H8;0/XBV?:N_P!9\(Z;J_@F M7PKM:#3S;);1!26,03&PC)R=I53R><5QUU\.M:U[1/#GAS7)M/72-%>-GEMY M7:2[6-"B*4*!4^4X/S-U-`%2WU_Q;??&/Q/X2M==*V=O8F>U,MO#F!V$3+@A M,L`9-OS9^7KD\U3^.\FJV?PKTE+K4&-S)"+ MGQ[X272[.ZBM[J&Y2YB,V=C$*RX8@$@8<\@'H*`.5\;:UXK\">+-!GNO%%Y< M>%[RX6*Y>2UMA)$V>0S+$!M(YX`.`W?!KNO#YU2[\1ZY=RZQ-V]>P5YIX^\&^*/ M%'B_P]JFG#2([30[D7$0N+J0/.=T;$,%B(49CQP3Z^U`'3>.+:WC\#>*KE(( MUN)=(N%DE"`,ZK$^T$]2!N;'ID^M>-:5XGUWP3\$_"6NV.HJ;9M1DMY+(VZ% M'B,DS'+'YMV4/((X(XXR?;O$MAJ>L^"=2TVWCM$U&^LGMRLD[>5&SKM;YPF2 M!DD?*,X'3/'EVI?"GQ7?_"C1?!JRZ*DMA>R7#W!NI2KJ=Y7`\KKF5P?3:.NX M@`'7^+/%=^GQ`\/^"M*N/L.)5<@(&!7)\MN2#CCBL.X\::W: MW'CKPQ+J9.IZ'I[:A9:DD,8=T6-9-KH5V$_,JDA1PQP!P:Z/7_!U]J/B?0/% M]E]DBUS38S'-;22MY,R,K!D$@3<,%WPVSG/053L/AS/<:AXLUC6;B%=2\06K MV6VV9I$MH2@3`9@I8\+V`^4<4`<-K?Q`\76WP0\->*K?7'CU.YO9;>X86T)6 M5=TVTD%,`@1`#&.ISFNO\?\`CF]\,>-=+L)[R33-(N+1G6]%LLL;7.[`23(S ML`&3L(;YASBN>U/X3>+;_P"&.E^#DN]%1=.O7G68RR_OE8R$$_N_E(\PC'S9 MZY&,'O?$.B:_K@EAN;31+W3)K&-'TV[D<*ESE][K*(]P`!4#Y_P!3^(VN M>&)]2?5+&VMENK2]FMEAE92(\@A54$9DX.T9`ST-5-3^%>O_`/"'^$=&TS6; M1WT2X,]PEXK&&X8OO&0`HK6\/\`@77=+^*VH^+;^_L;N'4+$6\O MEAHG1P(_NI@C;^[P,MG!YR1R`Q?$F.7Q-,3X:\S[))]CM]S;#-] M["8((B&>.O3'(-N;XGZS=^!_!)M&@@UKQ)=?9#&[U[BSE21W@F5I!(0^45E.0!P#]WWX`*NH6MU9_M,>%(;O4)+YQIDA M6:6-$?&RYX;8`I.<\@#M]3[77G%QX'\1:E\4M(\9W-[IEL+&W$+6L:O+P?,# MJ&.W/$APV!@G[IQSZ/0!YOHGB36O&7C[Q+86.I_V;IN@NENJ1P)(9Y2S@ERX M)VY1AA2IZZ9X(UCPUXV MU[5M#N;)['72)9TNBX>WERQW*`")!EV.TE>O7CG,\)?":YTOX=ZSX2UO4+:> M#4I/.5K:-LPR87G+'Y@"B$#`Z'KG@`J:AXS\0^%?"GA;Q=J6J"^M-6DA%[9- M!&B0K+&9`8F50PV@?Q%L^U-^$'_)0_B=_P!A4?\`HVXK0NOAUK6O:)X<\.:Y M-IZZ1HKQL\MO*[27:QH412A0*GRG!^9NIJ?P+X.\3>%_$'BW5;Q-)E.MR&ZA MCANY#Y1E1B8A\I\PY8& M/EP@]QG`R<9YQCO6G-\0M4TOQ?X2M5UE]0BU>1;;4+.6"(K:3-Y8*I+&H#$, MYR-S8QSU%3^&/AEXGT7X7:_X3?4;"WN[Z;SK>[MII&'(0.C`HI4$1XR,_?/' M',3_``N\52Q>"'GU#1G?PW<(WV>)'B1HU:-B0^TEG/E\DJ!SG&C^&K+5F72]1LC.]N\$1$9V2@E6V[N/+#8)//'3BD\8>*/$?@C2O#2:S MJ$C1S7,R:GJEC:HQ503Y0"LNT9!&>,_(V*OZOX,U^]^,ND>,(/[-_L[3X!;> M4]Q()70B0,V!&0"/-.!GG:.1GCI?$>G:QJ$]M'9KIMQIGDS+>V%^IVW+'9Y8 MW!6*XP_.#U'RGJ`"3PA>W&H^&K>[NM4L]3EE>5Q=68Q&R&1B@`[$(5!!Y!!R M3U-7QUJ?B#2?#PN?#FGK>79G19064>5$<[G&X@$C`'/`SD\`U#\/?",G@W0+ MBQD>+=<7LMWY,+,T=N&P!&C,`2`%')`))-0_$[PIJGC/P>^D:3?QV)\7;/PS#K;ZUI&H6KRI/-;HABD7S"0CQJJ MNN(\;@",GKP:-/USQ/J'QJ\1^$_^$BFBTZUL_M,&+6`O&6$3``[.0/,(^;.0 M.>>18A^'_B0_$CPYXKO+[2IAI]H;6>W@C>!47;(H$0PV0!)GDCD=A@":P\&^ M)K#XM:[XQ5-(DM[^T:VA@-W('7:J"-F_=8Y,2Y`Z;CC=C!`.4L?C#K$7P4E\ M070AGUE=0.FQRM&%5F*!PY4<9"D\#`R!2_$6QU.Q\<_#%-3U>34I6U,$N\,< M>U_-M]V-BJ-O3`(R.Y/:?2?@MJI^&FH>%-7O+%)C?C4+.YM9'D`D\L(5=61< M#`Z@G[W3CG<\1^!?%OBK5/"VI7=_H]G.< M@`]0KRC2+R2[_:9U^&7E;/15BBRG+M7J]<=J7A2]M_'B^,-#^RR7D MED;*ZM;J5HDE7(*L'56((VC^$Y`'2@#R,ZO#3#K.OZ[K0@DU#6U6*:&!BT44*H$"!B`6R!R2!GC@4`>7%$ M/[(ZR%1O5MX;'(;[=C/UQQ7M?A>\FU'PEHU]<9\^YL8)I,]=S1J3^IKAE^&V MK#P5_P`((UW9GP_]IW_;/,;[3Y/G>;Y?E[-N[/\`'N_X#7I<$$5K;Q6\*!(H MD"(H[*!@"@#@;_Q-J>M_$VZ\%Z1J!TQ;'3S=W%VD222-(=FU`'!4*!(I/&3R M!CK5/Q'XM\4?#WX:/?>(9=.O]<>Y^S6TELK",[@2&<87D!7.``.!]:NZQX&U M2#XDP>-O#LUDUS)%Y%]:7KM&DRX"@JZJQ!P%Z@_='TJ;Q7X'U#QUX+GTO6[V M"&_-T;JV-L"T4!`*JA)`+C!.20#ECQP!0!GZ/KWB67QD=$,FM7FDWMB2FK7& MC-:M9W(#9'S1*I7C(W`\E1D\YXG2/'OC.\^#6L^+I?$+&^T_4$A1/L<&UT)A M!5OD_P"FG&,'KR/5)=,\^TMRBK;2N5O)`N%,C-'F-?4*&. M>NX]-HR`1?$ M35;W6M3^%-Q'?7%K%JUQ!<-%#MVQR%H"KJ&!RP\PXW;AP..N>A\<>-;_`,)> M+-&TNZU.XL]+EL2?[2>U219KG=@";"C"@#+>7M/SC&!2:K\.=%FCW0M,_DSJACZ/Y>X$B)?X>-Q'.,G=UO0O$FM1RP:A!H.I:?+9JC:?/Y MD:"XWOF19`K,`%*#U)!QL[@'2Z#)<2^'M->\O(+RZ-K'Y]S;D&.:3:-SK@`8 M)R1P/H*X7XO:S<11>'O#%M.T!\0Z@EK/(A(;R-RJX!'3.]?PR.]=5X(\.2>$ M_!NFZ'+=?:9+5]B68L0/8;L#V`KE/B_HMS-%X>\3VD+3-X>U!+J:-02?) MW(78`=<%%)]LGM0!K^/_``G?ZQX3LK/PW+'9WFE74-Y91X`1C$"%3T`Y!&>, MJ/K7%?#W5M'\8?;_``YXAL9;+Q,@OHKD(Q02Q37)EFC4@]F^4@Y.`<'DUZ5K ML&J:O8:9>^&]2@CDAN4NAYC-Y-U$48%&*_PG>#G!Y4'%"_$;:C%K\UKI M5KJNGR:BUC";AW61KF>1MTL@3.Q5=I)``,O6O`VDS_%_PS%X:L(+$ MZ6!>:HUJ@1%0,IB4@<;F*L/4@Y->F:Q?7!ECTK37"ZAE1V-W=>=?M;@^=(&8;R'\D-NV\#YAC``(`KO\` MQ)\._"OB[48[_7-*^UW4<0A5_M$L>$!)`PC`=6/YT`>%VLK:)H'QG2U:3$=Y M%;*6>N=9?`.K:GI7 MAO0=CUX-\/[@ZM\#/']_6S@HHWG'\9,A') MX3MWP4\`:MI6E^)-!T6:P&D:[-+(9+AW$EF)4"2!4"D2#`XRRX]Z`/._!.LW M>J^.?A;;7>XK!I5R5#'/3[3&#S_LPI2>-]7N=(\9?%.UM04AN--M6?:<#);WP]&T$:7+%4N8F4JP9@"5;+$Y`/WCQZ+! M\.TU%_%%]K[1&^\0QK#*MJQ9+:-5"J$9@"Q&T$D@9('`[@'">/[E],^"?P]U M&U3%U:S:?)$5X.?L[-@$>I`KW>O.%\`ZMJ>E>&]!UR6P;2="EBE$EO(YENS$ MI6,,A4",8/.&;/M756MKXD3QE?W-UJ%H_AU[=%M;18\31RC&YF;'(/S=SU'` MP<@'D?P_N#JWP,\?W]RH>6YFOYW+J^.?A;;7>XK!I5 MR5#'/3[3&#S_`+,*5Z(G@#5M*TOQ)H.BS6`TC79I9#)<.XDLQ*@20*@4B08' M&67'O5NZ^'26%QX7U#P^\2WOAZ-H(TN6*I%9M-\0ZUXFU1X#JNJF,.D#%HX(D4*J*Q`+'@$L0. M@X%JYB7![\^E`'H^I7\.E:5>:C< M$B"U@>>3']U5+']!7COQ"DU_5?@C:JIAU"*VN'T]8$$<43RQM&%;&\N, MKDDD'G`'%>Q:E80ZKI5YIUR"8+N!X)`#SM92I_0UYOJ7@3Q;?_#67P0UYI+V M\8BB@OG>02/"DBLJM'MPI`4#(9LXQ@9R`#4BOM<3XNW_`( M5$HWD#>P4`DG`YZ5TS^&_$L7C2Q\4)-I5U>?V8VFWD3&2"/'FF17CX+A>M M>^*]0TYY$A\B&VTP2"(Y(+2/OZO\H`XP!G'4UU-`'C_B'Q?XC\->'&UK4M;2 M+6X9UDGT"*&*:%(#*%`9U4NI*D'<7`)X`S6^=2\3/\7+CPV^M1)ILFD-?QB& MT57B!F"``MNRPQU/RG)^7IC'F^''B>7X9ZEX/-UI#/<3F;^T7>3S+HF829E& MWY6XQNR_``QWK=T[P_XI;XH_\)1J<>CI:'36T[RK:ZE>14\PR*WS1@$YP",C MJ3[4`4=,\>WFF^`/%&JZQ(+VZ\/ZC)M@C^TLC*(RP7@9+J#@5G>.;#7;2 M3P/)JNLB^\SQ+8F:/[.D:QRY;_5E0#LQN&&+'HYN=$CNM( MU&"]-QYDL@N#$&PQ7:-I)/*Y.<(!(T:E5+8Y(! M)(&>V3]34E`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`445RWCSQ?-X)\/OJZZ/-J$$9`E*3)&L62%7<3D\E@.%/OB@#J:* MY*[\97.E^(M*T_5M'-K9ZM(8;2[6Y#D28R$E3:-A/;!89-94;EKO%PJ>9Y?F&$IC;N[;\^U`'H-%RN[>Y6)_+D,,@<(^`=IP>#@ M@X]Q7,#Q-='Q%9>&O$>A6]M_:]O,;9Q M'$LLJJ9&)P%4$\DD@8'K5FO*/'%WI/B&S^'OB:Q@C9[KQ#8+'<-&!*(R7)C) MZX##D9QD5V.I^*+N/6;O2=$TG^T[NRMUN+L/<>2L8;.Q`=K;G8*Q`P!QR10! MTU%9V@:U:^(M!LM8LBWV>[B$B!NJYZ@^X.0?I6??^([G^VY]%T73X[^_MH%N M+CSKCR(HE8D(I<*QW-M)`VXP.2*`.AHKSC4_BN=.\+7VK?\`".73W.FW!MM1 MM&N(U^RR94+EN2RL6&&53WZ5O_\`"67%OXPT[0M0TK[+'JD,LEE/]H#LS1@, MZ.F!M.TYX9A^N`#J***\H\'^'M+T[XK>/6TS1[$3Z>EF;!"HC6)I(&+!6"GR MPQX)`/!/!Z4`>KT5Y_;?$/5;KP?KVMIX<@%SH=[/:W=FVH\;84#.ZOY?)YQM MP,@9SVIT7Q(N9=4\+V7_``C=P!X@M!)?[*FZCAF\]71UW1LC;5)+=,$#FK.G>*KQ_$%IH^LZ M/_9L]_;/<696Y$H?9C>C?*-K@,#@;ACO0!U%%4]5MKF\TR:VM+EK:64!//0X M:-20&*G!PVW./?%>:ZAX'L_"GC7PQ=>$WN[>_O+XK?1/W.,$ MFKWPVU*XO-!O["ZG>XET;4[G3/.D)+2+&WRDD]3M91GOB@#LJ**X+Q/\/=%U MR'4-7\2W5TUQ$))(;B.Y=%LHESMV*"%S@!B2#DYYQB@#O:*\CM;S6[O0/AUX M9UR63[3K#227VXD/+!"AD$;GKEE,8;N>0>IKH=!:/0/B=J?A>S58M-N-,CU2 MWMD&$MV$AB<(.B@G:<#C.<=30!W=%><>)[.*W^-7@2ZC,HDN_M_G`RLRG9;@ M+A2<+C<>@'4U=^)JZAXWM\P&,97.TD;5P<9&T>E; M=%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111 M0`4$9n!3T[2K'2()(-/MUMX7D,IC0G:&.,[1T4<=!@9R>YJY110`4444 M`%%%%`$:00Q22R1Q(CRD-(RJ`7(``)/H7E>>#GCIW`,?71<>-M9\ M-6EMIFH6L.FZC'J=Y/=VSPK&8@=L2E@`[%FZIE<#.:XCQ'9:WXF^&.K_`-KZ M'K5UXM\[F(VS^3;H)U($`^XP\L8RNYSSDXKV_3X[V&PBCU"YAN;M01)-#"85 M?G@A"S8XQGD\^G06:`.-\>::_B/P+-=VGFVE_8G^T+&29-CQRQ$LI(/*Y`(Y MP0&YQTJE,_B:T^%VH:OI5IN\3ZB/MIA50Y1G*@*`>I2(*`.R[TR.W0_:N23F4_,JD8!4=1GUKHJ`/(9K%8_'O@K6]/T77Y MX81=B]O+NUE,[N\`5`^[E?F)'(5!DX.,XT?#=QJ7A.7Q?9SZ)JZU=7]A MY-JTD,ZR;=F91\B?=YWE<5Z;10!XKJ^AW?A;PEX!\.1Z?J6HW&E:O;ZC>26- MC+-&B!Y&?#*N"X.T]/3%>T44`8_A:"2W\.6D76C:Y;P9FL[9[AH)H5V!61`6"D$G(!YKT&B@#P[Q MQI&H3^&_&=[!HVJ27?B>YM1:6<%E)(Z16YC^>3:"(RWS':V#T[YQTWBV]D;X MC^!-6CTO5YK&TBNYKB6'39Y/*6:(*@8*A(;(.5^\.XKTNB@#,\0ZG=:-H-WJ M%EI<^J7$"ADLX#AY/F`..#T!)Z'I7.>#+"YE\5>*O$TEMA%=M10!Y##;:EIGASXDZ(^C:E+>:E>:A=6ABM7:.:.: M+"E9,;2W'W<[B<``U3TJ?49/$OPRAG\.:[:C0[66TO)9=/D,:L]LD:D.H(V[ MAR21COC%>U44`>&>)=)U/7=7^)FG6NE:FLFKBQ^PRO8RK%,UL,R`2%0HSM(4 MD@-D8)R,]+X)D@O]6TY[;X;)H%S;(S7U[<:7';X.PKM@888DD\G&-N1W!KTZ MB@"IJ=^NEZ9<7K6]S<"%-WDVL+2RN>P55Y)/_P"O`KSNV\?74EXT\'@+Q6VK MW6R!)+O3C%!$I;A2^250$Y)QR>3@8`]/HH`X:6";PM\0=7UQK.]N=/UFTA\P MV=LT[I<0@JJE4!(#*>&Z9!R1Q5;07D^'W@NXU36[&]DGU'49K^]CM(O.-MYI M+$N0?NJJCUHH`\U\87LB_%7PA=)I>KSVFDB\^V M7%OIL\L:>="%3#*AW<]=N@&><@;> ME:A_:NFPWOV2[M/,S^XNXO+E7!(^9>V<9'L15RB@`HHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@ M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@ M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@ M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`****`"BBB@`HHK%\1S:]&FG1>'X[0S3W@CN);N)I$A MAV.S/A64DY50.>K8]P`;5%>=66N^-]1\2^*-#MKS0#/HBVYC=].F47#2QEP# M_I!V8QC/S>M17GB?QM!X@\(Z6?[%MGU^V9Y5FLI6>TECA5Y5($P#?,2!TQT. M<9(!Z517#^/_`!#XC\.W.AG1WTHV^IZA#II2\MY'9))"V'W+(H*X'3&??GAO MC77O$WAR3PX+.XTB1-2O[?3)S-92$K+)G,J@3#Y>/N$Y']XYX`.ZHKEKE/'- MK/9/#=Z'?P-=1)=1K820.L)#OZBM^^GS+IDMM%>X_=/< MQ-)&#G^)593R,C@\9SSC!`+5%>>>"]=\:>+_``=9^($N]`@:Y\S;:FPFP-KL MG+^=QRN?NFMGP[XHO=<;5M(O+./2_$&G`+)&Q,T)W@F.5<%2Z''3(/;(-`'5 M45Y[X2UOQEXGCU@R7^@VCZ9JD^G,%TR:02&/;EP?M"XSNZ8[5#= M=U&\&BI?Z:\L\++;R-#26]B M9TAMVB9]Y564YR$`YZMCW`!TM%>=66N^-]1\2^*-#MKS0#/HBVYC=].F47#2 MQEP#_I!V8QC/S>M;,GBF_M[#0+%["-_$VJVRR-9[C''`0@,KN>2J*3C'))P! MZT`=917*ZA>^+-$M)=2N!I>J6D*&2:VM8)()E0R5KFUDD=#-DB0%9%!&!]T@'(Z\\`'?45Q6H>(M?\` M#&M:/!K9TV^T_5+Q;%+BS@D@DBF<'9E&=]RG!&01BNUH`**@O+VUTZTDN[VY MAMK:,9>:>0(BC..6/`K,;QAX92TCNV\1Z0MM(Y1)C?1A&88R`V[!(R,CW%`& MU16+JFLVCPQV-CK^F6>IWL8>R,SK(9`3PRQ[@7!&<$''UZ5S_P`.?&0UCP+H M=[K^JVBZKJ+3!%D=(FE(F=5")QG@`<#MZT`=U165>W&-?TR!-;MK;_6>9I[! M#)=Y3*[23N&W!;@'(!STKG/!VL:[<^./%^BZQJ$-W'I9L_LYBMQ"JB5'<\9) M_NCEC]WWH`[BBJ4&LZ7YH`=16:OB+1&:U5=9T\M=L4M@+I,S,&VD)S\Q!!&!W&*M7M]9Z;:M M=7UU!:VZ?>EGD"(OU)XH`L45S'B7QUH_A_P=<^)([JVO[9!M@$$ZE9Y#T16& M?QZX`)[5NZ?J=AJUJ+K3;ZVO+Y11%NR%W9/R MYP<9ZX/I0!I44R*6.XA2:&1)(I%#(Z,"K*>001U%4M7U2STNR9KK5++3GD!2 M&:\=53>1QP67=SC@$9H`T**XKX;:WJVM66OC6+V.\GL-:N+&.6.)8U*1J@&` M/4DGDD\]:ZBQUG2]4DFCT_4K.[>$XE6WG60QGT8`G'XT`7:*\PN?'/\`PDGB M?5]&T+QAIFEM9I;II\N^"5-0GD!)7+9W*,*F$^8%CST%=M9^(=-66VTN_P!9 MTK^V]BK-:Q72[C+@;@J$[L9SC(S0!LT5EIXET&2XN[=-;TUI[)'>ZC6Z0M`J M'#EQG*A3P2<8[UQ_Q&\77=M\/KSQ%X/\0:>Z63JDSP*ESN9G10`VXJI&\'!! MSD=.X!Z)17,>(?'.D>&O$.CZ1?W-O"^H&1GEGG$:V\:HQ#L3Q\S`*,D9)/IB MNA=FN+)FLYXP\D9,,Q7S$!(^5L`C<.AZC/K0!-17G_@?Q?,^GZZ?%>MV2RV6 MNW&G0S2[+9&$80`*">Y)/))YZUVU_J5CI5L;G4;VVL[<'!EN)5C7/IEB!0!: MHJE/K&F6M@M_<:C:0V;CJ:?,UTL5];.UF<7(6928#C. M'Y^7CGF@"W168OB/0GTV74DUK3FL(6"RW0ND,2$D##/G`.2!R>]13>+/#=O9 MVUY-X@TJ.UNMWV>9[V,)+M.&VL3AL'@XZ4`;%%59M3L+:[CM9[ZVBN9`2D+R MJKL`"QP"0!BADMI5D4,.HRI(SSTH`M45YUXQ\ M7W5KK7AX:#XATZ2VGUJUTZ^M(5265?,8EMS;CM!5<8V@\DY].YU#5],TE8VU M+4;2R65ML9N9UC#GT&XC)H`N455N-2L+1H%N;VVA:X94A$DJJ9&)``7)Y))` M`'K3K+4++4H6FL;NWNHER9)=LNTL`55@20%+%<@X4].M`&K17G_@?Q?,^GZZ?%>MV2RV6NW&G0S2[ M+9&$80`*">Y)/))YZUV>I:QIFCPK-JFHVEC$QPKW4ZQ`GT!8B@"[17,^+M4O M%\"ZAK/AW4[16MK:2Z2?RQ.DBHC,57#`9.,9YQZ5RNI>)?$MMH'P[U2+5(1' MK%SIUM?1FU4O*TRAG;=T4$`C`48SD'I@`]0HJ.=97MY5MY$CF*$1NZ;U5L<$ MKD9&>V1GU%<%X'\8R-9ZXOBS7;!;BTUVXTZ"64QVRNL80`*">>M`'H M-%0W-W;65J]U=7$4%O&,O+*X5%'J2>!3;*^L]2M4NK&Z@NK=_NRP2!T;Z$<& M@"Q14-U=6]E;/&O'VB>)[[4 MK2UO;19K2[DMXH_M"EYT15)E5>#MR6&>1\N<\\`'4T5QFK^,;3PIX5UG7;O6 M;;6$ANG6WBA*)L9@"EOE=V6`.2Q&<')&!5#Q=XJOHKGPO?\`AW7;"?2;_6K; M3KA;=$FW[V);$F2!PN,`9&]`$M%>=W?BR\E^)WAFRTO7]/O=#U-KI) M8;5$[UJ[42>4`L4._:9I#]U`<'K M]#@`GM0!OT54L=5T[4[,WFGW]K=VH)!GMYED3(Z_,"1Q4>GZYI&K22QZ;JEE M>O"<2+;7"2%/J%)Q0!?HJ*XN;>S@:>YGC@B7[TDKA5'U)J"UU?3+Z?R+34;2 MXF,2S^7#.KMY;AH`N451LM:TK4GF2PU.SNF@.)1!.KF,_[6#Q^ M-02>)M`BC\R37--2/S?)W-=Q@>9@'9G/WL,IQUY'K0!JT51U#6=+TF!)]2U* MSLH7.$DN9UC5OH6(!JO=>*/#]E;6US=Z[ID$%R"8)9;N-%E`QG:2<-C(SCUH M`UJ*SKC7]&M(+2>YU>PABO`#:R27**LX(!&PD_-D$=,]13M:U>TT'1;S5;Z0 M1VUK$9')/7'0#W)P`/4B@"_17EGB_P`?7US\*O\`A*_"VL6%O/##!)=VZ!+I MXGE*#RRV<*RESGYG_`-3#-.J/)_NJ3D_A5V@`HK&C\7>&IDN'B\0Z2ZVR M[IRM[&1$N0,M\WRC)`Y[FG_\)1X>_LS^TO[=TS[!YGE?:OMQ^*O%]IXDUZPDL-,%D;>YV);P@31N^G'6N_2>&6 MW6XCEC>!D#K(K`J5(R"#TQCG-`$E%9EMK6FZS'V1]:YWX;ZUK&L6?B!-:O$N[C3];N+!)(X1$NR-4`PH]RQY)//6@#M:* MI6.LZ7JDDT>GZE9W;PG$JV\ZR&,^C`$X_&KM`!16>=>T<:H-,.K6(U`]+0W" M>:?^`9S^E+<:YI%G+-%&Z1Y!CKE0:2\C5)@IPVQB<-C(SCIF@#7HK.N-?T:T@M)[G5["&*\`-K)).")?O22N%4?4F@"6BLZ+7]&GNX;2'5["2YGC$L4 M*7*%Y$(R&4`Y((((([&I=1U;3M(@$^IZA:V4).!)H8G%87B7X@Z#X;:UCEO[.6>:_BLI(AH6ME"3@27,RQJ3Z98@4`7**HS:SI=OIZZA-J5G'9.- MRW#SJ(V'J&)Q3H=6TZXU";3X-0M9;V`;I;9)E:2,>K*#D#D=:`+E%%%`!111 M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`> M?^$O^2O?$7_N&?\`I.U5_'=O+=_%+X>P0WL]E(W]I8G@"%TQ`IX#JR\].0>O MKS72Z3X%T#1-8EU:P@O([Z8YFE?4+B3SN"/G#R$/C)QN!QU'-&J^!=`UK6H] M8OH+M]0B_P!5-'J%Q&8N,?($A>*+FWN-7MKB>2V(,.V]FB6-@20P5'`#<_>QGISP*9JW@?0M M<>Q?4H;V=K`(+8G4;A3&5^Z_$@R_^VYH`SFTFX\/>)E\3:MXDN+S38-/E MM2+Q(P\;O+$5V"*-0V[9CIG.T#.>.SKFV\"Z%+#0!Q/P2_Y) M#H7_`&\?^E$E-T65-9^-.LZII[!["PTJ/39Y4Y22X,OF8!Z$JO!]*U[3X<>& M;"Q6QM;>_BLE)(M5U6Z\KDY/R>9MY/M6Y:Z-IUAI!TJQM4L[+8R".U)AV@]2 M"N"#S]X'.>'FN8I;_2/#AM[L19**_P!F(&"0,YVYQUP1D#(K4LOAWX=T MQ)4L$U2T6:0RR"#6+R,.YZL<2\DX'/6I?^$`\-_V)Q%0K\//#@L4 ML##J#V**$6TDU6Z>':.B^69"N/;&*Z2VMH+.VBMK:%(8(E"1QQJ%5%'```Z" M@#A/"7_)7OB+_P!PS_TG:G:F#IGQMTG4KHE;/4-'DTV!S]U;@2^;C/8LO`]< M5MZ3X%T#1-8EU:P@O([Z8YFE?4+B3SN"/G#R$/C)QN!QU'-;5_IUGJMF]I?V MT=Q;OC='(N1D'(/L0>0>U`$>L:C::1HUYJ%\RK:V\+22;NA`'3ZGICOFO&+G M1[_3/A5\,]-O))K6]_X2*T.\*/,AWM*R\,",J&'!!''([5ZO#X.T2&YBN'M[ MBY>)MT0O;R:Y6,CH561V52/8"FZ_X,T+Q/=6USJ]O<3R6Q!@V7LT2QL#D,%1 MP`W/WL9Z<\"@#C([.33/BM:P^+KVZU2*8;]`O;@JD<I5D:MX9TC7=%CTC5+5KNSC*%!+,Y<%/NMYF[?N_VLY.3DG)K.B\%V5MXDTK M4[7SD_L^%XEDEO)II)%8,/+.]B-@+;NYR%'`'(!TTD<A9V1?HS$=*]SJG!I5C;:I=Z ME#;(E[=JB3S#.7"9VC\,F@#BOAWJ"^+;>Q\1RQC_`$+3X[&-B.DQ`:W#PWI2:#)HD5N\&GR%BT< M$\D1.YR[?.K!ADDY`/0XZ<5F'X=>%SX8'ALV$W]CB;SQ:_;9]N[Z[\[<\[<[ M<\XSS0!@^*+*T@^-7@*[AMH8[FY&H>?*B`/+MMP%W'J<#(&>E9Z7<]CXN^,% MY:$BYM["TEB*]0ZVCD8_$5U2P:C)=6HVV\SZO=EX1Z(WFY7\* ML:9X"\/:/JTVJ65M=+>3@B>234+B7S\@C]X'1D'@T`>"Q00V_[)ZWD42)::Q#=#=&3YB/]H1J?H"?6M7_`(5U MX6_X1C_A&_[/F_L?SO/^R_;9]N[Z[\[<\[M?0%8A\(Z$^CWFE2V`FM+WFZ$\KR/,>,%Y&)=B,#!)R,#%7 M]-TNSTBT^S6412,MN8L[.[MP,LS$LQP`,DD\"@#A/%%E:0?&KP%=PVT,=SY+.3N'9A\PR<$9H`Q?@M*\WPCT)I&+,%F4$^@FD` M'Y`"DTB:/4?C'XHM]0C1Y;&RM8[!9!G$+J6F*CW8J"?8"NE\.^%='\*6CVFB MP36]LY!\EKJ65%//W0[$+G)SC&>^<"G:GX7TC6-0@O[NV<7MNI2.Y@GD@D"G MJNZ-E)7V)Q0!XWYKZ+\(?B:NE_N1%XBN8(Q'QLC9X4(&.VTFNWTC2U'B7PSK M0U[2?*>TEM;2WT[3'A^TPE-X4L9GP$V`C@#.1U(KHK'P'X6TT7PM-$M4%^'6 MYRI;S%2<*3C@<<#T%,\._#_PMX4O9;S1-(CM;F5=K2^8\C;MON[F3[4`9%V@ M!1N+#=P1\X>0A\9.-P..HY MJ!_AQX3?3KG3VTD&QN&+O;?:)?*5B0247=B,Y`Y4"@#&6.-/VAW*HBF3PMN? M``W'[5C)]3@`?A7G^J"*/X-_$Z.$(L:^*90BI@`+Y\&,`=L5[-<^#M"NKBTN M)+247%HC1Q31W4L01Q@DC&!C`Q6N;.`V!L40PV_E>2%@8Q%%QC"E2"N!T M((([4`>/Z59VLO@+XM3R01/(=5U8;V4$_+&&7\FY'O46G:C?7GC+P-9M?V4# MMX3AFMGO[5IT:X?`?:HD3#E5ZYZ9&.>/1;3X?>&K#1M1TBVLKB.PU)@UW%]N MG/F'NZ5;Z9=:0T]K;$F!9;N9VB!`&U7+[E7@? M*#M[XYH`\\\;>'K#3?@OXDA:ZLM3N+#428)8[+R19&6:%GBBW,Q`^8]&[X/* MFND^+26NB^&]+^S0VEI!>:Q9V]]*T&Y6@3<1YH!!=!M'!8<9&1FNFO/AWX6O MM"M=#FTPC2[4DQVL5S+$F2GO@G\,U[+X:\&>'O"$V<55?X=^%9;*YLI-+W6=S)YKV[7$IB#[@V53=A"2!G: M!GH>"10!S?B[2].;XR^`I_L5L9KK[>9Y!&-TNR!=FX_Q8[9KFO$FH7FD7'QA M?2R8W1-.*B+C:98]LKC'?!))]J]*C^'OAB+5;'4HM/EBNK`@VICO)E2'U"H' MV@'G<,8;)SG)S+#X&\/0:W>ZNEG,;R^W?:R]Y,Z3@@@J\9HV3W&^`Q[I`F)4P-S_-USQTQSUK_#;PE+:06DVE&:VMY/-@AFNIG2 M(X(PBLY"KS]T8'3C@4[6_AOX0\0O;/J>AP2M;1K#$8V>+:B_=7Y",@=@>E`' MGFOZ%IEOX6^'`?#6K_V>+NPDV:A M54<`,/[V,\#G@5)+X5MW\4Z5K*;T?3K. M0"[XF$#>%-8%U=O:6QL9A+BVBW=O MY@TO6]**^1<@P.#&ZD97Y-S#H,KQQU])O[&WU/3KFPO(_,M;J)X9DW$;D8$, M,CD9!/2LRU$Z+9%_LUO-$IC:*-5NY0L"L,'R5W8A..\>TT`>9Z59VLO@+XM M3R01/(=5U8;V4$_+&&7\FY'O6CH5Q#-J/A.2T@>^\3R^%821T:U:"QN$DM5,<$@O[C>D9_Y9AM^?+_V,[>3QR:`.$\.B6'X5_$ZV ME,7^CW^K1*L2[(UQ$.%4DX7).!D]:DUD_P#%O?A(/^HKH_\`Z*-=O)\.?"LE MK>6HTV2.WO96FN(H;N:)'9L;N%<``X&5'!VKD<#$$GPO$S6]I;RV=\\%F0U MM&VJW16`CH4'FX4CVH`["O+_``%8Z9VD\1:@ERSJ#F(!3@^PR M3[5Z9!"MM;Q0(9"D:!%,DC.Q`&.68DL?G>$-*;2-?\1QRZO:W=Q!K,W5K;6L]W<.TEY"981*L8$6Y0Z9^9SC MYA@X/;%4]7\.6MKX:^(4>H7VGZE.]HVHFUAT\PQV<_D2*)%W._SMLSPF-NLX_MTX\H]CN#Y)'1YS0!XWJ4$-M\&/B;;V\2101>*)4CCC4!443VX``'0`5Z)\4SSX M*'_4U6/_`+/6K:?#;PI8V=_9PZ=*;74`1=027L\B2DD'<59R-^5'S?>'K1>_ M#?PMJ(MA=6-S)]F8/$?[0N`0X_Y:$B3E^@WG+8`&<`8`.;\2W=W+\;M(TY+V MQM@-&>2T-]:M/&9FE(8*HD3#[$ZYZ9&.:R=9@3P[X,AT=M5AOM-F\516^HF& MV:"&W@D82R0@%FR@)QD,?O%3R#7H>N^!?#?B:SM+;6M-%ZEHH2%Y9I/-48`Y MD#;SG`SDG)Y-6H?"NA0>'/\`A'H]+MQI)4H;4KE2"2<\YZYYH`X_Q/96 MEM\9OA[-!!%%(\=_&Q10,JL`VCZ#<<58^-O_`"2'7?\`MW_]*(ZUY/AUX4GD MM'N=*^UM:`K`;NXEGV*!Z5%I?A71]'N$GM+>8RQH8XGN+J6JIYC-L!P.%QT%`%# MXC6-G>_#S7_MEK!/Y&GW$T7FQAO+D6)]KKGHPSP1SS7$:[''I/[.4.HZ?;QQ M7S:':0FX1/WGER&/S!NZX.YCCI7INNZ#IWB33&T[5(Y9;1SEXX[B2+?UX8HP M)'/0\=..!45CX8TC3]!?0X;5GTQU*&VN)Y)U"8`VCS&8A<#H.!0!Q^GZ+!<: M]X=U.;6M&EM+BRFLH+.QTIHUO+=H]VQR9G&U=N>1CJ.K"J/PZT;1GT?Q]9W% MK;)9_P!OWUO(NP!4@4+@8[`4WF/'YL\FT'M/UJ\\5)K>B:S;O?:QA(S7I=_P"$M#U&_M;Z M>RVW=K%Y,,UO*\#+'_.YM*N+F'9+I$)>^B8?%)'4A0 MH)[D$]ZV+BWAN[:6VN(UE@F0QR1L,AE(P0?8B@#R3QD?^,7K;_L%:;_Z%#6Y MXB@AL/BW\/8[2*.%7BU"%PB@918595/L#S^=:]S\,O"5WI<>FSZ;,]FF,1?; MK@`@?=!P^6"_P@Y"Y.,9-6]1\#:#JUY87E[#>276GQ"&UF74;A'C7U#+("6/ M=C\Q[DT`>;:9:3^+;GXBV%SJVE6I;4IX;C[78---';H`L3J_G(`J[21\IP1G MG.*]N#R,UB:M\-?!^NZQ_:VI:'! M/>D@M)O=0Y'3G&XT`<'X9L[6Z^+_P`16N((I<)IZ?.H/RM;G*#42>GV47,FX'_9^55^AKU?3?`N@:1Y+.3N'.&'S#)P1DT[2_`WAW1]&NM'L[!O[-N1MEM)[B6:+')X5V(7DY M.W&3CT%`'/\`CJQ%GXK\%:II<21ZFVJI9OY:@-):LC&0''5552%&Z?[+&O6;+P?HNGAOL\-SO,+0)))>SR/"C#!6 M)F)?#.M#7M)\I[26UM+?3M,>'[3"4WA2QF?`38".`,Y'4BNQ\1W%U:>% M]6N;%2UY#9320`=3($)7]<5F^'?A_P"%O"E[+>:)I$=KQT?5/V'M+@F^+]B MU_IMJEW<^#TN;Z,0JH>Y>8"5F7'+')!SUKOHO`_AV"Y::+3V56E\\VXN)?LY MDSG=Y.[R\YYSMZ\TB^!M`3Q(WB%8+L:JS9:X_M"XR1G=MQOQLR!\F-N.,8XH M`O:U%I]MX4U&&Y9K/38K&19&MQM,,(0@E,#C"],#M7D^K><-'^&MW96,-CI* M:S80V'F'?=O"ZM\SE<*NY1DJ,Y)!)'(KV>XMX;NVEMKB))8)D,3$V[J21Y;;\H,G.%('M0!S<6E:=!^T0[ M0V5O&S>'#=/LC`W3&YP9#CJQ'?K65X>\,P>*O!WCG1@J(\'B6^_L]U`'V=U* M,FWT&[]":]`LO`^@:?XA&O6MK.FI!#&)3>SL-A_@V%RNP=EQ@8&`,"LUM(T7 MX=03:GH^AZW>2W.YM*N+F'9 M+I$)>^B8?>(!=VT,_D:?<3Q>:@;RY%B;: MZYZ,.Q%6_"FEOIVFSW%Q:QVU[J-S)>W,28.QW/"DCJ0H4$]R">]5_B#.T?@/ M6H(K6\NI[RSFM88K2V>=V=XV`R$!P/4G`_$B@#SWQ)86Z?L_^'+FRBC74X(M M.FL&11O^T,8P<'U.6_+VKJ-'N4N_C1XHM=016EM["U73PXS^X()F*_5V4'Z" MCX>^&M'?PSH5W-I5]!J&GV\<;0WZSQK#.(P'=(I#L!)).]5Y)/.&=) MUNZ@N[VWD^UVX*Q7-O/)!*@/4!XV5L>V<4`>(>,]'M;/PQ\2K:*SMSI^G7]H M^FOY8/V>68Q-.D9_A'*@@8KO?B3IUE8MX->UM(87?Q3IRNZ(`SA0X4,>IP.F M:Z34O`/AK5])ATN]T]WL8G:00)=31J[L7;;@+N/4X&0,]*L:/K>&=)UNZ@N[VW MD^UVX*Q7-O/)!*@/4!XV5L>V<4`>(>--'M;/PO\`$JUBL[6$CV,3M)Y"74T:N[$$L^UQYC9&=S9/7U-+J/@;0-5N]/N[R"\> MYT^(0VLRZC<(\2^H99`2Q[L?F/&2<4`='1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%N>-+'1)[N$65_?R64*SWBV,2O]FC;.UG MRPZ[6.%R<`G&*Q]3U36_!_B;0Q?:M)JFCZO="P83V\:26\[`F,JT:J"I((PP M)&.IK(\(:7>CXM^.%/B#4F-LVG-(QCM\W0,).V3]U@`#CY-AP>I/-`'IEE=P MZA8V][;-O@N(EEC8@C*L,@X/3@UFZUXHTW1-"EUF0S75G$S*[641GVE20^=O M`"E6!)(`(P>:U9XVFMY(EE>%G4J)(\;D)'49!&1[@BO&_!D%R?V41[(SNFRP(0.23DG&&!GYL'T MK2UOQ;>W7C#5M"LK^^T]-+MXB9++2I+UI9I5+*'VQN%0*!Q@$Y.#QP`>BUSN MI^.=!T?6X]&O9KQ=0E&8H(].N)3*,9.PI&0^!UVDXP<]#5GPGJ=]K/A73K_4 M[&6QOY8O](MY8FC9'!*M\K<@$C(SV(KC_'M]'IOQ1^'MW+%9^ M84&0B`L<9R<`\`F@#LM(\3:1KEQ-;6%V6N8`#+;S1/#*@]3&X#`>^*UZ\XG@ MU#Q3\2M*UG2K"ZTZUTJSN8WOK^T>+[0\B[401/M=E5OFYQWY'!IG@^\\8>(X M-;$WB2&*?2M=GLE<:>C),D:J"K+D$`DY&&SR1DC&`#OM/U#^T/M7^B7=M]GN M'@_TF+9YFW'SI_>0YX/>KE>5:?XC\67'@/QI>MK%L=1T+4[R))VLEVO%!&IV MJH(VDG)R=V,XYXQ,?$GB'3]&\`:W?'D2`@;@P(R< M':<\`"@#T^J>H:A_9_V7_1+NY^T7"0?Z-%O\O=GYW_NH,)M#F\(2IJ%I$E] MJEGI]_;PV^[>SDF0J['A<*0!M!YSGT`._HKSUM1\32?%RX\-MK<<>FR:2U_' MY%FBO$#,$`!;=E@`>3P=Q^7IBC:>(O&$EQKGAQ;FWFO])U*VCGU21(X_+L95 M+F8J2$+J%Z`8YZ<4`>F3S+;V\DS*[+&I M7-A#=1):7;VOT5QFK^)+O4_A=+XH\.WL-JXL7O@98/.X1&9H\9`#;AC M/.,'@USUYXC\4V/AWP'K*ZO'-+K4]G:7-O+:H(F,\>1)\H#`@@D@,`<\`4`> MJ45Q6EZMJMG\4+OPQ>ZB^H6LFDIJ4+RPQHT)$OELF4`R#UYR1Z^M+3=2\2>, M?"TWB71=9^Q%Y9CI]F+:.2*6.-V0"4L"^YBAY5EQGH<4`>A45Y1I'C35]9\4 M>`[ZWU.1=*\10W9N=.:&+9%)!%@A'V[\;P3R>WH<#3\.WOB:Y\4>-_#S^(?M M$FF_8_L-U=6<1\OS49VW+&$#'H/PSCJ"`>B5$MS`]S);)-&T\2J\D0<%D5L[ M21U`.UL>N#Z5X]!XS\4K\&+/QW/JX:X@GW2VRVL82XC-R8BK<9!P>"I7@P)B`B*RJT3,$;*$A5R0-I4\\DGF@#TRHKFY@L[ M:2YNIHX((E+R2RN%5%'4DG@"I:\]^-PD'PFUB2*XEB*&'<(R!YBF5%*MQT^; M/&.@[9!`/0J*X[6-3U#1K[0/#=OJDUSJ&L7$H^VW<<1:**--[D*B*I;&`,CO MDYJ"VU?6/#_Q`L?#FJZBVIV.KP2R6-S+"D<[0>U`';DA5 M+,0`!DD]JQ]:\3Z?H?A\ZY+Y]U8;!()+*(SY0KNWY7C;@9W$XZ<\BJWCT2?\ M*]\1-#<2P2)IL\BR1$!AMC)QD@]<8/?!X(/-+'CK0!WVDZE#K.C6.J6ZR+!>V\=Q&L@`8*ZA@#@D9P? M4UTL[*UT>6ZCNI(@"XED6-@NYB5`#(1P3P:`/5JYS5?'?A_ M1=:CT>_N+M-0E_U4*:?<2&7C/R%$(?WVDXY!Y%;6GW37VFVMV\$ENT\*2F&5 M2KQE@#M8'D$9P0:XCQ;_`,E>^'7_`'$__2=:`/0***\IU'QMK.H7/B231[F_ MBETBZ>TL[*UT>6ZCNI(@"XED6-@NYB5`#(1P3P:`/5J*\XU37_$P\=>#K6WO M8[33M=AFD>SELL2P>7`'(V&K>-].UF]>^@\/"*Y M2Z>)$D,,D)DVL$`4E=IYP,T`;?B_QCI_@O2O[1U*WOI8,X)M;@^9N%7) M(`W$9[5T->)_$*37]5^"-SK]YJJF'4(K:X?3U@01Q1/+&T85L;RXRN220><` M<5T^M^+;VZ\8:MH5E?WVGII=O$3)9:5)>M+-*I90^V-PJ!0.,`G)P>.`#T6B MO*M7\5^+UT/P5JB.FERZIJ-MI][87-@5<2,[!R2YRJ'9P`H.&R&Z5Z-I5I?V M<,R7^IMJ#M,SQ2-`L92,XPAV\''/.!F@"_17->*KG6(;C34L[R+3=)9I&U/4 MF:(/;(J_(%$F5RS<9(./2N)@\8^(+C2O'$%AK<<\GA^-+NWO[FP`>>%H7DV% M1L4'*.P)K$\'G4I]$6_P!2U*XO M#>,9X%GBC0Q0DDQC"(O)7:3GN<5ROCFVN;GXK>`H8-4O+,3"_P`&`1GRV6'. MX!T8$D,5.0>.F#DT`=]R:FB MS02)YMG';)Y=P@G\EMY(+!CURI4#ICO74^*O%4]OXQL_#5M=7ED&L7OKBYLK M![R;;OV(JH$<*"G2NDH`**X"[O==T_XJVFE7.O7)T?5[*X>SC$$`,4ZZ3XNLI==N)=4@N88M)GDMH$9DF.('VA,$-D$ MD@_+SQ0!ZGHKB+W4?$>B_$;PAHTVMK>:=J270F5K1$D9H MH-V68<!\M`'7^%_%=AXML[RYL(;J)+2[>SE6ZB\MO,55+?+G(^\!S@Y!XK=KQG1) M-7L_#'Q*U+2]4^PO8:]J5T@6!)#(R*K%6W@C:0`.,'OGM756WBN^\1ZGH&D6 M-Q_9\M_HJZQ=SQQJSQQMM55C#AE!+,>6#<+[T`=Y17E.KZ_XFTQO$WA^;79% MU#3-,;6K#4([2+=<0*RH5*<-@94`GKZ@R:GX@\16^A_#K6H=;E7^U[G3K M2_MOL\)2;SEW.^=FY2<$8!`Z8`[@'IJW,#W,ELDT;3Q*KR1!P616SM)'4`[6 MQZX/I4M>9^%[2[E^,?CIO[8OECMWL"8@(BLJM$S!&RA(5V1GU%`$E%>2:?KOB^]\&>-=0F\0*EWH%_>1 M0R0V<8$@@12596!^4\]/F!;[Q``K?MO%=]XCU+P_I%C.-/EO]%76+N>-%=XT M;:JI&'!4'U4+[5X;713JMO#/J,!1'C6P3SGE5 MB,%`#\PP^(_"OP)TS7-(\0/NBTZSY`/!8C`&>,G)!QBLW6=7 MU[P+X6\1:OJM]!JMO:A&TYY$"3$L0NV8(JK@.RX*@9&>E`'6TAN)[G1);1+2=0",,T2#8PW``[CD#GFO0*`"BO/=-U+Q)XQ\+ M3>)=%UG[$7EF.GV8MHY(I8XW9`)2P+[F*'E67&>AQ6-8^-_$.OZ[X'GLM1M[ M?3?$45SYMLMJ-T+P18?YV)W?/N*\#[HSD9R`>MT53TJVO;33(8-0O_M]T@(> MZ,*Q&3DX)5>`<8''I7$MJ/B:3XN7'AMM;CCTV326OX_(LT5X@9@@`+;LL`#R M>#N/R],`'H5%>6CQ_JOAS1_&\.LO'?WWAMX?)G,8C\]9P/*WA>,Y/.,<>E7M M(UOQ"?$=KIZW6IW]M>VDOF75YH4MM'97*@%3S''F-OF&TDG(`WB45Y)I M^N^+[WP9XUU";Q`J7>@7]Y%#)#9Q@2"!%)5E8'Y3ST^8%OO$`"MR77M8U.VT M;4IM2CT'0;K28[N6]C,+2MF:`-_Q?XQT_P`%Z5_:.I6] M]+!G!-K;F3;T`W-PJY)`&2,FMN2Y@AEABEFCCDG8I$C.`9&`+$*.YP">.P)K MQ+Q+XDO?$?P&\7&_E\^?3]3%A]H\GRC,J7$)5V3C:2&&1@=.E=1XYMKFY^*W M@*+RS$PO\&`1GRV6'.X!T8$D,5.0>.F#DT`>E45Y\+S7M$^*5EIVJ^(+J MYT74H9&L5>"!!YZ]8G98P?NGZKJ,VJ3W&GO=/%96[QQ MA41#M9@RH&.7#@9)^4`\YS0!T5%%%`!5.PU6QU-[M+*Y29K.^'7_`'$__2=:/"7_`"5[XB_]PS_TG:@#T"BJ>KW-S9Z+ M?W5E;_:;N&WDDA@_YZ.%)5?Q(`_&O/\`0-?OO$]_8_V!XP>_LG:0:G%+;017 M5G^Y<*RJ5'RB7;P5;D#DKNR`>F45Y/I^M^)[KX?^-;F3Q'.-1T#4[V."[6T@ MS)'!&"$9-FW!.3D#.>^.*V8O%>HSZ-X%TY+A5U;Q':K+)>-&#Y82`2RL%QMW M'.`,8!.<$#%`'5>(=?M/#.CRZI>Q74EO%RXMH&E91@DD@=%`!R3@#UJSI.I0 MZSHUCJENLBP7MO'<1K(`&"NH8`X)&<'U-\74?,L]0:QTV:Q$";-DL/RN& MQO##`S\V#Z4`>KT45YOH5YXLU?QEXNT"[\1I$FF"U\F>TL8U*F6-GX5]XQT! MSD_*,$9-`'I%%>::/XG\5ZUX1E2(VJ:K8:T^EZG>D*B0PQG,DZJQVDA2O'(S MGBH],\0:KJGB_5/"NG>*9KJ*32A?6>JM:0[XG$H0J,((Y$.1R%]0#D4`>GT5 MYGH/B+6KKX=ZBEYJUP?%,%XVGN3%"#%.);*[\50_ M$]O"MYXD%S:'13?"9;&..0'SA&/4;@`><;>3\O3`!Z/17D]EK_BN]\$^+KU] M>$=WX8MXB\4_\(GXJDAN;F*71PUS::CJ M&D/";N`1%]NQ@@#AE*E@N.GR\@TA\2>(=/T;P!K=SJOVA=:N+.SO+3[/&J-Y M\>1("!N#`C)P=ISP`*`/2EN8'N9+9)HVGB57DB#@LBMG:2.H!VMCUP?2I:\S M\+VEW+\8_'3?VQ?+';O8$Q`1%95:)F"-E"0JY(&TJ>>23S5?2/%FJZ_=6D>F M>(=NKK>0KJNA7=M%&]O&)1YPA)`+!5R"27)&2,-B@#U2BBB@`HHHH`****`" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*YSQMX5'B[0!91 MW1M+RWG2[L[@#/E3)G:2/3DC\:Z.B@#DGT/6M?U#2)O$4>G00:7<"[2&RF>7 MSYPI5&)9%V*NXG;\V3CGCFCX8T#Q1IOCO7]3&57`: M)0^DE<*H^I-+!/#=6\5Q;RQS02H'CDC8,KJ M1D$$<$$220,#UH`\^U3P;XGNO"/ M@K3+9=(%WH%S;7$YDNI/+D-NNU`I$6?F&2<@;>@W=:=?^$O&5GXTN?%'AF]T M>&?4[:)-1LK]I7B#HH4%&506QC@D+WXYQ7?KJ-D]^U@EY;M>*AD-N)5,@4$` MMMSG&2.?<5)<7-O9P-/*-1\>Z#KNGV^CM9Z+Y_EI<7DJ23^=&$;.(F" M8QQ][/7O@=M!/#=6\5Q;RQS02H'CDC8,KJ1D$$<$$#_&]IX:\5Z08?#[MX@NKJY:87TP$!G4*PV^3\V`.. M15K5/!OBBZ\(^"M,MAI`N]`N;:XG,EU((Y#;KM0*1%GYAR<@;3P-W6O2Z*`/ M-X/"?C31-9U*Y\.WVB06FLS?:[R&\665K6=A^\,14*'&&/$V MLQ^&[;3)-.GCT>\M[^2XO[ATDN)8LC!5(V`!SDG/4]!CGOJK+J-D]^U@EY;M M>*AD-N)5,@4$`MMSG&2.?<4`>;W;ZS_PO:WDL[>Q-Z/"H,]O-.XC/^DG*K($ M)X;&"4Y`Z#/$NI_#G5]0T^ZO&O+%];O=5M]0O(G#_99HX052V)QN*`8Y(Y(Z M5T4!")?,'S[/F!QC=@8SG:<8+_A_P"'O$?AV?6UUE-+:'4M M0FU(26=S(S))(5RFUHU&W`/.<^W/':R21PQM)*ZI&HRS,<`#W-16EY:W]LMS M97,-S`Q(66%PZD@D'!''!!!]Q0!7UDZL-+F&AQV;Z@1B(WDC)&I_O':K$X]. M,^HJKX8L;_2_#5I97T-LMW!'M8P7#2+*W=RQ12"S9)&.,]ZUIIHK>%YII$BB M0%G=V"JH'T?5I#'INK6%ZX4OMMKE)#M!P3A2>,\4`>"-,@72?M&@ M75M&O%^D^+O$FOVT^BSG5UM\6\IE3#1Q[!\X!V@$M_"VX*/NYX]`HH`\F/PZ\3 M?\*1'@;?I/VWSL>?]ID\ORO.\[/^KSNW?+MQC'.>U=!H/AWQ-I_C/5]=N/[) MC361;&ZCCFDE,)A4IA,HN[C8R>YHH`P=#U'5[S6=:MM0BLC:6TRB MTGM"YW*2V4?=_&H"D[>/FQU!J'Q]X:F\7^"-2T*WGC@FNE39)(#M#*ZN,XYP M=N/QKI*K7VHV6F6YN+^\M[2$=9)Y5C4?B3B@#D]>\+:UKT>D:LUQ86OB#2;H MW%JL>]H"C`!XG8C<0P'W@H^G>KUKH6HZCXGLM?UU+.&73X)(K.VM)6E56DP' MD+LB$DA0`-O'/)SQT]%`&?KVF'6O#NIZ4)/*-[:2VPD(SMWH5SCVS7(MX>\6 M#X8OX84:*;DZ>NF*QGE"+&(C&TA;82S'C"[0!S\QZ5WU%`'FNJ>#?$]UX1\% M:9;+I`N]`N;:XG,EU)YK7.@:GHL- MEK4YN[F&[\V5K69^9#$0!OYS@MMR`,@5ZA4,EW;0W,-M+<1)//N\F)G`:3:, MMM'4X')QTH`2QMC9:?;6IFEG,,2QF65BSO@`;F)Y).,DUQGB70/%&H^/M!UW M3[?1VL]%$_EQW%Y+').9HPC9Q$P3&./O9Q[X'=44`2S/-*1M7>3&@V@%CCGG![#',IX,\:Z#XDUN?POJ^D+I>LW+74J7 M\F5#:W=M?6R7-I<17$#YVRQ.'5L'!P1P>010!P M]_X6\13>./"FHPO82Z;H"/%YES=R&YN!)$L;NP\LC<,9`W'<1R1GAMGX0UMO M&/B^ZU&+37T;Q'&EO((KJ3SXHTB:-3M,>TE@>1NXSU..?0**`/+=2\">+;_X M:R^"&O-)>WC$44%\[R"1X4D5E5H]N%("@9#-G&,#.1)-X.\=:=XMN/$NAZKH M3WFI01QZC;W44J0%D&U60*6;A0.I'.?7`]%DU&RBO8K*2\MTNYL^5`TJB1\` MD[5SD\`GCL#5F@#SGQ%X1\6:C:>&K6WNM.O#I6H1:I37.:CX+\827WC*>T?0Y/^$F MMX;=S+-+'Y"K`\1P`C9/S#!R,X/`S@>H44`>::IX-\477A'P5IEL-(%WH%S; M7$YDNI!'(;==J!2(L_,.3D#:>!NZU<\>>'QXAN/"Z22K9ZNUR8G%NY?_`$=X MF^TH&(!*[1@,0.2.`3BN_K&TSPGH6CZS?ZO8:='%J%^Q>YN-S,SDG)QDG:"> M<#`H`V%544*H"J!@`#``KD_%/AS4]2\3^&]>TI[0SZ.UP&ANG9%=9HPA(*J3 MD8SC'/J*ZVB@#@?$'A_Q;J'CCP]KEK'HDD&BI,`LMU+$UPTL81S@1OL`(X&6 M]SVI_AW0/%.F^*_%>NWL.C[]8BA,$4-Y(PCDA0HBL3$/E(/+`9&/NG/'=T4` M>3'X=>)O^%(CP,'TD7OG8,_VF3RS%YWG9_U>=V[Y=N,8YSVK5\0^$_%EYXDT MKQ;H=UI5GK<%H;.ZM;AY)+:2/<6P&"ACR2?NCMSQ7HE%`'%74GBSP]X6:[-Q MIVHZY/=^;+!(9%B8%<>3;CD@_*N,\9+,>]=K3)98[>%YII$CBC4L[NP"JHY) M)/0412QW$*30R))%(H9'1@593R"".HH`YCQOX1?Q7;Z6(+G[+/9WBRF8$AO* M(*RJI'/<"HW\$1?\`"Q;3Q)$\<=I#8B!K9>-TJDB-L8Q@([#V(6NNHH`X M3Q+H'BG4?'V@Z[IT&CM9Z*)_+CN+R5))_.C"MG;$P3&./O=,]\"?PWX*;7P;XST MJY_L6AN%"N&S%D;0,C`.+4-4TQM+ MC2V8R):P$-P&8*7)9RQ.T=`,=SA7G@GQ;?>&/"VE&XT:"7P_>6TT;AY9%F$" M,JL1M4@_=RO.^#CT-244`>::7X,\4VO M@[QII=S_`&.;W7KJXN86CN9/+0W"[7#9BR-H&1@'.<';UHT[P1XCT\^'-6B; M2X]:T:R&F21"XD:"]M0H`W/Y89 .-K#I]*]+HH`XR?P==ZP=?O]6DMH=2U M32VTN);=FDCM82&_B(4N2SEB<#H!CN<'6_!GC+5?A?!X.4Z$NVWM[9IC<3#: ML)0AA^[.XL4'&!MQU;/'J-%`'$>)O"^N^(+;0]7MY=/L/$VD2O+"N]YK9MPV MLA;:K88!3TXY'/6F7_A'Q!XI\':SI?B?5+(7>H1QK&EA$XM[8QMN4C<=S$L! MG..``*[JB@#B?"^C^.8;JR'BC5]-DM+!"(UT_P`T/G44`%>9:FVII M\?HWTJ.TEF7PQEXKJ1HU=?M)X#JK%3G:<[3T([Y'IM?VKNS]H_M"XSC.[9CS,;,_P8VXXQCB@#!NOAS-K'AGQ-;ZK>1#5O$+I)/- M`I,<'!(%=U10!YII?@SQ3:^#O&FEW/\`8YO=>NKBYA:.YD\M#<+M<-F+ M(V@9&`HY MKJ]9\/>(=5UCPKX@1=+BU/2&N1-;&XD:%Q,FS*OY88D``X*CKC/&3VU%`'%? M$72FU/PG:1FZ2+6HKRV:PN(DQBZW@`JI)..6)&3@9)Z5TL%@^E>'DT_2A'YM MM;>5;>>3M+*N%+XYQG&<<]:K+X3T)?%$GB4:=&=8=`ANF9F(`&W@$X4XXR`# MBMF@"&T^T_8H/MOE?:O+7SO)SLWX^;;GG&'M2\3^%SIVE+:+>>?'-%<7, M[1_9W0[@Z[4;)XQCC@GFNLHH`\WO]`\=ZEXI\,Z[/;>'?,T5)PT:W\P$[2IL M8Y\CY.`"!S5WPQH'BG3?'FOZYJ4&CBUUHP^8EM>2N\'DQE5QNB4/G(SROK[5 MW=%`&?KMK>7WA[4[/3KC[/?3VDL5O-O*>7(R$*VXZNHKB61Q)$\R;2C($QMR!\P;(&>#4<_@'Q"WASPR8-3TU=?\-X6RD\E MQ`\?EJA23DMR%&6`'ICO7I5%`'"7^B^.-2\(:Q:7MWHT^IZI`;7RHVEBM;6( MHRLRDJSNYW=\#IZ8-#5/!OB>Z\(^"M,MET@7>@7-M<3F2ZD\N0VZ[4"D19^8 M9)R!MZ#=UKTJB@".`S-;Q-<1QQSE`9$C1W\W^ MNF?4+B3SN"/G#R$/C/&X''4Q^Z*T8?#GB$_$F'Q3,VEI"VE_V?+`DDC-$/.\S*DJ`_&1D[<9 MZ''/;5#=VL%_93V=RGF6\\;12IDC'+:7XOWFJ6LY$,5K%- M>6Z_=-UB1(V/N(R_'NI[BIK?P_XA/Q9D\47,>F+IO]G-IJ)'TGPQIBZ=HUE':6H8ML0DDL>I))))Z M$FL[W3K+Q#X:416[B1Y()DV*AW'8",A!D8/<9YKU"B@#@KS0?&VH^$]:MKZ[ MTB?5M6A-H8DEFBM+6$HZED!5F9SN.<@9XY^4`T=4\&^*+KPCX*TRV&D"[T"Y MMKBCMKG2=)-VADD6=#(\<^UXCM'W?+X;`.21@8Y=X<\ M67&B>%O`EO=Z5MT[4K:TL([LW`WK,81LS'C[K;3@[L^U9C6][H_P_P#%.G6S M>(=6TRZM&M=*CNK"9KI97CD5DVE`XC'R89@HZ@=LU]:%X/`'PSB31]7EFT^_ ML)[N&/3IFDA6W3;)N7;D2"[EEN_ M)E9HP&D,:;"&"@]2RY[5C_$,Z=JL?P^\06UO&9;G7].\JX,8\SR7W.%SUQT. M,XS6?J?]I^)M-\81:QH^M7%TR3KHEL+21+<0&(^5)@@+YN3DA_G!P``O&<8()`.BMK&TLOVAIS M:VT,!G\,F:;RD"^9(;H99L=6.!D^U;_Q%L;2^^'GB`7=M#/Y&GW$\7FH&\N1 M8FVNN>C#L17,6^J-<_&^/5DTG6UTV31!IRW4FDW")YQG#\[D!5<'[Q``[G'- M=QXKL;C4_!VMZ?:)ON;K3YX8E)`W.T;*!D].2*`.-T+Q9=>'/`OA&XU#2`NB MRV5G;/>K<@O"6C55=X]N-A..0Q(SR!TK7U3QU-:?VS<:?H[7^G:(VS4+C[0( MV#!0SB--IWE%()R5]LUS$UE?>*?AEH_@=-+U&TN?)M+;4);NT>*.W2'8797( MVN24PH4GKSBLB'3F\/>+/$UMK/PYE\0C4-1EO=/OHM.CN%Q(I9<]JZW2H)+;1[*":&W@EBMXT>*V39$A"@%47LHZ`>F*\ MNUN'5==M?&EGKFDZO=7J_:8M&MXH'^R^3Y9$4@(^1I,\G<2PX"CM0!T^N_$' M^R8?#MU;:)=7MCKV:XL$M;Q)%N@N-R9<)M8#)(Y&`<$\`\9XBGGM?AS\-!+I]ZEQ9:QI<;6TD) MCE=TB(*A6PW7@6+QC%X9=M+!<=21CGK7-^"=1N;SX"1>';'2=0N- M0OH+JT@86S>01))(#(9<;%5=QR"0V5Z'BM;0HY-&^*^G1?V;K#V%EX^<[T9K32=;D\NPNVN`SEBI:/S(]OR;U!(PS M>^*Y.R2ZUKQ5\1X(]+U>U3Q#916^GW%UIL\4;,EL\9+,R@)R1C=C/UXJMX%M MRD.BZ1/\,5L];LI(EN=5NM+C6$)&1F59>"TI`X(S\QSDB@#NM4UO^V+C5-)M M?#T6M6%B52_,\JJC/@/Y<:E2)'4;3@E0"1SFLWX)?\DAT+_MX_\`2B2H_#37 M_A#Q#XFT^^TO4+B#4M2DU*QN;6W:5)/,`S&S#B,C:!\^![XJ3X-0ZA8?#NPT MK4M)OK">TWY-U&$$F^1W&T9WJQ?$Q:VMM:265SKUE& M_FW+*9GW,PB=?+($9*J2V2>/NFI/#-];P_$_4=-N?"%OI&M75@U[<7D-V)EG MC641J5PHP&^\<9P_.Y`57!^\0`.YQS0 M!JV/CW5]3U?7-*M/"4XO]),!>":^C4NLN3]X;E#;<$#)!YY&.9?^$ZO&M=,U M*+0TGT?4[JW@MKJ&]#,@ED5`TJ;1LX;.`6YPIV]1E>#+V67XH^,;R32]7MK7 M53:"SFN=-GB23R8F5R690%]MV,Y'?BLCPSHT\>HZ5J^EZ=K.@:U=R12ZKIGV M>06$J,097RV50["@(!W;EY).T&LSX?:SJ'A_X`:5JFG:2-4>V%Q)+;_:/*;RQ-*69 M3M;)&!Q@<9Y['1\(W5UX5G\7Q:AHVKOYVNW5_&]O9/*KPR;=A4J/F)(QAU^'%CI%]I]_9WED9!-%>661EVEU`;@\XSCOC(H`USXLOI M/!FEZW::99W-UJ#Q+':)?,$(D.!B3RLD@8)!48PW/'-[Q9J&H:7X(U?4;-(1 M?6UC).H9SL5E0DD'&3C!QP,X'3.1R/@O0+[3/%NH:+(0VAZ)&TM=/U&U@TW4H]2N9KVSDMRGEJVV,!P-Y9 MF&=N0`#STR`='XPO[S2O!FM:AIXC-U:V4LT?F,0!M4DG@'D`$@=R`,CK7EOC M1+K5?V=H]2UNRM)+R&QL7M;SSS/,P=H0SLS(I1F'4`MGU->J^+;*?4?!FNV- MK'YESA?$9<0>,-.T+4-*^RQZI#+)93_`&@,S-&`SHZ8^4[3 MGAF_PSY/B$5MAJZ:46\-_;19MJ)N`'SYGE>8(]O^KW\9W`]]M9GBV]D/Q'\" MZK%I>KS6-G%=S7$L.FSR>4LT01`P"9#9!RN-P[@5QOA31YM$TQ_"VI?#--0U MJ*=X[;5I],CEM9%9B0\LIYP,]`22`!P:`/>)Y'BMY9(X7F=$++$A`9R!PH)( M&3TY(%<+IGQ!U?6-(UF^LO"C;])O);:XMYKY58F,*6"$*07&3\O`X'S_$^.+3 M?#>IV6AW=YI^N3PVZ3B:-?+DD8@IMR6+C:W8*<8W>CV\57:^/-#T;6O",=M< MWZGCTFX94 M$\*A!C9DGU`&1T/((`!O'QM?-X[N/"D?AV5;A+-KR&>:Z14D0.$#':&*J3GG MEA@?+SPEA\0K6X\-7.I7=C)!>VVH-I4EA'()&:[#!1&CIQ^(]>2\O;.Z\)W!N(K<7%NUI MTWQM=ZA#3N)8-#J<%[,TPC"O*GV52FXCK@- MQZ5Z/J-]#IFF7>H7&[R+6%YI-@R=JJ6.!W.!7CEK>W46M_#-Y-`\0+#H.GR0 MW\G]DW!",]JB#&$RV&!!P.U>OZQ+>PZ)?RZ9$LU^EM(UM&W1Y0IV`]."<"@# ME(?'U['_`,(_=:EH2VNF:[-'#:3I>>9(CR*6C$D90!=P'9FQ5C_A-+Y_'=QX M53P]*LZ637D4\UTBI(@D"!B%W%5)SZL,#Y>>.!U"RO-1TKP=JD^CZ_=:W;:S M9W&K7%S9REH0I8R*B8_U8."/+7;@#)S72V-U/??'3^T!I.K06?\`8)L/M$]A M*D?G";S"N\KMQC/S9VDC@G(R`6(/B/?W7AG5]6@\-'S-%EFBU&&2]"A&BY<1 MML.\A?FY"CWS6Y-XOBG?2;;1[7[;>ZI:?;8(Y)/*1(,*=\C`,5&64#`8DFN! MT<7H^'WQ+C;1]72?4-0OYK6!]/F629+A`D952N6YSG'W1R<"GZ%;ZGH^H>$/ M$PTO4I+2'08]$U*W^Q2B>W9`&WB(KN9=P`RH/`H`[+3_`!A?Z@^K:6-$2'Q' MIJHYL)KP".9&/#I,$.1C/51@X!QG(P[CXI7J?"^S\
'8I;60N+FW;4-K0X MF\I2I\L[\GKTQD=>2-?1M.EU3XBWOBW[-<6MH-,33;=;B)HI)_WAD>0HP#*! M\JC<`3@\8QGSF33-93]GVX\&KH.J/K%O+LDC6T?81]K#AD>6&!\O/'-^+O'NHWG MPAU_5=-@_L[4K&[;3KQ1<$M;N)%1C&Z@;C\RX/RXR3V`,VD:C=:M\;%U5M!U MNQM&T)K#S+RP=%$RSF0@N`5P5!P=<>1%$K$A%+A6.YMI(&W&!R16KINH#4[ M3[2MI=VR%L(MU$8G8<<[3\RCMA@#QTZ9XKRK[PI\3]9UB>RO+K1M'=(FTJS>WUOB*[CU`G:0H+?(8P2/FPIR,\9VU%H MWA8ZK<>,]1O[>2UM_$FR!+>5<.L*0^6'9?X68EFP>1QG!ZXV>E`'9:KXNU"#3O$D\WA=+W2],9X7,=X MC>>@CWR,R.H`4*<$`L&9FL];%I#%Y$T:I;M,`1$ MHX)*KG'RJIP!D=K'B2UET;X4ZCIOV:[OK^[LIX2MG;/.TES,CEFPH)"EV8Y/ M`Z9R1GBM2O;BX\'_``ZT^+0]?:YTB_T^>^7^Q[D>2D*;7.=F&Y/&W-`'H^F> M*9[CQA>>&M1TY;.[BM%OH&CN/-6:$L4)/RKM8-P1R/?UPV^)VSPZ?%1T223P MT9S"EU%Y%13S36_QZ%Z^FZFUD=#73OM<=A,\(F:< M2`%PI&,'ELX!ZD8..#TN^M6T62RU7PGXW;3?MTMS)IFG622Z?Q*64!_OE1@9 M`;;N!P,4`>_PR-+!'(\3PLZAC$Y!9"1T.TD9'3@D>YI]8>F^*;/5X=)GL;6^ MFM]2$I680'9;F/[RRG^`Y!4#N016Y0`4444`%%%%`!1110`4444`%%%%`!11 M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11 M10`4444`%%%%`!1110!R'C3PCJGBJYTEK76[?3X--NXKZ-&L3,S3QD[26\Q? MEP?NX]>?3H;F'4Y-(,-O>VT.I&-1]I:U+QAN-S"/>#CK@%CCC)..;U%`'+>` MO"E[X+\.QZ'/JL.H6L!)MV6T,+IN9F8,=[!N6XX&/?MU-%%`!1110`4444`% M%%%`!1110`51UBUO[W2;BWTS4O[-O7`$5WY"S>6<@D[&X/&1SZU>HH`R]!T8 MZ+I[12WDM[=S2&:ZNY5"M/(0`6('`&%50!T"@5J444`%%%%`!1110`4444`1 MSB9K>5;>2.."O".J>%+C53=:W;ZA!J5W+?2 M(MB866>0KN(;S&&W`^[CTY]>OHH`****`"BBB@`K&\5:/>^(/#EYI-E?PV/V MR-H)II+8S?NF4JP4;UPW/4Y[\=QLT4`8WA71[W0/#MGI-[?PWWV.-((9HK8P M_NU4*H8%VRW'48[<=SLT44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%` M!1110!7O[-=0TZZLGDEB2XB>)I(6VNH8$94]B,\&N=T3PYK^AZ9:Z3#XAM9- M/M8UAB+Z;_I"HHP!O$FS(`ZE#[YKJJ*`*]E90Z?:+;0`A%+,23DLS$LS$]R6 M))/J35BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**** M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH` M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**** M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH` M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**** M`"BBB@`HHHH`****`"BBB@`HHHH`****`"N-^)GB'6_"7A*;7M'.GNMH5\^& M\A=]X=U0%2KK@@MSD'/MCGLJX+XTQO+\(]=6-2Q"PL0/03QDG\`":`.J,6N_ MV"4%WIQUG;D3&U?[/NSG'E^9NQCC.[KSC^&N7_M_Q3_PJG_A*//T?^T/L/\` M:?E?8Y?*\GRO,\O_`%N=_P#M9QVV]Z[-[ZV336U`RJ;583/Y@/&S&[/TQ7%S MPR6WP"D@F4I+'X7*.IZ@BUP10!`/$OC"U\#VGBZ9='OK1K&._N;*"WD@E2-D M#MM=I'#%5)/*C.*V&\8-JMW8:?X=ACN+J[LDOWEN"5BMH'^X7`Y+-V08Z$D@ M#GG=!\,:[XB^&6AZ9>>(X8=)N--MQ)%:6!2=H3&I\LRF1AT^4D(,_C5GPU9P M^'/BQK^G,GDP:C86;Z:I^[Y=O&8W12>I&0<>AS0!KZEK6O>%H?[0ULZ=?Z0K M*+B>R@>"2V4D#>49W#J"><,"!S@XJGXR\5ZSX0O+'4VCL[[P_5<`1NQ^4<<>]:'Q(NHK;X>ZW'(OF27=J]I!$!EI)9`415'WN%@F)YW,NGW"M^H-`&AXFUN\@\#W7B#PY=6$H@M6O5 M:XC:6.:)4+$#:ZD$X&#SZ8YR-O3UODL(EU*:WFO,'S'MHFCC)SV5F8CC`Y// M7CH/(/&"7'PVT?7M-CC>7PEK5G-OW?_7-R>/0_F?:*`*NHK?O MI\RZ9+;17N/W3W,321@Y_B564\C(X/&<\XP>&\%Z[XT\7^#K/Q`EWH$#7/F; M;4V$V!M=DY?SN.5S]TUZ'7G_`,$O^20Z%_V\?^E$E`&MX=\47NN-JVD7EG'I M?B#3@%DC8F:$[P3'*N"I=#CID'MD&L?PEK?C+Q/'K!DO]!M'TS5)].8+IDT@ MD,>W+@_:%QG=TQVHT65-9^-.LZII[!["PTJ/39Y4Y22X,OF8!Z$JO!]*Q_`^ MC7^JIXY^Q>(]0TS=XEOXPEM'`R9^7YCOC9L\]F'08P>:`.CU'4_&VE>#==U& M[&BI?Z:\L\++;R&&YMDB#_=\W'#;W8BW%5<6Q'!(&< M[$/#&I3Z1X"U?^WKNXM+.TBF>QN%B5$#VC(-FR,$E2X`WD\$\ MYZ@';V=[
&H+_6XX[:ZCLUFODCY6)PF9`.3P#GN>G4UE>"/%,WB?3;O[=: MBSU2QNI+:[M1_P`LR#E>YSE2.>F/M!T+3I]'6SUH3^7)<63&';.V50^<\?=ZX[9.QXQO M]=TS3[6YT273E+7<%M*E[;O)GSI4B5E*NN-I?)!!R/3'.#XR80_%;X=W$AVP MB2_B+GIO>!0H^I-=!XQ8'2["`\7Z9XU\. M:#;76AM%K*2CSI+"7=$T,8:0[1-R&))`R,9P2<9/?UY_XM_Y*]\.O^XG_P"D MZUV\^H6MM>6EI-*%N+MF6!,$E]JEFZ=``.IXZ#J10!Y]XJ\3^-O#GA/6_$<@ MT6.&SO&CM;.2RE9Y(?/$2.SB8`$@[N%Z8Z9XZ?3I/%D'B@6FJMIEUI+V;R+= M6EK)"ZS!T`1@TKC!5F(]<'ICG"^-O_)(==_[=_\`THCKT"@`JO>WUGIMJUU? M74%K;I]Z6>0(B_4GBK%<#J5V'^.&BV%\`;4:/--8ANANC)\Q'^T(U/T!/K0! MV4.KZ9*]+LK MRTU)K:QTZ4Q.E]#&H+2$\R$-ER&3`PO?DC2T:S_LOXSZW:Z;&L>FW6DPWEW' M&,*ET9&53@<`L@8GUZT?"LY'C4C_`*&J^_\`9*`/0*S]1U[1]'>--3U:QL6D M^X+FX2(M]-Q&:T*\_,=O<^/_`!-::+:I=:E-;VR:I-J+9M[9"A\N-$`W,67+ M$9`]\\4`=K-JNG6XMS-?VL?VDJL&^91YI8@*%R?F))&,=!QTKT:)(XOC]-!$B)%+X75Y450`S"YV@GZ+Q]*`.OL?$>AZG#Z218EY.6(/RC@]?0^E6=/U.PU:U%UIM];7EN25$MM*LB9'49 M4D9KS&.YE\!^(]<\+62>7#K(%WH?'RQSR,(Y$QZ*S!\<84&O3M-T^WTK3+;3 M[5-D%O&L:#V`QS[T`6))(X8VDE=4C499F.`![FLT>)-"+6ZC6M.+7)(@'VI, MRD$J0O/S8((X[@BKE[8VFI6F&)P:\J\+:1;'XJZ M8+W3[<74_@R.XO4,2CS+AY0)&<8^9CD@D]:Z#0GMW^,/B73KF"-?L>FVD>F1 M;`%2VVGS=@Z`;V4''H!VH`Z^[\3:!I]O;W%[K>FVT-R"T$DUW&BR@8R5).&Q MD=/44ZX\0Z)9QVM>6KX.&M1?$3PQ M9Q(NGV]W#<:5M`"P731"1U7LH#;00.@8UT?A?7(_B`VA7;HI&FP?:KU"/N7A MW1*N/;$K8[9C/I0!UFG7'GZUJ@76[:]C7RMME$$W6?!!W$')W$$C(&,$"GVO MB'1+Z3R[36-/N'\PQ;8KE'.\*6*X!Z[58X]`3VKS72['3+#Q3\6K.,QZ5IR6 M5IO>UBP+=3:R%G55'49+8`ZU8TRVO;OQ3H=KXRT"Q>:-98]/U?3@K6UXK0.& MAD0C(!CW-C@$KP,=0#O]#G^T)?/_`&U;ZJOVM]A@5`+=2`1"=I.2H(.3R=PJ M6VU[1[V_DL+75K&>\C^_;Q7"-(OU4'(KQJ&6?1_A/\3O[&C$)A\07D4:P#:( MXBT2MMQT`0GITQ74?$2SL1\.]*U?P]#"EY8S6=59$!`+,">%!(Y/'(]:4:QIC:5_:HU*S.G;=W MVL3KY6,XSOSC&>.MO7%]H+Z)KTB6WVZW1E:"51YH MCFC('.[YP>3]T=\Y[N@"GJ.K:=I$`GU/4+6RA)P)+F98U)],L0*H:[XITO0O M#,^N2WMJUNL+O;DSJ%N'"EE1#G#,VTX`ZUS>CW*7?QH\46NH(K2V]A:KIX<9 M_<$$S%?J[*#]!7/QVQTO2/BWI=HJIHMO!(]JB#"1RR6I>5%[``E>!TS0!O\` M@O5]7\0S:9JL'BG3M1M)K19-4TU%CWV+QK&G:'JUA::E;73VULTKK,TJHJ%I1%E25 MR64')'RYR>E0?#GQD-8\"Z'>Z_JMHNJZBTP19'2)I2)G50B<9X`'`[>M0_"P MX'C4G_H:K[_V2O.X8(;?]E!+V**-;I91,LNT;@XO=H8'UQQ]*`/;[VXQK^F0 M)K=M;?ZSS-/8(9+O*97:2=PVX+<`Y`.>E27/B#1;.[DM+K5[""YBC,LD,MRB MNB`9+%2<@`]T^WU_P`&SWMTT]W:@)>Z:_F-YI(8?-Y;`X(!^51SC`H`]EK!\9:A MJND>%-0U32'LUN+&![EENX6D21$0L5&UE()QP>?3'.1O5S_CO_DGGB7_`+!5 MU_Z*:@#G!XE\86O@>T\73+H]]:-8QW]S906\D$J1L@=MKM(X8JI)Y49Q756W MBO0KFPBO/[5LX8Y+5;S;-.B,D+!2&8$\#YUYZ9(]:XO0?#&N^(OAEH>F7GB. M&'2;C3;<216E@4G:$QJ?+,ID8=/E)"#/XU!9>&]$T[XZKI]GI=I#:+X6W&%( M@%9C<;"6'\1*\$G.:`/1KS6M*TZSCO+[4[*UM9`"D\\ZHC9Z88G!HFUG2[?3 MUU";4K..R<;EN'G41L/4,3BN*T)[=_C#XETZY@C7['IMI'ID6P!4MMI\W8.@ M&]E!QZ`=J\\\9Z1:V?A?XE6L5G;G3M.O[1]-?RP?L\LQB:=(S_".5!`Q0![P M-:THWD]F-3LS=6Z&2:$3KOC4=69F)]OCL':7$5Q,A>,2_;CY:N`#E&?:K=L,<\5'?1W=U?7S^)-/M_#WB86 MB10:C`!+97J_:K.@!ZM8ZYI.J%1I^J65V7#,OV>X23< M%(#$8)X!90?3EH;A/-/\`P#.?TKSB"XU>'5-:O]6\ M/)IWBZWT*Z^S7-DP:VOT4HVX<;@ROY8`)SASGMACV.CZI^SG'8-*-VEQ M_&MVBY9@W4,9%()ZG)H`]/N-5TZTN4MKF_M89W!9(I)E5F`!8D`G)``)/L": MI6/BSPWJ=Y'9V'B#2KNZDSLA@O8Y';`).%!R<`$_A7G=]8)/\0_A=>ZA8P)J MMY:W,FH.(@KR2I:H1O(Y.TYQGITK2\26=EX"\7:1XKL;6&TTNY/]FZJD*!$1 M7.8Y2!P,/U/H:`.]MM8TR]OKBQM-2LY[NV.)X(IU:2+G'S*#E>?6KM8/A.$O MI.",%48`1*?=8P@/OGUK>H`X+7O&>J>#_%=E#KGV*;0;X2LM MS;0.DED%=%#2DNRE3G`Z5L^+]1UO3].L[O0I]-`DNH+>07D#RAA-* MD2LI1UQ@ODCG([C'+=7M+>_\;:99W<*36\^CZA'+&XR'4RV@(-<%=3W_`(+N MK'P3J!EN=+N=4L'T.];DJBW<+-;N?50"0>X_(`'J=SJEGHVGPS:WJ=C;':%> M>5Q!&[XYVAF.`3T&3CU-9GBKQEIOA?PA/XB:2*Z@51]G6.48N'/W55AGKZ@' M`!/:L/1[E+OXT>*+74$5I;>PM5T\.,_N""9BOU=E!^@K@/%UJVF>#/BGI=FH M71;>^L7M4082.21HGF1>P`)7@=,T`>W0Z[I%SICZG!JMC+IZ$AKI+A&B7'7+ M@X'YU8LKZSU*U2ZL;J"ZMW^[+!('1OH1P:\\^)E]+#XP\#69NK6VM9[NX=I+ MR$RPB58P(MRATS\SG'S#!P>V*W/"&E-I&O\`B..75[6[N+F6&[FM;2R:WCMW M92I(R[Y+[`2,Y&,]&%`'7U'//%;6\EQ/(L<,2EW=S@*H&22>P`J2B@#SF;X@ M?\))\.M2UOPUJEC::A9PW%TUO)MGD$41<+N3(*%PJL"0<;L8/6NC\*^([;4- M`T!+[4[5]9O=-@N7@,B++(6C5F81C'')/`Q7!>#3C]EZY_[!6I?^A35'?P0V M7@3X336T4<4S:II8+JHW$21'?S[]_P`*`/5[O6=+L+N&TO-2L[>YG_U,,TZH M\G^ZI.3^%7:\4TRTG\6W/Q%L+G5M*M2VI3PW'VNP:::.W0!8G5_.0!5VDCY3 M@C/.<5ZYH;^9X?TV3[6;S=:Q'[28S&9LH/GVGE<]<'D9H`EU%;]]/F73);:* M]Q^Z>YB:2,'/\2JRGD9'!XSGG&#S'PT\0ZUXM\(P:]JYT]1=EO)AM('3RPCL MAW,SMNR5XP!CWSQV->?_``2_Y)#H7_;Q_P"E$E`'?22)%&\DCJD:`LS,LZ7J%I)=V6I6=S;1DAYH9U=%(ZY8'`KS_`.*FO07'@W1KFSNHCIMW MK=O!=IUOIA MCAE2*0;)F+22`D;\#IG@C[IH`ZM?$6B,UJJZSIY:[8I;`729F8-M(3GYB"", M#N,5:OM0LM,M6NK^[M[2W7[TMQ((T'U).*\#B@AM_P!D];R*)$N5E$RRA1N# MB]VA@?4+Q],UZ/J5RMQ\;=(TZ^56M8='ENK)7Z&Z,H4D?[0C!^@)H`/`VOZO MJ?C'Q9INHZK;:C;:>+-K26U@6.,K+&[DC!8G^$GO786.LZ7JDDT>GZE9W M;PG$JV\ZR&,^C`$X_&O$/$KG0W^,?]E*(#LTP8B&,"1<2$8Z<.WYUW&D:6H\ M2^&=:&O:3Y3VDMK:6^G:8\/VF$IO"EC,^`FP$<`9R.I%`'92^(-%@,HEUC3X MS"R)*'N4&QF)"AN>"2#@'K@^E:5>7>$-`T8?%#XA6*Z79"SC73U6W$"^4H:$ MLPV8QRP!Z=:]1H`S=0\0Z)I-Q';ZEK&GV4\@W1QW-RD;.,XR`Q!//%$/B'1+ MC5&TN'6-/DU!"RM:)#7U:UB#:AHD\>I6[8Y'EL M"PSUQMW'\!7(ZSKBV7C;1/B+%&6TB[$NEJ%0!I5\LLC9')+2AU'LJD=:`/1; MGQ!IFI-:+I7BS2X2E[&LH26*;SQG!@^]\K,2`".?0R\`S2VEL-6;Q+9_:;E(U# ML\CR22#=UV[R3C/I6[XM/_%W_AT/^PE_Z(6@"QX.UC7;GQQXOT76-0ANX]+- MG]G,5N(542H[GC)/]T6`TI2!=FX_Q8[9IT>DV4_QKURT-G;SZ9=Z M)#-J,$D2M&UP)OW98$8)V@GGZT`=W;ZYI%W-!#;:I932W"NT*1W",T@4D,5` M/(!!!QT(-);:]H][?R6%KJUC/>1_?MXKA&D7ZJ#D5XKI,7V+]ET:G8VL9U&. M*XV3A`9(P]PT>G85UOQ$L[$?#O2M7\/0PI>6,UG)HSQ*`QWR(JHN M.JE6Y'?%`' MQO[2Q\7:5IU];G;+.TT4IMB&^8.C,`#PR\XQ^%IR$`!2WS12$]N5P3Z`5SWQ'TJTNO@_KOB2[L8#J-]-%=PRR1#S(8VEB2-03 MRI\I5R!W+4`>Q7%Q!:6[W%S-'##&-SR2,%51ZDG@5P>C>)M1OOBS-I2:W9:C MH.KE6\:^!M+O55M*N[R=YU?[CRI M%F%3Z_.V0/4"N?\`$9_L?XL^(K[3HUBN_P#A"I[D&,8+3"7@\=_E7\J`/4(- M9TNYU"73X-2LY;V'_66T.>%=-%[X5\#ZN?$&E6\%G/!Y0M MM,?SY)7&R2%W\XY+%CN;8.1NP`*]CH`YSQ;XQT[PA%IK7TD0:_O8K5!)*(PJ MLP#R$GHJ*0JQ0R6\JR*&'494D9]J9!K.EW.H2Z?!J5G+>P_ZRVCG5I$^J M@Y'XUYK!=SZ9XE^+TEA\CVMG;W,"QC&)3:.Q(QW+`?C5/PKIHO?"O@?5SX@T MJW@LYX/*%MIC^?)*XV20N_G')8L=S;!R-V`!0!['1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%1SP17,$D$\22PR*4> M-URK*>""#U%244`^G>W4CIB%G*8]MM:6N:%I_B M/36T[4XYI+1SEXX[B2'?P1ABC`LO/0\=..!6E10!G:)H=AX>TU=/TU)H[5#\ MD,;GPO';WR7]O;M:`+%EX5T>PO4O4 M@FGNHP1'/>W4MT\>>NUI68K^&*;K'A/2->O[:]U!+QKBU'[AH;^>`1GGE1&Z M@-@D;NN.,XK;HH`IZKI=EK>EW.FZC;K/:7*%)8VZ$?T(Z@CD$9JY15/^T/\` MB=?V;]DN_P#CW\_[3Y7[C[VW9O\`[_?'IS0`[4=/M]5T^:QNO-\B8;7$,SQ, M1G.-R$,/?!Y&0>#7/6GPX\,V%BMC:V]_%9*21:KJMUY7)R?D\S;R?:NKHH`H M6NC:=8:0=*L;5+.RV,@CM28=H/4@K@@\_>!SGG.:Q++X=^'=,25+!-4M%FD, ML@@UB\C#N>K'$O).!SUKJJ*`.:_X0#PW_8ESH_V.X%C=3FXN$%].&F7-A#=1):7;VI5&`)'8GD=JVZ*`,F[\-:1?Z-%I-[:FZM(2IC$ M\KR.K#HPD8E]P]P7C:A$,13QZC<1&(8P=@20!,CKM`SSGJ:F MT_P?HVFZPNK0Q7ZOI[AE0D$@>8[8Z#I1X7\5V'BVSO+FPANHDM+M M[.5;J+RV\Q54M\N. M6",`V,<9SCG&,FM'3[+&*SMC,88@0OG3O,^,YY=R6/7N>!QT%5-8UVVT8 MVL4D\6QB5_LT;9VL^6'7:QPN3@$XQ6SIFIV6LZ;!J M.GW"7%K.NZ.1#D'L1[$$$$=000>E`%>ST#3M/LKFUM8I8UNL^?+]HD,TA(QD MREMY8#@'=D<8(JGX?\&:%X6GGET>WN+M:D_@W1+CQ.OB.2"Y&K*%43I>SI\JXP MNT.%V\21SA54=235+^W+*/1/[8NV>RLP- MQ:Z7RR%SA20>1GC`//(!`/%`'/Z7/)XN\26FK7&@7^FVNDK*L!U*`1RR3/A2 M47)(0*&Y[EACI7951T?6=/\`$&E0ZGI=R+FRF+".55(#;6*G@@'JI%8.J?$S MPAHVNMHE]JXCU%65#`EO+(0S8P,JI&>1QF@#HM1OH]-L);R6*YE2(9,=M`\T MC9.`%1`2>OIQU.`":\N^$WA/39_!-A:ZSHNI0:C92M+/;WL=Q#"[F1VC?RVQ M'(0H7G!(P,XXKTN/6;236IM(8O%>1H)521<":,XRR'^(`G![@]1@@G0H`YU? M`V@)XD;Q"L%V-59LMV\GVN MW!6*YMYY()4!Z@/&RMCVSBG>(=?M/#.CRZI>Q74EO%RXMH&E91@DD@=%`!R3 M@#UJSI.I0ZSHUCJENLBP7MO'<1K(`&"NH8`X)&<'U-`"Z=IMGI-F+6Q@6&$$ MM@$DLQ.2S$\LQ/))))J/3-&T[1OM?]GVJ6_VNX>ZGVY^>5OO,<^N/I5^B@#E M(/AOX7M[B^GCL[LRW\3PWC/J5R_VA&4J0^9#NX8X)Y'48(!K0M?".BV1?[-; MS1*8VBC5;N4+`K#!\E=V(3CO'M-;=%`'/:'X'\/>'&NCIEG-$MV&%Q')=S31 MR[L9+([E2QQUQG&1GDT[3O!>@:5/#+:6\<;,40\GE0.M M;]%`&#;^#=#MO$[^(X[>Y_M9PRM.][.^5;JNTN5V^BXP,#`&!6=#\,/"$#EE MTV9]TYN666_N)%:8@CS"K2$%\,<-C(SD'-=?5*#4EGU"^M#:W4(LPA-Q-'MB MEW+G]VW\6.A]#0`FF:/9:1'(MHDI:4AI)9YWGD?'`W/(S,0.P)X[5>JM_:%E M]D@N_MEO]FN"@AF\U=DF\@)M;.#N)&,=3R!6Y10!G:)H=AX>TU=/TU)H[5#\D!?#LT]].;&1)+YS).8;J6/+MPS+M8;68##%<%AD'()%0'X=>%SX8'ALV$W] MCB;SQ:_;9]N[Z[\[<\[<[<\XSS74U%265PJHHZDD\`4 M`$>B-YN5_"KJ>"O#\=U+<1V3HTT[W$Z M)1F+EI$#;9.3QN!QP!@`"M/5=0_LK39KW[)=W?EX_<6D7F2MD@?*O?& M(5@NQJK-EK MC^T+C)&=VW&_&S('R8VXXQCBMVYN8+.VDN;J:."")2\DLKA511U))X`J6@#( MU;PSI.MW4%W>V\GVNW!6*YMYY()4!Z@/&RMCVSBJ6I>`?#6K:3#I=Y82/8Q. MTGD)=31J[L02S[7'F-D9W-D]?4UTE%`&%<>#M$N]6TO5)X+F2^TM!':3&]GR M@'K\_P`Q/1BV2PX;(JLW@#PZVH:C?""]CN=2/^F21:E,*[D#Y@"0,!N^14[>"O M#\MG/:7%D]S!/LWI=7,LWRHX=4&]CM0,H.P84XY%;]%`&9IF@:=I$CR6D3N\O.> M<[>O-=#10!SNI^!M`U?7(]:O8+MM1B&(IX]0N(S$,8^0*X"9'7:!G))Y)K/\ M2W$OB*_E\'C0;][61HFN]0GA`M/)!5V"-G+.<;<`<$Y[5H^'_&.G^)-5U73K M.WOH9],,0G%W;F$_O-Q7"M\W1<\@=170T`(````,`=`*6BJ%UK%I;Z5-J49D MNX(BP(LD,[,RMM90J9)(8$'TPVZS"WN([F+/5)(V#*P/8@C\B1T)JIX9\1 M67BSP];:WIZS+:7)<1B90K?*[(20">ZG'M6O0!D:MX9TG6[J"[O;>3[7;@K% M=V$;OP] MI>DV\5EEG=9Q_;[@&(]CN#Y)'1E?VCJ5O?2P9P3:VYDV]`-S<*N20!DC)H`HW_PO\&:IJ$=_?Z)'<7<:JOF MR32DR;0`#)\W[PX`R6R3WS76JJHH50%4#``&`!4#7.VW MPW\-66G?V?:PZE!8X(^S1:O=K'@\GY1+CG)KK**`,>7PKH<_AJ/P[-IT4FDQ MQK$ELY)`5>G).>%M%TR\T[3-,:T@O0!<&&YE61P#D#S`V\#V M!QR?4UU%<]K_`(QT_P`.:II>GWEO?-+J5Q';0216Y,0=VVJ&?]E^VS[=WUWYVYYVYQGG&>:N7/@[0[RPL MK.XMII4L6+6LS7GZA_:'VK_`$2[MOL]P\'^ MDQ;/,VX^=/[R'/![T`8T?P^\*1WMU>G1+>6YNE*32SEI6<%=ASN)Y(ZGJL_& M.GWWC&Y\+QV]\E_;V[7+--;F.-D5U3*EL%@2W!`P<'FNAH`CN((KJVEMYT#P MRH4=#T92,$?E5!O#VDOIECIK649L[!XGMHLG$;18*$<\XP.O7OFM.B@#`U_P M7H7BBYM[C5[:XGDMB##MO9HEC8$D,%1P`W/WL9Z<\"J][\/_``[J.I6VHW<- M_)>VR*D$_P#:ET'B`4+\I$G!(')ZDY)R234VO^,=/\.:II>GWEO?-+J5Q';0 M216Y,0=VVJ&1(8HXUW/+(YVJBCN23C_ZU5-!\3VV MO7.H6BV=[97NGR*EQ;7D85UW`E2"I96!`."":`.'\?B._P#B3X3\_2-9NM/T MPW1O)[73[AEC,D:^65>-,M-\1:GJ MVGVL%[!-I7E_:/M.2-@RNI&0 M01P01SF@"KK&CZ?K^F2Z;JEJES9RE2\3D@':0PZ<]0*I^(O">C>*[2*TUFVE MN+:,Y6%+F6)">/O*C`-C'&H(K+'@#PV-9L]76RG6]LB#;R+>S@1>N%#[<-SN&/F)8MG)ST%OYDWQN&&Y2589'<$$'T((J6@#`M?!>A66OW>N06UPNH79)N7-Y,RS M9!&&0OL(`/`(P.,`8%5-)^&W@_0M9_M?3=#@@O@25D#NP0GKM4DJOX`5U5%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%<+\6M2UG0?`UUKNB:O+87%D4RBP12+,'D1/FWJ2,9R,8[YSQCNJYWQWX M:D\7^"M2T**=8);I4V2,.`RNKC/ME<4`8?B/4-?T[XG^&M/LM;9;#68[P-:2 MVT;I$\4&58$`.1N(8C=V(R`<#"T_7?%][X,\:ZA-X@5+O0+^\BADALXP)!`B MDJRL#\IYZ?,"WWB`!6QK?AOQIJVO^'=?ADT*WOM(2Y'V=Y)9(G:1%3.X*IP> M>PVX'WN:KZ7X,\4VO@[QII=S_8YO=>NKBYA:.YD\M#<+M<-F+(V@9&`.TU+Q-$LPE9-X@C6$2R%5/5L$`9XR>ZI?/J$=EX1DN%E>-4D:);C=AM@"[LAN0HXQQ6FO@GQ`^@^%9/-TZVU[PSB M*U:.:22"XB\M8W#DHK(6"XX#8QWSP:CX)\2:YXPN-8O+C2;6TO=%;2+F",R3 M,L;N6?:Q"9/(PQ`QG[IQD@%/0_%^OW.](AT[1=2UO3'T+3Y%:.2U6474J(@#G[KQ3K=Q)JFC6? MB@6WBZU\R"#3+JTBCBNL<))&6'WW`W@;RH+8*X&3T5GK&NQ_&.XT"\U"&?3& MT=M0AACMA&8R9PB@MDEB`#SD`[N@XJKJ'@O6=9MKO3]732K^&:]N)K2_EDD% MSIT;RLR"/Y3N95(Q\R!<`?,!RZYTGQ%9?$R?QG=+HL>D0Z!@=JW=8L?%OCC2_# M-Y#8Z3:MIVI)?W"3WD@\R:"1TVIMC8>6P&X-DY##CC)`+;^)]0\.>.=:TO4K M]]0L(-!;6HR\2(T.QRKH"@&0<9&02/4]\W0_%^OW2!V&>)-"DLYH]3ACBO[ M.[E>(%HQA)$=5;D+Q@C\>>&>!?#&N^&KO7#J5YITUMJ.HSWZK;QN'#R,.I)P M!A?NX/)^]QR`5_%FH:WH?C;PS<)K4R:#J-X+.YM1##A9"I\L!RA;#,#GG/H1 MGC&TWQ9J=EXU\5Z9JFO7=QI]II[W-A(]M`C'8Q20KM0;V60%1G@D'@UV?C?P MY+XI\+3Z=:S)!>B2.:UG?.(I4<,&X^A'XUEZE\/H;O6/"UU!,$AT@-'N6H`R-:OO&/AFT\&&ZU]+B2_P!5M++4$>SC#LTA)<*R@*%` M7:`%SR3NZ87PO:7(_$5UH0TA-+%OIFH0ZDS7=S(C221EL)A8V`7!ZYSSTXY2R\/>)-,\8Z MYKUJ-*8:S#:O-#+/)^ZDAC*F-2$Y5L_?(!'78>E`'(Z))J]GX8^)6I:7JGV% M[#7M2ND"P)(9&158JV\$;2`!Q@]\]J]5T#4FUGPWI>J,@1KVTBN"HZ*70-C] M:X72O!GBFU\&^,]*N?['-]KUU<7,3Q7,GEH;A0KALQ9&T#(P#G.#MZUUW@ZP MU32?"FGZ7JT=FMQ8P1VRM:3-(LB(BJ&.Y%()P>.?KS@`'&^-=/NIOB]X&$>M M7T'VC[?Y?EI`?LVVW7.S=&<[N^_=UXVUIZ9J>OVOQ:?PW?ZLM]IXT0WT0^RI M&^[SEC!*-1\?:#KNGP:.UGHHG\N.XO)4DG\Z,(V M=L3!,=OO9QGO@`T#Q3_PM8^*3!HYT_[#_9HB^V2^:(?-W^9_JL;_`/9SCMN[ MT`8?A?1KZ7XI^/(!XEU6-X?[/WS)';;Y\PL1NS"5&.@VA??)YK/\#:Y<^$_@ M&/%,M]6*V81UMKF$.TCL M9O.1G!P%`/!4;L^HZ$`NZ#KNMCQ786,TVK:G87EM(;B>YT26T2TG4`C#-$@V M,-P`.XY`YYK`MOB!K>J:7'XCTUM4N%>](32;?199(9+42["1.(SF3:"^0^,_ M+MSQ74^%]'\'=/UW34\,R3,R3%91>P1L)G^+EQX;?6HDT MV32&OXQ#:*KQ`S!``6W988ZGY3D_+TQI?#W7-0UG3-6@U2<7-UI6K7.G-<^6 MJ&81D88JO`.&[`=*@M_#_B$_%E_%%S'I:Z;_`&1J%])V;6VK>&?%8+>5 MHEVXN<+G9;S+Y;O]%^4GT&3VKK+^2]_LZ232H[:>[*@PK<3&.)L]RRJQQCG@ M<].,Y`!Q7P3S_P`*@T/'!_TC&?\`KO)61+>>,/AB1>:Q*4 M4@`L!P3D9Z=[LNEZ_P"(-.73O$4.E06K,INA9323?:%!!V@.B^6"0,_>.,CC MK0!G_%2X;2/#-MXDA;9<:-?07`8=3&SB-T^C*_(]J[FN)^)-H=?TVP\*PY:7 M5+R(S*!G9;QL'D<^@&%'N6`KMJ`/*=3U+6?%OPQ\1>)+;5A!ITMK>K;6*P(R M/;H'C8NQ&_>=K$;6`''!K1TZYUB'P)X'2SO(M-TEM,A;4]29H@]LBP+L"B3* MY9N,D''I4=OX'\1:1X1UOPCIEQILND7<5PEE-E`\$>)H['P=ON])O)/#K%3:.)(H9T$2QHQ;YSYB88AMN,MT&.0"EIVN>)_ M$4/BW1M%\0R-?:.\$UA?O9QJURLD;,(W5DVXR.&"C/!&1UT].UZ_U_P%X>;3 M];NX]7U"X6*6X:&$R(REC.K)Y>T!55@/E'(3)YYT/#WAO7-,\=>(-V MU@6Q982^^,Q1E-H!&.I'S9[?=&>*WA'PY;6GCGQ-J=I.7L!18VN M"OKDK&/8AAZT`8NH>*M6NKO6-(TSQ*;+Q3;-+#:Z5>VT*QW*@D1NCLHW.Z@/ M][:"<%,"O4YD:2"2-)6B=E(61`"4)'49!&1[@BN`U#P7K.LVUWI^KII5_#-> MW$UI?RR2"YTZ-Y69!'\IW,JD8^9`N`/F`Y]"H`\GM=8\4+I7C33;KQ)=OKND M7:+9R1VEOF1)%_<+L\O!+LP!_#!'.;WAG7=9\5:#X/:WUZXBN[A)9]3D2"`E MTC.U@04PI\PHHP!QNZXS6]<>#?.^(\7B83*ML+14FMQG,LZ$^6Y[8"NWXA3V MH\'>#1X6OM`01SG/O-7\0W-K\4='U+6!)_9&G1R6TMI; MK!MWP22L`#N/.%4Y).!P0>:Z#POH'B?3?'7B#7-3AT@6VM&#>EM=R.\`AC95 MP&B4/G(SRO<^U9MMX-\4W&L^,I]171XK7Q/:BW-"`8E#_`'AG ME?7VH`YO5+"]B^'_`,,2->U$K^ZNX\6^(KK MP[+X>T**^NWNM3ED5[X6?VB=8XDWN5BB3!G2 MS:4MWX?O+*XMT5Y/+F%NI4[Y-N1N!!X0XQU.>+GC'PAX@U]=!U;3M1LK3Q#H M\LDD;,C^0P?`9#U.,*!G'//`SP`9K>(O%/\`PB?BJ2&YN8I='#7-IJ.H:0\) MNX!$7V[&"`.&4J6"XZ?+R#2'Q)XAT_1O`&MW.J_:%UJXL[.\M/L\:HWGQY$@ M(&X,",G!VG/``K2O-!\;:CX3UJVOKO2)]6U:$VAB26:*TM82CJ60%69G.XYR M!GCGY0#1U3P;XHNO"/@K3+8:0+O0+FVN)S)=2".0VZ[4"D19^8/-#\.O$W_"D1X&WZ3]M\['G_`&F3R_*\[SL_ZO.[=\NW&,GW?V)VL'U"ZN517D6,.(U6,,"H)8DDD'@=.:\T^)>M: MU:^&_%7A35M2DN)K>VMK^TNXXEB:XMVG6)TE"C'#,.5VYQZ9![_4?#.NW6O: M1XLM?[/M]>M('M;JT,[M;7$))(7S-@8$$[A\IY..<9.?XF^'FH>+=,UZ>_GL M[?6-1M(;2W6)F>&WBCE$NTN5!8LPY.T8XP..0"7XCWOB/PC\/;K5-+\0/)/: M,IDEO+2)Y)`[H@`*JJ+MW$\H,SQUX>\6^+O`\VAHNBQ3WCJ9W-Q*%A5&1E53Y9,A)4Y8A M,#`P>M)K?A?Q3=ZSI?BO29=(M/$5O;/9W%M.\DMK+$6)&'"J_!Y^[U.,\9(` M:[KWB'P=X4C75+RVO-2O-42PLKN&V9SY(?!&O^)O!Z6U] MK<"Z]%?IJ-O-#&RP02*,*B@DMM`)Y.3DYQVK7\,6'BX7K7OBO4-.>1(?(AMM M,$@B.2"TC[^K_*`.,`9QU-`&-\;A(/A-K$D5Q+$4,.X1D#S%,J*5;CI\V>,= M!VR#HZQJ>H:-?:!X;M]4FN=0UBXE'VV[CB+111IO>.":Z5-DD@.T,KJXSCG!VX_&L[7O"VM:]'I&K-<6%KX@TFZ-Q: MK'O:`HP`>)V(W$,!]X*/IWH`9;:OK'A_X@6/AS5=1;4['5X)9+&YEA2.:.2( M!GC;RPJL-O.=H/:M?QO=:KI_@[4]0T>\AM;FRMY+DM+!YNY41F*@9`!)`Y.< M<\>D-KH6HZCXGLM?UU+.&73X)(K.VM)6E56DP'D+LB$DA0`-O'/)SQ9\9Z?J MNK^$]0TO1TLS<7T+VS/=RM&D:.I5F&U6)//`XZYSQ@@'%77BCQ#I'@KP_KUS MK`GGUN"SM$@%B'$4\P#&8!!N<[`W[L`@MC'I6IHNJ^(K[5M4T>"\U"2`VJ3V M6K:EHDD'ER;MLD3*4B5SC!7&."<[L&J^H^`];UGX::1H,]S9V.KZ,]N]GQQW%_K%WHUQJ*6_D6EI:R316Q)8%I)6 M*L2W'&%XY`QN)`!Q:>,_%8^"5KXZ;6$:\AFW26XM8Q'/']I,6UN,C@C!7;P. MX%`&%J/C;6=0N?$DFCW-_%+I%T]I9V5KH M\MU'=21`%Q+(L;!=S$J`&0C@G@UT-UXAU#6/$&C^']/FETF>YTW^U;R1X09X M8LJHC57!`"?J<<#CBM?4/"&IVOB#1_$&AWD<^H6-C_9US'J$K@7<'7+2`,0^[YLX.30! MSOA>PU>;QW\2K)=8,&IXTX1ZA'`A(Q$Q4E&!7)7`;CN<8XQ;T'Q%K5U\.]12 M\U:X/BF"\;3W)BA!BN2ZHBJHC"F,Y#9*DX+'/'&KX>\,^(M-\>Z]K]Y=:6+3 M5_(,D$2R/(OE1;%`8X`Y)R<'('1XH`[&"TN$TI;2;4)YKCRBC7FU%D+$??`"[0?3C'UK@O@C!S:G=SK/YY%O*(]D9\^3+`A`Y).2=S'J>E>D5PO@_P[XG\'^#O[#@.D7)L MQ(MFSRR)YI>4N&D.P[,!C\H#9('S"@#@O#6K:SX9_9^TKQ'9:CY<5A,6:S$" M,L\;7;(RN6&X'YB05*]/QKLM;\6WMUXPU;0K*_OM/32[>(F2RTJ2]:6:52RA M]L;A4"@<8!.3@\<99^'7B7_A2(\#!])%[YV#/]ID\LQ>=YV[_59W;OEVXQCG M/:K<_A/QU:>+KCQ3H=UH5O>:G!''J-E=232P;HQM5D8*K'Y0#@@8)(YZT`=K MX3U.^UGPKIU_J=C+8W\L7^D6\L31LC@E6^5N0"1D9[$5F:UJ][=^,[+PIIE[ M]AE>S?4+NY6-7D6$.$58PP*[BQZD'`7I6YHEE=:=H]O;7UZ][=J&::=L_.[, M6.`2<*"<`=@`.U8.O>&=2?QAI_BO0IK;[?!;-97%M=NR1W$!;7.,=\8KJ=!UW6QXKL+& M:;5M3L+RVD-Q/(4M]R11R2/&T"#R\$E1@,.3@[@.BYP-[POH_CF&ZLAXHU?39+2P0B-=/\` M-#W+%2H,Q;`(`).`.N#U%`&%X0TN]'Q;\<*?$&I,;9M.:1C';YN@82=LG[K` M`''R;#@]2>:I>(?%_B/PUX<;6M2UM(M;AG62?0(H8IH4@,H4!G52ZDJ0=Q<` MG@#-=+X8T#Q1IOCO7]3&57`:)0^;K2&>XG,W]HN\GF71,PDS*-ORMQC=E^`!CO0!MQ7VN)\7;_PY)KU MQ)IUQH;W\"^1"&M9&G$8VL$^;:,XW9Z\YKA_$>K:MJGP4\>PZQJ#7\VG:X;" M.=H4C)CCF@`R$`'4D_C7H-SX=\0+XZM/%=K_`&9).=,;3KJVEFD144R^8K(P M0EB.`\0ZKK'A7Q`BZ7%J>D-,GLX1*((Q.R/*%&]D4JI;')`).!GMD_6@#R+Q#XO\1^&O#C:UJ6MI M%K<,ZR3Z!%#%-"D!E"@,ZJ74E2#N+@$\`9K?.I>)G^+EQX;?6HDTV32&OXQ# M:*KQ`S!``6W988ZGY3D_+TQCS?#CQ/+\,]2\'FZTAGN)S-_:+O)YET3,),RC M;\K<8W9?@`8[UNZ=X?\`%+?%'_A*-3CT=+0Z:VG>5;74KR*GF&16^:,`G.`1 MD=2?:@"CIGCV\TWP!XHU76)!>W7A_4;G3Q-L$?VED91&6"\#)=0<"L[QS8:[ M:2>!Y-5UD7WF>);$S1_9TC6.7+?ZLJ`=F-PPQ8]#D=*N:;\/=:NO#_BS0=?_ M`+-CM-=O9M06>SN))'AE=D95*M&H904!SD=,8YR)];\+>-M?TOP_;W-SHD=U MI&HP7IN/,ED%P8@V&*[1M))Y7)SD_,,8(!Z).LKV\JV\B1S%"(W=-ZJV."5R M,C/;(SZBN'\"ZCKGB/2/$EKJ>LR+>6.MSV$=Y:01(RI$(_NJRLO)W?>#'YCS MP,=I_ID>G=()[Y8NF3%&\F/^!%5)_P!X@>M<-X1T#QEX:M?$(EM]"GGU*_FU M&$I>RJJ2R%04;]S]T`$Y'.0!CG(`*OP.L[A/AKI%XVIW5&?/? MY@0@?/!ZL1\QXZ87QS;7-S\5O`4,&J7EF)A?X,`C/ELL.=P#HP)(8J<@\=,' M)K9^&GA[6?"?A&WT'5UL&%H6\F:TG=_,#N[GM"_\`PB@5 M[@HK28^T]0,;=V<=01UXJE'\0M6L?"%ZEU.+C58?$C^'XKS[*6+'=Q*8HQ\S M!,_*HY(`P>^]8^'O$W_"TO\`A)]0&DFR_LPZ;BWGD\S:'\P2;2F,EA]W=P#] MYL<\P_PR\4WVCZM9W-SI5I<3ZX^OV5S;W,DABN#@!&4QKE<9^8'(./E/8`ZS MPIK6JS^)K[3+EM4OM.%LEQ;:A?:4]F5?<5>(YC16/W6&!T)ZX-;7B_Q#'X4\ M):EKDD?F?9(MRH3@,Y(50?8L0*H^&+#Q<+UKWQ7J&G/(D/D0VVF"01')!:1] M_5_E`'&`,XZFM#Q9X=@\6>%K_0[F1HH[N,+YBC)1@0RG'?#`'%`'GOCFPUVT MD\#R:KK(OO,\2V)FC^SI&LUOPMXVU_2_#]OFX\R607!B#88KM&TDGE/LACC!@=@[;\.A8 M2+G&&)7CEPF@T:\MKYY]0NY!+/)%D;3B-NH.2Q)))Z<9-K4?# MVO3^.-+\30#39?)TXVDEEI:SIGQ7\+6,6KRMI6 ML"[\ZQ>"+:AAAW#:^W?R2#R>H].*QY/AMK=WX2\8:!=7NGA=:U*7489XM^0[ M/&X#*1\H!C(."WWNO'.EJOAKQ=K'B;PSKS3Z+:7&DBX#Q`RSH3*BH2.$)R-W M'&,#ELG`!SVH"3^W/C0T-Q+!(FFVDBR1$!AMM'.,D'KC![X/!!YKM_AS:36W M@'0GEU"YNEETZV=$F6,"$>4ORKL121_O%C[USMMX-\4W&L^,I]171XK7Q/:B MW-"`8E#_>&>5]?:NM\':;J^C^'++3-6:QS96T5M%]E+MD(NW< MS,!R<`X"\<\GL`8WC[6-=T34_#$NGZA#%8WVL6NGW%N;8,[AV)8[R3@;5Q@+ MGDG/I3U[Q9);^+KS1I/$/]A7L81M-BN;9#;7JE`27=AG.\E,*R_=[YJ[X_\` M#WB/Q%=:$-(32Q;Z9J$.I,UWN<\]..6:AX;U_59M434[ M/0]4T^^>)XK*\GE(LF$**Y1_+Y&\,0H">NX%B``=5H7]H_\`"/:9_:__`"$_ MLD7VS[O^NV#?]WY?O9Z<>EQT_SGG^RV\<'FO\`>?:H7'=`\4Z; MXL\5Z]>PZ/NUB*$P0PWDC>7)"A1%8F(?*0>6`R,?=.>`#+T+Q]J>N^&?!42/ M%#JWB!YXY+@Q@A$M]WF.J]-QVC&>`6Z<8K374]9T7QQ;>&-3U:6]L]:M9FL+ MTPQI<02QC+*=JA&PIW`[>N`0:P=$^&GB*P\,:!:RSZ9#JWARY>?3[B&:1XYU MD=FECE!C4H""!E=WT'?L[70M1U'Q/9:_KJ6<,NGP216=M:2M*JM)@/(79$)) M"@`;>.>3G@`Y[X(P7)^&NEWLVIW1;RB/9&?/DRP(0.23DG^&]8\(^'X M-"O9K&6SL_-$$D.\R2[Y&<,V0`F`Q&T;L]\Q[0<`@8VO\Q#8SC!#'`!SC^*-=TGPZTUQ?V.HW&J:U#I^C7D:K MY+Q2K&%D(0\X(E)!/)!QA<5:U/5-;\'^)M#%]JTFJ:/J]T+!A/;QI);SL"8R MK1JH*D@C#`D8ZFH+GX:+=^#KC2X7@TJ[.H#4[-+0EX;*95`4)N`)7@D\+RYP M!TK6?0]:U_4-(F\11Z=!!I=P+M(;*9Y?/G"E48ED78J[B=OS9..>.0#K:*** M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH` M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H MHKEO'GB^;P3X??5UT>;48(_]:R3)&L6655W9RW)8#Y5/?..X!U-%22\*FWCRV!P#G([@FF6_BV_-]J6E76@L-9M+>.Z MBM+:[21;F)V*AD=P@&""#D#';-`'5T5YPGQ4F;P#:^,V\/.NDO-LN,W8,D:> M:8PZKM^?D#()7D\9`S6\OBVY@\7:;H>HZ3]D75899+*;[0'8M&`S)(FT;3M. M>&8=J`.IHKC=4\=36G]LW&GZ.U_IVB-LU"X^T"-@P4,XC3:=Y12">7Y^4?*W7T/I4Q%MJ%E@^5,:%J"^'=> M^)ETGA1?L]O'9&YTN!HECCC$$AD;G`*'!/`R=P^7KCT1?%EG8>`]'UH6!C%] M!;+9Z?;D]>;_%;5Y/$GPMNM6;PW&+!S&=/OY9%:=%:5/GV M;?D1U&!AB3D9`H`]LHHHH`*K7VHV6F6YN+^\M[2$=9)Y5C4?B3BLWQA?WFE> M#-:U#3Q&;JULI9H_,8@#:I)/`/(`)`[D`9'6O+?&B76J_L[1ZEK=E:27D-C8 MO:WGGF>9@[0AG9F12C,.H!;/J:`/;:*YC_A++B#QAIVA:AI7V6/5(99+*?[0 M&9FC`9T=,?*=ISPS?X9\GQ"*VPU=-*+>&_MHLVU$W`#Y\SRO,$>W_5[^,[@> M^V@#MZ***`"BN-U3QU-:?VS<:?H[7^G:(VS4+C[0(V#!0SB--IWE%()R5]LT MFH>/9+3Q7HFC6^ASW,&L([VEZ)T"2!8O,)"\G`RH.[;U)&<<@'9U#=7=M8VS MW-W<16\"8W2RN$54:GYHM[LW"*CE(][849;`)4$D# MN0#CE[^*]26;3M+70E'B"[@DN)+%[P>5;Q(VW>TJJ<@DJ!A2>><8H`ZNBL?P MSX@C\2:2UVMN]M/%/);7-L[!FAFC8JRDCKR,Y]"*V*`"BN5\5>++WPSJVAP_ MV1%&61B/\`5[#N&!G.X=QQP35D\:ZK!XTU#PV_AOSIH-/. MH6K6U\K-<1^:(P,.JA#R2![/Q@^@&+2'G\JY9KL;X4,QB#JNW#C M.,@E<$X&0,UKZUXUNM(\9Z7X=70+B;^TA+]GNOM"*CE(][8')P"5!)QU)`.. M0#KZ*X.Y^)<>D-KUMKFDR6M_I,"7'DVTPG6YC=@BM&V%/WBH.5&,U<_X3#4K M+Q#9:+K&@I![CWH2TJ*IDD& MXQ8.8SI]_+(K3HK2I\^S;\B.HP,,2R[@"".5((Y`Z&GZ9I=CHVFP:=IMM';6D"[8XHQ@*/\>^>]>6>&?"/A M:3XH^/M/N-$TMK:W%BUO#)`A6$-"6!,;I97"*N3 M@9)X')`J:O,O$/Q!NX?`\6OWW@@7NAW-E!#@5 MT/B[QG/X4OM(A_L.YO(-1O(K,7$!GT`.LHKE[/Q>P M\4ZAH.KV,=A-;60U&.5;GS4DM]Q5F/RKM((P1R/?UAM?&&I7ATJ]A\-W$FBZ MG*J0W4>#;YT2N"T>X97 M<.HR.1GK4U<9X<\3C5/$7BFU'AA[#4M-6W,X\R(S71='*`E3MR%48RY'S=L5 M4TSX@ZOK&D:S?67A1M^DWDMM<6\U\JL3&%+!"%(+C)^7@<#YN<``[ZJU]J-E MIEN;B_O+>TA'62>58U'XDXKDK/XA#79=,M_#FF?;+B^T\ZB?M4_D1Q1A]A5G M"OE]^1@#MUQ7(?$;6+'QA\&==U*;2T@U'2KP6;I+MD:VF6>-7"/CH01R,9%` M'LM%%%`!16?K=^^FZ1/<0J&N"!';H>C2N0J`^Q8BN0^'TMQH>KZSX)U"X>>6 MQD^V64TGWIK:4DDGU*N6!^M`'?T5R6L>,[K2O&NE>'1H-Q,-3\WR+O[1&JL8 MX][87).!D`YV]R,XYKV/C75=1U+7-'@\.J=7TAE\V(WV('1UW1D2;,Y8=!LX M[D4`=K17'V7Q`L]2\-:%JEE:2RW6M.8K6SW@'S%W>9N;LJ[&RV.@Z9.*DL_% MU\VO7'A[4M'BLM8-LUS9*+SS+>[4<8$FP,I!Z@ID#G!H`ZRBO/[;XAZK=>#] M>UM/#D`N=#O9[6[LVU'C;"@9W5_+Y/.-N!D#.>U.B^)%S+JGA>R_X1NX`\06 M@N8)OM*%0?)$K*.Y"E@I)"]R`<8(!WU%<%>>-M1E\/\`C2)+"&SUSP_`SO&; MDRQ%6B,B2*VT$Y4$X*CD`9&JWO@G1Y]5CBWO86[),MTTSS`QJ=\FY M%VL>I&6Y)Y-`'3445@>(/$Z@]FUZYN+@P0I$&V#YPCDL6[!?QH`V-4%B^F7,6IO$EE M+&T4QEDV*588(+9&.#ZUE:';>%O"ND6=GI$EA96-TRM;`7`(N&?`4JS$ERV5 M`.3GC':N:UG6+'QM\*?%,UWI:1W.FQ7L$MO/ME^SW,,;BBB@`HKA[WQ[?);:[J& MG:"+K3=#GD@NY9;OR96:,!I#&FPA@H/4LN>U:,FM_#TFH:MHUY87B7GV%+)OF:XF M+!4$3'`=6)&&X'7TI4\1Z]'=WMG=>$[@W$5NMQ;M:7*R0S@L%*>8X0*XSDJ> MP)&>,@'445PF@^.==\4>';'6=&\*I)!=";(N-1$6PHY4?P$D,!U`X;@\?-5" MX^*5ZGPOL_','AV*6UD+BYMVU#:T.)O*4J?+._)Z],9'7D@`]*HK`UCQ%+9: MQ:Z)IEBM]JMQ"]QY4DWDQQQ*0"[OM8C+$``* M.P-6:\DU(7#_`!L\$7%]H-MIM],M\TLUO,)1.HM\*&?:I++@C!!`R,$BO6Z` M"BJVHWT.F:9=ZA<;O(M87FDV#)VJI8X'HH?S M%9@"R!@I(`QC<#DY(Q4]K\0;74/"FBZO864MQ=ZRWE6EB'`8R#.\%N@5=K$M MCH.F3B@#J%U&R>_:P2\MVO%0R&W$JF0*"`6VYSC)'/N*LUY3H,;1_'^[,VCV M^F7+^'F>=+=PZ3.;E29`VU2V>`25!R#]:]6H`**Q?%FLWOA_PY=ZM9:=%?FS MC:::&2Y\C]TJEF*G:V2,=.,\\]CS][X_O;.S\(7_`/8<3V'B*2TA,GVW#VTL MXSC;Y?S@#OD9P1@<9`.ZHKCCXVOF\=W'A2/P[*MPEFUY#/-=(J2('"!CM#%5 M)SSRPP/EYXR;_P"*LMCX,O->/AR>633[R6QOX$NDV6TJ.JX+D98$NN"%]CT5R5WXRN=+\1:5I^K:.;6SU:0PVEVMR'(DQD)*FT;">V"PR:J7OCV^2V MUW4-.T$76FZ'/)!=RRW?DRLT8#2&--A#!0>I9<]J`.RDN[:&YAMI;B))Y]WD MQ,X#2;1EMHZG`Y..E2221PQM)*ZI&HRS,<`#W-<2_C*UN_&7A:S_`.$?,D6K M023Z?JDSQY1?(\Q]@&6&054YVYSW`YM:IK?]L7&J:3:^'HM:L+$JE^9Y55&? M`?RXU*D2.HVG!*@$CG-`'3VEY:W]LMS97,-S`Q(66%PZD@D'!''!!!]Q4]>? M_!+_`))#H7_;Q_Z425Z!0!#)=VT-S#;2W$23S[O)B9P&DVC+;1U.!R<=*FKD M-4\1QVOQ%T'0[GP]O>\\_P"QZG(\9V;8M\FP#+#^%3G;G/<#EI\;7S>.[CPI M'X=E6X2S:\AGFND5)$#A`QVABJDYYY88'R\\`'8T5Y-K_C[5]2T?0Y-,M$LK MO_A*(M)O[=KMAB5'SY8=5Y1L?,V.AQM;-=SJOB.XTF'3+:6PCFUK4I3#!9P7 M!,>X*68F0J#L5023MSZ`T`=!17$S>/KBVT36[F70)GU'1)"M]9PW*$(GE^8) M0[;=R%>GR[O]FFIX_NET.PUBY\/R1V>HVUNUGLNE:26YF("P;2!CKD/TP,X! MXH`[BBN>T;Q)<7NO7FA:IIZ6&I6\"7*I'<>='+"Q*AE;:IX92"".#ZUE_P#" M=7C6NF:E%H:3Z/J=U;P6UU#>AF02R*@:5-HV<-G`+H`.UHKS[X_\3'4HK5[>#6[FVWB\=FA,:HHCC0QX*<9SN7)8G;Z^@T`%-DDCAC:25U2- M1EF8X`'N:HZYJ\.AZ3+?S@%49(U!<*"[NJ("QX4;F&2>@YK"359]7UT^%O$/ MANW6.>SDNR_GBYMY522-0!E%).7!.5&,#&6M_;+=I4,SQW5P;@(T:O9Q'$LLJJ9&)P%4$\DD@8'K1)J-E%>Q64EY;I=S9\J!I5$CX!) MVKG)X!/'8&O*?%>J:7XKTGX=^*[2S1)KKQ%91B1T7S44/)NC+#L'4\=.,UL> M*+&T@^-7@*[BMH8[FY&H">54`:7;;@+N/4X!(&>E`'H]%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5Y[\9_M-U\.KW2 M+'3M0OKV^:,11V=I)-@)*CL6*@A>!QGKVS@X]"HH`\X^)]C>^*/!.FWVCZ7+ M?-9:E#?-I]U;,CS(F]61HW`)SGH1R.F:/3IV$0GB"(&`3*MD< MJ>5[@5Z310!X?#IS>'O%GB:VUGXIW=L@C(Z\5[)10!YCHUA!XCL-8AT MGP.OA:*YTN:S:XNM.2UG>60``+MY,8P221R=N,8-8FO'6-0^!K^$SX=U8:W: MPVUF\*6CM&PBEC`=9,;7!"@_*21G)``)KVFB@#G])\5QZIK+:5+I&JZ==BW- MPHO8`JR*"H;:RL02-Z9';=ZY`Z"H$L[=+R2\$?\`I$BA&D)).T=`,]!WP._/ M6IZ`,?Q;93ZCX,UVQM8_,N;G3[B&)`?O.T;`#\R*\N\47%]>_`>U\.6_A[7G MU$V5G;",:;*?GB,9DS@9`&WJ0`V?EW8./::*`/-?%M[(?B/X%U6+2]7FL;.* M[FN)8=-GD\I9H@B!@$R&R#E<;AW`KC?"FCS:)IC^%M2^&::AK44[QVVK3Z9' M+:R*S$AY93S@9Z`DD`#@U[Y10`4444`>'PZ.:WM3^UK\1_A]%_8UVL>DPSQ7LMEITHM('E@5%5 M&"E=@/'!(4=3P<>I44`>020WUWXJ^*-JFDZHIUJQ2WL)GL95AF>.VDC8>85V M@%CP20#V)R,U?%%Q?7OP'MO#D'A_77U$V5G;",:;*?GB,9DS@9`&WJ0`V?EW M8./::*`/*]?UK^T?B3X+U2WT;7S8Z:MX;J9M&N1Y9EB"J,&/).1S@$)-&;3C8SVT5HMR\+B1G#A#WY`SZ9YYKUBB@#G/!4031I9 M8_#T&@V\]PTD%DENL,@3:H#2JO&\D$^PVCM71T44`,=)\06NOV=J-)\W[);R::TH_>(%DWMYJ[LXXP%Q^I`.;UN/Q+> M:OXA\:>'=-NHKJ'28],TZ.YMRDL_[X222B)P",`_*&&21T]:MY;1VGC;P;XA MLM$\17%O:QWAO[NXLII+AV:`!`RD;@PT4`>3^"K:[U30O'FC2 MZ?JFFW&L:A?W-M)>6,L*^5,JJK;F4#<#_#G/MP:SM>.L:A\#7\)GP[JPUNUA MMK-X4M':-A%+&`ZR8VN"%!^4DC.2``37M-%`%73KM[ZPBN9+.XLVD&3!O?%/Q7=ZSX6N9[74/LO]GSZGHDFS]W"5D^: M2/$>2!UQG`[X%==XX2'3?AUJ]AI^F3R&YLYK2VM=/LVD^=T8#Y44[5]2<#\2 M,]910!XSXIENKW]G^RT&UT;6I=4>SM+4VPTN?QTC7)E@UNVU&?;I-QF&&-G5MPV9#9_AZD<]""?4**`/*/$UI60L,NJD!0&&6Z#N1@XO>"?$.OVVEZ/X6N/". MJPWU@D5K^*])HH`\T\&WTDGQ3\87-?#=OX8UM M;G4=>EN+.&'3I'181)"R_,H*XPI`P2.*^A:*`*VGWT>I6$5W%%<1)("0ES`\ M,BX.""C@,.GISU'!JS110!Q&MW<.O>+[+0;FQUN.PMBTSW<-M(*@)*#'/4]%[D8. M)O#<\]I\3/B#J$^F:G';3):O!(;&7;.((BC^6=N&.2,`9+=1D5Z/10!X/X5T MG6[#PGX&U./2-2%WX:NKI;ZQEM)(Y&AN';+QA@/,(4YPN>M>@&U?Q3\0-"UV M"TO+:QT6"X_>W=L]NTTLRJ@0(X#84!B3C&2,9YQW%%`'D,-MJ6F>'/B3HCZ- MJ4MYJ5YJ%U:&*U=HYHYHL*5DQM+PF>Q ME6&9X[:2-AYA7:`6/!)`/8G(SW'@"XE;P9I%G-I]]:2V5A;V\GVJ`Q9D6,*P M4-\Q`(ZXP[ACTZ9I(5MTV2;EVY')XS]X21G'=44`>+:;%=:+X#^(&DGP[K$ M4FH:A?BQMX=/D<%)8PL0&P$8X/()4;>3RN6:G?7,_@[X=V$6@^('N=(O]/GO MD&CW(\I84VOR4PW)XP37ME%`$<$RW-O%.@D"2('421LC`$9Y5@"I]B`1WJ2B MB@#R/6X=5UVU\:6>N:3J]U>K]IBT:WB@?[+Y/ED12`CY&DSR=Q+#@*.U5-.& ML^&[WPKXH7P]K%Y:P^'HM&O;6"V)N(W7:^X1-AB-WRYX^Z>V"?9Z*`/-?%T/ MB'Q3X1L=6M=$GMKO3-8AU*UT^9E$\L4?9ADA7)9CMST`[\5M:;XVO-0AN;^3 MPMKEAIUM"2PNK-OM,LI8!5CA3?_!I;BS^'&GZ5>V-] M9WMF9/.CN[22'[\LC+M+*`W![9QWQD5PTFF:RG[/MQX-70=4?6+>79)&MH^P MC[6'#(Y&'&"/NDXY)P!FO>:*`/'O&%M=/XZT?Q;>^"+S6=(FTPV5QI[V:7,] MNPD9@_EY89.1@YZ9!(/%6]5T34K_`,%6>H:+X7ATIK#7(=6M](B@6"66*,`8 MD53CS#R<>@4=17JU%`'EWB#4KW4_'_@G6M/\.Z[<6E@+W[0#9-"R&2-4"D2; M0,'N2`><$X./4:**`*6L2WL.B7\NF1+-?I;2-;1MT>4*=@/3@G`KQ[4+*\U' M2O!VJ3Z/K]UK=MK-G<:M<7-G*6A"EC(J)C_5@X(\M=N`,G->W44`>8^#M0F; MQ_XYUF;1M:M;2\AM)[?[3ILR-((8BK@#;RV2,*.3V!Q7)^$[#6M.\.>!]0&B M:J;CPU<7:W]E)92QR&*Y9P)(PP'F%1SA@((SZ7110!D>*[&?4_!VMV%JNZXNM/GA MB4G&6:-@!^9KR_4FU.Z\#_#^UMO#NLRW&BZC8/>Q&S=&3R8V#`;@-P.#AA\O M(&X@"D,R@9X^Z>?;@X^AJY;Q]X4 MO?&GAU]$@U6'3[6<@W#-:&9WVLK*%.]0O*\\'/'3N`8^NBX\;:SX:M+;3-0M M8=-U&/4[R>[MGA6,Q`[8E+`!V+-U3*X&(%AT'3Y(;^3^R;@A&>U1!C"9;#`@X':NH M\--?^$/$/B;3[[2]0N(-2U*34K&YM;=I4D\P#,;,.(R-H'SX'OBO1**`//\` MX-0ZA8?#NPTK4M)OK">TWY-U&$$F^1W&T9W@444`>:>,;Z1/B MMX0NDTK6)[321=_:[BWTV>6-/.A"I@JAW<]=N\73-42R71 M&TX7)(?#$^K6>GS3_:]+FMUDD>.0*H;R M^!KG1H-1M&LK2T@TG9=SR&.0%I4B M!VH-P`+8Q\W/S`52U[2M3UKX-^%X['1KFYO-#ELI;K3;RT>-IO*BVNFQP-Z_ M-VR"`1R>*]CHH`X+P.UK>:K)>:=X#'AJV2V,&)[':3YL;RHKXP1@A2Q#9`4C)X%:3KD=_ M>!-+F94B6>8G!"\G#*<#UKM/%.J--\3?!>HP:3KDW#!!/"H08 MV9)]0!D=#R"!Z?10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!65XCN/L^BS%=;MM%D.-E[+=-&&VGJ,C@XZT`=[-J=A;7<=K/?6T5 MS("4A>55=@`6.`3DX`)^@-5?^$DT+[`]_P#VUIWV-'\M[C[4GEJ_]TMG`/M7 M$>+M+T\_&;P%-]BMO.N?MYN'\I=TNR!=FXX^;';/2G>%;"RD^+?Q%$EM"R*+ M$`,H('F0$R?]]$#/K0!WMQJVFVEBM]695C92,@AB<8QS31K6E M&\GLQJ=F;JW0R30B==\:CJS+G('N:\(NK:WO?V4+:\NH(IKJV!6WFD0%X@;W M:0IZC*@`XZ@5W?BS3K$?%GX>0BUA$;+?JR!``52(,@(]`W(]Z`/0+#4[#5;< MW&G7UM>0JQ0R6\JR*&'494D9]J9!K.EW.H2Z?!J5G+>P_P"LMHYU:1/JH.1^ M->:PW<^F>)OB_+8?(]M9V]S"J#I*;1V+#'$O$NH:[\(;'6-3\0VNEZC=&4G4)XXPB;9W&-IPOW%V M_KUI?!2VNO:OXZ.JP137@U:2RD65HX.!S7FEJLL.G6=K*8_P#1OBZ2:[I$.EIJA[UE^,=1OX/ M`^H:OH&HVT4EM:R7:3&(3K(B(6PO('.!\W(]JY3Q+=WW`S#;23JLDG^ZI.3T/2O.KW09=2^#OA?5=.B!U MK1M.M+ZR8+DL4B4LGN&7(QZXKH?"NJVWC/4?^$FMU_T2"U2WM=W)61U62;\L MQI]4?UH`K_%?6-=\.^![K6M#U"&T>T*^8'MA*S[W5!M).%QN)Y4Y]N_66^L: M9=W\UA;:E9S7D`S+;QSJTD?^\H.1^-<9\;?^20Z[_P!N_P#Z41TWQY:Q6?B# MP+)I<"1:BNKI`@B7!%IL;SEX_A"X]J`.UN]9TNPNX;2\U*SM[F?_`%,,TZH\ MG^ZI.3^%7:\4TRTG\6W/Q%L+G5M*M2VI3PW'VNP:::.W0!8G5_.0!5VDCY3@ MC/.<5ZYH;^9X?TV3[6;S=:Q'[28S&9LH/GVGE<]<'D9H`KZ[J4-M;BRCUO3] M,U*Z^6U:[*MN;/9"RECVX/7UZ5S'PZ\=6^K>#-$G\0:Y8+K6H&0K#)+'%)+^ M_DC0*G&?NA1@8OBF%0^!D`W$Y(SZ<#\A0![E:Z[H]]J,^G6>JV-Q?0;O.MH; MA'DCVG:VY0%_(56\*Z:+WPKX'U<^(-*MX+.>#RA;:8 M_GR2N-DD+OYQR6+'QUFVOB+1+Z_:PM-9T^XO%SNMX;I'D&.N5 M!S2^(#:#PWJAOYI(++['+]HEB.'CCV'0,D5Y)JWG#1_AK=V5C#8Z2FLV M$-AYAWW;PNK?,Y7"KN49*C.2021R*`/6IO$.B6ZW+3ZQI\2VI43E[E%$6[(7 M=D_+G!QGK@^E7DN(9+9;E)HV@9!(LJL"I7&=P/3&.S00112/'?QL44#*K`-H^@ MW'%=!\1;&TOOAYX@%W;0S^1I]Q/%YJ!O+D6)MKKGHP[$4`:\6OZ-/=PVD.KV M$ES/&)8H4N4+R(1D,H!R00001V-+J.O:/H[QIJ>K6-BTGW!W`S#;23JLDG^ZI.3T/2O'?#VC7. ML?`/0-7L5WZYHS2WEB^,L?+GDS'[@J,8]<5UMKJVE^,M,U3Q-<220Z/!I36Z MRH?WD6^+S+AE./O*"BY`X*-ZXH`["U\1:)?7[6%IK.GW%XN=UO#=(\@QURH. M:X[P[XJOK/Q?XPT[Q5KM@+32VLQ!,Z):QKYJ.Y'))S]TV@G^,'Q%::&.0A M-.3+J#\K6YW#Z'`S]*`+7Q2UW6-%\`SZ_P"'=4MX1`$8MY"S>:KNJ*48G:,; ML]&SQTKL;_4K'2K8W.HWMM9VX.#+<2K&N?3+$"O#-5W)^S_XRACXTV+6I(], M]/LPNH]NWVW;ZZ[Q+=W03C..H-=50`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5B^(_"FC>++6.UU MJWEN;>,EA$MU+$A/'+!&`;&.,YQSC&36U10!S$?P^\.Q:K8ZIY%_)>V)_P!& MFFU2ZD,0]!ND(VGH5Z$<$8JS;^#=#M-2U74(+>YCNM61DO9!>S_O0?;?A2.0 MI7!4'"X%;U%`''-\+?"+:,FCM871TU'+K:?VE<^4&)SG;YF.O/U)]36I<>#M M$N]6TO5)X+F2^TM!':3&]GR@'K\_S$]&+9+#ALBMVB@#"L_!VAZ?KE[K-M;3 M+?7Q)NG:[F99LYX9"Y4@9(`Q@=L52TGX;>#]"UG^U]-T.""^!)60.[!">NU2 M2J_@!7544`8EYX1T.^U9]4FLB+R1!'+)%-)$)E'\,BJP$@[88&LA_A5X+;2Q MIHT;99Y#-%%=3()".A?:X+XYQNSC)QC)SV5%`'//X'T!Y;*9K6X-Q91F&&X- M[/YPC))*-)OW.O)^5B0,XZ5`?AUX4,<\8TD(DUS]K(CGD39-D'?'AOW;<#E, M=!Z5U%%`'-:Q\/\`PKKUA:V6I:-#/#:Y\G#NC)DY/S*0QR>3D\GD\U++X)\/ M2^&8_#@L&BTA#_Q[6]Q)$&ZY#%&!8'))#$Y/)Y`KH**`.2GDM_`.F6>EZ%X? MUG44G9E@AMW>=("```[RN?*3IC'`P3CUU_#.BIX?\.66F*L8:),R^4NU3(QW M.0.P+$XK6HH`K:AIUGJUA-8ZA;1W-K,NV2*5 M>$=#OM6?5)K(B\D01RR1321"91_#( MJL!(.V&!JE!\.O"5MHSZ3!HL,5F[I(P1W#EDSM;S,[\C)P<]SZUU%%`'.CP) MX9.J0ZG)I4<]]#&(TGN)'F?`)8$ER=S98_,74]Y9S6L,5I;/.[.\;`9"`X'J3@?B172T4`.-H;]9XUAG$8#ND4AV`DDG>J\DGG.:Z2Y$Z'=:U M)J\MC_ITR".9TF=!,HZ"158*X&!]X'I6W10!QTJ6'P]LK:P\/>&-4O/M;,L< M5GF6.)L[@)'=OW:%G8^@RQQ6MH/AVVTKPG;Z'-!!)%Y+)3$V[J21Y;;\H,G.%('M5B[\$^'[ MR\%X]BT5QY0@:2UN)8#)&!@(_ELN]<`##9XXKH**`,#6?!7A_7]+MM+U&Q9] M/MAB*UAN)88P!C&5C90<8&,YQSC&35?5/A[X7UO3;2PU33&O(;0$0-/1[$XX`["NGHH`Q5$:%'X:_X1V/3TCTG`'V>-V7HP;.X'=G(!SG)[ MUM444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`5F:WXATSP[;V\^IS21IU:=03V=O=2VTL\2R/;2>;"6_@?:R9'OM=A^-`'--\2?#* M27L;3:BKV*JUVITB[!MPPRID'E?*".1G&11-\2?"T%U96SWEV9KZ))K1(]-N M7,Z,H<%-L9W<$9QTZ'!!%97A15?XN?$=6`92--!!&01]G:J7B]5T7XC?#:+3 M].EN([6/4(H;2V*!M@MT4!3(RKP/5AP.YXH`Z[Q!XUT'POP/?A#;+_9UPQD+=$P(SA_] M@_,.,CFN-^(6JWE]<>#(KCP_J6GH/%%BPENI+=E)R_RCRY7.><],<'GIG0^+ MRM/L3WP:_$3EY8Y8@A M0QNZC;NSSSG:1C'/74`\34)1F*&/3[B4R\9^0I&0^!UV MDXY!Z5-9^,M!O=1CTY;UX+Z09CM[RWDMI'_W5E52?PKG/%O_`"5[X=?]Q/\` M])UK0^)^EVNH_#W6);@*LUC;/>6TW1HI8QN4J>H)(QQZT`:6N^,=$\-WEK:: MK/^#7XB><[2,8Y`+$ MWC_P]!K<^BM+J#:E""SVT6EW4C[0<;@%C.5ST89!R,&M+1_$6DZ]YPTV\662 M`@30LC1RQ$]-R,`RY]QVKA]2O9['X^K);Z9=ZB[>%]IBM6B5@/M1.X^8Z#'& M.N>1Q3?#6H?VG\8]3OKVVFT:Z.EI:PZ==+MEN5$FXS9&4;'W?E9CU]*`.CN_ MB1X7L8[Z6XO+M8+"=K:ZG73;EHHI%;:5,@C*YW$#KW'K5_3?%VC:MK+Z1;2W M2:@D!N3;W-C/;MY88+N_>(N1E@*Y7XQV=O9?!S7XK:)8D>2.5@O=WND=C]2S M$_C75^)F73=%U/7K>W1]2L=-N#`^W)QMW[?<%D7\J`'7OBK2+"ZDM7GFGN(@ M#+%9VLMR\6?[XB5BOXXJ>RU_3-2TZ:_L;H74$`;S1"C/(A49*F,#?N_V<9]J MR/AS:PVWP]T22,[Y+NUCN[B4G+232*'=F/1>'?&+>$+#QQ>2:)?WELGBF\W M7,+1B&-F9%`Z@`?F:`.MK%UGQ+;Z1=1V26=YJ%_)"]PMG9(K2>4A`9_F91C)`'.23@`UM5 MY7<:7>S?'R6*/Q!J4#OX<,RRQQVY:-3=8\H!HB-@ZY(+<8A5A@D$$'H001^%:%>3Z?K?B>Z^'_C6YD\1SC4=`U.]C@NUM M(,R1P1@A&39MP3DY`SGOCBI=7\2^*K?PW\/]4M-5ME_MB;3K:[C>T4M(\R[G M8MG`4XQM501DD'I@`].DN8(988I9HXY)V*1(S@&1@"Q"CN<`GCL":P[/QCI] M]XQN?"\=O?)?V]NURS36YCC9%=4RI;!8$MP0,'!YKB/$FEZQ'\4/!%M<^*+Z M0W$NHO%+%!`A@40@@`%"K-ABI9@>.@!R3=N;>ZD^/206]ZT+_P#"*!7N"BM) MC[3U`QMW9QU!'7B@#TNBO)X_B%JUCX0O4NIQ<:K#XD?P_%>?92Q8[N)3%&/F M8)GY5')`&#WW_#FL:W=:[J>DF;4;FT-F)[+4]1T>2V\N7)5HW!2,/C*L`,$C M(SQD`'72KJV>9]*TV"&&<7-O&N1)(-K.-Q!R05"]ZTK M7Q9>^)-2T'1[*?\`LZ:_T1-9NKB-%=T1MJJD8<,H)9CRP/"].0!N;A5R2`-Q&2:Z"O*?B9;ZW:_!+Q%!KUY;WLZ3 MQ"&XA389(?M$6TNN``_7.WCI74Z9-?\`B76I-7T_Q'<1:#$XBCM(HH&\Z1&( M'[KQ%'&-,6U^SW%K8QJ4:5&?A M7W#'0$-G[HP1DU!H7C[4]=\,^"HD>*'5O$#SQR7!C!");[O,=5Z;CM&,\`MT MXQ0!Z?17")JFM:)XYM?#.I:M)?6>LVTSZ?>M!&D\$L8RRG:H1AM.X';UP"#6 M%:ZQXH72O&FFW7B2[?7=(NT6SDCM+?,B2+^X79Y>"79@#^&".<@'JD\RV]O) M,RNRQJ7*QH78@#/"CDGV')K&\+^*[#Q;9WES80W426EV]G*MU%Y;>8JJ6^7. M1]X#G!R#Q7)>&==UGQ5H/@]K?7KB*[N$EGU.1(("72,[6!!3"GS"BC`'&[KC M--\!:C'I&C?$/4Y@6BL_$>I7#@=PBJQ_E0!Z9574K^/3-/FO98KB5(ADI;0M M+(W..%4$G_)Z5YMH?B_7[N;PYJ&_4[Z+5)$%]9KHDL<%HDBDJ\-80Q+`DGGSHJES*6!.S+!0%*G@G/:@# M?\,^(K+Q9X>MM;T]9EM+DN(Q,H5OE=D)(!/=3CVK7KP_P)K=_8_#[X>Z/:71 ML(-6N;R*?4!&K&+9)(RHN\%0SG@$@]#P:[OP?KFLW_BGQ'H]]>6]Y9Z.\<4= MTMMMDF9UW_,ZMLW+RK!4'.#QTH`[6BO(+;X@:WJFEQ^(]-;5+A7O2$TFWT66 M2&2U$NPD3B,YDV@OD/C/R[<\5MZ]XLDM_%UYHTGB'^PKV,(VFQ7-LAMKU2@) M+NPSG>2F%9?N]\T`>B45GZ%_:/\`PCVF?VO_`,A/[)%]L^[_`*[8-_W?E^]G MIQZ52\5S:W#IMN-#,,9;>WEG=9&6-"Y6-"[$` M9P%&23[#DUC>%_%=AXML[RYL(;J)+2[>SE6ZB\MO,55+?+G(^\!S@Y!XK,FU M34=?\::EH.F:FVFV^D00O=311))+)+*"R*-X90H555/FE&`2JG)R`.HZ?>ZX+\ZK?Z39Z<=0A MOKW2WLV!3/F0G,:*3@*PPO0GK@T`>@T5Y9H?B_7[N;PYJ&_4[Z+5)$%]9KHD ML<%HDBDJ\)[>2:*TT>[MHA% M.H)$31NX!9V7##+$9."N!0!ZI44ES!#+#%+-'').Q2)&<`R,`6(4=S@$\=@3 M4M>:^.;:YN?BMX"A@U2\LQ,+_!@$9\MEASN`=&!)#%3D'CI@Y-`'I5%<;_:6 MI:YXNU7P[8:K+81:/;0&XNHXHWFEFE!9?OJ4"A5R<+DEN,8I_@G7]1O[[7-` MUIXYM4T6X2-[B./8)XI%W1N5Z!B`<@<4`=?1574HKV;3YH].NHK6[88CFEA\ MU4.>I7(SQGO^?2O+-*\0>,=3^#B>,TUQ!?V\<]RUO]DC\J:..1]ROQN!VKP5 M*]!G))-`'KM%<'=Z[JFI+I6I?VDN@^'+K2TNVO5,+3-<28*PA9`W&TYX4D]! M7,KXE\8:U\/M6U32M8E2_P!`U*XMIBEG&IOH8]I+%'0['"DD``Q45 MQS:C;BN%;YNBYY`ZBN4\+VEW+\8_'3?VQ?+';O8$Q`1%95:)F"-E"0JY(&TJ>>2 M3S3-'M-0O/BM\1X;#4CI[%=._?I$LCAOLYVX#@KCKG(YXP10!Z?17DME\2=0 MU#P?X,9Y)(-0UUITGN;:S:X=$@W"1DB16RS$#L0-Q.,#CK?!.L:KJ$NKV>I) M?2Q6U8GA_QIH7BFXN(='N;BX:WR)BUG-&J,"`5+.@&[G[N<]>.#6_7 MG_PL_P"9U_[&N^_]DH`]`HK`\;>(_P#A$O!NIZX(EE>UB!C1LX9V8*N<=MS" MN:TC6_$)\1VNGK=:G?VU[:2^9=7FA2VT=E8V^8;22<@#=S0!Z)17 MDFGZ[XOO?!GC74)O$"I=Z!?WD4,D-G&!(($4E65@?E//3Y@6^\0`*Z*[\77M M]IO@^UT]X[34O$T2S"5DWB"-81+(54]6P0!GC)YS0!L6?C'3[[QC<^%X[>^2 M_M[=KEFFMS'&R*ZIE2V"P);@@8.#S70UY*T]UX=^,NI7NJ7SZA'9>$9+A97C M5)&B6XW8;8`N[(;D*.,<5/H?B_7[N;PYJ&_4[Z+5)$%]9KHDL<%HDBDJ\:Z->>,-6\7^+=`F\200G2S9M!<0Z>@`,BER-C$Y4 MC@Y8G@$$,^'D2&*.-=SRR.=JHH[DDX_P#K54T'Q/;: M]Z?(J7%M>1A77<"5(*EE8$`X()KC_BU9W$MQX/DCU.[@1_$5E" M(HUB*HQ+GS1N0G>.F"2OJIK3MKS5=5\3:IX9M->NH4T:WA:XOS#`UQ-+-N=1 MCR_+"JH'1,G(Y[D`[BBO+V\4^)AX<\7V+ZA:Q:[X8W2R71M-RW,'E-)&=FX! M';;SU`QTYXZ;P6VN:AHVD:UJ>L"XCO-+@=[46R*!*RJWF!A@\@\KTR>,#B@# MJJ*K:C)=Q:9=R6$*SWB0NT$3MM$D@4[5)[`G`S7F,_BO6=#U+PPEUXA&H7U_ M?P66JZ:((C%:O*#D+)&H*E6XPSL2.>E`'J]%>?'4O$S_`!(&8(`"V[+#'4_*F,&77?&>H>!M;O-.UJ0:EX",5#>:UX@T\>%_#M[-O+"JPV\YV@]JP M](\6:KK]U:1Z9XAVZNMY"NJZ%=VT4;V\8E'G"$D`L%7())9(9HY&A?RY0C@F-\!MK8Z'#*<'L1ZU+7D_@%=4L['QYJ-OJ%]?W%GK>H+% M92"(K>(=8TR71/%0U;3O,9^%[2[E^,?CIO[8OECMWL"8@(BLJM$S!&RA(57-A#=1):7;V,Z))J]GX8^)6I:7J MGV%[#7M2ND"P)(9&158JV\$;2`!Q@]\]JZ/6?'5P-*\');M):W'B.(3O+;VC MW,D,:PB1]D:ABS?,H&0P`))!Q0!Z'4<\RVUO+.XD*1H781QL[$`9X502Q]@" M3VKEO!.L:KJ$NKV>I)?2Q6=Z1K?B$^([73UN MM3O[:]M)?,NKS0I;:.RN5`*GF./,;?,-I).0!NYK(T_7?%][X,\:ZA-X@5+O M0+^\BADALXP)!`BDJRL#\IYZ?,"WWB`!0!ZW7/>'_&.G^)-5U73K.WOH9],, M0G%W;F$_O-Q7"M\W1<\@=16'#XJO_$E_X=TC3[H:=/?Z.FLWDZ1J[QQ-M4)& M'#*"68\L#@+T-8WA>\GT'QO\4+[5)Q=O8P64TDJH$,B);NP)`X!V@9QQG.`. ME`'JU%>6:'XOU^[F\.:AOU.^BU21!?6:Z)+'!:)(I*O',8QE5)4%B[`@Y&!S M5G1KSQAJWB_Q;H$WB2"$Z6;-H+B'3T`!D4N1L8G*D<'+$\`@CG(!Z51110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11 M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%0 MW5W;6-L]S=W$5O`F-TLKA%7)P,D\#D@4`<5X8T#Q1IWCS7]3&47`:(!\Y&>5]?:CQ-H'BC4?'V@Z[IT&CM9Z+Y_EQW%Y*DD_G1A&S MMB8)C''WO7O@=W10!Q'C_P`/^(_$5SH8TA-*%OIFH0ZDSW=S(C221EL(%6-@ M%P?O9S[<29/M5Q;ZC-+,(=P+B/]RF&(R,YXS^-=;110!PO MB70/%&H^/M!UW3[?1VL]%$_EQW%Y+').9HPC9Q$P3&./O9Q[X$NL^'?$7C"- M-/UR>PT[12X:YM;"5YI;E000AE94VJ2.<+D],UVM%`'#^.?#>O:Y/X?BT:#2 MDLM)U"#4#]IN7C9VB)Q&%6-@%P?O9_#CFWJ,_C73_:[;[9]C^T1?:O+\WR-XW[,XW;>N,\9J:@#@)M M!\7)\3I_%4%IHDMM_9QTV*WDOY4IZU=A\-ZSJOC?3_ M`!)KSV-NFEQ2I9V=E(\OS2#:S/(RIGC@#;[UV5%`'&_$SP]K?BWPC/H.CC3U M%V5\^:\G=-@1U<;0J-G)7G)&/?/'3V8N[G3575K:VCN'4K-%!*98NXX9E4D$ M>H[XYZFW10!R.E:)KOA.S_LS1!8:AI:,3:Q7UR\$ENI.=F]8WWJ#G&0"!QDX MJ>S\/7RZO/XCU)[:[UH6QM[2!"T=O;IUVAB&;+'&Y\9QT7`P=Y=1LGOVL$O+ M=KQ4,AMQ*ID"@@%MNM`$U<(-`\4?\`"UCX MH,&CG3_L/]F"+[9+YHA\W?YG^JQO_P!G..V[O7=T4`><_P#"$^(+73?&6D64 M^FFRU^>ZNHKB61Q)$\R;2C($QMR!\P;(&>#5*^\%>-)]#\):4DN@S1Z!=6UU MYAEFB,GD#:J8V-VY+9&<_=&,GU.B@#C_`!%X=UG4]?\`"WB"R^P)>Z1Y_FVT MTK^6WG1A&VN$R=I'&5&?]FJMCX>\3?\`"TO^$GU`:2;+^S#IN+>>3S-H?S!) MM*8R6'W=W`/WFQSW5%`'CS_#+Q3?:/JUG.#SG\.X[:D M)`!).`.I-06>H66H)(]E=V]RL3^7(89`X1\`[3@\'!!Q[B@#@CX*\0QP^,[* M.?2Y8O$+SNE[,TGGQ+(A18F4+@JHX4[N.3M/2JB^!/%6GIX>U;2+S1XM>TK3 M4TN2*X\Q[:>!5`&6`#9W!FZ#J!VR?4**`/./%GA/QEXC\!7.A27NE7%[J,PE MNII'DABMU5D98X5".6&4ZL0>3USQ-:^'_%FF>+7US3K+18HKZWQJ5@-2E$4M MP&.)E/D'!VXSQSDYZ9/H-%`'">'=`\4Z;XL\5Z]>PZ/NUB*$P0PWDC>7)"A1 M%8F(?*0>6`R,?=.>,#1/AIXBL/#&@6LL^F0ZMX.=9'9I8Y08U M*`@@97=]!W]:I"0`23@#J30!S-KH6HZCXGLM?UU+.&73X)(K.VM)6E56DP'D M+LB$DA0`-O'/)SQ%<>#?.^(\7B83*ML+14FMQG,LZ$^6Y[8"NWXA3VKH;?5- M/NH)I[>_M9H8&*2R1S*RQL`"0Q!X."#@^HJ2TO+6_MEN;*YAN8&)"RPN'4D$ M@X(XX((/N*`.6\*^#I?"DOB&YMVBN)+VZDFLH6D*I%&,=< M8K,\+>#=>M-,\4Z5KXTS[)KUQ=73RV5S(SQM.H5DVM&HP!DYSGVYR/0Z*`/- M_"GA3QWI$.G:+J6MZ8^A:?(K1R6JRBZE1#E(V)PH3@`CG(XY!K3T[PSKGASQ M!K,VBS6$VF:O<&\>.[=U>UG8?.RA5(D!X."5Z8S7:U#;W=M=^;]FN(IO*D,4 MGEN&V..JG'0CTH`\0A\)^*]*M/#7@F'4?#E] M0A0%'//.WCM?#3^+M`UBPTC5]'\,PZ7=EUC.A+)&(7",^61OX3MQD#JR\\UU M.K>%]'UN[@O+ZSS>0#;%=0RO#,@]!)&58#KQGN:L:=HUEI>YK=)6D8;3-<3R M3R$>F^1F;'MG%`'G6@^`_&WARWF\.Z?KNFIX9DF9DF*RB]@C8Y98R,*">?FR M<$Y%;VL>&=9U.^UB.[MM'UC2+V9&MK74))%-IB)$9E(1NK!CL&WUW`L<=M10 M!3TFQ_LO1['3_.>?[+;QP>:_WGVJ%W'W.,UA>//#E_XFT:SMM/GMEDMK^&[> M"ZW>3'O%X\=?\`"56::&9FTG^SA;2W$JK' M^^$F=PC._C/.%ZCCCG&/PZ\3?\*1'@;?I/VWSL>?]ID\ORO.\[/^KSNW?+MQ MC'.>U>EVVM:5>7TUC:ZG93WD/^MMXIU:1/\`>4'(_&KU`'"VWAWQ+I_BN?Q- M:+I?VC4X(XM4L'NI/*WQ_*DDIO`OAC7?#5WKAU*\TZ:VU' M49[]5MXW#AY&'4DX`POW<'D_>XY[,D`$DX`ZDU!9ZA9:@DCV5W;W*Q/YY:UGN;:2&.=>L3,I`8>X)S^%>>/X%\3 M2>&/"NE*NAPGP_J%M=XCED`NO*W98G9\C-G)&&R23D=*]*DN[:&YAMI;B))Y M]WDQ,X#2;1EMHZG`Y..E34`>0:AI?B3Q/XRUF\TM?"6LVMH8;)TUJVD=+:>- M-TBQ`9_B%/'>D0Z=HNI:WICZ%I\BM'):K*+J5$.4C8G"A.`".5F01_*=S*I&/F0+@#Y@.?0J*`"N2\4^' M-3U+Q/X;U[2GM#/H[7`:&Z=D5UFC"$@JI.1C.,<^HKK:*`.*E\+ZUIOC*7Q/ MHTMC<3WUJD&I6ER[P1RN@`61&57*D`8P0>#UK6\.:!)I=UJNJ7TD4FJ:K,LM MR80=B*BA$C7/)"J.IP223@=!LQW=M-#5#P[X5T?PI:/::+!-;VSD' MR6NI944\_=#L0NYXZ4`IW- MM<-/9RWTASW&T^E=W4=O;PVEM%;V\210Q*$CC0855`P` M!V%24`&]8TSXA:YK=K-8M8:S]E,WF[_-B\E"A55`P=P/WBPQZ&JGAS0/ M%.F^*_%>NWT.C[]8BA:"*"\D81R0H416)B'RD'E@,C'W3GCNZ*`/&;'X8>+[ M+PUX>M[>^TFUU?PY/+)8W"3221SK,Q:19`8P5[#C=D$]._H_AFQ\0PBZO/$M M]:37UQL406.\6\"+G&T.<[B6))[\#L*WZ*`(YS,MO*UO'').$)C21RBLV.`6 M`)`SWP<>AK@/">A^-/#":T'L=`NGU/4YM1)74IHQ&TF,KC[.<@;>O%>AT4`< M1>^#]6\2>`-8T7Q#?P_VAJ4K2[[=G>&##*8U3=@[1L7(P.2WKFF>'M(\?V[6 MYU_4])N(]/A86T5F\L9NY-A5?M#D8"C/93S@X)`KNJ*`/--+\&>*;7P=XTTN MY_L6AN%VN&S%D;0,C`.YZ*,]2? M2IJ`/.-1\$^)-<\87&L7EQI-K:7NBMI%S!&9)F6-W+/M8A,GD88@8S]TXR4\ M*>%/'>D0Z=HNI:WICZ%I\BM'):K*+J5$.4C8G"A.`".`0QLJX#1*'SD9Y7N?:NZJO9ZA9 M:@DCV5W;W*Q/Y(O$5WH0TA-+%OIFH0Z MDS7=S(C221EL(`L;`+@_>SGGIQRLGAK6[#QA)XJT@6#7.H6D<.IZ?<7#K$70 M#:Z2K&22`"O*O%`'':AX0UI_#WB7[*=.EUSQ'F.[DFE>.&"+RC&JIA&+;5XY M`R6)X^[70^#[#4M)\*Z=I>JQVBSV-O';!K69I%D5$50WS(I!.#QS]?3%=*5=#A/A_4+: M[Q'+(!=>5NRQ.SY&;.2,-DDG(Z5ZA10!PUEX>\3?\+3_`.$GOTTD67]F'3=L M%Q(9-H?S!)M,>,EN-N[@'JV.5\">'=?\/S:\FLQ:4UKJFH3ZCNMKEY&1Y-N8 MRK1J"N`?FS^'/';221PQM)*ZI&HRS,<`#W-8NJZ/X>\<:-%#>I!J>G>=YB&* M@T>SU.YMKAI[.6[EAT_/2.U21RJK[;VD.>X MVGTKNZCM[>&TMHK>WB2*&)0D<:#"JH&``.PJ2@#@M7\*^)K'QI=^)?"-YI2R MZC#'#?6VII(4)085U,?.<<8/Y^DVL^"]4U"QT&]75HY?$6C7#7$=S,A6*;>? MWD9`R50C"C&2`!UKMZ*`.8M="U'4?$]EK^NI9PRZ?!)%9VUI*TJJTF`\A=D0 MDD*`!MXYY.>,2P\%ZS.F@KX@32KJ^TQH9#K44DGVIMA!,>"OS`XVER_().T$ M\>A44`>?V/A#Q)I5KXNLK"]L8X=8NKR]MKD/(LT%'`^3:P!W@L?8'FKU MAX5O7\36&LZG:Z5'>V2L'U"R+"6^RA3$B%0%7G=C<_*C!`KLJ*`"N+A\.:]I M7CGQ#KNFMILUOK"6S,ES(ZNC0QE-@VJ1AL_?R=O]UNE=I5:34;**]BLI+RW2 M[FSY4#2J)'P"3M7.3P">.P-`'GNE>#/%-KX-\9Z5<_V.;[7KJXN8GBN9/+0W M"A7#9BR-H&1@'.<';UJ"\\!>*;GP[X5:VO-,L?$'AD"*UD6626">/RT0[LHI M4G9R,'C///'ID=W;37,UM%<1//!M\Z)7!:/<,KN'49'(SUJ:@#`\,V/B&$75 MYXEOK2:^N-BB"QWBW@1^#CT-25#]KMOMGV/[1%]J\OS?(WC?LSC=MZXSQF@#@O">A^-/#":T'L= M`NGU/4YM1)74IHQ&TF,KC[.<@;>O%7+WP?JWB3P!K&B^(;^'^T-2E:7?;L[P MP893&J;L':-BY&!R6]Z]=7%S"T=S)Y:&X7:X;,61M`R M,`YS@[>M>DR21PQM)*ZI&HRS,<`#W-16EY:W]LMS97,-S`Q(66%PZD@D'!'' M!!!]Q0!YWIG@KQ-IDOA_5H&TI=6TK3UTF:#[3(8+RU4#:2_EAD<,"<;6'3GM M5BT\$:[-XD\67FI7FFKIWB.W2">&!9'D15@,8"L=H&-QR<'..BYP/0Z*`/-_ M"GA3QWI$.G:+J6MZ8^A:?(K1R6JRBZE1#E(V)PH3@`CG(XY!J]X7T#Q/IOCK MQ!KFIPZ0+;6C!O2VNY'>`0QLJX#1*'SD9Y7N?:NZHH`****`"BBB@`HHHH`* M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KD/B/XCC\,>%9K MZZ\/?VS8C'VB-WC$:?,H3<&R3EB,84XQDXXKKZ\]^,_VF[^'5]I%CI^H7U[? M&,11VEI)-@)*CL6*@A>!QG&>V<'`!J:SXTN=)\:Z5X=_L"XF&I^9Y%WYZ!6* M1[VPO)P"0#G;W(SCFQH7B[^T;S7K'4[2/3[S1'7[4JS^;'Y;IO20-M4X*@G! M`QBN5UC56UGXH>!KZTTC7/LED;M;F:72;B-8FFB"("60=QR>@ZYQ4%M:7.I> M.?B3I[V&IVT>O6T5I9W"3@]LY&0#J;7QAJ5X=*O8? M#=Q)HNIRJD-U'+NF16^Y+)%M^6,C!W;B0#R!TJ#2?&.MZIJ/B72?^$>M8]6T M3[/B'^TBT=QYH+#$GE#;\HR,JC^%KCPCJL-]8)%:W-W M/&JV@B3"ETDS\YV@8`'7OBI]-6\T+XI^+KF?3+Z:'5X[)K*6"W9XW,<11E9P M-J')_B(&*`*UO\69Y_#WAK6?^$8N?L^MWBV89+I&6*0RO'M'`9FQ&6^Z!R!F MNCE\2ZM%-#I\FB6T.K7,DYMK>;40(YH8MF9!($)R=ZX7;GKG@9KR'3?[7M/` MO@70KCPMXACN=)UR'4+EQITCH(1+*Q(V@G(#CY2`:](\=VEGX@DT6VU#0K^] MTF:&:Y>[M;>47-C(/+\M@!\P)W-E-I8D=/E-`'1>&M?GUY-3%SIDFGSV%X;1 MXI)`Y)$<;[LCC!\SCU`!XS@;EZANS)$9;F%90JHN#PK,20 M&88(&0,\9]K\2=1O?#NO:O!X79?[#NIH+N&:]53B)07*D*06&3\O3`^]SBJ< M^J-;_&^;5I-)ULZ;%HATXW4>DW$B&83[SC:A)7'\0!![''-9>B_;3\/?B4CZ M-K$4^H7]]/:P2:?,LDJ7"!(]J[IP.:`/6M.OX-4TRTU"V)-O=0I/ M$3U*LH8?H:EN)'AMI98X7GD1"RQ(0&<@<*"Q`R>G)`]ZY[X?SM)X$T6WDM;R MUGL[.&UFBN[9X&61(U#8#@9'N,CWX-=#/,MM;RSN)"D:%V$<;.Q`&>%4$L?8 M`D]J`.-\.>.-4\2-<_9O#$D0L]5;3KP27J9A"@;G'&&*DD%0>F""U9@OI#\>#?G2M8% M@-'_`++%W_9L_E&?[1N^]LQLQ_']WOG'-9VMPZKKMKXTL]I_%6QM]*CMIM*G\.K?PPS7;Q!D MDE3]XP","XQ@+TP2=PR16QX;\4V^H^(_%%OQQBN/\`"T>I:7XL\.ZG/H.KF!/"4&E86T8-]I1U9E8'&P=?F?:# M@\]"9]*CFUSQE\0[=M.UBRM_$5K#;V5U'I&\.2`2-<+H+KJV#:6J MFU?[,1M,:R^?CR]H7#'G/&`":;?6DNG?$'X=Z=;V&J7%KH-O-:W-ZEA,809+ M=8XSO"[2,@9(.%SR1@X`.R\-^)Y-:U/6M)O;%;+4M)F1)XXY_.1ED7*+ M^YO-2MO#VC)J9TQQ%=]HW[6/1/EYRQ`]ZB\/F]\$^(_$UIJ-AJ%QI^I:@^IV5U9VD MER"9/OQMY:DH1M4#/'O0!UOACQ':>*M#AU2S62-79HY(91AXI%.&1AZ@C^5; M%C:IKFJ_$ M[QCH]W;65UI5LMI`T,MT^V.)XW;*QF,J[.&^8$J.`,L!FL'P;JUQX4\/^.[C M3-$2YM--\0WTKQB<0*D*!,A/E.2JKG&`,8Y[5O:/\()XK`T3[:?AY\2DDT;6(KC4;^^GM;>73YE MDE2X0+'M7;\W.W6M[?L%OO";P4\PLS<[ M55>20#[`U-X=\1-K4NI6=U9_8M2TV<0W5N)?,4;E#(RM@95E.02`>O%>5ZMI M]_=>&/A]JJ^%KS5(M`A^R:EI5U8,)&W0QJ2(Y%^<#:<$`C./0X]"\#+!*+^\ MLO"*>&[&7RTBBDLDMKB8KNW-(JG[OS`*#S]X]Z`.OK$U;Q`UGJMMHVGVJWNK M7,33K"\OE1QQ*0"[OAB!D@#"DDGIUK;KSKQ6NJ>'?B18>,+;2+_5=/?3&TVZ MAT^,2S1_O/,5@F1D$X'MC\P#;'C-K7PY-J6K:->6-W'=_85LCAFGF+!4$3'` M=6)&&X'!]*CD\47$.NVN@>)=#AM8=55XK6>.Y%Q#,VW)BD!12K$=L$'H":Q? M%=OXB\6>$+35;31Y;2^TW5H=2L["X8++-'%T#@$A6)+';GL.]3:_)_PF-UX? MD@TW5;>UTF_75;N6YL)8G01*Q$2(5W2,S$<(&''K@$`K?#'2M.GTKQII/$]Y&+5X@8PJ^7M&T\8&!CTP*J?#37H/#OP-T&[EBDGEEFDM[>WCQNFF> MYD5$!/`R3U/09J7X>:M)I5KXNFO]&UV`W&M76I01OI5QNEBD*!=N$Y;/\/4# M)Z`DRZEH.IK>W.G7MC)&+B/S)CM4.H$@(<9`SZ$"I!!''O5:U\8:E>'2KV' MPW<2:+J$=5AOK!(K6YNY MXU6T$284NDF?G.T#``Z]\4`2>`=>\2:E/XJEOK2"ZBM=9NH%6.]8NC1H@6*) M&0+MX^\77EB2!5WPYXUTV3PYXDUJZTA=%BTO4)XKV-2K,\J*A=CM`!:I^!FNO#]_P"+K2_TK4E\_7+S44F2U9XS`RJ592/OD[2-J;FSVKEM,T;4 M/$_@GQ]H"Z=J=A>ZIJ]QJ5G]MLI8$DC+QLHWLH4$E,8SGG/0'`!W=WXUO]'F MTZ?7-`^Q:5?RI"ETEV)'MW?[HF3:-F>F59@/6H=.\=:MJVL:_I%KX6DCO](6 M)C'=7J*'\Q68`L@8*2`,8W`Y.2,5FZ_+>_$#P7!X1ED8!7^Z0H4DG(Z#-)X2OI1\1/'FKRZ5K$-G=Q6LUL\VFSQ^6QR48$JRY[X8$9K8KS[X,BX MM/AS8:3>V%_97MD9!-'=VDD/WY792I90&X/.,X[XR*]!H`YZ_P#$=S_;<^BZ M+I\=_?VT"W%QYUQY$42L2$4N%8[FVD@;<8')%<_J7C2]U7X?^)+G3;$6>K:9 M%<0WUM#,UG;/<- M!-"NP*R("P4@DY`/-9>I:?=6^B?$#76TS4/.\2Q?9;*RAM'EEPMNT:.Z*"4W M$LQW8P,9Y.*`-?X?:(EUX=\,:KJ.C:?#Y=Y&1XAO+KL0`G.<9? MEFY[GOJYKX?S,_@31;>2UO+:>SLH;6:*[MI(&61(U#8#@9'N,@^O!KI:`/.] M&U37-5^)WC'1[NVLKK2K9;2!H9;I]L<3QNV5C,95V<-\P)4<`98#-8/@W5KC MPIX?\=W&F:(ES::;XAOI7C$X@5(4"9"?*TYKK0/BCXRO;K2 MM2EM=22RDMYK:U:5"L43+(21QD'^'[Q_A!/%8&B?;3\//B4DFC:Q%<:C?WT] MK;RZ?,LDJ7"!8]J[?FYSG&=O4X'-`'5R>,;6Z\9^%K/_`(1\R1ZM#)/I^J2O M'E%\CS'V`989!53G;G/<#G3O_$]Y'?ZC!I>DIJ*:85%XJW8CG!9!(!'&5(;Y M67JRY)(&<&O.+2^N8]7^&,KZ#X@6+0]/E@U!_P"Q[G]T[6ZQ`8V9;YE_ASP: MU_$^C0ZMXMU2\N=.US2]1M)(XM-UK1[>5VN%\I&*.%R"`[,-S!5P-N[Y30!Z M+H6I_P!M^'M,U;R?)^W6D5SY6[=LWH&VYP,XSC.!4VHZ;9:OI\UAJ-K%=6DP MQ)#,H96YR.#Z$`@]B`:;I/V[^Q['^T]G]H?9X_M.S[OF[1OQCMG-.U&^CTVP MEO)8KF5(ADQVT#S2-DX`5$!)Z^G'4X`)H`\=^'OA_P`(3_!.SU75[>RM9T2X M,NI(!'<1,)9-I$@PVX#;@9].*U]%^(.MZ/X*\'S:WHEY>W&K2Q6C77FHGS/( MP3Y?O,QC4-T`.1\V2<)\(O"^CGP590ZOX4CAUNT+^?+J&DF.0[I'*$2.@W_+ M@<$XX!QQ5_XI3327GA2UM=+U2[-IK=KJ%P]I8RS)'"A8'+*I&>?NCGCIR,@' M07'BF]L(K>&_T8Q:G>7K6MC:172R"=0-WFE\#:H4$G(R,=#D9JIXUU"#5[C0 M]0\/.FL"W^TV<%M=I)'>("`VR1PF",Y(8`X!(S53QK9ZC-JWA/Q;I5I<7<>E M32-/:K$PF:"=`K,(V`;==)>;9<9NP9(T\TQAU7;\_(&0 M2O)XR!FMY?%MS!XNTW0]1TG[(NJPRR64WV@.Q:,!F21-HVG:<\,P[5Y>=/U0 M?LQ#01HNK'53-Y)M/L$WF`_:?.SMVYV[/XNF>,YXKL/%5U++\3/`>I0Z9JLM ME:Q74L\T>G3L(A/$$0,`F5;(Y4\KW`H`T-'\96DFJ^,'O?#[:3-HL,,]]*6C M>6=3&[KNV9!PBC'S'[V.,5=A\5ZFFM:/87VAQ1P:K(ZP7EM?">-0L+R_-\BG M<=F,#(ZG<<8/&Z?J=['XM^(VHP>']6?^TK.)M.6[TFX$5R\%LX*,"HP&.``< M%LX')`K0\'Z`-&\26K:!#K>FV,HM<-X9T:>/4=*U?2].UG0- M:NY(I=5TS[/(+"5&(,KY;*H=N2J[MP.!M')K<\/F]\$^(_$UIJ-AJ%QI^I:@ M^IV5U9VDER"9/OQMY:DH1M4#/'O0!+JWQ2BL_`:^*['1+J\ME8QW,;3)$;60 M.$V29).=Q`^4'CDXXR[7_'7B#0=2M(Y?"<(TZ\N8[:"^GU/8H9QQYBK$Q3G@ M]1GN:Y#Q3H6HZ?\`"37M.32=0GU3Q%JDFHI9VEJ\_P!G!FC?:[("JX1!WY). M,X)KTW6]-M/''@R[L&2>&*]B*H;B!XI(G!^5BC@,"&`/3G''!H`FN]7OXO%- MEI%KI\$\$T#3SW#7)1H%#`?E;5<7\-UU2]T'^V]<`_M*[1(2 M0V?W<(V`Y_VG\R3_`+:5VE`'(?$K1=,U3P+K-S?6,$]Q8Z?\LYK6&*TMGF=G>-@,A`<#U)P/Q(!@\2:#!X[\.6]S9O#0!D^&VT/P-X0O;ZVTV.-YM7NK5 M([:,"6X<7DL4,8)ZX&`,G`&?>MA?%UY8^)+'1]?T=+`:B66RNH+OSXG<#)C; M**4;'3@@]`37'W&@^)]2^%NE7!L\>(=,UR75I+/[HED6ZF8JO;!WY'KQCK6[ MK"MXYU+PVEKI^HVL&FZE'J5S->V>F0"#P#XBUR M]F\5W.LK:?8;/6;J*2;[6[&W$2(-B(8\%`!G.Y222=OKI67CN:>;19[O1FM- M)UN3R["[:X#.6*EH_,CV_)O4$C#-[XKGM$TK4AIOQ`\-R:;>Q7.KZEJ,UO<- M"1!Y8<`Y/&%R1W`'-9?@6W*0Z+I$_PQ6SUNRDB6YU6ZTN-80D9&95E MX+2D#@C/S'.2*`/:**R-*\06^JZIJ>G):7MM<:>ZJXN8?+$BL6"R1G^)"4;! M]JUZ`.0\8^(X]%U/0+6Z\/?;[>]U*WMXKN1X]EO.[$*0#EMR@,V0`.V[FFGQ MM?-X[N/"D?AV5;A+-KR&>:Z14D0.$#':&*J3GGEA@?+SQD_%2>=[KPK;VNEZ MI>-9ZW:ZC<-:6,LRI"A8'YE4C=S]W.?;D9987LFH_'(:G%I>KQZ>V@FQ6ZN- M-GAC,HF\W!+H,#;GDXR>.XH`V+#XA6MQX:N=2N[&2"]MM0;2I+".02,UV&"B M-&X#9)')QU]JT;#5-1U#5;O1=;\._9XFMO-6=)/M%M,A.TQLQ1+;S6 MVGNI/#>KZ7IMO`SNVH6Q2=Y`0=L<2EF8;=W;).``:`.*\'ZC<>%/"?CN^TG2 M;>ZAT[Q)?NUJ9_LX2!$4G80C#(`&%P.._&#TE[X_O;.S\(7_`/8<3V'B*2TA M,GVW#VTLXSC;Y?S@#OD9P1@<9YKPK#?:CX5^(FDG2=4M+S5KO4;NS6\L985D M29`J?.RA=V?X551GP'\N-2I$CJ-IP2H!(Y MS7G_`(9\1Q^&/V=])OKKP]_;-B/.\^-WC$:?Z4P3<&R3EB,84XQDXXKIO"DV MH^%M9\16FHZ-J;Q:IJ#ZI92PVYE!,H&879,K&RE0/F(7KSC!KA7AUB/]G8>% M)/#&O+JCL!&@L'<./M/G$_+DKAV%Y.`2`<[>Y&<WO[>%;4364J071@MW5T,A7:`3P"3@YX)R,@&VOQ$NH+ M+1=0OO#DRV6N/''IYMKN.21GD&Z-9%?8J%EY&';TZUW=>":!K%E9:3H$FM>' M/'MS!I2QSPQ/IZM96\H'$B-P[*N3MW,V!BO=+*\@U"QM[VUD$EO<1++$XZ,C M#(/X@B@!+VQM-2LY+.^MH;FVD`#PS('1L'(R#QU`/X5Y'\.O$FH>&_@MI&I# M1?M6EVOGM=2K8]V>?O8Q_%7+>)OB#K5_P#"?Q3J=I8KI.H:9J#:7-LO#(T>&C5G MC<*OS9DP.F.N>U7H-)N/"/Q&T:Y:SOKK3(?#":0MQ:VSS8ECD##<$!V@@=3Q M[UR]WH_B"^^'OQ$TA?#FI1W5[K4VH6^^-=LB>?$=J\Y9L(Q&`00.#R,@'MFG MR7\EJ&U*VMK>XRFZ@-3M/M*VEW;(6PBW41B=AQSM M/S*.V&`/'3IFY0!P^G>.M6U;6-?TBU\+21W^D+$QCNKU%#^8K,`60,%)`&,; M@9N;LJ[&RV.@Z9.*Q/"5]* M/B)X\U>72M8AL[N*UFMGFTV>/SEAB*/M!3);)&%^\>PX-+OS;>Z4<<2;`P(/4%,@\#V>H:LL,B3M/(MS]I=Y7/GO M\I0IA5'08=N`.G02FU?Q3\0-"UV"TO+:QT6"X_>W=L]NTTLRJ@0(X#84!B3C M&2,9YQ7^$45[I7@>QT#4-,OK6[L?/$[S0E(\F9V`5C]_(8'*Y'OGB@#T"O./ M%%C:0?&KP%=Q6T,=S="%3!5#NYZ[OZO#X89?[#NIH+J&6^4'$2J9- MI52"PR>.F!PQS@4O"FJ-%\2_&NI7&DZW!9:BMJ]K-+I-P!(((6#_`,&0?0$9 M/`')`K+T7[;_`,*\^)2/HVL17&HW]]/:V\FGS+)*EP@2,JNWYNWCYT/AV\ETAH]'UV:.WM[E[@>:KR+NCW18QM;!P=V?4#I3HO$C3_$>]T(> M'$@U.+2GN(+ZXE3,\0E"JN4#,J%B3R26PO["> M[CCTZ9G@6W39)N4+DVBC35NGTNX6/SC<;^ M24X7'\1X]\)?*:R1;BX-RMP\DTA\]_D\LJ`H'W5`<\` M=.W2:=XJO'\06FCZSH_]FSW]L]Q9E;D2A]F-Z-\HVN`P.!N&.]>=6'A[6K[X M`W7@M=)OH=6MDTWY-U&$$ MF^1W&T9W=_#_Q!KNH7'BF?5UM/L5IK-U"\WVQR;<1H@V( MACP4`&=VY>2QV^OHE>7^'=)OC:^//#5U87UO)J^J:A-%=&$B%89HP$?S#P>> M,+DCN`.:`->Z^(%Y:Z%#XE;P](WAR0"1KA;D?:$B)P)3#MQM.0>')P>0*[:* M6.>%)HG5XY%#(ZG(8'D$5YA:3ZM+\+7\&76AZ@NNK8-I:J;5_LQ&TQK+Y^/+ MVA<,><\8`)KK=/O[;PW/H/A%X+YV^QI##>>0?(9HXS\A?/#E8V;'H*`.EHHH MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@ M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`" MBBJU]J-EIEN;B_O+>TA'62>58U'XDXH`LT54CU33YFNEBOK9VLSBY"S*3`<9 MP_/R\<\T:?JNG:M"TVFW]K>Q*VTO;3+(H/IE2>:`+=%9MKXBT2^OVL+36=/N M+Q<[K>&Z1Y!CKE0P@N8HS+)#+E`&C M15/4=6T[2(!/J>H6ME"3@27,RQJ3Z98@4V;6=+M]/74)M2LX[)QN6X>=1&P] M0Q.*`+U%4X=6TZXU";3X-0M9;V`;I;9)E:2,>K*#D#D=:AO/$6B:=>+9WVLZ M?:W3XVP3W2([9Z84G-`&E17":_KFLZ1\3_#-B^IVZ:'J:W32P>0%*"&#=EI" M3D;B#QMQC'/.=#Q/KTDW@75-8\+:U8.]E!+.9XPMRC>6A8H,-@,<#DYQZ4`= M716+X7U*6]\$Z+JFH3J9I].@N+B9L("S1JS,<8`&23V%7]/U73M6A:;3;^UO M8E;:7MIED4'TRI/-`%NBH;N[MK"UDNKRXBM[>,9>69PB*/A*M@]]I]*`+=%9]MKVCWM_)86NK6,]Y']^WBN$:1? MJH.17*>$M@#NZ*S/#\ MCRZ);M)K$.L/EPU]`BJDA#D99$R.OS`D<4`6Z*S[#7=(U5YDT[5;&\: M'_6BWN$D,?\`O;2 MKV%S(9#%LAN4<[PI8K@'KM5CCK@$]J`-&BJ]]?V>F6)M.21[B1[S09!&6BM!(4##:#('QM.2=I M+CH,9`/3J*I6.LZ7JDDT>GZE9W;PG$JV\ZR&,^C`$X_&AM9TM-373'U*S74& M&5M3.HE(ZYV9S^E`%VBJ5UK.EV-[#9W>I6=O=3_ZJ"6=4>3_`'5)R?PJS!/# M=6\5Q;RQS02H'CDC8,KJ1D$$<$$VDGEBCQ).^^5R2 M68]LD]AT`Z#M4]%%`!1110`4444`%%%%`!1110`5D^)M!A\3^'+[1;BXGMXK MN/8TL#8<<@_D<8([@D5K44`<_::5XB6);:]\06TMN%VE[?3S#.P_W_,90?<( M/;%;=M;PV=K#;6\:Q00HL<<:C`50,`#V`%2T4`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`5`UG;O>I>/'NGC0HC,2=@/7 M`Z`GN1R:GHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH` M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H MHHH`****`"BBB@`KS?XYV-G/\+-4NYK6"2YMO*\B9XP7BW31AMIZC(X..M>D M5B^(_">C>+;6.UUNVEN;>,EA$MS+$A/'+!&`8C'&(K3R[_07- MU#I=@\&(8_\`EXW&23Y@KE1Z\8^Z:["Y\-:3>Z`=#O;5KO3R,&.ZF>9CSD?. MY+9!Z'/';I5/0_`?ACPW97EGI6CPPP7JE+E69I#*N"-K%R21@GCIS0!YKJWG M#1_AK=V5C#8Z2FLV$-AYAWW;PNK?,Y7"KN49*C.2021R*GU^.[-CKEO>Z?;Z M_P"#9[VZ:>[M0$O=-?S&\TD,/F\M@<$`_*HYQ@5WH^'?A;[';6G]G2&&TF6: MV!O)B;=U)(\MM^4&3G"D#VJ:W\"^'+20M;:>T*O*TTD4=Q*L4SEBV9(PVV3D M\;@<#`&``*`,+1[E+OXT>*+74$5I;>PM5T\.,_N""9BOU=E!^@KSCQIH]K9^ M%_B5:Q6=N=.TZ_M'TU_+'^CRS&(SI&?X1RH(%>WZMX9TG6[J"[O;>3[7;@K% MOJ:`.?\100V/Q;^'L=I$D*O%J,+!%`RBPAE4^P.3]2:E>ZBV]C<+%EHX4`!PF!AF("D\!J[W4?`V@:K=Z?=WD%X]SI\0AM M9EU&X1XE]0RR`ECW8_,>,DXI9?`OAN:XU"9]-'_$Q+&[C$T@BF8@@LT8;;NY M/S8SWSF@#@8P+[7O@NUTHF+Z;<2-O&=L8S)('WR@]!0!YWXIOGL_@MX# M0RQQ6MQ+I<5V\T9>,0^4&.]01N7*KD9&1QD5U^A:5)8^/;B^N-;T^>YO]-7= M9V&GM`CK&XVS%C*XSA]HZ9'3[IK6C\%>'X_#;^'FL6FTEB/]&N+B28+C&`I= MB5`P,!2`.HZFE\->#/#WA".9-"TR.S\\@RL'9V;'0%F)./;.*`*7CM+M[+2O M[,OK2UU5=05K%+Q&:&XE$"_'E^NA2Z'XF M>UM4OH(75H9(R[J)XV4=U,N>3C8.^2?6]8T+3-?A@AU2T6YCMYO/B5B1MD"L MH;@CD!FQZ'!'(!!8Z'I^G6T\$,+R+<<3-"]`TJ>&6TLY%%NQ:"*2YEDB@8]XXV8HAY/*@ M=:HQ?#7PQ##D#GUJ MUHG@[0O#VF7&FZ;9NEA<#;):S7$L\1!SD!9&8#.3G&,]\X%5-'^'7A/P_+=3 M:3I"6DURC1O-'-)YBJW4(V[,?_`2.WI0!Y'J4$-M\&/B;;V\2101>*)4CCC4 M!443VX``'0`5Z/\`%J]^Q^'-+$W_`"#9M9M(M2/;[-N)<'V)50?K6E:?#;PI M8V=_9PZ=*;74`1=027L\B2DD'<59R-^5'S?>'K6O'XE`''?$'2H%\1^#[RSM8&O9]273YX_+!$UF\;^:KC^ M)0J]#P,U7^%>CZ9M\6C[!:E+?Q3="!?*4B(1[=FT=%VY.,=*["R\'Z+IX;[/ M#<[S"T"227L\CPHPP5B9G+1]ON$=!Z4GA_P9H?A:2=]&MKBW\\EI5:\FD1V. M,L5=R-W`^;&?>@"UXF$#>%-8%U=O:6QL9A+BVBW=OY@TO6]**^1<@P.#&ZD97Y-S#H,KQQU])O[&WU/3KFPO(_,M M;J)X9DW$;D8$,,CD9!/2J&G>%](TFY6>RMGC**5BC:>1XX`>HCC9BL>?]D"@ M#7)P,FO"M/O;FP_9-,]HS+-Y4L>5SD*]XR-T_P!EC7M>HZ?;ZKI\UC=>;Y$P MVN(9GB8C.<;D(8>^#R,@\&LG2?!/A_1-(N=)L;%QIMRNV2TFN)9HL'.<+(S! MTGRGM);6TM].TQX?M,)3>%+&9\!-@(X`SD= M2*XGPM!/XE^&$NH7?B#2]/:#4'OKN9M,DENX+A9BX8L)AN8C``V9VG:,GFO5 M?#OP_P#"WA2]EO-$TB.UN95VM+YCR-MSG`W$X'TQ4'_"L_!O_"0#7/[!M_[0 M$OG>9N?;OSG=LSLSGGIUYH`YOQ$-837_`!#_`&;IMEXFT>9XDU32V&RZMW\E M,>66&&4H58#GYF;&#FNZ\+I9Q^$M&33GE>Q6Q@%LTV-YC\M=I;'&<8S[U!=> M#M"N]1NM0DM)4N[ME-S+#=2Q&8!50*^QAN3:H^4_+U.,DYORZ-I\U]I]XUL! M/IX=;4JQ41!EVL`H.",`#D<=J`+U%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111 M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111 M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111 M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%9FM^(=,\.V]O/JWUBYGMY+C M`AVV[FLIIFVQ+J%G-:;SZ`RHH)H`Z&BL'7?&.B>&[RUM-5GN8IKLA;<1V4\HE8 MG`161""V?X@Q75I;7#:C;27VBTNZD?:#C<`L9RN>C#(.1@UI:/XBTG7O.& MFWBRR0$":%D:.6(GIN1@&7/N.U`&I17.:AX[\/Z9?:A9W-Q=F;3E5[SR=/N) ME@4IO!=T0J!MYSGU]*33_'GA[4]0T^QMKFZ$^HH9+,3:?<0K.H4N65G0*1M& MH^(M+TNY6UN+AWNF7>+:V@DN)MO\`>\N-6;'OC%-L?$VDZG;W M4UG`0R">,8SS"5\S)[#;D]LT`:U%L_ M&.GWWC&Y\+QV]\E_;V[7+--;F.-D5U3*EL%@2W!`P<'F@#H:***`"BBB@`HK MGO#_`(QT_P`2:KJNG6=O?0SZ88A.+NW,)_>;BN%;YNBYY`ZBNAH`****`"BB MB@`HHJGJNH?V5ILU[]DN[OR\?N+2+S)6R0/E7OC.3[`T`7****`"BBB@`HHH MH`****`"BBB@`HHHH`***BBN8+AYDAFCD:%_+E"."8WP&VMCH<,IP>Q'K0!+ M1110`4444`%%17-S!9VTES=31P01*7DEE<*J*.I)/`%2T`%%%7MM"'AMI"`=K_,&.-RY*J0,@'F@#JZ***`"BBB@`HHHH`** M**`"BBB@`HHHH`**BGN8+5%>XFCA5G6-3(X4%V(55&>Y)``[DU+0`4444`%% M%%`!142W,#W,ELDT;3Q*KR1!P616SM)'4`[6QZX/I4&GZA_:'VK_`$2[MOL] MP\'^DQ;/,VX^=/[R'/![T`7****`"BBB@`HHK%UGQ+;Z1=1V26=YJ%_)"]PM MG9(K2>4A`9_F91C)`'.23@`T`;5%9^A:U9^(=%MM5L#(;:X4E/,0JPP2""#T M(((_"M"@`HKGO#_C'3_$FJZKIUG;WT,^F&(3B[MS"?WFXKA6^;HN>0.HK5TK M4/[5TV&]^R7=IYF?W%W%YH:A_9_V7_1+NY^T7"0?Z-%O\O=GYW_NH,)9'MI/-A+?P/M9, MCWVNP_&IZ*`//O"BJ_Q<^(ZL`RD::"",@C[.U4O%ZKHOQ&^&T6GZ=+<1VL>H M10VEL4#;!;HH"F1E7@>K#@=SQ6GX8T#Q1IWCS7]3& M47`:(!\Y&>5]?:CQ-H'BC4?'V@Z[IT&CM9Z+Y_EQW%Y*DD_G1A&SMB8)C''W MO7O@`&-\0M5O+ZX\&17'A_4M/0>*+%A+=26[*3E_E'ERN<\YZ8X//3.A\6Y& MAM_!\J0R3NGBBR98HRH9R`_RC<0,GIR0/4BKOC_P_P"(_$5SH8TA-*%OIFH0 MZDSW=S(C221EL(%6-@%P?O9S[<,K?0K_P`-SV5I]B>^#7XB><[2,8YZZN2U.'QMJL4-FD&D:7;R3)]JN+?49I9A#N!<1_N4PQ&1G/&? MQKK:`//_`(I_\R5_V-=C_P"SUUWB#1K'7]!O-,U&.-[6>)E8N,[..&'H1U!] MJYOQ]X?\1>(;O0AI,>EBVTS48=29KNYD1Y'C+80!8V`7!^]G//3CF75]-\8> M([*339YM,T6RG&RXELYY+F=HS]Y4+1QA"1QG!Q0!YY<:Q>:E\*?ACJ-S#+<7 M2^(;-/+4C?-Y;2HN"Q`RP4&-,\.6VEQ:9H5[;WJBZNI$=S%D M"/"QM@$'.XDG)Z<29/M5Q;ZC-+,(=P+B/]RF&(R,Y MXS^-`&!J5[/8_'U9+?3+O47;POM,5JT2L!]J)W'S'08XQUSR.*;X:U#^T_C' MJ=]>VTVC71TM+6'3KI=LMRHDW&;(RC8^[\K,>OI5^;0?%R?$Z?Q5!::)+;?V M<=-BMY+^5',?F^8'8B`@,?[HR!GJ>M78?#>LZKXWT_Q)KSV-NFEQ2I9V=E(\ MOS2#:S/(RIGC@#;[T`6_&EG;VW@/Q=-#$J27.FW,DS#J["W*`G_@*J/PH\%V M5M<^!/"$\T*/+:Z;;20.1S&QMPA(_P"`LP_&K/C+3]5U?PIJ&EZ0EFUQ?0/; M,UW,T:1HZ%2PVJQ)&>!QZYXP5\'6&IZ3X4T[2]6CLUN+&".V5K29I%D1$50Q MW(I!.#QS]><``P/A)(=1\&'7KD9U+5KN>>[9OO!A(R*GL%50`.U+X\E;2?$G M@[5[08NY=533)0O62WF#;@?4*5#>QYJ_:>']4\,WE\WAW['<:?>3-L_8I;K3T=M.T^&1A`DK#&]Y2NYC MV!V`*,D*30!P?AWQBWA"P\<7DFB7]Y;)XIO-US"T8AC9F10');>HZ9(0@9'- M=U\/-`NM!\/W!O);=Y]1O9=0:.V;=##YI!"1GNH`'YFJ'@KPKK>EQ^(;/Q%; M:1/9:S?7%])]FN)'PTNT&,HT:@K@'G.?;G(M>$]#\2^%YFT?S+"]\.12,+.2 M6XD6Z@B/(0C85<+T'S#C\J`.RKS:]AN9_C^([6Z^S,WA;#2J@9E7[4?NYR,Y MQU!'7BO2:XFW\/\`B$_%F3Q19YBN08PN2>"N>`>IQ MR`<['\0M6L?"%ZEU.+C58?$C^'XKS[*6+'=Q*8HQ\S!,_*HY(`P>^_X,CEW^&7BF^T?5K.Y MN=*M+B?7'U^RN;>YDD,5P<`(RF-_\`$=[I<]U' M;&&UL[!I8X'8X.^1F!.XE0,A3M!;`YQ0!S7AW7O$UUI'B34]3U]/*\.ZQF/H6GR*TPQ([[OLYV_?#+CKD8R>,$55NO$/B_5OA_J&H MZ;J9M]9\/7MQ9Z@EO;Q,MX(B-S*'5MK;.1CC)(QTQT@\.Z_I'C;7=>T8Z;=1 M:TD`EBO)9(F@>)-BE2JMO!!)(.WZBMCPOX;A\-Z+)9M+]IGN)I+J\G=<>=-( M@'6@#+;4;G6CX7BT37KI([F`W=Q.L4+--;JJC+YC(5F=E'RA>K\< M8'8UPGPS\/0:/9ZG MN[C3[33WN;"1[:!&.QBDA7:@WLL@*C/!(/!KL_&_AR7Q3X6GTZUF2"]$DL>%KJ"8)#I`:.Y#'YKE,!@#QR?,4,<]G)I\.N^)/L5@+'S;O5`EL)7O&8`0(A0KM`R00I)Z9KF+_`,=^*F^%NN:W M9ZM#'=:)JHYH`Z+XF7VO:''IVM:?KES9:1'EZ5IM[>.2[@>&XCMI3(@SD95F53TP>1P?7&3A^'/!=Q9> M`[K0M:O1=WM];O;W5S'GE/+\I`N0#Q&%_')[T`<]H?B_7[N;PYJ&_4[Z+5)$ M%]9KHDL<%HDBDJ\)[>2:*TT M>[MHA%.H)$31NX!9V7##+$9."N!5SPIX4\=Z1#IVBZEK>F/H6GR*TW$UI?RR2"YTZ-Y69!'\IW M,JD8^9`N`/F`Y`/0JX;XKZQKOAWP/=:UH>H0VCVA7S`]L)6?>ZH-I)PN-Q/* MG/MW[FO/_C;_`,DAUW_MW_\`2B.@!/$^J>)/#&LZ%*-7CN+/5[P:=+#+:(4M MYI`?+>/;M8J".59CD#J,\1>![[Q5XA;5C?>((Q_9/B":S;R[)`+B*,*&0CJH M.<@@Y!)R2,"M&_T#Q#KNH:9/JZZ7Y&D2?:X(()Y/]+NE4B-G)3]T@))P`Y&> MII/A_P"'O$/AV36EUE-+9-2U&;4O,L[B1BCR;.#SG\.X`.6MOB!K>J M:7'XCTUM4N%>](32;?199(9+42["1.(SF3:"^0^,_+MSQ6WKWBR2W\77FC2> M(?["O8PC:;%&9)F M9)BLHO8(V.66,C"@GGYLG!.16]K'AG6=3OM8CN[;1]8TB]F1K:UU"213:8B1 M&92$;JP8[!M]=P+'`!EWOBK6+>_T#PU?75Y9:DVCK?:I1[K3&C:\0RHD6:6.*W"LA6.%-K';\@ZDS\17,= MPGB*\@7[3!%-&Q7RQYC`*K%L<8#JHP/E[';\1:!XHU+Q?X6U^R@TC_B3Q3&: M":\D7?),FQU5A$?E``PQ&3_='==%\.^)_#,_B+^S3I%S#J.ISZE#]HED1MTN MT;&PA"A<9R-V[&,+G<`#DD\9^*Q\$K7QTVL(UY#-NDMQ:QB.>/[28MK<9'!& M"NW@=YV?\`5YW;OEVXQCG/:N@U[0/$NI>-/"FO M6T.E"/2(IC/#)=R`M),FQPI$1RJ@`@G!/<"@#"U'QMK.H7/B231[F_BETBZ> MTL[*UT>6ZCNI(@"XED6-@NYB5`#(1P3P:OZIK_B8>.O!UK;WL=IIVNPS2/9R MV6)8/+@#D.6.2V6Z87!4`@\YB3P9XUT'Q)K<_A?5](72]9N6NI4OXY&DMY'^ M\T87@GZG'`XXJ]?^%O$4WCCPIJ,+V$NFZ`CQ>9ZK/<_V-/8O%<>7'&\L4Y4^6^Q0"!D\@`GOQD5 M[5I]I-9VHAGU"YOWR3YURL8?Z?NT5)]01Z@UY3\/!+H]KXWUBYUF_DM= M.U[47GMRD&VXV(I+N1'N#=_E*KD#C&0?5IS,MO*UO'').$)C21RBLV.`6`)` MSWP<>AKA/!_A'7+"S\2Z;XBBTN2RUR[N;R1K.YD9E,P"M'M:,#&`?FS^'H`5 M+O5?%J>`(/&]OJJ-*+1=1ETHVZ?9V@*[R@;'F!@A^]N()'05%9^(/$FN>/QI M=IKT<.F:CX?_`+6M'CL4#VX>0+']XMN8#&!QB[9>$?$UOX/?P9)=Z?) MI1B>T74?,?[0+9LC;Y6S;NVG:#OP.#@TMCX5\0V'Q)BUV&VT=-(@TU=(A@6\ ME\U+=9`P?_58+8'W=(U628)L\Q@.6V]LGG':N*^ M(>K^(=$OO#2=WIW=>=?%T3M:> M$!:M&MR?$]F(FD!*A\28)`Y(SB@"V=6UK0/B3I.AWVHMJ.FZU!.T#2P1I)!- M$H9@"@`*$>H)YZUS/B'Q?XC\->'&UK4M;2+6X9UDGT"*&*:%(#*%`9U4NI*D M'<7`)X`S7:VWA_5-1\86OB'7191'3H)(K"UM)6E"M)@22,[*O)```"\<\FN1 MF^''B>7X9ZEX/-UI#/<3F;^T7>3S+HF829E&WY6XQNR_``QWH`VGOM=T?XK6 MEAJ>NW$NAZI%*]A%Y$*JLR\F%V";B`IRIW`G`!SSG$\9ZWXLTKPGX@\5:5XC M*64%V8K6VFLHG^3S$B+*^T?QE\;@V5"^N:Z+X@Z9-JOA&U6::&VUQ+Z!]/D@ MRWEW!D`4+G!8!2SNA58V1EP% M1MQ)7DDC\<\`#-:U/Q'I?Q!\.:1%J\[>_B\.K'=1W#QI&[1/"9=AV`*2-I&<=ZL:SX?\0:GX MY\):ZD>F);Z3'+]IB-U)N+S)L<)^[PP4`$$[=W0A>M5+7P;K4OBGQI<:B-/_ M`+*\20K;DPW#F:)$B:)3M,8!)#9/S<'N:`,W0_%^OW^+-6\7^,/#]UXBCC&F+:_9[BUL8U M*-*C/PK[ACH"&S]T8(R:/"GA3QWI$.G:+J6MZ8^A:?(K1R6JRBZE1#E(V)PH M3@`CG(XY!J[X=T#Q3IOBSQ7KU[#H^[6(H3!##>2-YS6MS=^(+:"8VX0!F$CKYF"I&08]P'W)[7P)H.A3OI'VG0=6BU*V=+F4 MI<[9)'9'S&"GW^"-V?0=^U_M'Q#!XFTJPFCTR>TGA=KPP>8)8&&\JP!X\OA$ MR>68D@``@`'2UP/B35?$EC\3?#&E6FJ6\>F:O]I!A^R`LGE0[CER3DDMD8VX MP`^KB==\/^(=3^(_AW7((]+73-':88DN9!-*)D".=HC*@KV&XYQR1G@` M@T3Q1>Z?JOCC3]9O7OH/#HBN4N7B1)&BDA,FTA`%)7:1G`SFJ5WJOBU/`$'C M>WU5&E%HNHRZ4;=/L[0%=Y0-CS`P0_>W$$CH*MV/A'6O^$S\6WFHPZ9)HOB) M$@D6.ZD\Z...)HU^4Q[26!Y&[C/4XY99>$?$UOX/?P9)=Z?)I1B>T74?,?[0 M+9LC;Y6S;NVG:#OP.#@T`8_@M[K7?B+XSU+3](QJ@PI&&&/GR=O7:W2H/"/A#7 M+&R\3:9XACTQ[+7;JYNY'LKF1G1I@%9-K1@8QGYL_@<\`%O1F\6:O8:#XAAU MBW$5\([BZTV2%1"EO(N[$;!=_F*".2VTGL!7/ZCXVUG4+GQ))H]S?Q2Z1=/: M6=E:Z/+=1W4D0!<2R+&P7+$P95*,@$>XJI8A MF[@8SD(-`\4?\+6/B@P:.=/^P_V8(OMDOFB'S=_F?ZK&_P#V MM:O>W?C.R\*:9>_897LWU"[N5C5Y%A#A%6,,"NXL>I!P%Z5UE(]7O)D-W=21W]_;6RLUM%Y MDH#A-I7@K&F=IX;.":T]/\-^,=+\6^)/$%O+H>%&,8`.ZJUCJ MVL^'?"WPWO%U'S+/4&L=-FL1`FS9+#\KAL;PPP,_-@^E:5SX*U6/P_XC@TC3 MM$TZ[UV$6TEK'#?$]UX1\%:9;+I`N] M`N;:XG,EU)YH:QXPO=?&F:T^DV^EWS:?`8 M;>.5I)452[2>8#EPU%!:^8'E$B M1Y0L<*,.&Y!].,<]/IGAOQ#XMPW2O;^0BK!)"@?*-2\7^%M?LH M-(_XD\4QF@FO)%WR3)L=581'Y0`,,1D_W1W;H7A;Q'X1L[W1M#ETV72I9GEL MY;J5UELP_)78J%9`#DCYESGF@#%O?&FKZEHW@/Q-I>IR6EMK&J6NGWNG^3$\ M;;G<2$,REQRC+P>F#P>NG)>^)E^*U_X:78!PH)[$-MZDC:.M`#_`(::CXC\4>%M$\0Z MEK2E9/M`GM4M4`F`D=4.X`%2N.W!`&1G)KT"N'\":%KW@WX?G1KXZ3Y]C%*U MM<+G745K=L,1S2P^:J'/4KD9XSW_`#Z5Y'!XS\4K M\&+/QW/JX:X@GW2VRVL82XC-R8BK<9!P>"I7@E_;M0ME@U/3WNI!"S(<))'*(MV=HQ@IW/)ZU7UOX=W6M^$ M_$]M-=VZ:UK\D4TLJ@^5'Y13RXQQDJ`F-V,DL3CM0`OBZ]\1^%[GPN+;Q`]S M:7VM6UA<"YM(C,ZR,2WSHJJ!M7;@(#R3NZ8T9=5U'Q#XOUGP_IFI/I<>CP0- M-<10I)))+,I90`ZE0@5>>,G/!&*S?%GA_P`:^(QH12/0(SIVI0ZFP-U,,O'G M$>?+.1R3OXZXVC&2[4/"WBRS\5S>)O#-QHT-YJ5M%%J5G?\`FO$'08#1N@5F MP..0OKWP`"?Q%XCUSPIX)TPZG):R:[>WD6G^?:PO+&'=C^\6,#(YC16/W6&!T)ZX-1^*?!& MJ>(_!5GIS:T#K=E=)?0WS1[4\Y2Q'RC.%`<@=<`#K6AX8L/%PO6O?%>H:<\B M0^1#;:8)!$N)L_#.M^&O$>LWV@?8+JPU>;[5+;7L[PF"VE^MJJ;)9(HVW+\ZMA& M!4G&&'8BND^'%E/;>!=#EFU.[NTFTRU:.*98@L`\H?*FQ%)'('S%CP.>N:5U MX/U.T^'^JZ)I3V5QJ>L-W-T[0H7G#>8ZA5<\9`"\<#D\<[G@ZPU/2?"FG M:7JT=FMQ8P1VRM:3-(LB(BJ&.Y%()P>.?KS@`&GJ45[-I\T>G745K=L,1S2P M^:J'/4KD9XSW_/I7D<'C/Q2OP8L_'<^KAKB"?=+;+:QA+B,W)B*MQD'!X*E> M!SDG->N:DU^NGS'3(K:6]Q^Z6YE:./.>K,JL>!D].<8XSD>8'X=>)O\`A2(\ M#;])^V^=CS_M,GE^5YWG9_U>=V[Y=N,8YSVH`ZF35=0\0>,M7\/Z=J3Z;!I% MO`T\\,2/*\LP9E`\Q64*%7GC)SU&*Y]O%7B8>&_&%BU_:QZ]X8S+)=&TRMS! MY321G9N`1V"\]0,=.>-6+PWXCL?%3^*K*/2_MVH6RP:GI[W4@A9D.$DCE$6[ M.T8P4[GD]:;J'A#67\/>)?LITZ77/$>8[N2:5XX8(O*,:JF$8MM7U`R23QP* M`,T^)/$.GZ-X`UNYU7[0NM7%G9WEI]GC5&\^/(D!`W!@1DX.TYX`%=O_`,)9 MX;_M'^SO^$@TK[=YOD?9OML?F>9G;LVYSNSQCKFN,U3P;XHNO"/@K3+8:0+O M0+FVN)S)=2".0VZ[4"D19^8&]&CU0N)Y)H[9' M99L[BPD*!B=W.[`)Z\4`;E%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%%`!1110`445RWCSQ?-X)\/OJZZ/-J$$9`E*3)&L62%7< M3D\E@.%/OB@#J:*Y*[\97.E^(M*T_5M'-K9ZM(8;2[6Y#D28R$E3:-A/;!89 M-94;EKO%PJ>9Y?F&$IC;N[;\^U`'H-%,]4T.[U7[/X=&H6& MF6JW-Q<17JHZ`JS$%&4#@(2<,3@KQSP`=E17!S?$6YM=.\,ZG<^'I!8:Z88H MS%=*\J32IN1=F`"#R`VX=.0*U]+\4W%SXON_#6I::EG>Q6:7T+17/G++"6V$ M_=4J0W&.?K0!TM%<1)\0BML-732BWAO[:+-M1-P`^?,\KS!'M_U>_C.X'OMJ M8^-KYO'=QX4C\.RK<)9M>0SS72*DB!P@8[0Q52<\\L,#Y>>`#L:*\J\7>/=1 MO/A#K^JZ;!_9VI6-VVG7BBX):W<2*C&-U`W'YEP?EQDGL`?2]/DOY+4-J5M; M6]QDYCMKAIDQV.YD0Y_"@"U1574KFXL]/FN+6QEOIT&4MXG56W7@6+QC%X9=M+!F6[ZUJ,[0VMG M;79>-L*69FD:-2JA02?E/;&:`.DHKDH/',:Z=J[ZC9"SU#2KF.UN+;SPR;Y2 MHB82$#Y&WK\Q`QSD<5FZ_P",]?T^UU:R?0X;2_@T:ZU&&Y6\\V!A$4'RG8&+ M8PMV29;IIGF!C4[Y-R+M8]2,MR M3R:Z:@`HKA].\=:MJVL:_I%KX6DCO](6)C'=7J*'\Q68`L@8*2`,8W`Y.2,5 M",\<#/%`'64R66.WA>::1(X MHU+.[L`JJ.223T%001U%9OB#PWI'BG3TL-:LQ=VJ2K,(R[*-XS@_*0 M>YXZ5FQ>*K&R\"Z1K361A2]M[86MA;X),DJKY<*=!U(&>!@9XJ6R\0ZBNI7E MIK>B-I\5O:_:UO8IC/;L@/*E]B[7'7;@\`D$B@#>M[>&TMHK>WB2*&)0D<:# M"JH&``.PJ2N,LO'C-::3KH)&&;WQ783 M31V\$DTSA(HU+NS'A0!DDT`/J"\O;73[5[J]N8;:W3[\LT@1%^I/`KC;KX@7 MEKH4/B5O#TC>')`)&N%N1]H2(G`E,.W&TY!XD6=[::C:I=6-U#L?2=)M?#VD7']GZ5'!+,S7 M';:PT&YEMM>CD>UNI)T4$I'N==HW$;6PK$X[D;L<[+>*;]7T[36T4)X@O(I) MFL6NP8X(T;!=Y54_*25QA2>>G!H`ZBBO)?'/Q!U2+P1XFM8K,Z1K^G"$3I]I M+8AE<()874`MU`Z*5SZC![K4O$5QH6@K>ZO8Q"]EG2VM[2RN#-YTKL%10[(F M"2>-#;7.L6FNV`T^ZTRR_M!UAG\]);?#9=#M4Y!4@@@I:78S:!; MC^U3(+2ZBU#S87!QT%6:X+X2:SKFO>![/4-66&1)VGD6Y^TN\KGSW^4H4PJCH,.W M`'3H.]H`K6^HV5W<3V]M>6\TT&/.CCE5FCSG&X`Y&<'KZ'TJS7E'AF*?1?B9 M\0K7P[HMJZH-/9+?S1;0K^Y8D`A6P26)'RXZY(K5U3XI"Q\"GQ/;Z#=7*02- M!>P&=(_LDJN$*.3DG+,,%5/')Q0!WEU=VUC;/L^-+G M2?&NE>'?[`N)AJ?F>1=^>@5BD>]L+R<`D`YV]R,XY`.NHKAW^)$&GZ?XGEUO M3S:77AYXUN(8)O.602@&(HQ5?O9QR!BK2>,KZT\0Z9H>LZ!);WFJ!FM3:7:3 M1X49DWE_+(9002%#<=,T`=1]KMOMGV/[1%]J\OS?(WC?LSC=MZXSQFIJXR+Q M.'^(U[HK^&'34(-*>ZANS)$9;F%90JHN#PK,20&88(&0,\9]K\2=1O?#NO:O M!X79?[#NIH+N&:]53B)07*D*06&3\O3`^]SB@#T.BN6U#QI#&GAZ+2[3[;>> M(%,EC%)+Y*>6(Q(SN^&P`I'0$G/`J7P]XL;6]9U/1I]*N+._TO:+LF6-X@SC M*!#D.P9>02@'![\4`=)167K^NVWA[2S>W"22EI$@A@B`+S2NP5$7.!DD_P`Z MR%\77ECXDL='U_1TL!J)9;*Z@N_/B=P,F-LHI1L=."#T!-`&[J&LZ7I)B&I: ME9V9E.V/[3.L>\^@W$9JZ""`0<@]"*\FTB/5?$'Q)\;:?J^C:5=6YBL+:ZAD MOG98(6C9B(CY.7)R6P=F&`Y[CT/4+RR\*>&U=(PMK:K%;01F3`&66.-2S=!E ME!8]!S0!KT5P&M^//$&B37$$WA2"26WT^?4I'75/W3PQ%`WEMY66;Y\D,JX[ M$YJ6]\?WMG9^$+_^PXGL/$4EI"9/MN'MI9QG&WR_G`'?(S@C`XR`=I]KMOMG MV/[1%]J\OS?(WC?LSC=MZXSQFL;7_!FA>*+FWN-7M[B=[8@PA;V:)8V!)#!4 M<`-S][&>G/`K,B\2-/\`$>]T(>'$@U.+2GN(+ZXE3,\0E"JN4#,J%B3R\#V>H:LL,B3M/(MS]I=Y7/GO\I0IA5'08=N`.G0`'I*P/$'B.32-1TK2[.Q^V:CJCR+;H\OE1*(U MW.SOM8J`,=%)-4=,\8W=_P#V[9-H4G]M:,\:S6,%RCB02+N1DD;8,$9/(!X[ MGB@#47PGH2^*)/$HTZ,ZPZ!#=,S,0`-O`)PIQQD`'%;!(`))P!U)KSJ#XI33 M>![/Q@^@&+2'G\JY9KL;X4,QB#JNW#C.,@E<$X&0,UT.KZ[)/JTWA[3=)AU6 M<6WFWJ7$PBACC?(56.ULL^&PN,8!R0*`-VSU"RU!)'LKNWN5B?RY##('"/@' M:<'@X(./<58KS7X,K&NE>*5BM/L<0\2782VP!Y(VQX3`X&.G''%=;K7B&2PU M.RTC3[(7VJW:M(D+2^4D<2X#22/ABJY('"DDGI0!J6^HV5W<3V]M>6\TT&/. MCCE5FCSG&X`Y&<'KZ'TJ&37-)BTY=0DU2R2Q;.+EKA!&<9!^;..,'\J\S\"O M)IGC7XB-8^'?)FB_L\+I=J\:#=Y;YVL=J[23$S@-)M M&6VCJ<#DXZ5-7(:IXCCM?B+H.AW/A[>]YY_V/4Y'C.S;%ODV`98?PJ<[F2Z\G!D!9$C&UM[%03SM'O0!U5%0Q^9ZEI5UH+# M6;.WCNHK2VNED6YB=BH9'<)C!!!!`]LT`=717G,'Q2FF\#V?C!]`,6D//Y5R MS78WPH9C$'5=N'&<9!*X)P,@9KJ]6\0-9ZK;:-I]JM[JUS$TZPO+Y4<<2D`N M[X8@9(`PI))Z=:`-NBN3/C22U\.R:AJFB7EE?+>BPCL6()N)V8*GEN0`R,3P M_`X/I5O1O$EQ>Z]>:%JFGI8:E;P)_MFQ&/M$;O&(T M^90FX-DG+$8PIQC)QQ2ZSXTN=)\:Z5X=_L"XF&I^9Y%WYZ!6*1[VPO)P"0#G M;W(SCD`ZZBN=\-^)Y-:U/6M)O;%;+4M)F1)XXY_.1ED7LOB)X-TW2TMW@O#=R-%+=/")F2$_*Y5&PH#!APV6`X&`:`.^JM?:C9:9; MFXO[RWM(1UDGE6-1^).*P]1\37L'B&W\/Z=I4=UJCV1O9?-N3#!'&&V8\P(Q M8EN`-ON<5Y_\1M9LO%_P9U[49M+2#4=*O!9NDNV1[:99XE<(^.A!'(QD4`>R MU#;W=M=^;]FN(IO*D,4GEN&V..JG'0CTK`N-?UIM>N;+2]"M[ZQM54RW7V_R MVW]XE0QX,@'8L!R,LN>,_P`+>*#JNB:_>V'A=K:[LM3FMIK&&6(//,H3>[-\ MJ[LL(=3T?1=(74)M*BBEO3)=>3@R`LB1C:V]BH)YVCWH`ZJBL M7PKXEMO%V@0ZS9VUS!:SEA$+C9N<`X)^1F`Y!&"0<@\56U7Q+=6_B6'P]I6F M)>Z@]FUZYN+@P0I$&V#YPCDL6[!?QH`Z.BN(3XA/+X-U/78M"N9+C2KB:VO[ M-)TS`T0)<[R1N4#'09YZ4D7C^X%OX7OKO1/L^G:^T,,Y4=*`.XHKD/#'B[4]:\2ZOHNI:+;Z9/I@4N%OC,TF[E64>6H*$9YSD' M`QSQJ^&M7O\`6[&:[O-/@M(_.>.`Q7)F\U58KOY1<`D<=9N;H%7:Q+>@Z$G%`'7U#=7=M8VSW-W<16\"8W2RN$52-WE:2WF&PMOCDV`M@`\;1S@'&F0#U6BL/5 M_$#66K6FC6%H+S5;J)YDB:7RXXXTP"\CX8J,D`84DD]*S=/\:75W)JVG3:#/ M'KVFJCOIT=PC"9&^Z\?RKE MFNQOA0S&(.J[<.,XR"5P3@9`S7HU`!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!7G_P`;?^20Z[_V[_\`I1'7H%H7E>>#GCIW`,?71<>-M9\-6EMIFH6L.FZC'J=Y/=VSPK&8@=L M2E@`[%FZIE<#.:XCQ'9:WXF^&.K_`-KZ'K5UXM\[F(VS^3;H)U($`^XP\L8R MNYSSDXKV_3X[V&PBCU"YAN;M01)-#"85?G@A"S8XQGD\^G06:`.-\>::_B/P M+-=VGFVE_8G^T+&29-CQRQ$LI(/*Y`(YP0&YQTK,U$WD?PEU>YNM/NYM7U^V MG=K:SMWG<231%8T(4$@(@12QX^7W`KH]>\.:AKNHPJVNRV^B&/9=Z9';H?M7 M))S*?F52,`J.HSZUT5`'CVLK>'P'\,H4TC5GEL+^PGNXTTZ9G@2W39(74+D< MGCCYAR,BMUY)X_CW]L;3M2^Q?V$+`7:V4K0^<9A)C>%VXVGKG`/!.:]$HH`\ M#\*:/-HFF/X6U+X9IJ&M13O';:M/ID MGO%TS5$LET1M.%W)82I"TRS^80'*XQ@'#9P3T)R,^C44`>"S6.J:M\.OB'I% MOHFKI?7^M2ZG:QSZ?-$)H#-"WREE`+84G;][VZUZO-XPM[.:2T*K&2553("]H&+QY)PK>N.A/H3TY MQUH`GKP[P3J-S>?`2+P[8Z3J%QJ%]!=6D#"V;R")))`9#+C8JKN.02&RO0\5 M[/J,5[-82QZ==0VMVPQ'--`9E3GD[`RYXSCGKCKT.!X"\*7O@OP['H<^JPZA M:P$FW9;0PNFYF9@QWL&Y;C@8]^P!QVI0R:+XW^'UI'IVKW5GX[O(--G MDC&^W5$P50[N5YVYQG'4$#9\J^\*?$_6=8GLKRZT;7+>#,UG;/<-!-"NP*R( M"P4@DY`/->@T4`>.>*O">JZMX1\?ZK:Z=<"YUV6T:VLBF)3%;E/F*]0S8=MO M7IGGBK?Q$AO-9N?"_B6V\+7>JZ?IMQ.MSIMS:`R31R(@WB%LGC!P&`.0#C'- M>L44`>7HHF\(ZU<:9\.H[.RNI+6W73)+!;>YNT,H65G5"-H"N=I)&TAF)Q5: MQ\-7-MHGB72O#KZT^C76CW,4=AJD+Q_9[EEPB0F0`E2"^<97.WYCFO6:*`.* M\+ZU+I7PWT]I]#UDR:986T$D"V9$TD@548(C$,<$ZA2>(L,$JRAAD=N#3[JVBO+9[>=2T4@PZABN1Z9';U'?I4B(L:*B*%1 M0`JJ,`#T%`'FWA*^E'Q$\>:O+I6L0V=W%:S6SS:;/'YRPQ%'V@IDMDC"_>/8 M<&N6T/1-;N_@UH=C::7?PZYX6LD'G[9I7"JSJ`W#9X/!`!ZC/NE% M`'`ZPK>.=2\-I:Z?J-K!INI1ZE'9[&XDLKFW>"21X(P&50X&[KD$9!Q@<\5T)U?5/'6@:UI\' MAW4M)M[C39[=9=5B$,C3NNU0J9)V@$DL<=L=Z[FB@#Q?P+;E(=%TB?X8K9ZW M921+L:[IS:QX>U/3%D\MKRTEMP_]TNA M7/X9K0HH`\MM)]6E^%K^#+K0]0775L&TM5-J_P!F(VF-9?/QY>T+ACSGC`!- M0:M&^B^.?A_:Q:=K%U9>';6>WNKN#3)Y4&^W6-""JG=TYVYQGU!KUFB@`KR3 MP1X@;2!XZB32M2O9SXEOFMUMK5Y4E:]7G$S6\JV\D< M$=4\*7&JFZUNWU"#4KN6^D1;$PLL\A7< M0WF,-N!]W'ISZ@'GVFZ5=^$]<^'6G3:;JMPF@Q7K:A+8;.YO--?3WTR]2UB:66$;S(KA%!9@6P#C)`%= M[10!XQ\0/#6I^+K7Q-KVFZ;=C?I5OI]I!)"TB7-RVGZI#>FPO+?:UU&@8$>6W.#N^ZP!.#QTSZ710!YA MI-PLFFZUJ>A?#A-&\C2IP([O2EAFNY\;EB54PS1_+@C^(E<8Q2^#]`&C>)+5 MM`AUO3;&4.=3TB]C>$_AE!I M^H:!K37>EB;SXH;0DNS3L5$>2/,R'#97*@`Y(KT33KZ#5-,M-0M23;W4*3Q% MA@E64,,CMP:?=6T5Y;/;SJ6BD&'4,5R/3([>H[]*D1%C1410J*`%51@`>@H` M\\LWNO#/Q-\7:A>Z7J4MGJZ6;6-V![BN6\4:#JNG_ M``CUS3WTN^N=:\2:F^I&ULK62<0%IHW*LR`@850.3R2: MW\+;FSTS2]7NKK4C&(88]-GWKY7PYJ-W#J<- MK%:>=8S+!*T491V\S:`-I^93D;MHVDDC-S3O$VDZ;K%AJVN:+X]+649M[>]U MG3T6"R5AAFR@'4#!9@QQ7I7BKPV/$^FP6HOY[*6VNHKN&6$!AYD9RNY3PRYY MP>X'I34TC5[R!K76]5L[JT==LD5K8F`RKW5RTCY4]P`N<^E`''3ZHUO\;YM6 MDTG6SIL6B'3C=1Z3<2(9A/O.-J$E.W52(XY``ZL2,G#+A".O3HO`NOZ-%X@N;)M*\3V6L:LWFR7>O68B>[ M9%.%!7Y1M4-@``8!KI=8\+W=WXGM?$.F:P;.^@M6M/+G@\^!XRP8Y3BZIJ MWA^QN=&B$]_I.HP:E%;EL><8L_)]><_A536%;QSJ7AM+73]1M8--U*/4KF:] MLY+69AG;D``\],]]10!YIX-O9)/BGXPNY-*UBWM=5-I]CGN=- MGB1_)A97RS(`GMNQGIUXKJ_&_G-X2NXX=(_M MST4`>86^I33?'!-4?1=;ALFT0::9I--FV+.9P^TL%*[1TW@E>,YQS5_X117N ME>!['0-0TR^M;NQ\\3O-"4CR9G8!6/W\A@^>*]`HH`XSQS=:Q#J.@06T M6HG1)YY!JLNFQ,\Z*%'E@;`7"EB=Q49`'4=^=\+`>%O&OC2]'A[6(--NDLGM M%BL9)"X6)@Q&T$EB[#(Y;YLL!AB/5:*`/!CI^J?\,Q#0?[%U;^U?.\G[)]@F M\S/VGSL[=N=NS^+IGC.>*Z_2[NZTGXA:OKTFEZK+HWB&WMS'*MA,9+:6%3'L MDBV[T!R3DKCISCFO2J*`/._A@NHVMWXI@OM$U&R6[UN[OXIKB-51D=E`4?-D MGY2<@%<=^1F?7X-0T7XH:?XI2QNKW2Y=,;3+D6D3326Y\SS%?RURQ!.`<`XQ M]*[VB@#R[1-2O-*^(OC76+CP[KAT^_%F8)H[)FSY4.W[@^N-%H_BI%DL[:%KGPY M;).;@88DR[P0I&0JD`-\IYP17L-%=6T?5=4N]&UZ)8=2NFNYH-0LC<;) M"`#L99(R!A0`#G``H`\^UJ.U\1?#JRTSPGXH`\&.GZI_PS$-!_ ML75O[5\[R?LGV";S,_:?.SMVYV[/XNF>,YXKJM;N]0T_QSI?CNQT/5]1TR?2 MWTZYM8+-A=0D2EP?)<*W)X^@ST(SZ?10!Y7X]M]?\7>!K34(O# MEW2JTL]NBD8D3)&26.4YX]^*U_`[6MYJLEYIW@,>&K9+8QRRW.G);3RR%E.U M-O)C`4DDCD[>F#7>T4`>>_&?[3=_#J^TBQT_4+Z]OC&(H[2TDFP$E1V+%00O M`XSC/;.#BCK&JMK/Q0\#7UII&N?9+(W:W,TNDW$:Q--$$0$L@[CD]!USBO4* M*`/.?"TTT/Q=\:23Z;J<4&HM:I:W,EA,L,AAB97_`'A7:!GH2<-V)R,V?&MO M=P^/O!.MQV%W=65@UZER;6!I60RPA4RJ@G!(QGH.^*[VB@#@O$5WJEQXPTVU MOK'5U\,S6!DD6QB9V:Z+<13-%DJH7T(4D\DBO-]3L=1M/AQXU\-V_AC6UN=1 MUZ6XLX8=.D=%A$D++\R@KC"D#!(XKZ%HH`\RT'6;CPSX@>QCL==N?#%[$]Y; MN^DW32V,I<[H6'EEBI.YAGD9[@@F/X>:M)I5KXNFO]&UV`W&M76I01OI5QNE MBD*!=N$Y;/\`#U`R>@)'J-%`'@QT_5/^&8AH/]BZM_:OG>3]D^P3>9G[3YV= MNW.W9_%TSQG/%7M5UYI/'FKWUKH?C.WBN+*WB,VBZ>#+-PV[SDE7*$<*IP&P MI()!%>UUR5IX5U;1]5U2[T;7HEAU*Z:[F@U"R-QLD(`.QEDC(&%``.<`"@!G MP\U?1+K1#I&C:;J&EKI86-['4(#%,@8L0Q&3G<0YSGJ#57Q1/J;^-K&QO+;5 M'\+O9,SMIT3L9;K=@)*8_F5-O/8$GDD9QUEAIWV226XFF-Q>3A5EG*A/)S5Z@#Q;38KK1?`?Q`TD^'=8BDU#4+\6-O#I\C@I+&%B`V`C' M!Y!*C;R>5S-K7VW_`(0#X9Q)H^KRS:??V$]W#'ITS20K;ILDW+MR.3QG[PY& M17L=%`'F_CFQU'^V-!\3>'"T5]>*=+E$B&)C%,I*.RL`P,;?/M(!^F#7H-C9 MP:=86]E;)L@MXEBC7T51@#\A6)9^'-0'B235=5UV74(8I'?3[/[.D26FX%3R MO+L%)4,>Q/K714`>?:@]_?>/=3L-=T[5+C0TAA_LR&UA8V]PQ&9/.9>,AL`" M0A<`G&<&N&\/Z5X@T;PIX&U9-`U.6Y\-3WBWME]G*RO'.[@F-6P7(7!XX^88 M/!Q[U10!Q5SJ&J^,/!/B6--`O=.2XT^6"RAOU$=Q-(T;@[DR=HR5`R_`>V\.0>']=?4396=L(QILI^>(QF3.!D`;>I`#9^7=@X]IHH`\YU%[V M#Q]H_CBTT_4;C2KC3GTV\A%G(+BW'F%U?R2N\C<`#@=!D9!&;,"D^-=3\% M%P^PQG>`0^1G&.1R.#6M10`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11 M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11 M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!116+XCU?4-*33DTO2EU&YO;P6PC>X\E(QL=S(S;6X`3T[^O!`- MJBN"@\:^)KO6=?TFV\+Z=->:(L+3HNKO^]\U"ZB,FWY.!CG;S44WQ`UU=4\, MV,/A>V+>(;;S[9I=3:/RRL2R2+(/))&W=CC.<=CP`#T*BN/\:^+]4\*7.E+: MZ'!J$&I7<5C'(U^866>0G:"OEM\N!][/KQZN\;^+=3\&^%5UTZ+;7L<*K]MC M6^*>4S%5&PF,[QN;&2%/0XY.`#KJ*Y?4?%5YI?\`8MA<:5&^OZN\B064-WF) M=@W,S2E!P%P3A2V5MJ\,F@*FLZ3;_;;BQEO=J26H!)EBE"$/@C&"%[]QBGG MQOKD'A6V\3W7AFW;29;5+R3['J1EGBB90VXHT2`X4Y(#=J`.ZHJI%J=E-I": MLMP@L'@%R)V.%\LKNW$^F.:P[;Q%K6KV:7^C:!%+82`-#)?7IMY)D/1T01OP M>HW%21CI0!T]%<=?^.)XO#6JZE8Z/YE]H^6U'3KJY$,D*A"Y8,JN&R`"N.&& M>M+XT\7ZIX5NM)2UT.WU"#4K MN*QCD:_,++/(3M!7RV^7`^]GUX]0#KZ*YB^\4W<&N67AZSTR&YUR:S^VS1&Z M,<$$8(4DR;"S#?P,)D]2!4N@^)KC5]=U;2+K2);"?38X'6505B3IN;G';IDX%`'145S) M;:+[5-X7C>U`W/';Z@'N5'?]V4"$^PD/MFLK7OB!/80>'[[1],M=3TW6[F&S MM[E[YH2DTA(`9/*;"C')SD$$$<<@'Z_BM;.XG%NLZP1WA\J0'!PDNS)R#Q\O)P.^:MZ#>:O M?Z5'^T=B@'V&?K0!J45GZQ<:I:V)ETC3H+^Y#C;&YS@8.!SUXYSO!?C#3_&WA^+5+',;_=GMW.6A?&=I]1CD'N#^%`'0 MT5SGAW7-:U;5-4M-1T:TL8]/F^SO)#?FHZ9S+KQIXFLM;T'2+GPQIL=YK2S-" MIU=R(C$@=A(1;\'!Q\N[G\Z`.\HKSK6?B)KVA>&-3UJ]\)PH-+O?LMS#_:1R M5(BV21GR?F5C+CL1COSC8U;6_&6EZ9/>KX4TZ^\E2QM[/5I'E8#KM4VXR?8' M)[4`=;1110`4444`%%%<=X3\3:SJWBSQ-HFKVEC;MI!MMGV1W<-YJL_+,!G@ M+_".]`'8T4A(`))P!U)KD-1\937/P^NO%7AJ"WN8H%GDQ>.4#1PEPS+MSG)3 M@9&0>2.E`'845E^&M2FUGPKI&J7"QK/>V4-Q(L8(4,Z!B!DDXR?4UJ4`%%%% M`!15/5?[2_LV;^R/LGV_CROM>[RNHSNV\],XQWQ5R@`HJKJ37Z:?,VF16\MZ M!^Z2YD*1DY[D`GIGM^76L+X>^)+KQ=X'T_7;V&&&>Z,NZ.$$*H65T&,DGHHS M[T`=/168=>L1XH3P\&9K]K-KT@8PD8=4YYSDEN./X3^.G0`4444`%%%%`!15 M74FOTT^9M,BMY;T#]TES(4C)SW(!/3/;\NM87P]\277B[P/I^NWL,,,]T9=T M<((50LKH,9)/11GWH`Z>BBB@`HKCK/Q-K+?%*Y\+WMI8QV0TQM0@EA=WD9?. M6-=Q(`!^\2`#VY]=7QAJNI:'X6O]5TNWM9YK.%YW2YD95\M%+-C:#D\<#CZT M`;E%<_I6I:QK'A7P[JEJEBL][%;7%ZLN\*(W0-)Y>,G=D\9./6N@H`***0D` M$DX`ZDT`+16-I>NQ^)?#+:KH11O-$R6K7/",Z.R`G:2=A9<$_$,^G:QH MFAV`A&HZQ),L4MPI:.)(H][L5!!8]`!D=>O%7/#D^NSZ?(/$-G:VU[%.T8:U M?=',@QMD4$DJ#S\I.1B@#7HK,.O6(\4)X>#,U^UFUZ0,82,.J<\YR2W''$_ M'!L_$VLM\4KGPO>VEC'9#3&U""6%W>1E\Y8UW$@`'[Q(`/;GU`.QHHHH`*** M*`"BBB@`HJ"^O;?3K"XO;J01V]O&TLKL>%51DG\A6<-2O-8\*6VJ>'T@6XO; M>*XMEO\`(0*X5L/LR<[2>F>:`-BBBB@`HHJ.U@N=.U:;3]EJ6*GRU3)RW)Y+!]/UV]AAAGNC+NCA!"J%E=!C))Z*,^]=/0`45Q_C3Q-K'AS4_# MR6EI8R6&I:G;Z?-)*[F5&D8YVJ,#&U3R2>>WJ:MXFUC3?B1X?T`VEC_9>K"X MVS[W:;]U%O/'`7YBO][(ST[`'8445QVJ^)M9TWXD>']`-I8_V7JPN-L^]VF_ M=0[SD8`7YBH_BR,].P!V-%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11 M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`'G_`(2_Y*]\1?\`N&?^D[57\=I> M2?%+X>K83P071_M+9)/"947]PN>E;NB>!H]#\27NNQZ_K%U=7 MY4WB7+0%)]JE4R%B!&T'C:1T].*-:\#1ZWXFLM>?7]8MKNQW?8TMV@$<&Y0K MX#1-G!@V7Y+-,X(QGC'< M<\FZ=>W4UIJZB6YTVYMF*2Q%-H=E;&/XTRIZ_AD9&D:OK6B^-]/\ M.>*4L[^>[MYAIFLPQ".215PTD;K_``G"J3MX.%Z]MRZ\&6U_-I-S>:IJD]]I M23+;W?G+')F0KEFV*H8@(%QC!!.03S4UAX4M[76UUF\O[[5-1CC,4,UXR?N$ M/W@BQHBC.!DXS[T`;]>9:G)JD?Q^C;2;:SN)O^$8_>)=W#0KL^TGD,J/SG;Q MCIFO3:Y4>!XQXT/BK^W]8^W&/R/+S!Y7D;]_D[?*SLSWSN_VL\T`U.H3>'[BQM[:S+&*"`(SD;F`+,6YS@?X<]IX&<5ZSXCT)?$FB3Z5+?WEE!<`I, MUH4#R(004)=6P#GG&#QUQD&MI_A*SL_";>&KJYNM2TXP_9U6\\LLL6T*$!1% MX&."$KTV$`C'X8K*\.>&O^$=L#8C6-3U&T"!(XM0>.3RU'&`516(QQ@DCC MBH(O!\=E&;?2=:U72[(DD6=LT31KDY(3S(V9!UX4@#/&*`.&\6EY?&/CM[7/ MV:+P;)'>8Z>>=[1Y]_+)_`U<,D7P_P#BW=2S.(="\30-.SG[L5W&"S9]-RY/ MN6]JZR]\$:?<^&[K0[>[OK&"\9C>3V\BM/<[@0WF/(K$Y[G@\``@<5)J7@^P MUO1[#3M9N+G4197*723S[!([HQ(#;5"D8)4X`R/?F@#BKR*;_A9OP[O;J,QW M5^^IW,J-U3=;J$0^ZH%4^X)[UK?%/_F2O^QKL?\`V>M76O`T>M>)K+7WU_6+ M:[L0PLTMV@\N#V>8/"FNZF/%U_X;\26=D-;BLX[A+^T7"WEL&*@D'D%69N.F6;&.^M< M>#K>XUJ/6O[3U./58[*.R%U%*BDHK,Q+)MV,6+9(*E>!@#O8T?PQ::1J-UJ; M7-U?ZG=*$EO+QE+E!R$`5555!).%4>]`'&VWAZ]TC3CX@^&VHI-IEXINO[&N ME)MYMW),1.&B8_W>F>N,8JB^N6FMZA\+-=MK=;31'FN(/LX`"0S&(QQ(,`#A ME<#I]*ZRQ^'UMI6AQ:+INNZW::>B;&BCGC;?ZG:-0R^A=(UD(] MX"@<]!QC M5TZSEL;&.WFO[F^=/^6]SL\QA[[%4?I]=^"=/>#Q;KGA22=I=(\-7,-Q M8Q/R?WZ&1%8]Q'\VWW(/51CTZN4T3P-'H?B2]UV/7]8NKJ_*F\2Y:`I/M4JF M0L0(V@\;2.GIQ75T`%>16FDW^@^$O#7CCP[`9;J+1[1-5L4X^W6XB7D#_GH@ MZ'TXYZ'U/4;22_T^:UBO;FR>08%Q;;/,3GG;N5@,CC.._&#@U4\.Z&OAS18- M*CO[R\@MU$<+7?EEHXPH"H"BKD#'<$\]>F`#D-+U-/$_A7QWJ'A^8RF]D'!J" M:;%Y,5]>->/$/NH[*JMM'8'9G'J3VP*J-X2A@N+B;2-4U#1_M,AEFCLC$8W< M]6V2HZJ3W*@9/)H`P]>+R?&;PBEGGS(;*]DOL?\`/!E41Y]O,'Z4SQ;_`,E> M^'7_`'$__2=:ZS2-`LM'>>:'S9KNX(,]W<2&267'0%CV'8#`'85D:UX&CUKQ M-9:^^OZQ;7=B&%FENT'EP;E"O@-$V=PZ[B?RP``97QM_Y)#KO_;O_P"E$=:4 M]EXP7Q'H=Q=:K83Z3!-*]ZEI;/:G:8)`I?=,^]0Q7@=R#VR+GC#PA;^--)_L MN^U&_M;)CF6*T:-?.P05W%D8\$9&".O.>,5M2\%W.KZ=+I]]XO\`$$EK,NR6 M-?LL>]>X+)`&P>AYYH`ZB&:*X@CG@D26*10Z2(P964C(((Z@BN5^(263Z%9C M4-2FM+3^T(/,@AC,CW_)Q;!003O..GIZ9KJXXTAB2*-0D:*%51T`'05D>)?# M-EXIL+>UO);F%K:Y2[MY[:39)#*F=KJ2",C)Z@B@#SO1],B;XJ:EX?.D-HND MZAH`NGT^VN?+RZW`4/\`NB`C$9!"DC'4G)%H!!.0.I.3S7JUU\/H+K63K`U_7(-3:S^QR7,4T09X_,$G0QE5Y M'\(`QGCDU6/PMTL^`1X,_M;5O[*$WFYWP^9C=OV9\O&W?\W3.>^.*`(]<>'7 M?BI8>%]202Z9#I+ZD;=S^[N)?-$:AUZ.%&X[3QSGM5+P#I]OI?Q0^(-E:J5@ MC.G>6I8G:#"YVC/89P!V``KH[WP5;7_]F7$VJ:E_:NG;A!JJ-$MP5;.5;";& M&.,%.WJ22:3X&T_2/$UYX@COM4FOKS:9_-NCY;E4V`E%`!XR0#D`G@#```.D MFABN()()XTEBD4H\;J&5E(P00>H(KQCP1IEA!^S=J&H16-M'>W&D:@LURD2B M20!I@`S8R0`!U]*]JKB4^&>GP^&Y_#]KK6M6VF2AT\B*>/"1.2SQC*'Y26SD MY;L&P2"`<=/96^D^%OA5K%HFS49;W3;22Y+$NT,L)#QD_P!WI@=!BK^HK<^* M_B=XFT:;3=/U.#3+6VCMX+Z^>`1>8F]Y$"Q/E\E1NX*X&.O'37WPYL[_`$+0 M=)?6M7CAT.1);22-H1(63B,L?+P=@X&`/?)YJ/6OAEIFM:O#K#:MK5EJJ0+! M+>V%RL$EPH&,OM7&3WVA1[=*`-GP9%J%OX1TZVU6^MKZ^MT:":XMI3*CLC%? MO$`EAC#9&=P-4_B-8PWOP^UPRF8&VL9[F(Q3/'ATC8J3M(W#/8Y'3CBM[2], MM='TRWTZR0I;P)L0,Q8GU))Y))R2>Y-5/$F@IXET2?29;^\L[>X!29K0H'D0 M@@H2ZM@'/.,'CKC((!X]XO\`#.E1_`"SU]89!JJ:18)]H$[@LK-$"K`'#`!B M!D'`Z5W/Q%1VUGPH;N!KS0S>2I?6$:&1IV,1,9\LM6 M$-E;SSQ^(O/6!C(Q"^49%0(K;1DD@<`#DL30!L^`=,NH-?\`$-ZEOJ%IH3R1 MQZ3:W3RQB--N9=L#'"*7^[\H.,]J\VM;*WL_V9K'Q#$G_$UL)A/:W)8[H6^V M[?D/$()R!USFNWTKPU+)J47_"/?$+Q%J6GS*Z7LTEZETJ)M.#%(4*!]VP<` MG:6/!Q6N?A;I9\`#P8=5U;^RA-YH.^'S,;M^S=Y>-N_YNF<]\<4`9=WHVEW_ M`.T)MO--L[D?\(V+C$T"O^]%SM#\C[P4``]<<5S_`(ICMWFUBU\0Z4XM;VXN M(;;Q9IY\XP*SE?*G"D,JI_JRI.#M(QU->B-X&MI-5M-5EUC5GU""U-E)X@+[]CE$&,'NFUN.2:(_`MG#]MBCU/4Q97]S-<7ED94:*34IYKF(SRA-#CA$G]I/LXW`D`*G+$M\OKBNUK"U M_P`*VFOW^F:@]U>6=_ICN]K`'!#*RD$``@B@#RE++-C\4](EM9-.M M=,MHKZTL;:[<);2-;2/P4(!!(4E<;<^N`:N3V5OI7A;X4ZQ:)LU&6]TVUDN< MDNT,L)WQD]UZ8'0=JZ^]^&%A>3ZO*NN:Y;G6$C2_$4\9\\(C(`2T9(!#'(!Q MTP!@5+??#BRO]"T'2'UK5XX=#D26TEC>$2%DXC+'R\'8.!@#CKD\T`9?AZRL M?&^L>*[W6(O.N+'59=-M`S%1C>XV?*Y[M'LZ\8JQX1\'Z?X+TK^ MSM-N+Z6#L+JX,@7DD[5X5\07\NE>&M5U&!/,FM+.:=$QG!Z5ZVZ+(C(Z MAD8$,K#((]#7)V_P[TRULWTR*_U(:&TAW]I#>N[WMQ"Z&>Z+@A][NC=<]@#@`#`XH`\^U MBRA'A#X2ZB#,+@WVD6YQ,^PH4W8V9VYRHYQG@XK6G^%MM2XDB!<<#;$,@TGPO!$;:>^E)G#!BS%7QED!$1!Q@D-QCKK3>`K:ZU'2=1NM;UF M>^TL2+!.\Z!BKIL8$!`.1_$H#=\YQ@`\Y$^']*F_9PGU'[&D5^+"]G:Z@)B MED:-YMF]T(+@8'RL2.!QP*W=2U6;3?A#X%@CGDMX=2.EV-S/$Q5HX712Y##E M/"1.2SQC,9X);.3ENP8`D&_%X&T MP^#?^$5U"XN]3TY46.+[64\R)5`"!615^[C()R??'%`',>+-"L_"_B#PW?Z# M:_8EU/45TK4+:T=HEN(I5;+D*1\RX+;QAL]ZYK2=`TZ7X=_$L3PM/_9^J:E] MD,TC.83#$I1E).0PP/FZD#%>H0>$42:*XNM:U2^N;:-TLY[IHF:U++M+H!&% M9\?Q.&/7L3G.L?AO96'A[7=%36M8D@UJ1I;J21X3('?B0J?+Q\XP#D'VP>:` M,'5+G4M1\(>#K]]*M_$:R:8)[[29I5$D^Z.(F=%;.\H21C!_UH[X-;WPU73& MT;4KK2I+P0W6H-(]K>HRS6;B*-#"VXDG`0$>@8#M4EM\/;6U@TE$US63+I$4 MD-A.98@\*.(QMXC"N`(Q@.&'S'.?EQT6EZ7'I<$J+--<332>;/<3D&29\!=S M;0!]U5&`````!0!@_$S6KSP_\.=:U/3RRW44*K&Z]4+NJ;A[@-G\*YCQSHFG M^%O"MKXM\-1>7J=A+;L)XF.^_C=U0I*?^6F[<#ELGWKTN^L;74[">QO8$GM9 MT,!K.RCLK:;4]3OK"P=7M+*ZD1HH63[G*H&;;Q@,S`8'<"@ M#F/&NA:/=_%[P-]ITJQF^W?;_M?F6Z-]HV6Z[/,R/FV]LYQVKTR""&UMXK>W MBCA@B0)''&H544#```X``XQ7,:UX&CUKQ/9Z^^O:Q;7=B&%HEN8/+@W+M?`: M)L[AUW$]?3`'5T`>97>C:7?_`+0FV\TVSN1_PC8N,30*_P"]%SM#\C[P4``] M<<5)>V%OJ/Q_$%W'YL/_``BV6B8_*X^U$88?Q#GH>.!74ZEX1LM2\20Z]]KO MK6]2U-FYM9@@FAW;]C'!(^;G*E3[U!;^"X;?QQ)XL;6-4FO9(6MC#(T7DB$G M<(P!&"`#@@YSDV89=,LKUY3YR,`955HD`4JX#8'7;G MK4*_"31GTW4].O-4U:]M-1N&O)HYY(AMN203,I2-2&XQC.W!/'2MKPOX*LO" M\DLT>H:IJ-R\8B%QJ5T9G2,3^%_"^D7/Q)^(&EW=N]Y M8Q"P"P7L5XUX>O-)\0_%_QI]@\4R6LEVMHEJ]A M<1'[4JP$2A=ZL&VE>JC(YP0,T`1Z4R-X#N]-U?6;J/3M+\4O8PJJM-)J,*.- MML.76X"ASY1`1B,@A20 M1U)R17:7G@#1+KPW8Z)']IM8;&X6[MIX)<3).I)\W<01_"`.O')H`\\\,^'M+U#]GE]9O;47. MH0:9J;Q32L6*$M+T&<$94-SG#']*MOV<;34;6S2UNAIUC*SVQ,0E M>3RE=I`I`D)!/+`]3CK7I.@>!+#0/"UQX:2^O[S29HGA$%TT9\M7W;PK(BGG M>>I/MBL^_P#A?8ZCX7B\.SZ_KITY%2,QB:+YD3'EJ]%E?730PRR&39EL1OO*JIPI&.29%N+-I MK>6))I('="JRQA2R$C[PW`C(Z\@CU!H`\5LM'L=0\#_%.YNX?.EMM9U26`L3 MB*1$#*ZCLV<V`4*%5E0`@`#[P)]^!@`YR_\-W5 MAX+\;V=^UG;6L-L^HZ?I^G:C*QLV\E^#\L?[LNA95QMSNX^6LO5;>WT3X:>" M]0LX]E_K":;IEU<-H:IJ-R\8B%QJ5T9G2,:;*-Z5)YZ_:'VL([ M)-H"YPHPQ!P!G)SUK;T6\'A;7OBC!IT"QV.E0P7UM:(,(DC6S.^U>@!*C@5L MV/PMT[3M7TC48-=UUCI&19P2W$7N`4'`PV>.2><@'F?C'0M.E_9_\`^$B*F75[ MJVM;JYO2^9)GDDC+J[=U!;A>B[1@#%;NHK<^*_B=XFT:;3=/U.#3+6VCMX+Z M^>`1>8F]Y$"Q/E\E1NX*X&.O'03_``MTFX\/S^'VU/5UT620.EBLZ;(<.'PI M*;MN>S,1SD8."&:A\*-&OM0@U&'5=>L=0BB\E[RTU!A-,OH[L&)].W``Z`4` MK1:]::;/=65[(\;*LD@.,X&\%%RQ7<&4C/%>M:5HN MG:'#-#IMLMO%-,T[HI)!=L;B`3QG'0<5SFJ?#?3M3@T>V35-5LK72'2:T@MI M(]HF4DB5B\;,S\]SCVY.>N@C:*WCC>9YG10K2R!0SD#[QV@#)Z\`#T`H`Q?& M:78,Q]>KUQW@4:;<>-9)4T6Z\-:I; M6$L4^C2)^X8/)&3-"1A<90`E5&Z>$V\5XS0^;;Q%E+*G[O;\VU,VME;V?[,UCXAB3_`(FMA,)[6Y+'="WVW;\A_A!!.0.N- MM9MY[0^);Z2W@"6,JA8=*3:>3*Q(5G/S?*"_'3'-7S\+=+/@`>##JNK?V4)O M-!WP^9C=OV;O+QMW_-TSGOCBKMEX#M['5[C5(]:6=_=>-[:*\^*WP M\@G4M$_]I;ER1N`@4X..Q[CN.#7HM8>O^%K/Q!27%W:7^G.[VEW:2!9( MMX`8?,"I!``((-`'E7C+4I_`&I^+K+PW_HEE)HL-Z(H3M2UN'N!"2@Z(2K;N M,<@&NJT#P]?:3XJTC4+6VT32].N+>2WN(K?4Y)WOR4WQN`T*!I!M)+$DE2WI M72?\(5I$VF:G9WPFOVU0`7MSHC4`!']-LA:K']MU*_@TZV M:4$HDDIQN8#J``3COC%`'1T5RP_MSPW+J>HZIK"ZEH5O8M0<#GK7/7>J^+4\`0>-[?54:46BZC+I1MT^SM`5WE`V/,#!#][<02. M@H`]*HKS;4/$NO7'C;P8FF:I!'HOB*":=(6M!O14@#_,Q)R3N!&-N,`'(SEB M^+-;TN3QQIUQEDA5+,0`!DD M]J9!/#=6\5Q;RQS02H'CDC8,KJ1D$$<$$^UC4=:\,:_=Z3XM.JZ`FA7 MDGVA(X8KF&X`5D20!5(!02`813@MDYVD0:C>^(_"OP)TS7-(\0/NATZSN0#V.BO,_B/-XL\,^#]5\16GBN2-X&A:.U2Q@ M,:[G1&7J:7'XCTUM4N%>](32;?199(9+42["1.(SF3:"^ M0^,_+MSQ79ZUJ][=^,[+PIIE[]AE>S?4+NY6-7D6$.$58PP*[BQZD'`7I0!; M\/\`C'3_`!)JNJZ=9V]]#/IAB$XN[[/SO\`W4&.3VK@?`,5W!\4/B#%?7(N;A#IP:8($WCR7VD@ M<`[<9QQG.`.E:7C[6-=T34_#$NGZA#%8WVL6NGW%N;8,[AV)8[R3@;5Q@+GD MG/H`=Q17GQU+Q,_Q(&8(`"V[+#'4_*F-+X> MZYJ&LZ9JT&J3BYNM*U:YTYKGRU0S",C#%5X!PW8#I0!U]%(O^$?M;J6 M`QJ[,PVRO'P00I)*\0/+ M55*$>O(.!SUKG-)U+Q/XR\.IXET'5X+,2W+_`&2PGA4P/"DA0^:VTON;:3E2 M`,@8/6@#T&BN/DU74/$'C+5_#^G:D^FP:1;P-//#$CRO+,&90/,5E"A5YXR< M]1BN'\1>-_%VF>%?$\2ZI:Q:OX:N(HYYA9`_:HIBHB<`G:C8+$C:P.!TH`]H MKGKKQCI]IXQL/#$MO?"^O0YAD^SD0G9&7;#G`;`&/ES@D`XYQE^(=4UGPQ8M M+)JD5W=ZO>VUAIT4EN%CM9I#M/*\NG5@#SQC)S6#J]EJ=C\8/`"7^K/J,;#4 M#')+"D;JWV<;A\@`V_=QQD&WUJ)--DTAK^,0VBJ\0,P0` M%MV6&.I^4Y/R],`'H-%>9Z?X_OM+^'WBC5=687]UX?U*XT\2[!']I*NJHS!> M!DNH.!VKJ++3O%-IK-E/<:Y!?6#Q,+Z"6!8_+DQ\I@*KG;G@AR3CN30!TE%> M06WQ`UO5-+C\1Z:VJ7"O>D)I-OHLLD,EJ)=A(G$9S)M!?(?&?EVYXKUR9&D@ MDC25HG92%D0`E"1U&01D>X(H`?17D]KK'BA=*\::;=>)+M]=TB[1;.2.TM\R M)(O[A=GEX)=F`/X8(YS>\,Z[K/BK0?![6^O7$5W<)+/JO.*`-:BO-;/Q3=67 MQ%T30XO$;:[9ZG'<),SV\:B"6)-_R/&BJ0>05RQ7N>13M#O?%FK>+_&'A^Z\ M11QC3%M?L]Q:V,:E&E1GX5]PQT!#9^Z,$9-`'I%<]9^,=/OO&-SX7CM[Y+^W MMVN6::W,<;(KJF5+8+`EN"!@X/-HP6';373J\NFQZ9JG]D M^((;6VA=4VR;6FC,B,0<,N0'3[:S\^]MD MCB9)"S$1#<4+`MB0G#=$7`&FMJEPKWI":3;Z++)#):B7 M82)Q&*`/7Z*\ZGU#Q5-\5;OPRFO0PV4NC/?0/%9)NMR9@B? M>+;V&.2<`Y/`XQ%X>N_%VI^*O%OAV]\2IG2X[00W=O8QHP:2-GSM;<,=,@YZ M<;>:`/2J*\MM_B/?O\)-`UV0(-4U:Z33UD6!I`LAD9#((TY8X1F"CJ<`#M6G MHWBG4++4=:347U6]T>TT_P"WQ:A>Z4]FRE<^9$+_&. MG^"]*_M'4K>^E@S@FUMS(%Z#YFX56-HPK8WEQE8JJ6^7.1]X#G!R#Q6[7D_@JPU MF]M?'1TC66T^=/$]\80L$<@=_EX?>#\IX'R[2.>346I>+O$&I>!O#_CBPU:X MT_3'*1ZO:VUO"Y1?,,;RQF1&(PPZ'(QCT)(!Z[44]S!:HKW$T<*LZQJ9'"@N MQ"JHSW)(`''5CNH[AHTC=HGA,NP M[``2-I&<=Z`.^K+\0Z_:^&M'FU2]BNI+>$9<6T#2LHP220.@`!R3@#UK@-#\ M7Z_=S>'-0WZG?1:I(@OK-=$EC@M$D4E7CF,8RJDJ"Q=@0%K/Q//>VT MFEB^M-4-K#YD+B780,((Y%Y'(4CJ,Y%`'IE%>+3^*O%8^%-YJ"Z_=#Q-IM_/ M:7"):V[+(\9W,NWR^`L2L^1SP>O`';:3J-_KVLZ--8ZU.-.32HKN\C$4)$[R M?ZO+;,J2%D+!<=%QC-`'9T5Y7I'BS5=?NK2/3/$.W5UO(5U70KNVBC>WC$H\ MX0D@%@JY!)+DC)&&Q7;^,O$2^$_"&I:XT8D-K%E$)P&L:[ M;:,;6*2.:XN[R0Q6MK;@&29@I8XW$``*"220!ZUR/B;4O$G@G3K3Q%>:S_:% MC'+$FJ6;VT:I&KL%+PLH##!(X8MG/6J7C73[J;XO>!A'K5]!]H^W^7Y:0'[- MMMUSLW1G.[OOW=>-M`';^'O$EGXDTV6\MXKFV\B9X)X;N/RY(9%QN5ADCC(Z M$BJ7B?QQI/A70HM9NENKNQE4.DMC#YR%3C:=X^4`[A@DC.>*3QM%/#\-=>1; MZY$\.ES-]I&U9'*QDY.%"@MCG:!U.,<8\[\3VDUM^S'NEU"YNEET[3G1)EC` MA&^'Y5V(I(_WBQ]Z`/:J*XB[U;6=&^(_AW3+G4?M5GK<-TKV_D(JP20H'W(P M&[!!(PQ;_#`U'QMK.H7/B231[F_BETBZ>TL[*UT>6ZCNI(@"XED6-@NYB5`# M(1P3P:`/5JR-1\4:1I5\MCT^Z:^TV MUNW@DMVGA24PRJ5>,L`=K`\@C."#7$ZKH_B/PWXQU+Q7H%O%JUMJ4<*WVFNX MCE'E*55H6/'3/RGJ2?;`!U-AXGT34["\O[/5+:6RLY#'<7&_$<;!5(^,[_1M2^#OB_4-`FO;.2;4(YM0LY4$TQ=,MXM)M0U?P#X]TN35Y[R+2)K%H+SR%@>XBF M9?D%-:U6?Q-?:9()_#^EV?V,1_;M1OX-/M3*"4625L;F`QD`!CCOB@#HZYO7/&E MCHD]W"+*_OY+*%9[Q;&)7^S1MG:SY8==K'"Y.`3C%8^IZIK?@_Q-H8OM6DU3 M1]7NA8,)[>-)+>=@3&5:-5!4D$88$C'4UD>$-+O1\6_'"GQ!J3&V;3FD8QV^ M;H&$G;)^ZP`!Q\FPX/4GF@#M=1\8Z)I.DVFJWMQ/'8W<0ECG6TFD0*0""Y53 MLX8?>QW]#6N;R`6!OD<&@4REUQG*A02V1T`!)[5C>._P#DGGB7_L%7 M7_HIJYC3KA_AKX@AT&]D8^%M1E(TNY3;NQ_A/)4GZ=B0`=AH/B;2O$ MT,TVE2W$L4+;&>2TEA7=D@@&15W$$$$#..^,BM>N`D\1_P#")?#+7-<$2RO: MZCJ)C1LX9VOI57..VYA46DZSKTOB*VTPWNLWEI?VU%A<*H*LI>)5 M*GYL!MW(&2F>]`'> M5SVO^,=/\.:II>GWEO?-+J5Q';0216Y,0=VVJ&-I+V[;58=!$#VES+`('G$R_(K`*H^]@;@HR#D9XJ+QS8:[:2>!Y-5UD7WF M>);$S1_9TC6.7+?ZLJ`=F-PPQ8]#D=*`/6Z*\Q\3Z[XATJRU^_O->72KJV>9 M]*TV"&&<7-O&N1)(-K.-Q!R05"]Z[WP_J3:SX;TO5'0(U[9Q7!0=%+H&Q^M` M&C1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11 M10`5S7CGPJ_BW08[2WNA:7MKF"1^/X5TM%`'(Z7HWBC4X M+V/QE>Z8\%Q:O:?8]+1Q&ROPSLTG);'````R>M9=EX1\36_@]_!DEWI\FE&) M[1=1\Q_M`MFR-OE;-N[:=H._`X.#7H5%`'!:CX4UN3QUX5U#3X-+BT3P^DD, M4;W,@F>.2(1L=OED`J!P-QSCDC/&?<>$?&J^*?$^I:==:3:)K5S9/'.+J4R0 M);L,$H(P'WH""FX#YB-Q'7TVB@#@SX&FOY-;N)[/2]*N=2TR?3Y#I[LZSF0# M]]("J8(QP,$_,V6/%9.N>#/&6J_"^#P/4J*`.5\6^'=0\9?#Z^T2[-M97]TBY,4K2Q*R2!U^8JI(.T9^7C)ZX MR(_$5UH0TA-+%OIFH0ZDS7=S( MC221EL)A8V`7!ZYSSTXY[>B@#A;#0/$[_%$>*=1@TB&T.F'3C#;WDDLB#?Y@ M8$Q*&.[C'&`>^,&3P#X?\0^';G7%U:/3#;ZGJ,^I*]I.VHH`X_6/#NL2_$"P\2V#6%S#!8O:?9;UW3R69MQFC*JWS$84C`R!C// M'-'X8ZU'ISZK10!S7ANT\ M7_:GN_%-_I9*Q&*.UTN-Q$22#YC,_);C````!/K7,Z/X*\9>'$FT'1M9TJ'P MW),\D(+B.;4)YII$2%(MGE M1Q@(Q8`)RQV]SCG`]1HH`Y/Q1X:U#Q;X7M89Y;?3M9M+E+VVD@D::*.>,G:< ME5)!!YX&,]\7X9ZEX/-UI#/<3F;^T7>3S+HF829E&WY6XQNR_``QWK=T[ MP_XI;XH_\)1J<>CI:'36T[RK:ZE>14\PR*WS1@$YP",CJ3[5WE%`'F&F_#W6 MKKP_XLT'7O[-CM->O9M06>SN'E>&5V1E4JT:AE!0'.0>,8YR-[PUIGCB*ZM5 M\1:KI+65DI5$T^.3S+KY=H,I?@8ZX4=>_%=C10!Y7H/@/QMX M&9)F9)BLHO8(V.66,C"@GGYLG!.17JE%%`')W'@WSOB/%XF$RK;"T5)K<9S+ M.A/EN>V`KM^(4]J/!W@T>%K[7)_.61+Z\>6V12<00DEMG(X.]G_#;7644`>9 MVW@WQ3<:SXRGU%='BM?$]J+=S;W#D.@H%M[>V>8W$WRK#L(8?NSN+%!Q@;<=6SQZE10!POB+0/$^I>,/"VOV4 M&D?\2>*8S037DB[Y)DV.JL(C\H`&&(R?[H[[?C;0;OQ/X-U+1K&\^QW%U&$6 M8YP,,"0<+^S5L)K9#),P3S3(P5B$R>F&(XS]TXR>[HH`X M;XF&\O-/TG1-*O+2+4[^_0Q6UTI:.ZCB!D='QR$X4MZCY?XJS-(C\:^$[VS2 MZT+P?%I5U=1PSIH<$P3G.YE*H^X-P2"!TZU?T[P7:6_A/4=$OG%RV MJ//-?S!=OF2S$EF4'=/UW34\,R3,R3%91>P1L:'\P_NL;NORYQVW=Z3P[ MH'BG3?%GBO7KV'1]VL10F"&&\D;RY(4*(K$Q#Y2#RP&1C[ISQW=%`'D=K\,? M$3_#"R\+7-WIUK?Z1>+>Z=>VTTD@:3?(WSJ47;C>0"-WT&.>ITO0/%&J6]]' MXTO["2.XLGL5MM+\Q8BKC#R/OZO@`#C`&<=379T4`>6ZEX$\6W_PUE\$->:2 M]O&(HH+YWD$CPI(K*K1[<*0%`R&;.,8&8_>M;1LD9.> MP8D],=_RZ5:HH`X+3_"WB;09?$5KI5QICVFLW\U\MU,\BS6KRXW8C"D28P,? M,OOZ5O6GAG1]&\#_`/".R`?V3#:M#*9F`RA!WLQZ`G).:WZQM=\*:'XFELI- M9T^.\:R7M"Q M*1VQ&J#'KFI_'/AR]\166D-ITENMUIFJP:BB7#,J2^7GY"R@E<[NN#TKJ<8& M!10!P.H>'O%FI>/?#.N3KHOV31S,'"7$JO()D"N0IC(&T=!N^;;GY=V%C@\' M:Y+XL\8W%\NF_P!D>)85MG,5S)Y\*)$T2G:8PI)#;^%/"G MCO2(=.T74M;TQ]"T^16CDM5E%U*B'*1L3A0G`!'.1QR#75>,]/U75_"FH:7I M"69N+Z![9GNYFC2-'4J6&U&)//`XZYSQ@[U%`'G-WX,\1ZA\.]#T*9]+CO-( MGM6,0FDDMKV*!0`DF4!4,>2,,/E'KQH0^'/$)^),/BF9M+2%M+_L^6!))&:( M>=YF5)4!^,C)VXST..>VHH`X_3_`\=KXUUW69I$DL=04&*TYPDC(%F<^[!5P M?=O6I_`'A)_!OAL:;-<"YG\UF:4'/R`[8UY`Z(%X]\1/IK:?"T)N;BWE=Y;Q8F#*I1D` MCW%5+$,W<#&*-1\?:#KNGP:.UGHHG\N.XO)4DG\Z,(V=L3!,=OO9Q MGO@=W10!GZ]IAUKP[J>E"3RC>VDML)",[=Z%)]2\8>%M?LH-(_XD\4 MQF@FO)%WR3)L=581'Y0`,,1D_P!T=\U/!GC70?$FMS^%]7TA=+UFY:ZE2_CD M:2WD?[S1A>"?J<<#CBO3**`(+&V-EI]M:F:6 M:7&GB)+-@RF3,3VXX7&.A('S9/0_+SQT'B_PGK7C'PI#;SWEG8:Q:WD=]:/; M[VBB=`0`6."W5OFVCJ...>WHH`Y;PQ8>+A>M>^*]0TYY$A\B&VTP2"(Y(+2/ MOZO\H`XP!G'4U-XV\*CQ=H`LH[HVEY;SI=V=P!GRIDSM)'IR1^-='10!R3Z' MK6OZAI$WB*/3H(-+N!=I#93/+Y\X4JC$LB[%7<3M^;)QSQS1\,:!XHTWQWK^ MN:E!HXM=:,&]+:\E=X/)C*K@-$H?.1GE?7VKNZ*`,'QEI^JZOX4U#2](2S:X MOH'MF:[F:-(T="I8;58DC/`X]<\8,E[HR^)O"\NE^)+.V!N4*SQ6\QD13GAD M=E4Y&`?N\'UQD[5%`'`Q_#R>?X2W'@N^U#S)Y&F(O,$EB;AID=AUS]W(SZ\F MK'A?1_',-U9#Q1J^FR6E@A$:Z?YH>Y8J5!F+8!`!)P!UP>HKMJ*`.-USP1)J M?CK3M>M[E(;7RO)U.`CFY5'$D0Z8X<YN=$CNM(U&"]-QYDL@N#$&PQ7: M-I)/*Y.(#,YOV$BR)OC*"+9@_(O\` M#\YV@G@]*Z/PWIWB'1]'\/Z9<'2S;V=L+>[,;2,Y"1*J&,D`$E@2<@8!`&<9 M/344`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110` M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110` M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%>>_&?[1:?#J^U:QU#4+&]L3&8I+.[DASOE1&#!2`W!XS MT[8R<@'H5%>"B+0_V1K^N6%\HS'/)J,URI8=-\IVEQ+97T<8PJS1M@X^HP?QH`Z:BO/O'?B#5-'U*TU:QD%A=VLI1Q&)%9MC+R"4#` M'W]*`-BBO+CHZGXQ'P__`&IKHTW_`(1[[9Y0UJ[SYWVC9OW>9G[O&,X]JJ>* M]$U#P]IO@Z"3Q%K<\\OB"+3YYEU.=#<6TLLK@/AA\P7:NX8/&,X`P`>N45QE MWX;TY==TZRL?$.M6>I1NM_Y#:I=3K/!'(@=75Y"NUMP7MUZ$`BL.?2SK7"(LQGV$KM<%5Q_"#@=ACB@#T^BO._$9U'X?R6>NVFK M7MUH7VF.#4;._E:?RHW;:)4D;+@J2,@D@YKT2@`HKC&^)>DK9IJ8L=2;1'N/ MLZZL(D^S[M^S.-_F;=W&[9BH;SQ;JL'Q83P[#I=U<6*Z2;HK`T.79I5429=U MPJX9<9R23\I`!H`[FBJNHV,>IZ?-9RRW,*2C!DMIWAD7G(*NI!'(_'H<@D5Y M;X!L!J_PFLM>U3Q)K=O?ND[O?/JTY5-LKJI*,Y0@!1P5YH`]:[^ M&.G^(_$-+:\NS9G2M4M[Q[1KRU@ MN(T1KN-<9\OY\!N1\KE2,C.!S0!TM%*],U&_L=(U.)+&1H6BN%B1 MY)5&6C4>8<,.!\VT?,.>N"#QQ8S>']/U9K#4(CJ4@CL;-T0SW!(R"H5RN,`M MDL!@9..*`.GHKE)/'^EP:'?ZG/9ZG&=/F,-Y:BU+S0,%WDL$)4+MYWYV^]<) M\5=Y4DS45S'B7 MQK!X8U33K&?2-3NFU!Q%;S6PB\MI23B,L\BX;C//'/!ZXT;S71:>(;+1QIU[ M/)=QM*)XO+\N)5(#%\N&&-R]%.,=)6Q^&FJ1VNH:K%)IUE-'&N'$DS.-[7*@D;B=HPJ\#`&.E;VL^/++1+6\OI],U2 M;3;0R))>V\*/'YB':R`;MV=P*[BH7(.6XH`ZJBBN;\;^(;CP[H*26*1R:E>W M45C9)+]PS2-@%O8#)_"@#I**Y@^#W:UW/XAULZF5_P"/Q;QU4-ZB`'RL9[%3 MQQFI_!-GK5AX4MK;Q#+K>TNKRVL]-U'59;$*;M;"-&\G(R`=S+N;'.U=QY''-#DMIU MHMM`K0RQ)Y(D1V:1F#JXW@KC;N("]%-`'>T5Y!X$UVV\(Z+XT9K+4KRUL/$- MWYA@'F-%"H10S,[#=@+S@DX&<5Z/J/B;3M/T^QNP9;DZ@RK90VZ;I+@L-PV@ MX_AY))``ZD4`;%%9.A>(+77X[KR8;BVN+28P7-K* M/$.EWNLWNMZ)8:2-3^T7LF^:W;+?NF?ON56;\!@=:K2:IJND>`])\?W6I73W M,LD%S?V[3L;=K:9PNQ8R=J;0ZD,!NXY)R:`.J\3>.K/0[;7(K417.J:59I=M M:R2B,.K;N`>22%4L>.Z\\\=+;WUG=RS16UU!-)`VV9(Y`QC;T8#H?K7!>,=# MURZE\6IIVDO>+J^DP6L#I/$@5T,P8'
#LZ5IU_#\0M2U)].D MM["YTRVBC:Z5?6=K\<-3OI8;[3XX_#DMS>17\A,#IB@#URBN2M?B#87$^E>=INIVEIJ[!+"]N(D$4[,,J/E&_&L'B75]2TV/2-3LI].(6Y^V")=C'[JX61BM M[B=-.O;..&=X`;GR_P!XR,58KL=L@$$9XJ/4_$L%AJ!TZWL[S4M0$/VAK6S5 M"R1YP&8NRJ,D'`SDX.`:`-JBL'2_%=KK>B3ZCI5G>7EK%A:W9^(=*CU"Q,@C9F1DE7:\;J2K*P[$ M$$4`:5%%<-XA\*:UKAO-0D\7:IHK0E_LD-E*$@C1>C2@O2@#LZ*X#Q#/J%C\7O M!L46JWOV+4?MOG67F`0_NH,KP`,\L3\Q/.,8P*ZK7-0GM8(K6Q"MJ5XQBM@P MRJ'&6D8?W5')]3A>K"@#5HKB?A%J-[JWPOT>^U"ZFNKN4SF2:9RS-B>0#)/H M``/0"NVH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"O M-?CKJ5E:_"[4;*>ZBCNKPQ"WA9@'EVS1LVT=3@&WCCICWKTJB@ M#RP>(M%/[1!7^U;/(T'^S_\`7+C[3]ISY.?[_P#L]<\=:7XQZEHP?PEIFHW5 MGDZ]:7%Q;SNN/LPWJ[NI_@Y()/'7WKU*B@#S-]3^'GAW6H-5\,OI$VL7,?\` M9T%AI,T06X,DB$;Q&#MP5'S=@3U.*JS>*=`MOC_--<:U80PP>'C9RRRW"JB3 MBYW&,L3C'7_`(.:O-)<&QO(9MJ^'K.+RH[)1<+_`*U%&22/FW-A MG44`5=2 MU*RTC3YK_4;J*UM(1F265PJKS@V*]YHH`\6N+7Q%J_P!\06S)?7#?:&_LS[2I^TR62 M2HR[QC);:'^HQ6IX-UGPEXF\0Z/=:-;:O>:I;1R-7UY(NG!D(8?O69&+- MM7`^O\->JT4`>5ZM9W^A_$&_TC3XY!9>,8@PDCZ6TR86=_;,1+9[M@4WXK"/ M1=6\&:M-;W@T'3I9XKLV,LD30J\:HA#1D,``&Z$9Z=\5ZM10!X_=:QX2C\!^ M-=5TDW$5GJ-D;5-1O[J=VO[CR9%5$$Y+':,#(Z\]DK-\7^(='E_9KL;*/4[2 M2ZEL;*W2%)E+F2,PM(N`_B75;=H+NXCCM5C88VK$"'(';=*9/P M"^E;'B.+Q/.+6+P[F6MA;[O M)MXEB0LY/4GN:`//_`(ZZE96OPNU&RGNHH[J\,0MX68!Y=LT;-M'4 MX')/;CU%1>,=.^'D/PUU76+/3O#:1W%E/'8W4-M"-\Q1@HC8#[^X'IR"IZ8- M>GT4`>&>+?$>BS_LUV5G#JEI)=2V-E;+"DJES+$83(FWKE1R?3(]16W\3O%G MA^XB\$RP:S92Q_V_:7Q:.96`@1G5I#@\*#D9]01V->L44`>46_BKP_=_M`1S M6^LV$L,GA\64Z%JWV2ZDU"ZAN?# M&H#SK?52LC(QA1@#F3!R5!`)()`!->V44`9FF>(-*UF\U"TT^\6>XT^7R;J, M*08WY&.0,\@C(R.#Z5B?$31+[6-#L;C38_.O=)UX8,X\XQ$Y0>Y!./?%= M';:=#;7MU>`O)[^[Y'^LW=L8K/\`%/C&VTOPY;P:E6^./#`M/`8OE\87FS25CN]--S]D2(21C]V`R0J>1\HPW.1 MUKH=+^)GAF]\)V>O7.IP6\4S1PS)DL89F!.Q@`2.C:2X-C>0S;5\/6<7E1 MV2BX7_6HHR21\VYL+EN`"*^AJ*`/'=9OM/O_`!9K.IZ)XH?P]J,$D46^<[[+ M51Y*,/D(`9\,%PNX[0I`.X5ZEH7F'P]IIELH[&3[+%OM(UVK`=@S&!V"],>U M:%%`'F?A?6+?PAXE\6Z7XDNHK`W>J2:E97%RX1+B*0`!48\$KL`QUYZ5QWBI M(=#^"?B2&\E%K)KNKR7FFV4QV2^2;B-@`AY&%7<1VW#.":]]HH`K:?J%EJMC M%?:?=0W5K*"8YH7#HV#@X(]""/J*\\TC5;'0OB[X[;5+A;47::?)`9`1O1(6 M#N/]A3]YNB]R*],HH`\0T'7-,G^&GQ5N([Z`QS:EJ,J'>`2LT86(X]';@>I& M!5+5-6LAX8^&.NB6XNM%TJW-IJCZ=<.CVTC6\:89HB&4K\V1D9''1N??**`. M)\`3>'[^YU?4_#EM>O9W)A#ZC=W%Q(UVZAAP)B6P@VC=WSC^$5K^*_&.C>#M M/CNM7O(X/.;9"K!B7;OPH)P.Y`./Q`K?HH`\PTWQ3X4\70:EX8T&_EU'4=9M MK@WMW]GDC"9CV;FW@':,JBJ,X&/JV?\=M'`Z[Y M)!U5,1@ANC;AC.:]DHH`****`.`^($LVE>*O!WB*5)&TC3KFX2^=`2(O-CV) M(V/X5R:E:PG5[=_";P11V\#3QW4AF9A'E58%6`(+?=X(/ M0U['10!X-JNK6FI:'X#U:761-,FN6#W-K`/*M-.4;LQ[`,(5X7+DM@'&`:Z[ MQG_:.A^)]+\5^'X#,^JP_P!EW$6TC<[@FWD8'IM?@DC('%>EUS,&E^(;[Q*; MK6[C3?[*LIWET^WLT?S')!56F+'&55CPHQDY["@#;TO3XM)TJUT^$DQV\2QA MFY+8'4^I/4^YK@H]13PG\6M?N==F2TTO6K6V>SO9V"1*T*[6B+'@$EBW.*]( MHH`\]\,RVFEZOXT\7W5REGH-]<0&WEG.Q&$<81I!GL[M@'^+`QU%0?`O4+*Y M^%NF6<%U#)=6AE%Q"K@O%NFD9=PZC(Y&>M>DT4`>7?%#6[3Q!H^M^!+-9AKK MFT\F)X\"<-+&Q,9_B"J"6/;!]#6C\6#Y.G^&+]P1:V/B.SN;J3'$42[LN?89 M'YUZ!10!Y3)XETF/XZ+J376=/?PV(5NT1FA)^T%MV\`@)A6RY.T;3D\5C:%K MFF3?#7XJSQWT#1RZEJ,J'>.5FC"Q'Z.W`]2,"O;Z*`/G>#7='LM3\&ZSJ5W= MMH'_``C4.ESW6G74T?V6Z3#,DAA8,#C;E3UR#@X%>E^'-?\`"OAWPS-JB+/I MFCWVI,8+B\DGE:[=U&93YF64,5;KQA=QQDUWM5-2TZ'5;-K.Y+FVDXEC4@"5 M>Z-_LGOC&>G3-`%NO._%?Q(\%0W]QX=U;7%A2,[;U(X99-X[Q912!GHW/3Y> MI)'HE%`'ENH:S9:]>>%/'.EQ2?V-I%_<6KRO&5'D2QB,S!>H16&.<8P21BM7 M0$77_BAJGBFT=9M+@TV/3+:Y0Y2=O,,CE#T90<#(XSG'0UWM%`'EOC;Q#HUG M\8?`ZW.JV<)L!?&[\R95%OYD"A-Y)^7=VS[>M=?=:-KQ\07.IV.KZ;&LD:Q1 M1W6FR3-"@Y(#+.@Y;)/R_P!T'.T5T=%`'F_P,2\7X6Z6TT\#VK>;]GC2$J\? M[^3=N8L0^3TPJXZ<]:[S2M5LM;TV'4=.G\^TFSLDVE221L*JCJ2?2@"6BN;'B\R0+=VWA[7+FP8;ENHX$`9?[PC9Q M*0>V$YJS-XE@;08]8TJRO-9MY"<)8*AD`&,=<`&W165X=\1 M:;XIT2WU?2IO-MIAT/#(PZJP[,/\\55T'Q.VNZA?V?\`8>JV#6+^5/)>"$() M-JL$&R1B25=6R!C'?ID`WZ*YGQ1XTA\*7>GP7.CZI=KJ$R6UO-:+$4:9R0L9 MW2*0QQG)&/?@X=%XRMDU>TTS5-,U'2;F\8I;?;$C*3,!G:'B=U!QV)%`'245 MRNL>-TT?Q/9Z`V@ZOZ%'H&LVMU8;?MC MW*PA(-REDR5E).X#C:#^7-`\=1GQK_PBO]@:S]OV>=YFV'RO(W[/.W>;G9GV MW=MN>*`.LHI"0`23@#J365X<\1Z?XIT==3TR1GMVD>/YQA@RL5.1VZ9'L10! MK45RG_"=1_\`":_$K_8&L?;]GG>9M@\KR-^WSMWFYV9]MW;;GBNGN)6AMI9 M4ADG=$++%'MW2$#[HW$#)ZTG#&U0 MI*F-RD-.#D9'M6UX>\0Q^(8;UEL+VQEL[DVLT%XJ*X<(CY^5F&,.O.:`-BBL M_5]:L=$MDFO96!E<10Q1H7DF<]%11RQ^GU/%9<4`=)17*ZOXYCTCQ-9:`=!U>ZNKX.UG)!Y'ESA$WOM9Y M5QM'7=CVSD9FB\6N-;T_2[WP[K%@]^[QPS3_`&=HMRQM(03'*V#M1NU`'245 M5U&\DL-/FNHK*YO7C`(M[4*9'YYV[F4<=>O;C)XKAO\`A;MA_P`(JOB<>&_$ M!T9FV"Y$=N1G?L^[YV[&[C.,9H`]#HK/T/6;3Q#H=GJ]@S-:W<0E3<,,,]0? M<'(/N*RKCQK91^-D$V]C?7FH^0MQ,T"Q^7!&6`W.6=3QD'`!.",9/%`'2T5 MQTOQ'TRT\
$K[3]2L[ZX;$$TR1^3*#NVL&5R<,5(&1G/!`YKK;B>*UMI;B M=PD,2%W<]%4#)/Y4`245Q%I\2[6^\'S^*;;P_KT3Q`=>\.KK5OI-_#'+'YMO!/Y0EG0J&4KARHW9P-S+[X'-`&S1 M7-Z5XNDUC2+S4;;PYK*BVE,(@E$"R3.KE'"#S13@JZ@G'3U/Z&@#;HK`M/$[77BFYT'^P]5BDME$D MEU((?)\MBX1P1(6(8HP`"Y]0,'"2>+(9;BXATK3-0U9;0(7C0`DN0[+D#'. M,GGIC.,5_B`D?A6'Q(?#>NG39(S.65("R0[582LHESM()/&3\I)`&,@'8451 MM=5MM0T9-4TTF^MY8?.A$!7,HQD`;B`">G)&#UQ5+PUXC'B6UGN4TG4;"**5 MH0;U8U+NC,C@!'8_*RD'./;/.`#;HK.UC7+#0K>.6]E8-,XB@AC4O),YZ*BC MEC_DUS^L_$.T\.:=)?ZWH>M6%LH^1WACD$A[+^[D;:3VW[:`.QHK+U;7[+1Y M+>";S9KRY)%O:6Z%Y9<=2`.@'=C@#UJDGBV&*]AM=5TO4=(:=Q'#)>)&T4CG MHOF1.Z@GL&(SVH`Z&BN5UCQNFC^)[/0&T'5[F[O@YM'@$'ES[$W/AGE7&T=0 MP'MG(S9T[Q?:7NM_V+=6-]IFIF,RQV][&H\U`<$HZ,R-CN`V:`.AHKD9O'HB M\5S^&X_#6MSZC%`;D",6P22$-M\Q6:8<$]C@^H!S6GH?BFPUVZNK*-+BTU&T MQ]HLKN/9-&#R&QD@J?4$B@#;HKGY/%D,MQ<0Z5IFH:N;9S',]DL81''5=\CH MK,.X4G%.@\5VUW8WLMI8W\]]9;?/TSRECN5ST^5V52,9((;!P<$GB@#>HKB= M.^)$.J>'X]?M?#6O/I+AV%RL<#8"DJQV+,7X*G^'M75Z9J5GK&F6^HZ?.L]I M<()(I%Z,#]>GTH`MT5DZ_P")-.\-6]I/J4ACCNKJ.TC(`X=S@$\\*.I/:K6K M:E#HVC7VJ7"R-!96\EQ(L8!8JBEB!D@9P/44`7**XN3XA^3J&DV$OA37X[K5 MED>RB?[*K2!%#MG,_P`I"D'#8/XU*?B!;KX>U36#H.M!-+N7M[VV,<(FBV1A MV?'F8*`,.02>)K;5O#:Z_+;7.F6#Q^.G3-8>+S)`MW;>'M' MX]>M;*_U32RCR2SV*(WD*OWBZNZL,6'SH1 M`5S*,9`&X@`GIR1@]<4`7J*Q/#7B,>);6>Y32=1L(HI6A!O5C4NZ,R.`$=C\ MK*0V4 M!_XET5[;RQ8Z":2+,P'_``(#/UK8CT;Q-!;K:0^)X3;(NT33Z<'NL=OG\P(3 M[F,U8M?#QT;0;BQT*Y6VNYG:5KV[B-PSRL71[K3+3^W+&(?=_=*/M2#^\/X@.HY/)KVSG2 M>VGU**2*5#D,ILK7!%7/#&BW6B>&;71M0O;?4%M85MXY$M3"#$JA0&4NV3P< MG@'/3U@\(^$++P;;:E::*+(QI(Y16;$F`6`.`3WP<>AK-\;7FL#6/#MUXJTV#3_#VGZE%=/= MV%R;H+,,B/S"RQE$RW)"GT[UT_C/PCJ?BJ[TA[;6[>P@TR[BOHXWL3,7G0G: M6;S%^7!Q@#/7GIAFL>#M6\410V7B'7;:;2UE26:TL=/:#[1M.0KLTLAVY`X& M/K0!D^.WO(_BE\/6L(()[H?VELCGF,2-^X7.6"L1QG^$^G'6NCT"]\2W/B76 M8=$-9U;QGI7B&VUVSMAI M0E%I;2ZH$H%`',:+-K$7Q>^(']DV-C=9_L[S/M=X]OM_T#]:T;Q MAJVOW6OVEW_:WE_:[=--,7^K0K'L;S6VXSSD-GZ\T#P?K7_"Q3XM_M^T(^S? M8?LG]FG`MO,W[=_F_?S_`!XQG^''%`&CXSU%+/1DM&%PS:A*MJ1;0/-((SS( MP1`6.$#<@<$BN0\.:M::-\4K[3[6&]@TKQ"GVJ`7-C-;!+M!^\51*BYW*`W& M>0!76MH6M2>,H]:DUJT>RBB:&*Q-@>Z%?>*[+0_B))X:TZTN)5\0:BR2M. MWG(^%^Y#Y9#D#!`+0KN M(;S&&W`^[C\>QZ^@#@KQVE^.NF0W7-M!H,TUF&Z"=I0KD>_EX_"NTU&&VN=, MNX+W;]EDA=9MW380=V?PS5#7?#MMK;VESYLEKJ%C(9+2\AQOB)&&&#PRL."I MX(]\$4+OP[K6L6[V.LZ]"^G2#9-#861MWF0]5=VD,XYZXZ]#P.E_#GQ!I'A*Q\-VWBJQ^Q6= MRES&[Z0QD+),)@I/GXQO`/3..,T`4O`]\G@+5/$O@^_=_LFGAM3TTGDO;/R5 M7U(;CW8FI-$LY;3XY)]I`%Y/X6,]SCG]XUWDC/<#[H]E%=3JW@NWUS7/#^LW M\X^VZ4293#&42YR`<$%B0HE;VE>(X/&^A:!]GVE=1C^TWB#D1I$1O0_63:N#U7=Z5I6>AZU;^,;S6I MM9LY;2ZB2`VBV#*R1QF0Q@2>:?F!E.25P>P7C%31_!'_``C<6O-H=\EO=:G< MF>*2>W,J6JDYV*@9<@$N1R.6&0<<@'&^#?\`DUZY_P"P5J7_`*%-7H'@3_DG MGAK_`+!5K_Z*6J'@WP5-X9\(/X8U#48-3TX(\<8%H86VR%BX8^8P8'=Q@#'O MV;I7A3Q!H6E1:/IGB:%=.@^6`W&G>9<11YX4/Y@4X'`)0T`:/@P@Z%<$'(.J MZB01W'VV:N%&C:AI5M/XU\-PF74;?4M134+%#@:A;B]FX_ZZ+U4]>W/`KTNS MTQ=*T5=/TUQ&T<;"*2=3)\YR=[@$%LL16?X4T35-!LKBUU'5;?4%DG MEN$>*S,#*TDCR/G]XP(W/Q@#'OV`.77Q)%K:>*==\.S^:S^&;>6V9?O+(&O< M*1V8,,8K?^'$=O'\-O#@M=NPV$3MM[NR@O\`CN+9]ZDT'P;8>'/$6N:II_[N M/5_):2W"_*DB>9N9?9M^<=CGUP([3PM?Z$LMOX:U6WL[!Y&D6SO+,W$,1/=2*%"1@Y$<: MCA%SSW)/))JH/#%WIFH7=UX=U.*PCO)#-/:7-J9X#*>LBJ'1E8]_FP>N,T`; M;:99MJ\>K&`?;HX&MEFR<^6S*Q7'0\JI]NW4UQ7P2_Y)#H7_`&\?^E$E;\>@ M:C%'=W@U>.379XQ$E[-:;HH$SG;'"'&!U/+$DX))``K%\-^#/$WA7PO!H&G> M)]-^SP!Q'-+H[M(NYBQ_Y>`IY8]10!M^._\`DGGB7_L%77_HIJY__FWK_N5/ M_;2M.Y$7S?#W_A%K368XI9H7AN[Z:T\TRB0-YK!0Z[69F)R2<9/4\B$^#]: M/PZ_X1+^W[0'[-]A^U_V:<_9O+V;=GF_?Q_'G&/X<\T`9%PS?"W7S&K;1()WFAMGE,;N/FV MO*S@'U(#8SWQGB@#G;R0S_';3;>Y&8+;099[3=VF:8*Y'OL'Y5V6J:99ZUIE MSINH0">SN4,1AE(/#( MPZJ?T/-5GT#5=39(M=UBVN;%6#-:V=D;<3$'($A:1RRY`RHV@]#D9!`,70': M?XR^,#=\R6]G9166[J(&5FDQ[>9UK5^(\=O)\-_$/VD@*EC+(A])%77/(Y!!Z$) M-6AO+%'60V5G9FWBE*D%?,W.[,`1G;D`X&0:`.*U:[U:?Q1$KL6\,^K2V5V M\D5Q,85,C6L9?+!6(ZL?NGD8]ZT/#4EWXQ^($FJZV(;"^\--+;Q:3%EFC,JX M\UI#C>K*.,`#O]=G7_!^LZOXRTGQ!:Z]9VHTD2"TMI--,H_>($?>PE7=G'&` MN./J;/B#PA/J.O66OZ+J@TG5[=##)/\`9A,EQ"?^6;IN7.#R#GC\L`'.:G>W M5C\?HY+72[G46;PQM>*V>)75?M).[]XZ@C(`QG//M3KG3/$3:GXG\:SV8TVZ M30I;+3K-95DE)4&0.Y4E=VX```GCOZZMOX.U]?'L?BNY\16$DPLQ8R6\>E,B M&#S-Y"DSDALY^8YQZ'I7;$9�!R_P`.([>/X;>'!:[=AL(G;;W=E!?\=Q;/ MO67KLCVWQE\)&T/[R[LKR*^`[PJJM&3_`,#Z?6M2T\+7^A++;^&M5M[.P>1I M%L[RS-Q'`6.6$>V1"JD\[22!DXQ3XO"]U;->:C%JBR^(;F(0C4;JV#I#&&SL M2)64!>IQNY/)+8Q0!Y5X1\4>(/#?P8T%X+&Q@TV>:6W.JR3M)]EWSR#S)(0@ MP`QP"'(X&>N*]?\`"/AZW\*>%-/T2UF,T5K&1YI_C9B69O8$L3BLKP?X'?P[ MX/?PMJ=];:MIFUT139F%MKLS.'/F,&R6XP!CW[.\/^&/$/AW3)-,@\36]U9Q MH4LA=Z<6DMQGY07$HW@#CD#MR`,4`97BR72_$-]K.CZE#J,EM%9_8XGM=,N+ ME%F?#LVZ-&&5VQ8&<@[O6M+XO6GV?4F3[38KIQ56"#"D-YIP^.K8P?3T`*7BW_DKWPZ_[B?_`*3K M6]XYC1/A]XH9$56?2[IG(&-Q\EAD^IP`/P%9WB#PAK6K^,M*\06VOV=J-)$O MV2VDTUI1^\0*^]A*N[..,!<1M!--);&;]TRE M6"C>N"<]3G'/'<`'GFN.W_"HOA[;O_QX7-QI,-^#]TP%%)!]MP6O7:YC3/"( M7P/'X6UZX@U2TC@2V5DMS!^Z15"9&]OG!7.X$=N,C)?'HWB:"W6TA\3PFV1= MHFGTX/=8[?/Y@0GW,9H`X>61XX?C%90'_B716[2Q8Z":2T8S`?\``@,_6M*X M9OA;KYN5!_X0W5)_WRC[NF7#'[P':)SU'13^`.]?^"R?!U[X?T:_6R.H>8+R M\N8#8")&/S+\[9^]R`.`.F-L::]]H3:=KK6VH&:-H[@I`8HY5.?X"S$< M8_BZ\C'0`&?X+97T&=T8,K:IJ)!!R"/MLU=#6)X1\-Q>$O#5MHD$[S0VSRF- MW'S;7E9P#ZD!L9[XSQ6W0`4444`%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111 M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%<'XK^+_A#PE<&TN+R2^O%?;);6"K*T7+`[B2%! M!7!7.X9'&.:`.\HKYLN?CGXZ\3W%S9>%M#CA)0.@M;=[NXB4%=Q)QM()XR4X M#`=>:CM?`WQF\5>>=1U6^LK6]B:1Q?:DR1N'ZQF&,DKD,?D*```CCI0!]+T5 M\J:K\)_'WP^TNXU^QU*,")-MPVD74JRI%U+'Y5)0$`G!..I&`2/9_@QXMU?Q MCX*FO=:FCGNX+V2W\Y8PA=0J."P7`S\Y'`'`'?)(!Z)1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110` M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%>!ZS^T%J6A^-=8TV70;2XT^SN);6)5F:.4LC;=[/@@@[6 M.T*,9')QSTFC?M!^#M0V)J*WVER>4'=IH?-C#\913'ECU."5&0.QXH`]8HJG MINK:;K-NUQI>H6E]`KE&DM9EE4-@'!*DC."#CW%9^D^,-`US6=0T?3M2CFU# M3G9+FW*,C(58JV-P&X!A@E<@9'J,@&Y1110`4444`%%%%`!1110`4444`%%% M%`!1110!'//#:V\MQ<2QPP1(7DDD8*J*!DDD\``*$#L3Q5/\`:)\7?8]'M/"ELW[Z^Q M5_B=&8I8-^LZCYLU[,[G,158_W*A6*;07.6P2 M2,@@';0!];T57L+7[#IUM9_:)[CR(DB\ZX??))M`&YV[L<9)[FK%`!1110`4 M444`%%%%`!6/XG\3Z7X1T.;5]7G\JWCX55Y>5ST1!W8X/Y$D@`D;%?+GC[Q# MJ_Q8^)$?A;0[F-]-BN&BLTWA8G95/F3LP)##`FTAV((8;B0"#]T&O0/!/@O3?!'A^#3;)(Y)P@%S>>2J27#98Y M8CD@%B%!)P.,GK724`5[&PL],LX[.PM(+2UCSLA@C$:+DDG"C@9))_&K%%>? M_%/XD6?@;0Y+>&;?KMW$PLX4P3%G($S9!`4'H"/F(QTW$`'#_M!^.DBLU\&6 M1W33>7/?.&4A4!RD1')#$A7/3`"]0QQWGP@\*3>$OA]:6]V)%O+US>W$;Y'E M,X4!,$`@A50$'.&WS0REGN)E#RQ&3Q][Z+H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#'OO"?AO4[R2\O_#^ ME7=U)C?-/91R.V``,L1DX``_"N/UGX&>!M7WM%83Z;,\IE:2QG*YSG*A7W(J MY/15&,`#`XKTBB@#YLU+X!^+_#EPNH^%M;CNYX4!1HG:SN-S$JP3YBN-IY)< M9&1CUX_X9>+X?AQXUN;O6-/NV0V\EG/$BA986W*WW6QDADVD$C&2>V#]AU\Z M?$#PUI%U^T19VFN7$AL-=MT)\L%6BD:-H(@",Y/F1HV2,H*E6'4,K`%3T."!P0>A%:E?+GBCP)XK^#VJ/XD\.:C(V MF[VA2YC`9XD;&%G0KM()X!P02JG"DJ*]?^'/Q9TCQQ;V]E99D$+ M)M`):-CP01SMSN&&Z@;B`>B4444`%%%%`!1110`4444`%%%%`!116/XLOKC3 M/!NN7]G)Y=U:Z?<30OM!VNL;%3@\'!`ZT`>">$(#\2/V@;[Q$(HYM+L;@W(E M59$4K&-EN?4.2J/M;&=K\<;:D\<16_Q`_:)T[0E6"2UM/*M;@^>2LR1[IIER MHRK8+IC/#+U';B_!@\:>'O">M^,O#NI1V&GVSQVUSN*N9V+*`%C96!*[U.XX MP&."`_`GQ`\3RSZ_HE_/IRW'F!]3FO)(3<-N!8;ER[Y;DG&W*GG(Q0! M]5ZEJVFZ-;K<:IJ%I8P,X19+J98E+8)P"Q`S@$X]C7G>I_'[P-8>5]FN+[4M M^=WV2U*^7C&,^:4ZY[9Z'..,\)IO[-.I2V[-JGB2TMI]Y"I:VS3J5P.2S%"# MG/&.PYYX]#T;X&>!M(V-+83ZE,DHE62^G+8QC"E4VHRY'1E.U M2(;YE=5N68-N**Z@@`J.,MC<.?7J--TG3=&MVM]+T^TL8&U^7)VHH665F4+DX`CQ@_WN.E>C_&W_`))# MKO\`V[_^E$=>0?\`(!_9>_Y[_P#"0:K_`+OV?:WX[L_9?;[_`+<@'J?PF^). MI?$.XUYKVSM+6"R>$VR0[BP5S)P[$X8@(.0%[\>GIE>9_`;38;'X5V=Q$TA> M_N)KB4,1@,',6%XZ;8U/.>2?H-#XF?$RQ\`:6$01W.M7"$VMH3P!T\R3'(0' MMU8C`Z$J`'Q,^)ECX`TL(@CN=:N$)M;0G@#IYDF.0@/;JQ&!T)7QSX=_#O5/ MB=KDOBOQ7-/)ICREY)'.U[YQQL7&-L8Q@D8QC:N,$J?#OX=ZI\3M4O)(YVO?..-BXQMC&,$C&,;5Q@E?IN""&UMXK>WBCA@B0)''&H544#`` M`X``XQ0`000VMO%;V\4<,$2!(XXU"JB@8``'``'&*DHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@ M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@ M`HHHH`****`"BBB@`HHHH`*^>/C[]LT'XA^&/%$'D/Y<2^1&^3^\@E\P[@,? M*?,7H<\'IQ7T/7A?[2VFS2Z-H&J*T?D6]Q+;NI)W%I%5E(XQC$39Y[CKV`/< M)X(;JWEM[B*.:"5"DDU^!/^2>>&O\`L%6O_HI:Z"@#S/X0?$QO'6ES M6.IB--:L44RLI51/,"]00YU.ZB?;YAD<_O'.,&0(!&@()X;G;G;]/_P#$B\$>%_\` MEAIFC:=%[[47/XEF)/NS,>Y-%YTE56!* M-YSMAO0[64X/8@]Z]$H`**\S\+?&*Q\2_$&[\++8QPHCSI:7L=UYRW1C)Q@! M,`,@9\[B.,F4`%%>?_$KXIV?P\^PP?8?[1OKO<_D+<"+RXQQN8X8\G@< M8.UN>,'T"@`HHHH`X/XSP37/PDUY((I)7"1.512Q"K,C,>.P4$D]@":\(\4Z ME-%\"/`>EJL?D7%Q>W#L0=P:.9U4#G&,2MGCL.G?Z?\`$NFS:SX5U?2[=HUG MO;*:WC:0D*&="H)P"<9/H:^,+J>%O`NDVZRQF=-3O7>,,-RJT5J%)'4`E6`/ M?:?2@#ZCTZ_O/#7P-TJ^T#1_MM]'I5L\-G!$3ODD5-S%4&6Y=G;')P>1G-?- MFA>*[%O&KZ]XTTV3Q")W#2AY=I5]RG?M^ZX"J5$9PI!`X`K[#T+3/[$\/:9I M/G>=]AM(K;S=NW?L0+NQDXSC.,FI-2TG3=9MUM]4T^TOH%<.L=U"LJAL$9`8 M$9P2,^YH`XO1/C3X&UOR$_M?[!<3;OW-_&8MF,_>DYC&0,CYNX'7BN#\5?&K M7M:U2XT?X=:?)=I&@?[?!:O/*R_(25B9/D`8E"6#9R",<5QGQ2TO2]6^*"^' M?!6B0+=+MAF6R&%EGQ\P`#;%5%`!X7#"0MTS6Y\#)K[PU\4M9\+S"29'26"X M-M'OC66!R!(S$`JGWU![EU!'3`!T?PC^*FNZQXHN/"WBU]]\^\V\CP"*1)$' MSPLJJ`.`S9.""I!SD`>X5\T>+K&XT/\`::TV:"/[''?:A9S1&!@OF(Y6.4G; M_>82AL]?H/7_$>D>%M+;4M:OH[2T#A-[`L68]`JJ"6/4X`/`)Z`T`:$ M\\-K;RW%Q+'#!$A>221@JHH&223P`!SFO*[[]H;P5:7DD$,6JWL:XQ/!;J$? M(!X#NK<=.0.GIS5/XX^(X=1^$-E>:-?1SZ?JE[$C2(`1)&%=\L=?UZV@U2^OHDN88I5+0P1NF578>'8ALDL"`<8Z;B`=9X M,^+GAGQOJCZ98&[M;P)OCBO45#,!G=LVLP)`&2.#CD9`..\KYH^+OPMB\$_9 M_%'A9I[:Q25%DA1W9[23^&19.2%)`Y)R&(P3N`7V/XU0[+]Y.3E"RN!DY^7D#C(!VE%%<'XK^+_A#PE<&TN+R2^O%?;);6"K M*T7+`[B2%!!7!7.X9'&.:`.\HK'\,>)]+\7:'#J^D3^;;R<,KA_\`@QA_^*H_X3OP?_T- M>A_^#&'_`.*H`Z"BN?\`^$[\'_\`0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\` MXJ@#H*\S^/.FPWWPKO+B5I`]A<0W$04C!8N(L-QTVR,>,<@?0]9_PG?@_P#Z M&O0__!C#_P#%5A^,-6\$^,/"=_H,_C/1K=+M%`F2_A)1E8.IP6Y&Y1D<9&>1 MUH`C^"7_`"2'0O\`MX_]*)*V/'7CK2_`>AF_OSYMQ)E;6T1L/<..P]%&1ENV M>Y(!\OD^)VA?"SP79>%]`OH/$NI6WF@W$8*01[RTBL2"P?EP-JM_"V64\5P& M@:>?BAKDVL^-_&EC80Q;(BUS<0QS2@8)2.,E0BX).[&-QZ,=V`#J/A';:[XZ M^*]QX[U%=L-MO,DJ1!8VD:/RUA7G^%&SGYB`HW>&UMY;BXECA@B0O M))(P544#)))X``YS7#W/C#P;X5\%74'AS6O#X.GV4K65FE[&X=U4LJX#[F+- MUYR23SDYKR#2=)!D1K?\`Q$\&P6ISOD@U$2NO!QA3M!YQ_$/7GI0!];U3U+5M-T:W6XU3 M4+2Q@9PBR74RQ*6P3@%B!G`)Q[&OF#4OA)H,5NK:7\3O#%S/O`9+JX2!0N#R M&5W).<<8[GGCG#OOAI+:6R+C$$&LH'?)`X+A5XZ\D=/7B@#U>__ M`&@WN]8N=+\*^%Y]5D.]+.;S&W2D*3O\E4W%1@G&X$J.=IZ4Y/V@=>T-(;3Q M'X(D@U`IO.Z9[4.I8@%8W1B!QC.3D@_0>>:3-XYT'0Y]&TGQ#I5E8SR^=(L& MNV"/O^49$@EWKPBC@C]376>%?AQX0_M274O&WCSP_J3N[LUM;ZJI$S-CYWE+ M*Y.2QP!UP=QY%`%/_BN?CQK'_/GX<@N_;R;7*_@TT@4?@7_@5J]/\=>"[/0? M@7K.A>'K3$<,27#EF&^79(CR2.QQEMJ$_@`!@`5U%CXL\!Z99QV=AX@\.6EK M'G9#!>P1HN22<*#@9))_&B_\6^!]3TZYL+SQ/HJ@EV4=<[#SV'F'Q#O;[XM M?$&\M/#D4EQ::+93%1YV]9A&27DC5^) M/AAM/N$VLMWJ:Q.5W[@C;-P<#:ASQDC.T8%>K_#FT\`_#S2[F"#QKHUY>7;A MKFY:_B0.%SL54WD*`&/7 M3IX8Y?\`2;8R*%%S#RKJ"0<;E)&<9`=6'!4GW.?]I#PJMO*UOI6LR3A"8TDC MB16;'`+!R0,]\''H:[R^\6>`]3LY+._\0>'+NUDQOAGO8)$;!!&5)P<$`_A7 M)Z;H'P3TJX:>WF\,.[(4(NM22X7&0>%D=@#QUQGKZF@#P#7K_6OB#\08S>F2 M"[U.XBAM(KIB%MXI2/)484?)M<'(7YLEL$GG[3KY4\6:MIMS^T;;ZI!J%I+I MXU.P#C`P(?M`R^']:_LC6]'UG2KVZCW6EPEM>K+(4.7C.Q20%!\S)XY=1SV`/H M/2=2AUG1K'5+=9%@O;>.XC60`,%=0P!P2,X/J:Q_'FN3Z!X.O[NRFM(M0=/) MLS=745NOFMP"&E.PE1E]IZ["*YOX<^/_``W)\.M"2_UK2M/NH+1;9[>>_C5U M\K]V&()!&X*&QC^+OUKC_CWK.F:_X2L3H_B;2KN.UN_,N+*"ZA=WRI59!AMW MRY(VJ#GS,GA:`.#I8',*KX8NM3B\NUC*LK1P;LDG.`=Y56'!^55(/S$#@/A;X9\-ZK MJ+>)O&_B+2MOFM)'8WE_'YES)GF28,V=N<_*>6/)^7[_`-#_`/"=^#_^AKT/ M_P`&,/\`\50!XA^TIIGE>(=#U;SL_:;1[;RMOW?*?=NSGG/G8QCC;WSQV>OZ M[X/^-'AIO#6DZO'%K3H+RSBNHI(S'*@Y4_PL=K.IVEL`E@&VUJ>/Y_`_CSPN M^CS^,M#MI!*DT%Q]NB?RG4X)VB1=V5++R?XL]0*P_AMH/@'X>W%W?'QUHVH: MA<)Y(F-Y%$L<602H3S#DEE!))[``#G(!XY9:K+X;T[6O`7BZPGBL99?-/EPH M]Q972@;94W$!U8!5(W#*'*L,G=U'A3Q-\0_"'ARXDTBYT/5/#FF1%B'NK=DB M61RRN0'28,QW81\-\V-N1@>M^*Q\+?&=N4UG6O#\DX3;'=QZC"D\?#8PX;)` M+$[3E<\D&O-/^%3?#C^V/-_X678_V9_S[_:[?SON_P#/7=M^]S]SIQ[T`(=1^&?BNS%KKFL>'+V-?N%]0B#QY()VN&#+G:,X M(SC!XH`\@\<_''5/%7E:-X0MK[3XY95`F1L7WRD,<[<,0.0'KT?PV_PJ\(^ M8=#U3PY:229#3?VC')(0<97>[EMOR@[6]I; M(0&FN)5C11W$3$4`6;/Q;X;U&Y6VL?$ M&E74[G"Q07L;L?H`/ M2L3PE\1]17X=>%(#&+W7M4NGL()+EB$PCX,CD@#V.BN)L_%6K6 M/CV/PEKPL7DO+1KFQO;2)XUD*YW(T;.Q!`!/#=![\8&A>-O'>OOXAT^PTS1) M]0TF^DM?M#F2&`A"1]W^&QUP>E`'MVLZS8Z!IWT M:UO);73TTVS:!9`CG>^-Y4`MN'`Y()S0!POAGX3>#/`DMM>^,]:TVZU"1&V6 M]])'';#A0VU'YD*DD;CQ\P.T$`UZQIWB;0-7N#!INMZ;>S`9\NVNXY&Q]%)- M>?\`QW*1^&O#\K*24UVWY52S8V2$@`FZ[IG]M^'M3TGSO)^W6DMMYNW=LWH5 MW8R,XSG&17SQIFA_%KX2SRC2K#^TM-DE!>&V0W4,KE#\VP8E3'0L`N2J@DC& M?2X?&GC"X\?>(O"MG8:3=36"QO;S-YD*(CJ&!E.YB2`RKA1R>>!6Y8W?CZZT MA5NM/TBRU-('=Y&+2PR2^8X1%59-RC8J,6+?Q@8R"``>0:MX4^)WQ:E@N]6T M72M&A2+$_\(_`OPMX^$$GBS2+.Q75+;>T]M+&[QNJ$[MF&!!VX8 M*`.\ MIDTT5O"\T\J11(,L[L%51[DTJ!@BAR&?`W%1@$^PYQ7FOBN4:Y\8?#?A:\R^ MEPV;ZG+;GE)Y`65`X[A2F<'CF@#MK+Q1X>U*Y^S6&NZ9=3_\\H+N-V_('-03 M>-?"EO/)!/XGT6*6-BCQO?Q*RL#@@@MP0:-6\(Z3K&L:3JL\1CO=+F\V"6': MI(QC8W!RO?''3KUSYQ9:U:>'OCEXZNKB"[=!9V[;;6TDF.1%&QSL4[?JV![T M`>K:9K6E:U'))I6IV5^D9VNUK.LH4^A*DXJ&W\2Z#=W_`-AMM;TV:\SC[/'= MHTF?]T'->3^*=3L_^%5V^LZ/8'2)_%]_!%>""8L1NW;L'@#*H0<`9W&NR^(7 MAC3&^%^HVUK:Q6PTJT:ZLFB&TP-$-X*$<@G;C/?-`'=5GW.N:;9ZQ::3/4L,;GVX+?B03^ M-<]X._XJ/QUXC\5M\UO`_P#8^GG_`*9QG,C#U#.>#[4`=`OCGPB[!4\4Z(S$ MX`&H1$G_`,>K=1UD171@R,`593D$>HKP_P`'ZQX:TR^^)%EKUQ9K%-K-P%LI M&&^9=SC")U8]N!1IFN^+/AQ\*/"DLT,!-S?_`&66UO('::.-V9DVX=<'"G@C M^(=,8H`]RHK@;WQ7XK\/#4M9\2:1IUOX?M[%IXA:SF2<3;T5(G8D#)W'[JD` MCKZPR^-/$&BCPS?ZY;ZHKSU/'NNZUK_B+2=$_L>UO=)F M:&WL=0#&:^*YR5(=`H..#ANH)P*37]>U:S\8^`(-4T?17EU-2)!-;F2>QG"H M9?*DWD`991D#^'J>*`.#^)UI;6/[1/A>YBB*O=26$\Y7X>'_%>B^*5NFT>[:?[))Y4X>"2(QOZ$.H.>*^?OB%KRZ]^T#HT>F;%FTZ M[M;!9)@60S+.6)(!!VAGP1G/RFNL^'_B#_A&-/\`B3KFKPH)+75I'FA@;Y3( M68;%)[%C@&@#VZBO.Y?&GB#11X9O]093+EB)!USA M5Q@XS2Z9XL\4:A\1O$7A7;I`33HTEAN?)D&%<*RAEW_,<,!P5Z$^@(!Z'6'X MP\-0^,/"=_H,]Q);I=HH$R`$HRL'4X/4;E&1QD9Y'6N$_P"$OUGQ1\,_&D<_ MV2PU?1A=6UT8HF>.14C;.P%@5)PPR2V,9P>E;'PBBU5?`&B27%Y9R6!M/W4$ M=HR2H=W!:0R$,.O1!U'IR`;_`()\,?\`"'>$+'0/MGVS[+YG[_RO+W;I&?[N M3C&['7M705F:G)K'VFVM]+AM@DBNTUW<9982,;5\L$%BV3SD`!3GJ!7"Z7X_ MU_4/!GBZZDM]-AUOPY-/'(!&[02B($G`WA@3M8?>]#[4`>FT5Y3=_$+Q3:?# M"P\;FSTIX&\MKJU"R!F1GV;E;=A>2."&XYSV'1ZUXSN/^$@T3P]H,5N]_JEN M;LS708QV\`&0Q52"Q."`,CIUH`V(_%VB2>*&\-"ZD&KJAD^SO;2KE0,[@Q7: M1[@U>U+6-,T:!)]4U&TL8G;8LEU.L2LV,X!8C)P#7ED8U9?VCM.35VLY)ET5 MQ'+:1M&LB;I,$JS,5.=PQN/05O\`QN56^$6MD@$J;<@D=#Y\8H`ZW3_$N@ZO M/Y&FZWIM[-C/EVUVDC8^BDU:N=3L+.ZMK6ZOK:"XNB5MXI955YB,9"`G+$9' M3U%<)XQT6TU+X1?;718[[3M+2\M;I?EDA>./>-K#D9P1^-8H\7:A=:SXS\2Z=\44\+6=CI][ M#=6'VNV!#Q.IR5_>.6(V@JS$A(O M);QV:J,2;=X9F+[UP2GW>W6@#TJBO.X?B3)I=MXLB\0VT7V[PX49S:@HERD@ M_=E0Q)4G(!!)QD=:UM#O_&5X^CWM];Z4=.OT,EQ%`KK+9@QEDRS.1)SM4X48 M+>@S0!X=X-_Y.AN?^PKJ7_H,U?3]?*'B>SNK3]HR.!);-;MM7LY%ECM2D0=_ M+8,8P^3RV6^8%CDY&>/9[;QOXB\0:!K'B/P_;Z:-,L))4@M[E'>6\6,99@ZN M`F><##?A0!Z117E_B/XFW]KX-\,>*=$BLWL]5NH[:X@GB>21&;=D(5=1E2CK MR.3CI74:+>>-)_$DBZSI6F6NBO;-)";>]0#J** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@ M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`K!\:VU[>^"=:L=.LWN[ MN[LY;:*)'1,EU*Y)8@8&<]>U;U%`'F>@V_B_3OAS9>&;;PY):ZDEL;9KR[NH M/(BSG+CRW9VP#TVCFH-0^&EUHND>#F\/JE[=>&KAI6AE81FZ$A!E().`V1QD MX`[\<^IT4`<#%H.JZ]\2K'Q7J&FR:9::59O#:VTTL;S32.&#,?+9E"@-@#.< M_I7^&>BZYI&L^*[C6-'FL4U347O8&::%QM9F.T['8AN?3'O7HU%`'G\VA:QH M'Q/U#Q3I^FOJECJMHD5Q#!+&DT,B!0I'F,JE2%'?/]<6P^$R:C;>*]7UK3;% M-#M.1E3)NP2X&1V/)KUJB@#RW2M(\2V7P+IT MUFH%U!^]DD+#)KB`!0DH MD+[O,P0=N!SGGI7K]%`'EOB[2]831/!^IZ7";+Q%:2)8+',58[98S&X.PD$+ M@/UX"DUZ+H^EV^B:-9Z9:+B"UB6),]2`.I]SU/UK#T7P%I6AZ]>ZQ#/>SS75 MU->"*>4&*&67[[(H`P2/ER3GJ:`/._BWH>M^(=-T6ST;2I+TV^I1WDS M+-$@54##'SNN2=WZ4WQ1I.O>.-2T"!=$GT>ST[4([Z:[O)X3*=F?DC6)WZYZ MDCH*]&HH`\X\.:-KMM\8?$VNWFC3P:;J,4<4$YFA8?NU5.._.*35 M?#FM7_Q'OKO4](76=">T2/3HI9D-O;28&XRQ,PSDY.0K'&/P](HH`\_^$?AW M5/#7@J31=;TYK>9+B1OGDCD25&[C:Q].0<53^&_AR[L=6U`7<@ET[0[BXT_1 M\DDA'??(23U(^1,]MK"NN\5>%+/Q=96=M=W5Y;?8[Q+V&6T=5=9$#!3EE/'S M'MZ5IZ9IMMI&G0V%FA6"$$#,=&\8:'''<7EA&]M<6H M^(-(CL-"GTO2DGWZA->36S/(F#\BJCO@9YSD'I[U@Z9I_B+2_BMXH\13>%K^ MXT_48HH8/(N+4L=BJNXAIEP#MSZ\]*]1HH`\HN_"'B/Q;X8UK3+RPAT%+>]B MN/#]OB$I;A`<9\HD#.3GKC<<9`Q6UK@\5^*?"TOA]]`;3;F]C$%W?2W,3P1J M<;S&%37>T4`<;XJO$\!_#-X=+4^=;VT=A8)_$TK`1I]3_%^!K7 M\)Z$GA?PEINCQC<;6`*Y7'SR'ES^+$G\:?K/ANSUV_TFZO))\:7<_:X848"- MY0,*S@@D[F.#S3_BWH>M^(=-T6ST;2I+TV^I1WDS+-$@54##'SNN2=WZ5Z)10!SGC M7P])XQ\#:AHP/V::[B4IYN/D=65U#;2>Z@'&?QKG?#_AJUBM-/MKSX9Z;!?0 MK&LUXT=H8B5QEU92TA/&0"HYZGO7HM%`'E7B_0=8\4V.L6FI>"8KC41+(ND: MK:3PQ[(\_NVD9I!(",`D`$'T%0ZMX9\5G6_A[(]A/JG]@H6O[Q+B(;W8(#MW MNK-C9U(YSW.:];HH`^6O%_A^?PS^T)ISQA;C[?JEOJ,"!L$^9/RI)X!WAA], M&N_TWX?>(-1T7Q_HVKV0LWUN^:[M;I9D>%B)-Z]&W@$@=5''OQ75>*_AG#XF M\=:#XI75)+6?2WB+P&$2+,L M?#/38+Z%8UFO&CM#$2N,NK*6D)XR`5'/4]Z;X=T?7;7XP>)]>N]%GATW488X MK>;SH6SY:JN2HI^.M(N7T^35O#$5NRSV,=PB#SR3AW1V4.N-O'., M'CUYK1?"'B/1?#OQ!TQ?#N'UAIOL"VDT"P[9`RA5!<%0N[."!P/7BO9:*`/( M-2\,>)KCX!0>%(="F.K%8X'B:X@`4)*)"^[S,$';@9XEF10#AD)?83EB<;NF/P].HH`\S?1_$ES\:=-\3S:)(F MEKIIM"RW$)>$EG/SC?U^;)V[A@C!)S6M\5])U;7_`(?7VCZ-I[WEW=O$H"RQ MH$"R*Y)+L/[N.,]:[:B@#SO5++Q/XB\'P>%H-%ETF.:WCMKR^O9H7V1@`/Y: M1.Y8G&!G;UJCXF\*:K%XJ\!KHFB3W.D^'01)*LT*DJ0B@`,ZDD!,GCOWKU*B M@#SB]T;79OCE8^(5T:6)=MVTONVC?CIGCI3O&?@N74/'6D^ M*%T:VURV@MFL[O3IO+R5RS*Z"3"$@L>"1]?3T6B@#SS5O!%KX@\&ZYI>G^%K M+P[+>0JL3!(4D=U8.`_DY`7..=[PM=:X-+T^PU/0)+&6WA6*XF>YB M:-BJX!CV,S')`X8+@$\G'/2T4`?*GQLCO?#WQD;6+>=4GE2VO[9E4,8R@"#( M(P3NB)[C&*]5T+P]XG\'>$M:\*6>B?V@DTDW]GWR7$21!)!@&4,X<%>^T'/3 MWKS;]H[_`)*'I_\`V"H__1LM?3]`'CGB;P!K=E\//"?A?1M/DU-]-ODO+F9) M8XU&"Y8#S'4G+2''L.<5[#&Y>)':-HV902C8RI]#@D9^A-.HH`****`"BBB@ M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@ M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`^8/VCO^2AZ?_V" MH_\`T;+7T_7@_P`8O`6N^+_B=H(L;**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** $*`/_V3\_ ` end EX-101.INS 9 imcle-20140131.xml XBRL INSTANCE DOCUMENT 0001520047 2013-02-01 2014-01-31 0001520047 2014-06-30 0001520047 2013-07-31 0001520047 2014-01-31 0001520047 2013-01-31 0001520047 us-gaap:SeriesAPreferredStockMember 2014-01-31 0001520047 us-gaap:SeriesAPreferredStockMember 2013-01-31 0001520047 2012-02-01 2013-01-31 0001520047 2012-01-31 0001520047 us-gaap:PreferredStockMember 2012-02-01 2013-01-31 0001520047 us-gaap:PreferredStockMember 2013-02-01 2014-01-31 0001520047 us-gaap:PreferredStockMember 2012-01-31 0001520047 us-gaap:PreferredStockMember 2014-01-31 0001520047 us-gaap:CommonStockMember 2012-02-01 2013-01-31 0001520047 us-gaap:CommonStockMember 2013-02-01 2014-01-31 0001520047 us-gaap:CommonStockMember 2012-01-31 0001520047 us-gaap:CommonStockMember 2013-01-31 0001520047 us-gaap:CommonStockMember 2014-01-31 0001520047 us-gaap:AdditionalPaidInCapitalMember 2012-02-01 2013-01-31 0001520047 us-gaap:AdditionalPaidInCapitalMember 2013-02-01 2014-01-31 0001520047 us-gaap:AdditionalPaidInCapitalMember 2012-01-31 0001520047 us-gaap:AdditionalPaidInCapitalMember 2013-01-31 0001520047 us-gaap:AdditionalPaidInCapitalMember 2014-01-31 0001520047 us-gaap:AccumulatedTranslationAdjustmentMember 2012-02-01 2013-01-31 0001520047 us-gaap:AccumulatedTranslationAdjustmentMember 2013-02-01 2014-01-31 0001520047 us-gaap:AccumulatedTranslationAdjustmentMember 2012-01-31 0001520047 us-gaap:AccumulatedTranslationAdjustmentMember 2013-01-31 0001520047 us-gaap:AccumulatedTranslationAdjustmentMember 2014-01-31 0001520047 us-gaap:RetainedEarningsMember 2012-02-01 2013-01-31 0001520047 us-gaap:RetainedEarningsMember 2013-02-01 2014-01-31 0001520047 us-gaap:RetainedEarningsMember 2012-01-31 0001520047 us-gaap:RetainedEarningsMember 2013-01-31 0001520047 us-gaap:RetainedEarningsMember 2014-01-31 0001520047 us-gaap:FairValueInputsLevel1Member 2014-01-31 0001520047 us-gaap:FairValueInputsLevel2Member 2014-01-31 0001520047 us-gaap:FairValueInputsLevel3Member 2014-01-31 0001520047 us-gaap:ChiefExecutiveOfficerMember 2013-02-01 2014-01-31 0001520047 us-gaap:ChiefFinancialOfficerMember 2013-02-01 2014-01-31 0001520047 us-gaap:ChiefOperatingOfficerMember 2013-02-01 2014-01-31 0001520047 us-gaap:ManagementMember 2013-02-01 2014-01-31 0001520047 us-gaap:ComputerEquipmentMember 2014-01-31 0001520047 us-gaap:SubsequentEventMember 2014-06-30 0001520047 us-gaap:SubsequentEventMember 2014-06-29 2014-06-30 0001520047 us-gaap:PresidentMember 2014-01-31 0001520047 us-gaap:PresidentMember 2013-01-31 0001520047 us-gaap:PresidentMember 2012-02-01 2013-01-31 0001520047 us-gaap:PresidentMember us-gaap:NotesPayableOtherPayablesMember 2013-04-24 2013-04-25 0001520047 us-gaap:PresidentMember 2013-04-24 2013-04-25 0001520047 us-gaap:ChiefFinancialOfficerMember imcle:PromissoryNoteMember 2013-10-21 0001520047 us-gaap:ChiefFinancialOfficerMember imcle:PromissoryNoteMember 2013-10-20 2013-10-21 0001520047 us-gaap:SeriesAPreferredStockMember us-gaap:ExecutiveOfficerMember 2013-12-12 2013-12-13 0001520047 us-gaap:SeriesAPreferredStockMember us-gaap:ExecutiveOfficerMember 2013-12-13 0001520047 us-gaap:DirectorMember 2013-12-11 2013-12-13 0001520047 us-gaap:DirectorMember 2013-12-13 0001520047 us-gaap:ChiefOperatingOfficerMember 2013-12-11 2013-12-13 0001520047 us-gaap:ChiefOperatingOfficerMember 2013-12-13 0001520047 us-gaap:ChiefFinancialOfficerMember 2013-12-11 2013-12-13 0001520047 us-gaap:ChiefFinancialOfficerMember 2013-12-13 0001520047 us-gaap:ManagementMember 2013-12-11 2013-12-13 0001520047 us-gaap:ManagementMember 2013-12-13 0001520047 imcle:ChiefScientificOfficerMember 2014-01-22 2014-01-23 0001520047 us-gaap:NotesPayableOtherPayablesMember 2013-05-29 2013-06-01 0001520047 us-gaap:NotesPayableOtherPayablesMember 2013-06-01 0001520047 us-gaap:SeriesAPreferredStockMember 2013-02-01 2014-01-31 0001520047 us-gaap:CommonStockMember imcle:ImmunoclinLimitedMember 2013-12-11 2013-12-13 0001520047 us-gaap:CommonStockMember imcle:ImmunoclinLimitedMember 2013-12-13 0001520047 us-gaap:CommonStockMember us-gaap:ExecutiveOfficerMember 2013-12-11 2013-12-13 0001520047 us-gaap:CommonStockMember us-gaap:ExecutiveOfficerMember 2013-12-13 0001520047 us-gaap:CommonStockMember us-gaap:PatentsMember 2013-12-11 2013-12-13 0001520047 us-gaap:CommonStockMember us-gaap:PatentsMember 2013-12-13 0001520047 us-gaap:CommonStockMember us-gaap:ShortTermDebtMember 2013-12-11 2013-12-13 0001520047 us-gaap:CommonStockMember us-gaap:ShortTermDebtMember 2013-12-13 0001520047 us-gaap:ComputerEquipmentMember 2013-02-01 2014-01-31 0001520047 us-gaap:FiniteLivedIntangibleAssetsMember 2013-02-01 2014-01-31 0001520047 us-gaap:LeaseAgreementsMember 2013-02-01 2014-01-31 0001520047 us-gaap:SubsequentEventMember us-gaap:LoansPayableMember 2014-02-07 0001520047 us-gaap:SubsequentEventMember us-gaap:LoansPayableMember 2014-02-18 0001520047 us-gaap:SubsequentEventMember us-gaap:LoansPayableMember 2014-03-10 0001520047 us-gaap:SubsequentEventMember us-gaap:LoansPayableMember 2014-04-07 0001520047 us-gaap:SubsequentEventMember us-gaap:LoansPayableMember 2014-06-30 0001520047 us-gaap:SubsequentEventMember us-gaap:LoansPayableMember 2014-06-29 2014-06-30 0001520047 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2014-03-19 2014-03-20 0001520047 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember imcle:ConsultingAgreementMember 2014-04-22 2014-04-23 0001520047 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember imcle:ConsultingAgreementMember 2014-04-23 0001520047 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember imcle:ConsultingAgreementOneMember 2014-04-30 2014-05-01 0001520047 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember imcle:ConsultingAgreement1Member 2014-05-01 0001520047 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember imcle:ConsultingAgreementTwoMember 2014-05-06 2014-05-07 0001520047 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember imcle:ConsultingAgreementTwoMember 2014-05-07 0001520047 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember imcle:ConsultingAgreementThreeMember 2014-05-26 2014-05-27 0001520047 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember imcle:ConsultingAgreementThreeMember 2014-05-27 0001520047 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember imcle:ConsultingAgreementFourMember 2014-06-03 2014-06-04 0001520047 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember imcle:ConsultingAgreementFourMember 2014-06-04 0001520047 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember imcle:ConsultingAgreementFiveMember 2014-06-20 2014-06-21 0001520047 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember imcle:ConsultingAgreementFiveMember 2014-06-21 0001520047 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember imcle:ConsultingAgreementSixMember 2014-06-29 2014-06-30 0001520047 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember imcle:ConsultingAgreementSixMember 2014-06-30 0001520047 us-gaap:SubsequentEventMember us-gaap:DirectorMember 2014-06-30 0001520047 us-gaap:SubsequentEventMember us-gaap:ChiefOperatingOfficerMember 2014-06-30 0001520047 us-gaap:SubsequentEventMember imcle:ChiefScientificOfficerMember 2014-06-30 0001520047 us-gaap:SubsequentEventMember us-gaap:ChiefFinancialOfficerMember 2014-06-30 0001520047 us-gaap:SubsequentEventMember us-gaap:ManagementMember 2014-06-30 0001520047 us-gaap:ComputerEquipmentMember 2013-01-31 0001520047 us-gaap:PatentsMember 2014-01-31 0001520047 us-gaap:PatentsMember 2013-01-31 0001520047 imcle:ImmunoclinLimitedMember 2013-12-12 2013-12-13 0001520047 imcle:ImmunoclinLimitedMember 2013-12-13 0001520047 us-gaap:OtherIntangibleAssetsMember 2014-01-31 0001520047 us-gaap:OtherIntangibleAssetsMember 2013-01-31 0001520047 us-gaap:SubsequentEventMember us-gaap:DirectorMember 2014-06-29 2014-06-30 0001520047 us-gaap:SubsequentEventMember us-gaap:ChiefOperatingOfficerMember 2014-06-29 2014-06-30 0001520047 us-gaap:SubsequentEventMember imcle:ChiefScientificOfficerMember 2014-06-29 2014-06-30 0001520047 us-gaap:SubsequentEventMember us-gaap:ChiefFinancialOfficerMember 2014-06-29 2014-06-30 0001520047 us-gaap:SubsequentEventMember us-gaap:ManagementMember 2014-06-29 2014-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 51956 167146 54093 10-K 72997 11. Subsequent Events   Appointment of director and officer   On March 1, 2014, Dr. Khadija Benlhassan was appointed director and Chief Scientific Officer pursuant to her management agreement dated January 23, 2014.   Loans   On February 7, 2014, Intrinsic Venture Corp. loaned the Company $10,000 via a third-party payment to the Companys attorney Dean Law Corp. in trust.   On February 18, 2014, Intrinsic Capital Corp. loaned Immunoclin Limited, the Companys wholly owned subsidiary, $100,000.   On March 10, 2014, Intrinsic Capital Corp. loaned the Company $15,000 via a third-party payment to the Companys auditors Sadler, Gibb & Associates, LLC.   On April 7, 2014, Intrinsic Capital Corp. loaned the Company $25,000.   On June 30, 2014, the $240,000 loaned to the Company by Intrinsic Capital Corp. was secured by a non-interest bearing promissory note due upon demand in 12 months.   Intrinsic Venture Corp. and Intrinsic Capital Corp. are owned and controlled by the Companys CFO, J. Scott Munro.   Agreements and Equity   On March 20, 2014, Prestige Performance Corp. cancelled 92,361 shares of common stock.   On June 18, 2018, a meeting of the Board of Directors with the unanimous consent approved the issuance of 2,000,000 stock options to each management staff of the Company. Each unregistered stock option is exercisable at a price of $5.60 per share and converted into one common share with expiry five-years from vesting. On June 30, 2014, the Board of Directors signed the resolution to ratify the issuance of the previously approved unregistered stock options. Dr. Dorothy Bray, Chad Johnson, Dr. Khadija Benlhassan, J. Scott Munro, and Raymond Dabney each received 2,000,000 stock options at an exercise price of $5.60 (current market) that expire five-years from vesting. 1,000,000 options vest on each of November 1, 2014 and November 1, 2015. The Black-Scholes fair market value of stock options granted to each management staff was calculated to be $3,161,900 with a total expense of $15,809,499, or $3.16 per option.   Subsequent to the year ended January 31, 2014, the Company entered into the following agreements with scientific advisors:   On April 23, 2014, the Company signed a two-year management consulting agreement with Dr. Marco Kaiser to act as an advisor for molecular biology, genetics, infectious diseases, and DACTELLIGENCE. Dr. Kaiser was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $42,500, or $4.25 per share, in addition to performance bonuses for services rendered under the agreement.   On May 1, 2014, the Company signed a two-year management consulting agreement with Railton Frith and his affiliates to act as advisors for DACTELLIGENCE. Mr. Frith was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $37,500, or $3.75 per share, in addition to performance bonuses for services rendered under the agreement.   On May 7, 2014, the Company signed a two-year management consulting agreement with Professor Antony Bayer and his affiliates to act as advisors for neurology and aging. Prof. Bayer was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $37,500, or $3.75 per share, in addition to performance bonuses for services rendered under the agreement.   On May 27, 2014, the Company signed a two-year management consulting agreement with Professor Jean Mariani to act as an advisor for treatments targeting central nervous system diseases and aging. Prof. Mariani was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $50,000, or $5.00 per share, in addition to performance bonuses for services rendered under the agreement.   On June 4, 2014, the Company signed a two-year management consulting agreement with Professor Iwona Wybrańska and her affiliates to act as advisors for nutrigenomics, metabolomics and functional food. Prof. Wybrańska was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $56,000, or $5.60 per share, in addition to performance bonuses for services rendered under the agreement.   On June 21, 2014, the Company signed a two-year management consulting agreement with Dr. Gundula Piechotta and her affiliates to act as advisors for infectious diseases and DACTELLIGENCE. Dr. Piechotta was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $56,000, or $5.60 per share, in addition to performance bonuses for services rendered under the agreement.   On June 30, 2014, the Company signed a two-year management consulting agreement with Dr. Heinz Ellerbrok and his affiliates to act as advisors for infectious diseases and DACTELLIGENCE. Dr. Ellerbrok was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $56,000, or $5.60 per share, in addition to performance bonuses for services rendered under the agreement.   Common shares reconciliation table:   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 71%; text-align: justify">Issued and outstanding as of January 31, 2014</td> <td style="width: 10%"> </td> <td style="width: 18%; text-align: right">26,503,515</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; padding-bottom: 1pt">Subsequent event issuances and cancellation</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(32,361</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Unissued and outstanding as of June 30, 2014</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right">26,471,154</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>    In accordance with ASC 855-10 the Company has analyzed its operations subsequent from January 31, 2014 through the date these consolidated financial statements were issued, and has determined there are no other material subsequent events to disclose in these consolidated financial statements.   Immunoclin Corp 0001520047 false --01-31 2014-01-31 2014 FY Smaller Reporting Company 26471154 722030 Yes No No 14309 34399 7745 510329 584339 201545 6241 1262 6241 1262 654992 654992 21039038 202807 2062 2704 56685 0 56685 177817 456510 1000 1000 21039038 202807 20313570 -310388 -280839 1000 5182 5361 26504 23290 72094 33164274 11879 1785 -15439 -321190 -389628 -12862769 -15439 1785 -12862769 -389628 33164274 72094 26504 5361 725468 513195 0.001 0.001 290000000 290000000 26503515 5361015 26471154 26503515 5361015 26471154 0.001 0.001 0.001 0.001 9000000 9000000 1000000 1000000 1000000 1000000 1000000 1000000 -1.21 -0.01 2156 75747 89 47 -12982473 -144185 12982473 326806 98276 93124 54918 88758 167464 143416 1611 1508 182621 10774666 5315824 -110629 156000 469888 -236584 -193691 312005 7746 -20090 -117715 20555 39000 12000000 6000 11994000 12000000 42500 37500 37500 50000 56000 56000 56000 1611 2396 -6590 6590 -115190 113053 2029 -42947 56377 33 2029 880 1507 12550 200000 100 199900 200000 20000000 10000 19990000 20000000 700000 10000 690000 5000 -5000 5000 -17224 -10094 1000000 5181698 5361015 26503515 179317 12550 179 12371 36433 36433 1000000 1000000 180000 1000 179000 180000 10000000 10000000 10000000 6000000 6000000 10000 10000 10000 10000 10000 10000 10000 100000 100000 -5000000 92361 454992 -52184 507176 1. Nature of Operations and Continuance of Business   Immunoclin Corporation (the Company), formerly Pharma Investing News, Inc., was incorporated in the State of Nevada on February 8, 2011.   On December 13, 2013, the Company acquired through a share for share takeover transaction Immunoclin Limited (IML), an England and Wales corporation, which is now a wholly-owned subsidiary. The Company changed both its name to Immunoclin Corporation and its stock symbol to IMCL in conjunction with this acquisition. The Company works on advanced immunology research and development skill to serve the pharmaceutical, biotechnology and food industries, providing comprehensive, clinical and basic science research expertise at a commercial scale and quality.   Going Concern   These consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of January 31, 2014, the Company has not recognized any revenue, and has a working capital deficit of $141,129 and an accumulated deficit of $12,862,769. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Companys future operations. These factors raise substantial doubt regarding the Companys ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. 2. Summary of Significant Accounting Policies   A. Basis of Presentation   The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (US GAAP) and are expressed in U.S. dollars.   The operating results of Immunoclin Limited (IML), acquired on December 13, 2013, were consolidated with the financial statements of the Company for the years ended January 31, 2014 and 2013. An independent valuation firm validated the purchase price for IML to be $20,000,000 consisting of $19,800,000 in intangibles-R&D, 654,992 in goodwill, and ($454,992) in net tangible assets acquired, which was confirmed by a third-party valuator assessment. A total of $654,992 in unimpaired goodwill remains at January 31, 2014.   The Company recorded adjustments of ($52,184) to additional paid-in capital and $507,176 to deficit for the year ended January 31, 2014 to reconcile the consolidated statement of stockholders equity (deficit) as a result of the acquisition of IML.   The Companys fiscal year end was changed from February 28 to January 31 during 2014.    B. Use of Estimates   The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the consolidated financial statements in the period they are determined.   C. Basic and Diluted Net Income (Loss) Per Share   Under ASC 260, "Earnings Per Share" ("EPS"), the Company provides for the calculation of basic and diluted earnings per share. Basic EPS includes no dilution and is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the years ended January 31, 2014 and 2013, basic and diluted loss per share are the same since the calculation of diluted per share amounts would result in an anti-dilutive calculation.   D. Cash and Cash Equivalents   The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.   E. Accounts Receivable and Allowance for Doubtful Accounts   Accounts receivable consists principally of trade receivables, which are recorded at the invoiced amount, net of allowances for doubtful accounts and prompt payment discounts. Trade receivables do not bear interest. The allowance for doubtful accounts represents managements estimate of the amount of probable credit losses in existing accounts receivable, as determined from a review of past due balances and other specific account data. Account balances are written off against the allowance when management determines the receivable is uncollectible. The Company does not have off-balance sheet credit exposure related to its customers.   F. Prepaid Expense   Prepaid expenses consist of $510,329 in prepaid stock-based compensation under management contracts. Prepaid stock-based compensation expense is amortized over the service periods pursuant to the agreements.   G. Long-Lived Assets   Under ASC Topic 360, Property, Plant, and Equipment, the Company is required to periodically evaluate the carrying value of long-lived assets to be held and used. ASC Topic 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.   The Company is adopting ASU update number 2012-02IntangiblesGoodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment whereby the Company will first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, we conclude that it is not more than likely than not that the indefinite-lived intangible asset is impaired, then we are not required to take further action. If the Company concludes otherwise, then we will determine the fair value of the indefinite-lived intangible asset and perform the required quantitative impairment test by comparing the fair value with the carrying amount.   H. Fair Value Measurements   Under ASC Topic 820, the Company discloses the estimated fair values of financial instruments. The carrying amounts reported in the balance sheet for current assets and current liabilities qualifying as financial instruments are a reasonable estimate of fair value.   In accordance with the reporting requirements of ASC Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of those financial instruments (see Note 4). The estimated fair value of other current assets and current liabilities approximate their carrying amounts due to the relatively short maturity of these instruments. None of these instruments are held for trading purposes.   I. Goodwill and Intangible Assets   Under ASC Topic 350 Intangibles-Goodwill and Other, goodwill is not amortized to expense, but rather that it is assessed or tested for impairment at least annually. Impairment write-downs are charged to results of operations in the period in which the impairment is determined. If certain events occur which might indicate goodwill has been impaired, the goodwill is tested for impairment when such events occur. Other acquired intangible assets with finite lives, such as acquired R&D and patents, are required to be amortized over the estimated lives. These intangibles are generally amortized using the straight-line method over estimated useful lives.   The Company tests the carrying value of goodwill and indefinite life intangible assets for impairment at least once a year and more frequently if an event or circumstance indicates the asset may be impaired. An impairment loss is recognized if the amount of the assets carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an assets fair value less selling expenses or its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows (cash generating units).   The Company did not record an impairment loss on goodwill for 2014.   J. Revenue Recognition   Revenues are recognized at the time clinical and laboratory services are completed and delivered pursuant to percentage of completion and/or milestone payments as per contracts with the Companys customers.    K. Research and Development Expenses   Under ASC Topic 730 Research and Development, costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a product receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a product receives regulatory approval, any milestone payments will be recorded as Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, amortization of the payments will be on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.   L. Income Taxes   Under ASC Topic 740, Income Taxes, the Company in required to account for its income taxes through the establishment of a deferred tax asset or liability for the recognition of future deductible or taxable amounts and operating loss and tax credit carry forwards. Deferred tax expense or benefit is recognized as a result of timing differences between the recognition of assets and liabilities for book and tax purposes during the year.   Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.   Deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carry forwards. A valuation allowance is established to reduce that deferred tax asset if it is "more likely than not" that the related tax benefits will not be realized.   Unfiled Federal Tax Returns: For the years ending January 31, 2014 and 2013, the Company has not filed federal tax returns and may be subject to penalties. The Company estimates that the amount of penalties, if any, will not have a material effect on the results of operations, cash flows or financial position. No provisions have been made in the financial statements for such penalties, if any.   The Company is planning to have its accountants prepare and file overdue federal tax returns for the years ended January 31, 2014 and 2013 by Q4 of fiscal 2015.   M. Stock-Based Compensation   Under ASC Topic 718, Compensation-Stock Compensation, the Company is required to measure all employee share-based payments, including grants of employee stock options, using a fair-value-based method and the recording of such expense in the statements of operations. The Company has adopted ASC Topic 718 (SFAS 123R) and recognizes stock-based compensation expense using the modified prospective method. As of January 31, 2014 and 2013, the Company has no employee stock options.   N. Comprehensive Loss   ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As of January 31, 2014 and 2013, the Company had foreign exchange translation adjustments of ($17,224) and ($10,094), respectively, which are included in other comprehensive income in the consolidated financial statements.   O. Recent Accounting Pronouncements   During the year ended January 31, 2014 and through June 30, 2014, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Companys financial statements.   P. Reclassifications   For comparative purposes, certain prior period consolidated financial statements have been reclassified to conform with report classifications of the current year. 3. Fair Value Measurements and Disclosures   ASC Topic 820, Fair Value Measurement, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows:   Level 1   Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities that the Company can access at the measurement date.   Level 2   Inputs to the valuation methodology are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.   Level 3    Inputs to the valuation methodology are unobservable inputs for the asset of liability.   The asset or liabilitys fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.   Following is a description of the valuation methodologies used for the Companys liabilities measured at fair value. There have been no changes in the methodologies used at January 31, 2014.   Intangibles from IML acquisition: Valued at replacement cost. The replacement cost is determined as the cost of replacing the asset with a modern unit of the near equivalent utility.    The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. The following tables set forth by level, within the fair value hierarchy, the Companys assets at fair value as of January 31, 2014. The Company had no assets as of January 31, 2013.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Level 1</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Level 2</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Level 3</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Total</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 7.95pt"> Intangibles from acquisition of IML, net of accumulated amortization</td><td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">  </td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">  </td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,793,466</td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,793,466</td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 7.95pt">Total assets as of January 31, 2014</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">19,793,466</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">19,793,466</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table>       4. Related Party Transactions   During the years ended January 31, 2014 the Companys former President and CEO, Robert Lawrence, advanced $0 (2013; $56,685) to the Company and paid expenses of $0 (2013; $0) on behalf of the Company. The $56,685 owing at January 31, 2013 to Mr. Lawrence was unsecured, non-interest bearing, and due on demand. On April 25, 2013, Mr. Lawrence assigned his loans payable of $55,145 to Jagpal Holdings Ltd., a non-related party that was secured by the Company under a non-interest bearing demand promissory note due and payable on April 25, 2014. In addition, Mr. Lawrence was paid $33 and he forgave $1,507, which has been recorded in additional paid-in capital as of January 31, 2014.   On October 21, 2013, Intrinsic Venture Corp. loaned the Company $2,062 that was secured by a non-interest bearing demand promissory note due in 12 months. Intrinsic Venture Corp. is owned and controlled by J. Scott Munro, the Companys CFO.   On December 13, 2013, the Company issued 1,000,000 shares of Series A preferred stock, with a fair market value of $180,000 or $0.18 per share, to executive officers and directors and a management consultant pursuant to a Control Shareholder Agreement.   On December 13, 2013, Dr. Dorothy Bray was appointed a director and CEO/President under pursuant to a five-year management agreement with the Company. Under the agreement, Dr. Bray is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Dr. Bray shall also receive 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payments one year following the signing of the Agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock. The estimated fair value of the initial stock compensation package to Dr. Bray is $4,000,000, based on the closing price of $2.00 per share for the Companys stock on December 12, 2013.   On December 13, 2013, Chad S. Johnson entered into a five-year management agreement with the Company for acting in the capacities of Chief Operating Officer, General Counsel, Secretary and Director. Under the agreement, Mr. Johnson is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $15,000 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Mr. Johnson shall also receive 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payment one year following the signing of the agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Rule 144 restricted common shares of the Company common stock. The estimated fair value of the initial stock compensation package to Mr. Johnson is $2,000,000, based on the closing price of $2.00 per share for the Companys stock on December 12, 2013.   On December 13, 2013, J. Scott Munro entered into a five-year management agreement with the Company for acting in the capacity of Chief Financial Officer (Principal Accounting Officer). Under the agreement, Mr. Munro is to be paid $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under this Agreement, considered to be November 30, 2014. Mr. Munro shall also receive 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payments one year following the signing of the Agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock. The estimated fair value of the initial stock compensation package to Mr. Munro is $4,000,000, based on the closing price of $2.00 per share for the Companys stock on December 12, 2013.   On December 13, 2013, Raymond Dabney entered into a five-year management agreement with the Company for services as Managing Consultant. Under the agreement, Mr. Dabney is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Mr. Dabney shall also receive 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payment one year following the signing of the agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Rule 144 restricted common shares of the Company common stock. The estimated fair value of the initial stock compensation package to Mr. Johnson is $2,000,000, based on the closing price of $2.00 per share for the Companys stock on December 12, 2013.   The aforementioned management agreements are incorporated by reference to this Form 10-K as filed on Form 8-K filed with the SEC on December 20, 2013.   On January 23, 2014, Khadija Benlhassan, PhD entered into a five-year management agreement (the Agreement) for acting as Director and Chief Scientific Officer for the Company and undertake the duties and responsibilities of these appointments as of March 1, 2014. Under the Agreement, Dr. Benlhassan is to receive compensation of $16,667 per month for the first three months (March through May 2014) and $17,778 per month for the nine months thereafter through to the end of her first year of service under the Agreement. Dr. Benlhassan will earn 2,000,000 Rule 144 restricted common shares of the Company on November 30, 2014 pursuant to the Agreement and May 30, 2014 Addendum Agreement.   During the year ended January 31, 2014, the Company recorded the following related party stock-based compensation:   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="text-align: center; vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Related Party</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">Position</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid">Amount</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 30%; text-align: left; padding-left: 5.4pt">Dr. Dorothy Bray</td> <td style="width: 7%"> </td> <td style="width: 28%; padding-left: 5.4pt">CEO/President</td> <td style="width: 7%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 26%; text-align: right">4,000,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-left: 5.4pt">J. Scott Munro</td> <td> </td> <td style="padding-left: 5.4pt">CFO</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,000,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-left: 5.4pt">Chad S. Johnson, Esq.</td> <td> </td> <td style="text-align: left; padding-left: 5.4pt">COO and General Counsel</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,000,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Raymond Dabney</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Managing Consultant</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">2,000,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="padding-left: 5.4pt"> </td> <td> </td> <td style="padding-left: 5.4pt"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">12,000,000</td> <td style="text-align: left"> </td></tr> </table>   The above table includes stock-based compensation paid to companies beneficially owned by the related parties. 5. Notes Payable   The Company has two non-interest bearing promissory notes due upon demand in 12 months to Jagpal Holdings Ltd.; one for $55,145 dated April 25, 2013 and one for $17,852 dated June 1, 2013.   On October 21, 2013, Intrinsic Venture Corp. loaned the Company $2,062 secured by a non-interest bearing promissory note due on demand in 12 months. (see Note 4) 6. Equity   The Company is authorized to issue 290,000,000 shares of common stock with a par value of $0.001 per share. These shares have full voting rights. There were 26,503,515 and 5,361,015 shares of common stock issued and outstanding as of January 31, 2014 and 2013, respectively.   The Company is also authorized to issue 1,000,000 shares of Series A preferred stock, with a par value of $0.001 per share. The shares of Series A preferred stock have 51% of the total vote on all shareholder matters and 66-2/3% of the Series A preferred stockholders may make any affirmative vote to amend, alter or repeal and provision of the Articles of Incorporation or the Bylaws of the Company. There were 1,000,000 and 0 shares of Series A preferred stock issued and outstanding as of January 31, 2014 and 2013, respectively.   The Company is also authorized to issue 9,000,000 shares of preferred stock. These shares have full voting rights. There were 0 and 0 issued and outstanding as of January 31, 2014 and 2013, respectively.   During the year ended January 31, 2014, the Company issued the following common stock:   On December 13, 2013, the Company acquired Immunoclin Limited, an England and Wales corporation, pursuant to a Take Over Agreement. In consideration for the acquisition, the Company issued 10,000,000 shares of common stock, with a fair market value of $20,000,000, or $2.00 per share, to Dr. Dorothy Bray in exchange for all issued and outstanding shares in Immunoclin Limited. An independent valuation firm validated the purchase price for IML to be $20,000,000 consisting of $19,800,000 in intangibles-R&D, 654,992 in goodwill, and ($454,992) in net tangible assets acquired, which was confirmed by a third-party valuator assessment and opinion contracted by the Companys auditor. A total of $654,992 in unimpaired goodwill remains at January 31, 2014.     On December 13, 2013, the Company issued 6,000,000 shares of common stock, with a fair market value of $12,000,000 or $2.00 per share, pursuant to management agreements with executive officers, directors, and a management consultant of the Company.   On December 13, 2013, the Company issued 1,000,000 shares of Series A preferred stock, with a fair market value of $180,000 or $0.18 per share, to executive officers and directors and a management consultant pursuant to a Control Shareholder Agreement.   On December 13, 2013, the Company issued 100,000 shares of common stock, with a fair market value of $200,000 or $2.00 per share to the co-inventor of the of the DACTELLIGENCE patent to acquire the remaining 50% ownership pursuant to a License and Royalty Agreement dated October 1, 2013 with Immunoclin Limited.   On December 13, 2013, the Company issued 42,500 shares of common stock with a fair market value of $85,000 or $2.00 per share to a consultant for settlement of $85,000 in fees due pursuant to a settlement agreement.   Stock Options and Warrants:   The Company has no stock options or warrants outstanding.  7. Income Taxes   The Company has $4,544,793 of net operating losses carried forward to offset taxable income in future years that expire commencing in fiscal 2034. The income tax benefit differs from the amount, computed by applying the US federal income tax rate of 34% to net loss before income taxes. As at January 31, 2014, the Company had no uncertain tax positions.   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center">January 31, 2014 $</td> <td> </td> <td colspan="3" style="text-align: center">January 31, 2013 $</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 58%; text-align: left">Net loss before taxes</td> <td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 11%; text-align: right">(12,980,317</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 11%; text-align: right">(68,438</td> <td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt">Statutory rate</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">34</td> <td style="text-align: left; padding-bottom: 1pt">%</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">34</td> <td style="text-align: left; padding-bottom: 1pt">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Deferred tax assets:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left">   NOL expense (benefit)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(136,850</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(22,454</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt">   Valuation allowance</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">136,850</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">22,454</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt">Net deferred tax assets</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> </table>   The significant components of deferred income tax assets and liabilities at January 31, 2014 and January 31, 2013 are as follows:   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: center">January 31, 2014 $</td> <td> </td> <td colspan="3" style="text-align: center">January 31, 2013 $</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 58%; text-align: left; padding-left: 5.4pt">Net operating loss carried forward</td> <td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 11%; text-align: right">(4,413,308</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 11%; text-align: right">(23,269</td> <td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-left: 5.4pt">Stock issued for services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,205,688</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">  </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Depreciation and amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">70,769</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">815</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="padding-left: 5.4pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Net deferred income tax asset</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(136,850</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(22,454</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> </table>   8. Equipment    <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="text-align: center; vertical-align: bottom"> <td colspan="3"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid">Cost</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid">Accumulated Depreciation</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid">Net Book Value January 31, 2014</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid">Net Book Value January 31, 2013</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 1%; text-align: left"> </td> <td style="width: 20%; text-align: right">Computers</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right">11,327</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right">5,086</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">6,241</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">1,262</td> <td style="width: 1%; text-align: left"> </td></tr> </table>   All equipment is stated at cost.  Maintenance and repairs are charged to expense as incurred and the cost of renewals and betterments are capitalized.  Depreciation is computed using the straight-line method over the 5 year estimated lives of the related computer equipment.   9. Intangible Assets   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: right; border-bottom: black 1pt solid">January 31, 2014</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: right; border-bottom: black 1pt solid">January 31, 2013</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 58%; padding-bottom: 1pt; padding-left: 0.25in">Patents</td> <td style="width: 8%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">200,000</td> <td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td> <td style="width: 8%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 11%; text-align: right"> </td> <td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Research and development</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">19,800,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Less accumulated amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(206,534</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 0.25in"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td> <td style="text-align: right">19,793,466</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td> <td style="text-align: right">  </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>    Intangible assets are stated at fair value on the date of purchase less accumulated amortization. Amortization is computed using the straight-line method over the estimated lives of the related assets (13 years for intellectual assets).                      On December 13, 2013, the Company acquired the remaining 50% interest in the DACTELLIGENCE patent from one of the inventors for consideration of 100,000 shares of common stock with a fair market value of $200,000 or $2.00 per share.   On December 13, 2013, the Company acquired R&D intangibles in the IML acquisition. An independent valuation firm validated the purchase price for IML to be $20,000,000 consisting of $19,800,000 in intangibles-R&D, 654,992 in goodwill, and ($454,992) in net tangible assets acquired, which was confirmed by a third-party valuator assessment.   The Company will recognize approximately $1,538,462 in intangible amortization expense per year over the next 13 years with intangibles being fully amortized by fiscal 2028.   10. Commitments and Contingencies   The Company has a 1,668 sq. ft. laboratory facility in located in Paris, France at the Centre de Recherche des Cordeliers (CRC). The laboratory has operated under a lease with University of Pierre and Marie Currie (UPMC) in Immunoclin Limited since 2001. The Company is currently under negotiations with UPMC to extend the lease. Lease commitments are approximately $38 per square foot or $63,000 per year, plus charges of approximately $4,000. The lease is paid semi-annually on January 1st and June 1st.   The Companys corporate headquarters is currently on a month-to-month lease with no commitments.   The Company has no other commitments or contingencies.   A. Basis of Presentation   The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (US GAAP) and are expressed in U.S. dollars.   The operating results of Immunoclin Limited (IML), acquired on December 13, 2013, were consolidated with the financial statements of the Company for the years ended January 31, 2014 and 2013. An independent valuation firm validated the purchase price for IML to be $20,000,000 consisting of $19,800,000 in intangibles-R&D, 654,992 in goodwill, and ($454,992) in net tangible assets acquired, which was confirmed by a third-party valuator assessment. A total of $654,992 in unimpaired goodwill remains at January 31, 2014.   The Company recorded adjustments of ($52,184) to additional paid-in capital and $507,176 to deficit for the year ended January 31, 2014 to reconcile the consolidated statement of stockholders equity (deficit) as a result of the acquisition of IML.   The Companys fiscal year end was changed from February 28 to January 31 during 2014. B. Use of Estimates   The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the consolidated financial statements in the period they are determined. C. Basic and Diluted Net Income (Loss) Per Share   Under ASC 260, "Earnings Per Share" ("EPS"), the Company provides for the calculation of basic and diluted earnings per share. Basic EPS includes no dilution and is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the years ended January 31, 2014 and 2013, basic and diluted loss per share are the same since the calculation of diluted per share amounts would result in an anti-dilutive calculation. D. Cash and Cash Equivalents   The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.   E. Accounts Receivable and Allowance for Doubtful Accounts   Accounts receivable consists principally of trade receivables, which are recorded at the invoiced amount, net of allowances for doubtful accounts and prompt payment discounts. Trade receivables do not bear interest. The allowance for doubtful accounts represents managements estimate of the amount of probable credit losses in existing accounts receivable, as determined from a review of past due balances and other specific account data. Account balances are written off against the allowance when management determines the receivable is uncollectible. The Company does not have off-balance sheet credit exposure related to its customers. G. Long-Lived Assets   Under ASC Topic 360, Property, Plant, and Equipment, the Company is required to periodically evaluate the carrying value of long-lived assets to be held and used. ASC Topic 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.   The Company is adopting ASU update number 2012-02IntangiblesGoodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment whereby the Company will first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, we conclude that it is not more than likely than not that the indefinite-lived intangible asset is impaired, then we are not required to take further action. If the Company concludes otherwise, then we will determine the fair value of the indefinite-lived intangible asset and perform the required quantitative impairment test by comparing the fair value with the carrying amount. H. Fair Value Measurements   Under ASC Topic 820, the Company discloses the estimated fair values of financial instruments. The carrying amounts reported in the balance sheet for current assets and current liabilities qualifying as financial instruments are a reasonable estimate of fair value.   In accordance with the reporting requirements of ASC Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of those financial instruments (see Note 4). The estimated fair value of other current assets and current liabilities approximate their carrying amounts due to the relatively short maturity of these instruments. None of these instruments are held for trading purposes. I. Goodwill and Intangible Assets   Under ASC Topic 350 Intangibles-Goodwill and Other, goodwill is not amortized to expense, but rather that it is assessed or tested for impairment at least annually. Impairment write-downs are charged to results of operations in the period in which the impairment is determined. If certain events occur which might indicate goodwill has been impaired, the goodwill is tested for impairment when such events occur. Other acquired intangible assets with finite lives, such as acquired R&D and patents, are required to be amortized over the estimated lives. These intangibles are generally amortized using the straight-line method over estimated useful lives.   The Company tests the carrying value of goodwill and indefinite life intangible assets for impairment at least once a year and more frequently if an event or circumstance indicates the asset may be impaired. An impairment loss is recognized if the amount of the assets carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an assets fair value less selling expenses or its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows (cash generating units).   The Company did not record an impairment loss on goodwill for 2014. J. Revenue Recognition   Revenues are recognized at the time clinical and laboratory services are completed and delivered pursuant to percentage of completion and/or milestone payments as per contracts with the Companys customers. K. Research and Development Expenses   Under ASC Topic 730 Research and Development, costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a product receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a product receives regulatory approval, any milestone payments will be recorded as Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, amortization of the payments will be on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter. L. Income Taxes   Under ASC Topic 740, Income Taxes, the Company in required to account for its income taxes through the establishment of a deferred tax asset or liability for the recognition of future deductible or taxable amounts and operating loss and tax credit carry forwards. Deferred tax expense or benefit is recognized as a result of timing differences between the recognition of assets and liabilities for book and tax purposes during the year.   Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.   Deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carry forwards. A valuation allowance is established to reduce that deferred tax asset if it is "more likely than not" that the related tax benefits will not be realized.   Unfiled Federal Tax Returns: For the years ending January 31, 2014 and 2013, the Company has not filed federal tax returns and may be subject to penalties. The Company estimates that the amount of penalties, if any, will not have a material effect on the results of operations, cash flows or financial position. No provisions have been made in the financial statements for such penalties, if any.   The Company is planning to have its accountants prepare and file overdue federal tax returns for the years ended January 31, 2014 and 2013 by Q4 of fiscal 2015. M. Stock-Based Compensation   Under ASC Topic 718, Compensation-Stock Compensation, the Company is required to measure all employee share-based payments, including grants of employee stock options, using a fair-value-based method and the recording of such expense in the statements of operations. The Company has adopted ASC Topic 718 (SFAS 123R) and recognizes stock-based compensation expense using the modified prospective method. As of January 31, 2014 and 2013, the Company has no employee stock options. N. Comprehensive Loss   ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As of January 31, 2014 and 2013, the Company had foreign exchange translation adjustments of ($17,224) and ($10,094), respectively, which are included in other comprehensive income in the consolidated financial statements. O. Recent Accounting Pronouncements   During the year ended January 31, 2014 and through June 30, 2014, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Companys financial statements. P. Reclassifications   For comparative purposes, certain prior period consolidated financial statements have been reclassified to conform with report classifications of the current year. F. Prepaid Expense   Prepaid expenses consist of $510,329 in prepaid stock-based compensation under management contracts. Prepaid stock-based compensation expense is amortized over the service periods pursuant to the agreements. The following tables set forth by level, within the fair value hierarchy, the Companys assets at fair value as of January 31, 2014. The Company had no assets as of January 31, 2013.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Level 1</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Level 2</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Level 3</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Total</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 7.95pt"> Intangibles from acquisition of IML, net of accumulated amortization</td><td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">  </td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">  </td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,793,466</td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 3%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,793,466</td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 7.95pt">Total assets as of January 31, 2014</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">19,793,466</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">19,793,466</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table>   During the year ended January 31, 2014, the Company recorded the following related party stock-based compensation:   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="text-align: center; vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Related Party</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">Position</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid">Amount</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 30%; text-align: left; padding-left: 5.4pt">Dr. Dorothy Bray</td> <td style="width: 7%"> </td> <td style="width: 28%; padding-left: 5.4pt">CEO/President</td> <td style="width: 7%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 26%; text-align: right">4,000,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-left: 5.4pt">J. Scott Munro</td> <td> </td> <td style="padding-left: 5.4pt">CFO</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,000,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-left: 5.4pt">Chad S. Johnson, Esq.</td> <td> </td> <td style="text-align: left; padding-left: 5.4pt">COO and General Counsel</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,000,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Raymond Dabney</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Managing Consultant</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">2,000,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="padding-left: 5.4pt"> </td> <td> </td> <td style="padding-left: 5.4pt"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">12,000,000</td> <td style="text-align: left"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="text-align: center; vertical-align: bottom"> <td colspan="3"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid">Cost</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid">Accumulated Depreciation</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid">Net Book Value January 31, 2014</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid">Net Book Value January 31, 2013</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 1%; text-align: left"> </td> <td style="width: 20%; text-align: right">Computers</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right">11,327</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 16%; text-align: right">5,086</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">6,241</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 15%; text-align: right">1,262</td> <td style="width: 1%; text-align: left"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: right; border-bottom: black 1pt solid">January 31, 2014</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: right; border-bottom: black 1pt solid">January 31, 2013</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 58%; padding-bottom: 1pt; padding-left: 0.25in">Patents</td> <td style="width: 8%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 11%; text-align: right">200,000</td> <td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td> <td style="width: 8%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 11%; text-align: right"> </td> <td style="width: 1%; text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Research and development</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">19,800,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right">  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Less accumulated amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(206,534</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 0.25in"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td> <td style="text-align: right">19,793,466</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td> <td style="text-align: right">  </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> 19793466 19793466 0.34 0.34 -136850 -22454 11327 5086 206534 1538462 -136850 -22454 469888 -2245 -75794 -17224 -10094 Common shares reconciliation table:    <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 71%; text-align: justify">Issued and outstanding as of January 31, 2014</td> <td style="width: 10%"> </td> <td style="width: 18%; text-align: right">26,503,515</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; padding-bottom: 1pt">Subsequent event issuances and cancellation</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(32,361</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Unissued and outstanding as of June 30, 2014</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right">26,471,154</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> 141129 It was unsecured, non-interest bearing, and due on demand. A non-related party that was secured by the Company under a non-interest bearing demand promissory note due Non-interest bearing demand promissory note It was non-interest bearing promissory notes. Non-interest bearing promissory note 2062 17852 Due on demand in 12 months Due upon demand in 12 months Due upon demand in 12 months 2014-04-25 86507 36433 43 86464 55145 85000 Under the agreement, Dr. Bray is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Dr. Bray shall also receive 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payments one year following the signing of the Agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock. Under the agreement, Mr. Johnson is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $15,000 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Mr. Johnson shall also receive 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payment one year following the signing of the agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Rule 144 restricted common shares of the Company common stock. Under the agreement, Mr. Munro is to be paid $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under this Agreement, considered to be November 30, 2014. Mr. Munro shall also receive 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payments one year following the signing of the Agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock. Under the agreement, Mr. Dabney is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Mr. Dabney shall also receive 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payment one year following the signing of the agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Rule 144 restricted common shares of the Company common stock. Under the Agreement, Dr. Benlhassan is to receive compensation of $16,667 per month for the first three months (March through May 2014) and $17,778 per month for the nine months thereafter through to the end of her first year of service under the Agreement. Dr. Benlhassan will earn 2,000,000 Rule 144 restricted common shares of the Company on November 30, 2014 pursuant to the Agreement and May 30, 2014 Addendum Agreement. 0.18 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 4.25 3.75 3.75 5.00 5.60 5.60 5.60 The shares of Series A preferred stock have 51% of the total vote on all shareholder matters and 66-2/3% of the Series A preferred stockholders may make any affirmative vote to amend, alter or repeal and provision of the Articles of Incorporation or the Bylaws of the Company. Expire commencing in fiscal 2034 P5Y Lease commitments are approximately $38 per square foot or $63,000 per year, plus charges of approximately $4,000. The lease is paid semi-annually on January 1st and June 1st. 10000 100000 15000 25000 240000 On April 23, 2014, the Company signed a two-year management consulting agreement with Dr. Marco Kaiser to act as an advisor for molecular biology, genetics, infectious diseases, and DACTELLIGENCE. On May 1, 2014, the Company signed a two-year management consulting agreement with Railton Frith and his affiliates to act as advisors for DACTELLIGENCE On May 7, 2014, the Company signed a two-year management consulting agreement with Professor Antony Bayer and his affiliates to act as advisors for neurology and aging. On May 27, 2014, the Company signed a two-year management consulting agreement with Professor Jean Mariani to act as an advisor for treatments targeting central nervous system diseases and aging. On June 4, 2014, the Company signed a two-year management consulting agreement with Professor Iwona Wybrańska and her affiliates to act as advisors for nutrigenomics, metabolomics and functional food. On June 21, 2014, the Company signed a two-year management consulting agreement with Dr. Gundula Piechotta and her affiliates to act as advisors for infectious diseases and DACTELLIGENCE. On June 30, 2014, the Company signed a two-year management consulting agreement with Dr. Heinz Ellerbrok and his affiliates to act as advisors for infectious diseases and DACTELLIGENCE. 2000000 2000000 2000000 2000000 2000000 12453670 -12997541 -78532 -10094 -17224 -68438 -12980317 -12980317 -68438 12369671 4000000 4000000 2000000 2000000 4000000 2000000 4000000 2000000 42500 42500 P13Y 5.60 5.60 5.60 5.60 5.60 15809499 3161900 3161900 3161900 3161900 3161900 3.16 3.16 3.16 3.16 3.16 20000000 19800000 -454992 19793466 19793466 200000 19800000 206534 The significant components of deferred income tax assets and liabilities at January 31, 2014 and January 31, 2013 are as follows:   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: center">January 31, 2014 $</td> <td> </td> <td colspan="3" style="text-align: center">January 31, 2013 $</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 58%; text-align: left; padding-left: 5.4pt">Net operating loss carried forward</td> <td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 11%; text-align: right">(4,413,308</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 11%; text-align: right">(23,269</td> <td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-left: 5.4pt">Stock issued for services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,205,688</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">  </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Depreciation and amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">70,769</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">815</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="padding-left: 5.4pt"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Net deferred income tax asset</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(136,850</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">(22,454</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> </table> The income tax benefit differs from the amount, computed by applying the US federal income tax rate of 34% to net loss before income taxes. As at January 31, 2014, the Company had no uncertain tax positions.   <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center">January 31, 2014 $</td> <td> </td> <td colspan="3" style="text-align: center">January 31, 2013 $</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: right"> </td> <td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 58%; text-align: left">Net loss before taxes</td> <td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 11%; text-align: right">(12,980,317</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 11%; text-align: right">(68,438</td> <td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt">Statutory rate</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">34</td> <td style="text-align: left; padding-bottom: 1pt">%</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">34</td> <td style="text-align: left; padding-bottom: 1pt">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Deferred tax assets:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left">   NOL expense (benefit)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(136,850</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(22,454</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt">   Valuation allowance</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">136,850</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">22,454</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt">Net deferred tax assets</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; border-bottom: black 1pt solid"> </td> <td style="text-align: right; border-bottom: black 1pt solid">  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> </table>   -4413308 -23269 4205688 70769 815 -136850 -22454 -32361 1,000,000 options vest on each of November 1, 2014 and November 1, 2015 1,000,000 options vest on each of November 1, 2014 and November 1, 2015 1,000,000 options vest on each of November 1, 2014 and November 1, 2015 1,000,000 options vest on each of November 1, 2014 and November 1, 2015 1,000,000 options vest on each of November 1, 2014 and November 1, 2015 EX-101.SCH 10 imcle-20140131.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements Of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Stockholders’ Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Nature of Operations and Continuance of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary Of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Fair Value Measurements and Disclosures link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Equipment link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Summary Of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Fair Value Measurements and Disclosures (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Subsequent Events (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Fair Value Measurements and Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Income Taxes (Schedule Of Income Tax Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Income Taxes (Schedule Of Deferred Income Tax Assets And Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Nature Of Operations And Continuance Of Business (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Summary Of Significant Accounting Policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Related Party Transactions (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Notes Payable (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Equipment (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Intangible Assets (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Commitments And Contingencies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Subsequent Events (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 imcle-20140131_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.LAB 12 imcle-20140131_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Common Stock Equity Components [Axis] Castor Management Services, Inc Supplier [Axis] Subsequent Event Subsequent Event Type [Axis] Former President and Director - Robert Lawrence Related Party [Axis] Dr. Dorothy Bray - Director And CEO/President Jagpal Holdings, Inc. Debt Instrument [Axis] Intrinsic Venture Corp Take Over Agreement - Immunoclin Limited and Wales Corporation Business Acquisition [Axis] Controlling Shareholders Series A Preferred Stock Class of Stock [Axis] Management Agreements Type of Deferred Compensation [Axis] Dr. Dorothy Bray, Chad S. Johnson, James Scott Munro, Raymond Dabney Title of Individual [Axis] Promissory Note - Jagpal Holdings Ltd Notes Payable - Intrinsic Venture Corp Preferred Stock Additional Paid-In Capital Cumulative Translation Adjustments Deficit Level 1 Fair Value, Hierarchy [Axis] Level 2 Level 3 Dr. Dorothy Bray - CEO J. Scott Munro - Chief Financial Officer Chad S. Johnson - COO Raymond Dabney - Managing Consultant Computer Property, Plant and Equipment, Type [Axis] Immunoclin Limited (IML) President And CEO - Robert Lawrence Short-term Debt, Type [Axis] Promissory Note From Intrinsic Venture Corp Executive Officer And Directors And Management Consultant Khadija Benlhassan - Director And Chief Scientific Officer Patents Finite-Lived Intangible Assets by Major Class [Axis] Debt Extinguishment Extinguishment of Debt [Axis] Intangible Assets Asset Class [Axis] Lease Agreements Intrinsic Venture Corp Rule144 Restricted Stock Consulting Agreement - Dr. Marco Kaiser Consulting Agreement - Railton Frith Consulting Agreement - Railton Frith Consulting Agreement - Professor Antony Bayer Consulting Agreement - Professor Jean Mariani Consulting Agreement - Professor Iwona Wybranska Consulting Agreement - Dr. Gundula Piechotta Consulting Agreement - Dr. Heinz Ellerbrok Research And Development Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity's Reporting Status Current? Well Known Seasoned Issuer Voluntary Filers Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Statement [Table] Statement [Line Items] ASSETS Current Assets Cash Accounts receivable Other receivable Prepaid expenses Total Current Assets Property and equipment, net (Note 8) Intangibles, net (Note 9) Goodwill Total Assets LIABILITIES Current Liabilities Accounts payable Accrued expenses, primarily management fees Due to related parties (Note 4) Notes payable, related parties (Note 5) Notes payable, stockholders (Note 5) Total Liabilities STOCKHOLDERS' EQUITY (DEFICIT) Preferred Stock, $0.001 par value, 9,000,000 shares authorized, 0 shares issued and outstanding at January 31, 2014 and January 31, 2013. Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at January 31, 2014 and 0 at January 31, 2013 Common Stock , $0.001 par value, 290,000,000 shares authorized, 26,503,515 issued and outstanding January 31, 2014 and 5,361,015 at January 31, 2013 Additional paid-in capital Accumulated deficit Accumulated other comprehensive income Total Stockholders' Equity (Deficit) Total Liabilities and Stockholders' Equity (Deficit) Preferred stock, par value Preferred stock, shares authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Operating Expenses Amortization Depreciation Management and consulting fees General and administrative Professional fees Research and development Total Operating Expenses Net Operating Loss Other Income (expense) Interest expense, net Tax credits, research and development Total other income (expense) Net Loss Other Comprehensive Income Foreign exchange translation adjustment Comprehensive Income (Loss) Net Comprehensive Loss Net loss per Share - basic and diluted Weighted average shares outstanding - basic and diluted Statement of Cash Flows [Abstract] Operating Activities Net loss for the year Adjustments to reconcile net loss to cash used in operating activities: Depreciation Common stock issued for services Expenses paid by related parties Foreign exchange translation Changes in operating assets and liabilities: Accounts receivable Other receivable Accounts payable Accrued expenses, primarily management fees Net Cash Provided by (Used In) Operating Activities Investing Activities Purchase of property and equipment Net Cash Used in Investing Activities Financing Activities Proceeds from the sale of common stock Related party loans forgiven to share capital Proceeds from related party notes payable Repayments to related party loans Net Cash Provided by Financing Activities Change in Cash Cash - Beginning of Year Cash - End of Year Supplemental Disclosures Cancellation of common stock Common stock issued for prepaid services Common stock issued to acquire IML Common stock issued to acquire patent Common stock issued to extinguish debt Interest paid Income tax paid Balance shares Balance value Common stock issued for cash, shares Common stock issued for cash, value Director loan forgiven to additional paid-in capital Preferred stock issued for services, shares Preferred stock issued for services, value Common stock issued for acquisition, shares Common stock issued for acquisition, value Common stock issued for prepaid services, shares Common stock issued for prepaid services, value Common stock issued for services, shares Common stock issued for services, value Common stock issued to acquire patent, shares Common stock issued to acquire patent, value Common stock issued to extinguish debt, shares Common stock issued to extinguish debt, value Cancellation of common stock, shares Cancellation of common stock, value Adjustments to reconcile additional paid-in capital and retained earnings from IML acquisition Net loss for the year Balance shares Balance value Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Operations and Continuance of Business Accounting Policies [Abstract] Summary of significant accounting policies Fair Value Disclosures [Abstract] Fair Value Measurements and Disclosures Related Party Transactions [Abstract] Related party transactions Debt Disclosure [Abstract] Notes payable Equity [Abstract] Equity Income Tax Disclosure [Abstract] Income Taxes Property, Plant and Equipment [Abstract] Equipment Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Basis of presentation Use of estimates Basic and diluted net income (loss) per share Cash and cash equivalents Accounts receivable and allowance for doubtful accounts Prepaid expense Long-lived assets Fair value measurements Goodwill and intangible assets Revenue recognition Research and development expenses Income taxes Stock based compensation Comprehensive Loss Recent accounting pronouncements Reclassification Schedule of fair value measurement and disclosure Schedule of related party transactions Schedule of income tax benefit Schedule of deferred income tax assets and liabilities Schedule of equipment Schedule of intangible assets Subsequent Events Tables Schedule of common shares reconciliation Intangibles from acquisition of IML, net of accumulated amortization Total assets as of January 31, 2014 Stock based compensation Income Taxes Schedule Of Income Tax Benefit Details Net loss before taxes Statutory rate Deferred tax assets: NOL expense (benefit) Valuation allowance Net deferred tax assets Income Taxes Schedule Of Deferred Income Tax Assets And Liabilities Details Net operating loss carried forward Stock issued for services Depreciation and amortization Net deferred income tax asset Cost Accumulated Depreciation Net Book Value Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Finite lived intangible assets, gross Less accumulated amortization Total Subsequent event issuances and cancellation Nature Of Operations And Continuance Of Business Narrative Details Working capital deficit Purchase price Intangibles-R&D Net tangible assets Due to related parties Debt instrument description Notes payable Note maturity description Note maturity date Repayment of due to related party Forgiveness of related party debt Assignment of related party debt to non-related party Shares issued for control of shareholders agreement, shares Shares issued for control of shareholders agreement, value Terms of employment agreement Fair value of stock based compensation packages Share price, per share Preferred stock voting rights Shares issued for service, shares Shares issued for service, value Stock issued to acquire patent, shares Stock issued to acquire patent, value Income Taxes Narrative Details Operation loss carryforwards terms Tax effect at the expected rate Estimated useful life Amortization expenses of intangible Estimated life of intangible assets Lease commitment terms Loan Debt maturity description Cancellation of shares Prestige Performance Corp,shares Consulting agreement terms Shares issued for share based compensation Stock options exercise price Fair market value of stock options granted Option vesting period Expenses per option Document and Entity Information [Abstract] Former President and Director Loans Payable [Member] ConsultingAgreement1Member Assets, Current Assets Liabilities, Current Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses [Default Label] Operating Income (Loss) Nonoperating Income (Expense) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Depreciation, Depletion and Amortization Increase (Decrease) in Accounts Receivable Increase (Decrease) in Other Receivables Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Shares, Outstanding Intangible Assets Disclosure [Text Block] Deferred Tax Assets, Net of Valuation Allowance Income Tax Expense (Benefit) Notes Payable EX-101.PRE 13 imcle-20140131_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 14 imcle-20140131_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT XML 15 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8

Intangible Assets (Narrative) (Details) (USD $)
12 Months Ended

Jan. 31, 2014

Jan. 31, 2013

Amortization expenses of intangible $ 206,534

Intangible Assets

Amortization expenses of intangible $ 1,538,462

Estimated life of intangible assets 13 years

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

EXCEL 16 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#9;-]]]`$``/`9```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F4%NVS`01?<%>@>!V\"B M2;II&EC.HFV6;8"F!V#$L258(@F22>S;EY*3H`A> M8I%WVUBQ)B5_R7FL&^IU+)TGF[\L7>AURH]AQ;VNUWI%7$ZGY[QV-I%-DS34 M8(OY-UKJ^RX5WS?Y]8XD4!=9\76W<,BJF/:^:VN=,BE_L.95RN0IH!,G!AG^;RQ\)(<$X5`@ M'#,0CD\@'.<@')]!."Y`.+Z`<(@I"@B*406*4@6*4P6*5`6*506*5@6*5P6* M6`6*626*626*626*626*626*626*626*626*626*626*616*616*616*616* M616*616*616*616*616*616*66:.A&].VHWCB M)LRNZ%O)C0YD?J60)P\G!_B[]B&.W)>_"<['/*$(=/PI/(\@AMT3GPM12"V] M#"'V-?-?$O-TX_C`5],$&N8GALR>;#[.:Q9_````__\#`%!+`P04``8`"``` M`"$`M54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D M0/?VA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I M%,<:CAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E M0V8+J<_;J)I"RTF#%?.&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0! M**```0`````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````"\F#%""R0\+ MSLR2NKO_?=A7/T-,NZ&O#2V6I@I],[2[?EN;[T]?+V],E;+O6[\?^E";8TCF M?GWQZ>Y;V/M<_I2ZW9BJ,DN?:M/E/'ZV-C5=./BT&,;0ES>;(1Y\+L.XM:-O MGOTV6%XN5S;^/8=9G\U9/;2UB0\MB:F>CF-9^O^3#YO-K@E?AN;'(?3Y'VO8 M7T-\3ET(N4SJXS;DVDR/DCV](5D49F/?P2GUT,6Y03B\4L;A%<*16V4$Z<7"0?RH2OJCH-[>D7UN1Z3H9)RF\FKO&[AM2+LT!&O#VIT%P\Z"M3L+AIV%:#N@0`<4[3`7&.9NUC!/ M^;@OEYC33<7+&)F,=GCC[%;N^F!?0]JJ)JAJTE8U056SMHP8RDAFE=$'PE+@ MWA%M6+XLJRD6X4CA17]&0 MTRG/V;7,FXH)LQ)1K*0&PM=S7NOP['3*2_:TRBB@=7U'*XC[HPR#DFIS4W## MBF$X@*5<,.<+U=27#2_AZ7':2\/H;)/D@PH*-J5-:2:0WEH=_$KZ29+97UHK MGCA;Z.TFNPP^GKDHY,+^%*Q=;E8I!+!H'SWSPLSA>:_7VWSWF_'9W*R_!/D( MZ;<.PCGM9R#:]-:.$*@4N1&&FR49B97[7$()K>LCR"P.`W7"X0\U*F(;.%:Y M`A-ER0L*%I%+6E*1,S*V6S622)!$\@T)\D"12HI46J\_#61L(!Y;;DWNI^2^ M9DBECU3Z>V-Q5:XHS@A\WY@R^*J*G)*QP=9F2*5E`F=T1TVC&(%-D(!:\=H6 M"SPW'&>$[3WL!C-NJHJJI35BS&>"0S=08:R<:;/!Q5^;1=AZ@\D`5\#915&B:MZV((\'NQKVNQITT3(/" MDKZ43F6QG;&'ZLU;`XSC8PZ1_;''Y0B&6L7(A'[``-NV0Q_&VZ;TL<>A/:6V MUN`MQWB+!]U(P+2<<4B&7&CM=LX`1L#VM!VD514WVTJT:(@9S&/N!#UPFMA# M;=R\:/;60-3DYMVV#0I^@.F*OXD7'-LB;>?(`/,5?Q,P1P@3%G\#,:CE"PX( M8P:SMC/:@5\T="IC(Q"-R M?[,#$)NB)HZ''I^?MSNY9KA%,LSYZG[$L]"IQ3B?LZ*!;H&1UC[`\3CF>K1^ MJG/-IDQA'<=B#]9-E]LT*"]QPR2.MQZ>7K?OD$BQ&[#HD.D7V(\BPQV?>GP^ MLES".QQ,XK&]K'%[I;CA8>$=ON\^P6QDCI"'Z1XV[BBN188'1^K!ZEP'!+;: MN_*=_;<5U33#
ICJ)K>X'3P"7-L.TI]X8=>CJ!N+HX.&1>I1NZ=HGDF)$ M8=%)Q^<,BR%;4LPK+#HZ5W)[Q5S`9>]<,03I9+CU^E^`]I-X,IQ7OR4W:FVVB!L0"O=_\^/?08F"%VX&6]0%$NJF:Z M:6^^?9:%]D'K)F?55B>&I6NTRM@AKTY;_:\_WU:AKC5M6AW2@E5TJW_11O^V M^_FGS8W5[\V9TE8#AJK9ZN>VO:Q-L\G.M$P;@UUH!5>.K"[3%@[KD]E<:IH> MNIO*PK0MRS?+-*]T9%C7@V.=%WGYUI+I69NOOIXK5Z;Z`Y_XD;IK=N;N#"7V99S5KV+$U M@,Y$H=-GCLS(!*;=YI##$W#;M9H>M_H+62>VHYN[36?0WSF]-:/_M>;,;K_4 M^>&WO*+@-N3$$]@S]LZAWP_\%-QL3NY^ZQ+XO=8.])A>B_8/=ON5YJ=S"W%[ M\$3\P=:'KU?:9.`HT!BVQYDR5H``^*N5.5\:X$CZV7W>\D-[WNJ.;WB!Y1"` M:WO:M&\YI]2U[-JTK/P'0410(8DM2.!3D!![,8DC2.#S3D*,T/-4+V2R!N:[/?@PO6&/_`*C.,D+9]GJL&?`B@9" M_MCYT<;\@%PR`8FG$"(CDCN"QPGJ>HG@VECB?R=W5\+!7`E/DDN+\01P]])L MY7NG"&>`2$K`H/E*.!A6R^B+`TO^YA@A[@CBRXCD&4*2!B3SI7'P5H?G[CT) ME#!BA(RE.8&B#2%^%S<);=\>."1IL#CG2^-@Q;4A#$P4(6-IJFO/$)(T?XDT M#E9<R1!R!S'HB7B.%@1IZRB M&"%WQP+75RQ-)(#KN&1@D%PCT+7FV]:A%6G*UHL%!K5Y;D2&O#!."1!"@Q@` MLC1>=&&55R2-FE! MB!&)VB#.#90=G)`QQK']T!KTR_)X:9XO#POY6%ZH=@."&)2W(@_TR2#7)>&P MJ62!O#[/%\C1KOJ$2 M?B)==8<-)8M:U!#(M".$RGJ*!4:$:D.-DTM@(@,"+X@>[8=%'8%,6T(X$(NM M.B[Z-O$F88ZO@[*'KBUJ"V3:%T9+6"@;-X9N*\`+]Y"96&L2R`]=9ZA%@1*R^#S:HVS.!ZT[-*-HGO6P@S= M_7N&WTPH#'"6`>`C8^W]@(^'_:\PNW\!``#__P,`4$L#!!0`!@`(````(0`< M2[_HK0(```\'```9````>&PO=V]R:W-H965T26G&J=%6W2JLT3?MX)AC;J,980)KVW^]B%I:D[92^6`8? MSKGGWLOU\NI)]NB1:R/44.$DBC'B`U.U&-H*__QQ>['`R%@ZU+17`Z_P,S?X M:O7QPW*G](/I.+<(&`93X<[:L23$L(Y+:B(U\@&^-$I+:F&I6V)&S6D]'9(] M2>-X1B05`_8,I3Z'0S6-8/Q&L:WD@_4DFO?40ORF$Z/9LTEV#IVD^F$[7C`E M1Z#8B%[8YXD4(\G*NW90FFYZ\/V4Y)3MN:?%"WHIF%9&-38".N(#?>GYDEP2 M8%HM:P$.7-J1YDV%UTEYOG+Z="O!-HYHW=-O;[VKWA8NVLU#M`@PY7V7]?,,-@X0"3906 MCHFI'@*`)Y+"=08DA#Y5.`5A4=NNPMDL*N9QE@`<;;BQM\)18L2VQBKYVX.2 M*2C/-85V0RU=+;7:(2@WH,U(7?,D)1"[F#)PYAE"E&\%"=$YDK5CJ3#T*1PW MD-C'59[/E^01LL'^8JX]!IX!DRWR@"$03P@*`CD,ZO4$[;4=V&F[A+E@KOW& MH5">O"&4O4?(@:?L!P-Y4@0#7MMC\@.3LX`XL@B0\RTZ\+%R6F2!URM[S&Q* M?C)?%&GX?J0+G7*^K@-#8X"I?Y:S.!![80\ZP_+L/=(./$F'LOJ=0YT\2T(L M1R;G[U%RX%.3Z6E=/>A0_(VZNEG]RGWZ?PN[0\=F_*OI!XV^SY+KE MGWC?&\34U@V1##HA[(;YMD[=/3G=+\KU[+7]>;F>[A4)!V`>C;3E]U2W8C"H MYPU(Q=$875HU@"*:2LC")IM<.?CP<[F<<`;A1RNX7$!`)O[+5'P`` M`/__`P!02P,$%``&``@````A`*JR:0L;"@``L#L``!D```!X;"]W;W)K&ULI)O;@>)^!PS&8%>270'C\[GF<$T3 M)Z$:<`I(I_OM9\FRP=)R>SD]?9%T?GU:DJ7?DBS+]W__/.P'/_+3>5<<'X;* MW7@XR(_;XGEW?'T8_OM?UE^+X>!\V1R?-_OBF#\,?^7GX=^/__S'_6=Q^GY^ MR_/+`"(9L4C;8@\5@)^#PXY9`UID M\[/\_;E[OKP]#*?:W6P^GBJ`#[[EYXNU8R&'@^W'^5(<_LLAI0K%@TRJ(%.H M?96NW"UF,U5;S/M'4:LH\/O/JP+%E=<#O^L@ZM>KHE51X'<=Y>NM,J^"P.\Z MR!]4!6[4\H+T6Y2O5T4!7_%N9@:K^GGVY7Y6KF[YO_J(^9/7YM9+$PC=TVU* MW3L*M$U],;W;9,1O@/)^,C>7S>/]J?@WE;,$C.*2*QJ@MVP+*Q9"[>P MTX4J9EK73)W)X@+\O-9%*L>NB3J+4\>X94'EN#539_+J*+=,4CE^G>5&H+!! MS=1A0UF(9"'F`OS\W04FF$`%IYB1JI]AHAEE!`ZZV@C&0L%&[0-Q[19&,[?4 MU[RLA=L53<1>7F%B*B$F1YK-HBJR6=H832S*PHQR7()+96$E"R871`O.Q+Y8MS%SD;%Z,'8/QNG!N)B9+J3Z>#T8 MOP<38$:=C,5K#]L8:62*,#-=2)Z/>S!)&Z.+]4E[,!EFU,EM^A.\"&N(/_`B MRR5X4196LF!R@2]9V62ZE@5+%FQ9<&KA-BZKBN1GMV;JP=R3!;\6FE&D5@XP M,Y.0L$;J@B)9B&4AD854%K*&('03K-&$;NH>*AC],(01Z3HCJQ-IZEER1BL7 M1Y/Y6$I>-9-GFK:0FMGDZ5#=:Q'25+$F"8LHPVZF2[>E0T9W2<(C"9\D`I(( M22(BB9@D$I)(22+K(@0WPMK_"VYD-*SG85"Z>D6=2'Y:7`JK6N6'.J+7$Q3FP MDIJ3();,2FIV@SJ5GI?7.)^%)1M+#I9<+'E8\BM)K)8\AN%\(98B+,582K"4 M8BD3)+&_V&YG\>\9C+P6D*4^=RE->!34;09[S:,2DD36-6#1BTXA3(;-J MBW\^DQYC73J&1R,^C00T$M)(1",QC20TDM)(UHF(7F5[GU_P*M\J%;8GIE+' M+14.-;TZE=;%JXKA:Y*9-IU+@-D21#+\^HJPET3R'6-=4V^/KE(`FT8<&G%I MQ*,1GT8"&@EI)**1F$82&DEI).M$1)^R?=$O^)1OHXH^E?#3BTTA`(R&-1#02TTA"(RF-9)V(Z%>V>]P<7'OZE6\Z MBX.L-+(MV5D5:9"5W+:B$9-&UC1BT8A-(PZ-N#3BT8A/(T&%5//*N/PGOG0, MZ2@1C<0TDM!(2B-9)R*ZENTE_X%K^1:TZ%II`W;)CDB!:ZMV7;!V%9MU51$= MHZA)(VL:L6C$IA&'1EP:\6C$IY&@0G[?N"$=)**1F$82&DEI).M$1,^R7?*F M9XFM`;ZISE8>M_=O4VF7?ZE+A^ M`;>L)&$[DE,-R<34&DL6EFPL.5AR*ZGI'%651GD/Y_.Q%&`I;(TN[:5&K9"T MLQGCX$EK/FG',,7YLDJ:P>1V&T[4V_:-V-]L@QKU-WG43>'[VL+T*J_JEQ7$ M3[`HDZFF:W.I<585T^P?>1?);&&D@6]-(Q:-V#3BT(A;(?RRU;;5FD@O- M7SA74'OI);*B$9-&UC1BT8A-(PZ-N!52'3,3.]ZC\_LT$E2(7KX#&-_)AXW# MKBI$78DQ77C2E3^E\[.ODG[_9,LMR;\ZXE])'/+3:[[*]_OS8%M\L"^*9F.X M[JO,/W>"U8K!9AV8*Z446*,8;/+!*;`R,=@4W4U(%,MW(6A.>(-93:RQ8FAILML>EK"!EU9H"RU"#S?TX#RP^#;8$P"FP MY#382@"GP$+38`L"G`++2X.M"W"*IT,7M+5`H$,[MR6$NL%>-^)0D6ZPEXXX M(=:A8]H2$MU@+R!QCE0STGF+GFD&G+W!_),.G=(6:*E#G[0EK'3HDK:$M0[M MWI9@Z=#L;0FV#JW>EN#HT.AM":YNL/?!^#H\S8#33U@/-`/.-V$]U`PXY83U M2#/@K!/68\V`$T]83S0#SCUA_4DSGMKTI6;`63/,KS0#3IQA?:T9<*8,Z[9F MP*DQK+N:`>?"L`X?2#ZI+?I2@=YLT4T%.K-%=Q3H@!;=5\#"+?IR8BS;REU- M##A!#O4<7<]K!EY*+EB@8BLJ6 MO:"D&":UC>TY3F2WA'78,"3B%@Y>EBRG&<^W+>V4(1&T(0KTRYKU\L#6YK?0 MM40\;_N[G+<]4&Q8P]3;0(I1FR=/5<<%V320]ZL;D/S`/0S.Z%N6"RYYJ2R@ MLXW0\YSG]MP&IN6B8)"!MAT)6J;XP4VR"-O+Q>#/+T9W\N@=R9KO/@E6?&$= M!;.A3+H`&\Z?-?2IT"&8;)_-?AP*\$V@@I9DVZCO?/>9LJI64.T0$M)Y)<5; M1F4.A@*-Y86:*><-"(`[:IG>&6`(>1V>.U:H.L5^9(4SQWF*3'* MMU+Q]K\SJ'..=(M;G"'\"R0P$[N-"?AR--#8D-68&KA]G]G[%#PEHL$Y` M[P"=T6H:6$\#F0D<2PF<^?M2H/"W2]'@%`/[F&+@.B.O46$`;&^ MBL@,(AJJ!4UIN,9E3IR$=6Z7K\%3^>[(:^0;S"7Y5Q&90X\OB`?CMCM M\C5X(G^R!U<&8E:.PF`^GP#6!G"ZU/A1MC(Z_@0=/G[Y) M?.4FVM^$* M&O;P6L/_F<*I=RP`EYRKPT`O,/[QEW\```#__P,`4$L#!!0`!@`(````(0`/ MK(A8+`(``*4$```9````>&PO=V]R:W-H965T%A@92[N2MJKC.3YQ@Q^+ M]^^R0>F=:3BW"`B=R7%C;9\28EC#)36!ZGD'7RJE);5PU#4QO>:T'(-D2R9A M.".2B@Y[0JK?PE!5)1A?*[:7O+,>HGE++?@WC>C-A2;96W"2ZMV^?V!*]H#8 MBE;8TPC%2++TN>Z4IML6ZCY&,647]GBXPTO!M#*JL@'@B#=Z7_.2+`F0BJP4 M4(%K.]*\RO%3E*ZFF!39V)_O@@_FYAF91@T?M"@_B8Y#LV%,;@!;I79.^ERZ M5Q!,[J(WXP!>-"IY1?>M_:*&CUS4C85I)U"0JRLM3VMN,,$D<22F6C`` M5R2%VPQH"#V.]T&4MLGQ=!8D\W`:@1QMN;$;X9`8L;VQ2O[PHNB,\I#)&0+W M,R2*@D62Q+/%_+\4XAV-!:ZII46FU8!@:2"GZ:E;P2@%LJLL_FME4)*+>7)! M8RBH#4SC4,1ADI$#M)"=-:M[S>2J()#\Z@"ROG8PA0G]N;<7!RX(NHC1C8/9 ME3^Z7'E-?*/YI?C-`6!N'?P[LQ/G&-@WF>>O,GO-;.Q,%$?19'D5^,1^T_P@ M>EKSSU37HC.HY15@P\`-5/L]\P>K^K'A6V5A/\;'!GX''*81!B"NE+*7@]OD MZP^F^`D``/__`P!02P,$%``&``@````A`'/4/9BK`@``M`8``!D```!X;"]W M;W)K&ULE%5=;YLP%'V?M/]@^;U\0U(44C6INE5: MI6G:Q[-C#%C%&-E.T_[[7>.$A&;KLA>,S?'QN>=>7Q8W+Z)%STQI+KL"AUZ` M$>NH+'E7%_C']_NK.4;:D*XDK>Q8@5^9QC?+CQ\6.ZF>=,.80<#0Z0(WQO2Y M[VO:,$&T)WO6P9=**D$,3%7MZUXQ4@Z;1.M'09#Y@O`..X9<7<(AJXI3=B?I M5K#..!+%6F)`OVYXKP]L@EY")XAZVO975(H>*#:\Y>9U(,5(T/RA[J0BFQ;B M?@D30@_[[X<$?%6H9!79 MMN:;W'UFO&X,9#N%@&Q<>?EZQS0%0X'&BP895+8@`)Y(<%L98`AY&<8=+TU3 MX#CSTED0AP!'&Z;-/;>4&-&M-E+\ M!<8#R\R+YFF89O_6XKNX!IONB"'+A9([!*4'RG5/;"&'.3#_V1>(Q6)O+;C` M<#4@9`VY?%XF0;SPGR$!=(]9G6.B*6+M$/`<68X#$Y>?;,$%!O8QGFPVTCHM#C(;+(NR-(@A:U/(>@I) M9F&8_D5<\C_B+/B-N/GTY)6#O"MN"GE/'-3SJ7/VOL5P:]^O*[MI*C).CL$[ M"QT&A!Q=GL8!;<2RN#BNXBC.PA'@DNNZA"M_P53-UJQM-:)R:SM`!-D95\?F M=!O9BGJSO@IS*"_;=\8/T#1Z4K-'HFK>:=2R"B@#S]YOY=J.FQC9#Y=N(PVT MB^&U@;\#@XH-/`!74IK#Q!XP_F^6OP$``/__`P!02P,$%``&``@````A`*NB MP?'O`@``8@D``!D```!X;"]W;W)K&ULE)9;;YLP M&(;O)^T_(-^70R`D1"%5H>I6:9.F:8=K!TRP"AC93M/^^WW&.6#24I8+`N'Q MZ_<[A(_U[4M=6<^$"\J:&'FVBRS29"RGS2Y&OW\]W"R1)21NN8 M(R=R0&FSSBE$H-)N<5+$Z,Y;I9Z+G,VZ2]`?2@ZB=VZ)DAV^<)I_HPV!;$.= M5`6VC#TI]#%7/\%BYVKU0U>!']S*28'WE?S)#E\)W942RCV'B%1@J_SUGH@, M,@HR]FRNE#)6@0$X6C55K0$9P2_=]X'FLHR1']KSA>M[@%M;(N0#59+(RO9" MLOJOAKRCE!:9'45\<'^\[]G+^3P(EXL/51SMJ`OP'DN\67-VL*!K8$_18M6# MW@J4WXX(0E'LG8*[)6!60!F>-WX4K9UG2%UV9))K9F82Z37A7Q`'?)W-0DQH$ND887B$C?H>Q[TI.$:@??;FNPMS MYT0S89?>F1O._<`$4@WTS?L7#<,;,-.]*=CTYLT&64DTL^B\>=$B\H-P@*0: M@>,EQ'?<0=-.=Z=@TYWO#K9.--/?>D"D8X21N=#T-JWSU**/.D\S8Q['",/C MPO0XWGD*-O,7N)[96(EF='5APL#'!%(-],V_UWEJ\DU^K"AXZ.WR1.@>/8EF M^EL/:SM&&'F+3&_3:JL6?51;S8QY'",,CS#-_B.!'3W,X+"Z1T@_6+QH^5:! MCTP_A*L*ZRFIATB+=^0[YCO:"*LB!?SE75L-(ZYGI+Z0K.V&QI9)F&W=:0GO M,@0FBFL#7#`F3Q=J"I_?CC;_````__\#`%!+`P04``8`"````"$`:R$_['T" M``#!!@``&0```'AL+W=OAGOP#?-,IY03>5_:YVG[E8E196.X6"7%WC_/6)&P:!@DV4I,Z)J0H` MX(FD<#L#`J%[_[L3N2VG.,FB9)C&:09ZM.3&/@OGB1';&*OD[Z"*#U[!)3FX M]`'_T!]'PS0=9,/[?[J0@.0K?**6SB9:[1#L&IC3--3MP7@,SF^7!+4X[:,3 M^R$`:V`9MK/^*)N0+63'#IKYK29I*Q:WBOY90H#K!`)Q;'_>2J?Q'ZX7E*_(H,MVIW,B:_)KE,+FD"6]H;G:?U> M783N#F#9_X`Y<1NL?Q-9T+R[R2Z[W]ADX18*9[2A*_Z5ZI6H#:IX`1'W(G?6 M=;B#0L.JQI_)I;)P=?C7$CX5'`YL+P)QH90]-MPM=_KXS/X```#__P,`4$L# M!!0`!@`(````(0#U5BSH\0(``+<'```9````>&PO=V]R:W-H965T=/JP/C#Z(F1%K@T(D,U5+V2\<1>4U:+&S6DPYV2L9; M+&')*T?TG.!"'VH;QW?=V&DQ[9!Q6/+W>+"RI#FY9?F^)9TT)IPT6`*_J&DO M3FYM_AZ[%O.'?7^5L[8'BQUMJ'S6ILAJ\^5]U3&.=PW$_>2%.#]YZ\6%?4MS MS@0KI0UVC@&]C'GA+!QP6J\*"A&HM%N?B])TNP`]N%:3$^T;^9(>OA%:UA&I' M$)"*:UD\WQ*10T+!QO8CY92S!@#@UVJIZ@Q("'[2_P=:R#I#06Q'B1MX(+=V M1,@[JBR1E>^%9.U?(_*.5L;$/YH$0'_<]^PTBL(X3?[KXA@B'>`MEGB]XNQ@ M0=/`,T6/50MZ2W!6D060'\,QQ/I:J!"C,KE1+AF";H?C`LKSN`X6X*K9O*2:,8#)F?#M;2IPA2,`Y M.6DZ??+&:&)=UJLP](+`G4FV$XD?^/%B\)BP0:[>SZ;$,[;%K&4V1I-HMM!W MHWA.OS4*`!PB#)*7X>*/P"GQ'.[<-*;SC,;`)6XR2HK>WYK]4,.GWKDE)BE+ M/D*EQ'.J8(C64!G-L9Q>$*>1.U7`)%4N1X7OA]'Y539H9E":.=(27I$M:1IA MY6ROAJ`/`0UWA_E\XZM7.*?,>\HIVP&E*"I6NK$5JH@3)\*24?3FQ#,P^OW.QA[<_M<5\839IS0)C9=RS$-W&0T)\TA-G__NK\)38,+ MU.2HH@V.S1?,S=OMYT^;$V6/O,18&*#0\-@LA6C7MLVS$M>(6[3%#3PI**N1 M@%MVL'G+,,J[E^K*]AQG:=>(-*926+-K-&A1D`RG-#O6N!%*A.$*"?#/2]+R M7JW.KI&K$7L\MC<9K5N0V).*B)=.U#3J;/UP:"A#^PKB?G87*.NUNYL+^9ID MC'):"`OD;&7T,N;(CFQ0VFYR`A'(M!L,%[%YYZ[3R+2WFRX_?P@^\=%_@Y?T M](61_!MI,"0;RB0+L*?T4:(/N1R"E^V+M^^[`OQ@1HX+=*S$3WKZBLFA%%#M M``*2<:WSEQ3S#!(*,I872*6,5F``?HV:R,Z`A*#G[GHBN2ACTU]:P;BGDA)T\B.7-#ZKX+#:JX"K^3ALE9,NQ2D2:+MA]&1`VT+4O$5R$;AK$.QSJS(Q9/M_R88L2Y$[ MJ1*;L-X@CQP:Y&GK1\[&?H*J9FFW M&Z'W)F'IK5=-U`!H#V:]B9%+PI\@Z1O((*)YA5J/O)=([0\K[ZB'L)ZWGWH\FR2Q0S MYUX1*]58GK<()J5)-<#UEV'P^J72S,OCP^C3.-_S$IZ:]_6F2!0S9UX1,^8U M8,Y\]!'S$M;->^'K2NJZ(E',G/E+PI^L:#@ER(G&(B-$)5\=`]0>56-VP#M< M5=S(Z%%N\1[4=1@=3A]WGORZ3\83=PT["HS;PP,X%;3H@+\C=B`--RI<@*1C MR;V7J7.%NA&T[7;&/15P'NC^EG#\P[`G.1;`!:6BOY$3#`?*[3\```#__P,` M4$L#!!0`!@`(````(0`I&O)S`P8``%H<```9````>&PO=V]R:W-H965T:=T#<[W!.$Y1DJYQ!,])H-(=K2IP$-80( M:-/]]GL90XIM-B;M19,L/GZ6UV\;C#??/XJS](ZJ.B\O6UE;J+*$+EFYSR_' MK?SO/\&WE2S537K9I^?R@K;R#U3+WW>__[:YE=5K?4*HD4#A4F_E4]-<;46I MLQ,JTGI17M$%CAS*JD@;^%D=E?I:H73?GE2<%5U5ETJ1YA>9*-C5'(WR<,@S MY)796X$N#1&IT#EM(/_ZE%_K7JW(YL@5:?7Z=OV6E<45)%[R<][\:$5EJ'9@%R"DF4;_-:62N@M-OL'.#EH'_JJD/3JD;^?F[_(6H?QX:L!N"UJ$&V;O?WBHSJ"B(+/0VS2R\@P) MP'^IR''7@(JD'^WG+=\WIZUL+!?6DVIH@$LOJ&Z"'$O*4O96-V7Q/X$TG-1= M1.]$#,B^.ZXM5I9E+E=/\U7,3@4^>Q5SH:\LS5H^D`MK MAVF8E,&D^YQD6DS*#H&,8==D6NZ*$4^,^&(D$".A&(G$2$P0*/R],$R;DTD1 MRA-X.J`\:6]_NK!KX]-:<_I^X)`(.-%'7"[B<1&?BP1<).0B$1>)2618$M-B M[V##LZ@:P+,-5P/QZ,9G;668IN\N:"8S*3J$&:;%..4*"8\03^TSA::2/WK@ M^D*10$B$0B(2)Q(+19(I@C(%K^[8YS*Q*?@LQA3V:<$AS+(M*"SUVC^ZH"Y! MAKX93S3B#55:6^CC/B_!6!\(B5!(1,,LQML2"T62*8+R!)[`*4^F)W!,TUZ8 M)E,#AS##0C.$*R0\(>$3HG.<]BF8.!9.'(LFCL7DV$2K$D*LVSZH+K3/E0)5 M;[P>>:#@+NKX>W;M)B%M*,1:%AQIEJN&/$Z9'@'9UT1 M7B<0BH3B3"(Q$HN19!*A/<$KK`<\(0LRVA.+KI6#%P0PG$@U2=>C";/.[KM MC.FXN@WOHGC^V;*?Q_)Q+!L6_#SO6C8L^_FX9]FP^.?COF7#*P"(*_?"P<[. M-3VB/]/JF%]JZ8P.4'-U@3=A*K(W1'XTY16\@/V=LH$]G?;K"?;P$+PT4Q<` M'\JRZ7_@"]QW!7<_`0``__\#`%!+`P04``8`"````"$`#`3S8,\"``!L!P`` M&0```'AL+W=O-``^FZ[`6P?3CWW',OE]7MLZC0 M$U.:RSK%H1=@Q&HJ,UX7*?[YX_YF@9$VI,Y()6N6XA>F\>WZXX?54:I'73)F M$##4.L6E,4WB^YJ63!#MR8;5<))+)8B!I2I\W2A&LO8E4?F3()CY@O`:.X9$ M7<,A\YQ3=B?I0;#:.!+%*F)`ORYYHSLV0:^A$T0]'IH;*D4#%'M>F]2KCD(&U'2F6 MIW@3)KL9]M>KUI]?G!WUV3/2I3Q^4CS[PFL&9D.9;`'V4CY:Z$-FM^!E_^+M M^[8`WQ3*6$X.E?DNCY\9+TH#U8XA(9M7DKW<,4W!4*#Q)K%EHK("`7!%@MO. M`$/(ZYI<2('K21XK<#A2!Y,0XAY+HLXCF:+?TOQ75JM2W?$D/5*R2."S@/ANB&VC\,$ MF#M[7#*]87_S"XRR)!O+DF+X9,`*#35^6D?Q;.4_06'H";.]Q(1#Q*Y#V'J" MO%XCV':N\>W2=5(LV$JQI;3:MFX#N'MMDU'<2\3T%3)0`@Y=K\2"H5W.`D?Q M?!AZZS#1&69DV^X]Q$`;D%ROS8*AY$-QBY$X!WI/G$-,S\U]U3]0!WU^O3H+ M;M7U170[YU*B>#F4NW,8$#/NG]G_Q+;@%$-+].T2S8)AI*W#Q'';Z8$WC8;G M,,\LQUOGSA,WK=QW*)@JV(Y5E494'NPDBH"VW^V'Y&9B\QKM;V%XMOF.]C=1 MLFFGV6A_%R5@D_6G/X!AUY""?26JX+5&%P_+X8$D)3!*G25=TJ;=(T[<]KQQQ@!6-D.TW[[7?&"4W63`(;' MO[OG[DQQ^ZPZ\@3&2MV7-(EB2J`7NI)]4](?WQ^NEI18Q_N*=[J'DKZ`I;>K M]^^*O39;VP(X@H3>EK1U;L@9LZ(%Q6VD!^CQ2ZV-X@Z7IF%V,,"K<9/JV"R. M,Z:X[&D@Y.82AJYK*>!>BYV"W@6(@8X[S-^V&;SKT_9RD7!S9X^(-7DEAM-6UBQ#'0J)O/=^P&X:D55%) M=.#+3@S4)5TG^5U*V:H8Z_-3PMZ>/!/;ZOU'(ZO/L@S-[L?Q@9\-:2"FN\Z]TWO/X%L6H?=7J`A[RNO7N[!"BPH8J+9PI.$[C`! MO!(E_61@0?CS>-_+RK4EG6?1XCJ>)R@G&[#N07HD)6)GG5:_@B@YH`)D=H#@ M_0!)LBB=+:Z7%U!8R&@T>,\=7Q5&[PD.#<:T`_4Q>_V45/7K( MVE-*BM..+BRVYVF59DG!GK"FXJ"Y"QJ\3II7!<-LII0PC=.4_E[D8V0O]I%] MT7TJ=^'%:9C9E,A9F/G_A/'BDB)[2GY^LYRX(7+0I">:;%*<14;)Y0:]^#QR MFKTZ"I&#YC1RFLW_B!V&._1>@6G@`W2=)4+O_.`FV+3I[72FUK/Q6$P?<*8' MWL`7;AK96])!C5OCZ!J'V(13$19.#^-D;;3#:1X?6_QY`?8GCE!<:^V."W_N MIM_AZC<```#__P,`4$L#!!0`!@`(````(0"F>Y0/'04``!45```8````>&PO M=V]R:W-H965T&ULE)A;;ZLX$,??5]KO@'AOP#;F$B4Y.E!U M]TA[I-5J+\^4D`0UA`CH[=OOF'$#'MH$7M*D_C'\/5?PZMM;>;1>\KHIJM/: M9@O7MO)35FV+TWYM__/WPUUH6TV;GK;IL3KE:_L];^QOFU]_6;U6]5-SR//6 M`@NG9FT?VO:\=)PF.^1EVBRJ8J/:[8HLOZ^RYS(_M6BDSH]I"_J;0W%N/JR5V11S95H_/9_OLJH\ M@XG'XEBT[YU1VRJSY8_]J:K3QR/L^XUY:?9AN_LQ,E\665TUU:Y=@#D'A8[W M'#F1`Y8VJVT!.U!NM^I\M[:_LV7"(]O9K#H'_5ODK\W@N]4GX8W+3BH*)N@_=IFVY6=?5J M0=;`/9MSJG*0+<'RYSN"K2CVNX*[2T!L`V%XV0BV!7V^JU"?/.,2+>`/%-(KE&&-+@/M.E*7AM@^U>FF?>.$;$ M[WPJ622IL.$Z\P/F]8"A"S8W79>"B2Y)="$2=+J8)]S(7$^&Z\(34;]NR(+\ MG"Y+P416O]LN$6-$4%80>$1U@LN@K7=XS*(P1%"89*[@ MO4,Z($%@BK1@CC0%$VGDSC$B6EKH"4&`9`APE\F!6PV?J:DVN64HV!3FN<1G MB*`PGWNDHR3#9<;]+WI%-$>4@HDH:99K33I!=%A$@T,4G>O"&`#7S8SCS::1DR*(]#'42N(*62F(S+0_>+ M&F6J*T].N(XV!X%'NZUFAKZAP;V*&.7`9LV"CB;!)>TKUHQ.OB`(6>\9["(& MX4D?6LVEJ$QQL,>A[]23BX!LO#'GU55$)'%0S)!!D9X?A>$HP$C`Y\TVK!ZF MAC)OR!M/"(]X*.XLKFV=@8%+4B`QUJ7OAWT03`?.FA!L/"(\XI98,UJ9.VAH M.K;31P2;-2,ZFD25S(!8,R@NX%%$_)IH8%)09PT*-IX4LD]JW?6&LR#@ZM'W MDO;:>4-",@&/4A?"C.NL@<&PUT.E7U)9THFAF:%G2,TD5Q%#'B<3HWOC$)#W MURNCN\P,L22#(=8,AIBY+G%RHM>'^Q!]%I@JR>!0*M6[R`V1XP$BZ0#AQ@#Q MY:A^#4`*OX^&J7#6[."*)NXCC2/6#+I/".9[/"!,8C`!=Z,>,-7-&AT<7P*& M@U?VV8T5HAE4=\=XZ//`)T6>F)`((Y_W=60*A"P8]N5IXX.KJX@;22G$FOD0 M*N'=X5*H6,H&P8*O&K1Z@QY*O)%[X]$A^^36/D0&I7%X21?PJD[%#9D[`4\X M@_%GNI`,D(DN'`\2V<=(ZT1&Z_S\(8L;S)6'+#YKE'0TB3")7ZR981\A29!< M14POSIHE'*?`U7:MF:ORT,SGB"F/3).I[1K'BE'1HW:-#!X-?-:N<7TH5`<_,_````__\#`%!+`P04``8`"````"$`#?Y11)$# M```T#@``&````'AL+W=ON7YQR; M2P2GN\6[N]?3W<3UY&*Y@E-11K2@SJN"VW'FR*!E-S*0L M]8:^'WD9Y;F+#K.RBX?8;GG,'D5\R%BNT*1D*57`+_>\D.]N6=S%+J/E\Z&X MBT56@,6&IUR]&5/7R>+9UUTN2KI)(>Y7,J+QN[>YN;#/>%P**;9J`'8>@E[& M//6F'C@MYPF'"'3:G9)M%^X#F:W)Q/66VS(_?B^+GDR3>>,\@V MK)->@8T0SUKZ-=%?P63O8O:368$?I9.P+3VDZJPW"%$I`.;)6^/ M3,:04;`9#$/M%(L4`.#J9%QO#<@(?37_CSQ1^X4;1(-P[`<$Y,Z&2?7$M:7K MQ`>I1/871:2R0I-A91(`?35.!I,P'$63\7]=/"0R`3Y219?S4AP=V#7P3%E0 MO0?)#)QU9`'DYWID$)*>\Z`GF:F@EK`<+\O(GWLOD,&XDJPN)<.F8GVI",X2 M#_!.C!!YG;&=38L7+ES/;*3YY!5*I@:9L6.TUZ_U=HZ8#G.YQM0+2_G)JL05WWB<(AY(*+@K]("167MR(:25C:4=&`C4&6[)\ZHFW3AU**K-->?;0)8MTH:>XY8C:%]78VZ MB1?95;?2W'P=;H\WP71Y[KSA"!9SN)XJ4V17WDK35D-:)4V\7GV!7&D,=O6M M-*UX:%-?^5OUEX"H1_JTVEI7NP(;QX7;RHP'KRJ-*UL:%,5G8MJW03LU2G(E59A5^-*TPI8;R=A M$!&_5K";>+UZ!1SH+];6+LB5IA6OWE"NX^&Y'X_%!=VQ[[3<\5PZ*=M"U?`' M^GA=XJD?;Y0HS/%W(Q2[$+[`+&7.]3>+$OTD^RO__W161&'HJDVBV/US-` MN]NLS(SXXCN?(N*K?_C^:I)]*.;E>#;]^8.MC/:?_]-79;G(^'9:_OS!Y6)Q_;,OORR'E\55 M7F[,KHLI3\YG\ZM\P9_SBR_+ZWF1C\K+HEA<3;[;S+.?95.7[VU>+9T6RXO"JFBPPXLN?3Q7AQD[V<^@3` MG:V]/SG*'C[ZZLO%LZ^^U"?^V=9V]GHV75R6?#,J1NW'O\RG&]G.UB#;WMS: M[3Q3ZLN=]I=W`?M/!V?E8IX/%__<_O*+]@]AJ>^*B[$^`0%O\JNB M_=87+Z^NEM/9<#*>9H>S^77[>1CE$`3.\PF(&Q7?9]\6-^WWOMC+?'[#6B8(8?NY@^@/LT/0=S&;=^EV M(+:=)7W1)VWMSP/3]`_PXC?MV0]GTW(V&8]`T"C[.I_DTV$!T&B;%]?Y>)05WZ-4RR[WG5_"E=.+,?=E[\9C8;?1Q/)NT!'+`5"`SR^VJ3Y?0NR(ET%V/1]?Y?/QY":[RJ?Y16$ZY;SH#GVT+++%#$), MC%VN' MW_[B[:NCY^].OLB>_^/[EZ>_R=:.GK]X>?CRM`,"O'->H"E'48P?;FZ@X5G+ M//N03Y;%('LZ0.?K?UGI(IXO%Y>S^?CWQ6B053^.I?B)H&WV`-V5_D3W97T@;C\U MG*W"V_;^8&]S9["WM9>M`*^%H5U#V]Y@9Y_U\547L1T8#T8CY&8V1?BE']8Q M_HPR:`LBDK*\6CJOCXKS\7#PZW8X MMYJ%"(P-2Z)=4#1K1SY1AR4['&XK_[0Q>IC)!F@O_%:C<(Q!PS,L%F,\B$>K MC$2'72O1:4_6>;,C3W=^X;QRYVN)!+;?#48[B-9*6)NOW0EH[^O]P/:^>BO` MB=V6[V5:&T?C/'N+R&X]]GKV@;)Z@Y9QW)B+F:?2?JFF++:B0E#/KH:3\W= M7R![[3FQY>=%J6"-U_N&>E>4N,/#2QMKQ+HG,S/W[8%<$N]&P!N]0* M,(,%LMQGFA?C*9';':#,9\.B&)79^7QV96Q3YK`#@`W=;3/KUP;G74*N&R0, MX5OLFD:'71G)6R0W@B\6[-,@*']086UE)SW MP8KSD%A(HM<>UL1Q/?N:--)T*O2"+25-5KRG5,V*-TZ6U]<3L[:8GR/2+XC@ M$D7='8D(?!+TYQVT626+:%8+?5?)9-]WD#(?XH/.B^SEZU<=J!(.B5*??'&- M_]&KXY4),;9*/BJ^E\PLQ\C>J#CK6(;*W&D);3B"H5A@[?H>K]+#X-$!M M_Y]__>&__N\?_N5?.T[WW=ZL#=.&*N"S]UD2;APKW'@I1NL--PX]V%#8<)K8 MT$2/M^<-L4+[9W-0VC_&W(Z%KR%.JC*QVZO>-NDN[WR]CZ%D%&1>!L&FMJ>X M_1L#L_W)$=PY7#"NU%!#"^7W#NI636O,7UID./`8OSW[JB_;TO:)GTED#>$P[.+_)IB)@'^BADYBV28AC8N,3,>FC%.,&] MP9^H0H@R6QTU;&U0`_OS(&R5RV:>9\C6%(/\\(?_B;1<4SOYX0__Z]%`ZOFJ MF)-4/B8_>I4G;NR;XB-!*J9\8Y!]S.6^#ZF]:3"/0S2:K4BH?%-\R$=YAA_Q MHCB;+Y4R?6*EQ:V--KG>3K,C:@A79T2`6SOV$O_6:`&PZ.&,^'$^6UX0Z@?_ MU;2(\KC9(O^NF!$,>ARK0(BIDW6_&E^-!><:ZX79?*U8H^?3"XHGGNK]-7YU MB5?MBV(`UGDY'EZBLW![/S+K1SR1R$%."9%(98((E\ M17D-.%53@89:SCT7A[`(MQ9H0=?ZT_.#` MD*IWX&WXQBCG;BY.OJ7.-<7#K=VMP=;V4WL;HJDLI;P4\F2X ML*HFDN\/H$PO?+H+2V.4. MD1C-C'M0]9/E2")(3;69H!($8BXEXJRVZ577X00F'\-!%?'UTEP)&^/^++]2 MUPL0@_'NRZD@F&Q=*>&'<)(&BR0I+V?+B6Q";2AXOIP:[B'Z;0AHJXB3Y16U MU!OEX4](BQK@,"%U(D$INAY3;D=C=0+_GE=N,>9Q'H2J3.9!H.(\U[WSS-44 MM!W4'G_HGV/^5?Y>00_M1)L/OGSVU1#5;)G%*_J6MO3+_`4JR%\Y'5^AJ##B MV;L9XJ*GY_F5RL<^@G[XT@:U-J>?E=?YD&&N93(P"0^>98ZT9/8S/OD\$#Q+ M$'4O@@!5T@=UL$%31(D^`<_'B?O5)ONIZY<[A(!!4B;K,1.H"Y%P/C)?T8QT M2M(Y\C,FC51FKBCP(?1^<9UX3N_10`B'.5#DG'%3WI]DWQP<',M5<<6+FX.- M9#DA\?M^XV0#C4"P-R\#:]2M8%I:G1GF(ZHQAH_$"^EWBCR=9+:OQR_[2%%# MHE7C+/@DJ*U:/]=&M84\>6Q"IE+?)8UW4@B]Q6&:9G8P<5/Y%Y51D/_O"N5\ M/+\2XX86&`UY'7.V-$8,@8:9%%:@"5`+#[?K"K:@I]XDJ0:ZAUM/!T]"3P!T M'-=](.OO_DM^=?WW1X-L?V]W\/3IMFSR16C_<,6_]G#7'SW2LRG%C-A%XFH. M_1;0&3T&>[#U9/>1\'A';/=P;_/Q M8.OQOEZ-WD-*[U7DYG5-[V4.4;+!7I6#IN6;C^SI0+-WP1ROA>D0%);.:.)V MO:_1$D]9/\$3MV'"ACWW/CLQJ8"V<">Z]6;*JZ!F^XE66W-P-EHB[1?68=F: M!A6U>!8;GA(M.OY\6C29+=&.7V]D[]V7?(X4T++:M6JGDB=S@BO[W2!*KZ@C M`>)L'%:Y2*86>O1=OV*A?0.W&V4Z]"?H>X0PZXY_3%',`OO8#4K?S.9QJ!M@?B:F(C^@L11\,%\1!@;Z#\H+T M;D2$%WT>?<,TC#0JJ)73!5",6C*S>';HIGQHX!QY.1@O9J%$!#TZV=HK%9^S MXU@^;IOX]YB/>79PT6)XG*"+L#`^.S(=6..9E;8TC'..FL))KU;EE#T:4 M<,VWYP,M$%M@9=_\0SZ>U+ZM=:M:ABM41_2MX/_8KHU/EY9:,>ZNOX*>26=; M7*,39H-*E]7=,P%.`E=D5I"+4B`'$$(1O1)P419#^-4B*!-)YTB#+O(&JM3S M?6$](!:(-*3&(Z3/7O!$?]_+-2`=T6X2J/L(?&(QEL8KE7XA=8=/H#];9`P= M!M9_$+X+DLD0D2K^$;(8'9)U(,D3M@E0$LL=GTQ7WIYU;0K2E%HOW%,SHLBHW"G M[G_A&.]!7H"6C/HT9:4>)O-0T:QG@I]:GO1N@*NSB.=2-1:9J&4\MOD:TQY, MZ(VPL<0Z1PI+SY>3ZO6V%%;#8.A#M[!I"]PP6C_ZA>4IQD=7E62L:&G:` MPY4#HAU_@1+MB8]>;"@R5#4ZML*U>38^KFRRR28KA3X/][8V!SMDQ*#(=1C& M?%/`4W0FA4XOJ1N+I9F@!!D,!).C4FL85GX<9A>:8`^UYC&\9[JEV[Q])QAN M1(DL(2(.-68F^?D%6L$T1D>XO]F@,6QZL?X*538BE]C7^%\;S]/9-:RQ(Q-* M:'H<6F(&V3'9!E4"=03!=U\WQ^(T]' M/YK*8@_6Q?K$0`R.G.NNRP*71[,N03=3S845O*O83_/ M16&"NS-H2!&V3LPY.Q.)*I^ES!PLD(PMQ0072,8-)NE97^?-D%<-RH99/97MMK$QK+H#K?5(S\Z)-)'H^7=(744>/>@@4(R% M\>G%K>,?U""OK%EX;*@LT$YQAV(-20WI#]I$!P8&>MK6UP$#N0!1!,'+(0-& M1V8X<=G+PG]VSN?7"JS&Q8O064&X^P9L1G M.)X/EU?*+Y-6A>F-PR4GXJ4Q_V"T:!7%!?FNP!,Q5I0ZMN>PI;(S87$NI77^ MQ/E8(\0T!5QZ#FN>8Z#"(H0?\9#E-X(GLPHZW``+,3P5G0`H>`Q(@ZX74LWQ M2:":`IMJ1G&79D@UF*J-I._GAEXO-FIMMI1(,)1\D(IK8"J$X,9U==2*+&M\PX@IW#KG MD#C"[BVT@)6Y"8D`](F0VW0:I"0(6&Q+952VDH7P4YHF,"$[-YN$;]4+@G&( MO"SMA32G+>IXJ;=Z$1T4HK+EQ*598\'JL(LV@9SN\3-6;>6>;.\-DD:"EW5D MT$1M#%$";FM@3//B("7+3Y?M)B$LGI=6K-P]&ZM'2X6,J$J95JEB72]5UUU> MXV0/4`2[?$+7F1";'LAPRP*0&]4#%%(E0RK_6P M"1]E:R7ATQM@R78?.5-%*J:,*+2YNQR9)4%@_"E%9'Z-*_^]I:_$B#!T!58P MW>:/A^6;]XH^1]-2W:+`V8SP\##08E402&,(FV\%$B,W'QE/FH]D!I%H1OR$ M=RBSVRT6O-S(&M:L8Z'NDNF=O4WYA?5WY7IC0#./YA?&_+GL`J1/G%IP$)Q= M@OLE"C=G6;)>E25RPR>W@9\A3[#WB7[CU0ER*#>,QAVR6*CEQ*X2MA3K(]HW MW&D86N7=/#$/\TW/)&Y?8%%W6$%]XBHEDXK]JJ#+[`"-`E9##J9L1KU\'K[U M0F8TM'7B7D5XZSWP@;4=44R"C[Q)EWE0] MP@!.,._TQ-.'IV$`I/KJG5=`3*BO\=()8C'@YF_A[:OR`-7.,)+=T*06'QO< M9,J8-,+A-$@RQ-48ZG!POT"'`*CR2P@`IU_AS]!Q8M%//3SNNB)[GZ7-J*?@ M,%IDX<_#STH&*]50X5DFM3:\C'HNF8LP1]Q)JA(.J-A./2(XL%8XT$CFEIQ+ MCX,ZI'I,O$P,+Q]=3)QZ7YI5X450U:97D/\;H3?R!($.+E?-T)88A/T4SX3N M#F80WP3OWG6#0VTIAVKEX87HX2M8UBA6QE>SC27!7!%V?Y?P:A;EIQ!19F%5 M!K&73RK#[0%,24.J*%I%TL(>$SKV$2M(6.?_HI:R8$U M(M$MB*BSZ')5SJ;OO(!OA9JDJ>U(I/<=@#&QTTFXMCW2QSMFO5:-8W9+`:4C M)W`QN%'`9$:?#`2L@':K.#QX0,:4_BE(HH=+F3WRG73!@O.H7:FP8.RE6?%O MD!7]US^*XS.1T$;SBQ'>5'V@19JTAYTZGXB5JCQF_45E6_/AY1C^@%QO M75'?#S5J>ZI'JT"V(.XL`9L%ODQU2L=N#%P?XO57.]2#Y?1,(0L=H&M"U@?: M2=%)V=;^A0RNY4*E8*K@V^P4B'(3ZH,%W=\!%S5$BJ5A6%5+P?=!R(UAO8G` M."KF#_&WB#$1:Z%85+2Z7T2?6X6;Y.6M MT_S[;OFY(Z"[GG=,O^EF&:-.5[:XR?-%)+]9J,UQT?BJ9)B7`I-D""-?$;7(;V&PG.J[)F"OZL. M"')IJ(88'RG+]77RV'`;:(N2U)J\ M@,@?T?8KZF.G_36V#I67HD)35]SLKJPPXM:.12-^BTE/5;IW64$=!:,KG"6< ML&+^#C.XMKN%&P[,;0KZ(E:YQ`-86^=CX4TM-CJD_ZVQNE^ZMW>4]C4[@CTT`(]OO?PH]WQ54 M+:=EV-J;-,)\GE;"?H^J6VT6V]5]/'X,FO&[.M&:69785.UK.P]K,U[UM;G% MY!U@V_PWU(RUBN6V@6A@MAMPR7 M\Y5REAH3?'GBP<\2D9.J%Q*.X(V:]YI<;[L.5'5!/=2)S<=;3[*UDQ<')]G6 M]LX[^OF8M#)N^!.&_YX::S2+=>K@BB,=S\<,#B_+)[0ZB2^%,-HP\4GBGO7C MK<,E;^C\@#/J4S)4#&ORAU1COUJR/B7EQ_V#1#E^QB[!)KCN8W7F_SS*^1G% MO$7>*W6_15I_,!%9< MO,^A*<9;:P^W'@^VMVF<%>#\1?_QTUUZS'#-`C=.I,MM@YG<$!=5^!680XJY ML<2FCW-GHKQ7X[Y5L*RH/3;J2(J/"?:H4[,#3RAK* MENVX.^^72X+^>)*H:3*69WWCI>("#-64=I2@V34X$II`@"]CIZ^ADS4KNH"& MU>>$;B([O^#,-3_`9<)0X!.2/B.5,R`^"KE4;$`,TJS`"^1A5/$\8=U&]KH^ MMZCJ-3DCX0&D-KT7AC&I3*XXL()A-?R:_C+'RP^SM\VT\D(X!,%,!T@\<=;3 M0=]1,,=&Q,;^F@[57C"WQ$"I+D+^RE_'_(?4-$D(W@F9[3NYR4-.RT^CC'R]JEN5]I>^+?29D=U?D;5W8^T#@1_$>6=TV]&JZ7V$9KZ=C=%\EV7'>4" M$(_4+R+).L9',6O]%GEEU`0G\%C#`0UZXE67A0A[]S?LI]X0\,Z&8:>*8=!K'6#[/ED>H&MI"W=[MD^U\^/9)8$J MX+Z%NO,J7]6=_12HNWAR@UM7JE*>F9BD*LL>'M,!4<2I1Y.FE4,Z[7B74M' M(R9UWH$-$U3J*6Q4_GRM3ZK)0'`[G&NM1P;\6=*A@!7B0+76R2.UME/L]1?? M8OLK=5,90O"D)FS`-16F6I!K^/:O(DQ2&T!KBQGTOBCD;T?WW47`2DJ6M&6D[5VEYO!\C8W9&-2HSLY!$DT'ZI;8]HM`]FP M[+$A285"DPJ].?5$8BB`RZX"O#93^J$)9OXL(2$E&+:CA+="RKUF'W)K+[PQ M3WE-0H,)/0,Z,T2(B18C./CP$VY$VTS!ZK"?%<8PQE@/\POE(M-YK]C)4.BZ M/_3#6OF++;Y*L;AR#?(8<\UT\ECO@DR@6)9U0(YEM8\M;=L4H/5ZA(KHL]=) MMZ0+"&IK^U?(^,LUJ3+<.%J]VB56R]U;%P7-2%I2TJV^\8SPCLZ"#D@RYXX0 M.IEB5`;R5LWH*$C%WG@/Q#8@@EM97$=J&[E1Q5'(?_R^[XN=EIQKDV5'S+N; M0.NM(G4U[D]_3"MH;7-%SV]?!?IA^ST_:?8VD#MG$+T+VQ:.;1/PJ6\+\;EE9N8.5^[D3TW.H2+^+:',.SYNR9 M@!T^?SO@:`).`5IDK_*/-&<.);[Q$)N'F]F:,O%_S]Z+_<'^DSU<&;>@4:AE MZ6P_1\@%&J\DGVT^4LA]5ESF$PRE^R[A6U>N8>!L]E'LWS4H.YKQ]9SV]@"> M[0M>R!EN6H,0566HF'[$[>VK5Y^P`W3+)U,;I M]87&N/`.IT-@"'32CQ_>24[7]""`/]S;&VSM[@F:7^87UP0+ MT08S&B3S0,=`=+D@VGP>H&TE0K`$&(3P97L-`6YI]"N2,^H;0&43+K`JQWJ` M;=I<%LST$GT4VC\'7=P9N1[N[-@H4GN<4*I#>!YN<:#\XY@=J](Y&!S?MB$M M5S>5:A3P3AQPK?/@%;OTZ96VF+Z=9F^'"S%"N.,D+3#[-?H>HA M*S9C?KUA1)#;E1B1A]N#S?UMMV(MQ#H!/@6-@,_E/;Y]3UCKAP)N\+.GA'5S MZ[5ORI):M`B=#&>+1?9Z.9W/NAKX\,7;CIX$`STG/*1K#*FXSBT$X/>$FA/F MX4!^0*B66W;>K0.<9+:GO6'DX=83OWX!"\A5"&3[U1%DQ0M@5@P;1SP_$/:(KE6D=P44[3!_[;K2J@\YX"=/5#S(D#E%B4[54(-3UG-OB^4J3Q9?R*T@0=G/%,7FC):DOC0ZF,B;#W`NR5U MQZW=7?E;R*AU),37Q6>WCJ73]913<8F-53H,@YG2@%.RI-:=]\/5P MFWMB:DU4B4U@"'-:'(V,4,G-UK8;[WOJDD/YLB<;V2]GEVQRH`O8/`7EB(#[ MDU6#P2@?D75@/&Q9.8CP7?BLZ9!$176D)2^]=7TZR+X)=R\<4O2A,Y?+K@H: MCZPA4;Q^%#3:"MTC/R6NX"^O?K;V[`Z:OS[UDZ+E5@WTTRN0>^J/RGY\)OWQ M9RWLIQ+_E`S2`+AH?K337X4&:/IHGTT!6)'2Q?]%55`,XI^M'ZZJZK]M^%PL+#*PE(E5;;G#H]#O.9(N57@_VWMZG^X'(V8 M+;IJ\B%^2IU3"<=?F<_QCJ--9C+J^=F4LY9^`IS7`?_@,='K).8M!V/G.V">;=>UV1U=5"Q)]4YE@@[[]0D_^B]6 MRE#LNT$Z5705T2,]4F`@N MDXIERD4T`E>%GEMDL_/'WM"K9G]^:3< MC)H.[LK-5(L->9=ZL=9N1WYKFE6N=_;)Z@M&[.0U&LD]4;""P8@H5,1D4'8P M8A?6:'E5O]-AXU;I`D[M:VMLI%%AE)!^UO1UG:R99[2,OV7[8#$K:3TD;=WYJYC$&'"[YNPY^#]^^ M-;JTD@WML9K^2?NI]68V_8OV*Z>0@DVL")8VOU1=M&HE5J=^3Z>X!2XH20DB M]W:@!'Q7BVX:4)N-W>T0ND13TO)F9Y5O[.R*X_X;FX]T9'S=DWA+> M]@KWM"%C`9@KIA$&0I[*6G\6'W527;<0U:[>4*ZG?&/'['M92FFDJ@:A**^O MN/3WYCE(O\8JE$K'=/`WREE&>J4U[47TTI.];:LQTSFLYN!0;NG@\^U/4Y)) M2EPK*C%]E2RT3@\B-AHG@[2)HS//%C?]O]Y"\'T:FGN_3(F)HUQ?3BUZ6#$F MZ[F+&3.2!C9>1F#?+V6&T#:!G0E78<=JBT4_-`WA>"IK;=TVUMKU868YQ;F. M7:"9`HAP-ZQ[.[GF67:SOKXYC-$&(Q2/]&YZUBA6G#>C$]&X2%L>1[-#OL,B M;0PIS]^'ICJQ74-W9\GJ;HQ%?+&"5:,Y+O>V_BYF[OWP;O!J-6!5)PRD4))B M]Q858W=%]O?7M[_&#:TA,.JWQ5F?Y1B@/V&;!!EXCCO:`U!?4!&?JZYM)SG6HK'Q1JYP& M@]0X%\VKV]1OP]6_*8]T+H,'TNMF-?-'B`FMM+;ZS[*T'^.W!$!$M=IK215& MQS=!#U>1P!U7,G6O$U#Q\*Y[E9I5T5,=I_:6K2&)PZ;.@9B%\S[(Z-0GK3Q- M_RRLTW.2EI>L13]=[AT5ZOJF@(%DIE4;LBIUV^&2Z:QN4A:<$O(5]`\P\447 M=7Z^"Z[HM?Q1*MIU;YJ$6W_^.[CPP+V':PI^:"=XP)J7\3&"4Q:<'2O*Y4NN MSIZ11OE,5R3<+0B!RONQT)`8B$_@.4J)H5#1RW*IN/3G!"R0[S9/#*H&A5)B MN;IUHJ75VQ[-O?&P%6[2^)&25_>&M"JR&#/IK^&,1A^=GH2,!9##?XX.#D^? MOWKU\IOG;PZ?ZY+8:_Q2)$A6,%R0JP'JHRWV-K&S./OS\G)\W8@N\^R5':GB MS4WO9C?8SYM:-05'-O8.!5_6G:X>D?[1J-S=I@DJ-:(I/T4?K[_)YHF72;O: MR]!A>C6TS$A9^2$'UFD,,A^&CU%0YP7N@**$E/_86F"'(MC[^K^VXVD6<4-)\ZJ:(-06P=#O&8KMX6M@Y"B,L(&Y/K6^XQO*;>&(#PX9 MZ!XI4C^[3TQFO>+)[1FQ&?PSWGCT6&U?;?B[7=;`(U--9(MH$#9UUFHCH/SL_5T\OQQ7$B%E($[G]/C+?,6_-V712T@T`OUQ! M[6%H-:BVR._0WW>*3(T=;)U_$`Z("!W(Y!W58B^Y\P,-5%BK;SK0EDT[65,O MO#^IMO$GX^GL#ZUM9_?O!+J6:%M]S_QLH_I-G:EP@!/=W070]!%"/[&VN_H1 M?8(Z'GW0#?"3**4MQ[J#(H6%@;ISN/&G_ M?,(IKDOT'3E>D-%^^G?M'WI.)NFX=^IB_M,?W[Q]96>?T`22K07"=8':VMDG M>M]L3[.VO3W@ZJ/VSS[RKZI=>?A!?@Q_^T5AKWLJ2:?;6>R5;IH1^X2MW7!% M-4#-!Z1I86Z/IM*])CV,84HI(;#ENRVYKH1Y8_-;K:L$=U/(VB+67NG:[F`7 M'WIGLT/9-0I3V_M/VQ^XY@Q^A>MGZXWK(.=(%PN0MK+CA\RX)\<_M4=M(+R- MK_;+2DY<2\&W'QPW#WXW%%8OWY+P>.()C]XQ#]FMTI[GH.[))Q*IE]E^3ZOZ M6@<3B>6*3E+ATU[O[$^3KN5:EGD'\P>X]T7$D1+\=N2%[=OQO3I_^N/K7"VB M4[LB0[0A]&8O!HPI?5J?.QK/K8#E((H.(&847I=*K+?QL%^>AD9[P.%-0"3: MA+&\Z5G7`FQD?_ICBBP!5NG;^F",YM%?OB^E/OMKSP^OK#OQ[%S-Z&S%A&@8 MUO<+&55[C'%U:.:!R62;&-^$F]1L670\AZ/5XYGH]\JZ>:7[7F.S1'L MT/"5[1=-^.RVK1]L/=@?[.UT]%T"=E0\T+?FAF3_#;&,B*ITJ;")2P4;H'KM ML#<.$^@]$0ZCELCTCR+H'90,8*]M[82CNF?(W:`URY7[[O]O( MOSMPJ,Z:%7::[KG`4)^MG!,]7>7CFY>A=#-XU7LQ1)`:M^,FK9?']22OW!ZC MW.Y9;X?XAG%;B8&.`'S"TM^%8W99<.#E:JMC:W_B?V0(I/HZN#Z%ZM+62H1: M"5*U.CN(S3?R^0GTLV0'/XN-&S!5C6\YJ+I4T;S_I``_@W)@75#JZGVX:I>#E<7<] MREM?OD]HLWBVM6E'%-UW3HN%4@1K/TY.#6=__TE&Z2\[7[`_ICY)EKLH;..H M$#R9Z41CVP=_S'8HDA`O"..&Q`,$(*(9Q$1ACHKL'5>+=;Q.-,[^ M3M5N*;;DPO7)$FC,G;#,?&L8:X`/N+-I@=WJGV5Q-5Z/9Z2K\2/ZP5NNP!7O MAOW/H'%Q,&$[FK*//W]0!Z\;@SW2R2/0($S@^STS]QW`9IWBE\M\9 M/IX%[03B6]N]`_M;VC56A]BE7^0C,:F\9'-/*LF`J;3-G/OHUA>S=6](2014 MF_IK&>CHQ+:^X?7J4*Q*<;EQKW5E9Y03KD['3T=4L^?*&G:CJA2-9/<-Z:O?3T.55DC([R4<37:CUS?CL+#.?4]'63#D$7?_P MZM5A'[C>V]%#W+NA97\S=8V^0;N'Q.%0<\RSMA-$-FD07N6?58BZW_;;OJ:/ M5?TO'9#KJ9L;@^53U,^:&)'M7K5?-R&J,1*-5H.LV8O5@:%J>?-4@!(OW>:3 M2IV$%D[XZUA!U)@-S>`::>4<`,61-#,Y+[1>2EF:Y\+1[";K2GX9 MD'Q=5\::10$Y5SH4,-%HQ-U<2!FF#_8J'!W(INCB0N=W*,&2#B2C1=UL/AR7 ME@[',=6)^=J+RD`/]S;VTXV!HC80RR=BG+%V[BGNE"7#WEG1R_T_RYQS4'C< M[QM2X1PW)A3I_'G'7^Q9=,W2@[)P$("0!A5GXS!VP>9*]BV.:WRAZUV=4+C,V./B<1P9AZ7TV]^K=R8*UVL*MU1*0 MD>="#Z*S;)NW6)0U@PSMJ=?M``J0(;='JZ)DA<0.OT`E-5,'F?A)2/2.F\NY M"8;87Z&QD*IS3=#5Y`GD>:0D"\QC"^BB7GLU?)3/A_F=QZJ[1^%Z_!?'?.5H MB4[!BED1#`)^JG!0KSDGSPTS'&"K2(Y]G=\@(O M&I43*&RHOUTZ;'\>0OQ2(0L*:XP'E#)^4U>1%?Y! MBJJ\P:&YJO15ET1QFL]'I#WSV%U8]AJ'*'Q^-64.*.ZM!W,_J;2\_,A5GMFO M;\[F^?_]E_([0E,I+4G.G4IKNN1<$)*W')4DNT)]C=3HQ/ZR4<[I/5#%-I^@ MXV84[5R:DKD^([6\3.EW/5$:DNND!EG;]]3QM5_Z&?I26W?OO6AGRY*0@8-P"G14%23%'C<<2.Q-LCX\CQB$!C) MH:R,PPO*!55)[.K&G@0JP[2YPL0?.J'(>O+N"43'BS]97A$MWW#J3W9"[4:[ M8W5">UG/IC8=0QJU*!D1-!PO_K-']QSPU^.D$G"04E:7HI_AY`>46)#2VK MDR#6($/3JZ,QV0LH,Z5I)W0@K:F#[E$=V[1I?ZC+BL3$=FN16FXH0@%)9Y:P M,),.<@V>RI''&AO0+*`8S99G"UT6*X8"#YUACJU-9Q0#[C8XKV;3"ZZB52K# MNR+:+[SH/6^U,TVC]84L4FQ@Z1\T7OT9:MJ2^O:\[Z"/[4P6KD8ZO3I<@1DR M!QT(7E8]FUV*>0-:=^MD>U*9A]NNN5D\HZ@+L2*V%;R3C4JN^FB/R/N->RW: MSPV]WNKUFA!]Z7OE72O5_4*P]*D8H.PP-`D<;D73S5'IQ>SX:-58@5%-`!F^ M#R_RHEAI3 M(=6?;%.3NJ&/J^_$Z=@EU&M:;Y/2N^#9S%ZK]EZR$X]$;WO9>M8KA!LY-%V#OMA\U:5<8`=AI'Y\2Q]G=66CBI#Q'DP[>=F5M5A'42)E-+ M/JDY2HE@G)GVP$U54S'$6W!?[:O0"26Z,Q4RWH7`^B-\I-M'HPQMS-&&Z%X= M]C)G[LE7ODI[G`8H:RDL5;=__4KLGSW`$WC%W>;JQ<+-^W-6?/]95F$B44=W MX;W9TMU&A7P.M62W?Z_%+Z[_3@+#J>-%L?[*W+GN]__T2B?:OB3!5OYS>S;_ ME"M'Y`F.:QWIVHZR`E<.=ERNRD<399)KRMN#]RC'B+.[7FT_?\/6$>(.1.`M M10+C,HZY8WJDB"#`:ZP\_5K=X>J'7GNC?5;:0WX/?OGDT:O!5[')K[D[2E[B M,+1C8/^(43J2_BG!337G/1;4;?C(UM#;'5U_''NWK5#91GK-2N5Z:.QMOR(> MO\-$WJ;[/V5-)$DWLLVP2;$-!ZG'>*#[&QU/L$Y!L'.@?/LC:G@;U<'U[8<$ M4&JV5J@I-GO^EC%;A_JW/V$C)>/=$\(7=F=+;WM1>]SGU5'B\5@H$[SJ)''] M96;%+UGY?^Q=RVX301#\E8B+.00%/@!+$4DD+D8BX0,2L,$2#E+L"/+W5'5/ MS^[V]#CK:&,-K+?OA7`&=`[/4,+^D#@Y/4F MNTMHV16)*U_-&=@O,`6V+^:!\_`9)6F:V"%TM;6(/K[`CQHMH)>23($^I,Q/ M"(W@FW&ZO5`&ONI))**3%&+PC+6%,\K\VVHN2+Y0 MI@7>%VC4^)03KN6F>J`R/L5GL)$>LI-B.7<>?(8+1&;`J2"'!&ZS[7G&#MX4 M>S2>"\"=K(HR/63`-4A3` MIOMB[*Y`OQ)43`,"2Q=S];[:+^*:#A2OL;AK'(RL&(IQN('+"V)8T&K MPRR[S,R1%EQ6Z%#5'`,TU1IVCA"-O2%M]=._TW%A$U%)!3:'\UD'O/O3-5`,>YC(&!O-02M\*] MNG%T;EBTVO;1[T^C&QOA&`* M'G+^A_X0]_/E#S[E_(8*0&M&\K"Q1CKRJ#XQS5_/%5;56%WH1Q/!LK[W MG1PY0PT/SZB]*DU1S.L!(T8E+W@*$8?PY9\_HMCET\,P?S2=D?I@E'QZC$A8 MNTANJF7'R8WO`.MFGRDP\_/D'P02PG)*%YR?\UD!K8Q4?:;H50.I9^M.7'V\ M-70T5,PCAD;9QG3CQZ5I+MO935OQ_1F9+(0O"V.2*)I<_1:90+R M45KZLO@$OE:O,Q#-%["\5V.?$.XTV-"=DL#+$R1X1WF"K_"\%@1M,7W_2GZY MN\#HJY3!U7R!93N9_H:%`NP9II]=+^9@S6&QI^0G$@-^-5XG2#!H3<\F2#!H M*[0W#%$;X"Y5GLEK/;!T"5<\\N$P%U)^-,[?I*CZSVA83`\-_K(Q`TZP6Q^(6 M%`N?7PHWOH#_6"F\A]EY@'F%]** M_PC`'OXV29X@_%@KEM(,/H-<;ALK4-W4%QJZ'K%P?5#>N#JNF#$&%WR8?T.F M^;%>BWT;6__CM9D+HH-J-08M$0/+D.EI90Y&(6FOQSHA:R#RJ!\`=&M7V9:5 MICX/*VY`>F*EW2^9SA=T:3_(;[6.V;X_V"(O3@5Q].['Z.O-1*KUQDP]@_7& MG5/:EUZ4ZB?W)7BV"_#S.$U`W^,FPM`5>?`C)EC40F0>>`FGQX-!4E;`=^J` MEQZMGT0K7#0>A&<`[.77-U_\:"!1"%\N7MU`U/&8(/ZE#6V2G"R7J_%?```` M__\#`%!+`P04``8`"````"$`4]6/"I\+``"H9P``#0```'AL+W-T>6QEYE MQ[?=0$\H7/D+$2*^'3UOUQ>+T%_;L3MW/3=^9;1TS5]>P#UI6?: MBXPV.]@C[[N+*-R$J_@]D.N$JY6[=?_][7?__-%9_NNG;_8_ M^^E;O9.Q(33!!M4TWW5.*L'-]2H,B"#`@"GHZCD(OP86?@;.`.+A MUVZN-[]H7VP/SO00WB+TPDB+P^X\["0H3#Z(9./):IGLGP_(Q/$:U/,Z M1G\<+R9%M5S2>.W[Q9X.C^&5VXKPB1[G$]VR((?TNEU4*S78B9B-9UW@=S9F MEX.S2=:W^M90JF2<+^[;#1GV+9FJK&%H?1C>GDV=\IF529>FX7-%``:<7"VZ M$+H5\3VT\'4./SGSA'8:BS&J7-)GH5?DQ@?7=S;:O?-5^S'T[0`52R7DOTA]@M0YG;JZA+8J=*+#@ M0$O?/[RNH58/H(-#8W:2[]5\^S&R7WL&JUC%!FQ"SUTBBL<9ZQ#2"FUV>6?- M[AA?@DP410E1RYH-3T#T;CJ>R4$DF^F&`+\E$+?AO)DVG:=": MLD#F]+38Q8Z^^WXX'H]'OIQ[M!DOGQ<$F7YJ:]A$,`,&X M/QI?&@"D:XX8J[,BZ`.`X6`P&O3&A@G_L^1U>@2R=3K055N5(%!D58)`D559 M4]F1D/G32('U-<6Q2A`HLBI!H,BJ0\D9>*C*SV:M96S>[N++8PME^92:N/4UY8 MQ#?GQ;I&Z%/G8;2$M83LJAE<1,K.W5Q[SBJ&CC1R'Y_P;QRNX=]Y&,=P.>[F M>NG:CV%@>_"VDU`1&@D7+.':Y$2/G]S%,S#CUL,2W20L3L4ASWHF=A/FT.P. MS8%QF31LDEC[SM+=^OO2Y;P/^B6H$75;+SC189`S2=VA6)/MH/U2\PF.8*9F MEA8<`#Z1N83@"!DR%M:(`%^P&,.@R!C]O59.^2`1FO'-)45\LM>;$P-?+'J^("D-2/V MY:P9<$#*FA&B,O)^DUF7(YXO76!Z/H!D1]_HDHN M4E6FNW1*@1EJX7C>9YPS_K'*IRE8^;FY?EF171BP-0:W*>`F#WP+RZOIVV1J M2@X`8MD@HW209J_7WNO]UI\[D<7VRS`6["PNXQ9'4S:7%L=LQ=YWV-J5GI#Y M(0IC9Q&S_3SLFD$9GGX)GEY*2`3/,?S-$OZ@)V%]',,?UD8.&A'THI0_.)
M<4P<]$@V`Q\H6`+_4[&$')-)R;$\H91EZ1?X5TAI<>GW*#63?`N.7J@9#BH` M',6R+,6J2C'$[!!IA0K@H$(%%LRZMR,<48U$`BJ,B3Q!D-5BJ085.7(PA2&JA1)(*C*D-02 MJE(DQ:`J1Q)3J$J1!`)H1$F&I)90E2(I!E4YLC!%7U6*)!!494ABB?Z)4V2' M+ILFBZAD_70P:K5^JKVL:A=2>V5-$]@]&YYT3TGG"+9@O11II?$:I(V[G7'M M5'L*(_<7:#+Q-VX+..%$.OXF,G87],S7R%X_."_0BB:71EY6Y6N]@"1;W]AU M1AYA*::"/RRMZUH3YM+U4%*8P2680A;U3MKM0-<&$*98K+%`L)I\&V>SG[29V5Z\-\P=J M*+T2`$"YJH;/7N="9(#0;PN1L.><(L%C#_BVU('MV!M#1);;I3AQ[12`1DE3 MGR&;^:'4)P40KKA6Q?0T7>AME'6R&JHMPOYN9UV%T&)KX8WPX5^+[55W!KAL-D*Q+@JZ1*=PNJC)]V.=C^I6<=QF`D>P0DU#J8J:1$#O_UT3 MVV1:6:F\N:[I#;8)PF[+AU6I$]/4^3:Z[]JP*LN-U57XV\R-_'Q3EQPEE#Q' MUFW<_+,/M[F26^7[%A,27HX7R_>"@5/KIB6SX2EZ,!K$+73#5>8U%N:U(\$A MC\3+%1=P4%6""R7!-K4$5:`40&V=2PKS([U)>J11//OI*U\*27[%4EE@X,R1 MUGRG#D-Y0+F`K/%P/AZ%_+TY4'H!J]3SV\T-9YL-9)?C;0/VU&[8JJ2C1N4+ M%/GNUPY@Q;[HHR<`<43HXZLW=`73..5&@P9J0>LTOJ@J4CH*);1L`B]V`61G M#@4IVQ4"^T#(K^KXW]3ENT8TO"LAW$6Y^WOM0ONP0*+0L";NANW]?.MZE!1126KC+B^""(K@I+6"? MT.J#M(06_."P,2UPC)06[L$K<)G@N$UQP9"4%J_[@:#NS4-V9+M5"UPHL@@N M2JNP(T[E5=@1$!):)C!I2JNP(UB!T@)W:THKMZ,) MAB.T!H*ZOSQH1]Y7<6N9""Y*J[`C[ZM]05^EM`H[\KZ*(C?%5=@1J!)]F?!! M4UJ%'?D\80KF"2IC84=>]P-!W>]F5-[C#4&/3Z@4MH-W1$=8;8GH**%26(WW M\KZ@ER=4"GOQ_FT*^G="I;`4T",2F?"!N$2YC?J\=DU![4[M999U>8 M'=AQ&+UJN%TR)\<;?2!([D]AF.N(IX#5F0B@/\,S)^!Q%AKH)=$0[\.X3:T) MF3P6>/7@;Z>:D('1"1K>_[#9;T(&1B=D^*2*]9,(F8_!>IM;B,^E.'6+D/CD M!L_.DO<<7L,&@!2A=.]LX\C._8\/*4-0,?=X_X2[A= M0J9$[,1),L!^1`3X7["&1/!7VT;N M1/_U;CH3&\O!N9L>GMKC;M&=_9?4!D^PN8*GH%R MQ"-BV*-L8$MXS[S:>/`@F2@5-@7_N3@WT:9F6 M6%.B0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6 MU8=$(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/, M>$S:WIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7 M$53&`A\!W8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29- MG!4&.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6: M]?Y&K9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W! M&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&+ M+Y_\]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<% M#H%V">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y* M#7!#\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8 M**3G^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS M=Q=U."O3>H<],9&R;,UM`?H6G'X#0[TJ=?L>FT1.[P:3?$45*& M'=`X+&(_D%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D2 M7UXGW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/ MEN@=/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC M`S5GY*8TO;>$#6C M\S210*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@ MSK09HW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z M&P3]$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5'; M:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@ M58IA_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`- M005WU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/994FRE)") MJ(*X,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK M<^"?[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M- M^]<4X9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@ M^X4F!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^ M/J>Q\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\ M-I@Q)4TPP:-^0T``$9;```9````>&PO=V]R:W-H965T8/51W* M]I\?01#(3))8^.U_?[^_W?RUV1^VNX^'E'>;3MUL/AYW3]N/EX?4=%+[HY"Z M.1S7'T_KM]W'YB'US^:0^M_W__[GVZ_=_L_#ZV9SO*$2/@X/J=?C\3.\NSL\ MOF[>UX?;W>?F@RS/N_W[^DA_[E_N#I_[S?KI=-#[VUTFG;Z_>U]O/U*ZA'#O M4L;N^7G[N*GL'G^^;SZ.NI#]YFU]I/H?7K>?A[BT]T>7XM[7^S]_?O[QN'O_ MI")^;-^VQW].A:9NWA_#YLO';K_^\4;7_;>76S_&99_^$,6_;Q_WN\/N^7A+ MQ=WIBLIK#NZ".RKI^[>G+5V!:O:;_>;Y(57TPF(IXZ7NOG\[M=!LN_EUN/C] MYO"Z^U7?;Y\ZVX\--3=UE.J"'[O=GPIM/BF)#KX31]=.73#8WSQMGM<_WXZC MW:_&9OOR>J3^SM,EJ2L+G_ZI;`Z/U*14S&TFKTIZW+U1!>C_F_>M\@UJDO7? MIY^_MD_'UX=4]OXV[Z>S'N$W/S:'8VVKBDS=//X\''?ODZZ.?O7\=]5`C]C`JAKG.M@1\= M3#_C&N2O;DF*R]-ET,^XD.N[(X@*H9]1(=[];2Z3]PO7=*I'OJA=X]PAO^$; MRAEU,>>N\?S;3"'OY>^O\#$O[ASOHH&O;QLO;F'U2]S$N5LOE[ZJ,G$39\XN M_QMMDXE=7OT25R9_?=NH9CRU<>9\49GTK>^E@RP.P#N=$DX9IK(^KK]_V^]^ MW5#>)M\_?*[57<`+5K?B0 M,Y$MY,RZMF,FKFN'"UTN]+C0Y\*`"T,NC+1P;I%Q3"34=1(S<5VG7)AQ866CC79,6%8N059Z08^IFCE;?'UE&+AW`C, M^FX<`T)<.NJ26)K%G?-B0ZD.A" MH@>)OB1R/JOKP,:PN!QJ)N_K).3Y]VGS@D<(&`N`=?&$`]P'IAJX])-<@55C M9F-8[\TEPUID`8FE)'*\OBL;XYO-5BS:H`*#HD`TKSSX@HR0I[NJ$?+JSI.E MYY'DT%='&:'/A3(7*ERH:L&H9(;=`FJ2R1;8U=9M#&NVAHTY-\CI+M>4C)=A MKM"23"[-7+_MP'0-MF1$WNA()I=AB;TKF6R!Y9:>C6&YI2\9D5L&DLGY^:^D?HE`P9,4BOC;\1@^HH(P:Y M4.9"A0M5+5S$(!?J7&APH--U\`S`"'0:Y;TBT!5-PY3T_/D5Q;F`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`RQL@$(U.,S#`RQ\@"(TN,K#!"0:_C,2'4*`DD,6924//CERNI MDD!C04.05M.Q>_3/OBV4U'DI/%9?ME673 M4!4+PQXJJABI8:2.D09&FA%RS@#F);=P$6V,=##2Q4@/(WV,#")$7S&MXN:] M/#0`6N_+@1$^R1B5,3&`TU.8V?!3$U"YV01F")@C8!$!E^[,7'6)D15&*/QE MX+`S4?@G,6;X4XVO"7^%LW>!'#M]R=-00EN4,5+!2#5"HCDCLT]K2<9ZDK&1 M9&Q&QH2+:V&DC9$.1KH8Z6&DCY%!A`1Z<2KMUC';>HB+&!E%9&_Y0ITQL$\B MN^YK=OZI<7#^ECGD+-D\3S8O(G-"CR\QLL((A38,'`KM),8,;;5.X8H[>[2L M@5+'Q3PE6T%14EMF](C#F6+-779@*@Y,U8&I.3!U!Z;AP#0=F)8#TW9@.@Y, MUX'I.3!]!V80,0E!,,3(R.%,8US,!"-3C,PP,L?((D*2)EN6#LS*@:$$@:./ M,D0B9*8(M23B,D6H$<$`+F97^]TH"=!31CQI68JDBY'(LI0J4JI*J2:ENI0: M4FI*J26EMI0Z4NI*J2>EOI0&D709*;F`W;"&5HCET9$L?&P]CKTV3:P06YHW MM4)L;=[,`HE'^+D58L.&BPBZ\(^EE%92(I_7SG9Q)+GXI69ZM)K=YQZ-MV>H MC9OLN3:?%L-:&KKL6=9EY:B^*XEVLG6SN))N[R>9>LKD?F1/Z8X"1(49&&!EC9(*1*49F&)EC9(&1)496 M&*'(AT%#D9_$F)&O%FA<1K[CG+=>UV%F`/$NK*$$=RI[$*E$2+3H.%](![F` M/8=5<3$UC-0QTL!($R.M"-&7E/7NO8"/N+8QTL%(%R,]C/0C)*$?!Q@98F2$ MD3%&)AB98F2&D3E&%AA98F2%$4H+,)(H+20Q1EK(\(56*BWDZ,4Y^<'@=)@Y M_)U/LW>[4@0EN%,9(Q6,5#%2PT@=(PV,-#'2LB#Y-'N!:KM`'1>HZP+U7*"^ M!6+5'F!DB)$11L88F6!DBI$91N8866!DB9$51N@S#WK96T+4T!O0?L_X%D#C`PQ,L+(&",3C$PQ,L/('",+C"PQLL((A3\,KM.W#O\] M`'7XZV\9ZB^-O6_V+YORYNWMT M/TS6EG8ADG];+26RT&XQRS'D]]:34$#8XZ$O(R)GY(&_:D/O5#VK8G]9D?TN8]J<_]D+;P27WIA[1) M3^I=/Z1MBE+O^2%M5I1ZWP]IRZ+4!WY(&Q>E/O3#H4T?^2%M8I1\W0]IBZ;4 M&WY(&S6EWO1#VJXI]98?TJ9-J;?]D+9N2KWCA[2!4^K*(VTZ^:/5'>)3U\%9OF_Y)%36_BJ1PG`HK<\RC$6 M?>S1?=:BES(A?>%#UJ><">GC,5*O9$+ZA@SI=U\5I8\8?ZY?-MWU_F7[<;AY MVSS3PP-]\Y3&%_;Z,\CZC^/NDV;1Z2N^NR-]OOCTZRM]KWI#7PQ-WQ+\O-L= MXS_4";Z^@/W]_P```/__`P!02P,$%``&``@````A`'QA!*]E`@``EP4``!D` M``!X;"]W;W)K&ULE%3);MLP%+P7Z#\0O$>4'"^Q M8#EP&J0-T`!%T>5,4T\2$5$42#I._KZ/9,TZ2POW(HA/PYEYFU:7CZHG#V"L MU$-%BRRG!`:A:SFT%?W^[>;L@A+K^%#S7@]0T2>P]'+]_MUJK\V][0`<08;! M5K1S;BP9LZ(#Q6VF1QCP2Z.-X@Z/IF5V-,#K<$GU;)+GV)0XA4YQ<[\;SX16(U)L92_=4R"E1(GRMAVT MX=L>\WXLIEP\9$N&3.M5+3$#7W9BH*GHIBBO M9I2M5Z$^/R3L[=$[L9W>?S2R_BP'P&)CFWP#MEK?>^AM[4-XF;VZ?1,:\,60 M&AJ^Z]U7O?\$LNT<=GN&"?F\ROKI&JS`@B)--@DVA.[1`#Z)DGXRL"#\L:(3 M%):UZRIZ/L]FB_R\0#C9@G4WTE-2(G;6:?4S@HI@*G(%:]?<\?7*Z#W!=B/: MCMP/3U$B\<%39$@N_V82W7F2C6>I*,XIZELL[,-Z.K]8L0>LAOB-N8H8?"9, MD1`,W21+:./8TMOE.2A[L%?&P@4(\2Q`AIR?HP=@<)/\CO<@3<92.H!.D<5".I7V[%]BV?]?87PH64I%C M9#9_9NIE.^,BQ&E38%KX`'UOB=`[/^03'),43?NWF?A.OHQ/RTU8")8^X%Z, MO(4[;EHY6-)#@Y1YMD!C)FY6/#@]AAG?:H<;$5X[_`$"#FV>(;C1VAT.?G?3 M+W7]"P``__\#`%!+`P04``8`"````"$`K^>.J[8"```;!P``&0```'AL+W=O MSXX+&Y?18->F-)?JA+\!7A0I6DFUC MOLG=9\:KVD"U4PC(QC4OWNZ9II!0P'A1:DE4-F``?I'@MC,@(>2U_]_QPM0Y MCC,OO0[B$.1HP[1YX!:)$=UJ(\4O)PKW*`>)]I`8W._OA]XL39-L=OU/BN\< M]0'>$T.6"R5W")H&SM0=L2T8SH%\B,SY&&+]4Z@0HX7<64J.H=LA"@WE>5DF M6;+P7R"G=*]9337A6+$^*&PIP-[@$2(_]?A^U@]6K-A:L56PWE9N`]B#M^CL MW*DB/DI&3B!#ESNQXAP#?#@XR=+QT2NGR?J414&6QF=96SM!<@*)KP?&R!MH M+O=FQ6-O<1`/7)9(<>[<,'+OJF"J8FO6-!I1 MN;6#)H*.&7:'&7@7V;8_VU_!;.PGB3_<@-G4D8H]$57Q5J.&E8`,/#M&E)MN M;F%DUT^(C30PE?K+&CY"#%ZKP`-Q*:4Y+.Q+.WS6EK\!``#__P,`4$L#!!0` M!@`(````(0`:E@PZ1`0``,D0```8````>&PO=V]R:W-H965T&ULE)A;CZLV%(7?*_4_(-Y/P.3"3)3D:`!->Z16JGI]=L!)T`!.L3.9^??= MQD#L3997QZW[UY^O7YY< M1TA:9;3@%=NZGTRX7W<__K"Y\OI-G!B3#BA48NN>I#RO/4^D)U92,>-G5L$O M!UZ75,)E??3$N68T:VXJ"R_P_957TKQRM<*ZGJ+!#X<\90E/+R6KI!:I64$E M^!>G_"PZM3*=(E?2^NUR_I+R\@P2^[S(Y69G[]D#I=TFRR&!*KM3L\/6?2'KA(2NM]LT!?H[ M9U=A?';$B5]_JO/LE[QB4&WH)TGW?[""I9)ET'.NHWIDS_F;NO4;?.5#(Z(! M5"/BWZZ9ET"UXO7-F)^[)E^;;ONM=C)VH)="_LZO/[/\>)+0TA+*H*JQSCX3 M)E+H!FAK%BR5:LH+D(!7I\S5>((RT@_M+L_D:>O.5[-EZ,\)X,Z>"?F:*TG7 M22]"\O(?#9%62HL$K0B\7_7OP>,B\U8$WEL1`GH3'2S:F^&]NYG,%L$R?)J0 MP],U:(3<0=H3I0B2;&%QZX[2U#R4S+]X=!YTS!REFG M&NDO3",!,C(DYC:1#(E%3UA6H:--JZJZ$BA=,D98WF%^3_>N M8-O[L^TLTH3IG:!Q'@\1;'Z,L,RO'C&O8-L\01,LTHCE'@_](8+=CQ&6^_`1 M]PI&[M&`4CZ[?%0$]7C9C6 M")K1\1#![L<(R_WS(^X5C-RCAB.-6.[1G(Z'"!))Q@C+/8'E<7KQ&QKY1\M) MU#)6`#2QXSL,3C"*V!'4QC5Y_!"]S9E+9H#&=M0R9H0`S>[X#C.(H)LR96Z( M'4'M<-,CZ/W0BH!6ED@]Z,!(,]L>1A@R-W_M,\$88D=0&]ST"'H[M"+@%8@, MM\P`3?7X#C.(,)2Y(78$J-8#$11MSX4`+3,1T8S9"[>VFPK'WT>2%EDU:W$8 M!/[\-F#M`&JO,_I@VO./>K;'09#+J&5&@VB9L'$9K!8A(4O47AMTAI.:-&,6L:,$*"U*[[#H$HDHX@=06V`TR/H[=**@);-"(Z*>%(; M0Z$=3T-F$&$,T1'T05&?7$I6'UG,BD(X*;^H@Q^!/NZ_[4^R[1&S_P'.A&=Z M9+_2^IA7PBG8`6[U9R&,DUJ?*O6%Y.?F7+3G$DZ#S<<3_&7`X$SBSP`^<"Z[ M"W6&[?^$V/T'``#__P,`4$L#!!0`!@`(````(0"+(62\4`,``+D*```9```` M>&PO=V]R:W-H965TH2%!&"SRVWS&W'R=?OXR.E+WP%&-A`:'@ M8SL5HHQT_+X'ER.V,NA?(AI7@)B2S(BWBNH;>5Q MM-X7E*%M!N-^\WHHKMG5BX'/2[4Y&E3]_"#[RB]\63^EQR4CRC108S(:89`!;2E^D=)W((JCL&K47 M50`_F)7@'3IDXB<]KC#9IP+2[L.`Y+BBY'V.>0R&`L;I]B4IIAET`)Y63N3, M`$/06_5])(E(Q[8?./U!Q_=`;FTQ%PLBD;85'[B@^5\E\DXH!>F>(#[T_O2_ MYX3]?B$!_=3>B<*?)\HW<[G*=!>-:"@H?C]3P]H<(+`(JF[`@[+5A"T#XOD5R07B3)==`JEB;Z_R4/D4O*D\2,;1@7 MA,IAMKY._-`?N:\PQ>*39FIJ/%TQJQ5R/DGLO%WPK`K@>=%.3ZT,#4MRM)4&)25J6E1UJ;"H&Q,S9FBV0];C&:_ M7`8^+(>/8Y"UM!C:!;-VP5P57'KLAWW=P>=KFH&N6=RA65[3A#IG=8=F?4TS MU#F;CS6:U[`1:UY_[+%4CVT(LIF4?G!>0]4V,56:H-IWO*X?#(-!2S)3$GB> M,2U+YY>47J?ZZ(-\OJE8W%0L+Q5PIY$?O9753<7ZI@*N!M(UY4B[%16&.OK5 M69!CML3>:7M//NA$L"]"[ M#0AN#B7:X^^([4G!K0SOH`L=1Q[R3-T]U(N@975B;:F`.T/U,X4K(H:CHN.` M>$>IJ%]D`\VE<_(/``#__P,`4$L#!!0`!@`(````(0!N)KT5E`,``/4*```9 M````>&PO=V]R:W-H965T.$3DSJ"Y##\?'Y+OGLY?US55I/ MF'%"ZY7M3J:VA>N49J0^KNQ?/Q_NYK;%!:HS5-(:K^P7S.W[]<L0@(>V='A#<,H:Q=5I>--IY%3(5+; M2B%FMVC0/" M6E';JM+XR[&F#!U*B/O9#5#::;VLUZV^?E-$GW?EN\H.=/C&1?28TAV5`F68`#I8^2^B63 M$"QV1JL?V@)\9U:&3<#;U7:!;!\S%`Y&2MI6>N*#5'T5R+U)* M)+B(P/=%9#&9AV$0S6>WBP"S=0+?%Q'W5B.."JK-T0X)M%XR>K:@[\`V;Y#L M8C<&W2XY*A2=KK>R!6F2(ANILK+AA8%$<*CPT]J?S9?.$Y0EO7"2,<8:M)VN`(V?<1P^#,-"CGB1?)P?K&O.V2*=>97A42 MPOOSVA"!;S;$5I&\]@10,T,A_KR=0EX43OW0#@! M610D?4PH^(#.N](4/FRF!J$4,,-02&CV1&`:VBJ2%^G1LU-(8"X;QG%9)AUV M<]>;S;2V49C%E=!N*8Q<9T:DD$%AAA-%D?J%48@N3#!SW7"0![@&R,V\7F'4 ML:Z.K`JS(][BLN162D_RR)95UJB^36P\F<.!AWQ-\2.I.96B7,(<3J1 M-P2F[BWJ0="F[<0#%7#?:'\6<+W$<&1.)T#.*17=@]Q`7UC7?P$``/__`P!0 M2P,$%``&``@````A`'N*87;W`P``%0\``!D```!X;"]W;W)K&ULE%=;C^HV$'ZOU/\0Y?T08B!O#&IN"AW83R9A@$K4Y'Q\K@+ M__G[^=LJ#)2F949S4;)=^,%4^'W_\T_;BY"OZL28#B!"J7;A2>MJ$T4J/;&" MJHFH6`G_'(0LJ(9'>8Q4)1G-S*(BC\ATFD0%Y65H(VSDF!CB<.`I>Q+IN6"E MMD$DRZF&_:L3K]0U6I&."5=0^7JNOJ6BJ"#$"\^Y_C!!PZ!(-S^.I9#T)0?> M[_&H/4I<[GT?K`9^T3UQX1@-;(@#8>&9T1&7.+6WFTAB8,Z8>9W0.#SKL0 M/NO-D\6JCFN1K<^\X9/4'BV"X#*>(#I##=K0?FZMTPAHZ(?QT.ALH.OD.@O, M22,/ZWZ6R3U0Z-R&WEAE\?5))IOU44*Y' MSP(ZMZ&L!:!02II4UNVX1CT2&-TA-KBN#6$M'IL;\Q5#ML;3,=YM,&?J(13C MD#B6:WV!T MEQ[$74%PICY&GB0,$.EJ05R+@3^AL3?ZV-#+);[,A]+5E0$3JY.NQ8UT>=HP MP*FK"'$M"3XGXLW_:$YF8;O-G*G=`K,;PD,\=?B:D_'VT&I-Z'#R!,!(Z91, M\!0U`.,FO]'7I!:#YJ3>>)D33Q\&T)P(--&"1?'M\\T#0.((U?_`I:2B1_8'E4=>JB!G!X@Y->,C[;7&/FA106/! MI4)HN(V8GR>X?C(X>4_Q-7\00E\?$*"^T.[_!P``__\#`%!+`P04``8`"``` M`"$`!)RIVJT"``!7!P``&0```'AL+W=O!#&2MUD)`IG)!`-U[ELRHS\^GE[<4D"ZUB3LUHW M(B-/PI*K[<#9;4L5D0SQ#:J9PZ**07-QH?E"B<9[$B)HYR-]6LK7/;(I/H5/, MW!_:"ZY5"Q1[64OWU)&20/'TKFRT8?L:?#]&"\:?N;N7,WHEN=%6%RX$.NH3 M/?>\IFL*3-M-+L$!ECTPHLC(+DJOUX1N-UU]?DMQM"?/@:WT\;.1^5?9""@V M;!-NP%[K>X3>Y1B"Q?1L]6VW`=]-D(N"'6KW0Q^_"%E6#G8[`4/H*\V?;H3E M4%"@">,$F;BN(0&X!DIB9T!!V&-W/\K<51F)%^$B3E:7$>"#O;#N5B(G"?C! M.JW^>%34!>\\R7X;):C:?0$)]1IW!&^;8=F/T,8"F`4G;,FS!*`7B MMQV!%<3N$)P1:&K(U<(N/&SC)-K0!R@=[S'7'@/7`?."H"`Z*(/:=&4$HS+6 M%E.Y]H%3F7A(9"0S?X\,@C,"UR'Y.'GA]LSC!+-]6!LAT@PB&/1A+SP=B M+^U!$Z2AJ:9+([B3'HK;1^"N>4B MA,S^W:*X;*S01T:MDB1OF\%Y/?DT('@LU4?.S:S'O&@FB<+5?]W@NK%$'QF[ M>=V`?I#Y9:RTKQ MC9E2-C:H10&4L\Z+\9/1OSC=0N8PW+2#@=8]5O`#$W!X9[B-A=;N^06$Z?!+ MW/X%``#__P,`4$L#!!0`!@`(````(0#I)>(Y(0@``)@F```9````>&PO=V]R M:W-H965T2C!+L;H^T M*ZU6Y^/:`2=8`QC9SF3FWV^U^X.N?GU(R,Y<#.%Q5;G?KNIVV?CVRX_==O2] M;-JJWM^-H\EL/"KWJWI=[5_NQG_\+GZ[&H_:KMBOBVV]+^_&/\MV_.7^G_^X M?:N;;^VF++L11=BW=^--UQUNIM-VM2EW13NI#^6>CCS7S:[HZ&OS,FT/35FL M>Z?==AK/9A?375'MQSK"3?.1&/7S<[4JTWKUNBOWG0[2E-NBH_&WF^K0VFB[ MU4?"[8KFV^OAMU6].U"(IVI;=3_[H./1;G7S]65?-\73EG3_B.;%RL;NOT#X M7;5JZK9^[B84;JH'BIJOI]=3BG1_NZY(@9KV45,^WXT?HIL\F8^G][?]!/U9 ME6^M]_>HW=1OLJG6_ZKV)-=TH:4*^8/L\\Y87QI$_C.?_8 M6"^-(WW:4\:3:#[KI_C$[-`B[8=*G];O].Q,=7;[8DF+KKB_;>JW$:U`2E][ M*-1ZCFXHFJT2?6Y7-W]7-E0O*LB#BG(W)G\JB)9J_?M]'"]NI]^I/E?&YA%M M(FZQM!:J&%78-`19"$0(9`AR#TQ)LQ-.%?D+A*LH2K@=\J,%WDP$*JV%=4E# MD(5`A$"&(/<`4TG+YQ>H5%%H_;/T7G!9C\:&IMO50&"R="9..I`,B``B@>0^ M8?II$_@%^E446B!T%J M_>TR5L:]3CN^1TT2*B]/^157OG1&UBT%D@$10"20W"=,%NVT'Y>EC+DL39+$ MK=LED!1(!D0`D4!RGS`-M.G[&M36NZ#J.7/K55&X.$U(G)^SZR!GSLCE#$@& M1`"10'*?,+UT>?#UGBY%9+G#$@*)`,B@$@@N4^8AFNN0>4L7DRH3,_, MFHK#Y6G"LY;,@JPY(Y7X\;;TU%V:0GSA$*:(,D4`D M$>4,<3&J&PC:G4_E+U*!`IT:S>GCN%47Z8:"+GEV3(\&L3QJ*P^E:)4A$H@DHIPA+D9=\#TQ:AU>THW%V>M0 M7=/#/&H4K,0X6(G&D4EWCG;.,K02B"2BG"$N75WJ/>GOY%$W!A3.CNDQTL@K MMR6B%%&&2""2B'*&N!AU@??$J#Q>))/+3R1210H6I$9!(I,PD<[*SE"J;I,I MEI?;#)%`)!'E#''MJC'PM+^32-U&L$3ZG45_P[2,`*6(,D0"D424,\3%J*N^ M)^;S"U*W#TRGZRC\C74>YM%9'?,(*(L`"4024U,C.V,02Q9V,Z@589(()*(72R/5LDF@RTYUW?X^V/XM$4]..?=28HH0R00240Y0US?60U+C`V+ M07[GB2A%E"$2B"2BG"$N1C4"7K+4A2Y:])UGMZE6WQYK!0:?>R?T@%L_]HYU M-\%R:!!=K2F`>1:>A$]?K..E:\M3BYCC/'@`D%FKHZ,P**&KU_&,\^"^4QZM M[!+/&>*3HWH-;W+>N7CHSH3-@D9JX7MC"N^A8F/5_Y"EG_@?D>\8].S9T`TN#3!W0+]/J7U`'S(W5@7K&[\_!I_:./D@P-;H+ M"\HCW/^-(VUMMOA3BWA=!9M.9JV.CL*@Y-K%D@;-9_IGO.&I<0.%\CBK+5._ M*P0W[0918VO5+1&EB#)$PB)6,;`G&"M3"]'?%(,>*54M**;H?C&X96 M`I%$I%ZK4./2X;4^_9J$_N5[5S8OY;+<;MO1JGY5KT!0S=_?.JS?SWB,+VY4 M_T##"8\D";VZT5<"')G;ESK"(_&,HO5%#4?H11"ZSQDX3QS3D7CP"(U`UR)$ MHQ%0BSH4;4%'^C<]0I^(?.@9W8!/1#[T!&OH",T./0X:.G))1_KK#9SGBH[T MOY7#D6LZTF]"X1%R&?0@AT'[B.:9GO\/C8OFF1Z/#QVA>:9GS4-':)[U!3P8 M%W5=-)M#*NF]GH?A6!1JZ!PJR4-<%=D`?YC?/%"!#PR6LCC(*8>#*:0,#B:0 ME/7"IDXSO1=T*%[*?Q?-2[5O1]ORF1;-K&^6&_UFD?[2U8>^:7ZJ.WHAJ/]S M0V^`E?0NQTP]G'^NZ\Y^(0%3]T[9_?\```#__P,`4$L#!!0`!@`(````(0#T M(-BV/`L``)I````8````>&PO=V]R:W-H965T&ULK-Q;4]M( M%L#Q]ZW:[^#R^V`LWEVC`%7`%.VD\Q\^STMJ25U_[TLWIJ7 M"?QTNB7ZJ"4=7>;S[W^\/(]^KK:[]>;U9CP].1V/5J_+S?WZ]?%F_,]_>+]] M&H]V^\7K_>)Y\[JZ&?^YVHU___+WOWW^M=E^WSVM5ON1]/"ZNQD_[?=OUY/) M;OFT>EGL3C9OJU=9\K#9OBSV\NOV<;)[VZX6]W6CE^>)/2RO`X?7S?;Q;=G^;O_F)XMEKKO^A=T_[)>;C>[S/+E5@6^;S7<5&MXKDL83M/;J#!3;T?WJ8?'C>5]M M?@6K]>/37M)]+G^1^L.N[_^C^VP9=ZI?+#L1LLN6PV^,-)G33[;72(XWDJ/=VT(=O:;74^E.3XIFC^JFR7^;)3(]5"]?53DF\TA+L2#^)``$D(B2`Q)("DD@^20 M`E)"JJ$8N9!+G"-RH:+-7#0RFW5GH#O('.)"/(@/"2`A)(+$D`220C)(#BD@ M):0:BC'P-#.<'9`YQ(1[$AP20 M$!)!8D@"22$9)(<4D!)2#<48>*E0CQAX%6T.?"-R[V$X">SBI`OJ)@'$A7@0 M'Q)`0D@$B2$))(5DD!Q20$I(-10C%ZK\/R(9=;B9C9:&\X`T)[DDC^23`E)( MBD@Q*2&EI(R4DPI22:H,,G.A*LIA=?_^$4G=L+%F1DO6^<&QS@]]5#>I1OU?TRR9@Q54!S M1KDDC^23`E)(BD@Q*2&EI(R4DPI22:H,,G.AZL8C6UIPIHSBB7Y)%\4D`*21$I)B6DE)21M+(15MBRH[?5^73,WNJ=%$ZB7/UN,9,HDOR2#XI((6DB!23$E)*RD@YJ2"5 MI,H@,SVJC#PB/4W5::1G6(C6!Z0[]7C#'/@YR25Y))\4D$)21(I)"2DE9:2< M5)!*4F60F0M5*QZ1BZ:T-'+15IMRJ!I,E7-[JG11_50!N5.01_))`2DD1:28 ME)!24D;*206I)%4&F>E1%>41Z6D*4",]74W:IV=Z9=\_40_6[-D#IJ:U$A/6Z;*:6,P>^P'*-,NJI\] M()=1'LDG!:20%)%B4D)*21DI)Q6DDE099*3'.:[2K\/-2K^E8?E"FI- MR2<%I)`4D6)20DI)&2DG%:225!EDYD*5VT?DHJG.C5RT!;N4CX,+,/OYNWJ% M45T?]QF;DUR21_))`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`A:]7RI#XX8\DG M65)_=68OF4H;>3A[8`NFTD:>"QY:1SXLEGOS!WIS M9*SE3O&!)5-I(V_N'5HB;>0]LD-+9*R;\XJ]!5,9:WFAYE`;&6MYE^/0$AEK M>;/@P!)IR@C+RZ;<(JF2KE7!PR52X%RK M6H5+I#:Y5F4&ETA9(5DYM$2^$/]Z>.1EPP[T=*O2>\C51#K@7\^NO\HDYB;= M2OYJGW29E2_#WQ:/JW2Q?5R_[D;/JP>9T*=U6;IMOBUO?MEOWNKR]-MF+]^$ MUS\^R?\#8"6EQ*GZ@N-AL]GK7V3%D^[_*O#E/P```/__`P!02P,$%``&``@` M```A`.9M?M)J!P``JB@``!@```!X;"]W;W)K\JW4FGTSV\9@E)4$.(@.VVW_[&@V'Q MX`FX;[;=V?'\/1[[YU'BA_??JHOUM6C:LK[N;7>SM:WBFM>'\GK:V__\_>E= M8EMMEUT/V:6^%GO[>]':[Q]__NGAM6Z^M.>BZ"R(<&WW]KGK;CO':?-S467M MIKX55_C+L6ZJK(-?FY/3WIHB.^"@ZN)XVVWD5%EYM?L(NV9-C/IX+//B8YV_ M5,6UZX,TQ27K8/[MN;RU0[0J7Q.NRIHO+[=W>5W=(,1S>2F[[QC4MJI\]_ET MK9OL^0)Y?W.#+!]BXR^S\%69-W5;'[L-A'/ZB+MU?]>MO17DZ=U#N$#(2B>T.WS\6;0XK"F$V7B@B MY?4%)@`_K:H46P-6)/NVMST0+@_=>6_[T2:,M[X+[M9ST7:?2A'2MO*7MJNK M_WHGS,CI8^'4/F9=]OC0U*\6U!N\VULF=H^[@\##G/H(XRRY2<+L1)`G$65O MPT8%_196]NNC&R8/SE=8C5SZ?.A]X.>;S^CAP&S&*<$TIE/2+\^@+)R%LE@N M,94/O6$JX^EE?!,9X0SK/9U\F(YQ>^7>)YCX1*.'DB"XK$]0.$-Q%.EH.P;N MI7NG%=*P4:;2HMQ>)+8;LPN'91;CD;N."\EX4A5O5]1X:Q* M24M_NJ8[)3:)*YS5N-(R738W8G:+@/#DG-Q/03BK4M+2G\5I"JD:5Q0D"C:+ M]1##5`5IF6Y\-_+U]7"A:NNS06]5;##-\W'%,9\L%`(E`DXM[3`<2%1$+#"I M.05,3D;8<"4F_#=P#"9-3N)DDYSB>,6I$:>6E&DPJ3F%3$[B7$^$[^\ZMZ<` M*(R'=#!IZ<$8-) MA<3;W:9PSC6B!'J3W%A.N!I0N"GLXH4],0<%1IJ=JK?+3,G(,R(%>JL9#:;Y M#O2@@#^T`W$@41&QP*14*7Z[)=6G!.#2=GE,7._ M>D:<0&^R?A(=FHP()^YO-]%($#@,)K4TS"WK&<$!O4DB(QR`@6K5"0D$\$)W M$\.,%W*:0\&3)K4XS&7K&4$!O4E.+!0\#116M7,XD*A(4JAU8BY;WP@+Z*VJ M#:9`W%5*G7P=%K;!BD+A2"(CN:`6BKEM?2,NH#=1DZB8GR*?<.'^CD-O$EH2 M0JT.<\7ZXC1/[O8%->%-U*1)4QV"@[7]JC\'PV!2:\/JMJ M@VE^<`)Q@"=;&=O4``[#_2KA,*(A(H%)R2AA6H3`"`7H3=0D"N8G2$Q^FM%" M(O+<3WIZ#`!JRG9+F,X@$"=YLGX+:O+<3]6D25,:#0I2V`D+$G,0!-*D5H;I M$`(C$*`WJ0P+@H"`0.RU%' ME+ED(W&\5W<-Z$W41``PS=N?B/!AH3B2`),K"0-@Z,D7#RESMT9&4$!OD@@+ MA8A``>DM^LZ%C"0*IAE)DW*44N:2C8SH@-XD(Y8.T0_2`<<1$1T=4N:*C8WH M@-ZJVF":]PTQ08$HTG*/BJ.(A$2"6B/F>HV-D(#>1(U%0JQ!@NLE*WH&'$ED M)!/@D,&ZR.]M4^9^C8V8@-Y$33)!4R7"!%&E51_-B0_OR$<7@TDM%'/5QD9X M0&^2$XN'F.#A/A70FX265(!5FQ2'N6!C(RJ@-U%CJ1!KJ."&_HK/XW`DD=%P M`5ZAZ+^[28RX@-ZJVF":[[B$<.%^==";A)8\F%;'VS(M0F+$`_0F:BP/$AT/ MW'"Y1<"!1$73(GA;ID5(C'"`WD2-Q4%"<+!0G#D#,`"HJ<5A6H3$B`'H31)A M&9`0!F"+L`K6.)+(:+H$;\MT"8D1#]";J+$\2`@/%JHC#_RDW<$`L^HPO8&X MK-=WHNBM)C*8Y@R`IUY*Z-6W#@XD*A('\,\(:V]+VX/^95C__*HJFE/Q2W&Y MM%9>OXA77QZ\FQJMXXNT)T]\0T+MP>ZI?ZGFC'^!EV*W[%3\D36G\MI:E^(( M,;>(Z:9_:];_TM4WF#N\%ZL[>".&_SW#F\`"WDYM!3:.==T-OXCO9L97AH__ M`P``__\#`%!+`P04``8`"````"$`J++]8_X"``#;"```&````'AL+W=O[9ZH>Z`S^4$_.$ M[7/S4QZ^U>1!(29QHKXTL_EH0K9.R7'5J]\RPS5K)@P/]!K2N M&$X/#8"XS2A*R0Y(MLH0$!A7T-53V>4-]NG:?H1I1@[FS&'@>,1W" MA6RZE""-?DKCY6F5$8S*6"Y,YN,QL*(/.YQ>[T-39F1E>3=\<,-^VI MIR8T;,[RI#GV*K'G=<%5RC_S/-=.)/=X37APT';1[@K;>G@6GL;GP=9>;6[W M"UPM%4OY=Z9246HGYPEP3NM=H^SE9#^,K*!"<,%(`Y=*_9K!GP@.A^T4O2=2 MFO8#E-WN;\GF'P```/__`P!02P,$%``&``@````A`'+9-OD-"```8BL``!@` M``!X;"]W;W)KEK^JMKE M;\]__]OC1W/^UKY75;>`",?V:?G>=:>'U:K=OE>'LKUO3M41CKPVYT/9P9_G MMU5[.E?EKF]TV*_X>AVN#F5]7*H(#^*GW=?>K#[I<'+8/?[P=FW/YLH?S_LG\ MF;5Z[>PBW4@,=GW.R2E80Z?EQ5\,92.V+<_7ZM/R=/0C/ M6ZZ>'WM!_ZVKC];X?=&^-Q_B7._^61\KL`W725Z!EZ;Y)M$_=O*_H/%JU+KH MK\"_SXM=]5I^WW?_:3[^4=5O[QU<[@#.2)[8P^Y75K5;,`IA[GD@(VV;/0P` M_ET<:ID:8*3\V7]^U+ON_6GIA?=!M/88X(N7JNV*6H9<+K;?VZXY_$]!3(=2 M0;@.`I\Z"//OXR#PPSB:'\734>!SB,+C@`7A#6/Q=13XU%$X_#KS1&"PO0WX MU(V]^8U#W1@^+^/G-ZN,=!#XO`1AP!`LL<\>$4IW,$DD.V^5TVZIL"W4)B_WAF?/VX^@')N-5,.L4PS&RF&(Z9 M;(KQ,)-/,3YFBBDFP(R88L(KLP)E5V^0SZ8WNR\)/RWA7\-7=(W;.TT5`REU M93R";!02]L(#%E-3YF'N\81Q]X0`]F! M>3K?CH2IG1B/+56,:6>X+KV_C2*BBQP6)B1&YHR1.XG"20@;@1S!R*4(Y8E'B,9%CF#)$[B<))"!N!%,%"-%^1A(DBCTR!5#'0_^>3 M[(+TJQJ=(YDZJ@UR+R(K6GYI_7D'A1L1N)<@&$X#Z8&[B:E'KMT>5`GVM4@V MHIK(6:2*L6IR(YE"E"LO]#VZ:KM#%&Y$?-X+<@7WMMM=R4;4%5EU4\68KNC* MY"0R)Y$[B<))B#%AW&&0+/D$0(H"=V+)1E06N>2I8FRRG$3F)'(G43@),28^ MDY5\199L1&61BB55C$V6D\B<1.XD"BG5M^*ZB+%6ZHAFR\W MDKF1W(T4;D1,()]*DW7IS?.1J6H6:K;KS8YY9&U*-625IN)8D,P=)7,2HD[MEXG9!TM,!'&OD>>#`0FHCCPAKL\ MSBNX_#>HDC3-*])WRA1DS2N%J%,,O)"4:YD.H8Y'?&0@1P"#\\-/5P4Z?N?% M2*9J7N3,'YX1M#.S,(9I(7_P9=_H.!:MF1O)W4CA M1H05PZ4/JTJ-&2>#HIL>093[/;I MR64KFF>D7DPU9)[+*,]4'&4L)/-!.U.()4KN[JAP(\**X#0CA?Z\:H./"W[F MC9S-J/AUH$$:S3(50Z67+-.CL"YDF6]%, M(Q5I*K]^=-2U&C'F)EGD,W>0W(T4;D18$9QHY!%@9J)-/0J,E(T?!6@";.17 MPKW6_AT^O2MF^K!6VM\Y<2;FUP##JQ/:23&#$:@GE637GK"P+ST'\*GG`+)4 MI1HR9PQ!-AI10GP>C(VICBPQ.]*WH M77%XCZ122T.VU'(CF48N0CF+Z2R<"#(RAJ+`_&(1N7`"$7[@)\GPC(R-D2+? M/@F]<7$_>LVJ&:NHQT*?1X3)$7/'`I^^ MS"P(P>.01R$9JT`0!Y<>;+R[SGAL2I:[\TVIXAB9,O87Z!F(*O%^W1XZ[Y$- M;%R4-99*"2G+@\UXUP&JQ5TSEOS,W4CA1N0NRL_K:"5+[9)46]].Y5OUK_+\ M5A_;Q;YZA95K?2\W(Y[5'DGU1]><^BUN+TT'>QO[7]]A+VL%^]_6]P"_-DUW M^4/NPKSNCGW^/P```/__`P!02P,$%``&``@````A`$6%GK4,!@``,!H``!@` M``!X;"]W;W)K?_MHSA8 M;Z*J\_*XM-GR$:"R(/4V5X4:3TO3^((5[9E5:0-O*UV3GVJ1+IIOU0< M'.ZZH5.D^='&"'?5E!CE=IMGXK',7@MQ;#!()0YI`_SK?7ZJS]&*;$JX(JU> M7D^SK"Q.$.(Y/^3-9QO4MHKL[OON6%;I\P'6_<'\-#O';M\,PA=Y5I5UN6WF M$,Y!HL,UQT[L0*35_2:'%4C9K4ILE_8#NTN\T'96]ZU`_^;BO=;^MNI]^?Y; ME6_^R(\"U(8\R0P\E^6+A'[?R(_@R\[@VT]M!OZLK(W8IJ^'YJ_R_7>1[_8- MI#N`%*7)8&*))^M*_O^:;9+VTOG`>1 MZS&`6\^B;IYR&=*VLM>Z*8O_$,14*`S"51!X54$8OSF(IX+`ZSD(FR^"P`\7 MT4^I.+BL5J7'M$E7]U7Y;D'I`?'ZE,I"9G<0^2P/+J83[)I>()0,\B"C+&WH M&9"BAB2_K6)V[[Q!7C(%60\A!)&<$3*=P*ZC"*KI%"]G[LQ$@B43F4E);8T? M0.R.&C>9)4.$UT,,)B#0="82#-6BW3CNPR(WA/@:)"30,5')B8Q,.'"]Q8=P.`&U:ESDS7F02./)U)^B0J)6/NV'@$>X)`G3N7B^O02VZ MA9H$$VKDSFN$(#46,MJ%^F7NQ;VB!BEIC]K8&-=+@DU2<4!2B1!%BGMA'$:4 M&$*F*!;?0DZ"";E^S5AG"#DG,P@(^42_[L6NZW:+,S1C4//316O1A%A?(4A, M89#9C$6):EQ"?F-@E0\.(XVY& M*"UUQY@QYH:<0!*F0U@07A\T-UD&PXFO]S#31IBBAR"]SHC.B8IS&6+F^B;W M8$/[8"ZIL[4"89+#8-C#T]V#W60?+=KL$^;2?9X"J4:Y1`\M1-?N6AOSFURD M19O;*.;2S8H"Z7>GR1V%&,GE7S*2]EM4QKX)L0@52.>IJ=1B$H5!J>$9+>BG MN4F3&,FT3N9#0V':1%,T$31.Y@XJCK?KN- M72RN20DKG6XL7*)IING&1H'&)<1`F.D@]*(^B*G?EYQ%/MT/:!+C6"L04KBD M'P91?>_SV+_&D?C*^+:&#_V$N<0MU@JD[LU8P`9#T8`PYKE!/QE,"6\R%(Y> M`17>/9>!G]'20Q#28[#;'VQM5!A$!+ZK/:*:Y&YR$W[!3>@ST%J!U*U9')#& M20P`86^2N\E,.-J`8<6,FHD"Z;TQH#>TDQYB\)//X=-[MT63WF5]S>#X4R`E MGKY)P0FMKNO\M2ENLON2EWCXP&'6'_42!4*6$;"D6YY$(2;QE--\\K[?P]EO M\NNWQ4I%!"$_V#:W_\P>2E2@20R)B8P/&.^">;"^@A1#TSPD0?);M![[$:MX(@B57(2!2P")BH(`+_2]OJ+-:B1&\A,-+Q@(HP;B(>B* M0JI?1C$FPYML!([=A^I1&U&@<888Z`H&&>(!/1X]%Z+:B40<#K65E:_R\)W# M#J/[M/MAX('+8USR^1I^,&A/UYWN`IS7G]*=^)%6N_Q86P>QA9#N7)Z*5WCB MCV^:\M0>>#^7#9S4MW_NX9<9`&ULG)9=;]L@%(;O)^T_6-S7#G:^%:?JA[I5VJ1IVLO MNXLY"J0B34XJWM`4/5.)+M>?/ZWV7#S(DE(5@$,C4U0JU2ZC2&8EK8D,>4L; M>%-P41,%0[&-9"LHR4U0747Q:#2-:L(:9!V6XAP/7A0LH[<\V]6T4=9$T(HH MX)MV"Q8153S\84!76VO-\V7)!-!7D_X3')7KS- MH&=?LTQPR0L5@EUD0?LY+Z)%!$[K58-C%*U7ID!_&-U+ MYWL@2[[_(EC^C344J@U]TAW8Y_@F"HU[TG>G`#Q'DM""[2OWD^Z^4 M;4L%[9Y`1CJQ9?Y\2V4&%06;,)YHIXQ7``#/H&9Z:4!%R)/YW+-J.:4L49#NI>/W7BO#!RIK$!Y,$Z`_O<3B?3,;3^>Q=E\@2F01O MB2+KE>#[`%8-S"E;HM<@7H*SSBR!^KR>&:2D8ZYTD`D%M81V/*Z3.5Y%CU#" M[*"Y[FMB7W'35R2=)`*^(R2D_G%('90B>#J0G;])Y-IJIB8%O)@MDO%T>D)I M)6/'IE-XD%`]%W*X@EKLP\7QV)_YVFIF0W!6XL(ELZ.+1P>:\^FT^(0.G_;7 M:MRIN[J8XMX,*3PV6+TNVWEK4`?YC,G\M+U6XS(ZY;&0?4F7A@7O`$W^PB<%I_`X>2X:NP?PVI(?103YC MO[M6XS+VNMN7=&EXD`L?$PW1&?8*')R?] M/8A]F1NR99^)V++&AE4M(#C:Q3J$U[8BX<=*-Z:$WC# M%5P8S-<2+H@4CN=1".*"<_4RT%>;XY5S_0\``/__`P!02P,$%``&``@````A M`,9HA[G@"0``1"T``!D```!X;"]W;W)K&ULK)I; MC^*X$L??CW2^`^)]@81PB[I[U>3J:%U]M] M>=K4H^I2GJ'DI;J>-@W\>7T=UY=KN=FUE4['L3^9S,>GS>$\5!["ZT=\5"\O MAVT95]NW4WENE)-K>=PTT/]Z?[C4Z.VT_8B[T^;Z^>WRR[8Z7<#%I\/QT'QK MG0X'IVTH7L_5=?/I"./^Z@6;+?IN_V#N3X?MM:JKEV8$[L:JHWS,J_%J#)Z> M'G8'&(&4?7`M7QZ'SUY83(/A^.FA%>BO0_E>6_\?U/OJ/;L>=K\=SB6H#?,D M9^!357V6IF(G$50>L]II.P/_NPYVYX MK+>@*+@9^3/I:5L=H0/P[^!TD*$!BFR^MK_OAUVS?QQ.)Z/`GRV6'M@//I5U MDQZDS^%@^U8WU>EO9>5I7\J+K[W`+WJ9CV:+R;1U"1GIYEFX>AZ`!1$4-`?_ER5],'L9?($BWVF;-;3QJ$:&%C$CI M-G9!XH+4!9D+.P(D9B1A)&4D8R1G)&!".%3)0*2)2E;;U*"SL??)@`9" MTAEA(*2,9,QUWMG<<"TZ(W1=V(3((?.J._1HS:D@&MF*(+(D012H!&SBN7(8 M`^QTRE&&R'C.$76>G14GC`%Z+@BB>LB$Z^,+P5/Y&1R)Z'NM$=%#606FU[&Q MLB;2=[J>&"MTGW*4(3+N0S%&@7&*N$HY2CCOG)N)3@J"*)CEAG5'6-6"1@9LT(^30IF="^(9$H%^XS? M7IWU]:*KB'.3:*L`-#.3NG!2T!1]T187M,4,K4R+.2(3RZ*_Q27U59B*=K], MBU12F7[9DJI;W4C>@9O]8?MY7<'@8,'TG$!3V#STG4XE<=`RJK/V%/+AB+/4 M6=&^1FAEHBO6:+KJ?"4:!;+!+T]39Z]*T0EI:NG<*3.T,DWEO"EQNZD"G7RO M*:JM3.]L;7LTA*<4G8@J&R0B*F0%8B0?SKBQJ9%1/]%6$)LX(2E6-%89(COJ MF"_!?158L?5%QRPSO3O&K!)#,F:%:.`LGMC(S&",R\YQH1'>J MI7.ZI::BO6+-OM$N]0RM3(LY(M.BZ&_16;B%J=C?(I54YI"VI#^V4ZE,E`2< M0D[`L3-!6YD@B3V%R$ZE4#!I=RIO.E_.G'THU;6@.5R:&2+C.^>^A4;:M^\' M,Z9G-Q)P3<63&:ZK MP(I\*X*NTC'_4,"T7NC2U,@)&.?@C]#*3&JLD1TP&L'19BT!WUGF*?JR8@:1 M<9]S]^)#[@OTQ?RDD:YH7=)CCA*.4HXRCG*.!$<%050&F?'> M(8-*D.TM0YY=<*H%)FHCCF*.$HY2CC*., M.(H107TK.7:V\\18X4F11.=HBCF*-[`<3'*4<9=Q7SJT$1P5!=,PR\;IC=:@\C:P.G;J1/&#I7.TC M7UN9+"E&9&5<&CGIOG/U3DU%>P]R#JD,K4R+.2+3HNAM<>5DOH6IV-\BE51F M?W=(JI)%(JG.'^TP8BCV-3*'5(+(W/121,8J0V3(WUC M6TP63E4N:R\LC>#6@*=- MQ%&,R$QZHI%]%>16&2+C/D=D?`GNJR!6-%ID)FIO)C\6+2J?)5(HY$2+DUE$ M\B(`80;'*`H6:T2B15G1JR![2H.^2'PNW&T;K4R+.6]1:.2TZ&1Y!=STSELG!U6G_.M??B>#ZZ>,#16XD-)^[R6E4RA MI`U]MV0:X->!3@E\-OC#O>PY4D.)?)BTU<"G8(4OZ\$NM7K#=+. M4":5?76@R_TEJQ#>^/;4\"8P&^TVYTP?O#"$DKZ)@O=QH7S;UN<-`JBW9`T* MK'M'`W?3,.HM@2LJC+-/-;BB04F?:G!9@9*^.5BO0ODBEGG`L7V#%3MK7 M7E?U%:SZHZDNL#W!AZQ5`Q^OMO_=P]?*)3S'FLBO5%ZJJL$_9`/=]\]/_P`` M`/__`P!02P,$%``&``@````A`"3XZ2NA!@``8QP``!D```!X;"]W;W)K&ULK)G;CN(X$(;O5]IWB'(_Y`@!!(P:MG8M)\[E<??U>G;5O1=.6]66M6Q-3 MUXI+7N_+RW&M__U7^&6N:VV77?;9N;X4:_U'T>I?-[_^LGJKFY?V5!2=!AXN M[5H_==UU:1AM?BJJK)W4U^("+8>ZJ;(./C9'H[TV1;:GG:JS89OFS*BR\J(S M#\OF(S[JPZ',"[_.7ZOBTC$G37'..AA_>RJO+?=6Y1]Q5V7-R^OU2UY75W#Q M7)[+[@=UJFM5ODR.E[K)GL\0]W?+S7+NFWY`[JLR;^JV/G03<&>P@>*8%\;" M`$^;U;Z$"(CL6E,Z_J%F"9[@J"S@7J'=`;^:+1]<S]V?]5MJ9C@;GV7+1=6!*7 MNI:_MEU=_?4_W8T/U^H[PY*_\8)"P M2.E@X?E0D(N^'SS[?A9,_T=DM2`!63Z03&1S_7@ M)I:M",$M>!=?!8$*0A5$*HA5D*@@'0!)"%CY2`@'DF5\_^(Y07K!3B7EA"L' MNNUM8`9$XLQDDYTP$6(@$B`2(A(A$B.2()(.B:0)[&E($[*G/[APB!M8>_`: M(0!>.2,!$J(1(@$B(2(1(CDB"2#HFD$@@BJ70_8X@U%8,'L67$@<0< MR#-5,D08\6X^(@$B(2(1(C$B"2+ID$BQPQGT0.S$6HZ=$<<1&\<.$1^1`)$0 MD0B1&)$$D71(I$#AS)0"96?(A!SRW:G,7[8U3!XD[\CD.W!6L!.$.)'C[\GL M%C\B/B-3DQXYKC7S3#DW`F'`##<6VU:.Y(`9.7,J'WPI@'^R M?J%PPP.-T*MB9),PXMIBZM*AC20/E#\/R$.L97D8<>$A=@AO+@>Q8S;V+9/\ MGGAB@$%/%E0*:S$?$P/UBI#G&-DD/0$%Q`AM6SGQTV$W21]2E$D"?6IU42^R M<#U2$LM3I.NMAIG%$?MZ0>JT@"-YGU:F(>164DYZRALC;D6_4M%7QJ[WFJ8:!S!]C"8?74=?=[" M<6?*&@^YT2UI(XYNF1US=/>%";>ZGY3//XM5DN"/CW/; MH^EMZ#N,?(P"C$*,(HQBC!*,4@G),9.22'`S)66&A=2.LN(X^ M^7("&39(@0"C$*,(HQBC!*-40K)"I)8<*O1.5K#24Y*!H4$T.PLA'Z,`HQ"C M"*,8HP2C5$)RS*1"',;\^:P@GI3=E"$E*]#O*\+JEA4(!19"(4811C%&"4:I MA&2%2)$X5.B=K&`UI905#$E[!4*^A5"`48A1A%&,48)1*B$Y9E+X/1`SJQ.E MF!E2IEZI+W>6L+I-/4(!M@HQBC"*,4HP2B4DR0#UY2,R4'-Y!?0(?B3A`>XP M\C$*,`HQBC"*,4HP(O<*9+&R<;&8V3T!^QFV*IICL2O.YU;+ZU=R!P`B;58" MLPN*K35?DB2"T%#+`EIH#:JVV":_U5!;+!OZT"]GJ,6!%GKXHA876MS1$4RA MA5Y;H#XS:*&U*6KQH(66E4J+[RWA&SJ.,X8.8QRN;I[&(X$7C/C90NBC]A#X M6-Q/+OBG7T64@6Y!CU$Y0(U1,4`+*H4A',$5SS4[%K]GS;&\M-JY.,#TF_1W MDX9=$K$/77V%M("+GKJ#RQWZYPDN\PKXYF624O-0UQW_`,H9XGIP\Q,``/__ M`P!02P,$%``&``@````A`,N:2G6G!```F1```!D```!X;"]W;W)K&ULK%A9;^HX&'T?:?Y#E/=+5@)$P!5;%C0CC4:S/*?!0-0D M1DE:VG]_/\<+LB M/BW,O_^*ODU-H^VR^I"5N$8+\Q.UYO?EK[_,K[AY;<\(=08HU.W"/'?=);2L M-C^C*FM'^()J^,L1-U76P=?F9+67!F6'OE%56JYM!U:5%;5)%<+F&0U\/!8Y MVN+\K4)U1T4:5&8=C+\]%Y>6JU7Y,W)5UKR^7;[EN+J`Q$M1%MUG+VH:51ZF MIQHWV4L)=7\X?I9S[?Z+)E\5>8-;?.Q&(&?1@>HUSZR9!4K+^:&`"HCM1H.. M"W/EA'O'-JWEO#?HGP)=V\%GHSWC:]P4A]^*&H';,$]D!EXP?B74]$`@:&QI MK:-^!OYHC`,Z9F]E]R>^)J@XG3N8[C%41`H+#Y];U.;@*,B,W#%1RG$)`X#? M1E60:(`CV4?_O!:'[KPPO6`TGMB>`W3C!;5=5!!)T\C?V@Y7_U*2PZ2HB,M$ MX,E$W.F717PF`D\N\O0`8*A]%?!D;6>CZ7CL!]/)\U4$3`2>3,3Y,K&,GA!@:/!YT,D5@ M_BLO$!2BLB(R"Q.*@BBT$/+WI3<)YM8[!#-GG+7.<63&AC-("HGL5@5V*A"I M0*P"B0JD*K`?`!;8(KR!M/X,;X@,\897M>;`S2Q7,8(S>).M"NQ4(%*!6`42 M%4A58#\`)".\.T9X$);[>PC/!&D%N\4P$[8O%[IF')@!$1PE-AM!$69HR$Y# M(@V)-231D%1#]D-$\@1VH9\1#B(#:P^Z$09XDXGB$B5YCUP2%.&2ANPT)-*0 M6$,2#4DU9#]$))=@IP8PN[-X$6L*>)Y8O%L-&2K(3L-B30DUI!$0U(- MV0\1J5`X$Z1"Z3XZ(J=+=R[RUS6FA^0=`SS8+^DN2D3D^AD2W.K7D"U%QG:_ M[?I.,+'E^.P$@=L::4BLR2:"0W9SW_'LL2R;"@*7W0\1R9V)XLX=%^`VP6T@ M;-D&BOC2^6*K&P4EN?UUB!X?#!DN+M?UY#)VE.1->_O@<@H_,B,2,KS06.LJ MT3@I17Q73-U^R)'L@;JD\#RVA[!E>RCBP[U`;"*3J5S$AG+<6Y*V#)F(`>X8 M,NNM<&;3>V9HK6)-.=$X*4/@(4;HNLJIMQ\VD_R!PB1__M?B(B*R;1114J7L MO1M*&J:*(?2&2ZXI.X;`\2FJ\VQE`B)&DL*H[O2QUENB]9;>Z4WW4O0&F96\ M))<\ROILFT,@KCQ];!AT#!='(+0"U/TQ<=9/'*3F><'RL*...F6U)A# MMS@G''K88CXR@]74)?^A[4? MP@%^!Q^'<-X!;HD1P8OA)3NAW[/F5-2M4:(CU&[WIUQ#7RWIEPY?(#/P=H8[ M>"7L/Y[A7P`(%HL]@B/QB'''OY`.Q#\5EC\```#__P,`4$L#!!0`!@`(```` M(0!MT]C1;04``)(5```9````>&PO=V]R:W-H965T&]X]<16749VH5[W=W]S7%J$S%.$!K^^WWA$`*.5W;SNR; M&GX]^2^? MZ85TU'>2J+^[?_[1OM'X.3D1DBJ@<$DZZBE-KZZF)<&)1'Y2HU=R@?\<:!SY M*3S&1RVYQL3?9Y6BLV;JNJ-%?GA1N8(;?T>#'@YA0/HT>(G()>4B,3G[*?0_ M.877I%"+@N_(17[\_'+]%=#H"A)/X3E,WS-158D"=WR\T-A_.L.XWPS;#PKM M[`')1V$0TX0>TAK(:;RC>,PMK:6!4K>]#V$$+.U*3`X=]<%P=TU5Z[:S_/P= MDEM2*BO)B=Z&<;B?A1<"R0:;F`%/E#ZST/&>(:BLH=I>9L`J5O;DX+^9/1)Q< M!'YS$?/;'6CD=>$WK^O\O`,&))_G@KG`QVE^Y.+.^`V112CD-1LUP]8=EL1[ M%6&(O$DHY!4-*-ZK8A=5H)!7L;[5%G2%MP6%O&*SUC#TEM7XHI>%-<:'-X9= M:];KMM/\JBZL,[Q5*/RHNZVB(A1^U%VS\)$5\II?=%?CLR*;9'T_];OMF-X4 M6+C`S^3JLV70<)E<,;VX06+"_==\@XG&5!Z83$>%#,!42F"->.U:#;NMO<+$ M#O*8'HXQJA&/102;Q4RV+X.!##P9#&4PDL%8!A,93&4PD\%CS(NN>L"!'. M(C)`Q$-DB,@(D3$B$T2FB,P0F2.R0&2)R`J1-2(;1+:([,JDXBR86''V_LQD MT9F!1>)[G%B66$X?$>DC,D#$0V2(R`B1,2(31*:(S!"9([)`9(G("I$U(AM$ MMHCLRJ1B#AS4*N;PBJ#BE1DA,D;2$Q%3EFY6I:(3)'T@L1 M4Y9N5:67(JB07B&R1M(;$?,A;>EZ57HK@@KI79E4_(3F\*L? M_E4:D?A('LGYG"@!?6'7.G`DZK8%YE=./=N%;1M,D'G=A1WC$][,KZCD>,>% MU1S'>XX+2S'F$\>%=13SA>/"(HCYQG%A!<,S$]X#Z[2LI=+[J?IPG<$ MUNE9+AQ,,7^PW8?L*TX30G`E=O6/9.['Q_"2*&=R@-SJV7X9\TLU_I#2*^0< M[J5H"I=A6?$$=Y\$OL;U&FRN!TK3X@$:UL1M:O=?````__\#`%!+`P04``8` M"````"$`.>FFNXL)``!=*P``&0```'AL+W=OJ/)<%"=M_7N<'Y] M'/[W/^D?R^&@:3?GW>98GZO'X8^J&?[Y]/>_/;S7UZ_-OJK:`2B'/Z^NXN5RKS:YK=#J._A5`BO MG]&H7UX.VRJNMV^GZMQ*D6MUW+1P_LW^<&E0[;3]C-QI<_WZ=OEC6Y\N(/'E M<#RT/SK1X>"T#8O7EA=X`1"-L'U^KE74'XZ?'CJ#_G>HWAOC_X-F7[]GU\/N'X=S M!6[#=1)7X$M=?Q6AQ4X@:#QFK=/N"OSK.MA5+YNW8_OO^CVO#J_[%B[W'$8D M!A;N?L15LP5'06;DSX72MC[""<"_@]-!I`8XLOG>_;X?=NW^<3A=C.;!9.I! M^.!+U;3I04@.!]NWIJU/_Y=!GI*2(KX2@5^'R(V&4]5PUC?T@I$WFRQ$YS?: MP='NK.%7=>BM]%G?:+A0#>%7-9R-_.7J'?QBN^EG M1NA!)L@+(U)"FG[[5,?RRG:)$F_:S=/#M7X?P.R#:]=<-F(N>Z&0Q121-O5) M\U'.0+((E61A_`V2'D821E)&,D9R1 M@I'2),0D6*9^ATE"!B8C=-,;,&4NR:#I+9?ZD-XE1A)&4D8R1G)&"D9*DQ"7 M8%%F+OGS4;^B?WK%$4*=3SB^M213ZIP]L_H@;!8SDC"2,I(QDC-2,%*:A-@" MMQQBB_L.C:NMB*9CEP3&CL.*&(D921A)&1^C5*?4WZ(_CJJE28@) M4/[<88*(IB9(8IJ@B&%"'V-<.-\ZYZ0/PG-.&`NB7:N M%?+-Y=\/YC0K(XSJ]DVJQI1:T!"U$A4U@WJHOPG[@56'I*A%>PQHCQE&Z1YS M1+K'PMWCDFJ5NJ%Y7KI':JFHYDQ+96D_"N`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`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`9QN)591V`7&8H-FNL(?#T&>Q;7$1^.N-3@@[-G%U^#E%L)A%P]3.'# M-0=_GH7/L/UVG-(LA&\"''P>PDMQ!U^$\`[9P;T5G*FK!RC^0U'6\3:P!X!1 MN$XW]^&TH+!UM8$3B#@Z#=(T17MF% MXH600V93!&EV.P*8$C+L>@/(Y>>1\H^VOL`Z#Y\XUBU\UMC]=P^?L5;P3=I$?*OR4M&PO=V]R:W-H965TP->V%PA M76$Q^\[,/#O&@"N`*=OI=/_[N;(M8>DP-%3-2VR^W'LDZTBR++U\_WDZ%GYX M8>0'YU91*U6*!>_L!EO_O&\5_]K8WQK%0A0[YZUS#,Y>J_C+BXK?7__\X^4K M"#^B@^?%!5(X1ZWB(8XO5KDCOG\QBO@J^!Y^\/ M,=E=I2=B#V9M?W6]R*46)9F27F5*;G"D"M#?PLEG78-:Q/F97+_\;7QH%8U: MJ5JO&!J%%]Z]*+9])EDLN)]1')S^28.2)Q(B>B9"UTQ$,TN-:M6L->JD^6"9M2R3KEFF4=+,RN\*K&=I=.4%5DJF M7JTWDJ:Z4U4::TD;-Z^9#U95H_Z0VL,Z1N;/(Y6E+I5, M>;2^W!6-;IZJ+]F8/NC5ST?KR_W4S7UP?KJW%-V MDY7YF^%23@=M,@=TG=AY?0F#KP)-K&1N=''8-*U93(Z/_K0SBOG@OZ8#F@>8 MRAN3:16I"6BD1S2'_7C5F^9+^0?-.VX6T\8838[H\`@VR3#9K@IZ*K!5T%?! M0`5#%8Q4,%;!1`53%L%*XZPJ6]+.8JBOB,%8DT,Z(D38!J0'Q`;2 M!S(`,@0R`C(&,@$R!3(#,@>R`+($L@*R!K+)$\E'>DV!CVSY].0$RF1H#J9B MA&DX@Z9!QCUG18AP%D@/B`VD#V0`9`AD!&0,9`)D"F0&9`YD`60)9`5D#623 M)Y*S9*+D[/V1R:(3`WG#MU-BT`20LU0=B2*(IW6!](#80/I`!D"&0$9`QD`F M0*9`9D#F0!9`ED!60-9`-GDB^46KN"?\8M&R7RDQ\D-0:U:4F5,$";^`](#8 M0/I`!D"&0$9`QD`F0*9`9D#F0!9`ED!60-9`-GDB^46+;NB%+CT40EYX`F8+T3,3DI9NR]%P$<>D%D"5(KT3,5=JH M*.-C+8*X]"9/)/_I:T'R_X;/]`7/C6;1LM$IT0UA62T!0*FHF8.P7-I8)JNJFTW4*(\(*64-!*Q-PI:"T5I.DU76[;C1"A M@J1.0Q_+3W0:%BUWFI28UW'>`=(%T@-B`^D#&0`9`AD!&0.9`)D"F0&9`UD` M60)9`5D#V>2)9`[;;'K"G21>'>ZWC'8U1P@T^V7Z_5Z,TD<'J8T#8M^N`A6U1>M6AA?8/7+%K`W>!-BZ:! M&URKT&E%\B952]#$.8;ZG[I%"S+4LNL6K::0C^H6+860S^H6K6.0K^H6+4*0 MT\'*FWZ#MUE%;W'=HMT_T7``#__P,`4$L#!!0`!@`(````(0"9T<+M[00``/\1```9````>&PO=V]R M:W-H965TV<5Y1/]2X6[G! MQ'<=U%5X7W?'E?O/W]FW!]<9QK+;EPWNT,K]A0;W^_KWWY87W#\/)X1&!Q2Z M8>6>QO&<>-Y0G5!;#A-\1AW\Y8#[MASA:W_TAG./RCT-:ALO]/V9UY9UYS*% MI/^(!CX,"?S(/_$4TA\'O!,8\$)YBP.F' M`D&6^H7GYT:<\4!XBA&5/-V9ZIP'PE.,&$RFZK0WG M0+IE#1B4K:1(ZQ:26DAF(;F%%"JB^8<>\`7^B0IL$!A%>HMF"R,!C!3=2X"D MR`182&HAF87D%E*HB)8`:"-J`FZW?K&-"9GZ%//;,"12G8>1L;.WDB3"=A:2 M6DAF(;F%%"JBV8).^W%;A*S;8DC,7E2DU6PM9&8/9J_7&DD708EGC)1JZ-8ZHO3B,C%K=D'7S#`FUE@J23(;OF M.634@OE*$BRE&`2D%]'<\"]8U\!,0/1$3PLKYQ!??;C^D!]=J=#"]!R0LXMU M./MDAPC8`8C=,^BL-APR"L/LZH*E5(:`](HRFDLJ6-?`C$/10E99SJ'8I]7Q M3FK8W&&BYLX(R(%'2P.L"IFS@<'E^#&_@&W*IOH6' M"9R2;9U-E,#QT<8?X^01#-A_V,0)'+=NX-,$SBLW\%D"9X`;>``CLQ$\Z0VN MW^?RB/XH^V/=#4Z##I`6N-G!H:!G%WCV9<1G2!?&ULG)K=;]LV$,#?!^Q_,/3> MV-2W#3M%NJ);@148AGT\*[8<"[4M0U*:]K_?\4A)Y)&TQ+T$R>EXQ_O@CV=' MV_??+^?%M[)IJ_JZ"]C#*EB4UWU]J*XON^#OOSZ]RX-%VQ770W&NK^4N^%&V MP?O'GW_:OM7-U_94EMT"+%S;77#JNMMFN6SWI_)2M`_UK;S"DV/=7(H._FQ> MENVM*8L#+KJGNWKR\W,/%=P%3VSS8;T*EH]; M3-`_5?G6*K\OVE/]]FM3'7ZOKB5D&^K$*_!3AV4.X&(>&";PX^/9;N'C(*9AS#AEO;U&38`/Q>7BK<& M9*3XO@M"<%P=NM,NB-*')%M%#-07SV7;?:JXR6"Q?VV[^O*O4&*X*6$+M_:Q MZ(K';5._+:#>H-W>"MX];`.&^ST)"\,N79N$W7$C3]S*+H!&!?\M9/;;8Q3G MV^4WR,9>ZGP0.O!ST&&#QA)V,VP)MJ%NR9Z>WC-7YIYYNOA6/@B!ZB:TNXE\ MW'!ER+>Z^60]V!6>A4ZLZ*2#AA8@J,P/D"M#<53744Q="Z49KJ%1YKOFRNAZ M2*Z4J(Y8ZLAOZN.**^NNI$1TK]H>F6Z7=VP:/\#.[C<*7Z9[D!*U55@:V4O& M&:P"(F$RW\/C$PFCDN[]`++:A-8G*B)21H MF0AD((K:&N.N96L(+;5I;EGF&"!"`I>)L$VBH`%( MUEF.^1"VEEII4 M1RTC+\B@-HE5)DHW\`4M7QC9\CR"2TUI:Z$>C$FDD!1$RI%JB^6.8:ER`L[J$TR M*TED4CJR,85ETQ])<"'Q(C&CU\\Q+D5>3$%MXDUBQHPIMC$EAJ:^WR.X3/?1 MB[2(,*MIYB+V`@MHD5AM0,Q+.IGOJ) MS)I`00.P`4OU.`64SR$<*/`]W53Q^"H2D!3IQ7,,0K$73E";>).$L01$6,$# MFC'&QB8T>I$>T3A0Z`WA!8U8$@(J!=N37^HE(WME.PJM.>U(N#+1(.:`$DN1 MZHOEXX6KQ^H%D]@<4'J16;W$!I-9`PJNU)ND%^D%'*\A+:C$BR>H3;QQ`R"R M!$5@@2V9K6=\QY%(2BA762_2@W)@*O$"!VJ3H"1++$'Q\T[`,>LC<")!H<8D M17I,XW'0"^7%CD2"0C]IX\TO3IK44KO?E5&"E_LG+3&ITHM47RP?-Z3'ZD65 M9*#*\,&C%UGJ1Y`Q=Y),3'CT(KU\CDDD\8(':F-+JJ`<3-()^HGM=2I$>DN/B3KV` M@MHD)#F@F"%EA!:\2-/#,:[27?0B/2!'CV>@-;_'49MXXP9`9`G(0@T6YC,F MDQWR/E'_2R@+-GD9S0Y7X! M45N/M1>I!0Q78T=I!L$%MDEGGG,)G$K439]^`N%#WTHOT^M$,BO?PQ,MNE[)Y*7\IS^=V ML:]?^3MV\)_\Q^T@EB\`IM'F"6Y;QY$F^XT-0P_B2SFLK!%IYRNB8,X8DUF!""@?_GP<:6PR)X/?)6 MO)1?BN:ENK:+VV"($D[^A+AR_$Y]]QKKK.^?:XK M[XDK+623$.K/B,>;5&:B*1+R^]?#U37QM&%-QBK9\(2\<$UN-Q\_K`]2/>J2 M<^,!0Z,34AK3QD&@TY+73/NRY0V\R:6JF8&E*@+=*LXRNZFN@G`V6P8U$PUQ M#+&:PB'S7*3\7J;[FC?&D2A>,0/YZU*T^LA6IU/H:J8>]^U5*NL6*':B$N;% MDA*O3N.O12,5VU7@^YG.67KDMHLS^EJD2FJ9&Q_H`I?HN>>;X"8`ILTZ$^`` MR^XIGB=D2^,[&I)@L[8%^B/X00^>/5W*PV@",T%FU>1!(2;QTKXVL_SH0M4DY+IO: M/3-LLU;RX$&_`:U;AJ>'QD!\.1=(`K%;!"<$SB/(:"C@TR:BT3IX`M-IA[ES M&/CM,;1'!"#:*X/:=&4$HS)6!5.Y"Q M5!F"M%HK^(Y<,[L*5;N)G`+ M(ULH`4QS:6""V\<2;FP.(V_F0U5S*&ULK%I=;^,X$GQ?X/Z#X?>UK0_;B9%D$9N%+LIJN+%$ND>??;]^-A]"V_5$5YNA]'D]EXE)^VY:XX MO=R/__/O+[_>C$=5G9UVV:$\Y??C'WDU_NWA;[_CA5]^-] M79]7TVFUW>?'K)J4Y_R$EN?R:GVG1RR0]9#?[5OCA7;6_'[37=';/+U]?SK]OR>$87 M3\6AJ'\TG8Y'Q^WJ]Y=3>#JC[>Y1FV[;OY@_1_;'87LJJ?*XGZ&YJB,J: M;Z>W4_3T<+\JK\4U.5XM'VMZO+X/Q,4V:Y,)['M!)^VDV0QN)/$=H)/VTFTF$3I;$%$ MWOGRU.;AL\U;3M)XOKQI2G@G$_TVM>/39L:3932[39;!;YP:Z9J14%F=/=Q= MRK<1IC?$J:1>[L=X+B%WA8GT[2&);N^F MWS#X6QNSEC$1C]BT$332U*WR`>T`4Q3058'!^X0JJ!>JHOW^=0OT9<4>Y3:B M35$^H!V`4<94^03*U,O]&/_VPL%(P)V@05RZ!*(%H%V%L;CD;6FOC^01C/7"U MI7XX48.`J*MDXCWD75"GI$"TBS#N$=S]>BF;:$[10JZ8$E(2T@SBG,@.KA[> MR)@'5IBV_K6%O!F8>KKU46VBDI!F$*=)%G`]36,8C*:!F'0"4I&`-(,X)UK- M'4X?GHNT8'N3T4+>;)S[JII$IRC5)[9":P;Q"F@1=RIX_]F.S)*/[MJNUQ9R M"&PDI"2D&<0YT;KMU0D(,T@ M7@%9@E/!3U0U!L)HNIYB5160B@2D&<0YT5)_/2=C#(Q3YQ6NZ=SXTG51O70" MTI$+,9KQ(-]IHKGO6,AY(C824A+2#.*#'QEGG_IH>,*S\TMQ-^1$G]3TT>US)6$ M-(,XS4&^$TO?L1";D-)W9)1F$.=$2_SU#XDQ!/:0=![AK)")O\&)NZA>.@%I M%L5ITJI_/4WC$8RFL(U-+"`E()YLYC(8?`1D)*0II!G--G.0\=H7@/NH6\-=+? M#/51W6R5D&80KV"0\]!1BD]3V,S&1CE"*PEI!G%.`>=9))/^)/7JF@1F&/>#3SM M2*0G68CDZ`_:$G\OU$>U`BH):09Q_H,\*9&>9"&FJ?0D&:49Q#F1,W@+ZP>G MJO$8=UU-.MMQ9?4W0WU4+VN7V$*:1?$2!OE5(OW*0DQ6Z5KA#2#>`F#_"J5?F4A)JNP,"6C-(,X)W*&3UD$4N,Q[B)@(2YK MZF^5^JA>5NE7+(J7,,BO4NE7%F*RFB@'4C)*,XAS"OC5!V>KM*S40)ZL_C:J MC^IE[1);2+,H7L(@RTJE95G(T7`C(24AS2#.R;.L]W>@J;0E"WG2^=NH/JK5 M24E(,XC3'&1+J;0E"S'II"W)*,T@SBE@2_&BV47]1$7I0JF!YEA[^G>FU-\T MV2B8UY^NLAKGG2\UA&0:YWA?;K^N2-H;! MVP4)OLY<+FAZX%YEH3E[`4S]O8J-P@Z_*\9"M#`Y*OC5M(E$L[W0$"_[%R%> M8,#DKAHD>A?V-@L6\@;)?[&U4>X@60AO.'3Y(EZDRRB:>WKH-B\P2(-Z%2T)6IJ9[;.I0#K;%K#;5`:^P=0RW0&ENR M4`NTQK(1:(F1@V/'4`MRI96`%``#M%@``&0```'AL+W=O9YTAV=*G`0UQ!'0 MZ=^?;<`.>/56Z=5Y:>#K]O*P;+SM]L_WX&R\LC#R^:5CVJ6R:;"+Q_?^Y=@Q M__YK]./!-*+8O>S=,[^PCOG!(O-G]\\_VF\\?(Y.C,4&*5RBCGF*XZMC69%W M8H$;E?B57>@_!QX&;DROX=&*KB%S]TFAX&Q5RN6&%;C^Q4P5G/`>#7XX^!X; M<.\E8),[T M>.&A^W2F?K_;-=>3VLD+R`>^%_*('^(2R5EI0['/+:MED5*WO?>I!V+8C9`= M.N:C[>SLLFEUV\D`_>.SMRCW;$0G_C8._?W"OS`:;?))./#$^;,(G>X%HL(6 ME!XE#FQ"8\\.[LLYWO&W"?./IYCLKE./1,><_<>`11Z-*,F4*G6AY/$S-8#^ M&H$OI@:-B/O>,2M4L;^/3QVSVBC5F^6J3>'&$XOBD2\D3<-[B6(>_)L&V9E4 M*D*1B0C]2I%O:[0R#?K]WQHV]2)IB'C(5.CISE[855F:'K+2K=)#O5YK/#3O M'PR[(67HX?N-:,K2]/#M1EBIN\ED&;BQVVV'_,V@%4C^15=7K&?;L6GMRVF2 MFJHFSG_-&YHP0N51R'1,*D]3(J+)_MJM-NIMZY4FJ)?%]##&+D;T9828C4)V MH(.A#D8Z&.M@HH.I#F8ZF.M@H8.E#E8Z6.M@HX.M#G8Y8)$]RB.:J;_#(R$C M/)*CVY/@9EI%,T1&R"(#'0QU,-+!6`<3'4QU,-/!7`<+'2QUL-+!6@<;'6QU ML,N!@B'T&?@=A@@9^JSF%DVE_%!TH)?%T-10*ZM1#.FK$.42D"&0$9`QD`F0 M*9`9D#F0!9`ED!60-9`-D"V079X43*O]'M.$#'TLJ1IE2+6A6=)+@ZI?N:9" ME&M`AD!&0,9`)D"F0&9`YD`60)9`5D#60#9`MD!V>5)PC;;7PE+[/'V1VY"( M3LR1@]I+2;5H5U-;02I(%AL`&0(9`1D#F0"9`ID!F0-9`%D"60%9`]D`V0+9 MY4G!"TI;ON&%B"YZD1+R0@YS'\@`R!#(",@8R`3(%,@,R!S(`L@2R`K(&L@& MR!;(+D\*`T\97V'@TR2M)'+/^.1[SSV>9N*?+(XJ)6-IBB9$BGYDI''S`\@@ M)54Z?JC/7<76\K:A"I+&CH",07JB8O+2U>+2G*H@*3T#,@?IA8K)2VOYZ%(% M2>D5D#5(;U3,3=JN:-__K0J2TKL\*7@KSMMZ`EZAZ/N-%0I%8S-")Z:;:17- MM'X:5$E.D6FVG9'T""?R[V%&*`_*"6E)XB@+NBWK,4A/0'IZC_0,I.<@O5#2 M^39JTVB9!=62HXG=:K:J-7W37D%E:ZAL]3XDXH^D>P_%QB`]@9CI/=(S M*#8'Z86*R;=1]SX+:GWEO1*2"W8-E6U4S!>5;>^H;*>$J+*"]W0?]!WSD_"B M^QFBS%-VI(]H@&B(:(1HC&B":(IHAFB.:(%HB6B%:(UH@VB+:%=`J1?IC5IZ M21*P\,CZ['R.#(^_B-LR2OR[;873J[Q>W:&DB09H>V=(-C_XE,L[L0,-;3I*:,+VN3%]B?J5A MI\LZ'M,U8_)XHFME1OM3N42?N0/GL7P1%:B+ZNXO````__\#`%!+`P04``8` M"````"$`M*L*P#$!``!``@``$0`(`61O8U!R;W!S+V-O&UL(*($`2B@ M``$````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````G)%!3\,@&(;O)OZ' MAGL+;$87TK)$S4XN,7'&Q1O"MXU8*`&TV[^7=EV=T9-'\KX\/-]'.=^;.OL$ M'W1C*T0+@C*PLE':;BOTO%KD,Y2%**P2=6.A0@<(:,XO+TKIF&P\//K&@8\: M0I9(-C#I*K2+T3&,@]R!$:%(#9O"3>.-B.GHM]@)^2ZV@">$7&,#42@1!>Z` MN1N):$`J.2+=AZ][@)(8:C!@8\"TH/B[&\&;\.>%/CEK&AT/+LTTZ)ZSE3R& M8WL?]%ALV[9HI[U&\J=XO7QXZD?-M>UV)0'Q;C^U"'&95KG1H&X/?/_FZRR$ M78E_9Z62O1V3'D0$E:7WV-'NE+Q,[^Y7"\0GA%[EY"8GDQ6=,4(9F;Z6^-0: M[O,1:`:!?Q-/`-Y[__QS_@4``/__`P!02P,$%``&``@````A`&D/360;`P`` M3PH``!``"`%D;V-0&UL(*($`2B@``$````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````G%91;]HP$'Z?M/^`\MX&.C1-54C%@*J5MA8U MM'NTC',!JXF=V@Z"_?J=DT$2,&FWM\3^[NZ[[\YG!S?;+.UM0&DNQ<@;7/:] M'@@F8RY6(^]Y<7OQS>MI0T5,4RE@Y.U`>S?AYT_!7,D^A"Z)&W-B:_ M]GW-UI!1?8G;`G<2J3)J\%>M?)DDG,%4LB(#8?RK?O^K#UL#(H;X(C\X]"J/ MUQOSOTYCR2P__;+8Y4@X#,9YGG)ʱ_N1,22T3TYMM&:2!W]P,D%T$K%#< M[,)^X#=_@XC1%";H.$QHJB'PZX7@#J@5;4ZYTF&P,=<;8$:JGN:_4;8KK[>D M&BR=D;>ABE-AD):%53_E=YIKH\)?4KWJ-8#1@8^`:K'\;&*;WWP8#@I%[456;RR;S M0PX3*;1,>4P-Q.0[3:E@0**33#^")W/Z?HC(8"3;:9H\)N0QQX(=?%OIJT1: MK-HF$]HJP;LF,B&1<>?^0$VA@"`">:BR$74I'88WW$DL*K*,JIWE'O&5X'AV ML&O(F#%9".,TN<7N(R\T+8#\!*HQ8I6^K='4'>4)TK(>M@MV9*&HT)39<^). M_4$:T*C^CBY3MYZSMP)[P4GO'B=+!F1!M^#V;FUS2_F,.0ZB%&MP+!DMK'M<@;558[J^/T]JP*R=N(.\7:![<:1R%_A$NBYPMQI73LH=:DSA7)O4748BO(WB M`CL&3U$IDS-*2\"FR1024$Z36DOD07GJ5OQ4S"[TJ9I=Z"=@$F]NG*7E#'5W M4_<0^6?-'ZA;C=98((BR(VX#I.)_5D"<.,?8#*(UQ=[`:WJ_ M7R\$=_@.4:EU,EGC2(5XCSG=L$^GE^I]&`Z&E_TO?7P5-=8"OWX)AG\```#_ M_P,`4$L!`BT`%``&``@````A`-ELWWWT`0``\!D``!,````````````````` M`````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4` M``!,`@``"P`````````````````M!```7W)E;',O+G)E;'-02P$"+0`4``8` M"````"$`R:(TL`P"```%&0``&@````````````````!3!P``>&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$`*;_1*;@#``";#``` M#P````````````````"?"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@` M```A`/[N;YVZ!```RA$``!@`````````````````A`X``'AL+W=O&UL4$L!`BT` M%``&``@````A`*JR:0L;"@``L#L``!D`````````````````6!8``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'/4 M/9BK`@``M`8``!D`````````````````,"8``'AL+W=O\"``!B"0``&0`````````` M```````2*0``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/56+.CQ`@``MP<``!D` M````````````````["X``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A``P$\V#/`@``;`<``!D````````````````` MUSL``'AL+W=O&PO=V]R:W-H965TY0/'04``!45```8```````` M`````````'!!``!X;"]W;W)K&PO=V]R:W-H M965T&UL4$L!`BT`%``&``@````A`#;*M1AD/@``=^H``!0` M````````````````BDH``'AL+W-H87)E9%-T&UL4$L!`BT`%``& M``@````A`%/5CPJ?"P``J&<```T`````````````````((D``'AL+W-T>6QE M&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0#)1`>- M^0T``$9;```9`````````````````*^;``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`'QA!*]E`@``EP4``!D````````````` M````WZD``'AL+W=O.J[8"```;!P``&0````````````````![K```>&PO=V]R:W-H965T M&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`'N*87;W`P``%0\``!D`````````````````-+L` M`'AL+W=O&PO=V]R:W-H965T(Y(0@``)@F```9```````````` M`````$;"``!X;"]W;W)K&UL4$L!`BT`%``&``@` M```A`/0@V+8\"P``FD```!@`````````````````GLH``'AL+W=O&PO=V]R:W-H965TYX`D``$0M```9```````````````` M`+3R``!X;"]W;W)K&UL4$L!`BT`%``&``@````A M`"3XZ2NA!@``8QP``!D`````````````````R_P``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#GIIKN+"0``72L` M`!D`````````````````)0X!`'AL+W=O&PO=V]R:W-H965T`0!X;"]W;W)K&UL4$L!`BT`%``&``@````A`+-1)?YE"```GRL``!D````````````` M````AB,!`'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`*H7J65@!0``[18``!D`````````````````BS@!`'AL+W=O M XML 17 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary Of Significant Accounting Policies (Narrative) (Details) (USD $)
0 Months Ended

Jan. 31, 2014

Jan. 31, 2013

Dec. 13, 2013

Immunoclin Limited (IML)

Purchase price $ 20,000,000

Intangibles-R&D 19,800,000

Goodwill 654,992 654,992

Net tangible assets $ (454,992)

X

- Definition

Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477

+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of intangible assets, excluding goodwill, acquired at the acquisition date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The amount of identifiable intangible assets recognized as of the acquisition date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 55

-Paragraph 37

-URI http://asc.fasb.org/extlink&oid=35744172&loc=d3e2207-128464

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 18 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 19 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements and Disclosures (Details) (USD $)

Jan. 31, 2014

Jan. 31, 2013

Intangibles from acquisition of IML, net of accumulated amortization $ 19,793,466

Total assets as of January 31, 2014 19,793,466

Level 1

Intangibles from acquisition of IML, net of accumulated amortization

Total assets as of January 31, 2014

Level 2

Intangibles from acquisition of IML, net of accumulated amortization

Total assets as of January 31, 2014

Level 3

Intangibles from acquisition of IML, net of accumulated amortization 19,793,466

Total assets as of January 31, 2014 $ 19,793,466

X

- Definition

Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 20 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8

Income Taxes (Narrative) (Details)
12 Months Ended

Jan. 31, 2014

Jan. 31, 2013

Income Taxes Narrative Details

Operation loss carryforwards terms
Expire commencing in fiscal 2034

Tax effect at the expected rate 34.00% 34.00%

X

- Details

Name: imcle_DisclosureIncomeTaxesNarrativeDetailsAbstract

Namespace Prefix: imcle_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingLossCarryforwardsLimitationsOnUse

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements and Disclosures
12 Months Ended

Jan. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value Measurements and Disclosures

3. Fair Value Measurements and Disclosures

ASC Topic 820, Fair Value Measurement, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows:

Level 1

Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities that the Company can access at the measurement date.

Level 2

Inputs to the valuation methodology are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3



Inputs to the valuation methodology are unobservable inputs for the asset of liability.

The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

Following is a description of the valuation methodologies used for the Company’s liabilities measured at fair value. There have been no changes in the methodologies used at January 31, 2014.

Intangibles from IML acquisition: Valued at replacement cost. The replacement cost is determined as the cost of replacing the asset with a modern unit of the near equivalent utility.



The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. The following tables set forth by level, within the fair value hierarchy, the Company’s assets at fair value as of January 31, 2014. The Company had no assets as of January 31, 2013.

Level 1 Level 2 Level 3 Total

Intangibles from acquisition of IML, net of accumulated amortization — — $ 19,793,466 $ 19,793,466

Total assets as of January 31, 2014 — — $ 19,793,466 $ 19,793,466

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementInputsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 22 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\Q,V,T,3,X,%\W,3@S7S0Q.#5?.3@V,U]E8C$Q M-C9E.3-C.#4B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O5]/9E]3:6=N:69I8V%N=%]!8V-O=6YT/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O5]4#I7;W)K M#I%>&-E;%=O#I%>&-E;%=O&5S/"]X.DYA;64^ M#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-U8G-E<75E;G1?179E;G1S/"]X.DYA M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O5]/9E]3 M:6=N:69I8V%N=%]!8V-O=6YT,3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?365A#I7;W)K#I7;W)K M#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U8G-E<75E;G1?179E;G1S7U1A8FQE#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?365A M#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DEN=&%N9VEB;&5?07-S971S7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O5]/9E]3:6=N:69I8V%N=%]! M8V-O=6YT,CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E)E;&%T961?4&%R='E?5')A;G-A8W1I;VYS7TYA#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DYO=&5S7U!A>6%B;&5?3F%R#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D5Q=6ET>5].87)R871I=F5?1&5T86EL#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DEN8V]M95]487AE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D5Q=6EP;65N=%].87)R871I=F5?1&5T86EL#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DEN=&%N9VEB;&5?07-S971S7TYA#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D-O;6UI=&UE;G1S7T%N9%]#;VYT:6YG96YC:65S7SPO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-U8G-E<75E;G1?179E;G1S7TYA M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C M=%-T#I0#I0 M#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T* M("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I M=&@@36EC'1087)T7S$S8S0Q,S@P7S'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S`P,#$U,C`P-#<\'0^)SQS<&%N/CPO'0^)S$P+4L\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)U-M86QL97(@4F5P M;W)T:6YG($-O;7!A;GD\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!# M;VUM;VX@4W1O8VLL(%-H87)E'0^)SQS<&%N/CPO'0^ M)S(P,30\'0^)SQS<&%N/CPO'0^)T99/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA2!A;F0@97%U:7!M96YT+"!N970@*$YO=&4@."D\+W1D/@T*("`@("`@ M("`\=&0@8VQA'!E;G-E'0^)R9N8G-P M.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPOF5D+"`P('-H M87)EF5D+"`Q+#`P,"PP,#`@2`S,2P@,C`Q-"!A;F0@,"!A="!*86YU87)Y(#,Q+"`R M,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,#QS<&%N M/CPOF5D+"`R-BPU,#,L-3$U(&ES2`S,2P@,C`Q-"!A;F0@-2PS-C$L M,#$U(&%T($IA;G5A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2`S,2P@,C`Q-"!A;F0@2F%N=6%R>2`S M,2P@,C`Q,RX@4V5R:65S($$@4')E9F5R3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q,V,T,3,X,%\W M,3@S7S0Q.#5?.3@V,U]E8C$Q-C9E.3-C.#4-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,3-C-#$S.#!?-S$X,U\T,3@U7SDX-C-?96(Q,38V93DS M8S@U+U=O'0O:'1M;#L@8VAAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#`P,"PP M,#`\'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\Q,V,T,3,X,%\W,3@S7S0Q.#5?.3@V,U]E8C$Q-C9E.3-C.#4- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3-C-#$S.#!?-S$X,U\T M,3@U7SDX-C-?96(Q,38V93DS8S@U+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#8L-3,T/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E*3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#8L-3,T/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)R9N8G-P.R9N8G-P.SQS M<&%N/CPO'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'!E;G-E2!A;F0@97%U:7!M96YT/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#4Y,#QS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO2!N;W1E'0^)SQS<&%N M/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO M'1I;F=U:7-H(&1E8G0\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'1I;F=U:7-H(&1E8G0L('9A;'5E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^ M)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'1I;F=U:7-H(&1E8G0L('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)R9N8G-P.R9N8G-P.SQS M<&%N/CPO'0^)SQS M<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^ M)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/CQB/C$N($YA='5R92!O9B!/<&5R871I M;VYS#0IA;F0@0V]N=&EN=6%N8V4@;V8@0G5S:6YE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/DEM;75N;V-L M:6X@0V]R<&]R871I;VX-"BAT:&4@)B,Q-#<[0V]M<&%N>28C,30X.RDL(&9O M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P<'@G/D]N($1E8V5M8F5R(#$S+"`R,#$S M+`T*=&AE($-O;7!A;GD@86-Q=6ER960@=&AR;W5G:"!A('-H87)E(&9O2!R97-E87)C M:"!A;F0@9&5V96QO<&UE;G0@2!A;F0@9F]O9"!I;F1U6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/CQI/CQU/D=O:6YG M($-O;F-E3L@=&5X="UI;F1E;G0Z(#!P>"<^ M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2!W:6QL(&-O;G1I;G5E('1O(')E86QI>F4@:71S M(&%S2!A2!D96)T(&]R(&5Q M=6ET>2!F:6YA;F-I;F7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/E1H92!C M;VYS;VQI9&%T960@9FEN86YC:6%L#0IS=&%T96UE;G1S(&]F('1H92!#;VUP M86YY(&AA=F4@8F5E;B!P2!A8V-E<'1E9"!I;B!T:&4@ M56YI=&5D(%-T871E6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^ M5&AE(&]P97)A=&EN9R!R97-U;'1S#0IO9B!);6UU;F]C;&EN($QI;6ET960@ M*"8C,30W.TE-3"8C,30X.RDL(&%C<75I2!V M86QU871O3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2!R96-O65A2`H9&5F:6-I="D@87,@82!R97-U;'0@;V8@=&AE(&%C<75I6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X- M"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^5&AE($-O;7!A;GDF(S$T-CMS#0IF M:7-C86P@>65A2`R."!T M;R!*86YU87)Y(#,Q(&1U3L@=&5X="UI;F1E M;G0Z(#!P>"<^)B,Q-C`[/&D^)B,Q-C`[/"]I/CPO<#X-"@T*/'`@3L@=&5X="UI M;F1E;G0Z(#!P>"<^/&D^0BX@57-E(&]F($5S=&EM871E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI M;F1E;G0Z(#!P>"<^5&AE('!R97!A6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/CQI/D,N M($)A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P<'@G/E5N9&5R($%30R`R-C`L(")%87)N M:6YG2!P6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/CQI/D0N($-A3L@=&5X="UI;F1E M;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T M+VYO2!C;VYS:61E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI M9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T* M/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^/&D^12X@06-C;W5N=',@4F5C96EV86)L M90T*86YD($%L;&]W86YC92!F;W(@1&]U8G1F=6P@06-C;W5N=',\+VD^/"]P M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2!O9B!T&ES=&EN9R!A8V-O=6YT3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`Q,'!T+VYO'!E;G-E(&ES(&%M;W)T:7IE9`T* M;W9E"<^)B,Q-C`[/"]P M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C,38P.SPO M<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^56YD97(@05-#(%1O<&EC(#,V M,"P-"B8C,30W.U!R;W!E6EN9R!V86QU92!O9B!L;VYG+6QI=F5D#0IA2!T M:&]S92!A6EN9R!A;6]U;G1S+B!);B!T:&%T(&5V96YT+"!A(&QO6EN9R!A;6]U;G0@97AC965D3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS M1"=F;VYT.B`Q,'!T+VYO2!I6EN9R!A;6]U;G0N/"]P/@T*#0H\<"!S='EL M93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@ M3L@ M=&5X="UI;F1E;G0Z(#!P>"<^56YD97(@05-#(%1O<&EC(#@R,"P-"G1H92!# M;VUP86YY(&1I6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/DEN(&%C8V]R9&%N M8V4@=VET:`T*=&AE(')E<&]R=&EN9R!R97%U:7)E;65N=',@;V8@05-#(%1O M<&EC(#@R-2P@1FEN86YC:6%L($EN2!C M86QC=6QA=&5S('1H92!F86ER('9A;'5E(&]F(&ET3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`Q,'!T+VYO3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYOF5D('5S:6YG('1H92!S=')A:6=H="UL:6YE(&UE M=&AO9"!O=F5R(&5S=&EM871E9"!U3L@ M=&5X="UI;F1E;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`Q,'!T+VYO2!T97-T2!I9@T*86X@979E;G0@;W(@8VER8W5M6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/E1H M92!#;VUP86YY(&1I9"!N;W0-"G)E8V]R9"!A;B!I;7!A:7)M96YT(&QO6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/CQI/DHN M(%)E=F5N=64@4F5C;V=N:71I;VX-"CPO:3X\+W`^#0H-"CQP('-T>6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^ M4F5V96YU97,@87)E(')E8V]G;FEZ960-"F%T('1H92!T:6UE(&-L:6YI8V%L M(&%N9"!L86)O3L@=&5X="UI;F1E;G0Z(#!P M>"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO'!E;G-E9"!A2!A<'!R;W9A;"P@86YY(&UI;&5S=&]N92!P87EM96YT M6UE;G1S('=I M;&P@8F4@;VX@82!S=')A:6=H="UL:6YE(&)A6-L92P@=VAI8VAE=F5R(&ES('-H;W)T97(N/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P<'@G/E5N9&5R($%30R!4;W!I8R`W-#`L#0HF(S$T-SM);F-O;64@ M5&%X97,F(S$T.#LL('1H92!#;VUP86YY(&EN(')E<75I"!E>'!E;G-E(&]R(&)E M;F5F:70@:7,@"!P=7)P;W-E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI M9VXZ(&IU'0M:6YD96YT.B`P<'@G/D1E9F5R"!A M0T* M9&EF9F5R96YC97,@87)E(&5X<&5C=&5D('1O(&)E(')E8V]V97)E9"!O"<^)B,Q-C`[/"]P M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2!F;W)W87)D"!B96YE9FET6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E M;G0Z(#!P>"<^/'4^56YF:6QE9"!&961E65A2P@=VEL;"!N;W0@:&%V92!A(&UA=&5R:6%L(&5F9F5C="!O;B!T M:&4@3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2!I6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C,38P M.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^/&D^32X@4W1O8VLM0F%S M960-"D-O;7!E;G-A=&EO;CPO:3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P M<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^56YD97(@ M05-#(%1O<&EC(#65E('-H87)E+6)A6UE;G1S+`T*:6YC;'5D:6YG(&=R86YT2`S,2P@,C`Q-"!A M;F0@,C`Q,RP@=&AE($-O;7!A;GD@:&%S(&YO(&5M<&QO>65E('-T;V-K(&]P M=&EO;G,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P<'@G/CQI/DXN($-O;7!R96AE;G-I=F4- M"DQO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P<'@G/D%30R`R,C`L(#QI/D-O;7!R M96AE;G-I=F4-"DEN8V]M93PO:3XL(&5S=&%B;&ES:&5S('-T86YD87)D2!O9B!C;VUP6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C,38P.SPO M<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^/&D^3RX@4F5C96YT($%C8V]U M;G1I;F<-"E!R;VYO=6YC96UE;G1S/"]I/CPO<#X-"@T*/'`@3L@=&5X="UI;F1E M;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T M+VYO2!T:&4@1D%30BX@ M16%C:"!O9B!T:&5S90T*<')O;F]U;F-E;65N=',L(&%S(&%P<&QI8V%B;&4L M(&AA2!T:&4@0V]M<&%N>2X@ M36%N86=E;65N="!D;V5S(&YO="!B96QI979E('1H92!A9&]P=&EO;B!O9B!A M;GD@;V8@=&AE3L@=&5X M="UI;F1E;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT M.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z M(#!P>"<^1F]R(&-O;7!A7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2!G:79E0T*=&\@=6YA9&IU M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X M="UI;F1E;G0Z(#!P>"<^/&D^/'4^3&5V96P@,3PO=3X\+VD^/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P<'@G/DEN<'5T2!A6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P M>"<^/&D^/'4^3&5V96P@,CPO=3X\+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/DEN M<'5T2!A2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C M,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^/&D^/'4^3&5V96P@ M,SPO=3X\+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/CQU/DEN<'5T2!A2X\+W4^/"]P/@T* M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P<'@G/E1H92!A3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO3L@=&5X="UI;F1E;G0Z(#!P>"<^/&D^)B,Q-C`[/"]I/CPO<#X-"@T*/'`@ M3L@ M=&5X="UI;F1E;G0Z(#!P>"<^/&D^26YT86YG:6)L97,@9G)O;0T*24U,(&%C M<75I2X\+W`^#0H-"CQP('-T>6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P<'@G/B8C,38P.R8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E M;G0Z(#!P>"<^5&AE('!R96-E9&EN9R!M971H;V1S#0ID97-C6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$ M)V9O;G0MF4Z(#$P<'0[('!A9&1I;F6QE/3-$)V9O;G0M M6QE M/3-$)W9E'0M86QI9VXZ(&QE9G0[('!A9&1I M;FF%T:6]N/"]T9#X\=&0@F4Z(#$P<'0[('!A9&1I;F6QE/3-$)W=I9'1H.B`Q)3L@ M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P M<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$ M)W=I9'1H.B`Q,"4[(&)O'0M86QI9VXZ(&QE M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)3L@9F]N="US M:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&)O6QE/3-$)W=I9'1H.B`Q)3L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N M="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=W:61T:#H@,R4[(&9O;G0M6QE/3-$)W=I9'1H.B`Q,"4[(&)O6QE/3-$)W=I9'1H.B`Q)3L@<&%D9&EN9RUB M;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,R4[(&9O;G0M6QE/3-$)W=I9'1H M.B`Q)3L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@F4Z(#$P<'0[('!A M9&1I;F2`S,2P@,C`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`P<'@G/D1U M65A2!N;W1E(&1U92!A;F0@<&%Y86)L92!O;B!!<')I M;"`R-2P@,C`Q-"X@26X-"F%D9&ET:6]N+"!-0T*,S$L(#(P,30N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q M,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/D]N($]C=&]B M97(@,C$L(#(P,3,L#0I);G1R:6YS:6,@5F5N='5R92!#;W)P+B!L;V%N960@ M=&AE($-O;7!A;GD@)#(L,#8R('1H870@=V%S('-E8W5R960@8GD@82!N;VXM M:6YT97)E2!N;W1E(&1U92!I M;B`Q,B!M;VYT:',N#0I);G1R:6YS:6,@5F5N='5R92!#;W)P+B!I6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C M,38P.SPO<#X-"@T*/'`@"<^3VX@1&5C96UB97(@,3,L(#(P,3,L('1H92!#;VUP86YY M(&ES6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X M="UI;F1E;G0Z(#!P>"<^3VX@1&5C96UB97(@,3,L(#(P,3,L#0I$2!"65A65A2!S:&%L;"!A;'-O(')E8V5I=F4@ M,2PP,#`L,#`P($9O2!C;VUM;VX@6UE;G1S(&]N92!Y96%R(&9O;&QO=VEN9R!T M:&4@2!C;VUM;VX@28C,30V M.W,-"G-T;V-K(&]N($1E8V5M8F5R(#$R+"`R,#$S+CPO<#X-"@T*/'`@"<^)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2!F;W(@ M86-T:6YG(&EN('1H92!C87!A8VET:65S(&]F($-H:65F($]P97)A=&EN9PT* M3V9F:6-E65A2!C;VUM;VX@ M6UE;G0@;VYE('EE87(@9F]L;&]W:6YG M('1H92!S:6=N:6YG(&]F('1H92!A9W)E96UE;G0-"BAC;VYS:61E2!C;VUM;VX@28C,30V.W,@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/D]N($1E8V5M8F5R M(#$S+"`R,#$S+`T*2BX@4V-O='0@375N2`R,#$T M*2!A;F0@)#(S+#,S,R!P97(@;6]N=&@@9F]R('1H92!N:6YE(&UO;G1H65A M<@T*;V8@3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`Q,'!T+VYO6UO M;F0@1&%B;F5Y(&5N=&5R960@:6YT;R!A(&9I=F4M>65A2`R,#$T+"!A;F0@1F5B65A6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P M>"<^5&AE(&%F;W)E;65N=&EO;F5D#0IM86YA9V5M96YT(&%G2!R969E3L@=&5X="UI;F1E;G0Z(#!P M>"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2!A;F0@=6YD97)T86ME('1H92!D=71I97,@86YD(')E3L@=&5X="UI;F1E M;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T M+VYO2!S M=&]C:RUB87-E9"!C;VUP96YS871I;VXZ/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0M3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H M.B`W)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`W)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)W=I9'1H M.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R M('-T>6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/"]T6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6UO;F0@1&%B;F5Y/"]T9#X-"B`@("`\ M=&0@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&)O6QE/3-$ M)W9E6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H="<^,3(L,#`P+#`P,#PO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M:6YD96YT.B`P M<'@G/E1H92!A8F]V92!T86)L92!I;F-L=61E2!O=VYE M9"!B>2!T:&4@'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQS<&%N/CPO'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P<'@G/CQB/C4N($YO=&5S(%!A>6%B M;&4\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P<'@G/E1H92!#;VUP86YY(&AA6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E M;G0Z(#!P>"<^3VX@3V-T;V)E2`D,BPP-C(@2!A(&YO;BUI;G1E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!;06)S=')A M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!IF5D('1O(&ES2X\ M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M:6YD96YT M.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@"<^5&AE($-O;7!A;GD@:7,@86QS;R!A=71H M;W)I>F5D('1O(&ES2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@"<^5&AE($-O M;7!A;GD@:7,@86QS;R!A=71H;W)I>F5D('1O(&ES3L@=&5X="UI;F1E;G0Z(#!P M>"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M:6YD96YT.B`P<'@G/D]N($1E8V5M8F5R(#$S+"`R,#$S+"!T:&4@ M0V]M<&%N>2!A8W%U:7)E9`T*26UM=6YO8VQI;B!,:6UI=&5D+"!A;B!%;F=L M86YD(&%N9"!786QE2!I2!A M('1H:7)D+7!A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M:6YD96YT.B`P<'@G M/B8C,38P.SPO<#X-"@T*/'`@&5C=71I=F4@;V9F:6-E"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T M+VYO2!!9W)E96UE M;G0@9&%T960-"D]C=&]B97(@,2P@,C`Q,R!W:71H($EM;75N;V-L:6X@3&EM M:71E9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X- M"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^3VX@1&5C96UB97(@,3,L(#(P,3,L M#0IT:&4@0V]M<&%N>2!I3L@=&5X="UI;F1E;G0Z(#!P>"<^ M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO3L@=&5X="UI;F1E M;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T M+VYO2!H87,@;F\-"G-T;V-K(&]P=&EO;G,@;W(@=V%R7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A"!$:7-C;&]S=7)E(%M!8G-T'0^)SQP M('-T>6QE/3-$)VUA6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT M.B`P<'@G/B8C,38P.SQB/C6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P<'@G/E1H92!#;VUP86YY(&AA&%B;&4@:6YC;VUE(&EN(&9U='5R92!Y96%R"!R871E(&]F(#,T)2!T;R!N M970@;&]S&5S+@T*07,@870@2F%N=6%R>2`S M,2P@,C`Q-"P@=&AE($-O;7!A;GD@:&%D(&YO('5N8V5R=&%I;B!T87@@<&]S M:71I;VYS+CPO<#X-"@T*/'`@6QE/3-$ M)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E2`S,2P@ M/&)R("\^,C`Q,R`\8G(@+SXD/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E M6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M M86QI9VXZ(')I9VAT)SXH-C@L-#,X/"]T9#X-"B`@("`\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T M=&]M.B!B;&%C:R`Q<'0@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&)O6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/"]T6QE/3-$)W9E6QE M/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@ M6QE/3-$)W9E"!A6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3L@=&5X="UI;F1E;G0Z(#!P M>"<^5&AE('-I9VYI9FEC86YT(&-O;7!O;F5N=',-"F]F(&1E9F5R6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W=I M9'1H.B`X)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA M;&EG;CH@;&5F="<^*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`X M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F M="<^*3PO=&0^/"]T6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;FF%T:6]N/"]T9#X-"B`@("`\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T M=&]M.B!B;&%C:R`Q<'0@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q M<'0@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO M2<^/&(^."X@17%U:7!M96YT/"]B M/CPO<#X-"@T*/'`@2<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[('=I9'1H.B`Q,#`E.R!B;W)D M97(M8V]L;&%PF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q-B4[('1E>'0M86QI M9VXZ(')I9VAT)SXQ,2PS,C<\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T M:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D M('-T>6QE/3-$)W=I9'1H.B`R)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H M.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W=I9'1H.B`Q-24[('1E>'0M86QI9VXZ(')I9VAT)SXV+#(T,3PO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M M86QI9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@ M,34E.R!T97AT+6%L:6=N.B!R:6=H="<^,2PR-C(\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO M=&0^/"]T"<^06QL(&5Q=6EP;65N="!I65A6QE/3-$)VUA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q,V,T M,3,X,%\W,3@S7S0Q.#5?.3@V,U]E8C$Q-C9E.3-C.#4-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO,3-C-#$S.#!?-S$X,U\T,3@U7SDX-C-?96(Q M,38V93DS8S@U+U=O'0O:'1M;#L@8VAA2<^/&(^.2X@26YT86YG:6)L92!!6QE/3-$)V9O;G0M2`S,2P@,C`Q-#PO=&0^#0H@("`@/'1D M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@6QE/3-$)W=I9'1H.B`Q)3L@ M=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I M9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SXR,#`L,#`P/"]T9#X-"B`@ M("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@ M;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB M;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E M6QE/3-$)W!A9&1I M;F6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ.2PX,#`L,#`P/"]T9#X-"B`@("`\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M.B!B;&%C M:R`Q<'0@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O M6QE/3-$)W9E M6QE/3-$ M)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\ M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D M:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^/"]T65A M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'0M:6YD M96YT.B`P<'@G/CQB/B8C,38P.SPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M:6YD96YT.B`P<'@G/D]N($1E8V5M8F5R(#$S M+"`R,#$S+"!T:&4@0V]M<&%N>2!A8W%U:7)E9`T*=&AE(')E;6%I;FEN9R`U M,"4@:6YT97)E"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T M+VYO6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M:6YD96YT.B`P<'@G/CQB/B8C,38P.SPO8CX\+W`^#0H-"CQP M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E'0M:6YD96YT.B`P<'@G/E1H M92!#;VUP86YY('=I;&P@&EM871E;'D-"B0Q+#4S M."PT-C(@:6X@:6YT86YG:6)L92!A;6]R=&EZ871I;VX@97AP96YS92!P97(@ M>65AF5D(&)Y(&9I7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA3L@=&5X="UI;F1E;G0Z(#!P>"<^/&(^,3`N M($-O;6UI=&UE;G1S#0IA;F0@0V]N=&EN9V5N8VEE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/CQB/B8C,38P.SPO8CX\+W`^#0H-"CQP('-T M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/E1H92!#;VUP86YY(&AA2!H87,-"F]P97)A=&5D('5N9&5R M(&$@;&5A65A2!O;B!*86YU87)Y(#$\"<^/&(^)B,Q-C`[ M/"]B/CPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^5&AE($-O;7!A;GDF M(S$T-CMS#0IC;W)P;W)A=&4@:&5A9'%U87)T97)S(&ES(&-U2!O M;B!A(&UO;G1H+71O+6UO;G1H(&QE87-E('=I=&@@;F\@8V]M;6ET;65N=',N M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/E1H92!#;VUP86YY(&AA7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQP('-T>6QE/3-$)VUA6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P<'@G/CQB/C$Q+B!3=6)S97%U96YT M#0I%=F5N=',\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI M9VXZ(&IU'0M:6YD96YT.B`P<'@G/CPO<#X-"@T*/'`@3L@=&5X M="UI;F1E;G0Z(#!P>"<^/&(^/'4^07!P;VEN=&UE;G0-"F]F(&1I6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P M<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^3VX@36%R M8V@@,2P@,C`Q-"P-"D1R+B!+:&%D:6IA($)E;FQH87-S86X@=V%S(&%P<&]I M;G1E9"!D:7)E8W1O6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C M,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^/&(^/'4^3&]A;G,\ M+W4^/"]B/CPO<#X-"@T*/'`@"<^)B,Q-C`[/"]P M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2`W+"`R,#$T M+`T*26YT28C,30V.W,@871T;W)N97D@1&5A;B!,87<@0V]R<"X@:6X-"G1R=7-T M+CPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2`Q."P@,C`Q-"P-"DEN M=')I;G-I8R!#87!I=&%L($-O2P@)#$P,"PP,#`N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI M9VXZ(&IU'0M:6YD96YT.B`P<'@G/D]N($UA28C,30V.W,@875D:71O6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/D]N($%P6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C M,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^3VX@2G5N92`S,"P@ M,C`Q-"P-"G1H92`D,C0P+#`P,"!L;V%N960@=&\@=&AE($-O;7!A;GD@8GD@ M26YT6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/DEN=')I;G-I M8R!696YT=7)E#0I#;W)P+B!A;F0@26YT3L@=&5X="UI;F1E;G0Z M(#!P>"<^/&(^)B,Q-C`[/"]B/CPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P M>"<^/&(^/'4^06=R965M96YT3PO=3X\+V(^/"]P/@T* M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P<'@G/D]N($UA3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q-C`[ M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO&5R8VES86)L92!A="!A('!R:6-E(&]F("0U+C8P('!E M'!I2!T:&4@:7-S=6%N8V4-"F]F('1H92!P2!"6UO;F0@1&%B;F5Y M(&5A8V@@'!E;G-E(&]F("0Q-2PX,#DL-#DY+"!O3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO65A2!E;G1E6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P M<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^3VX@07!R M:6P@,C,L(#(P,30L#0IT:&4@0V]M<&%N>2!S:6=N960@82!T=V\M>65A3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO3L@=&5X="UI M;F1E;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q M,'!T+VYO65R(&%N9"!H:7,@869F:6QI871E6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/D]N($UA M>2`R-RP@,C`Q-"P@=&AE#0I#;VUP86YY('-I9VYE9"!A('1W;RUY96%R(&UA M;F%G96UE;G0@8V]N3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`Q,'!T+VYO2!S:6=N960@82!T=V\M>65A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI M;F1E;G0Z(#!P>"<^3VX@2G5N92`R,2P@,C`Q-"P-"G1H92!#;VUP86YY('-I M9VYE9"!A('1W;RUY96%R(&UA;F%G96UE;G0@8V]N3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYOB!%;&QE3L@=&5X M="UI;F1E;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT M.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU6QE/3-$)W9E6QE/3-$)W=I9'1H.B`W,24[('1E>'0M86QI9VXZ(&IU2`S,2P@,C`Q-#PO=&0^ M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4G/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q."4[('1E>'0M86QI9VXZ(')I9VAT M)SXR-BPU,#,L-3$U/"]T9#X-"B`@("`\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3L@<&%D9&EN9RUB;W1T M;VTZ(#(N-7!T)SY5;FES6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&IU3L@=&5X="UI;F1E;G0Z(#!P>"<^26X@86-C M;W)D86YC92!W:71H#0I!4T,@.#4U+3$P('1H92!#;VUP86YY(&AA7IE9"!I=',@;W!E2`S M,2P@,C`Q-"!T:')O=6=H('1H92!D871E('1H97-E(&-O;G-O;&ED871E9"!F M:6YA;F-I86P-"G-T871E;65N=',@=V5R92!I7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)SQS M<&%N/CPO3L@=&5X="UI;F1E;G0Z(#!P>"<^/&D^02X@0F%S:7,@;V8@ M4')E3L@=&5X="UI;F1E;G0Z(#!P>"<^ M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2!H M879E(&)E96X@<')E<&%R960@:6X@86-C;W)D86YC92!W:71H(&%C8V]U;G1I M;F<@<')I;F-I<&QE6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/E1H92!O M<&5R871I;F<@2`S,2P@,C`Q-"X\+W`^ M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X M="UI;F1E;G0Z(#!P>"<^5&AE($-O;7!A;GD@2`S,2P@,C`Q-"!T;R!R96-O;F-I;&4-"G1H92!C;VYS;VQI9&%T M960@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/E1H92!#;VUP86YY)B,Q-#8[2`S,2!D=7)I;F<@,C`Q-"X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3L@=&5X="UI;F1E;G0Z M(#!P>"<^/&D^0BX@57-E(&]F($5S=&EM871E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z M(#!P>"<^5&AE('!R97!A3L@=&5X="UI;F1E;G0Z(#!P>"<^/&D^0RX@0F%S:6,@86YD M($1I;'5T960-"DYE="!);F-O;64@*$QO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X M="UI;F1E;G0Z(#!P>"<^56YD97(@05-#(#(V,"P@(D5A2!D:79I9&EN9R!I;F-O;64@;W(@;&]S2!T:&4@=V5I9VAT960@879E M2X-"D9O65A2`S,2P@,C`Q-"!A;F0@,C`Q,RP@8F%S M:6,@86YD(&1I;'5T960@;&]S3L@=&5X="UI;F1E;G0Z(#!P>"<^ M/&D^1"X@0V%S:"!A;F0@0V%S:`T*17%U:79A;&5N=',\+VD^/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P<'@G/E1H92!#;VUP86YY(&-O;G-I9&5R2!L M:7%U:60@:6YS=')U;65N=',@=VET:"!M871U2!O9B!T:')E92!M;VYT M:',@;W(@;&5S3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q M-C`[/"]P/CQS<&%N/CPO'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P<'@G/CQI/D4N($%C8V]U;G1S(%)E M8V5I=F%B;&4-"F%N9"!!;&QO=V%N8V4@9F]R($1O=6)T9G5L($%C8V]U;G1S M/"]I/CPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^/&D^)B,Q-C`[/"]I M/CPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^06-C;W5N=',@'!E M;G-E(&ES(&%M;W)T:7IE9`T*;W9E3L@=&5X="UI M;F1E;G0Z(#!P>"<^/&D^1RX@3&]N9RU,:79E9"!!6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P<'@G/E5N9&5R($%30R!4;W!I8R`S-C`L#0HF(S$T-SM02P@4&QA;G0L(&%N9"!%<75I<&UE;G0F(S$T.#LL('1H92!#;VUP86YY M(&ES(')E<75I2!E=F%L=6%T92!T:&4@8V%R M2!W:&EC:"!T:&4@8V%R&-E<'0-"G1H870@9F%I6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT M.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`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`P<'@G/E5N9&5R($%30R!4;W!I8R`X,C`L#0IT:&4@0V]M M<&%N>2!D:7-C;&]S97,@=&AE(&5S=&EM871E9"!F86ER('9A;'5E6EN9R!A;6]U;G1S(')E M<&]R=&5D(&EN('1H92!B86QA;F-E('-H965T(&9O<@T*8W5R3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO&EM871E('1H96ER(&-A M2!O9B!T:&5S92!I;G-T3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS M1"=F;VYT.B`Q,'!T+VYOF5D('5S M:6YG('1H92!S=')A:6=H="UL:6YE(&UE=&AO9"!O=F5R(&5S=&EM871E9"!U M3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO2!T M97-T2!I9@T* M86X@979E;G0@;W(@8VER8W5M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/E1H92!#;VUP86YY(&1I9"!N;W0-"G)E M8V]R9"!A;B!I;7!A:7)M96YT(&QO'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/CQI/DHN(%)E=F5N M=64@4F5C;V=N:71I;VX-"CPO:3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P M<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^4F5V96YU M97,@87)E(')E8V]G;FEZ960-"F%T('1H92!T:6UE(&-L:6YI8V%L(&%N9"!L M86)O3L@=&5X="UI;F1E;G0Z(#!P>"<^/&D^2RX@4F5S96%R8V@@ M86YD#0I$979E;&]P;65N="!%>'!E;G-E6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P M>"<^56YD97(@05-#(%1O<&EC(#2!2)B,S.#M$#0IE9F9O2!A<'!R;W9A;"P-"G=E(')E8V]R9"!U<&9R;VYT(&%N9"!M:6QE M2!U2!M:6QEF%T M:6]N(&%N9"P-"G5N;&5SF%T:6]N(&]F('1H92!P M87EM96YT'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P<'@G/CQI/DPN($EN8V]M92!487AE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI M9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C,38P.SPO<#X-"@T* M/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^56YD97(@05-#(%1O<&EC(#65A6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT M.B`P<'@G/B8C,38P.SPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^1&5F M97)R960@=&%X(&%S"!R871E'!E8W1E9"!T;R!A<'!L>2!T M;R!T87AA8FQE(&EN8V]M92!I;B!T:&4@>65A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/D1E9F5R"!AF5D(&9O2!D:69F97)E;F-E"!AF5D M+CPO<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO"!2 M971U2`S,2P@ M,C`Q-"!A;F0@,C`Q,RP@=&AE($-O;7!A;GD@:&%S(&YO="!F:6QE9"!F961E M"!R971U2!E6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/E1H92!# M;VUP86YY(&ES('!L86YN:6YG#0IT;R!H879E(&ET'0^)SQP('-T M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/CQI/DTN(%-T;V-K+4)A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P<'@G/E5N9&5R($%30R!4;W!I8R`W,3@L M#0HF(S$T-3LF(S$T-3M#;VUP96YS871I;VXM4W1O8VL@0V]M<&5N2!I'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU M'0M:6YD96YT.B`P<'@G/CQI/DXN($-O;7!R96AE;G-I=F4- M"DQO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P<'@G/D%30R`R,C`L(#QI/D-O;7!R M96AE;G-I=F4-"DEN8V]M93PO:3XL(&5S=&%B;&ES:&5S('-T86YD87)D2!O9B!C;VUP'0^)SQP('-T>6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P<'@G/CQI/D\N(%)E8V5N="!!8V-O=6YT:6YG#0I06QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G/B8C,38P.SPO M<#X-"@T*/'`@3L@=&5X="UI;F1E;G0Z(#!P>"<^1'5R:6YG('1H92!Y96%R(&5N M9&5D#0I*86YU87)Y(#,Q+"`R,#$T(&%N9"!T:')O=6=H($IU;F4@,S`L(#(P M,30L('1H97)E('=E3L@=&5X="UI;F1E;G0Z(#!P>"<^ M/&D^4"X@4F5C;&%S6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU'0M:6YD96YT.B`P<'@G M/D9O'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^ M)SQP('-T>6QE/3-$)VUA6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU'0M:6YD M96YT.B`P<'@G/E1H92!F;VQL;W=I;F<@=&%B;&5S#0IS970@9F]R=&@@8GD@ M;&5V96PL('=I=&AI;B!T:&4@9F%I6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$ M)V9O;G0MF4Z(#$P<'0[('!A9&1I;F6QE/3-$)V9O;G0M MF4Z(#$P<'0[('!A9&1I;F6QE/3-$)V9O;G0M6QE/3-$)W9E M'0M86QI9VXZ(&QE9G0[('!A9&1I;FF%T:6]N/"]T9#X\=&0@F4Z(#$P<'0[('!A9&1I;F6QE/3-$)W=I9'1H.B`Q)3L@8F]R9&5R M+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!F;VYT+7-I>F4Z(#$P<'0[('1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H M.B`Q,"4[(&)OF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)3L@9F]N="US:7IE.B`Q M,'!T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT M9"!S='EL93TS1"=W:61T:#H@,24[(&)O6QE M/3-$)W=I9'1H.B`Q)3L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=W:61T:#H@,R4[(&9O;G0M6QE/3-$ M)W=I9'1H.B`Q,"4[(&)O6QE/3-$)W=I9'1H.B`Q)3L@<&%D9&EN9RUB;W1T;VTZ M(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,R4[(&9O;G0M6QE/3-$)W=I9'1H.B`Q,"4[(&)O6QE/3-$)W=I9'1H.B`Q)3L@ M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L M:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@2`S,2P@ M,C`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`@("`\=&%B;&4@8VQA2!42!4'0^)SQS<&%N/CPO2!T2!S M=&]C:RUB87-E9"!C;VUP96YS871I;VXZ/"]P/@T*#0H\<"!S='EL93TS1"=F M;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0M3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H M.B`W)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`W)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)W=I9'1H M.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R M('-T>6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^/"]T6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6UO;F0@1&%B;F5Y/"]T9#X-"B`@("`\ M=&0@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&)O6QE/3-$ M)W9E6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H="<^,3(L,#`P+#`P,#PO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S("A486)L M97,I/&)R/CPO"!B96YE9FET#0ID M:69F97)S(&9R;VT@=&AE(&%M;W5N="P@8V]M<'5T960@8GD@87!P;'EI;F<@ M=&AE(%53(&9E9&5R86P@:6YC;VUE('1A>"!R871E(&]F(#,T)2!T;R!N970@ M;&]S&5S+B!!6QE/3-$)V9O M;G0M6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E2`S,2P@/&)R M("\^,C`Q,R`\8G(@+SXD/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^ M)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B8C,38P M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI M9VXZ(')I9VAT)SXH-C@L-#,X/"]T9#X-"B`@("`\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M M.B!B;&%C:R`Q<'0@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O M6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^ M/"]T6QE/3-$)W9E6QE/3-$ M)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\ M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W9E"!A M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O"!A3L@=&5X="UI;F1E;G0Z(#!P>"<^5&AE M('-I9VYI9FEC86YT(&-O;7!O;F5N=',-"F]F(&1E9F5R6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V M,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W=I9'1H.B`X M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@ M;&5F="<^*3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`X)2<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^*3PO M=&0^/"]T6QE/3-$ M)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@ M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T* M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;FF%T:6]N/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M.B!B M;&%C:R`Q<'0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQP('-T>6QE/3-$)VUA6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$ M)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W9E6QE/3-$ M)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@ M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=W:61T:#H@,38E.R!T97AT+6%L:6=N.B!R:6=H="<^,3$L,S(W M/"]T9#X-"B`@("`\=&0@6QE/3-$)W=I9'1H.B`Q)3L@ M=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I M9'1H.B`Q-B4[('1E>'0M86QI9VXZ(')I9VAT)SXU+#`X-CPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q M-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ M(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,34E.R!T M97AT+6%L:6=N.B!R:6=H="<^-BPR-#$\+W1D/@T*("`@(#QT9"!S='EL93TS M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@ M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R)2<^)B,Q-C`[/"]T9#X-"B`@("`\ M=&0@6QE/3-$)VUA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q,V,T,3,X M,%\W,3@S7S0Q.#5?.3@V,U]E8C$Q-C9E.3-C.#4-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,3-C-#$S.#!?-S$X,U\T,3@U7SDX-C-?96(Q,38V M93DS8S@U+U=O'0O:'1M;#L@8VAA2<^)B,Q-C`[/"]P/@T* M#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[('=I M9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%PF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)W!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@ M6QE/3-$)W9E6QE/3-$)W=I9'1H.B`U."4[('!A9&1I;F'0M86QI M9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3$E M.R!T97AT+6%L:6=N.B!R:6=H="<^,C`P+#`P,#PO=&0^#0H@("`@/'1D('-T M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB M;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(&QE9G0G/B8C M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W M:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$U,3LF(S$V,#LF(S$V,#L\+W1D/@T*("`@(#QT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M.B!B;&%C M:R`Q<'0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A M9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ.2PW.3,L-#8V/"]T9#X-"B`@("`\ M=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H="<^)B,Q-3$[)B,Q-C`[)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2<^)B,Q M-C`[)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I M9VAT.B!N;W)M86P[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%PF4M861J=7-T.B!N;VYE.R!F;VYT+7-T2<^27-S=65D(&%N9"!O=71S=&%N9&EN9R!A'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T6QE/3-$)W1E>'0M86QI M9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N M8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPOF%T:6]N/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XQ.2PW.3,L-#8V/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`M($-%3SQB7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA"!"96YE9FET*2`H1&5T86EL&5S(%-C:&5D=6QE($]F($EN8V]M92!487@@0F5N969I="!$971A:6QS/"]S M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO2!R871E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"XP,"4\"!A'0^)SQS<&%N/CPO'!E;G-E("AB M96YE9FET*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA"!!F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XW,"PW-CD\"!A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q,V,T,3,X,%\W,3@S7S0Q.#5?.3@V M,U]E8C$Q-C9E.3-C.#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,3-C-#$S.#!?-S$X,U\T,3@U7SDX-C-?96(Q,38V93DS8S@U+U=O'0O:'1M;#L@8VAA M'0^)R9N8G-P.R9N M8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q,V,T,3,X M,%\W,3@S7S0Q.#5?.3@V,U]E8C$Q-C9E.3-C.#4-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,3-C-#$S.#!?-S$X,U\T,3@U7SDX-C-?96(Q,38V M93DS8S@U+U=O'0O:'1M;#L@8VAA2!/9B!3:6=N:69I8V%N M="!!8V-O=6YT:6YG(%!O;&EC:65S("A.87)R871I=F4I("A$971A:6QS*2`H M55-$("0I/&)R/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N M8G-P.SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA2!.;W1E("T@2F%G<&%L($AO;&1I;F=S($QT9#QB2!.;W1E($9R;VT@ M26YT2!"2`M($UA;F%G:6YG($-O;G-U;'1A;G0\8G(^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N+B`S,2P@,C`Q-#QB2`M($UA;F%G:6YG($-O;G-U;'1A;G0\8G(^/"]T:#X-"B`@ M("`@("`@/'1H(&-L87-S/3-$=&@^2F%N+B`R,RP@,C`Q-#QB'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO2!T:&4@0V]M<&%N>2!U;F1E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQP('-T>6QE M/3-$)VUA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`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`L(#(P,30I(&]F(&%N(&ED M96YT:6-A;"!S=&]C:R!B;VYU2!C;VUM M;VX@'0^ M)SQS<&%N/CPO2!I0T*8V]M M;6]N('-T;V-K(&%N9"`Q+#`P,"PP,#`@4G5L92`Q-#0@'0^)SQP('-T>6QE/3-$)VUA2`R,#$T M*2!A;F0@)#$U+#`P,"!P97(@;6]N=&@@9F]R('1H92!N:6YE(&UO;G1H65A M2!P87EM96YT(&]N92!Y96%R(&9O;&QO=VEN9R!T:&4@2!C;VUM;VX@2`R M,#$T+"!A;F0@1F5B2!S:&%L;"!A;'-O(')E8V5I=F4@,2PP,#`L,#`P(%)U M;&4@,30T(')E2!P87EM96YT(&]N92!Y96%R M(&9O;&QO=VEN9R!T:&4@2!C;VUM M;VX@2`S,"P@,C`Q-"!!9&1E;F1U;2!!9W)E96UE M;G0N/"]P/CQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!. M;W1E("T@2F%G<&%L($AO;&1I;F=S($QT9"P@55-$("0I/&)R/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA M2!N;W1E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q,V,T,3,X M,%\W,3@S7S0Q.#5?.3@V,U]E8C$Q-C9E.3-C.#4-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,3-C-#$S.#!?-S$X,U\T,3@U7SDX-C-?96(Q,38V M93DS8S@U+U=O'0O:'1M;#L@8VAA&5C=71I=F4@3V9F:6-E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQP('-T>6QE/3-$)VUA M2X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)R9N8G-P.R9N8G-P.SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'1I;F=U:7-H M(&1E8G0L('-H87)E'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'1I;F=U:7-H(&1E8G0L('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XD(#@V+#4P-SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S($YA'0^ M)SQS<&%N/CPO'0^)SQP('-T>6QE/3-$)VUA'0^)SQS<&%N M/CPO3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q,V,T,3,X,%\W,3@S7S0Q.#5?.3@V M,U]E8C$Q-C9E.3-C.#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,3-C-#$S.#!?-S$X,U\T,3@U7SDX-C-?96(Q,38V93DS8S@U+U=O'0O:'1M;#L@8VAA M'0^)S4@>65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)R9N8G-P.R9N8G-P.SQS<&%N M/CPO'0^)S$S('EE87)S/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0M86QI9VXZ(&IU M2`D M,S@@<&5R('-Q=6%R92!F;V]T(&]R("0V,RPP,#`@<&5R('EE87(L('!L=7,@ M8VAA2`Q/'-U<#YS=#PO3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q,V,T,3,X,%\W,3@S7S0Q.#5? M.3@V,U]E8C$Q-C9E.3-C.#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,3-C-#$S.#!?-S$X,U\T,3@U7SDX-C-?96(Q,38V93DS8S@U+U=O'0O:'1M;#L@ M8VAA2`M M($UA;F%G:6YG($-O;G-U;'1A;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@^2F%N+B`S,2P@,C`Q-#QB2`M($UA;F%G:6YG($-O M;G-U;'1A;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R M+B`R,"P@,C`Q-#QB2`P,2P@ M,C`Q-#QB2!"87EEB!%;&QE'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2P@9V5N971I8W,L(&EN9F5C=&EO=7,@9&ES96%S97,L M(&%N9"!$04-414Q,24=%3D-%)B,Q-3,[+CPO<#X\'0^)SQS<&%N/CPO M2`W+"`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htm IDEA: XBRL DOCUMENT v2.4.0.8

Equipment (Details) (USD $)

Jan. 31, 2014

Jan. 31, 2013

Net Book Value $ 6,241 $ 1,262

Computer

Cost 11,327

Accumulated Depreciation 5,086

Net Book Value $ 6,241 $ 1,262

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 24 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

Income Taxes (Schedule Of Deferred Income Tax Assets And Liabilities) (Details) (USD $)
12 Months Ended

Jan. 31, 2014

Jan. 31, 2013

Income Taxes Schedule Of Deferred Income Tax Assets And Liabilities Details

Net operating loss carried forward $ (4,413,308) $ (23,269)

Stock issued for services 4,205,688

Depreciation and amortization 70,769 815

Net deferred income tax asset $ (136,850) $ (22,454)

X

- Details

Name: imcle_DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetailsAbstract

Namespace Prefix: imcle_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible depreciation and amortization.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

+ Details

Name: us-gaap_IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

+ Details

Name: us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 25 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8

Intangible Assets (Details) (USD $)

Jan. 31, 2014

Jan. 31, 2013

Finite-Lived Intangible Assets [Line Items]

Less accumulated amortization $ 206,534

Total 19,793,466

Patents

Finite-Lived Intangible Assets [Line Items]

Finite lived intangible assets, gross 200,000

Research And Development

Finite-Lived Intangible Assets [Line Items]

Finite lived intangible assets, gross $ 19,800,000

X

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 26 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events (Details)
0 Months Ended

Jan. 31, 2014

Jun. 30, 2014

Subsequent Event

Common stock, shares issued 26,503,515 26,471,154

Common stock, shares outstanding 26,503,515 26,471,154

Subsequent event issuances and cancellation (32,361)

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: imcle_SubsequentEventIssuancesAndCancellationNet

Namespace Prefix: imcle_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 27 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary Of Significant Accounting Policies
12 Months Ended

Jan. 31, 2014

Accounting Policies [Abstract]

Summary of significant accounting policies
2. Summary of Significant Accounting Policies

A. Basis of Presentation

The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and are expressed in U.S. dollars.

The operating results of Immunoclin Limited (“IML”), acquired on December 13, 2013, were consolidated with the financial statements of the Company for the years ended January 31, 2014 and 2013. An independent valuation firm validated the purchase price for IML to be $20,000,000 consisting of $19,800,000 in intangibles-R&D, 654,992 in goodwill, and ($454,992) in net tangible assets acquired, which was confirmed by a third-party valuator assessment. A total of $654,992 in unimpaired goodwill remains at January 31, 2014.

The Company recorded adjustments of ($52,184) to additional paid-in capital and $507,176 to deficit for the year ended January 31, 2014 to reconcile the consolidated statement of stockholder’s equity (deficit) as a result of the acquisition of IML.

The Company’s fiscal year end was changed from February 28 to January 31 during 2014.



B. Use of Estimates

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the consolidated financial statements in the period they are determined.

C. Basic and Diluted Net Income (Loss) Per Share

Under ASC 260, "Earnings Per Share" ("EPS"), the Company provides for the calculation of basic and diluted earnings per share. Basic EPS includes no dilution and is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the years ended January 31, 2014 and 2013, basic and diluted loss per share are the same since the calculation of diluted per share amounts would result in an anti-dilutive calculation.

D. Cash and Cash Equivalents

The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

E. Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable consists principally of trade receivables, which are recorded at the invoiced amount, net of allowances for doubtful accounts and prompt payment discounts. Trade receivables do not bear interest. The allowance for doubtful accounts represents management’s estimate of the amount of probable credit losses in existing accounts receivable, as determined from a review of past due balances and other specific account data. Account balances are written off against the allowance when management determines the receivable is uncollectible. The Company does not have off-balance sheet credit exposure related to its customers.

F. Prepaid Expense

Prepaid expenses consist of $510,329 in prepaid stock-based compensation under management contracts. Prepaid stock-based compensation expense is amortized over the service periods pursuant to the agreements.

G. Long-Lived Assets

Under ASC Topic 360, “Property, Plant, and Equipment”, the Company is required to periodically evaluate the carrying value of long-lived assets to be held and used. ASC Topic 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.

The Company is adopting ASU update number 2012-02—Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment whereby the Company will first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, we conclude that it is not more than likely than not that the indefinite-lived intangible asset is impaired, then we are not required to take further action. If the Company concludes otherwise, then we will determine the fair value of the indefinite-lived intangible asset and perform the required quantitative impairment test by comparing the fair value with the carrying amount.

H. Fair Value Measurements

Under ASC Topic 820, the Company discloses the estimated fair values of financial instruments. The carrying amounts reported in the balance sheet for current assets and current liabilities qualifying as financial instruments are a reasonable estimate of fair value.

In accordance with the reporting requirements of ASC Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of those financial instruments (see Note 4). The estimated fair value of other current assets and current liabilities approximate their carrying amounts due to the relatively short maturity of these instruments. None of these instruments are held for trading purposes.

I. Goodwill and Intangible Assets

Under ASC Topic 350 “Intangibles-Goodwill and Other”, goodwill is not amortized to expense, but rather that it is assessed or tested for impairment at least annually. Impairment write-downs are charged to results of operations in the period in which the impairment is determined. If certain events occur which might indicate goodwill has been impaired, the goodwill is tested for impairment when such events occur. Other acquired intangible assets with finite lives, such as acquired R&D and patents, are required to be amortized over the estimated lives. These intangibles are generally amortized using the straight-line method over estimated useful lives.

The Company tests the carrying value of goodwill and indefinite life intangible assets for impairment at least once a year and more frequently if an event or circumstance indicates the asset may be impaired. An impairment loss is recognized if the amount of the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less selling expenses or its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows (cash generating units).

The Company did not record an impairment loss on goodwill for 2014.

J. Revenue Recognition

Revenues are recognized at the time clinical and laboratory services are completed and delivered pursuant to percentage of completion and/or milestone payments as per contracts with the Company’s customers.



K. Research and Development Expenses

Under ASC Topic 730 “Research and Development”, costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a product receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a product receives regulatory approval, any milestone payments will be recorded as Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, amortization of the payments will be on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.

L. Income Taxes

Under ASC Topic 740, “Income Taxes”, the Company in required to account for its income taxes through the establishment of a deferred tax asset or liability for the recognition of future deductible or taxable amounts and operating loss and tax credit carry forwards. Deferred tax expense or benefit is recognized as a result of timing differences between the recognition of assets and liabilities for book and tax purposes during the year.

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

Deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carry forwards. A valuation allowance is established to reduce that deferred tax asset if it is "more likely than not" that the related tax benefits will not be realized.

Unfiled Federal Tax Returns: For the years ending January 31, 2014 and 2013, the Company has not filed federal tax returns and may be subject to penalties. The Company estimates that the amount of penalties, if any, will not have a material effect on the results of operations, cash flows or financial position. No provisions have been made in the financial statements for such penalties, if any.

The Company is planning to have its accountants prepare and file overdue federal tax returns for the years ended January 31, 2014 and 2013 by Q4 of fiscal 2015.

M. Stock-Based Compensation

Under ASC Topic 718, ‘‘Compensation-Stock Compensation’’, the Company is required to measure all employee share-based payments, including grants of employee stock options, using a fair-value-based method and the recording of such expense in the statements of operations. The Company has adopted ASC Topic 718 (SFAS 123R) and recognizes stock-based compensation expense using the modified prospective method. As of January 31, 2014 and 2013, the Company has no employee stock options.

N. Comprehensive Loss

ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As of January 31, 2014 and 2013, the Company had foreign exchange translation adjustments of ($17,224) and ($10,094), respectively, which are included in other comprehensive income in the consolidated financial statements.

O. Recent Accounting Pronouncements

During the year ended January 31, 2014 and through June 30, 2014, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.

P. Reclassifications

For comparative purposes, certain prior period consolidated financial statements have been reclassified to conform with report classifications of the current year.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 28 0001517126-14-000195-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001517126-14-000195-xbrl.zip M4$L#!!0````(`&EOXD2OF^E*4WD``)&]!``2`!P`:6UC;&4M,C`Q-#`Q,S$N M>&UL550)``-U2+13=4BT4W5X"P`!!"4.```$.0$``.Q=Z7/C-K+__JK>_X#U M)EM)E27QT.%C9K8\/K+.>&9<]B3[]E,*(B$)&8K0`J1MY:]_#9"4*(F22=F4 M*!G9VD0F"72C^]<'[G?_?!IZZ(%P09G__L"L&P>(^`YSJ=]_?_#;?>WL_OSZ M^@#]\\/__@^"?][]K59#5Y1X[@FZ8$[MVN^Q4_0%#\D)^H7XA..`\5/T._9" M^81=48]P=,Z&(X\$!%Y$E$Y0LVYB5*OEJ/9WXKN,_W9W/:EV$`2CDT;C\?&Q M[K,'_,CX=U%W6+[J[EG('3*IBPX=[T?KPC+,IF':YA\/5OVI!RVXP`&\E8_A MK=&1_[*^F=9)LWUB-G-2"G`0B@DEX\F(_XF*OWOJR'\C4((O3IX$?7^0 M:MRC76>\W[`,PVS\W^>;>V=`AKA&?1%@WR$'22F/^M^SRIG'Q\<-]3;Y=.%+ M23RA83?DZRX6TYHE@RN^7^`$WKK!I$#ZXU8C>CGS*&O"B(154,\R:;2:?<]);RG*[`6^3#ZE@3 M%EWU3)0>E*5U9(2]2?A'L3O)?GW!X)*QW&`&DE=D"K%)ID18P*W\^M/!Q_`>LT6@*/9 M>=>8+SPEU\BD%U,;@0J8N\@%V!(/I-OY,&U.4M/TW4(Q\(Y)H;C=4_+N3)'D M^0P#R<-8I,OE?":^]B(:[9IM[)AL(T\5?)@V8$(B?O.J0@+M=78/@"DAQ0TH M54B[::6S2#++%I*]ZT*R-R"D6!%_Q''XCWNHC(BS6P@QA'/BW@?,^?Z9#+N$ M;TV04S=/^D.2DL#DE0O,/(T\ZM`@XA6Y%+Z,$O.X:2->WL MB8J##Y-/EK?^72.34)K)1C:7NV0L&@<5QD&I_B#.!:U4+KB;#G0F%[36R07M M#>2"UD[*-@5&:SM@G#BHO?9,E_\-@6\Y],-\^%/,>JU71?NE=HER9!\@IB'SWQX,%MJM\XZB>8>&3A6@ MLS,9AX;+]J/-)G(-'6&JI_=M#,!KO6]?[]O.+L]^^=X1`/L MO2D\K)2!SCJ+9IT:4E6&U,YDHQI&%8/1EK-4C8?JXF$;V:O&0W7QL/6LUG'" M8>B!#-UO'/L"?H&4SMP_0Q'(EKXMD.02ALYS"^>Y&F0[!;+=R7PUL*H.K&WG MPAHA.X20K63'&B$[A)!MY\MW),#4)^XEYC[U^^)-H2.[\3H?+IH/:Q!5"T0[ MD^]JX&P=.%O.9S4"JH2`;>2K&@%50L`FM@'.(^`*4Z[.X+CV1V$@;L@#\'9&A1SHMA74.19]SZ@ MI'?Y1)PPH`_D:Z]''<+W`R!W1`UCW4)?;JS&LK`CQ[+$QW'ZS=QZQ^7BT!W4 MM;!U17WL.Q1[&EO+Q:&QM1:VOH[D\7S0#=#86BX.C:VBV/J,?=PG^S/ULPZ@ MYF6@491SFPCDEH3+,8S1_@#HEC,04S"^]2`W/?/=2?,^CK^-1V1ARTB6#/8U MQYX]17!Z4E/8%>2_H1S/>M@;',PU:E'WF:W>KN;+.QHQCB2*AG6<1!*-@FJ@ M8":`Q#HJ'$#2X-E(`+GE1"C-[0=4ULD\YD2PYW$CXP`M#8"J`&!+1_MI,%0& M##NSU*A9LYH)AN!W:QF&)L^_L("(6SS&78]\#0:$Q[_W9#IY(U@KE#4-&`^^ M$3Z\(-V,G.D9=6R[^RWA51CW$H=5P;W&L\;0D@3,-&I6KDF+/YQ0!&P(T&)# M*@3C8VFU;Q=?+YK0*,*<=)G7D'SQ4+8P8D)=M'&2I8JM)HP*3"7/YDH:1NST M-'@U>%_122MH%772,Y@O*=!#\FU:">;AMYWG3/S)-_NYP*'L(_/+-L%*KK-0 M0"ML`1*19:!Q*P$*N``"X]Q M;=X!:M1L%S45B\515/%7-Z>C%S=5?W+Q+3D?CJ8)XJI#3 MT2N3*[4?BEJ]9UG2+@V4GDT#*N]X[--*.\V:C330/LTH: M6_4NL0:+>9=8U64OO&@E:YYMN4S6,-_*PJ+=7L?3*KP*.E9OR<&J$(1:K:;1 M.=)`VMZJV#0B-KYE75^"7I%+T"N^1R_/(,[\]49)@G0]'(8^'B8RBH3X0X#U\DDN;X+N MVT"R\K4G)3\W]+:H%.UWBT+>8B,5X*2<12V/2/-*8W"(FLXZEJ"X@ MS:.R`2F/L="`U(#,!4@)EK(!V=116P,R+R";&PC9SY]LK0&I`5G98]<^>X7X&0X\MB8D'O"'ZA#1&JUW\?Q?3B"2@F?V>FY#"S;-MGF.ML\FZ5M M\TSW0K69:C-]JV8ZW\FV2M^QWX0<,PF1K?2>V->UO:^^[OIH\\MO?A.\;#]0 MV@7/IXX-J>Q`6:*QFMI4M:GF-E6S"J&R5?8!`1&-=BI4YITL*6I]WQZ9MC]M M?[GM;X*7;8=*:1_KA,K.!D*E-E9MK&_:6!?"94G3M^EP::7"I56:!0[@A[9! M;8/Y;7"*F.V'3&N=D&EM(&1J@]4&JPUV/FQ:I8?-=LVPIXM,C&9)5GC%PGTY M!$0;X2:,<`J8;0=-:2%KK*4QFF4'36VNVERUNLMN;$KEATQMKMI8VP0E>*A`PJ[1?8ZU-<=I8M;'NI;%N:N??6E:W7_=$5\&4=OJNZNH! M=(]O&]Y5M%;SQN/J0/<-W"*X:]"MWDV&E43NC-/=S]N6=PVY,TZW\+)G?C:L>,>T$*GB>RR7M!-&*VCYA-W;VQ)&E0 M5YKOZ>4(ZP21%?)X8PF%1L8N(&,3R<;ZZV+TI%\51DBV.^E7\24D+\:XGC>L M'.`K-&^XK^C74X^50W_UIA[W%?QZ]K)RX*_@[.6^HU]/@%8#\MN>`*T@SD/H MWRN0"[G(5RP@$)\-P0$_0_9Y MT<_3S:HX>3\CA1PRO0TS1#G+V@A^YM?9)/Y@,4`Q)N](;W[<]0#)0NJ%A`UR MB4.'V!/O#XR##RWSN-5^UTA7E;=Z.T?U9KMC-M>LW\K#?M,XMK.K=PD]N6!. M.(S]Z@R)Y3>N`L]&[=.[QGSQ>:Z_L(`D]YJFC4WB M2S3T).B)3[WW!P$/R0%JS-<^%W/$-ZCVH\><[[E%^`\O.!TA$8P]B+-#S/O4 M/T'&*#CX1S\XE2\;(_7K[Z8=_RM=H`=43I`)WS=\QD%,Z!M$+8&^D$=TQX;8 M/XP>'*)[\,Z]4S2A<(HD>S7LT3[\^2?T%VEO'#^DOHSBDHVG"1M=^<,TZVC: M9,5.U&[%:+=*+./AZ/3O9MNH#$/586.BIU#^.!N-&/6#8:)0UH/,)QJ11-AW M$8N2=,5_.&F)UO4*AK[ZZ#/FS@"9ATC:^J%BY(+7T:9C9-D1%Y*?>D7D5#G%+5J'NI-+8[\0]J](ERO,==+PO_8#3J$_Y:#?H0"D M:^B<\5$=>2!AP&DPD`^&(^R/T0^F<0A=2_1`,<+PAG*W-I(]*S3"8X5MP'VJ M0"R$9OL43"D`Z_')&%T0,*X;_!B3H;[B`N*X"#3^T0#HSVAO MNEH#QH=2ZTKM6CO/AA6C@&IF#:NUOF&% M+@73$N@>NQ[AA^@7VNVBZ`O[*!+*F1#,H1!WH*4W-^=:D\LU>3;BU%OF(9]7 MI-72IK):P+^&/D'VC*5("?Y@-:/@DDAU!O"H.T;+U"`3-4$R&L,FJ99*2S^JE4#KK8ITPZ(0(EF(\.E-"9]!KAWIIQ8K?2W=`^0;>$]R1U MWTE2:4?^5E@_M@[MMHFB\5OHPH,=R-M7H0',^5X9;%=0XBIJQ*GO421PC(:$ MR)4J4H[2@WQDF,MQ$92LW(*DE@8#]2[TL4^'+!32\PC5(1]!2'B(XS=$AE`I M#$I;,@RI4*2T@MA(S27)B$0PJ'W:J5=LB`#W>@D+L1.KHTOY)3@LTJ="1B)W MIC*@A\@3X0X5@$*":6#F"5>:%B M'&C+Y4&]\8S8D@$J^6S$R0,%04-?8B+BI8(0=22'7RX89\%@C#YR#!V.\P%V MT:]LX`L&^,D>GIF/"S$D0%)WD#$S^.\%[LKNIE(9M(G(9:M+=2L5X"^YAJXZ^225YV/E>NW>@HP8FUL.4QPRA!^R%BE_5JD@;,;T^QVH`:Q&]*$*N M3)\<[#FAFBB5WW4A&[,/S;9Y>`R,*U1!IX3)4`YM)F`^2C309SDRC@^;Q\>' MB'$H4C?;"K41:>W-EC`T':B/DUS%B$00(O#I=&C0-M,FFF3"Q(_,2/D!^:(' M:11[E'X03\.[TIJ8CE!B]X%"\BM.*B*$RFEETO6S[/FN22+YV"."+3PR9?%I M8W(F)UJEAGJ5%J0#DPD#0Y\P.!Q;%OV:>1= M8[+2T*7#AB;$XW@\A-AC-IO2P8>@'H[8HK[0/6!I"\0."@GAI02J,Y]C%*FB<-R*2SKT&Y(5!V7AF4MYSUB!S,06<0!:&>CWA,>'YT*AY\ M$G+E954YW%<)FZRY'E=7.C:C1&T1G]IA;A";5GG@_%5.=4'HI]#W7![U`TYP M$&5M`;1#=6D5'PX\X]!X']0L0[X80P]J.(G\B[!-2+T62+*:I^([CCRL]+2K/&S4#X9J_!"PUE?K M#V7V.B0![H+'E7^IFGJAK];I@IQZC+D)C#/HKH?H>'SF67?<:J<1W7YE1$>1WB7L^\%D]RU@#LE]@J91&1#&KA5!.YYK*Y(?YP`$AT% M*AH'ST!.3Y0Y9AC]KVZUJ)_)>-EK=//1?U9O2DY(3O*)$7;`DN6J>/7W2*(X M_CO%;4W0OTC$\BGRJ$]J`T+[`VA%U(!3L!XW&,@OC!]/`?(<4%USF.?AD8"" MR:]3-*FMAEW)M*S!GSR'SD7@#)):#Z:<2Z9YPI&<6J(.]I+&=R%JL2&0Q<[W M/F=@4I(TXR>(][L_68;,/&TY&==J_3RM4Z[`5_6Z2;UQ&SKFC\N%>QVY%[6D M.0SD.1RN\H3*G\P/A2OY!^[S)$WCQRS5Y2IZ-,KZ7%``[)*,YD^(L9J+:H7>(^W.Z1F+(C<5C"9]XMB23R] M'7F-9^6RC$@132UH9V(A2:U=.5=15%'ZRU>Q[L>JEOI9+YN<2=%?, MQ'(ITJJW8H9_\^E*>TNG,<5U.:7S(FTFMM;LF(=F*PI>LF<]68L1)!.@D`S& MJ6LT1299<4E`^)#&ZQKDT@KXO\\0"Z+=&O`6JDISIOR=RK`A?78\!O0A,RW` M2';NF:W!A6UF&)Y-'9Y#>AY^D3&N4FF=ZXOK2U-[@RD[*K[]CSL?,K:HM:Z_GK=JQ791<^L"[I;5ED9OR=`5/ M1"&"LZ3F:EI.+.*I&+FK_V012]6TB,(K"AW9E;J%BZU`5U\3<7:[$VV?Y[;Z6(0\>R*PT0Q@1]B?RE+>9%5#\ M?^16]^=J6Z3Z;\A)/_GLT;\G6$"7R%4]#9Z;[!>6IKJDMD6ROS,O]`,(9`HA M^5LY2VZNEOG]S6<0@N&]N%,+VV2>\H4$+]S#;39MXW@:7E:1>"D[>?;=VTW[ M>$UVU)F3TP_%RV73Z31;4UZ6U_\R3M;<['[+R0A3]S):F_?"EK9,P[92Q.WZLI77>#Y2SUL;8ZWF\7&*=E)? M$3IKNH755>8ZK/TU6A:9];KRL\#A'AOVT;R;R$\EGRNRCHS.7Y8>X+O;!EI(%:@.`K\[HFY"Y"\HW-D7NA0#I&M\EE9N(`'.BSJ>+H<)FEL3%)KL;>V!)/L]G5.8S([G2.SLY@[KSZ1*3\/ M><#4;+4AE2S*`PB[1^!-='_U[VJF>%TA&(8QD\;.5[PF[?63]`(MFYXE23B@ MYFRV=)Y\H-S6K\/?2[T?J,]JJ\78)^C]!J2WJ>>0`[T$_1Z]//,_Y>S70P5&Z7_C*Q-.!Y,4V4DCC MA2BO\!YE"20U;)DGMII'5FGP7)^_%A#WD8M*WC\AS-*S#8L8SC$B0XK];U&;1ML]VT.IO0LN.$PVAGL#I7 M.5KD<:86&N4=F3"/.B5XUP5UOP*GG73R7IK:7\YHS6PU-Q&Q[DB`Y63Y)>8^ M]?LB#VNV99J;,.^U>#LZ;ELEI!GS*EZ'-],Z:EN==B&MIJ"D)AKDP"$G`WDZ M^@.Y]ATV)#=,R$F'K[UO^&G=Y'`>;@7)_G][;]K<-I(D#/\5A!][PXZ`V+Q% MM9^9"-FR>SUC6WI\S,3[:0,BBR*V08"-P[+FU[]Y5!4*($`")'A(YNYTMT01 MJ*RLS*R\RP!9P5,%,3DNH"(2ARVWEW?G7;K)L)1=A1N%=MZIASV[= M7WS0'Q9;\"6>I&IK5]ISI]>Y&-19V\#+C1->AYBA(":$HAL14HI&9408,PSR MJ2#M5KM=?!IEJS8$Z,9.H'UMAK-@+I-X%H0NIAY6PG99QLU%F_^O$+K\4EM" MM1EJ]P.YS-3?"I<@MGJ#SF`%0+S*%L`TBD(4>.W=PEMI?%"=Q+!M05V?JM;8 M81^6]J`^-+&E M1I6(B_Q%O'JM[2%;)O-C@6PSBBZ!OG,@O!XM]`TH:96@*M8EZD%43J/UHND5 M=[[',VL0.QM"O0D&FU+\*J&HLBY21_O;*R+V2$\[0=:.*$MY!M4M^\:)W/&E M/[ERO23.D?J*@HBJ-_]9I]4U;OXUJS<`;-<`MJXR>09ZRN;`?@[\0(UG9Y^U MS+C?"*=+:3+F%,72I;:":2WJ\FZ_P7G_?`.@/LCI#PVB9V0XZ'.OWV#UNH@P ML;!F]>LLAC"JT<3^SSK=BU&W?VZ,JBQ8:4-@ZJ+CK-/O=\SP3AU0)-X:P&H/:P!Q1<1"1QB@,)&_!!>0.4!#?(+X.7<`&CE>EL#5Q== M%[U.M[\A<+)+'H5ZWHMFR&C0O^B,3`T@N\0F(-1%R6AT/J@!PA_"!PKS`&.7 MD[GK4RUX[/YH\D+J#,_[0^.4UBS9`(1U<=;I]_J=X<807HE%*,;<;:D9A'4, MW<)\>]V5:R-BT!Y56_D+-E1(-N::=;KGJM?7WM2H.S0U2_7N_)K_IL9-8G+Y M`P[_3GQ.4&^^GI)"9RCB6ZO!I?;#.?#)T"##S0#:W;96([[4`]\9C$PAW3-P_=(3#[X^KZ\'`/#4FRW&:6ITQZ:U;35EV\6\/H,/`SM/C,!Z$\CO#R]&9E+Y9I#L;C^UE=YN M;S@8]?>^H688X:(WO.C4@+T1,&NKT9UNNSUH%,I\!X`FL(D"?Q60^36;@;(" M,M==S^7X3-=NA-S@&,TDU"KK-@5K?5NVJ41TY<#2^7T._#$(Z29]0NW! M(-_W(KO*AH#49LR+S'54`1#R8;)S_2K!":#<*(CB?_SQ^R#\JKK'-N(*R#MR M:X'0./P-L.LN<-A\.=2N`*Q7=C,\HJ-?M:O-JTXZG8N+_F/9Y49%%@'),60QCIME/L=' M_,GE'#M^_F#M,2#^\&7LZH;=GP/!Q?KW<<%BS<+ M=@,V\(WS0'V\OP67X[\2-Q2EO?6:P%L6;=77;A;J!M"&AP;+X']PJ1^.A^"P M$,@[N!J*M`PR=>=U`&@:^-K1EDZO/>@U`WL)P[SG]O1-\WFW72&Z5;!VLU#7 M=KGVNQ>9O+*-X?XB%I+3KJ=&H[>'*W&[J3Q8'^*NMV1=Y`R&O7,#-ZN6:P`; M8&;W%6CP\V"CMGN]WF;PPH&/A9A$"$Y#I[>".U:MMBUD];-]VIL!AI]]\$&! MI!;\2@B!+G<'.K0O-LXU7-MWEK0=W=C<5#=^9!? MOVG8=QP=VA!]>PL.;0M?O=A0YUA.?4>!H8N+BT>QP[T'A;:%>/V=ZF]#;2[E]CKH:LCK;<8C[$?\:>#!3+="P,48#^I(9)-9%-NDH90 M",UN][6OA*YM$+W_[*Y&H-W997!(>MG-A3&L<5T<[>X/EQW6"/P-7C)?Q$)J MU)-+?P(O=L,"\!NI<5PFFVJ+-PQW4V*T4&AFA#@D>[(B[QNB6;J48*Y^.;\Q$EB.]S(VE4:V,NJMM9P\0CWSN=VM>,' M(E1G++-&"LFVL/OVQK'Y\ZY9R;D;2`^'C_H5/^U,Z^C]X&.CSD8-M31:V\2H M$G#Y\02K[LJRJN+.J#.\-69TI,E4[CC8#61W]HG(;U_6@%:O"9L-=#[-_&;II.B61'YN1M'A>DM MW+O=WGE^0M5Q;>UPIO@FX#:C/&6''2P6[X?_=P+H=\[OSL2=RW3J7*B%8"6G8V;Y.2Z\!66.; MP;A4MS!&M:(9:?5RTT-MN3%O:6=4`]",SZMQ.+<=(WI,6]A8M.\.I"V4N_.+ MHT-PL_)\=W#N09:O@&O'TJ])<5+):MY5(LYJ,;[>.EZ&KN%M[235XL"[7AFK M/+[370GN9AO?1<>8DLT.-]MKS;+B6OO;2?^/Q[+]`W8!6<4.1X:@@S4#>30X M.F!/D$>$HP.V!GDT6#IDAY!'A*3#-0IY3$@Z5+^0@^-HEP5?*_78BKO;L*ZE MSN::+.+9VY;7YD!MYC'=X#@IUVZ#A+2L%[&IS<&&X!0U._=`_E4XS@TGBUYT M,V._M]EWZ@G"WB3%KB_RSS?2`7S0O[CHFC/:*RZ^:Z@;6%'\X(F_/9O" M0[];G?8B_LT/0H#3^N;.08!\%O?6EV#N^#9_8%OH9YR^MN9.>.?ZOUOMUQ:N M=N9X[AW\BMMPIP_R0]?'?@7PI<7/9_]U%[_&)6_QAT[+8LBM8&JEL/_7_^GT M7CO^Q`+E`#0#JL3';[Q)(A?[%.#SO]VJ-_VVH)_P&?[7#C?$X#OSQ>O_TQFV M][Y\"3Y3CR!@+%P$C$:"YB50BR4![I^_QB1!QW]0'XQ>O[*M*0`F0N_!N@&! M.WC&!7RQ\-TW%Q$J?IG99!%=)1;+U,*>'#IX\9*G!\ZYU_YR'7X3__ M=CS!?#A.*0JH8.:.9Y8;67YP#W#S@+[D'L61'H!N[$A8-O6=\,^.&. M]^_@[[=!#(^".9UNW;A"+\4R^#5\R#0+DCTF"=@\2R8(:0W&& MI9&E:UNX>7P+/7:+DV>L:.P*E'<:+/$3&Z^YD6"Q&`/>X2W`LF,7'HS@:4&/ M_Y4`T<4/)VY;<>NXZH<$?_@CP".!2V8L0I^@3/2EXA[B>GDLJ`3>XL9U4>"Y M$[P.")(I]SM#JL1;@?08:^8`W]P*X0,7B(6#@@P9T;H+9,8Q(I]H/]+R9;[P ML%-;/`-J-T7A/3+DF)4"$B&A`'C_(TA>.&0$:MUAXD8@><([_J-GC-*1-Y?$ MSSA(PHANL%NI7K2LRPA__X?CTS76ZY!H[ML96,!R@5?$`,(XN/-IVC=^'/*0 M+UO#@=]S2`+1?EF)`SDS=<=NC,L\[_0[=J=[8;'L!2FFU=[LU[KV:-BUSX<7 M+-PD'EAHPA[H2&TMH1FE#W@0U)$*",::)J3/N:1$D!@-Z$VH!;LB/9[@%K5E/@BX M`Z,(,3W![F1PJPGN\315_?-XR3N:CD>:"0C4*>`1)Z@$J3!GXIG""% M(H]8SIRFP11\F:"!!TQV(2Z()H(5#^6$VW060"8A"LS^@:"ZHT'*L.Q6SZXTH:K9JVG;BMG".'; MTKNAR:6^)O,YGCF0AG$(5GH*ECJ&,I".X^+2&\I=J09RI%IA'W_2O#\<7EY8QACK`C`906:/QQ[Q"_Z MWOK:@CO!\YPP.NGX*PY>3WA'$RKQI$H(!UW3(%9F=U!DI5OW(LS1F+1#A55X MFS.A$2B*V-!^Q^\_@)T76:B5399T3J(%7!&44A]M2JV^_7`\J?M-W7".OTHX MR$:5KG6DSS%["F!_>"O?,@S/NVV[W:9_:!WQ(S[RP1_(O+BX)JM"=BS/] MSKXP@GJCUU>V-1ST[8N++G[G#NQ=5,U937OYO,]_>H5_\T'?4&^0*KI&+2O) MK/.C?PD`P;V@KP"8"&WZ<'*VP$ZRP#7Q%%"%.`2.P(52F$6H#'%`U`<%T M=@HR((4YJ)NP=+R$XA,SK6`F1:M*@V3]W5!#`?9`XG@_:YW;G?(A?5<:-R0=E;$"V'FJ/KB>TARS#?IK7$"3R'P_^9R'">.IS0] M=.9YZ/H#?(3*'11$!@Y;*2M8>52BR@U@N.(>0.-%T#?O/6C`!>%9P0NWA`Y6 MTJ-33XP-M;\2R9"V1FOACP\$Q$3$`JC(%Y/C%(#'`)"2<6_92![3&5VY7J)\ M:EB?R6U0K)?8".65=0,T04DE)R&X#J#O\'MH77Y]:W6';=MZIG(:"!Z-QV?6 MRV?O;KX^>Y7UC'.T"V!2BATPT3CQM#?R5I_7A,_+$O+UR`D2R&%58Q!U*7^5A9D'-V54D(C2>Y):.\%O@\#?PC'^SI&I5UP%H0N?0XDC_!] M$09M(Q=](`5'JAZ&Y]C#PL]*\7Y/FY%J-OI3\'^Q>\8(^)%YVTGBK9-X5RV+ M.D]0@@S\0``98YY.TJV.83N6U5[R'O<\:P82`.Y\SP64XEVNN@!$K-/-,4R! M&AXQ7RB$!5(AGC%;XCP7J1J!ED&JD1OQ*!%VOEA8849VJ#RM$[VOH_=W+15G MB*PO8BP`<[?2"8`L<.EYP3TA&$7P%<;KIHFG'SD^;G@$%J3&=YC%M_041LIT M(>48^2!T)L+XLH[DLUZL@H_,&*[_(W#'6ONWR46(5HHZ2%8<)NHD'04,G#9! M`?H%J.R6'--%Y@M]H65]R\.A@JBWZ(=P93](#I\[&;I97BW$&9D1\7UJE.7= M',JNT,XCVA+^!D#>DKXQ#L7$C=6-#;>?^"F=KP/1C4S3D06*47("6'96+B%/L8[U@>=_"<"%Z7ZUW;$@?G8!Y#$)0X5`[ M(Z3T4^&DYX-.V^YU+Y"G%_*[Y'<&PL:8'9HE\"#KR`D95`8KH9LE=,8HM6[6 M/2PA0%O'X0F]TL;EG$_4SKFD25H?$<9_4.N(59:(HVJK3NRSEB3_:%D?`__N M["-8)J!><%;9L1'GT:$O]1A\"Q9P__2&;0[OI1%6-4+8MFB(,$<+]1SA-/B: M]2:XVCM*=T'&+RGM4X#W)FNHARFB0S9&ZEI>)/R)>DC\)1MAL9!^GZ\ MD:7&H?V-(#6D?'1'HEL6C8K\`'8;.=V11);,(I>H#`+#JESD2^4?QDR8L M:CBFL'DDMS]%G)X:/KB$4^3)*"I&-^,`,`6:`\(SY3Q'K42AQ\&*W+GK.22" M`5*!S+)WR&VETD8IEBW) M#5]#D)%C#E5](:N7B)-DTJ4;CI,Y^@^5!B_%@G+_@2(,2(.['EC!_5-X#\R_ MJ#YSP(=S0>0FF1O23`V9YNDJ^84"[L,4F'@*0,J-J+`*95"X\8/2:LJ@Q(P7 M2M^D9%0#2(2)`"4("Z%EJV\]N(P)"3+=`CZNBGS(F=;I-8`5+]8T"0G57/"" M>\P"(*Y#T&/F39I&$\R]4P12Q M&*(>CID$)2IYC@YPD02BI3DM1J43Y83HT4B<1Z#":QC_NV6]1_1R2[5/PD$3 M4B-1E#EHZ!5#])B9KTG30*:OA593E#3@5)H\0R_I%U%R@! M/J;!!IE8M?K(C'63V)[R^Z-B,$C.H*_%B0).8C>].^E&CH8!CXU0/BQERFHR M28/W4CCJY#&3K@:V]5Z?3-I^-\H:!"I8)&DM/1C2_'0A4&':`JNFDAC**8&M M=:HII""?$[*MH".17&Z8IKJYE/?!UKHN+XJ%KM*H5O%![K;`Q^J_(F;+^"XG.12R([$B7SF+11C\9"Z!Y^`]2WP\ MX5(M)@./+D./JD="5K^S`16LC\G(AL^!+PK_1/Q*9APIYZ%#<=]%$J(9!F!?@3$$,(,3]*&`UFR80"&JN9/@ M7F9#<0'EA+-O.<,*!43JUL@F,,%OJ>V?+JJ"`T9:$ZKJ8Q%2":"T.((QR!?Y M/%>;*9LH10O64E)U1L9(R*`MW;JI<6OW2Y1@1;6Q8DL:DCK=/Z_>R[`OFP`6 MF@!`,/0:)\UDMXS4>+8'N.^1+9T(J>$B\^_3D]4^W%0>TR*J6-!(P*>7&3F% M^AV)-N=`.CJ(/+!50&S.P10-Y!+IZY-(3!.NA.&5CH23CHZU31\&TE6D]9GE M^_?.9.S49H2SG(H"FLK1IV9+K(\$)93RIO%-9%E/0^ZY!&?N3F7`CXD8F=TT MTRW3CZ#LT[E#E9FI+^#2SSLV<+(5I@CEUC/5%')I1L+SE$M)!VD0K["V5)Y\)':P_51REE0.5%(L MNT%27-BFV_0N#))%&K;V@GLTVSUL$,'GIV5=*'02:,2)PZCAR))HEZ/`Z+P% M+9'>'*&Y<@Y2(N2Z*B.MYC@&`!2 M&N$_6M873L/&1!L4!CK5\J0'K@/HBTY@ESDO+$M9,A@I89F6+YYSBVUO`BRG M5[TW2?$":O<$Y:%24QJ\IU&!,..ZH'2-L23X3J;MTQ.R@//:=UB05^#X\NZ*/`Z/@+_XS^1L](V0P3/E=%J2.9IG,RM MVN;6>2]O;IF(M@PDFX86AO$B56.-F,=@(KIWT,4Q4:JW5BI<'?80\E$T@\!< M683!(G1%C-G5A@G`*LD4;AXR`8#'!&J&D7Q8K2-+AGQA-+)25I$'LL`G]00T M+*R;D^Z0-V(:D)\2EIXDXU@F85$-T1VZQ5"6D%<&5"!98*OBU5:RF(:!C"]K M\6!IT3#'[+G;!]"9V&'CAFC(A.3H89=8,52X,XFKEO5=KJ'>JE4C'3,G-Y?" M@5T&S/(C9-^H_+;T"6T4.N.9"\<-QW?-6G0>15)I6$83-5ECG`1@\?::8Y2C;SH22^#,L;T3HC9@WXISRY3*"/C`D[^T*IG"^! M3#V6LM;@+3>3D/:F1`:61=-YJ@PA"V&P`A7`7'!)DT(EF3/CAS&F*I+^*_!U MZ"=%?YX(C_F>.#K9JF#\V%*52C3C^_@`/?I+H+^4;)1!:%EJD9]QS:B4V:FT M(64)48ROT,T7I:<&N-^-9JK+. M5!/,-*&\66(^YZ=A'[/_/6ULP25-/JVF$F?)$L/LM MF)Y3=AN:[^80ENE(\HN%]\#Y%#_E MA48T+_VZ7$1FN'4QQA2+.?;J##EEQ"0/I4^-T\PTZ>MAMS3`'7NGHM;ZQYRQ M*+E>(946^CPRK+HL,.PU$L.Z-'K*I#4`KJYT8)FGP@&8%\?QA\D2V.A`9/'R MK"B'Z5F:%J2S_.%1*96D#L-E&ZK#XXEH5FD1"5^*4]!@)]9[@?8&4[@O#4*64Z&36W#IC/*&C8#XR<3M6>$=RN# M;>W'37]:65HA-4>\^RW0*;S@00CN`B"+DI23P98IR^@4PYOC+G1D-E?Z&($3 M<&<56^JB#H7PSB@V)U\I(]1I9QATM,A.=!RK5[5/TO^C!:U*6#8Z^F8N%>J[ MC%GG6,1C(M1Z^?7]Y5>KT^U]X5:+6K6*UI=@I9'V>0#JEBMT22IZIBC1E[=4 MUD1ZY:U:@K^3X%DG>#ZW").ZLSX!A!4C)Y&SMM8;F[QTV[:ED;F,27:FI+BT M4Q>(2%,D(\/#H=(]92=VN-(?5)1*OSIU8U"!+_PI\(71%JE(O9)=G^JQ%IE, M`G"!Z0G4A(X'9"R+TZ@S&PU:U>O[0QUXOAU''_=HF80F2;4!-1-&/CP^_B4WE_1Z9#UP;%V M3,`4\I?R@_XC\875:QN3$;"C@*`4F!^D@/L`9J;;G7DNU!9%U2L*"R[D-RWK MG0/!@Q M8HMSPK"@!)&09`W23$S)35)BP83G-A_`_:_(?;/S"XX\?I: M@-#OPT5G7).F'/'2*2)#SXO0A>_)G-[U30Q3WTBH3X0-"MD.DP/;K!/DYDWH M%F:RMH#@R(4"C+F1E>8_Y*=&8.$7U7T995\?_$421U>Z\:5^>+/A$?HP%O&S M8Z(_3TX[Z)67OZDP0HJ+`X[7>RQ\A$MN.UL#]&YVT>JBNE0#+SZL,OT;S.K0 MF0L<,40:.-OQ>%<916M@&V.5N_ZB;M+HY`M/9RY6)(&;DSF,=?# M(NL@>Z?1`II_YOZ%V6_4^\!P)F1!P!1?]?8[REK1:;^17NI!.?X2GU5S*J4- M.`V!4N1H)@,;VU2Q+_.I*3.#4NLX&&E$7S$Z]O(C)@-9'04;,<`K[7N0";[+ M0`2WF)LGPV.T>?FF7O9-O$'N"2?3A*5T,S*7T_TGRW65=,)J9(IL!1N-0_=6 M=["`C6)D1GKSCX`3CI$ULU/>Y*FGX8^3GK"^DE/Q.%*OYG,"A]U;\=BS(NCXZLR)A9R&2Q`HH665[%AHTOI'7C_'3G.'B6NK3QC)5E M0N+,=G_IFR;1R5`J?O\D*$O=5FCS4*EF1+FV:!,MS'FE&4:W4B9WU<$IGBYP MP)KZJ$Z>5!WA4LL5FTUH3Y-^8]HA1YHX<"-47FL.2G MC^:XKM]3\-EY0N@/Q<)SQJKI:J1KD+.?YLHOG"C3[8^_K<(D+-YX$B2F`>#P M<`0'JWB5&N13*$6W>;>2^%AUH6-C=CR=!5;L4!H(LQ1?&MH70MF%7)$B,OZK MS%@*GEL,WY29I+(TWJ7NT]1TG'-+26++.OY0S>J0WY*Y^=G.<%'+>L^=YS"Y MU;8<#V!4M0'I*&0*+46Z&MT43;+7U(++Q[#%!?77X?["U*\"B8L-"]F3DNJP ML.6ZSK\Q+I2T0U!6!/&\Q'165%#0\2YM8:#\_\5-A,;9(1[LCS)6+KG2'7,L M%=43H`U//#C58CWF9NT1]_6"K=\^\'5NKU,&ECJ19:9RRYJ$#'!.8>Y`/G<( MB\SU\T5/](Z0E7<'$/]_JSMP_4+85D8]>$[[6'C>`EMF^7=_>]9^1K]'"Y*J M]+N$\18+[<(S;"/O+"+QNZ5^>@VD,(EG"'_[Q;-T%5P@5$__$"&YFQ1XMT$< M!_/TVQ@8HBEC[VVY-;.>$7X=.6[ M]9Z5+F!B'?,>1/C:DLA2:[Z!2^I/7-FBD-VSO/?S"6RD^U0VTGO\&_F&K6-S MV_@M#FNQ)BP$+\96*_X$F3X(?[?"N]N7W7;?[O9&=G
+6*?:5,Z+=?O+96 M[LL3TV)4IA_B5WZWSEL7@R4$Y]7/@BFQZ1R3M/8W?8%9LUMZ\G(SO:*];$4$ MV?=W7JP[W@JXK"HHM=#>=M$0"YG-50>=LM*XZU=5SFJ34F,T MOULANRLP3_@Z"GR5RY_F9,H))4VC)"]&?R/'2L[?4NSY64I07>TTVKOGJ`(X M&^TIS1VNE06<3R'^PET*;IPP?OB&E4,\<:2Y!.*&7879[-\^YLISFP7:@65N M@7!UD&3?XXPUYLIAHE7U,&45'0"="'&L7T3Y;SRI^=VU#6#>@L)C?73NJ4N' M;3F3']AD8V(];ULOD5)>6\\'0WLX&KQ2^0O*)ZVGGV9F$N(--521*%\"@@UN^W&*W^W)PLH>K?@I;&D3KWL'>;S2>')NU^8%_IN:H$C@X M617>Q`)@(.`UJPV9=+D+7LW"R`Q?F9=Z-E0!W&&[#:0I>`$2))<;D M+:;YB@.[TQ\@1/]P[A9PWO\=>!.:@/XQGK1P)AE"(SN(2-P@>5/@!^&64.=* M@63BK9/9BR7W(6''Z-+#'&AGW-=;PI?;6A];>'%,1$Z%L)?Q2$?W MO->C-U$`)+S#D/+SCCUHGZN9N;JH27>=PW3G=-8$ON4,.P\@!T),//4W1`M7K\%R=[/E,XZ3.JNS5.,^W%F>_- MS++ANQQ/9,SUM2V$C"!RH[1U!6H6':8W)#,2,#H7BN<:Q:=!%/QZJA+F*82ZGR)K.<*?Z&(9 M`HMP@DU`Y&3CI&#/!`-E34R$'J]A?0Y^\!94=7(KQ0WP&3;B]:)`-86U4M9^ MC[6*7\]&B#X`V&#U3(6"_",UZ%"LF;[D2P+:0:??QTP)D.#4"J_R^VR9$\'R M7/=TQ9ZTA`\C8P)[H6!6([5*T4D0FK4IUUOA90DCK^2(A;0\@[=S&_A)I,8O MI!I'1101%&5HLAI"$>NQ9;.K%!38+M?5V\IT8A/.U9?TCF/D1 M=N`A=8KF\VP@..F4T.3%)%(U0PVS3RCM$T[U[LWU\ZRS&]9A9(9[0"UBWK"6?+U1@+:,H1S9U"R2B7A3%!L M)*"M*L+91,\J^4Q@-"]>UTO7[*8(C-U(UZJ;*Q6T:X6C54TPYB@639V\;-17 MSA;RT3JH;'QJJFG6_-N9O'Q(I64ZK%-*2N:-&S!<,5/5,UKSJ&^\6B$C&6Y7 M#71G;\E&VJM23BL+R%UHKZHV(2\@88.7]24D(V<#_=4LD=BU!MZKJ%YML(BW"T4EZ+I)BD>J7 M&80XMD"VZB,7.@7*>/)4Q-I,IWWV3Q[3[O'YTJ_+:CHRJ2)K<^L;"*WO@)4-W(HRXX!*JB4 MJP#<)0VJV4'"NZJ"L[`,SJI8!]=#:BPO>^-4^$&K+_&2CV97+H4X?[%I$45W M]*(17^U=G=4*P"YOB:].1?" M/7JJZ1XSU6PA,5947J>'EO62[D<1V1+D`M?KH>"NH+5L19^55MB"?NL6;1Y$ M%);1017,-G7[[6*M3=6ADJ*HO8FQ?#'47NW+W25LD6/U-L`9)6H^+_:4+9]4 M)IWFKAS`@/:[2Y.;<;;JF)JWR@1R615A&O$XF3/=8UH\5:/^*5\Z=25NXV,M MDUHW-F&`8T!Q+.D-5WT0:@Y2*_58'$S9)EJ1%=\'!$IA/42N$"*B2HADH0N( M,E41965`KRE2ACY052_$HTJRA4?:_96X\0.^\['*KV'+XDT< MG^!2(.:H?$\PKAE`["3Q+`AIUGH<DE,0QIEJ&WU[$1SS.$33U%?1P>8\5%`#+D$B1HE8>OIHL+; MB&((AD'GA8JHQ=34Y`=*0!QI"=04&25?.92F9-1R>=7_KZ0?+5I%2D#JH MSC&P2J'6Z=0%1%-]&J[%6<"`I+GP)]0)%1:C+JH+@:6I7.[(4]1UCA\:9!YO M\8-.`Z`O<-SQS8/GW.=#A1EV2'&O@L553N'$$;OEB(L"CL@=P0:BC\X8_EWE M\`B,PQ_@X]3O<$D:;9"+$A,\%"E>XI&B>MEMKC:F? M9"B#\1_F\\0/QA[.C7'G;HR-%QS?>N??>53Y"__\VT$):@A/.U=8^@U%]O6/ M3+DOB%N=_L@25X^Z2-M9+G545N?::1?P=S:9<67A<[>=YNNA!99-RK-509Z, M1Q(47)QGC&VFE"$0%R7"0,(%3RRCL&5=^M@#'&XF.AVC*3?>:?BKG'*)>P=D MPI)Z"BTFQN#:V'&>T_2-[:C&W3(O\WGGPA[)O[BXI&X=>O:%B;`W>GUE6\-! MW[ZXP*D[UET03#"?QI8CI_O\IU?X-^PJJM[`9JQL7"8I1K6-P$)D'+@)>U&6 M53QSP\D99V?P;KDAN(BBN>I+$BQ<'W&@1@,MMTE\''F+D.EM@?R=.V`A'F@:PC%)@N.60D;'@^%VS)XZ?@MYW915A4FB!`.M ML-P0P=9%]I&]LA5"3H,\G?:IO\53.O$M2U$*K_BM[O)G.,`P/L!X`6A MV;1`LNG5Y=MO[SY^_/#'N\]OWZD^C#T,!M)(##QNOO)DV`*O%+QR!^T7%-$( MHYF[R)''1Z`P/^+635^"![!/'XP:LXEN'*4REF9C.0WMZ[E MG!DET/_MA"'.J]FKW?!\JS-$"1A_.6Q=LGF``'XH#],1\KZ3[OVX-^'YOA*JE+ M@S%49Q4+:`H[5XZ!DEV>S`=$3:Y$T`@CLG9_JEP'.`J2U3R&BQMR4L<]\7.! MF@#>',(?RRX%4Z!8V&2WW9/SG-ST,.&E,@DBED.KY"0/"L M5BYG3R6^&L>%*RUD"OQ.9T0VT:K7>_3%%O4+*Y;+,YK/SBHH3BA9UJ0N$FRA M]1LEY*%+W/Q@15+7?L'JE8.U06I?T4GM^SB6^LD?Q:H;(+.QPI3!J*RTX7-. M:L;ZUJU2,3%JOO9CDW?E7Y8>QU>YWQ[T%X](;P,1W:_-VH8)PV1 M>#/Y[<_8,G+B),8\)M06UF_W":>$]_J;@%Z&D!]GI#>W18-,:GT>PP6[7[@\VN'(?@X:ZFB+_I;-D'$SIPFDUO[3BM3&I M-S.*\@EC=E,>.^IRT=/U^ZOM]?@$/'K8)LN*[R\M;%1^R?HYGR?I_B007L"6 M3Z1DO'*0EGK'3D'\4$+=?!'X.M,RF*82P@AP.C+5V)]8GNOH%HH%,4SZSM(P M04S,P>Z=5`T0[;(1G!&[/(4I#QO\.L4BC^HX3K'(2K'(\LX^GY>R5_*Y*^MO MKT<3E>O;_4[/[K6;#LP]W9W>-$P3O9E*1R\?=#1VFJ_TEX/(G&K2]FO M9H6V.=?BZ,^K;W?;`WLXJB`RGPAI-F;$/18WRHH.NF(1BK$K/>18MC0/`+;_ M.'MH6'S/"DU$3OJ#`[B+GE:/14?U^7]*^WUD4C^C%<][S/[ MI074YND`Y5*J@C'YE#':?&QTG26:=XX7.VR72KL*W*YI3=JJTK)\&=I-B#Z7 M^.'&<_SXTI]@#=L"BS&?3%F:7O26;G7NU4=;)$AN#P=3F6[_]+SHRP[B6I-5 M#"?H7A74S4:5O`VB75],&\Y0&8^3><)MB$V#ZBB!Q7O_31#\:?V+JM+S@;!' M"'/OX(K_#KRYW?PDG%1O?X&T`3 MIEH=\VNY@XCJ5WA)^4-/U&*[P&8A:J?699I3>126V].TUYI/L]F55KZ9H^?P MUD0C2)+MX&!E(UN=U_8:S8? MJ"'(#A24VTUDQ&"A+R(2-,8<]:B)^"&\(/5K[MV'WU"T*^WJ7!^$XXUI'VEB MR*,(5V_+)A]%A&V\4]_G*7=$Q[O:0WO0;(^+7SN"^$08M'*NJX*JVQJLY,%M MY"^]NQD)O/F`S0MLM&CWAQ7\E.O/<+,='2->=D_OZW9Y#+Z[`WKQ#->((ZO( M0F&X\JB_,S5V)F`"GUQ=$]E14XW?`-RON"-;UJ7Q&[H*:WO>M,N-H"ATNTGP M7W9ZL@$I9B>CW]'SQ#A.<,P5?>.5Z19\1#_MG32T!RT'Q)[\9EL.YUEN/J^' M5[I^E4;VU'46YY!*.E,M\9FPLO-YX"M+/?F5B[EBR_3RMOQ/?#S"EN=LS.HQ M9_BH0\9)0,;4I,VF"UEK)@O)H][3="$MJ)B.?(_?,)A"Z[>YH=Q&E"E&A?"`)D#=W8PK!7?H3'/4" MF\!VW^+IQ)36D7*GW;(,/.@P9P8;APL['2AQB$1L66+A18"+3=B;"^ MB/%,@+#'7R*I-Q:925'+]<:HQ_HXT<@!/1BO"V+K M[SYHJ6&$H,!]<.-B!CI)]D\`"JR=8&VR]?+[S:>WKXI'X5F@'`.PH!ET&`)C MPB>%QOU82B5>WA=W05AN\T@K!E?21`QRG%>Y5?7Q$XI&6ACTL'!?V*.;N MF>/[H*##]T!VJA@5Y:]$"1&@3(B4OW$3"YH%7_J=HYD%\[@X3$*)4P2E+L&3 M*X4U$\X$Z8#F$YL$2'.,>SVL%;QQ0AZ^GE^,Q#NV`)V\"SQT_\+^WU`;VQ[LN_G#9 MLF@W),C!NH-OIY8<`;5CX M.-80C!>^Q1T@IG!"5S@;TYJXT$2#]RY0B08:Q1$PJ$*/QV(A-0":#^/3O8K- MWN%[+Y6T.W_]_2O!\\?EY8WZ\0O^M[ZVK(FF"\3GL39 MJH-/N[$`\A(O[6%5H.H89P$FMG$&MK9S\:(I\`S0]/$,C1%IT'AK16S6$J$1 M*(K8U'AE-LJ*9VCK,>7-N1#8H#S$@.(E%P*!LNF`8L#(8YDQ_'B92=$J.B?` M.F'G%V?H:;I^^7S0M3NC_BN:D3B9D,L+8$)%&UZJE\.T.WI-18(*:7T3=G&_%[;'K@U24(413G6 M3/7#:AI>7B_\'HGKZ3L9SXD>A?[WIF4!U$B$&NZ3ZE>%)EEW4S$2[29?U@;- M"]JE*?<@B^8H(N@R+]#HBE6_4-"%%IE#J6EV^9]I##%USL$5ELSET$X:5^A, MIV(J4]-F4KI6)-HIX6JZTE^*2YQB,.!-071*FA1A2"Q;! M&(H?PD\D5-(/'2E63A\BO,'I!A,Y\I!#I%)1`Q@2;R(',*KYBT%DX+"5LH*5 M1R5JS`"&*^X!-%X$TT;P]"3@@O"LX`4A#X\Q.NC1*49L4ZV]$LF0LD5KX8\/ M!,1$8&F(ZVSGR3;.H"^D[?U\NM;JSMLV]8S12D$C\;C,^OELW(*`^F?,#Q/&=L/R$C#%C-KB,?J=3CUD)D7N5$D>1(FU`LGO$7P@P]H[4YH?@^^('EG+OZQAZ=L%9$+K2:>:.G'(? M.7,AO?4%1ZH>AN?8Z\'/2IE]3YN1JB_Z./!_L7O&"/B1>5NA&%LCJ):B=4XT M0W<>_`>KQ<">0Q'Z&*7;5V MYP)*\3*.XC#A^Y:4,K@UD2L?F-%"(3@(P"Q(^6"LV\#]2KH--HTDUQWG3XSQ MZ$1Z6L=LW!D^\2KNMT`ZK-ZT>.CVG5OG*$<4PP:GR' M67Q+AV*D3"2.L0*[ALY$&%^.5`X1Z]_L85+\Z_H_`G>LK0R;Y\1/TT%3K,M, MU$DZ"A@X;0X-`Z$N8FOA/)`]AF82?:%E?"$.F&/P\9.AFZ6 M5PNQPCLB\90:?WEOB+)?M(^)MD2IK&%PRT6WH9BXL5(B7$SFD3Y99QG+-CJN M4C.#325'6C_T6B>"'2<"=`F/<*7Y@"-[T4*,<=B#>CE:@HYF(/T4'X6R2P20@I3+F M4`RL>2:!`=U'``5(/(&)R2:ORL,%Z>ZB!0D$"SIF)D1BUJTW)!&7BMK)X8R; MOPZOW`A@<[SKZH[+S1\O"79S1-LPR]F.20T>GX*2FVK=@ M`5S6`X.-8='A)M5"P;:HB0*'3M(>;SH2E37C7.UK(HK/>#D$QTB4+1"&#R@] M=*JOA\>(*>S2A\_.(5:*9L+C?A=)A/TK,H"GSBU7$[D24_RTEMR!;ZRBW$^) MC%_*L!PE"8&\8%'@(_"4W8R:6OI^E#M2KFKO3>(K$8[=+E"-F^+<&*,O!H/# M7CMI>[+_R$EK#$A%!'/.U^$X_F,JLE/<25L).SFP!8A.+CPJ-LCH,&3.Y@2M M-D:!(>`!`+[@,DNF$4RRBL]5<" MV\>D%+BJI\Z8&)D">Y+<\#4$&7E$4*$1>),#R1`GL0]W[(9CN)/C5$^18D'Y M75SJ\S,/D'O=/S&OC_@7E01VGW-@7&Z2N<'-%1CA&U14&/AY"DP\Q68YO!'E MI*9P,MB6*F.@#$H,_^/U33XP$TB$B0`E"`NA9=UV/;B,"0DRW0(^KHI\B.\R MKX$8XPS3)"14PS%0Q<&';&:+@C9B#?#>C43Z4CK9]-0HB0'6)1`RHF@]X(@K MD/081Y'*GX03:`5=8DPLAJB/L3;F]H$\AHX.%^0*P'1N14Z(%FIYFRAC>87N M/;R!VB%^$@[JF?BVQYM)]M\M"SDA!.)7<"+D]H?)*X6"Z*J3:7F#=L)Y?O)V7D1#69X#'ZG-- M1<8G,\FA4*8^5^,KH]P``8/W+/$Q>F$D&LA7`5<0Z`31#`B"X,CZLP76*)BR MX7-:"YK]$_$K&6ZDCH<.A=@628B*?['[H_*EEK\-E:YYZ4_RA5J/\3K\T+), M[9EUW\)F?:>;L8Z78]#..3D,P^5LV5XQG1PZ45,JT6D58MJ=T[9N$U!\'6E1 M:*6;=7@T=D/2)ME"-?1G=BG$5!Z"&BI7_8"*;-@[(>JTD^#>7^H-JI)34#:D M/HQL[@?\EAKZZ:+*WVEDA*!>/A9A[*"+E\V+8`RB13X_QU"WI0R@%"U8FT%Y MZ1F+((.V=.NF>JU]+5$"KS=7;$FK42NWCN3L5,#$?FBT#JI#DC%%\$YG1 M4R0@KO=RIS*&P41,!4F&36Z93@-EC,Z=!_2&I8;_I9_W8N:\>&X^0*-?ME2C M5N+.VZ2/%KDJ+-!+G!?=HHWO8JH_/3\NZ M4.C\N8AS+E&Y<9&8W*G+@2WTU(*"2+[:E_2;]-`B!`F02O3JQ(<5^'#B3O!J M)%#8Y4Z>KQPY!VDY!AU5:1IU=9TNKPU^X5S/+\PU>!T^1B7P'RU+;L0R=J(/ M^J3ZK0+HBT[WE9%[%I]F;C'EWV"Q%8:GV!I-*]G5^%;6M8#`/1'+ENM8`@\R M$A/7DA!3=V(9Z<()/)C]QVE_^(2QX+=4OLPGW.04&NTJ[G+YCPA<4;F"^4G8-D#:L3;I1 M&&+-C_1EO!'3@)R,L/0D&<N[7$.]U2@.D"%N\E$I M'-AEP"P_0A:*2KI)G]!FG3.>N7#<<'S7K`?G422O_64T6:@;%,!`&H`9G8>E M/IB*V9)J;J_NIX>;Y4-)?!E%-X)K1H@9\$_).YFX')D#=O:%4KU>`IE:.V3M MN5LNA)<6HT2&:K/FW(5"%MT`#%:@XHT+KN=0J"2#9/PPQOPITF`%O@Z=G.B, M$V&)V%\KQ975 M5ETZ0I8,7##0[F;*=P+<[$8S5?KJI'-GX=MIA@OE1TO7=5I['J;J#(5YDCBA M"B9D&!(-^#WGIV&QLC,\+;+G4@Z?5E/9>60;XQKW3CB)6E)E2*'2G.:ZE0P)AZEL7W0DK6W"Y61$!PW[XW$L"Z-_A9IHK&KTZE9YBD'/::E<41@L@0VNO18O#PK M2B%ZEF;EZ%1B>%1*):F3<&XXQL9YPM>1G-'1$0TNF?"E.`6-=&*]%]BLECWN MEQBE=&-GZZAD;J0J^;J?TP2HOEB8;S%?&G8(B1N1X377TY`Y&5QL8G9B9'CTB3]6GEO45 M&[^N4GL&62,/JU\+*X"QV9394^1N`$W!G"ENHG]T`_HP"9?*4, M$Z>=+=!7(AMA<X]0SUC,\\:R&1.AULNO[R^_6IUN M[PMW>M/:5,1@2]#&!BXU&&FX>QZ`AN4*7>J&SB5*K>4M@09%&*EUD9;@KU#6 M;"!#"AHX@^2
R2\-2([7.N=WM]E_)/GJ=MMV^Z+^R47N4 M[.T]F$WSN!,%^?>YQBJ6;5N-K6:MZ+5-;0J9?1VGYCD;Z,1HSQ4&/OPXYO<_ MWB3ZZQ;5E8,ED.Z-SB*[P1/?KW4M9#UMK`,3,(5\I;R=U'J[U^:_V)Q]PFTX M(W3D`[`^@)EIT&6>"S6"4$6!PH([^$W+>N<`%ZGL6G65&@]1``P=4^Z8ZZYU MP`:S8&2X0EWSV7*IEO7)J(A65,FOR,?#Y#?%Y%O`34Z\#Z'T0RA(N MKO!2?G7IXY"1X47HPO=DTNSZ!FNIJR/4)\+&@FS5QW%GOO2M/+&IQG:EBE7]BV_BK.D'M?M];Z%/<1I]H$,7AX?33^"EB<*ASJ]0O8Z M4>;@\P$H;;WNA>7*%N(X:Z+,JN.\!*-QALY32@]KK4F("?`J'9JA4&G5,LE* MLEN4R:>B^T>%S8NE_PJ*7W(HC6=BDGCB>JI+3/@)L`0_IC$A678RN?:_8&LU MU`*HF>LWO%NW9*8NE4#- M7%!NPO'LP2Z[T%6\TYR;B(I+@:62<5(0(*A*@.FOWE'T5&^7WF)C0&4A8BM> M=S$G&PO/DZ,X__:L_8Q^CT`=4K]+:.5(7&Q"XRPB\;NE?GIMJ8'L[?:+=)(L M+;!F(.VJN;.(G;,(.)11M'HN:.EC6\X)AST"*OR_/>L]*UW`Q#^:.B)D7QZ+\Q0VTGTJ&^D]_HU\PY8,N6TT.*UM7)? ME>>\G[VEBQ+D2H"_6'6\% M7%85E%IH;[OH)B.BRW9?2`9-;_ETC*=CW.LQ/M_GZ17/KS^=U.FDED^J":7@ MWS,W%C44^177.NDM*ZVJ?E7EK#8I-4;SNQ6RNP+SA*^CP%>Y_&E.IIQ0TC1* M\F+T-W*LY/PMQ3Z@>F,^&_49ECLDOW!2[PU.D?N&H7?NC_>4?8[5XZO9=`5= M*19GG)8J+9H'\97YHW_?X>9KNP!-EU_>)5C&)EAF=C:C42._6PQ@QANH5:4B MKZ%^VQFG=.`;?/UY'(IX/%-O+7,K%CE(ZKL:<_K<;8%+1;*$13RQ7K0UH=Q6 M@.I&ICOO&*`"5U4%X"XI!7R';B@+_5!614=4#ZFQW._$NNB@U9=XN0I;UE40 M!O'LP7H3.A6.7*YS_F)3*Z8[>E$.S]MWU[_A/&-J$[('8#H%V%J^CE?O9_BB M[$KNJSFJV\.S4]OF?IUM4YV@_M&ROHYA(>M3XH=!^;[KGEQ-CY=Z( M)AP1U7P%RV/6>)(+S7&Y]"=ZB,LC]RZ)S"JK#.(X$YGR=T,,]&3=-XM]Y*D M%]9;GDX<1KNRV5<#=DA/1J?'W5UA9$\Z\'H=MCS"EN\>#(^KWL)-!-E.6NT&6FUU#?;06NMF?H?# MZUR-P'TT>M=@5):5E?5*<)T&Q^MXSD-EP5>RPB%E>OX=AE^V@9!.H]O=%_8V M>56AZK8&*WEP&_E+ M[VY&`F\>HBI,G-WT##?;T3'B9??TOFZ7*ST<15&ZROZ&I9G.-(B`9D#GWX'N M<=,[<1E=3PV/!(VIHC]\_WKU#%2UL0O&=X0^@+]W+H"P@*Z,,9LKU]D>JEXQ M5#\C]W??]>!,PD0\LWYK;/O_(]_P/SI1^X._2.*(:HP[GP0.K3\.8+K'!$RO M&)A&B><=-1G63=F^.3^_@(;T-L".30EPX74ZL+*B\RV%]B8)A0GNA\_OG_V] MW>KU4V"K+]\LX%T#\&5NV"G@JB\Z/,*G\B_5I_Q2MRDO)ICA6:^]DAC..KWA M:-!.H:RP5D/@E8B4+'C=;G_0;Q:Z05//0&1!]F(JYMA=?B9QZ?!"RX-8ZKTY;O:W*`],F1?4]`N M8<%X:%E_J"\9E_OM4"L!(U-X*4]`(LO[:JT/B@-^H/NYOB M[UK-EL"^NV]QDH0:)-&8*"Y?8CM@-A&\U6$!AH+#-\OIW@!@0%G65!Q_[" M!;<'KX*,6^X5_)Y[(',ON;&96HEGF/9#3E\-%_?UE`89 MA/2'.`[=VX3,PF_!C1/FKZ1-3Z-S#N>1;WFWIPT<'?9J$TNGW;XX%NRE_H&O MR6W$4\/?T;3[X\H_**G91?$6^#SN@`>A^6,0?HZ>24R;WV61;=T^?+]F"D5C M$??S?*#31/,';E5-<[.2F+K<4TO[M6U$5H=6VYMG4(W*0^5#>]#NV8/.8(\Y M4#L/YVIN+7/?IU+&PL'0,;47=_2XLS'^Z'D'"E'5B"#UNG9O6"&A;\,`TL$# MCJ4'F?JEO_ON2GXS^\X?PLN?X;7^>=5E[<['<(G].PC_ M!#C>.@LW=KPK,77'[N;N]WZGT[WXO[^M>/6RF^@V_N##-9"@KG$EHG'HBXBC MPP":B8#[>E+8F[ET"UOM%?;7/^OVU5[AYT'97O7G.`D"Y(`90_1Q5P MZ&H M:0C,TPC52$XJ)(#<9HL;F^]FN^16DMN5+B:]W9Q@S+'0QP!'9#$"-CWL)D_9 M/)QBYTHS%+W&H6JX`TV(ZD-;B_0&@W[[?+3ZRCD?#2H"E\7Y)R=.0C=^N`)Y M=V02Y,J\ZZ[W)DP.C86^*".,1 MWU5E+T4;>!OX8+*@#YI_BC'8H1[F%E&=)MR2H^&@?9X%LLK238)XU&E):X?+I'_%.+L&&0P9SO!O'A==)4Z?"KD;#_K!_Q!M+@[^% M/N'-4GMV!>T7@?.LQ.2=$^)XZ)(@YXZA:UQ&K@S5#SK]P:')!^121PDE_+F7 M7HFS((R_B7"."^2V78_[1X-VN[WY1MD1@9"`_OF.!NK2M]2PI;H;NW)#,8Z# ML,)-SN.;,Z.=;`N[_V'7/QP4I1MV@EU-TT7;;9P.Q9>]GJ$Z=4.P+.(9O$*J M`=;+*S&F]7G**5G4R@_-C411KV`58!O]>IKEZ$QC M@IZG/;@509(4[9L&<\'G/"_N5EB?@Q^\!>7+:Z6X MB68X=1HH(,#8B\`!=AW5T\9ZCX/FOIZ-$'U&D$:"9:[;-F.E=TA:@XV*.RRPZMNULJA(IS]Y=[Y<6C*"V2'>B9E5NY#?PDDG]S]`54CB("8_VVFD11QM)?QX.[ MXE6RS'1Z1L8RJ\^XGT+=6.]`O-L9E*QR#+QKHF@;!K>;[F MRB,85G+>/JX\@F*=9O"TK[QTR/4V_,HM0$\J:C'#2NR<;KGC9Q7R$W2[J<^@ MVU,^>;KDOHY=W#=<<*MN.9G%A:D:-=*W.EWX_KH,KI0%+W,VHO"]F1-%#FOO M?'5^3,3]3D0+'-)R>K9)[;Y^>CY3<1%+4X$/Y>S(%6 MLKSI5F[3%M8/6O"<;Z7=3!&$VG0'?UBB_*79RRD1(1(0)?JKEQ-@C4DR-V#= MA'IU>@8">1.Z984_.3<*D)6(+F]"64IC.$WT=][]%.,$BZ>R))SQJ?P/G.?_ MT-(%E5@=(U<\!6\[P'-NDJK`=%NFKZV*U0>:^YKT!13#8&O=K2O]T%25_H.6L.FMM7=%6.]A[OE<-NJG!53=UM? MW9\[VE56N?Y7@,M^P1SOVE6W*[3UE7Z8;VC":^.%WV)=6@OU'FF3SQPP_0:= M%\K"B6FF[8\@IEPQ=$;02V:!A^;5W(FQI389-$.@M]]Z^*".2)6MPD]'\/@# M_/.GL-"&&%:'O2>F`V.7`J$QN610L0;,10+`2.V.46OJ1NA6Z;9E7[#<7JI#6+G_`7QWFG@?W6G53:WM M&?#WF\'_5Z'G0;IP63$E[(@`B`&6 MO6/.R+R&..,YC3%K62@@/%K:C3AZ$HFY>^;X?@)L3SX.Y5NEVJ$H(2J3TR7D M;\2:5#U3_IU"=EMQ>/ES-G,=2^Z(;G7]JR!S[J6&E_^?`%^1?%.(K M.U(CHW;;8,KK*3UR':JO?6&W\:3$0]XW/.2[-V)77:#7OG6Y"%VX+7M%$Y$Q MS(%U@59\'YR14WFNO504O>$5C?C'O1O/R+.,/N_`^J?C1NAY#DBZ`N*PII`B M'*"O!"'YNN>!)\:)!R^_=0,ON'NPK3OA"U!@X-9P?6I4%8#@GL"KX'@B#F1= M7;[]]N[CQP]_O/O\]IWJXM[.-J#DD^OKK#?.@^`\B&42L4K(PQ=)2#*&R(I&6?X* M$F-PUC5H8R^.JPK4T=T->?Q#./C^T'5\-R\JLC=/'`I'6A4Q&@7T7AR"AR-T M?4`M7CO10Q2+N;Y]?BW"&8*VFU9@[<,SN(9NR)SJ[X1N/MP'OF/]^^$V=/CB MZ'7[KZ,_G53$8.'U>A&3P-9!@0GFI,#,1>S<@LC!WXAVIHD_ELD=8*D6E[<_ M.2KJME,JVHN&,^".*Y+.06Z[J^NZFY8`;JY MK[L*X:A,E<8(Y[^%Z__'>N=Y(KP-`\J1)-*IIM,\/K)Y:V1378;P5L;2FX?T M*S>)CMG/"1[-]93^&ETF\2P(W?_D:&8C=T)IT@P'!Y9#U^V<)ZGQ/3T" MI%5+[CEA-[.Q-PJK-TV$/$Y M<#)KU`:@MAC/'>3*U8OUCV;4@=[P8GC>6:?K;`Y1`]?]5MO/:M)5`!@5Y=E;)_2"OWB3DP&6S6(^-HD7O$#%>C-'L' MZ%W;'8EM7&YHWVC;MA(KO8^Y636Z-V7@V\7NFF]9M8^=E\]SVCS9=_V,J+_? M='I&WF\5(`I9YS9/MGE/"U5!$W:OR8F/F<41:`'AV(TX:?\+.G&NTV;P_+WH MWS210DPN`9O`7)E'WH@[UT?-]XWC8?O_S@X=]+4K$8X$)4_[N)JH^SV=W7[/ MKEY0XG1VQW1VM=6ST]D=W=EM7/=__`?&K3IP-O0G)_Q3Q#0A^GIJK!_]$3I^ MO#*>M:9@8M2^Z%_H^2=5UFH4N@;TF'PGZ?R3;JV7Y;[TG&=6-;D1XO5QAN4^[I]?J#-4^EJ#:.=!-:/^'V4&3.O`1 MG,&6FN!A=["Q/E0);*4NO4DBUQ=1!,K2+6`K9A<1=>ZC7RB$RK%\K+:.'S[( MB4/2873I3_"'I:K&C-NKFW%[U>F?5.R<--2]!N&O@)HO8AS<^:A`?I@P']$9C8C7\+9F;;JN2,=5;HZ9S,5J/FB;@WP^:^,M4`/YMYOB86DN- M^7:#O+/^`)3G[JYQ5[*IZC[7""]ENHZOW&CL!5$2EA43KX_M7IQ?]/K#814W M:]&Z.X,Z]1.KQS[X"S#$/HH?PBOLWK0^1KP?X+K'#%RODA#9&TW\$>93)4KV MLJ(17.'M4`EV6KT):)2L$J]^^,0Z*L!_1;(-%+$+NOU*B"M9>3>P;YI/H^?XOIM218U*O_KF_/P"ZW[)#*7_ MAK>@'O"[63.CS8?5%W;,D1^Z/M[3\*7%S[39%?:K!EO`H5JD^2+PD5M5.^J) M:DCETGZMV/EI.81U*B3RTJO=OUITQ+.4U4#E M!G!A-!(J&N9`#E^W<6$3RH?GIMZ;>=.929B6_P]>=Q*.+Q3+TU'?%= M96QXT4#PJE.W*T_GAHT`ROR_/>MI_)B$B+73(+'P29,@\.';T/J-1G@CQ9@? M/#\6L'KE8&TPQ?T8CB,=G'Y,JVZ`3&`I9_SG71@D_@39*@AAF;O;E]TVEH+W M1O"OP>!5$R5_#D8OLJ(S.QD>?X,OM?IR+OQG$5N!^W1]I"]>D)HZ?;L[O"B M89PTQ`/W,U"75I%]&6$W*@\*9,!&A[&YZ-H:A*>]UX-(W.I2E@(LEDM^2:IH MEV,KHJ,_K[[=;0_LX:B"R'PBI#GHF.\Z:G)=*QS+*91?"L)\L8)LK\0B!'.8 MS5#J"F38I>L14K#6UC)`FQ[JI;<>H`5?;46!YTZVIX5**YRW[?,J5V:E`Z@- M\Q-&[*@SV#U6#W);G!25TUX?C>1'L[#49_9+"ZB7G=[0'@W:34JI"L;D4\9H MMVOW!_V=(;2`Y7XC_RA^9*27;N$<+W>T7TDF@I=(+W\FD-R$CUV[B15)>#MS M1-=URAN2XU;X8NK&!,W$!0QC;R_8(D^7G(-PHW&9-"R`YE,ZBX7WH*91?O]J M305F?GCF.T,'YU1,K5[_!;8.\T%HD0?K5H"-9:XNHI9U:;KV"8Q>87N\F3.Q M_,!*_#%(8\?U::5%$%%OAZBU0^Q6FA=P\OVOE`N&(_P4%CB%!8YJU8.8':O" M`EK5,Z4FBG3B) M`Y!\J"W\THIVKU$=^\4)E[O!Y5ZOB9-7YE?;ZZ%$M(PH2)]2FH#U^Z]Z$+_2 M7@^B^JZ#K^"GS]ZW^_T>FVC<72C(.Y]_[7;9G=[W>'%87?_.?`G0%SC M&&OVY`+%/53?!E'6&9W'> M/J]`@#4!V]]VZS+$*S$@AUDU]H"I/H2K`OF566(N,M+ MKI$,-33QQP+OLK?X@\];F_844UHJH.WE"&5?=*8MM?L MG,1L*QPQC-,)OH<_*#O6F;Q;^Y#@S7*-W*H M+:]J4O64]U^EQ=53WG^5!EF_POZ7VFOM>=/_][>?MZ'G_H[_AE__?U!+`P04 M````"`!I;^)$,,O/L;P-``#NJ@``%@`<`&EM8VQE+3(P,30P,3,Q7V-A;"YX M;6Q55`D``W5(M%-U2+13=7@+``$$)0X```0Y`0``[5U;<]NZ$7[O3/\#JTP[ MR8.LBYV;$_>,8D=G/.,3:VSG3-\R,`E9:"A"`4C9[J\O0%(2;P"7DB@@3?/@ MV!)VN;L?L`OL`L3'WY[FOK/$C!,:G'4&1_V.@P.7>B1X..M\O>V.;L\O+SL. M#U'@(9\&^*P3T,YO__SK7QSQ[^/?NEUG3+#OG3H7U.U>!E/ZP?F"YOC4^1T' MF*&0L@_.G\B/Y"=T3'S,G',Z7_@XQ.*+Y,&GSLG1`#G=+H#MGSCP*/MZ<[EF M.PO#Q6FO]_CX>!30)7JD[#L_.@"7@IT^'U'VT!OV^X/>O_ZXNG5G>(ZZ))#PN+BSHI)< MJN@&[]^_[\7?KIJ66C[=,W_UC./>2IPU9_$MT;3/2,+)*8_%NZ(N"N/>5?L8 M1]E"_M5=->O*C[J#8?=X_))CT!4S3'03@*O,]!2,)GB1F;QR(+-6*>,X:G9QW9-^2SDZXAG_P" M0AP^+\2@X43V^8[3VTG83\B7YN4SC$->*UUEZQ;$N8T?,$%,6&*&0^(B'RJ; MAG2?@LJQAR50_'IZO9!N20!4;T`]65L"GB,^&_OTL9E\):JVQ+L-J?M]1GU/ M^.[//R+1Z2_PE+@D;"1N+9=]BO]%>%Z&LQB*`7M.Q8@-(MD+KZ>?(DX"S.M- MWIS5/A6Y(-SU*1<2\&@^1^R93CEY"(BP'`I"Y+HTDI(\+*@O;(GKU=F6X3Z5 M&B/"XJ#X!T92DKB'"*MF9*O5HP&/=O!@V!>=VUL@%CZ'#`4QUQ%! M0RS<[C.ZE[SJ^GQ%XW:L*#Z:"XUG"(*YGFR?`EZ*O^?X#CT!I*IHNT]1I*]< MR-Y=*TBIY7XM(N9Y#T1TB!'GD+F(BF"?0HEUQ9R$JZ&?..4'L9J!.$(`[5X# M:G3/\8](/.[S4CZS/G8J"/8K5!H";C.+'?2J>TE MON0Y[5.-FR0P3&1@N,L$!J#L,/*6_"501B5%*[X3*)2B?9M^%&PN'5F;C@HH MH)[LP&/\`H>(^'L9Y`56AQCE4.F!]"V-JV?:396VAX@-C55JRJBMG$/S#@<@WK=; M#)\;BZDG:RE<-9820-M*B-G*G%K*-H/.%F:%,3A0SJ.Q_%OP:C.B;N&O80QT M0KO(=R,_#FE7XN\!A;\5'2KV7^J+X6')*Z\$#I^NLJ+*_HL!S$A9. MCD?+"E17$7,2#X68Z^*.^%UT'2ZBHR=#C9/2.TFI;U6L78GK4S9B==0;]_HH18FX.]G*M M/6W1BRM"DE&7"&17]%-&YSI[I;:A%;)FS28>TG$>,7F8A4(\HV9.IW3\!KN8 M+.,)!@[KNXF6"@;+T#`L$,VM@^LZG&&VD9A#P-+1P*`Z-@Q5O=;6`35A>(&( M]_EI@0..:S%2-(?!K6H96MN10D]Y'H>%."O5KX&C$Q'ZG!>&YA'*L! M;@1D0\!>VP:8[<"43T>H<:EJ:S;KDVQHB>6*MU-IQ=&^<%ZMC!>$UOR$!PP=W!36H9@1-:ZC MR`/H#,_$DHDL<;(9YHIRF>^ZGHH%E':-V8R1^?D1?&AN9R3KP,Y,",5ZN,E, MJI[2_-0$JET!7,TL&82?T=Q($T4U#;6*?NP5];P2?Q]D9XWN#'QNF\TQ?)N- M\S+'[U7KNX1JCLKG]#C1Z;%AY%Q/G0PK@SL.$B&"AS3-IDE"5C0U&??FE(7D M/[$!Y5F*ZB.8%6&NALZ\&U1"4@QJ(`M8%\,NL`B]+LEM$JS(C.9:F7?94%"J MM+,.@N3U1;Z(/2-O3@+"PV0O::J;INY81VA^N08%"F@#Z[";,#K%<64$^6.L M\]?EEN979%!T5%I:!\<-YEB(,Y-'*?$2^S3>"U([D&K(S"^MH$"!]+<.M6SW M2H\#,.2&MY@MB8MY+7Q0>AB.;RS`L9E%K`-TK>9F,0^8R&8;&_4A2QQ$.E>^ M:6'1]+1LZI)OR.MEZW(M5].0&%1$+&PPP[P^II8: MFA\KM2`4^I="5_MZU_J4Y3G#'HG/U(V\?T<\.6&GPTA/9]X9-(<,8@G[$%3E MP<>4"0&#))/J9@]2RQU8\J\4CK62JZSY1*8CQ!=AR,A]%,J]"'^!6B*34R,<0I8)A6;F M^ST`A.*^L"I-;9V&-U?/C".PKM:F?U5RKCSU&EZ>DIRTXEEQ.#TH'>'?!6$-U@G<_=2?0 MFM*ZGO%KI;??V]RS?K'<]*V\&^>3&$&>U%DH7+-R4[4'IU(LAEYO"^N@4^A[ M&2PQWS&]5\G#Y)8S]!RG5N_HR/T1$8:5+Y+2;#MKP,/:Q*`&W.*>M,8FLV\N MK##"F`0H<'?KX94\S&ZJ=#'V^%ATA$O.DW?ELULD;X*H.YX&H;6V1VO`+.^R M!)K(.E=]@>_#RX"'+$KNQT@FK6(Z\2#F%]D[(:M2I;6DUF;!X=B"#60=M-E> MF;U$06H$&[)E*FL3W]L-5I59K,/R!B_2J'D]A6.II[(V!0['$F(6^R8/4F>Y M&5_F[45T6(HX(=,#F!'J%=,'FFTXC;B8C[+;:%TN*3==1]FZ*:8U8^CFX3L8 MHTV7WIXQ=)[$ZOT^]7>-Y_;_O`'N_Z%3)\OY'R_>#0=O/SC)$YR7Z3/:/WJ_ MQ97D.7W?RDM&UE<TMY3L]W13W3^[WD M1J[,#5_.YHHO9W,Y;99A0;] MHD+I5,2)YR+.78Y!VR.KZN+SG+2#TMB1)$ZI$->ZD2NO0,^).BR*6LP9M"1C MU87H.<&.BX(E%$[A-;TMB5?.C^6$.ZFR6B%]V)KA%)O$<@*^+EMO1>84]\^U M)"CD[O2$[H4)C=DSHJN=4&WNE$]I\8.4=!Y MN?JM_4E-\PO7U6K8(#8>3A'UU>TYV4N1,NOE#R>M MZD[WG*R5H3*F.J19M5>\Y^2MB*"%&'`XN6MN?L_)70JN)9=Z.+FWN/P]ITLI M#H,]3LK6G,O1ZE6*U3J?NK)) M23OIW!+S^CY]E%FA!KVOBMA\*KD!@@W,45,U,9$?K72@*Y767R:*B2B8V5VI M]:JEU87:JZX>EG6OZ61%/-#)/-$.;[LV2GH$`T%VGV[U00VO)/D!KM4K*[] MY,R20M11.,:>?`.@S'I'0J3G#;V8`P!4W\]CS'OV&O!5[SO9IY6MBP<*+;]0 MZ8PB,244$_=4T^HME^>40X;/;NS-QY2]])WMK/HS]YGLF4KPB=-]\3=?QVVM MUP#L:E\Y=YV`T0[C+7*E1*`:4D\]T;Z>)J:+8E?;TKBSLOU@UX=%,$XEW^M M+Q#`;%!**C8I%!C17I7?@NE;2D;J$EU&],N6HV$ZE9*2N?*T(362NC-,@5+V M<;6[QHCDF44S3/R:)*,Q\R>7L8-4**WH,S'5$`B%6\I!:I2F!A6!UH@ZFN(Y M2+.3TA0B6TP?%8OIQ@)3?FH!4PTRQU"KD\Y3Y8][L4@2G_P74$L#!!0````( M`&EOXD2%?]NYAQX``.$I`@`6`!P`:6UC;&4M,C`Q-#`Q,S%?9&5F+GAM;%54 M"0`#=4BT4W5(M%-U>`L``00E#@``!#D!``#M75MSW+:2?M^J_0]9"E MD7R)G7A/Z6)G525[IB0ENV]3%(F1D'#("2^R)K]^`7`NO#4`L)Q)&-/`_'HQ>'1]8Q'<"E_H/'P]^OST\N[VXNCJP MHMCV7=L+?/+QP`\._O7?__YO%OO?K_]Q>&A]IL1S/UB7@7-XY<^"7ZRO]IQ\ ML'XC/@GM.`A_L?ZPO83_)OA,/1):%\%\X9&8L#^D'_Y@O7XULJW#0PVV?Q#? M#<+?;ZXV;!_C>/'AZ.C;MV^O_.#)_A:$?T6OG$"/W6V0A`[9\*)SQ_O/D\N3 MX]'KX]'I:/IT\NIYQC2XM&/V5_YK]M?C=_P_)W>CDP^OWWX8O=;\4FS'2;3Y MTO'S\>I_*?FO'O7_^L#_^ANG1VMQ-IS97]UX M0Y!M_.8H_6.V*96PS@@=T0^1T.0Z<.Q8#$2E1!;8@O_K<-WLD/_J<'1R>#IZ M]1RY!VN<1&>'@4=NR,SB_\\&U.:K=#Y/_,!A;9P@7+"A-#_B38X8HLF<^/&9 M[W[R8QHO.;SA7(C,U!`\'T,R^WC`AQ'_=CJ*^)=_T"&.EPLVOR+*I\>!=;23 ML.>VQ[LW>B0DCI325;;N0)Q;\8&)';*>>"0Q=6Q/5S8):9N"\FE*.%#1>#9> M\!6,`:3N0#E95P)>V-'C9R_X5D^^$E57XMW&@?/78^"Y;)G_]'?"!OTEF5&' MQK7$57)I4_RO;)$.219#-F$O`C9C_82/PO'L/(FH3R)UE]=GU:8BES1RO"!B M$D3)?&Z'RV`6T0>?LIZS_=AVG"#ADCPL`H_U)5&KTY1AFTI]MFDH[.<78G-) MQ`AAO9J13:E'#1[=X!$2CPUN=V&'\3(.;3^R';TU1I]%JS,BB`E;=I?V/>>E M&O,5C;OI1?:K.=/XT=;!7$[6IH!7[-]S"C6RE(J66[ M/<+V>0^4#8BS*-+9BT`$;0K%7)`YC==3/UV4'YCCH[,0:M"V:E"3^XC\G;#/ M?7KBWU3;3H"@7:%6)N!V:P+.-B9@LC(!$UW;THS=GBW+'5_46K$O>4YMJG&3 M&H8)-PQW&<.@*;L>>4?KI::,($4G:Z>F4$#[+M=1[>Z2D76Y4&D**"?;\QR_ M)+%-O58F>8'5/F:YKO2:]!W-U[ZM&8ZH^OUK[0R:*HJP5$T.6RJ-_#4KHN%T9=$15T9L(> M7^V0MW@BNEKLSKJ#C>M8OM.LK>1N;/=A&VJK5)=15S&'^@-.@[CM93%>UA93 M3M:1N:HMI09M)R:F47=**;LT.@VZ58_!GF(>M>5OP*M+B]I@O=9C(!/:#IVU MW%6-LQ(`AY7K,U-^2OE&R/7(6(1.K1J M@\3B2X=S,K\G84UQ\Z3=RVI[7CT)!4'WE&ORO,SLU]2G?$]TS?Z9DYL\Q\1WB;N6G#-L);V` M_9IS6F6.C*Q#:TV5_='V72ME8>5X="M_=0Y!3N`3)N7F:)?]S`Q'Q/;&+M]H M6BMZ*SWH7Z=JK*7U`B''$#<$2\.%K_ M1IB$P^/1*CGDA]6OIQL)6;^0*_;C1AO/OB>>^/9TU;BJ[1$"T>^R)W`2L5?M MBB)OQ\99N!9^-3$T5Y]T-GYPV-:`C:9/GO@:F]'D(7O0-`N#N;(_5WT72#7( M=C`3Y,`*0I>$'P]&QUM9O"`B[L>#.$PJ5#:!TH5G1^L,A[-GJC/.RB2M8E>Y M?U!AE8<`P`G2M0(RH^!DY;Q<;4<@5*K:M@I'>6>DP@+LYD`I.83'R7&/`9F. M*J1O"Y/UQF#7Q:XQ:$(["+=3L[C=DI"Y@V>3X`/+#D'S!H_!US3TO3+PTKY_:WA:!`L2QLN)9Z>1 MULVQ(9'.#I@*.S)*V2&@WAD%ZC/O/W)-GWB^4^&P5`:5G`X[6!K20W#];!2N MWX+`_48]#P9FW0([!#DYH)`)@F.TLY(&8##.4J,.JM/TS3"X`4XH-`F0U.Y-,?Q"59 MZ;%#L;$YGUFGMTLG#Y7B@X>MAC.I1/$3'5R*+?L$2J7L("*&!U$_*AE/&,.O33D48=1 MGQ!NHAH(M]F01UG].GO%GNX1Y8"8C6ED5?/=.O"H*'MUT@(J`,*6B5/\>E30 MC7WYKWU<[)(58,W=\CK5O^5E_9CC]]-PZVNX]37<^AIN??7LDM%PZPL9(,.M MK^'6UW#K2S],RW9AXU`,3%?$S"8DO.4UDG4CMQ`]^FUY#35P&JZ\`D+:Z"R) M'X.0_K/=YZOP*]+U#+=*\4'#A@ZOJRA*ZF*5TO02IXSHH!%#A]$XB<4C2-1_ MJ`=4AK"7:!7EAR`S&^K+'/K4MV4:Q.BAT]4!@L]L8#`CO;X)DQ#U":Y:QLML MPE)):I7E`@CZ!X^&S3*;L%226,M@R:CZ!Y*NJ?K99#1=\5)8+I+^6A9)WS*R MQC,KRZK;.F_RI\1R\K_1EY]SLE:L]B>_^FVQG#YO-?4)9E:6\W_]\//)Z-TO M5OH%Z\?5-X;3CN&TX^6?=J2#GF<1!+ZH%ZQWXE%-UI-3#YG.V`)(!5E5L7:@ MN>'S#VF'!SH*(#T&:0.=7AR&[(H@YC.1>HI::FCJ3JH%$M--*S*"`C6`6,E&Q:M7`C`TFM`&B5#`.VS1$53\-XPO,\ M<_],(O$HA!(Y+?IIU;*-#4)]34#C9!;+8D:W"KOJ]M/7^+&22`X>:IC%ID8D MKQP!>X<\?%?1#^ST50&M$$9,Q?'E;I"66?0544`3T'29K39"[N,K/XI#\2+-E>^$Q([( M)4G_7UPLDI;QTZ-'#V4--2`.%I:8.$"9-3^&;8@+=UM91)[T#W6M$MBI`@)@]>Y>:X#.';:@BFCOEK;DA MR;+`BV0C32!`$10;`2SP3GB6./05SFI%(#3-5B31VR%_#7R'[:GXD3YU5[D4 MNSH053S[BKBN:K)#:GR#(+^IKE*JX227\^SK(-!5#>E!@][07F\[=IW]:SY] M!5NF#@@PRMA0?M@VQK>:35_AE6@#HHLR2I2.TTD2.H_[^!A,+9+>"(A3QI*?XKY$Q?KR%C6U(SD M44%]/NCA;:`."+#9BR%*3<[FO#KZ+M"N./0?U*PB()P(`EHW9+%:8MPSW[TA M,0VK3(QB*=;D@A[6VLJ`T"((;2GU4)0'K<'DA0"K#D$;+KN[33F*[@(@L4R< M-\GRZ319H,>TGB9@FH/Q:KW%PHOJPI02(O2HJ60'<Z6X\.T\BIGD$W)%[9QU:ES3B%W<8'_:/E"&_0[9E:=F^:V68 M\K]NV79[7VXK7)3,YW:X#&81??#IC#JV']OINS=LH5P$'G4H`=3\N:CF;CEN^T(L3!_'6-AAO(QY?JKMP-=-1\=%?59O:UC\<8VE=9=CT*T*V>8-)[$V-/OJ8D=DVD>YO7!>TI.BI.L,PFY%3%?0W-M->;E.BW*E%-:*I%OI M-L^05LOVNJK/5NV[[K;\NYO5\KTI]]V:S%K3=2NG>(4J7J]5J6UX(#ZX`H_> M%D7.<,C8EPV/CF]A)_<1^3OA-[^>N`35,I>,XY;,6M-U+>?*YF6,U-9&K4W4 M1&;[1CO8/NO']4\_(3"#XO(KH&138VC]F'+M7+_,0U'+K"F3*'52PR+N38_, MNBX3O60?LZO[WH3=+-LR42L-I*#:8Z?F5WV9N!5VL[#V[TWLXBHJ$[MD4DMK MZ=[$UEAJ+OEE'0]0I61]M=>:%=NA],90>N/%EM[8S*[SY>;'_Z$D9'(_+J_) M$_'D-3ATZ7$7XZC7"]@NG%6ND&4]5/4@:K(Q4\6C)E(`S'4Z"EVLUP3$/FF"WXG9PB-= M`9A5"T00'X2G32`\-5N6I"L(LVKIG,^9@)#W+;FF3SP))^_E;S3:^H@25&OQ M05\]M8$Z2%=96!'I%6,Y79_Q6XL/3DB3Y^50&%8:\"F=7"0AVAV0PASL*4# M%#%'52X>*9E]>B9.$K/-TW@VHPX)E45`82)#417)U`GJB(YS/11"LRVN[3O4 M]NJ`5$UD*G12#R6)[$CC(T+L59ZJ_U`'IVHB4_&1>CA)9$<:!/EB^_8#T:G- M6FQIJ@JK-B*5`H.V!T%!SW-^S80GNS/[K2HS4MD>?6Q"(K:&N=E_3"*34G7K M/!(W\9B=W/SRG/CL>[$T0%%*5,QG6ZVY\HR_[5^L%>>?,C&+_26/;36]7%7? MVOPQ#2.=^>XUM>^IQ[ZO2,@I93C"ZJ\_ENV'5=84^Z"5^>(>NV63<";5LI3B MF,E3&X).0]#II0>=)F'`-C[Q01>+ZAI-S-&J3A%'';=B6^DD)N%&;(V':ZH( M#,6KZLRW\KU@0(^>+;:_A4'4Q$0*.E..>(W7PY7B0WB9G5F91UPNR2(D#A7^ M*OO9(Z)K??=L'H0Q_4?\'M031K:M+Z`?`ZTJVK/9+>&D"F#;JLQ]!%,TPACSG*L??1@3GR,6';5#]6ODR9:V;JKE/#.1G( M-<&Y9(L2>B4U%2A)B(Q=CFD%-)5BX.J+UNXJPE4J2E,%!W?82VNIA',R2D3/ M!&6RP9=&R`*\7A;6,B4U0AVXT-_E$M2+0E7UTN*IR6!5L9*/-%A5JNU449`2DLX8@Z/%(16.>"5S4W=CU%/'"E`/;@@(\I#BTQ1AO M7\6P?MQ\:(_W2%:%OTS3]++ M(P$@`>Y(@$)/;%NL*G'YCR%1>IL:I&8B`RH(U(!5]@"Z"$&7V&&.&+2,;S>1 M`W!??;79F5S3.8V)"X8#1'N@N:'L"?W)$NCI@'M59-[8/?7%7I;M8B/JKC:V MH@A/>DLZ?2KJBHU@YJS%*Y^:;7N%DR#=C[3X$?3YZ6WKVIMA.-,'?@L"]QL53@8P M%M8MT(.7$U0C5O)B)G+:6&2AW3W:OAK2O8J!?MSLOS>@P?D:8WE>O9A5Z8TI M69W>(48UQ*B^IQC54+.WJ28X]^-#S=ZA9J^I(-5W5K-WPIQUZFHDMQ0:8J_- M6R$NSK6N]7J\ADI8ME*/5U;'\HU9G.K6M0;J0AO*^]=&1R(V!,P[LQ&62^8L M.HRW"I!\N^E[Y$!4B`L!\![!"M9FI>I1+TJ*RX0'38WAG,D=BE6/L-N5:HE! M)!J;$_"`4(R*6X>F`2U'-1$$D8QF.D)K+#1E!SO_G>EBX4$8WY%P?DGN=>ZV M5#?''060ZHCME*0DK/+&!$1@Z$Z+M+,5P"!W]=O"!K/3WP)^F)W\KT%,HHF] MY,N%.#%9_:PL*:$@-';TI)A"06TE0.`,^S9,ORL_BL.$#U^YE:IJB]M$P=IA M.U?.2ZI3,0FF,&.A)'TM`Z4'1:[:PP:SA=H9OSUG2TZ8`C2*@G#)EU^Y$U35 MUE084SG\`QW!P1BFX6WV>E46=9?&,W%=3>'[P"2XC8M25VEZB(DP6D9.U0I6 MU=:0YZ/LYD`I.5+#LAL@F(W)[J!A]G9N2<@3QB;AZCTL(;;R[CY,9.K,1C)5 M@EJR@PY`DAY@)!<=9_0T&^#0B^7@!Z(L;1\B`U_X77H:+R^9E@VF"D".'ZT: M:N#-$GPJ^#Z.\?2J3X4=-4`=R9&X?N(O"?2!BE]SW93S&_>[,)/\YY M7921'$$=#OT`4E\3",^?VP^O9GV]]*XM&UW,$WRB#HG2$E1PO%6#&#$T=96` M4'F_9U3^L+VD:C^AHX^@[3DF&1U`7[?U@PA^3,Q,YZ?YP@N$'3U["`F95T<9 M!`E,@;W_59*#O6XZ'8O-U7-F'UW^("GQ(T41_>KVB,'1D!N$QG1B%A-Y$K+9 MJX!#M.D)!!E9P6XW6_,O$_S0NQ[\IE35C[.P5CR&&\'#C>#OZT;PD.&+[!AA MR/#%>]`]9/@.&;Y0[;:X.`.>[&?DK`X>WXOQW;8L=+7`C1V5V?S[4IV^J"02HV=MB0WWZH3Z]*8/U MG=6G;ZGLMJ'3W5W+;B,N3?>9]QVY9B*7'F4Z7WZQ_PQ"$1R5&[5:3'!;M0;] M@>UZK42%K0(Z!=9J,S)C$)M`I@VZK,?0F4M3R&,VM'L?'9C-\(2M@'ZLS";- M-3-5PJ_II`P4JH"+MN'#GV?^"`%SH!_Y**8W.K"%+A-K$I3;"40JN35 M2:]7T9FQELK>5X/5@[L0W6"&VZPX'_$ M*9\8\T?`-;ZA#X^QQ(S!-&P4(L_F5LD.!K(-)P1MRCI<)B$3>4)"&KAIK8U, M%%^:'*3)`C^&-54!#1Y&2$6ICIT0+7'H+:"`)CC/X.L6;$"/24%6G`="TJ6@ M5`>GX>I8XM,#]!KH@S,V*EL;=@>XFDUO\96I@]-5EP[421(ZCW9$QK,TBM1P M_A;9]!9>F3J@?X$17C%.=T:WDDMOP95H`V';M+KAGJI59JW-+C4K/M/>HYC0!PP@9+?=_+_R*_7M.[NQG$NE=#G]7O!R>#9;KGQW,Q7. ME^I*;5K$N(\Q:^B/+0`,BJYS1*9%;.9LLPXDFF#VX*RS:S0QGWIVBCCF4U!^ M'3")2;@16^,Z8Q6!H1OW=>9;Z88CI$?/%MO?(S)+O&LZDVQQ-(BG5+\44T+E7`)/@ M]@V4NF(S4AN!5PFVQ.8+ESOV;XB3A#RL?&Y'-/K=#^XC$CYQU:]\9H?9GP/? MH1X5;R!DM56FF'?V14.W$)20`T.DHQY'YZ:\G"&&V2'",@PQ^TZRFP4*+TI) M:LB?ZGPUT;\2@]P=.YL'84S_$?J.9T7I8>3E=.B=,`WQ<>(%#S4=_UF'&CUV MVDJ`EM^D!\U+4M%X+BJ)^>X%LV=L-2)LT=$\-GQ]7'2F,QPMQM+*\1PRLJV5$>\]TF]Q'Y.^'5CY^XT'J>R:CHF6S9 M6"F?P1L9O)'ORQLIS"1U*B!(@-O+4.B)S0Q5B*M\'A0F,?3&@*++E0`AW_NW MB1'F_7Q+.&+>I1>$5I8IJ6INZM%6Y;R1XH-]/SX\*8ZM=,7PI#A>BS0\*:ZM M'E)+=!W8_OHE9V6PJ-2V%P^'5XN-<[7+O_\KMSU5;7$;'E@[;`5V\I+J!-1A M"C-V1]+7,E!Z<`;2'C:8[<[.^+U@JV/H)1OE3%':'<2OUPS/@&H_`VJV"MGP M#"AFXS0\`ZJ)(&;SM-,SH&_[^`SH6UG--M//JC&+2YU8\_GPRN;&BCK7``46 M'`+&<#5G45GJW(Z(^UL0N#Q[]RO3KSI>WR6+A41*J8JJ[ M\46^YVBEU\J#P7#AS)I:K752!PQWXVLJYML*QKL-G.HN1K=APCER4&_!\(VN M/3^(>Q'X$>M!ZC]L$OWD3^*"!*8V!BU-YD!;1W`/T33.6@>2#9-S33 M]R\9HKR:$$KO]X'2J#9&HTU8ZR5#E-,2C-X=[P.BNV]!;9`V--.1H;CI?F`J MZ`D"-=H+4(RD_IJ7H9J.##UFNR>PBIJ"<)WN`Z[/00*_.0SIL"6:C@P]@K@? ML(J*@EB]V0M6]*G^S-H234LM75!3$:B\;OUOZ7!NJ#2F2:9(H)07G$N&TUHN'BF9C9D5L+GQ'<]F MS'8K`9$034\,^67:Z"B%!Z$Z;0H5O"7DLMPZE"T*E,FAZOYTJR2AF9X8EA;T3!%E@7^QXR2D M;'`Q+;5*:&B1XT>KAAK@)$($8P/H>@R7-D2&'YOFZ6@W9+%Z+=(]\]T;$C,? MH.*Y4$D^1@TN^(&LKPV$[7?YI'4_\*VI#X3P=_BD=5_QE:F#,YPK1N0D9&(J M4N%$FQX`4Y`5ZG7#+TW7/"'*6/KQ3)",-Z/KACB$U[QK+Y51YVL]&0F=:`V- M*;,O7&_UY?<%"%,KQ8%IF'K$Y\MM$^:@B6NAW^S0_9KP#A_/4N-TEL2/04C_ MT1M0+7VJ3Z.I596AH63V*6TAZWU1V:(&O_M,5&$(QV+6\`?8HD_/)'1HE"[! M-[QSQDDS*`4?46&!=J/=^;/U_RQ0[_(K'8H+')N-4P^HU-X;ARM1/$.K2(T:^I`X@) MJO*"6F$>F`8Q7)JR@S"U?@+WZ9FO%21B_LT8ZG#1LM00<2_+!`:[-A-$@PH( MKW[/_\-76O:;_P=02P,$%`````@`:6_B1(8PM^$-P``^0P#`!8`'`!I;6-L M92TR,#$T,#$S,5]L86(N>&UL550)``-U2+13=4BT4W5X"P`!!"4.```$.0$` M`-U];7,DMY'F]XO8_X";O3V/(LB9X8SL.XWM=?!5;HDSY)&4=`[%A@*L0I/P M5%>UJZHY;/_Z!5#OA?=B$Y6T(RQ1W9GH!U4/$HE$(O&GOSRN$O1`\H)FZ9]? M';QY]PJ1-,IBFM[]^=5/U_N'U\>+Q2M4E#B-<9*EY,^OTNS57_[SW_X'8O_[ MT__\!? ML_Q+\2;*W)J[SC9Y1-JVZ"I*_N/]R?MW!]^^._AP\-O#^S>/2]:#$URR;_G' M[-MW_X?_X_W-P?N/W_[AX\&WCK]4XG)3M+_T[O%=_;]*_4$3;]\Y/^XQ05! M[+6DQ0%/1C(>"=9Q$N!;NL/X.T M$OR_]ANQ??[1_L'[_0\';QZ+^%7S\,43S+.$7)$E$MW\6&[7C+$%Y81[57]V MGY.E&DR2YV^Y_MN4W+$7'O,?^H[_T,$?^`_]>_WQ.;XER2O$)1D/M?WZ;M!6 MK?0V--A+DM,L/DVGH1YKSP2?C9V\?$('^OK!NW"3E3B9!+ZO&1SV9S+MB7=Z MX9\TFT[(M"?=TQS"3OB'Y^RO`7#R6+)YB,0-=-Z6P<")GQ)VMVZ[;3V+!NTF MW%AFN?*)B":7N+@5[6Z*_3N,UV_YG/26)&71?++//]E_=U!;QW^O/_Z-S;JK M++TNL^C+)[*Z)>V/B![^^95![NT8-=E* M?9EG*^//UP\H,PC]EMRV[55/DOVD!OA`+">%\`"\7F0?O>WIU<1'OQWC@@E_PBF^ M$UBO2?Y`(U(LTDAI:IRU0A#(LPN<0HXJLY/(#Z=DHH0>ZA11H[F'F"X0JW6/ MA=^OL2N&\.M<.=$Z=36-V^GC!'+.H4D.M M'L)IC!I-M(^N,J9;HG/\-2?LT<(P4UW;.3H8\YF\MAH0<*!_,:!AU0B')IC=\:@DPI'$R;"?Y&W22Y5EY MOT5'.=XR6]::-68MG9N>$( M<,R05@'5&HBK/!M#;O`76MEPW+#`[8BA$03""C.Z,26X M-.+BJ)5G_LABM=JD6<0:1^=T1;D;RU=?O^"$%((S62[R9&#,14>;@J:D*`ZC M?VQH03DPPX2DE0XY*UD@]ZCL;'/#-^9;(XUZXJ`61Y_PW[.)@N&7'*`6TA08Z1*T.R&28XP07Q<520'-)A)'E M9TF"T<%6)L",A>&PRH)0LEA<#&7+BDG/O5CK$B-:-Z\P>.,F\7`.N1UTYY/K M96=GB"/`,4%ZN2R=!@R+7](HWI`XTW..ER M&R[Q5G3B:,LW!"^6RF9,D:1G_M6P8:D@CW`8XWK6GYQ]G(7MI[20YGOV72LZ.^7<\-DV@/;0\3UF M+N4;]$-VGQ99NH=^P"OF<%Y'65FB3YLTS_;0%>-GQK?`\6U*MC`F@AM:)FRH M=,/)8+XULB&-KA%NWU0J!6=GFPLZR2QQ66Z7.FE0X9;/64D*9GKQ+>M2>4_R M^F^U=^JL%9)5CEWH\\NB`H9I;CC'G+MDCX<6199O$6\`[:/11B8Z+^-GFPNU MF"]28I@47=3"S8[NG>BF2;O.[+SR!#HFEE!$M33?IGB6_:S=&#:/8-_\43[7 M\![HN)Y'0`]D'.\PCL5V"$XN,8T7Z3%>TQ(G1NI8=$)RR`E^GTQ&!3"LG@[C2_B)%M1H0ID719K41Z8DBM3&I%K?QWS=%J=VG]U4.RCVO#@U(Z*0) MAXT^<*60&3' M.":3$$$'P,ATM&W__"LE.7N:]UN!U!#GA6).'5*RS:@)CW@N<*431TRC M*GFUAUHE4-$RU;AZ[VWEWD.QD%P=#)CM&AT-I MQZ<7@+AU1E.<1A0GSMS2:03GEAFZQ"VU."QN&3%*Q]C>]'>R.;-X$ZAM`]6- M`&+;Q9K7@V5+8&>VZ32"L\T,76*;6AP6VXP8I2C7,)>"T^T"B"'K4OHL1PK& M8F%/$JA!#@\0#&7`T$4#3#J;/\BE8101>OSPP'&6%INDQ%#JWO`LLDU)Y66]7`,,T=JR+;1FCN(:$K#FJVVGM!:B]UQT7KTZ*F<^`Z MV8"'P,UP>R?`U8*SD\8%G73V6S[2^WKQZ?P;*,:JKG=B2Y092@7.D5%!'*7' M]$5FYXD9ER(IIJZT55>A@5IDZ_H^R\L;DJ]XQ0M;)4"U;-BJIP:XPV*F"D$P M)#*ADPY,'4KW`0/Q:35U%$KQ'_U3E#N;EFO+RS/(U77 M$64_1QDB$WU<%`*6DW<`WJLD;Y">G4K.$,=T^O$>Q_3O&!V1-+G'18%3J2J? MB%EWK<(*6E_B4GND6R,3U'=6P1MXSGV!V6ED0B5-<)4,#!J/[MZ:RI'KQL+Z[&?30>U?+@B&1!:#LP??%J]()M[NJ6OKL MTZDY3\ZN!V3J-.3,V93`\,X5J:(:ZG`^!$*Z+H59P+)Z;'KYF5+,U;`U6>5# M83BDLB"4COQQ(8!^U#G!!;'4_++(AF21$6Z?04I!,.PQH9/3>/EMTM!*?)UG M.&W.Z)M)HQ`,RA@MT`%=)*F@7'D@^6W67MKK^!R#%O'>UJ!QK9 ML.-%PG.CLYW/`IZBC7\H-Z\/QTP"?6@0S]B&GQ]*"W#UO,97O,"K-RQE"J MQR0-ESFV\CP:\EQAFI19BLYR6MZ'9([Z_+==?%;6*$Y^VV2AN#*..*'3YN9K MYD>0VF+S@HE>B#IUGJ:\Q+)0FZF4JM.&`JC3%ZK,:^WZ3Q M)L'HDI+H/BO+H#2ZIH]^+.HIS$HB";B10ZTT7`J-(7HPZ*^$IO]$ITG"'/H\ M`U(#4Y2#]=IK-6J$#"8Z0.^'%`WBL]/-':-\Z75!&-C[*AN7%RC)UKO($=%: MIY,LJNY%3>/3M*3E=I$NLWQ5E46\+MKHUT9_IYNN!8G>W&4/;V-"*P/&_AC;+?;1;Q6@*W)'.8BT M_(Q79/0$]&(A"&8#R>FDDYF=/!9@4E91Q8Y.%G'A^6AQS&B;XV21QN3Q1[+5 M=DZ2"TL,#AV*"$U;!@\"6(MZ]")&7G-3*("\WQ MKH\W>2Y"/D6$D[^Q-9+>&.A%0S'`!K8A@TX.!"\LX.3B^$(<5?*(*\QJ'&K' MID)U1=99SJ,X_);9S3@3V"X>V)DT@A[YE$I9$`1R`"CEYA7U\O1W!6HU4*6" MZI;^,A^;?B%)\F.:?4VO"2ZRE,2+HMA(D34'^;!\LL`>$DHC#(A19H1C2G%I M),11(X\JA?EX]'.6;-(2Y]LSFI!<;XXDN;"\T<`<\F4D!(@G:F1C?K12J!*; MCQ7B]X_9='F7Y?I`QT@J+".4$(=\&(@`8H,*ER;`(411(SL?(2XWMPF-SI(, MCT/P&IFP9%#`&U*A)P"("#(J#0TJ020D9_1@L]4J2T6.N;AKN[C8E$6)4WX1 MJ-[I,BH%]F8=.C#R:0T:@(CD`%,7016:U<&!/50IHY[VG*&V;KUWQCY1^29: MR=#A-@W4<MBC@JOG2$P3(&!F= MC3-UO';GK'E"B1*VK*]R2_F9/4T*Q5@H:&$2)&!J[,CY$@,)JH MT>GVB""5BSG&Q;VF:]570:_^Z($9W//!/@?SQGM@I!?,OH+Q6@^C*-ND97%% M(D(?N'_SF90U_W1,-JH$OH[="GYT";M6'@QM'$!*LTNM@O)6!P:[1&)WUY'" MRBV30O`D>R-P*<=>*0V&55:(8TX)!7"$NLS)&M/X]'%-TH*8N:21#7R7AQ[N MZ$8/61`,>4SH%+=[<%E$*F$@WLO`^W+QT&;T<:V^;5!>E%F)DW-7QU9#BAO> M"(+HUFKOPV(&4CL:3"H@[BOK@7>ZJ(S)`S(V5I"ZJ\G$N1W2W4F6DA*]%M>! M_%\@]T\9:HCJ"6=3`E+C54,ZLP88VCG!U)=V+?IL^PX(V[[/LO@K371=[KX. MR:`QJ#Y7FN_`L&($:/S^FZ]AO.Z*K<9I>@ZW1N_/0'1DC!X,),_EG.);FM"2 M$EM87RD9M':J'NJ@>*HL!L80Z+%)=787AT>+\\7-XA1(O+\'W2WH;U*8B38. MX7^]-$02^6T$]!1A<*J).-:%A-T"QF/A.4+%:L"J(/%0$@R'C/"T@>%U)0V& M//F&Q#U2GV4YS_6C14&SM*CC3&SM=X,?B=:A\6TE,-VF=''$0Y\F(!%T`FX% MJB#X:@_YC%I10O-O+ZG(>_O`9+7G:2SD]&1=)#)Y46B@A^T MN,^2F.30&"0OG9S76',O6MT6J[!B85I\ZK@8N/7I=8_)?`.IW%IB'B:%L-G2 M-N##K&F=-!AC9(4H95'?7!S_^->+\Y/3J^O?H=/_]]/BYF_H])X<0/$ M&EVRM@@;%M5%..+^-GWJA"P9.`5%!W64@#(6`T,A/39%\DDEV9P9_%_OWKQ[ M=\"](O3`]?;0=WOOWKWC_T=%=9X0;\K[+*?_)/$>:C^DO/)!+/:3L^Z\(<(E M^@&G&WX*_L/!'N+L$#*C#S^\0=H@%3I(!R9(TI>>T-XIOOD`8Q3U M#H::AI`L%C356`-RD'8\D@$SF3CZ_@][OW_W8>_W M![_7L5-)S=_O??@#HS?3`DO1PSBFO/0K3BXQC1?I,5Y3YO#H0E\ZZ:"A1S/D M08A1+0J&OF9\4LBPE48\`W&?IBBJ%&!PZ8J4F*8D/L5YRL9$<1A%F]5&+-M/ MR))&5.>;NBB&O<[0M2/#NPUM6F!XYPQ5$;5N!%%<2<+@7@^82.QF%G^=DWN2 M%O2!+-(H6Y'SK."93A?+&_RH#^W[M1)XRV5*%T=;+CY-@.'K--PF\F8B^S_J MMX.H:`@&G^55I?/R<^[UO-LZ'E8X2(M/'0[JB[,EO%!@2_C*(`)9PO<3>M+8 MF4]VM;D2JTR=T&59J71@,<\1K34L*18<+X&7PV#')DV!&ZC6B4-FF8#B%:*5:%!N+S2 M%XQTUIJ;89J2D8XJH+EF+QHI$2Y[GDJ1.]GP\'3LG#1GVA;Q<>D?Y7K>IVSX/Y!THSW`UGT==O-^"&JX15]]!X80 M(T#R+>#5US!>]\6:Y)A?Q%6?<+,=RS?(!RUU9X,]J'2G$P9#&1M"J=\.XQ5-*9_'2_I`S)RT:@4M=N;6A4$--+,*&/JYX90JIE5: M@G1XH`>#<_U!=4:T:S=9;"X3UP>I,V9T;[ M$[;Z3#)1:M1LD2PZ85?_#O"'(0&#`AA.N:"4@P>5CC!%<:<%@V?2,M9UN3MS M\,`I:``KQ50'3YU3"C5>T.+J\OUM_>U+SD(:&:J2-IT84.)(`*4Z&Z3L$8<+ MPB#-YRS-AIUHJG.90Y<.>F%KMCAV8UC!Q:($9G9S1:J^PJ/>)GE=5U(#DN:^ M2$O"GI/%Z*$.11Z<-+>X,?CG,2T M+,0J\^^;HN0>FFYBLRF%WY6U=4#>G-5I`**6`TS)=<*/**KD>:DRR(ZWUMCZ M&F<@4Z#7U`?+O[+!5#OHU=%5"G+68WZ@U3T?R00ED0K>@#A]`3`F285*Y8'# M\;MUI[3/LIS0N[0JN19M;W*<%HG8+.IL++.EML2"7;4>_,:]W3T2Z7J^IS<- MAN^[[8]ZU3!HOEY#P!X[?'2KG@#K*7\"::Q\'I:*%\_U8Q!&UFX>F,M`>]HO M@1]W.^G>>!C6#;*U673//B>H[!I!N&T%]IB<_E0N>;H,^Z(L);PAB&UFRI(?30/KKEJE50L%*&P;]?F)F_9V@.'TB.[\CG MS>J6Y!=+@;IW[,F-EE,;"\G6IW6X3^)I+8'A]I/@CRG?-(9PU9KB"!S<,="> ML;I8'N/B_BS)OMI.MYA5PI;@LX,?%N/3RX/AI@-(J;!^>U`N6R*NA(06N&-S M;'+@Z"[S[('&)#[:_E3P.YG;_(E#YF4_N-Q[.J6AP.'VB1T=Q>0]6P%#XLG0 M]8>X.A43F>'LH;P/^C+8U'.;%<2XZ::$IW7@EEF.V`H9;0G.89B/WFXTOP:. MOS*:D$&W;K+=&)CG^:FPQ>*?[V$-*\WO_G?`F+%G[)QK*POK'>.9. M-2#9IQ&?VS?L%Q!-4;N#CG#[(Q]AC-3^83CV=T+JZ%G_K*3FD;NISG5BT=89 MW4E&G1ZT.<(#,_P#D$W8@L0\`D;2PL0[G7#0]8P1\&`EHY0$8S>-\$SU8YI; M9KCS4=3''6&02>P6?&;OD)E@<]Z84C+XII(:JK3U,Q0#0R`]MC%[FK,:XF88 M=+L=WYJ'@.!=LCJ(6>VB= MTQ7.:;)%JZY6%9Q",.Y[ET_>_(2Z*_VTW6A8:;[>N)4IE'SCI6F"1YE>\U;0 M(OT&^>Y0ST[D1?I`BEVD6Q@;`D!LAXXZ$-S0"IB`P63H/+\O MB<$D%_DU3LC%TG@EN(MBX.JPCAT9U8NU:($AHS-414U9H8CX`Q-IJP53X@Y" MU,LN@4''$W);+E(VEC;<56EB+&>L+?I`4J(M'^.@%S8MSK$;PYPXBQ(8*KHB ME8O/=NDG6Y1D.!6IU$*+IW"*PT$HPFO*W`T8A.R/NAK^)4?/'X'#0)55YK*) M.O`Z:SB6!T,^!Y!F"Y@/6)AF)0&VQW!%UO4R\&+IR#FS2MA:VW;PPU+;>GDP MG',`*=NZ1J5*69GK9H>1'K<#UNIX`^W.4+A\IO@>&I ML,P'?F".+=^)(SG-XO%.G>:1^341M$C'A,X-JG9XZ,.B\03DZA0_'DGBK%!HLUXG(@T!)\V9^T7*5FVK*FO<4@_!53OH42*_ M+@W.%KFI@G%<_?!*M1-ZVNB$%E&2%9L.*E#0G\(=WUX:U/)S5X3#5&[-L0=ES3>I:D2"CFZ*/"W&* M3^I4]?%9UISL.L[2@OG?N>B.;O'UE`:#\_E)'9?H/:DU6&Q_2A=<#XJNNWY@V.AS4P^]N^K3J?$FJXLN&+YZ`G;D*GGDJ57,2M^CF/T`#+(V M-W-=,H=%\S2&(G/$5C?'RW+!2Q6I8$I5BOI"$'<# M="#';#G""0^^U-5]9]H.$)[=?9:PI7*AS_B3I6!NQ!APZI[^`_=A@8Q4M9== M\:D-L&5:HG2G$2,4B*+<)`^C>-8!%UQ(GSV?9KN*I>:KJ*$"!Z^.ZA9*#[Z[9)] M3?*Y[RD_4PM M8E>O$7>J+N;QI6]/@ZN,ZXU\THM]*>;(F%KRI`"`ND$P!LNIX_Z1&E5K+\.D MN71A:HX18$,7--GL11E#Q[Y,Y\2+LY&-L_JDX=4U`L\6CCOH;_^:%EZ8S1O! M]KUTXP5&K:=Q6=<&`"J;N^=MP%\*D8VH_7G\4FSRTU(M=6T`H+&Y>\X&^:5E M6QI13TJW!.QS[CR5]D7YE5KT$U\S()-E307&IP!LL;^=1W"\A:N1VP5.[83FL"WH%9>0]WBCX8*S4! MM,^960@N59@ST.#LTQ3P?J\6D&$:7"1]V.:P\.3T17I<);"(G!C-P_+0G^V2 M<9=N:6\.-RF#,4:^B)WO^-9G-8FZYCDI,4WY'2HXYS5IZB)_BT_G_2VZN2K4 MR%=RFJXK-8C#LU$N8%75Q<1][3P,Q2O1;N>K'C3QE,8&2_\P__S8EE7`,3)-?M$5`2R M%;??4=M![P;?Y>,87$.]BX;!S/2[[(UTWV2O[3TT:%W,]OWVN5/;_@+J?@+] MVOS(?\$89I]QN[0I*"]H#H-(]4V#?`'(AD5DOV'$I!!T+60%/EC\:*7!$,T* M47.;*2^:V6B`LU/7]"ZE2QKQFZ:D_MV0Q_*(_?@7G2?DJ!PT*NC5H8'WZ:0) MAHY><.4JCZL5SK?#/T<0$HW(C$5)'3ZA47!F<2V9Y\(Y@BK\WIKMM3N4-LLHV<;L[#1IWM* M>KHT`(^O'J@-!.ZU4CF1X$KE]N^LN,EQ6K`1QEU>B]FTJX6]6<2M$\/;1&S#XRG-$ MNMY8+*5..'2VEA[P.'%'E@3#+2,\J1P"$^Y-N.#,WK`S-A.GE9Z/2$;3I1$% M2B6;2?H,[RZX:E/)8GW&0B')H@;8Y\A0`@PUE+#&C*B$P!D5>=N14]?=S'CH M!\_B\^F6><-8HPR&@;Z(U>2$PM:'`,P MFS`'O<#7/;MU8W3GLUD)#-5TAHB@AMJPO.Q&E[Z6[R_)H`P5!' MD^BC#Y^W?IZ>4('!T>^S+/Y*DX1U9I&6#"AEZ^7J>*>S^^?91DB63NI>GZ9> M#8#AZ1348Z(V;0@CV[6"JF9@NY:Z+ML]3`?-P%>5N'9E=(.)30W:&01WR(IK M3X;H6K<"V;`Z==YF8WT;`4=JH^7U:^%ET=IFB(V\AL'@Z\UM0?ZQ81!/ M'QQ.ONC%PUYR;@8]O-5<+0N&:1:`7!&<=PAZX:-7GY.4IDW9'3" M8&EESY0>\0H&F8YP08N+Y2CS>UO]T\8L5^60-//K4)]S;II@".@%5SY0RI1Y MUOZZ=R@.!B-_XO6^3HN2KG"IK28S%@K),#7`/I.&$F`8HX0U9@83XKP@C1@, M4IS6!1HN22Y.K+O9)ZM6T&07MRX,LE_,*F"(Y89398,BX;?'--GP=,Z4E(A6 M.WRO>:F';]":Y%7!`1@TY%=_\>4*^Q#`S2;*O_`CR69:?9)O; M+Z=YK3HT"&F"@\=;S)G=. M'TA<]L33?+0 MG_NW:6B%JD;2QWTPAYQ=NS&\&"S10D,%5V1RH>8 MA9XH5ULK0J%=0=BSY#&3$X8QR43ZZ&GE/QO#!4Z:8:GGW)4A^:QJ@.CGBE4F M8*59Q6`[W6:I!,0*ML=$'-=#6O%9#NRXK<LF`H9@&H.:13PCFD(W8ECG@U M?%YYFG&[*C*ZKBN/,L",]FQ!Q=/L"Z.%F]12T#2+Z5V5BE?[-0.&KM.Q2TD; MXHZ66]X4OP.A;0L&JU55U+/2)1_2HA8X`]*I$[9:]WT=,$QT!*K(:^S4T'D& MI8;L9_*UEVZ29RG[,ZK6]SZ!'O]F@A8RGMC)09ECSS;`$'8B<-FSY"9V4`9T MT!8,.C.4"5ONBZ*EIM+:"KFP:Q@-S.&*920$AE(Z9`K.#.1@<.0ZNB?Q)B$7 MRS8P6D69F"-Q3O$M3=C"G11UL#2^2%DW-CF_9TFDV-WPO4YK@NYN?R.HM_D< MCV?@A^[R!\",B>?HE>2[UK_!L_F6RJ!\G7O5G+:`-N!T90(]QY1K,_,,&[]. MJD>&6QL`R>\%W,3O''@]R*[+)V1)>37]_=L#.`8F=\(T$.)Z8/5'1+63*YR%IECY;F,<;>757;8.=FP#!X.G:SZ['C ME!FZBA(B&/ONH.:K^.BWKAZ`=.:6@]8=J?=5#L'*:1WB1/33G)U[D^#:C^)7 M:M",J/>!?!?->8RDWR%]N]KL1/3':C)ZS+=<96E]!7)[SS@%%*\^HRDMB4@I M'UM[Q4U;FH?EVTC0=.Q)'1SD9'NU`(;!DV#K2Y?5=]WW[KGG!%]\.M\3QW#9 MWSB*-JM-%5C#JRPOZ[MU9[KZV]#_ST1]_YU1(_!M[`X5Z1SQCM_I35;BI%WM MBJH./^!TPZ]E_'"PA[BAF.NV=F4BCGNZ$;Q79,$9*G_(P5=NHRNDZ"\`Z@^/ MJFCA"2DQ35P]Z&E-SN%7/Z7S*F][2GNS3QP[[(2I##MJ':0+-G]T5P'4#:*Z MQ9E,$#.<%2:>1:5.U>D)_/8AZ%LK26XV-VIPTM5#;+[FY3+0+5EF.:C$6W6P MM[XHG:9WUFOM?1H(6LW%NV.#PB[.VK-;D*\.0:%7M=[Z]_`8)4T1/C27YC> MMFJ+Z^!2:JY*<=Q"*F_0Z8`,53'I-SU&+*C\QN3)^[ M9\[QC=;7[`4ZZOMIV.^@W@^YQ#UF.$,]S+-J/ZZ/B]Q3SO^C5E.:^_R\2B/>._B!V8?CL_9*]54EC7>>Q7FBIC_3MD8K%UXT"/L MA/A."NLU]T^K6T`(VK:XW`827X-0Q]!DWJCWGRB1;&I MQ@HJ2/Y`(RBA88^NGY!U3J+J>S;-'O8VHY_^7(V-`QTR#@]DXI@QM/P2!XV] M.W(TL=.HBM0ZIC[,,'*&\ZOM:8VE9^&V&K*2K$-16&MQ,TCC7CYR0-W3VG*5F49*5S_-Q4@1P+D#KCF"/>ZH&AJ@=8J2R[ MA9A<'XD&X+/3M"2QJP%AI7998M-Y"6PT+4TJ-53=7R&=(MU#=SF8>H>&'O:\ M1H=PY)2&@/#4TE%'YFI:>0E<-D.7[F8A1?$O?W(*6):$UKEN:EG2XD9'3-= M%,6&9W")V^[Y'TE2!:VEU"E_]7`)+/Z=ZO)2W'5GMPH3`1O.K_.K'DJQ%R>: MJ&^4[!H)D)GU&9?LGQ?++E&?=Z3*W^=(+I9'FX)Y@47Q&>=D3#/,^J:UKD5?4:Y]\VS:.V_5UE6VG'T2]9 M_H6F=\=X3=FL<4*6-))VW(R2X9AMA-I15"D&A&LF;&/2U++,G`IAOM'&I6&L M(!JF'F>K6YK6&1MI0>.:WJ+J9;4QR$.AY98Y,(0]R[)8B+P-?ET!GS3T<<2= M_D+(-<BL[UT7/;=9M5?'^@"2,_V:S./K5T^,LLXV\5/01YS.^R?H3[+ M_M7_QJOU'T_^E0=A)2SN=+ZYQVE3C"[HJ]!B>/D#UO)XGW\8:P#\BP]NI12?D80G&W*3]6JRL[[5-ZVK&*.7AI=VX(!5R@/=$%1F@\KR8*H'GY#; M!Y3(PS&>-@0RIG%MR6BK0);J+8: M,&C%KR8K+O'6L-H;0U^)H=>>S/I;NZ"V11A&H53*C59$0K6H5>/9)WS7O9P&%>GY\>P$D M$X!+66`5(7B>V>PV<,MV2_S5RRJ MR-]G2:=O-:'71Q>T>8GW)!\ MQ2;]T]4ZR<1D?MC\LK+[)O%PF0IVT!W)]+*S>\6.`*7\0ZX@;H=J53J^O-2* M[,GWZTT/H18(>I1,`B812'P[ M^P#60E(:_BHW8@^M25X9>Q@T&,YH/V>\7M(5O;LO]:?W]0IA3^[;@`_/N^JD MP=#("E'*NFD4:I/S(%10+G3FF@DZO^ADPV\>OR0YS>+*]9'$>4`]VH!CH/X M1/QV9[&NPS23IV_IGO!\G_)^U0V\F-=K@>_Q=JT._URCMTGRNUA6F0K>@W?< MP(MYN1;XQ@IJ959=EL4=`%S.MU)WX>\3WK!2'YQ;/P6[[]M]W@6[LICMQ),W M3BW,7.9XRMD9!_79G;[IF(U%AW=^LN6Y;[0XIRM:5D=V+M*?"MU:U* MZ#KF=@/&6'MVODZ&/*9K>T2K*\K;-H%*'MN::6(,=C43.*]G`G8I*(D?$1'- M(%RB\IZ(6U`BON$$Y]HF;14IQM;E)CFG2YWY<=($4;90[HI3U:].#8RE<<-;#$:^T;]U3:ZY,$ML: M76T7&%9#7R;":C;<5&%4;#$;#A<],);#`ZS>='";,:3CCF[#V9%'S8^)'&*K.OX)3]E M>$5*?MY0#F%K`[J.^O#>Y23T4MGS7DFE-A>K0)>\!@*](X@ULLSRE:@C$G1GE-G<]96N4&$=)L1(D2#SBJ"F"WC+U8"I6+=K_JBD2$ MNTW6M)A=_E3PW))G>ECJ-*?=_0Z8V>P9.R=?2)`6FT2D-;0Y;I!<)76BV&'. M.G\GP!YM.Y'+ZKS$(8]U?MZL;DE^L:PLT^&FO,]R?GK<*R'M2;\SS[#;\6.R MIQ8^X4<`#KC=]LPA*T%DKLFYC(!&W^WXN8P[^U,:DUSX"1?"!O&`8G'Z2/*( M%E7:WA5_CA>;LF!+_5@$O$6T^Q?",ZF83\'\$'Q'!BI'Y(ZF*9,]P@GW"PY, MKPX,Q.!C'DS/->8""#Y8E@;60U'G7V15@XC43>RF\I@V[8)G>'_"^1=2BF01 M9E&[WA??,SM<2E.WCV*X)`N?CG2Y%2Y:LW/8&ZHRC7\E=,?9_`W=[JH&@$Q_ MPTK#]A"P22'HU&`%/C#46NG9*><,49Y!TL(^NCI M6&6N;"B106&H#CD0`/#HS;@4M3C$752UW*P/6?]TP3U6R_.`SC);G>B<_-7+-CK2AA5/7KMMO5`ZK=OP3QX`SAE.*L6_1VJA-%A6>;T M=E.*2;3,V'PZX_OHURQ.8[>W8].!.4C,4`U#IEHF"/&97E)[+J-992I3Z<9" M@%Z#'IOF!$EZA]H5]:\G9(F9IX-$JDAH=U/J0G6.XEQS4Z="#.)[4*#3OXGZ M$-IK+O[-3(__X:C M/6;$UNJ$WJ65KQ%M>_DBS`R+_ZH2L@[COV^*LK[L_6)Y@Q\O^I!$C-K#Q3J4.TA?@="MN1' M7_=0C0V6ZW1"6*\CBJLLJ'5"ZJ=LNQ+710\0T[S@ROFTG?(>:M7%BS^<_Q9< MQE516+4IL+I(#Z.(E^2L4]=T>>@N>H!>H1=-^K?(,J&8MT"ZIH` M\Q*%6>IP*1TUNQ;H%Z@%Z_CZ*LO=:P#,RVN(93@&8E4"_>IT6'T'WJ7]8H@Y M7QR?(J(HWY#^O4B3WJ:RI9?TBLT=F/C>JSFT:A;UVIUK@4;*8US<7^;9`XU) M?+3]J>`G--M5Y"$O0J#E@+LVH/<^`;3JHB_>!FH:0;=;])JWPU[Y-ZA;@W=M MP7J_B[1.[[=M:O[W MRU'R*]G9OW@L^P$G_"QS=8)N/(&IWK"//J!W/`FV?(20O6$^W8H_>NWLH:HE MI)BSYZS67?2RLY7[:V.AP,7\C-MK6FSJ$RU[J"<[FS,\+(S2E7Z[(8_E49)% M7]2>KU4-T%#R0:N_PQA5RJC31K]R?20:F&MWYZ0NMGR#'RM\S+"K8W>R'*!7 M9(0GQ^;J`M.\OE>3W5)'77EZ?1V239+L*S^R,=\ZLRI;5N]T')&4+*GRY6A$ M`;T?&T)]^<=F.Q2]KG7FVXCSN',3SI-7PE)?N*F/J_0_.F=_L8^;C]@_^,DJ M]LE_`U!+`P04````"`!I;^)$V0P@\%DK``"#``,`%@`<`&EM8VQE+3(P,30P M,3,Q7W!R92YX;6Q55`D``W5(M%-U2+13=7@+``$$)0X```0Y`0``[5U9?'*4B2&%<+-!U2*)__0)5 M1;(.'(EB%9%DTP^V+"%1R/R0.!)Y_/T?K[-@\$RBF++PIS?';]^_&9#09V,: M3G]Z\_/]T>G]^?7UFT&<>.'8"UA(?GH3LC?_^.]__[D(3P/^0? M_C3X^/;8&QP=`;K]A81C%OU\=[WJ]BE)YI_>O7MY>7D;LF?OA46_QV]]!NON MGJ613U9]T9D?_.?)QDL:K+[U_?5_\DY/_/:#A[Y_$OQZ]F`PX+&'\Z36F/[TI M\??RX2V+IN].WK\_?O>_7V[N_2A%1G?\XX\_OLO^NFS: M:/GZ&`7+;WQXMQS.JF?^5ZII7QI)3#_%V?!NF.\EV>PR?F:@;"'^[VC9[$C\ MZNCXY.C#\=O7>/QF*?Q,@A$+R!V9#,1_^2Q9?97.9FG(?-[&9]&X1`50\G`SG8EGB`)D%J"?K:X#G7OQT%;`7N_$UJ/H:WGW"_-^?6##F:_?E M'RF?]!=D0GV:6`W7V$N7P[_E*V]$RAARA3UG7&/#5,S"X>0LC6E(8K/([;OJ MDI$+&OL!B_D(XG0V\Z(%F\1T&E(N.2],/-]GJ1C)=,X"+DMB9J=MAUTR=>71 M*-L4OQ!/C"2;(5RJI;$9^;#HHQ\\(A+PR3V>>U&R2"(OC#T?ML;`N^A4(UA" M^+*[\!Y%7Z8Y+VGK,L!7O/_GY$'[Q4P*DG;+HTZV[+.\N#6-0Z MV5^J/77)QEV^,8S$QO!0VAB`8X>1][1>`L>HI.AE[00.2M&^SW44+"X=69\+ M%7"`>K(MZ_@%23P:=*+DM:ZVH>70T0/I>])S88H:IP&__ZQ^>49"?J5+H.-O MTUGOS/!+*8DB,E[],=I%H\4R@7&S>=0\'UZ'^I&G-Y&;=;F-OL&;)MJ.^;`[V$PY` MW/6RF"RLAZDGZVF[LAXE@+:7+::5.+64?6XZ+<0*ZV!+-@_K\;?HJ\\=M<5Z M#>M`-^@Y/^1SVFQ/N^&_J)"0UX2$8S)>=B2&W'`V65.4? MO7`\R+L8E/LHQK_D(&!^9="!>']ED5%ZV:]^TXWV]#%.(KYA++L*O$<29!_X M+2.&T;YK,]Y"QMFC<$S\MU/V_&Y,Z#O!@?@A8^7H_7'Q)/P7_JO?\C'&J>1/V#1F$0O7<>^4\T M6,VE2<1FUK(LY,8,G)3%R\>P=0S..2.1%UQSW7G])UGH0&@T!:)PC!`&!=LN M<%CR\<"[E8N_V@(H]1-44I!P MRDH M4#`Q[W#WS4=V1^8L$B?ZW!%1NPDK*(#`?(<*&(@0W('S*PF"?X;L);PG7LQ" M,KZ.XY1$.G24)$!XOD<(CT$,[O#YA04I%V&TR%R7M5K3:`K$XP>$>"C8=H=# M-HYSOIY.6:2]0-0:`C'X$2$&4I;=(3!*'P/J7P7,DQD`5J.N-`-?WA"*7\*O MPST\\W#+G&;O,S>W89ID,1E\*]/NY%HZ*#PH+]<`B;B\_*T/@E?\-XJ-0]D8 MB@S."[B"=_=PY%=3,""5YE!(<%[*E?Q+0/G[NP:#-_P7/=O)Y=$J%!H ML`HBX#^?LS!F`1V+)\U!03_(0TI:6<7+$VSBQ8\94&E\-/6\>3[+2)#$R]_4 MIUOQZ]]6(QQ.KFC(QT2YX%E,#2;T@AQ&O;'^=,#>0]D?7,-(T*PH\@ M)#X=187?8S;"+V3V*#5Z+;G7$3E[J]*(6JXJ9M:[/"*WQZAP036>5>KM7+V8 M:[8'*1!R_C#)OC!70R%H-'?V:JZ7L`P&!:LXT!!1U9KM(ONKZ_5'+T8F&3$F M"1<.M?$=\0E]SMP[25(PHYGV6BIGS^W1\^3HG84R,\"B:.WN`;X&,EF,M`,M$Y>[*W@0G&/`Z@/C,V?J%!H(9DW<+96[V-\.L, MX1!S-:F&:F]Q^2#?[HZ^+UM**9;7?*>7-G;W5F^+G(97',I2&B#8SJ*C#3I22O-LF`- MGUD".)`JQ\?7ABN>I^B$DK$1.JM.H%CV9J"PQK*%C/"!:P6B-5B]V1\V`@LE M*$V.;$Z/<$AZLS5L-10\8P#E)+WO0&19DLH'#U:,BSA4'&+`XO3\3AS7_6" MD4?'U^&Y-Z>)I[&X*@F@R/1FR+!&QL`[#H#N1/J9D(POO2BDX33F5\)TEF;G MSUK2^R96$%HH;+T9.:QA@TL$!X*E\66>`**"342>^,6=/I,\F]8-B\7KRW#" MK_%:@X==1U!L>S-XV*MD.UGA`+K)K_?3G4EV40CFT@-5-" M`>[-ZM'J&48GA4[1=AHZIBLF5(DC^P"/(QM\4^GOKX>XLD-&U1BH:;=2$KB.N&J/#<9]RC(!H8JU-CM4;PY0[1&";4]NC.&&HO45 M0_A'G2%\W=%@.!F4NG(W"_/GP]7`S%9O)8%3=X!G$J8ZM_AU"\<950SR;KSJ M5QG#L7(5$S><%I[V@``L#8EKTX(=(D;><4!T.A-)V?_,A"AJ?LI+A4N\*0QT MKDT*9O$S*WXP879!N#1]6BEC)0D&J;1R;3VPQ4/&(P[ICR(V(5D`D1<4M=H$ M'_J8^6085Z:P','K71@1;Q.SD@@/+SR3D3(KAGHYG-,PJ=XFJ=480C82N M30FVZ`$E@0.V\E2[(KKC7+.E:[O!)FI5YA4'$G=<>'P,3Z)4.S^"!BS+66)4 M'P.9:_N!+48@*>``K,&:Q5'-ALXSRL`ES?2< MX,*CJ*U^SA(B\,`YR^:X6"KY^ M`.SV77W`>9X:RZ-IMX+%/5O$O)8QQAD0C(5C*9OFT,R^ON<\3TXW.> M6NWY&XF'&_Z')(GH8YJ(N(8'ED>.=;-<=3`,YSF`^EO4.@-IUX\X$GF95SXM MD?,T17:S!B``'&O0,O7!TE7RS(NI+VRW-$@3G<.;D=!Y#B([Q(""P(':KWSI M>>*C.GWF%Z4IN4U%D,UPD@V\Y!0&!K-M?\Y3&MEAO)G84+K6B4HZ5P%[47C6 M?0OWK!,]#?*N$,29ECBS"BJ74+F]ZHL!C2+V3#G*9XN?8Y$L?V7#/^4'AF=@ M.NXV?6&IA*9!LVDW:"DQ'"MSO\8=7$!U^`+%%^1'%A/W)]>235@DW/59Z-.L M%M::V0?6F4[W\S77_H8M9E.?8L>Q,#AV+NVOR%R?R.V'7RK_.2"%9:#,@QIT M&+5KK\@M0F\CSMW?A)874#(6=@02QH;IHFKOVO%RBQ-$+S(<:T)F2KSE0N`< M&Q]TI8U=.VQN$5"-L!"A^?4\#/57$G#+P??$<4G!\'3Z3N*,74VU?SMVLNYLE`)GA MN(_P]:ZX_I_Z?Z0T(IP3/L.3Q2CPPH0O@Z)20!9&JL;:I@_G;M4;`,9:W(P!DAF-]X`/W"1G'5UP6 M(@VAJ(0RC.Z]@`PGIN(Y$%KGWL0;`-1(B0&4%`YD+\AC M%WTF(='Y3`%(G?L<=X8K6$XX8"U/PU)-ZX5@`Z:J32KGSL6]**E*.CAPO"/S MXD@YG,!QU%,Y+[3:&8X0Z>#`$SPD[.Z.5(]+^QZ05`5UGIFM)'3/LP-/>8HJL"VPG)CC.89]/SK4;(+ M2/UV@J`$;$NLQ-@[0>LR'+O'ZCZ=SX-,"EZPE,)U.&'1S`/6RX1V@*+83&"*D\RH8C9'FO^;W\<)%5016\E-DK;G=EI.@V@,4\MX,6OU!+A,5?H!'Q2HVG)@"M^QZ`8=Q[1[0*I'A M`%O8;OAJ\TPBD5$`>)FF M<^1130:,:BLH4/V9LS8"2L8R%C"*+)PD-N%1:PB%I#\[TH:02!E'F5,D6\R? M6,`%&N=OB!=D0GVZYJV28^0[8(X1-AF4>_ZOO_QPU03%*YHC0T4WX^H9ZN0,E6*^G3J`E*MG?R$BLYK.\4/6&DT6)`M0='SC M.'*7JL::8)$T19-+R`(3)<(F\!U>.[-*;]3F,`QD+G.`]0& M*)`DD(#F^^DLS5Q^I,D`C.@!Z5WG]&D%HY5L<.!Y1Q*^>Y+Q,NVK"3]5>]<=!SX6U=W;EW3O_R31N-;)TA89ZKCOL*M*\YIN>"^IM45S^C#BJ&1T MCX!LON_DTW?U>*OW3++I`\UI!@2\E6"0K*^0Q_A6>,JZ0'.J:0FG6BPXT*Q& MB]1=5/-4:D1CN8;2HSGMF'"T$\BF(-*9'Y`,F_?'!3+9KVI6D=4$6M8!SU<) M"2P9-9#8=4Y`,R8VW+@%1.6U!^'`SEFO_VC1C>#8'6^\?.)LY'%?"!`[ M6?>7E:[;NPK4GWJOUX_EJ6;3-6/=C_,4=!VO$W4)[=#:T!I<53=X$L5UL@+L M%+3YM-S8R5[5#9[L;ANI+6Z/>L3A$_VE=.M$9P&X[N@^;0P=*.]'F\1:U/IQ MGOC-RF)I+R$<&H\PAF8+Z=@V1E0=+K.C6@Z+]%5:O_])7+K&%65/7U'%;U2LT?AQ9<]LFD^' M_T_>H0BU77;P;$P.-;>RMD!-[TO/.\6WGKI3*1HT`?5KM8S3V6>#X61PO^YN<+KJ;S!:=N@T6*88 MS7(P9GW5T;C<<-=";H[P@<^,,_[QWS6;,)#>L;*:$:MOSE9R0:.55QZ-LKOX M%^()CNAGLJA)LJ@ MNP[G_*2_'BE`(2V[<:R7$`QKFME*3F@4=#W&*$^P/A<)UI-U-6:Y?AZ_K^MG MD9]]D"5H'SR4.W`9=;A.&E\>DEDMS91.@RGE@[-23*M.'*LE%,=&X*6UG-`H MYBU+2*.D:44%CQN744$R6-*X?9Y<#\RL:ZKVCE]8K;1)2>!8<_182%Y0=T$W MUF/TL]038WLY0( M&N4I94:4:\R'NL;D%(.7N76<(4Y6G-B@,@=5O_3CXZ*W6RZ\6Q>H&Q;!;#LQ85&J6[YKV% M4\KO,S4/W8KN?=O:V`K19LIPJ)`Z=H=QH\@B1R!-EN;__'5\2D+E2]SQ=W6=+O50>F%?]N$V MWZ.",QO]MNS&<8)+XT@!JF[;CV.M;X6S)%.FO>C0[,;WZ6-,_DAYIY?/@@>Y MYC:<9-9D@X+.H26CQ@*D(IR*PFF=N^J@(`88-8ECS3)ATJAB9^`=D;X4GBC: MU_N5`XE4FS;P2!E\L_S)99&'/7)..?-B&@\GM=$M\G\#5!!*OVO.*79RP>&# M_[,(^[R,$SKS$EUT5+V=ZU2GUN#(&<4!PC(C[HA$F2,Y6).,A*XSF5K#!!0% M#MP4!;NAZ`')72A-_Z%8LN6/J8 M3-*@D$1<+"-<_E](\L3&+&IG765D[^X3KO*;6,Z)S\>*8-5E,W7D:"9'E M]BN`UFN)7&$;](S%GL!XF0L,!N\PMU?*Z8M&%ZRRLU@!;BP<'JIJG!S"L-GVX3LMJC:N] M@'``>T>>29@2?DY@TS`+8P?C"2!UG9'5&D:P.+"@%Q,^!G'XO^`C#UCVP'[Y M.B=A3$SG8Q"Q\T2I+2`$RP0'B"MO)/AA2$GA/*NI_8G'P#T.C#+3R)G(^R+R M2/"9E(>TSHLX5\X$%PT_H0EGE]BD>*TZ?)1>R,34!HXL+LE+R4.(Q;R'_T\=-/R-F+?D_/LH];8MI46#JSY:2WPXCA[ MD33D3Y`T=9Y2M,4)1\$OF@=H0/AU5J9:\?;<-@A[\$W>J\MGYSV+QK[WG\@X M##E<#X-&[E75&!(]&EQMY%1K19)OILK)T]?JC\N%J-#/K`$Z/0B7;1)1!B%VI MG"4&!EW;G9@S@,G_@B0>#13ZULBE`+;Y%]WVIH9PSN"JV:9/IWFXBH3=#^6T M@+)D6]5V)B5LS.%>=;$]D(TD7%4VRTY0&%"ZJ5=LAL<<-I-7H!ONX;C]0D,`]AYZNR,Q>,O9/:HJVFF)7)M%6TU?55(JJ6" MPRPN&^A)&_A.+.'KSW%NB8+L`KR2`O4QV4RNLC:X@#'?DIJ@$-E0CE_HF1R^4K\5/A3#2<3ZI/(=(G3$KD^ MWZMG7#TFSLPZCL-\-M!5_54;C%1$KH_Q=ACI64>$45'I-IS:8*0B:4K6CO>I,!VR'T#.^%_:$4 M49",J&)UAC12/Y=C499]BJR%Z__,BAZ_FO_]@D;#N'&BG:].@W+ M3_+AW;!85^:^V@R)+]Y%T6+" MHA6MG24SWNZ*N?EYB25>@/?BL^1Y]4=9L++V-M0HWJ*^#2T_5KX6%;%J_(.# MTA==W9)LQ+'AU:G=IS#DCJQ&+J]^7:2]+%3N-+DB?`7P`F%[2/F0%I5CIGJY MZ?@SF.]SF\PV56K++L'!L5LI6+ME8@5,^0WF,2`%>W+SU3F+(5DX-NL>]06Q M_XG6#HV=FV`7A./JYW_GTCN=L2BA?QJLPEWUC_J2ZF:*`?!`-L>J"S%@TM0) MG-UN7ER:'. M03#^<6!UZOOI+,VI?173 M4[GV6-YA<5`TR M))^RZ63_46[RC,/4H!GR>L"WWLQH=K#N"`?F+>8Z''0YXRC,$B-^@@SY"`W& MB%HSUW>9EK.U?BJ6\8[CMC),GDC48,T`DI;(M;ML-Y`!Y((#0`V[!CN2F1*Q M]IDNHE"QH`>Q9"2!N8>TZ28.,?3AY"R-.?/"#AJ)%L]$>_5L5&+-/R!B<->?R&)N M2Q\1?UU^9O#-ZD-;",5MSS[\(MO%-[I5XE]9]#M?+,Z].4V\X(),J"\-",I: M*QHCB6[M#L"*1FLEA$9Y[]/9S(L6P\D]G8:4CU%X4OD^2P7[TQ$+^*@)4'$; M55V+SH5NEKH?K/L?+#^P795MQ[2-W6FS_C'80';<+-4%P`>K%38K"5ZKU7*+ M./7_2&E,,^%IK59*@AW"0\D##JN5;'CBQX@8K5<`4APX&>8=`+`:6QM:LY2[ M[_7J`')#9S0A8Z6)*FNO;.[:"@*>5)7#H(%['":1)6OG;/9(PR+?11C3<7$N MSK+QYT^?PM,^65R'">'B3PH#CZB:+NZMVH-#IQ]Q/1G`!I<>1(MVSHC$%_S4 M]2<97X^Y:/CQRRLY262J,J[F5.!_2V?EYW?`OMGY!W?&>->SR'',J\^,C5]H M$*@GPKH%?A-?8\B81-W/?,H;9XZ-#T]>:,9SR\-PG:K3L;H;X$%CGU)5`X)9 MI#[:5-[;I@4*RM;FY?@.5J:MU^4[V)4.=J5#@;Y#@;Y#@3XS<*BSD'I!0<3&L9( M&A4!$D1TL\L$#*KKWRU+2#SR%F)F99;QXF=CA@HCH?/'!OV M_O@1XG(V#UAVGCB=1H0H:L1E)#H**&P.C3I&'C`=<;.UX(SO]6-12I*$L2'I MNJJ]<[.%`O&)Y*=SKPSP:L0[`?UD?K&W3!?@='34S1>@='S8.C MYM9?J_?74;/'UTWWS@.'U\W>7S?=7UIW_G5S2PX?[J^I;1P^W-Q:\VQOL/OJ M=_7[:DZ\W8NJ?,#P*ZJ)'L,E:*X(!ZXMYC,< M=#GC*!;7$9_._%)O3!U=;>8Z$K'E;*UGE9;QCF-YO7P5B4GYL?E)K#7#B7@: MUJ^E:@H<"@9:.-5,E&84,E@@/G8F.AP0F28=`"QT3G<5US3CHX:LL>M`3-B< MTWE"8ES@JD\NOS#!XQV=/B6:)4Y'X_K)">SD8V8=L;?SE8HN^\:VU.(G_L4/J`( M/SQZER\7C8CLEDNII)^=R>?33D![H(F:M6?S>:'JQO6]O9.E^>N;%;DVC-+( M?_)B,ISDEHZ6JT6SFYU)-=1*/'L[*S)EV'A2*'IQ?>OM9*7H?$H@R=1@3+E4 MWCXWR495ZP=_#J.6C&$Z,B),,N8RDY$U3[VL^F["K*[Y_\_(@_=*@)7#OZ_' M6N4]#+(NMAMQI1D[/.P*U(E#75V5D+MA<7S.1[B8L.C%B\9QYKR4385X&/X< M:^[;-GTXLW*VP46JQ_82P[$J7TXFQ!=LKEB_XRL77X/T>'X]4D.UN8TSF!B'<()Q`_..)HE4.%N*2` MB''@9C$_H6"B\U,1H5UI0J+5"`%!:G("UYX0%K.R&;BFDP&.BX"2/7YEF:3! M#9UH#A<@8M<`6KBR@$6!)G--W5T4=DK_L6E7678SR/O9MG%%SX6-A07:$X9C MXDZ?W6U!.QSAD1T-$1_AKSP:94]>9XML8Q(]"U:O0WX,XG]FH4\#FDF]S)TQ`J>W+^*8 M%\:YKIHBGBNE+1Y4 M6T%+Y!HZ\*T!P#J:R\)]^AB3/U+>Z>6S&"OLAG!$X6"YT^=_6]`.AWYDAT?$A_[:W#([ERD)=@D/%0\X#NZ2X1DK!JI)D."B MGV=F@%`=L6OC,R8QDC=W?DXSS3,]*A@/TX?"IYB*+QP*GV(M?'K#O'!99M)H M()"T=;YT694W57.[^\^0U0J%^N5.UA:)9D'6.MGP<11KJ(X,8E-54^``1#VM MM*#@,X9NM-#]=N+^#=XTMXQKG6!B7U:[0]$M4-$MQ^4;#D6WOO*B6[WEI=JC MHEMWA*_IU$^`U1T5S5TGA;(!1,LQ#E"R)$1G7DS&GQD;"W>;6\[7;!ZP!2'+ MY':E6BYGB_MT/@\HB4R&ALWZ1;86ZBT2F[&*H_B&+1=+'LP6CLWZ13(1.E&3 M#2=.731]%7\[9V&&,XMET9;'IT>RX#7B.\=@H;8!]>&'6T)9HH.#V%^RP M%7`;4MJF[CUP$OL%LD(%A:F_!/3;@:DIJ6T"=<52=5%%U9C+1%"8^LLKOA68 MFG+:*DKTV5Z;RD10E';\/-B4TS91NJ>OUB"5:,#V_]W&J"$E'`:90UGG+LLZ M.Z[5=RCKK&0-Q=O`!8V(S_LVV:+K[:!+9&]'=W`=9SF'.):Z\R=*)JMDS,#* MVEHB*"[NZVL#>._OR""^?>]3S@[EWS4)/M]`M310N?=V^#;+'<`%.MVXHJ$7 M^M0+;'1#103%J+>CMYUNZ'G'`=(7+_2F>OMXT;39$ERAT#D<*BYQ8%!V_X%Y M.B%PYH3&"\J8PR'VJI/6%R])(\KG$><+%,X))'?MBF95&@8LCMWW2JNRVP+Q M-BB[+]9J9!N';F;.)G=D7E0>&Y^&XSN2$N`I&*=YN'>JA<@A@BJM+80SNXK M[*$&[*$&[*$&;&?38N]KP/93HQM!]5:L-;HMGSQ*9X_A)",9KJ;A'?&)R")C M@*[SKSEW];*:!#T)&]MT$H[*A#.2@\!YRF_R9XMU$WZ_S$*>1`6\VU3<\(>3 M?-\[39,G%M$_87.ILT\!)Y+[$J^]B1G1+'JLLU9BHA*'/'E M*XE\&N=+[9T0QS!-XL0+QUG5O>SYZ%="IT$/X'S;<^;D@K)&9G2,,PR*_/N M?**I-(MKE.X=*JTF+QJY]?SD(5)X?_&BWTF2'=VXYJU9BC]S?4VD:UQ&#*-U M[ZII!-Z"&U3+4#4+!\C:I*-Q[W<)5E$CY[TIS.6K6!)(S.\[0Y6LLY:2AE`! M.S3HJ8:NE*HZ!U_Q%_$OL9KRW_P_4$L#!!0````(`&EOXD1\)?7N]PH``!AT M```2`!P`:6UC;&4M,C`Q-#`Q,S$N>'-D550)``-U2+13=4BT4W5X"P`!!"4. M```$.0$``.U=;5/C.!+^?%=U_T&7J[V:_1!"`O-"!G:+"3"76R`4R#TR0NEO=SV/)W8HMCG]>F09Z(%Q09IUT M^GO['40LC>G46IQT?IUV3Z>C\;B#?O[I'W]'\._XG]TNNJ#$T(?HC&G=L35G M']$U-LD0?286X=AA_"/Z@@U7MK`+:A".1LRT#>(0Z/!'&J+#O3Y&W6X-LU^( MI3/^Z^TX,KMT''O8ZST^/NY9[`$_,GXO]C16S]R4N5PCD2UJ:L8/@[/!?O]P MOW_0__UAL+>:0P1GV(%>V0R]^^_EC\&L/Q@>OAOV#VN.Y&#'%=%(^ZO]X%\] M]2LJM$BY]\O"?GR_NJ6_+8CUP3W#UJWV%8\N/N.;HS_>K@:?_W>_?/CJ[,^_ MF-_>/QU:U_;M[)3>_G)P?F&.9^.1/^2QT);$Q`@XM\1))X'CX\$>XXO>8'^_ MW_OMZG+JR75\P>'*H-9]D7C_Z.BHY_6&HCG)U1TW0M,'/=E]AP6)+$,O5`B6+699K%J.C.[SG/-FD!T)=D"*< M:I%>M5):`7R0S<7>>3T%WLF)0R(-:IJNQ33@5V/, MFV=DCET#&/SF8H/.*=$[R,%\01QYT0L;:_5LAO,'6Q:#:09+2M`BVVR;PCR" MAK\=RPMN*`&>01A(?H"%1#6"%.G!5'2EQZ>6?FXYU'F2\Y*;WC@=1/63CE)" MC@Q^>&/K9$XMZCD8S/X^ZJ)0/?D16SKR;:&$L>->UDS"N"N(/K%^\C[;G`@P MXRE=0D.@&(B4*&G8T%RCF4[L2J%*T!!B_@P6/F%#SGVQ),01/NSI)C7.`P!7 M+L$D`'K$+,$,JD.+C@)#:.I9:D'V<;C!'*);$H>"SRG$B_K5\!_4AQ^]21G^ M<8?IB!`3D_G$END4C!E<_"5]:AH.533$%M%DCF*;+0$>R",LEA<&>RS`/^Y2 MP_^V/OS2)/)LMO![&$\=IMTOF:%#S7#^S84;(V0/5*-.GHYR434][VK2P^8H M.<2___5AT'__$?E#H3?!8+N\<%U#K<-)]H?T=)BW&3;BFB?D3FPNZL"`O MUS`$JFG,E9`M;)@3&B4!=8VUU`1^R!(X]:W*-7$:VT6GD6%T$UC>8>HN,.7> MWL`5P1(W;YV"*90@QV>KCJ":H*,L0=*DOS&!DD:]298PN\/LQ"AP8LB;B8VY M\^1P;`FL)5*Z&G)*;OK[66YN?3OH1AI"LX2E':;CFCD$BI0X/:3;%%# MW,_=8*0N"I1W&-48%&@RX0I;8IZ_1Z3ZU$@/LDC[^=4.0SR&WTTRPZL0UV2# M&LR#+)B^*O)T=QA2>4W9\G[E`QK_JH;SL.C:]!1W&,LQ1&,M*"R#IT)$FW2Y M5C6R;_,7:JB/?`,[C/`(5D_JA#F;7\$LB!4GXRH!->[OLK@G3"7JI<#8#G,P M=>\$^>9"4.9,ILOUB])`7,W;NJ4I>N.;WV7*@DK1*Q23=6*2IPH9 M)3F#!K5IRTJG/J&\FIYX:9#*/&C\1"QQQ4OPTTE"3 ME2O/TUE3:%[6@W$/"H;XL>6OC+\S,B><$SWJ]._7L-Y=4GQ'#7`LLSX^WXR: MZ5RI7\YT.&J2\B#?@)%18NCV"DAEUBE"9N5/G%Z37+?*Y_#J%?%FG&OEO2#Y[-HF?/4-OHA';6TCBFX")>E>_F.8U==44Y_8>FGPST));J^@J MIK.VM)K`W"Z&J@QK"2M];JID:55)J(G)[5^DGJMJN2A(KIVG8A9*^M3XY_8G MPJ?96^#+ZMIB]%4":@HJ=AU:(HK+R_))4-RM)B&W(9`H.%L&E,5GV7RHD%+S MD=L`*"A'6U[J/B563%$3!25;A[G-@^139*?9I\A:YBHV%RO3"&6D M;<6!%1ZI63B"D4,3F&LY*[D#-<`(LPF7F\N]T/O0@$,=J7Z3&`;)<>!JZ;U( MS`:^:QHSJ!#C.P9[*>V_;)1P`3:-,G/-?J=81_$H+QLQ3)^F$:=GW'<*^"P: M)!EO<)Q'+S[/(_@]>^;',43.N(.LW!$BJA-E_+-P+IGFF5*HR-^ZH5Y7-G7[ M@^Y!?V\E]-C3)D[$,#1S(M1;PPGEN38E7A3JR`_=6+GN^,I#6ES7":K!:EAR-VDDX[#7;GJ MR/.FAK`:4:;/O%53=_UM^@[R5U'_T*6ASDQ,K;%#3"D&04/&!(N5*T4_<^;: M)QW?%@4193CRU"/"Y;V:ZOZ!06>4$TUZGHJFAMSF@_DO7MC8^`\SY/EP>4;* MNS?O.E21'!9QJGV!=DB#1Y"'I[U72FP^@!F^)Y,'PD\7G'A]:>_+NS?O>CQ' M(^]$VGNEQ.8#.%\1S975$4Q+W]7,[%4);-[]Y"[]Q%G",N-_%A.+I..H);GY M@,91.7U)39#6,S.YM'OSKM]P9E(A&'^26*?]+NG;O-.C)27SJ4:A57[A.9G# MC^P4J)#9@B"8)5Q#;D:5+*$J@:UT/S=]*V2V,HA^90C][0Y@]L@J0TC*;&<0 M2_A0'49*:BL#N6!N=F&J$-K.,""7J`XC*;2584SIJC**I,SF@U"=['H*1CG6 MG#"8>K(X^!0&U3Q(7T+(\F3Q,CE(\&2S=ZC=6`B7Z%!_A@7T-#C()4Q*Z@FO M&Y6G_Q=$Y;T94S.H4+9!3'[?G7^PZ4E'`]ORI,)DJ":SB(/YTXMYQK[7?WFJ//YU;&PS)A5O*94#45MQFZ-O\@Y0.13K67EUN#1Y MC:8A6.N9WF8$L^^ME`-2+KG-\96\+*+BO4)AFZ,M>4&C_FWR%42;<5EF-=YI M^?(1'_G!\+]3OB91N(TT-I[@Q>2L_T9'.>$O87/[KHFOC-^#J1&VJ8.-Z`!M M/_BRSDJO_6_#G5S6JY.[ORKI7>==#]5L?YZ][2.^.L^KCTYS"]N'QXQP4TSF MYZ9ML*?4%TW1-V@JB8W[GUBH%.]<*):W6EK;QULZS8WQ/'VYX+_JK+Q/92C<^0=CCRK\4%3TO5D]W61/9\91-+P/V8<-_G^#F2 M?$?]((*O1%Q3=GL;\XV[YS_;!QS\!4$L!`AX#%`````@`:6_B1*^;Z4I3 M>0``D;T$`!(`&````````0```*2!`````&EM8VQE+3(P,30P,3,Q+GAM;%54 M!0`#=4BT4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`&EOXD0PR\^QO`T` M`.ZJ```6`!@```````$```"D@9]Y``!I;6-L92TR,#$T,#$S,5]C86PN>&UL M550%``-U2+13=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`:6_B1(5_V[F' M'@``X2D"`!8`&````````0```*2!JX<``&EM8VQE+3(P,30P,3,Q7V1E9BYX M;6Q55`4``W5(M%-U>`L``00E#@``!#D!``!02P$"'@,4````"`!I;^)$AC"W M[P@W``#Y#`,`%@`8```````!````I(&"I@``:6UC;&4M,C`Q-#`Q,S%?;&%B M+GAM;%54!0`#=4BT4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`&EOXD39 M#"#P62L``(,``P`6`!@```````$```"D@=K=``!I;6-L92TR,#$T,#$S,5]P M&UL550%``-U2+13=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`:6_B M1'PE]>[W"@``&'0``!(`&````````0```*2!@PD!`&EM8VQE+3(P,30P,3,Q M+GAS9%54!0`#=4BT4W5X"P`!!"4.```$.0$``%!+!08`````!@`&`"`"``#& %%`$````` ` end XML 29 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8

Nature Of Operations And Continuance Of Business (Narrative) (Details) (USD $)

Jan. 31, 2014

Nature Of Operations And Continuance Of Business Narrative Details

Working capital deficit $ 141,129

X

- Details

Name: imcle_DisclosureNatureOfOperationsAndContinuanceOfBusinessNarrativeDetailsAbstract

Namespace Prefix: imcle_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: imcle_WorkingCapitalDeficit

Namespace Prefix: imcle_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 30 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments And Contingencies (Narrative) (Details) (Lease Agreements)
12 Months Ended

Jan. 31, 2014

Lease Agreements

Lease commitment terms
Lease commitments are approximately $38 per square foot or $63,000 per year, plus charges of approximately $4,000. The lease is paid semi-annually on January 1^st and June 1^st.

X

- Definition

Description of the nature and terms of commitment.

+ References

No definition available.

+ Details

Name: us-gaap_OtherCommitmentsDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Balance Sheets (USD $)

Jan. 31, 2014

Jan. 31, 2013

Current Assets

Cash $ 51,956 $ 167,146

Accounts receivable 14,309 34,399

Other receivable 7,745

Prepaid expenses 510,329

Total Current Assets 584,339 201,545

Property and equipment, net (Note 8) 6,241 1,262

Intangibles, net (Note 9) 19,793,466

Goodwill 654,992

Total Assets 21,039,038 202,807

Current Liabilities

Accounts payable 177,817 456,510

Accrued expenses, primarily management fees 469,888

Due to related parties (Note 4) 2,704 56,685

Notes payable, related parties (Note 5) 2,062

Notes payable, stockholders (Note 5) 72,997

Total Liabilities 725,468 513,195

STOCKHOLDERS' EQUITY (DEFICIT)

Preferred Stock, $0.001 par value, 9,000,000 shares authorized, 0 shares issued and outstanding at January 31, 2014 and January 31, 2013. Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at January 31, 2014 and 0 at January 31, 2013 1,000

Common Stock , $0.001 par value, 290,000,000 shares authorized, 26,503,515 issued and outstanding January 31, 2014 and 5,361,015 at January 31, 2013 26,504 5,361

Additional paid-in capital 33,164,274 72,094

Accumulated deficit (12,862,769) (389,628)

Accumulated other comprehensive income (15,439) 1,785

Total Stockholders' Equity (Deficit) 20,313,570 (310,388)

Total Liabilities and Stockholders' Equity (Deficit) 21,039,038 202,807

Series A Preferred Stock

STOCKHOLDERS' EQUITY (DEFICIT)

Preferred Stock, $0.001 par value, 9,000,000 shares authorized, 0 shares issued and outstanding at January 31, 2014 and January 31, 2013. Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at January 31, 2014 and 0 at January 31, 2013 $ 1,000

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The carrying amount for commissions, taxes and other expenses that were incurred but unpaid as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Article 7

+ Details

Name: us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20

-Article 5

+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a)(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.

+ References

No definition available.

+ Details

Name: us-gaap_OtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=47804770&loc=d3e5879-108316

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Stockholders’ Equity (Deficit) (USD $)

Preferred Stock

Common Stock

Additional Paid-In Capital

Cumulative Translation Adjustments

Deficit

Total

Balance value at Jan. 31, 2012 $ 5,182 $ 23,290 $ 11,879 $ (321,190) $ (280,839)

Balance shares at Jan. 31, 2012 5,181,698

Common stock issued for cash, shares 179,317

Common stock issued for cash, value 179 12,371 12,550

Director loan forgiven to additional paid-in capital 36,433 36,433

Common stock issued for acquisition, value

Common stock issued for prepaid services, value

Common stock issued for services, value

Common stock issued to acquire patent, value

Common stock issued to extinguish debt, value 36,433

Cancellation of common stock, value

Net loss for the year (10,094) (68,438) (78,532)

Balance value at Jan. 31, 2013 5,361 72,094 1,785 (389,628) (310,388)

Balance shares at Jan. 31, 2013 5,361,015

Preferred stock issued for services, shares 1,000,000

Preferred stock issued for services, value 1,000 179,000 180,000

Common stock issued for acquisition, shares 10,000,000

Common stock issued for acquisition, value 10,000 19,990,000 20,000,000

Common stock issued for prepaid services, shares 10,000,000

Common stock issued for prepaid services, value 10,000 690,000 700,000

Common stock issued for services, shares 6,000,000

Common stock issued for services, value 6,000 11,994,000 12,000,000

Common stock issued to acquire patent, shares 100,000

Common stock issued to acquire patent, value 100 199,900 200,000

Common stock issued to extinguish debt, shares 42,500

Common stock issued to extinguish debt, value 43 86,464 86,507

Cancellation of common stock, shares (5,000,000)

Cancellation of common stock, value (5,000) 5,000 5,000

Adjustments to reconcile additional paid-in capital and retained earnings from IML acquisition (52,184) 507,176 454,992

Net loss for the year (17,224) (12,980,317) (12,997,541)

Balance value at Jan. 31, 2014 $ 1,000 $ 26,504 $ 33,164,274 $ (15,439) $ (12,862,769) $ 20,313,570

Balance shares at Jan. 31, 2014 1,000,000 26,503,515

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: imcle_PreferredStockIssuedForServicesShares

Namespace Prefix: imcle_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: imcle_PreferredStockIssuedForServicesValue

Namespace Prefix: imcle_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of other increase (decrease) in additional paid in capital (APIC).

+ References

No definition available.

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=35737396

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Net increase or decrease in the carrying amount of the debt instrument for the period for reasons other than accrued but unpaid interest, additional borrowings, forgiveness and repayments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(f))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph f

-Article 4

+ Details

Name: us-gaap_DebtInstrumentIncreaseDecreaseOtherNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares issued which are neither cancelled nor held in the treasury.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of shares of stock issued during the period pursuant to acquisitions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares issued as consideration for cash for development stage entities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 215

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6472370&loc=d3e38297-110927

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForCash

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares issued for noncash consideration for development stage entities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 215

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6472370&loc=d3e38297-110927

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of stock issued pursuant to acquisitions during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of shares issued as consideration for cash for development stage entities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 215

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6472370&loc=d3e38297-110927

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of shares issued for noncash consideration for development stage entities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 215

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6472370&loc=d3e38297-110927

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForNoncashConsiderations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares that have been repurchased and retired during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 33 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8

Notes Payable (Narrative) (Details) (Promissory Note - Jagpal Holdings Ltd, USD $)
0 Months Ended

Jun. 01, 2013

Promissory Note - Jagpal Holdings Ltd

Notes payable $ 17,852

Note maturity description
Due upon demand in 12 months

Debt instrument description
It was non-interest bearing promissory notes.

X

- Definition

Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

+ Details

Name: us-gaap_DebtInstrumentDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDateDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13, 16

-Article 9

+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 34 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Equipment (Tables)
12 Months Ended

Jan. 31, 2014

Property, Plant and Equipment [Abstract]

Schedule of equipment

Cost Accumulated Depreciation Net Book Value January 31, 2014 Net Book Value January 31, 2013

Computers $ 11,327 $ 5,086 $ 6,241 $ 1,262

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8

Equity (Narrative) (Details) (USD $)
12 Months Ended 0 Months Ended 12 Months Ended

Jan. 31, 2014

Jan. 31, 2013

Jan. 31, 2014

Common Stock

Dec. 13, 2013

Common Stock

Debt Extinguishment

Dec. 13, 2013

Common Stock

Patents

Dec. 13, 2013

Common Stock

Executive Officer And Directors And Management Consultant

Dec. 13, 2013

Common Stock

Immunoclin Limited (IML)

Jan. 31, 2014

Series A Preferred Stock

Dec. 13, 2013

Series A Preferred Stock

Executive Officer And Directors And Management Consultant

Preferred stock voting rights
The shares of Series A preferred stock have 51% of the total vote on all shareholder matters and 66-2/3% of the Series A preferred stockholders may make any affirmative vote to amend, alter or repeal and provision of the Articles of Incorporation or the Bylaws of the Company.

Common stock issued for acquisition, shares 10,000,000 10,000,000

Common stock issued for acquisition, value $ 20,000,000 $ 10,000 $ 20,000,000

Share price, per share $ 2.00 $ 2.00 $ 2.00 $ 2.00 $ 0.18

Shares issued for service, shares 6,000,000 6,000,000

Shares issued for service, value 12,000,000 6,000 12,000,000

Stock issued to acquire patent, shares 100,000 100,000

Stock issued to acquire patent, value 200,000 100 200,000

Common stock issued to extinguish debt, shares 42,500 42,500

Common stock issued to extinguish debt, value $ 86,507 $ 36,433 $ 43 $ 85,000

X

- Definition

The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockVotingRights

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of stock issued during the period pursuant to acquisitions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of stock issued pursuant to acquisitions during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 36 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events (Tables)
12 Months Ended

Jan. 31, 2014

Subsequent Events Tables

Schedule of common shares reconciliation
Common shares reconciliation table:



Issued and outstanding as of January 31, 2014 26,503,515

Subsequent event issuances and cancellation (32,361 )

Unissued and outstanding as of June 30, 2014 26,471,154

X

- Details

Name: imcle_DisclosureSubsequentEventsTablesAbstract

Namespace Prefix: imcle_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 855

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662

+ Details

Name: us-gaap_ScheduleOfSubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 38 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Nature of Operations and Continuance of Business
12 Months Ended

Jan. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations and Continuance of Business
1. Nature of Operations and Continuance of Business

Immunoclin Corporation (the “Company”), formerly Pharma Investing News, Inc., was incorporated in the State of Nevada on February 8, 2011.

On December 13, 2013, the Company acquired through a share for share takeover transaction Immunoclin Limited (“IML”), an England and Wales corporation, which is now a wholly-owned subsidiary. The Company changed both its name to Immunoclin Corporation and its stock symbol to IMCL in conjunction with this acquisition. The Company works on advanced immunology research and development skill to serve the pharmaceutical, biotechnology and food industries, providing comprehensive, clinical and basic science research expertise at a commercial scale and quality.

Going Concern

These consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of January 31, 2014, the Company has not recognized any revenue, and has a working capital deficit of $141,129 and an accumulated deficit of $12,862,769. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

X

- Definition

The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Balance Sheets (Parenthetical) (USD $)

Jan. 31, 2014

Jan. 31, 2013

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 9,000,000 9,000,000

Preferred stock, issued 1,000,000

Preferred stock, outstanding 1,000,000

Common stock, par value $ 0.001

Common stock, shares authorized 290,000,000

Common stock, shares issued 26,503,515

Common stock, shares outstanding 26,503,515

Series A Preferred Stock

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 1,000,000 1,000,000

Preferred stock, issued 1,000,000

Preferred stock, outstanding 1,000,000

Common stock, par value $ 0.001

Common stock, shares authorized 290,000,000

Common stock, shares issued 5,361,015

Common stock, shares outstanding 5,361,015

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 40 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events
12 Months Ended

Jan. 31, 2014

Subsequent Events [Abstract]

Subsequent Events

11. Subsequent Events

Appointment of director and officer

On March 1, 2014, Dr. Khadija Benlhassan was appointed director and Chief Scientific Officer pursuant to her management agreement dated January 23, 2014.

Loans

On February 7, 2014, Intrinsic Venture Corp. loaned the Company $10,000 via a third-party payment to the Company’s attorney Dean Law Corp. in trust.

On February 18, 2014, Intrinsic Capital Corp. loaned Immunoclin Limited, the Company’s wholly owned subsidiary, $100,000.

On March 10, 2014, Intrinsic Capital Corp. loaned the Company $15,000 via a third-party payment to the Company’s auditors Sadler, Gibb & Associates, LLC.

On April 7, 2014, Intrinsic Capital Corp. loaned the Company $25,000.

On June 30, 2014, the $240,000 loaned to the Company by Intrinsic Capital Corp. was secured by a non-interest bearing promissory note due upon demand in 12 months.

Intrinsic Venture Corp. and Intrinsic Capital Corp. are owned and controlled by the Company’s CFO, J. Scott Munro.

Agreements and Equity

On March 20, 2014, Prestige Performance Corp. cancelled 92,361 shares of common stock.

On June 18, 2018, a meeting of the Board of Directors with the unanimous consent approved the issuance of 2,000,000 stock options to each management staff of the Company. Each unregistered stock option is exercisable at a price of $5.60 per share and converted into one common share with expiry five-years from vesting. On June 30, 2014, the Board of Directors signed the resolution to ratify the issuance of the previously approved unregistered stock options. Dr. Dorothy Bray, Chad Johnson, Dr. Khadija Benlhassan, J. Scott Munro, and Raymond Dabney each received 2,000,000 stock options at an exercise price of $5.60 (current market) that expire five-years from vesting. 1,000,000 options vest on each of November 1, 2014 and November 1, 2015. The Black-Scholes fair market value of stock options granted to each management staff was calculated to be $3,161,900 with a total expense of $15,809,499, or $3.16 per option.

Subsequent to the year ended January 31, 2014, the Company entered into the following agreements with scientific advisors:

On April 23, 2014, the Company signed a two-year management consulting agreement with Dr. Marco Kaiser to act as an advisor for molecular biology, genetics, infectious diseases, and DACTELLIGENCE™. Dr. Kaiser was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $42,500, or $4.25 per share, in addition to performance bonuses for services rendered under the agreement.

On May 1, 2014, the Company signed a two-year management consulting agreement with Railton Frith and his affiliates to act as advisors for DACTELLIGENCE™. Mr. Frith was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $37,500, or $3.75 per share, in addition to performance bonuses for services rendered under the agreement.

On May 7, 2014, the Company signed a two-year management consulting agreement with Professor Antony Bayer and his affiliates to act as advisors for neurology and aging. Prof. Bayer was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $37,500, or $3.75 per share, in addition to performance bonuses for services rendered under the agreement.

On May 27, 2014, the Company signed a two-year management consulting agreement with Professor Jean Mariani to act as an advisor for treatments targeting central nervous system diseases and aging. Prof. Mariani was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $50,000, or $5.00 per share, in addition to performance bonuses for services rendered under the agreement.

On June 4, 2014, the Company signed a two-year management consulting agreement with Professor Iwona Wybrańska and her affiliates to act as advisors for nutrigenomics, metabolomics and functional food. Prof. Wybrańska was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $56,000, or $5.60 per share, in addition to performance bonuses for services rendered under the agreement.

On June 21, 2014, the Company signed a two-year management consulting agreement with Dr. Gundula Piechotta and her affiliates to act as advisors for infectious diseases and DACTELLIGENCE™. Dr. Piechotta was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $56,000, or $5.60 per share, in addition to performance bonuses for services rendered under the agreement.

On June 30, 2014, the Company signed a two-year management consulting agreement with Dr. Heinz Ellerbrok and his affiliates to act as advisors for infectious diseases and DACTELLIGENCE™. Dr. Ellerbrok was issued 10,000 rule 144 restricted shares of common stock with a fair market value of $56,000, or $5.60 per share, in addition to performance bonuses for services rendered under the agreement.

Common shares reconciliation table:

Issued and outstanding as of January 31, 2014 26,503,515

Subsequent event issuances and cancellation (32,361 )

Unissued and outstanding as of June 30, 2014 26,471,154



In accordance with ASC 855-10 the Company has analyzed its operations subsequent from January 31, 2014 through the date these consolidated financial statements were issued, and has determined there are no other material subsequent events to disclose in these consolidated financial statements.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information (USD $)
12 Months Ended

Jan. 31, 2014

Jun. 30, 2014

Jul. 31, 2013

Document and Entity Information [Abstract]

Entity Registrant Name Immunoclin Corp

Entity Central Index Key 0001520047

Document Type 10-K

Document Period End Date Jan. 31, 2014

Amendment Flag false

Current Fiscal Year End Date --01-31

Is Entity's Reporting Status Current? Yes

Well Known Seasoned Issuer No

Voluntary Filers No

Entity Filer Category Smaller Reporting Company

Entity Public Float $ 722,030

Entity Common Stock, Shares Outstanding 26,471,154

Document Fiscal Year Focus 2014

Document Fiscal Period Focus FY

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.

+ References

No definition available.

+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Details

Name: imcle_DocumentAndEntityInformationAbstract

Namespace Prefix: imcle_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary Of Significant Accounting Policies (Policies)
12 Months Ended

Jan. 31, 2014

Accounting Policies [Abstract]

Basis of presentation
A. Basis of Presentation

The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and are expressed in U.S. dollars.

The operating results of Immunoclin Limited (“IML”), acquired on December 13, 2013, were consolidated with the financial statements of the Company for the years ended January 31, 2014 and 2013. An independent valuation firm validated the purchase price for IML to be $20,000,000 consisting of $19,800,000 in intangibles-R&D, 654,992 in goodwill, and ($454,992) in net tangible assets acquired, which was confirmed by a third-party valuator assessment. A total of $654,992 in unimpaired goodwill remains at January 31, 2014.

The Company recorded adjustments of ($52,184) to additional paid-in capital and $507,176 to deficit for the year ended January 31, 2014 to reconcile the consolidated statement of stockholder’s equity (deficit) as a result of the acquisition of IML.

The Company’s fiscal year end was changed from February 28 to January 31 during 2014.

Use of estimates
B. Use of Estimates

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the consolidated financial statements in the period they are determined.

Basic and diluted net income (loss) per share
C. Basic and Diluted Net Income (Loss) Per Share

Under ASC 260, "Earnings Per Share" ("EPS"), the Company provides for the calculation of basic and diluted earnings per share. Basic EPS includes no dilution and is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the years ended January 31, 2014 and 2013, basic and diluted loss per share are the same since the calculation of diluted per share amounts would result in an anti-dilutive calculation.

Cash and cash equivalents
D. Cash and Cash Equivalents

The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

Accounts receivable and allowance for doubtful accounts
E. Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable consists principally of trade receivables, which are recorded at the invoiced amount, net of allowances for doubtful accounts and prompt payment discounts. Trade receivables do not bear interest. The allowance for doubtful accounts represents management’s estimate of the amount of probable credit losses in existing accounts receivable, as determined from a review of past due balances and other specific account data. Account balances are written off against the allowance when management determines the receivable is uncollectible. The Company does not have off-balance sheet credit exposure related to its customers.

Prepaid expense
F. Prepaid Expense

Prepaid expenses consist of $510,329 in prepaid stock-based compensation under management contracts. Prepaid stock-based compensation expense is amortized over the service periods pursuant to the agreements.

Long-lived assets
G. Long-Lived Assets

Under ASC Topic 360, “Property, Plant, and Equipment”, the Company is required to periodically evaluate the carrying value of long-lived assets to be held and used. ASC Topic 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.

The Company is adopting ASU update number 2012-02—Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment whereby the Company will first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, we conclude that it is not more than likely than not that the indefinite-lived intangible asset is impaired, then we are not required to take further action. If the Company concludes otherwise, then we will determine the fair value of the indefinite-lived intangible asset and perform the required quantitative impairment test by comparing the fair value with the carrying amount.

Fair value measurements
H. Fair Value Measurements

Under ASC Topic 820, the Company discloses the estimated fair values of financial instruments. The carrying amounts reported in the balance sheet for current assets and current liabilities qualifying as financial instruments are a reasonable estimate of fair value.

In accordance with the reporting requirements of ASC Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of those financial instruments (see Note 4). The estimated fair value of other current assets and current liabilities approximate their carrying amounts due to the relatively short maturity of these instruments. None of these instruments are held for trading purposes.

Goodwill and intangible assets
I. Goodwill and Intangible Assets

Under ASC Topic 350 “Intangibles-Goodwill and Other”, goodwill is not amortized to expense, but rather that it is assessed or tested for impairment at least annually. Impairment write-downs are charged to results of operations in the period in which the impairment is determined. If certain events occur which might indicate goodwill has been impaired, the goodwill is tested for impairment when such events occur. Other acquired intangible assets with finite lives, such as acquired R&D and patents, are required to be amortized over the estimated lives. These intangibles are generally amortized using the straight-line method over estimated useful lives.

The Company tests the carrying value of goodwill and indefinite life intangible assets for impairment at least once a year and more frequently if an event or circumstance indicates the asset may be impaired. An impairment loss is recognized if the amount of the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less selling expenses or its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows (cash generating units).

The Company did not record an impairment loss on goodwill for 2014.

Revenue recognition
J. Revenue Recognition

Revenues are recognized at the time clinical and laboratory services are completed and delivered pursuant to percentage of completion and/or milestone payments as per contracts with the Company’s customers.

Research and development expenses
K. Research and Development Expenses

Under ASC Topic 730 “Research and Development”, costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a product receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a product receives regulatory approval, any milestone payments will be recorded as Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, amortization of the payments will be on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.

Income taxes
L. Income Taxes

Under ASC Topic 740, “Income Taxes”, the Company in required to account for its income taxes through the establishment of a deferred tax asset or liability for the recognition of future deductible or taxable amounts and operating loss and tax credit carry forwards. Deferred tax expense or benefit is recognized as a result of timing differences between the recognition of assets and liabilities for book and tax purposes during the year.

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

Deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carry forwards. A valuation allowance is established to reduce that deferred tax asset if it is "more likely than not" that the related tax benefits will not be realized.

Unfiled Federal Tax Returns: For the years ending January 31, 2014 and 2013, the Company has not filed federal tax returns and may be subject to penalties. The Company estimates that the amount of penalties, if any, will not have a material effect on the results of operations, cash flows or financial position. No provisions have been made in the financial statements for such penalties, if any.

The Company is planning to have its accountants prepare and file overdue federal tax returns for the years ended January 31, 2014 and 2013 by Q4 of fiscal 2015.

Stock based compensation
M. Stock-Based Compensation

Under ASC Topic 718, ‘‘Compensation-Stock Compensation’’, the Company is required to measure all employee share-based payments, including grants of employee stock options, using a fair-value-based method and the recording of such expense in the statements of operations. The Company has adopted ASC Topic 718 (SFAS 123R) and recognizes stock-based compensation expense using the modified prospective method. As of January 31, 2014 and 2013, the Company has no employee stock options.

Comprehensive Loss
N. Comprehensive Loss

ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As of January 31, 2014 and 2013, the Company had foreign exchange translation adjustments of ($17,224) and ($10,094), respectively, which are included in other comprehensive income in the consolidated financial statements.

Recent accounting pronouncements
O. Recent Accounting Pronouncements

During the year ended January 31, 2014 and through June 30, 2014, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.

Reclassification
P. Reclassifications

For comparative purposes, certain prior period consolidated financial statements have been reclassified to conform with report classifications of the current year.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 17

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e716-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Reclassification Adjustments

-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Name: us-gaap_ComprehensiveIncomeNoteTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section CC

-Subsection 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 05

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6390181&loc=d3e202-110218

+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for other current assets.

+ References

No definition available.

+ Details

Name: us-gaap_OtherCurrentAssetsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for determining the estimated allowance for doubtful accounts for premium amounts due from policyholders, insureds, and other insurance entities. May include factors that management considered, such as historical loss experience and current economic and competitive conditions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5144-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 310

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6933075&loc=SL5748726-161290

+ Details

Name: us-gaap_PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_Reclassifications

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements Of Operations (USD $)
12 Months Ended

Jan. 31, 2014

Jan. 31, 2013

Income Statement [Abstract]

Revenues $ 182,621

Operating Expenses

Amortization 206,534

Depreciation 1,611 1,508

Management and consulting fees 12,453,670

General and administrative 167,464 143,416

Professional fees 54,918 88,758

Research and development 98,276 93,124

Total Operating Expenses 12,982,473 326,806

Net Operating Loss (12,982,473) (144,185)

Other Income (expense)

Interest expense, net 89 47

Tax credits, research and development (2,245) (75,794)

Total other income (expense) 2,156 75,747

Net Loss (12,980,317) (68,438)

Foreign exchange translation adjustment (17,224) (10,094)

Comprehensive Income (Loss) (17,224) (10,094)

Net Comprehensive Loss $ (12,997,541) $ (78,532)

Net loss per Share - basic and diluted $ (1.21) $ (0.01)

Weighted average shares outstanding - basic and diluted 10,774,666 5,315,824

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=35737396

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncomeTaxCreditsAndAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.

+ References

No definition available.

+ Details

Name: us-gaap_ProfessionalAndContractServicesExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.6-07.2(a),(b),(c),(d))

-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section 45

-Paragraph 3

-Subparagraph (k)

-URI http://asc.fasb.org/extlink&oid=6488370&loc=d3e13550-115849

+ Details

Name: us-gaap_ProfessionalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 44 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Equity
12 Months Ended

Jan. 31, 2014

Equity [Abstract]

Equity
6. Equity

The Company is authorized to issue 290,000,000 shares of common stock with a par value of $0.001 per share. These shares have full voting rights. There were 26,503,515 and 5,361,015 shares of common stock issued and outstanding as of January 31, 2014 and 2013, respectively.

The Company is also authorized to issue 1,000,000 shares of Series A preferred stock, with a par value of $0.001 per share. The shares of Series A preferred stock have 51% of the total vote on all shareholder matters and 66-2/3% of the Series A preferred stockholders may make any affirmative vote to amend, alter or repeal and provision of the Articles of Incorporation or the Bylaws of the Company. There were 1,000,000 and 0 shares of Series A preferred stock issued and outstanding as of January 31, 2014 and 2013, respectively.

The Company is also authorized to issue 9,000,000 shares of preferred stock. These shares have full voting rights. There were 0 and 0 issued and outstanding as of January 31, 2014 and 2013, respectively.

During the year ended January 31, 2014, the Company issued the following common stock:

On December 13, 2013, the Company acquired Immunoclin Limited, an England and Wales corporation, pursuant to a Take Over Agreement. In consideration for the acquisition, the Company issued 10,000,000 shares of common stock, with a fair market value of $20,000,000, or $2.00 per share, to Dr. Dorothy Bray in exchange for all issued and outstanding shares in Immunoclin Limited. An independent valuation firm validated the purchase price for IML to be $20,000,000 consisting of $19,800,000 in intangibles-R&D, 654,992 in goodwill, and ($454,992) in net tangible assets acquired, which was confirmed by a third-party valuator assessment and opinion contracted by the Company’s auditor. A total of $654,992 in unimpaired goodwill remains at January 31, 2014.

On December 13, 2013, the Company issued 6,000,000 shares of common stock, with a fair market value of $12,000,000 or $2.00 per share, pursuant to management agreements with executive officers, directors, and a management consultant of the Company.

On December 13, 2013, the Company issued 1,000,000 shares of Series A preferred stock, with a fair market value of $180,000 or $0.18 per share, to executive officers and directors and a management consultant pursuant to a Control Shareholder Agreement.

On December 13, 2013, the Company issued 100,000 shares of common stock, with a fair market value of $200,000 or $2.00 per share to the co-inventor of the of the DACTELLIGENCE™ patent to acquire the remaining 50% ownership pursuant to a License and Royalty Agreement dated October 1, 2013 with Immunoclin Limited.

On December 13, 2013, the Company issued 42,500 shares of common stock with a fair market value of $85,000 or $2.00 per share to a consultant for settlement of $85,000 in fees due pursuant to a settlement agreement.

Stock Options and Warrants:

The Company has no stock options or warrants outstanding.

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Notes Payable
12 Months Ended

Jan. 31, 2014

Debt Disclosure [Abstract]

Notes payable
5. Notes Payable

The Company has two non-interest bearing promissory notes due upon demand in 12 months to Jagpal Holdings Ltd.; one for $55,145 dated April 25, 2013 and one for $17,852 dated June 1, 2013.

On October 21, 2013, Intrinsic Venture Corp. loaned the Company $2,062 secured by a non-interest bearing promissory note due on demand in 12 months. (see Note 4)

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Intangible Assets (Tables)
12 Months Ended

Jan. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

January 31, 2014 January 31, 2013

Patents $ 200,000

Research and development 19,800,000 —

Less accumulated amortization (206,534 ) —

$ 19,793,466 $ —

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements and Disclosures (Tables)
12 Months Ended

Jan. 31, 2014

Fair Value Disclosures [Abstract]

Schedule of fair value measurement and disclosure

The following tables set forth by level, within the fair value hierarchy, the Company’s assets at fair value as of January 31, 2014. The Company had no assets as of January 31, 2013.

Level 1 Level 2 Level 3 Total

Intangibles from acquisition of IML, net of accumulated amortization — — $ 19,793,466 $ 19,793,466

Total assets as of January 31, 2014 — — $ 19,793,466 $ 19,793,466

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Intangible Assets
12 Months Ended

Jan. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

9. Intangible Assets

January 31, 2014 January 31, 2013

Patents $ 200,000

Research and development 19,800,000 —

Less accumulated amortization (206,534 ) —

$ 19,793,466 $ —



Intangible assets are stated at fair value on the date of purchase less accumulated amortization. Amortization is computed using the straight-line method over the estimated lives of the related assets (13 years for intellectual assets).

On December 13, 2013, the Company acquired the remaining 50% interest in the DACTELLIGENCE™ patent from one of the inventors for consideration of 100,000 shares of common stock with a fair market value of $200,000 or $2.00 per share.

On December 13, 2013, the Company acquired R&D intangibles in the IML acquisition. An independent valuation firm validated the purchase price for IML to be $20,000,000 consisting of $19,800,000 in intangibles-R&D, 654,992 in goodwill, and ($454,992) in net tangible assets acquired, which was confirmed by a third-party valuator assessment.

The Company will recognize approximately $1,538,462 in intangible amortization expense per year over the next 13 years with intangibles being fully amortized by fiscal 2028.

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Income Taxes
12 Months Ended

Jan. 31, 2014

Income Tax Disclosure [Abstract]

Income Taxes

7. Income Taxes

The Company has $4,544,793 of net operating losses carried forward to offset taxable income in future years that expire commencing in fiscal 2034. The income tax benefit differs from the amount, computed by applying the US federal income tax rate of 34% to net loss before income taxes. As at January 31, 2014, the Company had no uncertain tax positions.

January 31,
2014
$ January 31,
2013
$

Net loss before taxes (12,980,317 ) (68,438 )

Statutory rate 34 % 34 %

Deferred tax assets:

 NOL expense (benefit) (136,850 ) (22,454 )

 Valuation allowance 136,850 22,454

Net deferred tax assets — —

The significant components of deferred income tax assets and liabilities at January 31, 2014 and January 31, 2013 are as follows:

January 31,
2014
$ January 31,
2013
$

Net operating loss carried forward (4,413,308 ) (23,269 )

Stock issued for services 4,205,688 —

Depreciation and amortization 70,769 815

Net deferred income tax asset (136,850 ) (22,454 )

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Equipment
12 Months Ended

Jan. 31, 2014

Property, Plant and Equipment [Abstract]

Equipment

8. Equipment



Cost Accumulated Depreciation Net Book Value January 31, 2014 Net Book Value January 31, 2013

Computers $ 11,327 $ 5,086 $ 6,241 $ 1,262

All equipment is stated at cost. Maintenance and repairs are charged to expense as incurred and the cost of renewals and betterments are capitalized. Depreciation is computed using the straight-line method over the 5 year estimated lives of the related computer equipment.

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies
12 Months Ended

Jan. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10. Commitments and Contingencies

The Company has a 1,668 sq. ft. laboratory facility in located in Paris, France at the Centre de Recherche des Cordeliers (CRC). The laboratory has operated under a lease with University of Pierre and Marie Currie (UPMC) in Immunoclin Limited since 2001. The Company is currently under negotiations with UPMC to extend the lease. Lease commitments are approximately $38 per square foot or $63,000 per year, plus charges of approximately $4,000. The lease is paid semi-annually on January 1^st and June 1^st.

The Company’s corporate headquarters is currently on a month-to-month lease with no commitments.

The Company has no other commitments or contingencies.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8

Related Party Transactions (Narrative) (Details) (USD $)
12 Months Ended 0 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended 0 Months Ended

Jan. 31, 2014

Jan. 31, 2013

Jun. 01, 2013

Promissory Note - Jagpal Holdings Ltd

Apr. 25, 2013

President And CEO - Robert Lawrence

Jan. 31, 2013

President And CEO - Robert Lawrence

Jan. 31, 2014

President And CEO - Robert Lawrence

Apr. 25, 2013

President And CEO - Robert Lawrence

Promissory Note - Jagpal Holdings Ltd

Dec. 13, 2013

J. Scott Munro - Chief Financial Officer

Jan. 31, 2014

J. Scott Munro - Chief Financial Officer

Oct. 21, 2013

J. Scott Munro - Chief Financial Officer

Promissory Note From Intrinsic Venture Corp

Dec. 13, 2013

Executive Officer And Directors And Management Consultant

Series A Preferred Stock

Dec. 13, 2013

Dr. Dorothy Bray - Director And CEO/President

Dec. 13, 2013

Chad S. Johnson - COO

Jan. 31, 2014

Chad S. Johnson - COO

Dec. 13, 2013

Raymond Dabney - Managing Consultant

Jan. 31, 2014

Raymond Dabney - Managing Consultant

Jan. 23, 2014

Khadija Benlhassan - Director And Chief Scientific Officer

Due to related parties $ 2,704 $ 56,685 $ 56,685 $ 0

Debt instrument description
It was non-interest bearing promissory notes.

It was unsecured, non-interest bearing, and due on demand.

A non-related party that was secured by the Company under a non-interest bearing demand promissory note due

Non-interest bearing demand promissory note

Notes payable 17,852 2,062

Note maturity description
Due upon demand in 12 months

Due on demand in 12 months

Note maturity date Apr. 25, 2014

Repayment of due to related party 56,377 33

Forgiveness of related party debt 1,507

Assignment of related party debt to non-related party 86,507 36,433 55,145

Shares issued for control of shareholders agreement, shares 1,000,000

Shares issued for control of shareholders agreement, value 180,000 180,000

Terms of employment agreement
Under the agreement, Mr. Munro is to be paid $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under this Agreement, considered to be November 30, 2014. Mr. Munro shall also receive 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payments one year following the signing of the Agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock.

Under the agreement, Dr. Bray is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Dr. Bray shall also receive 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payments one year following the signing of the Agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock.

Under the agreement, Mr. Johnson is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $15,000 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Mr. Johnson shall also receive 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payment one year following the signing of the agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Rule 144 restricted common shares of the Company common stock.

Under the agreement, Mr. Dabney is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Mr. Dabney shall also receive 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payment one year following the signing of the agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Rule 144 restricted common shares of the Company common stock.

Under the Agreement, Dr. Benlhassan is to receive compensation of $16,667 per month for the first three months (March through May 2014) and $17,778 per month for the nine months thereafter through to the end of her first year of service under the Agreement. Dr. Benlhassan will earn 2,000,000 Rule 144 restricted common shares of the Company on November 30, 2014 pursuant to the Agreement and May 30, 2014 Addendum Agreement.

Fair value of stock based compensation packages $ 12,369,671 $ 4,000,000 $ 4,000,000 $ 4,000,000 $ 2,000,000 $ 2,000,000 $ 2,000,000 $ 2,000,000

Share price, per share $ 2.00 $ 0.18 $ 2.00 $ 2.00 $ 2.00

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: imcle_PreferredStockIssuedForServicesShares

Namespace Prefix: imcle_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: imcle_PreferredStockIssuedForServicesValue

Namespace Prefix: imcle_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: imcle_TermsOfEmploymentAgreement

Namespace Prefix: imcle_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(f))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph f

-Article 4

+ Details

Name: us-gaap_DebtInstrumentDecreaseForgiveness

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

+ Details

Name: us-gaap_DebtInstrumentDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDateDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13, 16

-Article 9

+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

XML 53 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Income Taxes (Tables)
12 Months Ended

Jan. 31, 2014

Income Tax Disclosure [Abstract]

Schedule of income tax benefit

The income tax benefit differs from the amount, computed by applying the US federal income tax rate of 34% to net loss before income taxes. As at January 31, 2014, the Company had no uncertain tax positions.

January 31,
2014
$ January 31,
2013
$

Net loss before taxes (12,980,317 ) (68,438 )

Statutory rate 34 % 34 %

Deferred tax assets:

 NOL expense (benefit) (136,850 ) (22,454 )

 Valuation allowance 136,850 22,454

Net deferred tax assets — —

Schedule of deferred income tax assets and liabilities
The significant components of deferred income tax assets and liabilities at January 31, 2014 and January 31, 2013 are as follows:

January 31,
2014
$ January 31,
2013
$

Net operating loss carried forward (4,413,308 ) (23,269 )

Stock issued for services 4,205,688 —

Depreciation and amortization 70,769 815

Net deferred income tax asset (136,850 ) (22,454 )

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Related Party Transactions (Details) (USD $)
12 Months Ended 0 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended

Jan. 31, 2014

Jan. 31, 2013

Jan. 31, 2014

Dr. Dorothy Bray - CEO

Dec. 13, 2013

J. Scott Munro - Chief Financial Officer

Jan. 31, 2014

J. Scott Munro - Chief Financial Officer

Dec. 13, 2013

Chad S. Johnson - COO

Jan. 31, 2014

Chad S. Johnson - COO

Dec. 13, 2013

Raymond Dabney - Managing Consultant

Jan. 31, 2014

Raymond Dabney - Managing Consultant

Stock based compensation $ 12,369,671 $ 4,000,000 $ 4,000,000 $ 4,000,000 $ 2,000,000 $ 2,000,000 $ 2,000,000 $ 2,000,000

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 55 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events (Narrative) (Details) (USD $)
12 Months Ended 12 Months Ended 0 Months Ended 0 Months Ended

Jan. 31, 2014

Jan. 31, 2013

Jun. 30, 2014

Dec. 13, 2013

Dr. Dorothy Bray - Director And CEO/President

Dec. 13, 2013

Chad S. Johnson - COO

Dec. 13, 2013

J. Scott Munro - Chief Financial Officer

Dec. 13, 2013

Raymond Dabney - Managing Consultant

Jan. 31, 2014

Common Stock

Jun. 30, 2014

Subsequent Event

Dr. Dorothy Bray - Director And CEO/President

Jun. 30, 2014

Subsequent Event

Chad S. Johnson - COO

Jun. 30, 2014

Subsequent Event

Khadija Benlhassan - Director And Chief Scientific Officer

Jun. 30, 2014

Subsequent Event

J. Scott Munro - Chief Financial Officer

Jun. 30, 2014

Subsequent Event

Raymond Dabney - Managing Consultant

Mar. 20, 2014

Subsequent Event

Common Stock

Apr. 23, 2014

Subsequent Event

Rule144 Restricted Stock

Consulting Agreement - Dr. Marco Kaiser

May 01, 2014

Subsequent Event

Rule144 Restricted Stock

Consulting Agreement - Railton Frith

May 01, 2014

Subsequent Event

Rule144 Restricted Stock

Consulting Agreement - Railton Frith

May 07, 2014

Subsequent Event

Rule144 Restricted Stock

Consulting Agreement - Professor Antony Bayer

May 27, 2014

Subsequent Event

Rule144 Restricted Stock

Consulting Agreement - Professor Jean Mariani

Jun. 04, 2014

Subsequent Event

Rule144 Restricted Stock

Consulting Agreement - Professor Iwona Wybranska

Jun. 21, 2014

Subsequent Event

Rule144 Restricted Stock

Consulting Agreement - Dr. Gundula Piechotta

Jun. 30, 2014

Subsequent Event

Rule144 Restricted Stock

Consulting Agreement - Dr. Heinz Ellerbrok

Jun. 30, 2014

Subsequent Event

Intrinsic Venture Corp

Apr. 07, 2014

Subsequent Event

Intrinsic Venture Corp

Mar. 10, 2014

Subsequent Event

Intrinsic Venture Corp

Feb. 18, 2014

Subsequent Event

Intrinsic Venture Corp

Feb. 07, 2014

Subsequent Event

Intrinsic Venture Corp

Loan $ 240,000 $ 25,000 $ 15,000 $ 100,000 $ 10,000

Debt maturity description
Due upon demand in 12 months

Debt instrument description
Non-interest bearing promissory note

Cancellation of shares Prestige Performance Corp,shares (5,000,000) 92,361

Shares issued for service, shares 6,000,000 10,000 10,000 10,000 10,000 10,000 10,000 10,000

Shares issued for service, value 12,000,000 6,000 42,500 37,500 37,500 50,000 56,000 56,000 56,000

Share price, per share $ 2.00 $ 2.00 $ 2.00 $ 2.00 $ 4.25 $ 3.75 $ 3.75 $ 5.00 $ 5.60 $ 5.60 $ 5.60

Consulting agreement terms
On April 23, 2014, the Company signed a two-year management consulting agreement with Dr. Marco Kaiser to act as an advisor for molecular biology, genetics, infectious diseases, and DACTELLIGENCE™.

On May 1, 2014, the Company signed a two-year management consulting agreement with Railton Frith and his affiliates to act as advisors for DACTELLIGENCE™

On May 7, 2014, the Company signed a two-year management consulting agreement with Professor Antony Bayer and his affiliates to act as advisors for neurology and aging.

On May 27, 2014, the Company signed a two-year management consulting agreement with Professor Jean Mariani to act as an advisor for treatments targeting central nervous system diseases and aging.

On June 4, 2014, the Company signed a two-year management consulting agreement with Professor Iwona Wybrańska and her affiliates to act as advisors for nutrigenomics, metabolomics and functional food.

On June 21, 2014, the Company signed a two-year management consulting agreement with Dr. Gundula Piechotta and her affiliates to act as advisors for infectious diseases and DACTELLIGENCE™.

On June 30, 2014, the Company signed a two-year management consulting agreement with Dr. Heinz Ellerbrok and his affiliates to act as advisors for infectious diseases and DACTELLIGENCE™.

Shares issued for share based compensation 2,000,000 2,000,000 2,000,000 2,000,000 2,000,000

Stock options exercise price $ 5.60 $ 5.60 $ 5.60 $ 5.60 $ 5.60

Fair market value of stock options granted $ 15,809,499 $ 3,161,900 $ 3,161,900 $ 3,161,900 $ 3,161,900 $ 3,161,900

Option vesting period 1,000,000 options vest on each of November 1, 2014 and November 1, 2015 1,000,000 options vest on each of November 1, 2014 and November 1, 2015 1,000,000 options vest on each of November 1, 2014 and November 1, 2015 1,000,000 options vest on each of November 1, 2014 and November 1, 2015 1,000,000 options vest on each of November 1, 2014 and November 1, 2015

Expenses per option $ 3.16 $ 3.16 $ 3.16 $ 3.16 $ 3.16

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: imcle_ExpensesPerOption

Namespace Prefix: imcle_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: imcle_FairMarketValueOfStockOptionsGranted

Namespace Prefix: imcle_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

+ Details

Name: us-gaap_DebtInstrumentDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDateDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a)(2))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_LoansPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Description of the goods (for example, inventory, equipment, land) or services (for example, consulting, office space rental) received or to be received from the counterparty to the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

+ Details

Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionDescriptionOfGoodsOrServicesReceived

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares that have been repurchased and retired during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 855

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662

+ Details

Name: us-gaap_SubsequentEventDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 56 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements Of Cash Flows (USD $)
12 Months Ended

Jan. 31, 2014

Jan. 31, 2013

Statement of Cash Flows [Abstract]

Net loss for the year $ (12,980,317) $ (68,438)

Adjustments to reconcile net loss to cash used in operating activities:

Amortization 206,534

Depreciation 1,611 2,396

Common stock issued for services 12,369,671

Expenses paid by related parties 20,555 39,000

Foreign exchange translation (17,224) (10,094)

Changes in operating assets and liabilities:

Accounts receivable (20,090) (117,715)

Other receivable 7,746

Accounts payable (193,691) 312,005

Accrued expenses, primarily management fees 469,888 (236,584)

Net Cash Provided by (Used In) Operating Activities (110,629) 156,000

Investing Activities

Purchase of property and equipment 6,590

Net Cash Used in Investing Activities (6,590)

Financing Activities

Proceeds from the sale of common stock 12,550

Related party loans forgiven to share capital

Proceeds from related party notes payable 2,029 880

Repayments to related party loans 56,377

Net Cash Provided by Financing Activities 2,029 (42,947)

Change in Cash (115,190) 113,053

Cash - Beginning of Year 167,146 54,093

Cash - End of Year 51,956 167,146

Supplemental Disclosures

Cancellation of common stock 5,000

Common stock issued for prepaid services 700,000

Common stock issued to acquire IML 20,000,000

Common stock issued to acquire patent 200,000

Common stock issued to extinguish debt 86,507 36,433

Interest paid

Income tax paid

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(f))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph f

-Article 4

+ Details

Name: us-gaap_DebtInstrumentDecreaseForgiveness

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Other expenses or losses included in net income that result in no cash outflows or inflows in the period and are not separately disclosed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_OtherNoncashExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementOfCashFlowsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of stock issued pursuant to acquisitions during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of shares issued for noncash consideration for development stage entities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 215

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6472370&loc=d3e38297-110927

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForNoncashConsiderations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Related Party Transactions
12 Months Ended

Jan. 31, 2014

Related Party Transactions [Abstract]

Related party transactions
4. Related Party Transactions

During the years ended January 31, 2014 the Company’s former President and CEO, Robert Lawrence, advanced $0 (2013; $56,685) to the Company and paid expenses of $0 (2013; $0) on behalf of the Company. The $56,685 owing at January 31, 2013 to Mr. Lawrence was unsecured, non-interest bearing, and due on demand. On April 25, 2013, Mr. Lawrence assigned his loans payable of $55,145 to Jagpal Holdings Ltd., a non-related party that was secured by the Company under a non-interest bearing demand promissory note due and payable on April 25, 2014. In addition, Mr. Lawrence was paid $33 and he forgave $1,507, which has been recorded in additional paid-in capital as of January 31, 2014.

On October 21, 2013, Intrinsic Venture Corp. loaned the Company $2,062 that was secured by a non-interest bearing demand promissory note due in 12 months. Intrinsic Venture Corp. is owned and controlled by J. Scott Munro, the Company’s CFO.

On December 13, 2013, the Company issued 1,000,000 shares of Series A preferred stock, with a fair market value of $180,000 or $0.18 per share, to executive officers and directors and a management consultant pursuant to a Control Shareholder Agreement.

On December 13, 2013, Dr. Dorothy Bray was appointed a director and CEO/President under pursuant to a five-year management agreement with the Company. Under the agreement, Dr. Bray is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Dr. Bray shall also receive 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payments one year following the signing of the Agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock. The estimated fair value of the initial stock compensation package to Dr. Bray is $4,000,000, based on the closing price of $2.00 per share for the Company’s stock on December 12, 2013.

On December 13, 2013, Chad S. Johnson entered into a five-year management agreement with the Company for acting in the capacities of Chief Operating Officer, General Counsel, Secretary and Director. Under the agreement, Mr. Johnson is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $15,000 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Mr. Johnson shall also receive 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payment one year following the signing of the agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Rule 144 restricted common shares of the Company common stock. The estimated fair value of the initial stock compensation package to Mr. Johnson is $2,000,000, based on the closing price of $2.00 per share for the Company’s stock on December 12, 2013.

On December 13, 2013, J. Scott Munro entered into a five-year management agreement with the Company for acting in the capacity of Chief Financial Officer (Principal Accounting Officer). Under the agreement, Mr. Munro is to be paid $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under this Agreement, considered to be November 30, 2014. Mr. Munro shall also receive 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payments one year following the signing of the Agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock. The estimated fair value of the initial stock compensation package to Mr. Munro is $4,000,000, based on the closing price of $2.00 per share for the Company’s stock on December 12, 2013.

On December 13, 2013, Raymond Dabney entered into a five-year management agreement with the Company for services as Managing Consultant. Under the agreement, Mr. Dabney is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Mr. Dabney shall also receive 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payment one year following the signing of the agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Rule 144 restricted common shares of the Company common stock. The estimated fair value of the initial stock compensation package to Mr. Johnson is $2,000,000, based on the closing price of $2.00 per share for the Company’s stock on December 12, 2013.

The aforementioned management agreements are incorporated by reference to this Form 10-K as filed on Form 8-K filed with the SEC on December 20, 2013.

On January 23, 2014, Khadija Benlhassan, PhD entered into a five-year management agreement (the “Agreement”) for acting as Director and Chief Scientific Officer for the Company and undertake the duties and responsibilities of these appointments as of March 1, 2014. Under the Agreement, Dr. Benlhassan is to receive compensation of $16,667 per month for the first three months (March through May 2014) and $17,778 per month for the nine months thereafter through to the end of her first year of service under the Agreement. Dr. Benlhassan will earn 2,000,000 Rule 144 restricted common shares of the Company on November 30, 2014 pursuant to the Agreement and May 30, 2014 Addendum Agreement.

During the year ended January 31, 2014, the Company recorded the following related party stock-based compensation:

Related Party Position Amount

Dr. Dorothy Bray CEO/President $ 4,000,000

J. Scott Munro CFO 4,000,000

Chad S. Johnson, Esq. COO and General Counsel 2,000,000

Raymond Dabney Managing Consultant 2,000,000

$ 12,000,000

The above table includes stock-based compensation paid to companies beneficially owned by the related parties.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 58 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Income Taxes (Schedule Of Income Tax Benefit) (Details) (USD $)
12 Months Ended

Jan. 31, 2014

Jan. 31, 2013

Jun. 30, 2014

Income Taxes Schedule Of Income Tax Benefit Details

Net loss before taxes $ (12,980,317) $ (68,438)

Statutory rate 34.00% 34.00%

Deferred tax assets:

NOL expense (benefit) (22,454) (136,850)

Valuation allowance (22,454) (136,850)

Net deferred tax assets

X

- Details

Name: imcle_DisclosureIncomeTaxesScheduleOfIncomeTaxBenefitDetailsAbstract

Namespace Prefix: imcle_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(c)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_DeferredTaxAssetsNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 113 169 1 false 38 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://immunoclincorp.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://immunoclincorp.com/role/Balancesheets Consolidated Balance Sheets false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://immunoclincorp.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) false false R4.htm 00000004 - Statement - Consolidated Statements Of Operations Sheet http://immunoclincorp.com/role/StatementsOfOperations Consolidated Statements Of Operations false false R5.htm 00000005 - Statement - Consolidated Statements Of Cash Flows Sheet http://immunoclincorp.com/role/StatementsOfCashFlows Consolidated Statements Of Cash Flows false false R6.htm 00000006 - Statement - Consolidated Statements of Stockholders’ Equity (Deficit) Sheet http://immunoclincorp.com/role/StatementsOfStockholdersEquityDeficit Consolidated Statements of Stockholders’ Equity (Deficit) false false R7.htm 00000007 - Disclosure - Nature of Operations and Continuance of Business Sheet http://immunoclincorp.com/role/NatureOfOperationsAndContinuanceOfBusiness Nature of Operations and Continuance of Business false false R8.htm 00000008 - Disclosure - Summary Of Significant Accounting Policies Sheet http://immunoclincorp.com/role/Disclosuresummaryofsignificantaccountingpolicies Summary Of Significant Accounting Policies false false R9.htm 00000009 - Disclosure - Fair Value Measurements and Disclosures Sheet http://immunoclincorp.com/role/FairValueMeasurementsAndDisclosures Fair Value Measurements and Disclosures false false R10.htm 00000010 - Disclosure - Related Party Transactions Sheet http://immunoclincorp.com/role/Disclosurerelatedpartytransactions Related Party Transactions false false R11.htm 00000011 - Disclosure - Notes Payable Notes http://immunoclincorp.com/role/NotesPayable Notes Payable false false R12.htm 00000012 - Disclosure - Equity Sheet http://immunoclincorp.com/role/Disclosurecommonshares Equity false false R13.htm 00000013 - Disclosure - Income Taxes Sheet http://immunoclincorp.com/role/IncomeTaxes Income Taxes false false R14.htm 00000014 - Disclosure - Equipment Sheet http://immunoclincorp.com/role/Equipment Equipment false false R15.htm 00000015 - Disclosure - Intangible Assets Sheet http://immunoclincorp.com/role/IntangibleAssets Intangible Assets false false R16.htm 00000016 - Disclosure - Commitments and Contingencies Sheet http://immunoclincorp.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R17.htm 00000017 - Disclosure - Subsequent Events Sheet http://immunoclincorp.com/role/SubsequentEvents Subsequent Events false false R18.htm 00000018 - Disclosure - Summary Of Significant Accounting Policies (Policies) Sheet http://immunoclincorp.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary Of Significant Accounting Policies (Policies) false false R19.htm 00000019 - Disclosure - Fair Value Measurements and Disclosures (Tables) Sheet http://immunoclincorp.com/role/FairValueMeasurementsAndDisclosuresTables Fair Value Measurements and Disclosures (Tables) false false R20.htm 00000020 - Disclosure - Related Party Transactions (Tables) Sheet http://immunoclincorp.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) false false R21.htm 00000021 - Disclosure - Income Taxes (Tables) Sheet http://immunoclincorp.com/role/IncomeTaxesTables Income Taxes (Tables) false false R22.htm 00000022 - Disclosure - Equipment (Tables) Sheet http://immunoclincorp.com/role/EquipmentTables Equipment (Tables) false false R23.htm 00000023 - Disclosure - Intangible Assets (Tables) Sheet http://immunoclincorp.com/role/IntangibleAssetsTables Intangible Assets (Tables) false false R24.htm 00000024 - Disclosure - Subsequent Events (Tables) Sheet http://immunoclincorp.com/role/SubsequentEventsTables Subsequent Events (Tables) false false R25.htm 00000025 - Disclosure - Fair Value Measurements and Disclosures (Details) Sheet http://immunoclincorp.com/role/FairValueMeasurementsAndDisclosuresDetails Fair Value Measurements and Disclosures (Details) false false R26.htm 00000026 - Disclosure - Related Party Transactions (Details) Sheet http://immunoclincorp.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) false false R27.htm 00000027 - Disclosure - Income Taxes (Schedule Of Income Tax Benefit) (Details) Sheet http://immunoclincorp.com/role/IncomeTaxesScheduleOfIncomeTaxBenefitDetails Income Taxes (Schedule Of Income Tax Benefit) (Details) false false R28.htm 00000028 - Disclosure - Income Taxes (Schedule Of Deferred Income Tax Assets And Liabilities) (Details) Sheet http://immunoclincorp.com/role/IncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails Income Taxes (Schedule Of Deferred Income Tax Assets And Liabilities) (Details) false false R29.htm 00000029 - Disclosure - Equipment (Details) Sheet http://immunoclincorp.com/role/EquipmentDetails Equipment (Details) false false R30.htm 00000030 - Disclosure - Intangible Assets (Details) Sheet http://immunoclincorp.com/role/IntangibleAssetsDetails Intangible Assets (Details) false false R31.htm 00000031 - Disclosure - Subsequent Events (Details) Sheet http://immunoclincorp.com/role/SubsequentEventsDetails Subsequent Events (Details) false false R32.htm 00000032 - Disclosure - Nature Of Operations And Continuance Of Business (Narrative) (Details) Sheet http://immunoclincorp.com/role/NatureOfOperationsAndContinuanceOfBusinessNarrativeDetails Nature Of Operations And Continuance Of Business (Narrative) (Details) false false R33.htm 00000033 - Disclosure - Summary Of Significant Accounting Policies (Narrative) (Details) Sheet http://immunoclincorp.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails Summary Of Significant Accounting Policies (Narrative) (Details) false false R34.htm 00000034 - Disclosure - Related Party Transactions (Narrative) (Details) Sheet http://immunoclincorp.com/role/RelatedPartyTransactionsNarrativeDetails Related Party Transactions (Narrative) (Details) false false R35.htm 00000035 - Disclosure - Notes Payable (Narrative) (Details) Notes http://immunoclincorp.com/role/NotesPayableNarrativeDetails Notes Payable (Narrative) (Details) false false R36.htm 00000036 - Disclosure - Equity (Narrative) (Details) Sheet http://immunoclincorp.com/role/EquityNarrativeDetails Equity (Narrative) (Details) false false R37.htm 00000037 - Disclosure - Income Taxes (Narrative) (Details) Sheet http://immunoclincorp.com/role/IncomeTaxesNarrativeDetails Income Taxes (Narrative) (Details) false false R38.htm 00000038 - Disclosure - Equipment (Narrative) (Details) Sheet http://immunoclincorp.com/role/EquipmentNarrativeDetails Equipment (Narrative) (Details) false false R39.htm 00000039 - Disclosure - Intangible Assets (Narrative) (Details) Sheet http://immunoclincorp.com/role/IntangibleAssetsNarrativeDetails Intangible Assets (Narrative) (Details) false false R40.htm 00000040 - Disclosure - Commitments And Contingencies (Narrative) (Details) Sheet http://immunoclincorp.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments And Contingencies (Narrative) (Details) false false R41.htm 00000041 - Disclosure - Subsequent Events (Narrative) (Details) Sheet http://immunoclincorp.com/role/SubsequentEventsNarrativeDetails Subsequent Events (Narrative) (Details) false false All Reports Book All Reports Process Flow-Through: 00000002 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Jan. 31, 2012' Process Flow-Through: 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 00000004 - Statement - Consolidated Statements Of Operations Process Flow-Through: 00000005 - Statement - Consolidated Statements Of Cash Flows imcle-20140131.xml imcle-20140131.xsd imcle-20140131_cal.xml imcle-20140131_def.xml imcle-20140131_lab.xml imcle-20140131_pre.xml true true XML 60 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8

Equipment (Narrative) (Details) (Computer)
12 Months Ended

Jan. 31, 2014

Computer

Estimated useful life 5 years

X

- Definition

Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

No definition available.

+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 61 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Related Party Transactions (Tables)
12 Months Ended

Jan. 31, 2014

Related Party Transactions [Abstract]

Schedule of related party transactions

During the year ended January 31, 2014, the Company recorded the following related party stock-based compensation:

Related Party Position Amount

Dr. Dorothy Bray CEO/President $ 4,000,000

J. Scott Munro CFO 4,000,000

Chad S. Johnson, Esq. COO and General Counsel 2,000,000

Raymond Dabney Managing Consultant 2,000,000

$ 12,000,000

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration


Nevada	32-0337695
(state or other jurisdiction of incorporation or organization)	(I.R.S. Employer I.D. No.)

9107 Wilshire Blvd, Suite 450 Beverly Hills, California	90210
(Address of principal executive offices)	(Zip Code)

Date: July 2, 2014		/s/Dr. Dorothy Bray
	By:	Dorothy Bray, PhD
	Its:	CEO, President, Principal Executive Officer


Date: July 2, 2014		/s/J. Scott Munro
	By:	J. Scott Munro
	Its:	CFO, Principal Accounting Officer

Intangible Assets (Narrative) (Details) (USD $)	12 Months Ended
Intangible Assets (Narrative) (Details) (USD $)	Jan. 31, 2014	Jan. 31, 2013
Amortization expenses of intangible	$ 206,534
Intangible Assets
Amortization expenses of intangible	$ 1,538,462
Estimated life of intangible assets	13 years

Summary Of Significant Accounting Policies (Narrative) (Details) (USD $)			0 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Dec. 13, 2013 Immunoclin Limited (IML)
Purchase price			$ 20,000,000
Intangibles-R&D			19,800,000
Goodwill	654,992		654,992
Net tangible assets			$ (454,992)

Fair Value Measurements and Disclosures (Details) (USD $)	Jan. 31, 2014	Jan. 31, 2013
Intangibles from acquisition of IML, net of accumulated amortization	$ 19,793,466
Total assets as of January 31, 2014	19,793,466
Level 1
Intangibles from acquisition of IML, net of accumulated amortization
Total assets as of January 31, 2014
Level 2
Intangibles from acquisition of IML, net of accumulated amortization
Total assets as of January 31, 2014
Level 3
Intangibles from acquisition of IML, net of accumulated amortization	19,793,466
Total assets as of January 31, 2014	$ 19,793,466

Income Taxes (Narrative) (Details)	12 Months Ended
Income Taxes (Narrative) (Details)	Jan. 31, 2014	Jan. 31, 2013
Income Taxes Narrative Details
Operation loss carryforwards terms	Expire commencing in fiscal 2034
Tax effect at the expected rate	34.00%	34.00%

Income Taxes (Schedule Of Deferred Income Tax Assets And Liabilities) (Details) (USD $)	12 Months Ended
	Jan. 31, 2014	Jan. 31, 2013
Income Taxes Schedule Of Deferred Income Tax Assets And Liabilities Details
Net operating loss carried forward	$ (4,413,308)	$ (23,269)
Stock issued for services	4,205,688
Depreciation and amortization	70,769	815
Net deferred income tax asset	$ (136,850)	$ (22,454)

Intangible Assets (Details) (USD $)	Jan. 31, 2014	Jan. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Less accumulated amortization	$ 206,534
Total	19,793,466
Patents
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	200,000
Research And Development
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	$ 19,800,000

Subsequent Events (Details)		0 Months Ended
Subsequent Events (Details)	Jan. 31, 2014	Jun. 30, 2014 Subsequent Event
Common stock, shares issued	26,503,515	26,471,154
Common stock, shares outstanding	26,503,515	26,471,154
Subsequent event issuances and cancellation		(32,361)

Nature Of Operations And Continuance Of Business (Narrative) (Details) (USD $)	Jan. 31, 2014
Nature Of Operations And Continuance Of Business Narrative Details
Working capital deficit	$ 141,129

Commitments And Contingencies (Narrative) (Details) (Lease Agreements)	12 Months Ended
	Jan. 31, 2014
Lease Agreements
Lease commitment terms	Lease commitments are approximately $38 per square foot or $63,000 per year, plus charges of approximately $4,000. The lease is paid semi-annually on January 1^st and June 1^st.

Consolidated Balance Sheets (USD $)	Jan. 31, 2014	Jan. 31, 2013
Current Assets
Cash	$ 51,956	$ 167,146
Accounts receivable	14,309	34,399
Other receivable	7,745
Prepaid expenses	510,329
Total Current Assets	584,339	201,545
Property and equipment, net (Note 8)	6,241	1,262
Intangibles, net (Note 9)	19,793,466
Goodwill	654,992
Total Assets	21,039,038	202,807
Current Liabilities
Accounts payable	177,817	456,510
Accrued expenses, primarily management fees	469,888
Due to related parties (Note 4)	2,704	56,685
Notes payable, related parties (Note 5)	2,062
Notes payable, stockholders (Note 5)	72,997
Total Liabilities	725,468	513,195
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock, $0.001 par value, 9,000,000 shares authorized, 0 shares issued and outstanding at January 31, 2014 and January 31, 2013. Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at January 31, 2014 and 0 at January 31, 2013	1,000
Common Stock , $0.001 par value, 290,000,000 shares authorized, 26,503,515 issued and outstanding January 31, 2014 and 5,361,015 at January 31, 2013	26,504	5,361
Additional paid-in capital	33,164,274	72,094
Accumulated deficit	(12,862,769)	(389,628)
Accumulated other comprehensive income	(15,439)	1,785
Total Stockholders' Equity (Deficit)	20,313,570	(310,388)
Total Liabilities and Stockholders' Equity (Deficit)	21,039,038	202,807
Series A Preferred Stock
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock, $0.001 par value, 9,000,000 shares authorized, 0 shares issued and outstanding at January 31, 2014 and January 31, 2013. Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at January 31, 2014 and 0 at January 31, 2013	$ 1,000

Consolidated Statements of Stockholders’ Equity (Deficit) (USD $)	Preferred Stock	Common Stock	Additional Paid-In Capital	Cumulative Translation Adjustments	Deficit	Total
Balance value at Jan. 31, 2012		$ 5,182	$ 23,290	$ 11,879	$ (321,190)	$ (280,839)
Balance shares at Jan. 31, 2012		5,181,698
Common stock issued for cash, shares		179,317
Common stock issued for cash, value		179	12,371			12,550
Director loan forgiven to additional paid-in capital			36,433			36,433
Common stock issued for acquisition, value
Common stock issued for prepaid services, value
Common stock issued for services, value
Common stock issued to acquire patent, value
Common stock issued to extinguish debt, value						36,433
Cancellation of common stock, value
Net loss for the year				(10,094)	(68,438)	(78,532)
Balance value at Jan. 31, 2013		5,361	72,094	1,785	(389,628)	(310,388)
Balance shares at Jan. 31, 2013		5,361,015
Preferred stock issued for services, shares	1,000,000
Preferred stock issued for services, value	1,000		179,000			180,000
Common stock issued for acquisition, shares		10,000,000
Common stock issued for acquisition, value		10,000	19,990,000			20,000,000
Common stock issued for prepaid services, shares		10,000,000
Common stock issued for prepaid services, value		10,000	690,000			700,000
Common stock issued for services, shares		6,000,000
Common stock issued for services, value		6,000	11,994,000			12,000,000
Common stock issued to acquire patent, shares		100,000
Common stock issued to acquire patent, value		100	199,900			200,000
Common stock issued to extinguish debt, shares		42,500
Common stock issued to extinguish debt, value		43	86,464			86,507
Cancellation of common stock, shares		(5,000,000)
Cancellation of common stock, value		(5,000)	5,000			5,000
Adjustments to reconcile additional paid-in capital and retained earnings from IML acquisition			(52,184)		507,176	454,992
Net loss for the year				(17,224)	(12,980,317)	(12,997,541)
Balance value at Jan. 31, 2014	$ 1,000	$ 26,504	$ 33,164,274	$ (15,439)	$ (12,862,769)	$ 20,313,570
Balance shares at Jan. 31, 2014	1,000,000	26,503,515

Notes Payable (Narrative) (Details) (Promissory Note - Jagpal Holdings Ltd, USD $)	0 Months Ended
	Jun. 01, 2013
Promissory Note - Jagpal Holdings Ltd
Notes payable	$ 17,852
Note maturity description	Due upon demand in 12 months
Debt instrument description	It was non-interest bearing promissory notes.

Equity (Narrative) (Details) (USD $)	12 Months Ended			0 Months Ended				12 Months Ended
Equity (Narrative) (Details) (USD $)	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014 Common Stock	Dec. 13, 2013 Common Stock Debt Extinguishment	Dec. 13, 2013 Common Stock Patents	Dec. 13, 2013 Common Stock Executive Officer And Directors And Management Consultant	Dec. 13, 2013 Common Stock Immunoclin Limited (IML)	Jan. 31, 2014 Series A Preferred Stock	Dec. 13, 2013 Series A Preferred Stock Executive Officer And Directors And Management Consultant
Preferred stock voting rights								The shares of Series A preferred stock have 51% of the total vote on all shareholder matters and 66-2/3% of the Series A preferred stockholders may make any affirmative vote to amend, alter or repeal and provision of the Articles of Incorporation or the Bylaws of the Company.
Common stock issued for acquisition, shares			10,000,000				10,000,000
Common stock issued for acquisition, value	$ 20,000,000		$ 10,000				$ 20,000,000
Share price, per share				$ 2.00	$ 2.00	$ 2.00	$ 2.00		$ 0.18
Shares issued for service, shares			6,000,000			6,000,000
Shares issued for service, value	12,000,000		6,000			12,000,000
Stock issued to acquire patent, shares			100,000		100,000
Stock issued to acquire patent, value	200,000		100		200,000
Common stock issued to extinguish debt, shares			42,500	42,500
Common stock issued to extinguish debt, value	$ 86,507	$ 36,433	$ 43	$ 85,000

Consolidated Balance Sheets (Parenthetical) (USD $)	Jan. 31, 2014	Jan. 31, 2013
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	9,000,000	9,000,000
Preferred stock, issued	1,000,000
Preferred stock, outstanding	1,000,000
Common stock, par value	$ 0.001
Common stock, shares authorized	290,000,000
Common stock, shares issued	26,503,515
Common stock, shares outstanding	26,503,515
Series A Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, issued	1,000,000
Preferred stock, outstanding	1,000,000
Common stock, par value		$ 0.001
Common stock, shares authorized		290,000,000
Common stock, shares issued		5,361,015
Common stock, shares outstanding		5,361,015

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Jan. 31, 2014	Jun. 30, 2014	Jul. 31, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	Immunoclin Corp
Entity Central Index Key	0001520047
Document Type	10-K
Document Period End Date	Jan. 31, 2014
Amendment Flag	false
Current Fiscal Year End Date	--01-31
Is Entity's Reporting Status Current?	Yes
Well Known Seasoned Issuer	No
Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 722,030
Entity Common Stock, Shares Outstanding		26,471,154
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Summary Of Significant Accounting Policies (Policies)	12 Months Ended
Summary Of Significant Accounting Policies (Policies)	Jan. 31, 2014
Accounting Policies [Abstract]
Basis of presentation	A. Basis of Presentation The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and are expressed in U.S. dollars. The operating results of Immunoclin Limited (“IML”), acquired on December 13, 2013, were consolidated with the financial statements of the Company for the years ended January 31, 2014 and 2013. An independent valuation firm validated the purchase price for IML to be $20,000,000 consisting of $19,800,000 in intangibles-R&D, 654,992 in goodwill, and ($454,992) in net tangible assets acquired, which was confirmed by a third-party valuator assessment. A total of $654,992 in unimpaired goodwill remains at January 31, 2014. The Company recorded adjustments of ($52,184) to additional paid-in capital and $507,176 to deficit for the year ended January 31, 2014 to reconcile the consolidated statement of stockholder’s equity (deficit) as a result of the acquisition of IML. The Company’s fiscal year end was changed from February 28 to January 31 during 2014.
Use of estimates	B. Use of Estimates The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the consolidated financial statements in the period they are determined.
Basic and diluted net income (loss) per share	C. Basic and Diluted Net Income (Loss) Per Share Under ASC 260, "Earnings Per Share" ("EPS"), the Company provides for the calculation of basic and diluted earnings per share. Basic EPS includes no dilution and is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the years ended January 31, 2014 and 2013, basic and diluted loss per share are the same since the calculation of diluted per share amounts would result in an anti-dilutive calculation.
Cash and cash equivalents	D. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
Accounts receivable and allowance for doubtful accounts	E. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable consists principally of trade receivables, which are recorded at the invoiced amount, net of allowances for doubtful accounts and prompt payment discounts. Trade receivables do not bear interest. The allowance for doubtful accounts represents management’s estimate of the amount of probable credit losses in existing accounts receivable, as determined from a review of past due balances and other specific account data. Account balances are written off against the allowance when management determines the receivable is uncollectible. The Company does not have off-balance sheet credit exposure related to its customers.
Prepaid expense	F. Prepaid Expense Prepaid expenses consist of $510,329 in prepaid stock-based compensation under management contracts. Prepaid stock-based compensation expense is amortized over the service periods pursuant to the agreements.
Long-lived assets	G. Long-Lived Assets Under ASC Topic 360, “Property, Plant, and Equipment”, the Company is required to periodically evaluate the carrying value of long-lived assets to be held and used. ASC Topic 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. The Company is adopting ASU update number 2012-02—Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment whereby the Company will first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, we conclude that it is not more than likely than not that the indefinite-lived intangible asset is impaired, then we are not required to take further action. If the Company concludes otherwise, then we will determine the fair value of the indefinite-lived intangible asset and perform the required quantitative impairment test by comparing the fair value with the carrying amount.
Fair value measurements	H. Fair Value Measurements Under ASC Topic 820, the Company discloses the estimated fair values of financial instruments. The carrying amounts reported in the balance sheet for current assets and current liabilities qualifying as financial instruments are a reasonable estimate of fair value. In accordance with the reporting requirements of ASC Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of those financial instruments (see Note 4). The estimated fair value of other current assets and current liabilities approximate their carrying amounts due to the relatively short maturity of these instruments. None of these instruments are held for trading purposes.
Goodwill and intangible assets	I. Goodwill and Intangible Assets Under ASC Topic 350 “Intangibles-Goodwill and Other”, goodwill is not amortized to expense, but rather that it is assessed or tested for impairment at least annually. Impairment write-downs are charged to results of operations in the period in which the impairment is determined. If certain events occur which might indicate goodwill has been impaired, the goodwill is tested for impairment when such events occur. Other acquired intangible assets with finite lives, such as acquired R&D and patents, are required to be amortized over the estimated lives. These intangibles are generally amortized using the straight-line method over estimated useful lives. The Company tests the carrying value of goodwill and indefinite life intangible assets for impairment at least once a year and more frequently if an event or circumstance indicates the asset may be impaired. An impairment loss is recognized if the amount of the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less selling expenses or its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows (cash generating units). The Company did not record an impairment loss on goodwill for 2014.
Revenue recognition	J. Revenue Recognition Revenues are recognized at the time clinical and laboratory services are completed and delivered pursuant to percentage of completion and/or milestone payments as per contracts with the Company’s customers.
Research and development expenses	K. Research and Development Expenses Under ASC Topic 730 “Research and Development”, costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a product receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a product receives regulatory approval, any milestone payments will be recorded as Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, amortization of the payments will be on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.
Income taxes	L. Income Taxes Under ASC Topic 740, “Income Taxes”, the Company in required to account for its income taxes through the establishment of a deferred tax asset or liability for the recognition of future deductible or taxable amounts and operating loss and tax credit carry forwards. Deferred tax expense or benefit is recognized as a result of timing differences between the recognition of assets and liabilities for book and tax purposes during the year. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carry forwards. A valuation allowance is established to reduce that deferred tax asset if it is "more likely than not" that the related tax benefits will not be realized. Unfiled Federal Tax Returns: For the years ending January 31, 2014 and 2013, the Company has not filed federal tax returns and may be subject to penalties. The Company estimates that the amount of penalties, if any, will not have a material effect on the results of operations, cash flows or financial position. No provisions have been made in the financial statements for such penalties, if any. The Company is planning to have its accountants prepare and file overdue federal tax returns for the years ended January 31, 2014 and 2013 by Q4 of fiscal 2015.
Stock based compensation	M. Stock-Based Compensation Under ASC Topic 718, ‘‘Compensation-Stock Compensation’’, the Company is required to measure all employee share-based payments, including grants of employee stock options, using a fair-value-based method and the recording of such expense in the statements of operations. The Company has adopted ASC Topic 718 (SFAS 123R) and recognizes stock-based compensation expense using the modified prospective method. As of January 31, 2014 and 2013, the Company has no employee stock options.
Comprehensive Loss	N. Comprehensive Loss ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As of January 31, 2014 and 2013, the Company had foreign exchange translation adjustments of ($17,224) and ($10,094), respectively, which are included in other comprehensive income in the consolidated financial statements.
Recent accounting pronouncements	O. Recent Accounting Pronouncements During the year ended January 31, 2014 and through June 30, 2014, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.
Reclassification	P. Reclassifications For comparative purposes, certain prior period consolidated financial statements have been reclassified to conform with report classifications of the current year.

Consolidated Statements Of Operations (USD $)	12 Months Ended
Consolidated Statements Of Operations (USD $)	Jan. 31, 2014	Jan. 31, 2013
Income Statement [Abstract]
Revenues		$ 182,621
Operating Expenses
Amortization	206,534
Depreciation	1,611	1,508
Management and consulting fees	12,453,670
General and administrative	167,464	143,416
Professional fees	54,918	88,758
Research and development	98,276	93,124
Total Operating Expenses	12,982,473	326,806
Net Operating Loss	(12,982,473)	(144,185)
Other Income (expense)
Interest expense, net	89	47
Tax credits, research and development	(2,245)	(75,794)
Total other income (expense)	2,156	75,747
Net Loss	(12,980,317)	(68,438)
Foreign exchange translation adjustment	(17,224)	(10,094)
Comprehensive Income (Loss)	(17,224)	(10,094)
Net Comprehensive Loss	$ (12,997,541)	$ (78,532)
Net loss per Share - basic and diluted	$ (1.21)	$ (0.01)
Weighted average shares outstanding - basic and diluted	10,774,666	5,315,824

Related Party Transactions (Narrative) (Details) (USD $)	12 Months Ended		0 Months Ended		12 Months Ended		0 Months Ended		12 Months Ended	0 Months Ended				12 Months Ended	0 Months Ended	12 Months Ended	0 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Jun. 01, 2013 Promissory Note - Jagpal Holdings Ltd	Apr. 25, 2013 President And CEO - Robert Lawrence	Jan. 31, 2013 President And CEO - Robert Lawrence	Jan. 31, 2014 President And CEO - Robert Lawrence	Apr. 25, 2013 President And CEO - Robert Lawrence Promissory Note - Jagpal Holdings Ltd	Dec. 13, 2013 J. Scott Munro - Chief Financial Officer	Jan. 31, 2014 J. Scott Munro - Chief Financial Officer	Oct. 21, 2013 J. Scott Munro - Chief Financial Officer Promissory Note From Intrinsic Venture Corp	Dec. 13, 2013 Executive Officer And Directors And Management Consultant Series A Preferred Stock	Dec. 13, 2013 Dr. Dorothy Bray - Director And CEO/President	Dec. 13, 2013 Chad S. Johnson - COO	Jan. 31, 2014 Chad S. Johnson - COO	Dec. 13, 2013 Raymond Dabney - Managing Consultant	Jan. 31, 2014 Raymond Dabney - Managing Consultant	Jan. 23, 2014 Khadija Benlhassan - Director And Chief Scientific Officer
Due to related parties	$ 2,704	$ 56,685			$ 56,685	$ 0
Debt instrument description			It was non-interest bearing promissory notes.		It was unsecured, non-interest bearing, and due on demand.		A non-related party that was secured by the Company under a non-interest bearing demand promissory note due			Non-interest bearing demand promissory note
Notes payable			17,852							2,062
Note maturity description			Due upon demand in 12 months							Due on demand in 12 months
Note maturity date							Apr. 25, 2014
Repayment of due to related party		56,377		33
Forgiveness of related party debt				1,507
Assignment of related party debt to non-related party	86,507	36,433					55,145
Shares issued for control of shareholders agreement, shares											1,000,000
Shares issued for control of shareholders agreement, value	180,000										180,000
Terms of employment agreement								Under the agreement, Mr. Munro is to be paid $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under this Agreement, considered to be November 30, 2014. Mr. Munro shall also receive 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payments one year following the signing of the Agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock.				Under the agreement, Dr. Bray is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Dr. Bray shall also receive 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payments one year following the signing of the Agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Form S-8 common shares of the Company common stock and 1,000,000 Rule 144 restricted common shares of the Company common stock.	Under the agreement, Mr. Johnson is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $15,000 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Mr. Johnson shall also receive 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payment one year following the signing of the agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Rule 144 restricted common shares of the Company common stock.		Under the agreement, Mr. Dabney is compensated $10,000 per month for the first three months (December 2013, January 2014, and February 2014) and $23,333 per month for the nine months thereafter through to the end of the first year of service under the agreement, considered to be November 30, 2014. Mr. Dabney shall also receive 1,000,000 Rule 144 restricted common shares of the Company common stock, followed by payment one year following the signing of the agreement (considered November 30, 2014) of an identical stock bonus of an additional 1,000,000 Rule 144 restricted common shares of the Company common stock.		Under the Agreement, Dr. Benlhassan is to receive compensation of $16,667 per month for the first three months (March through May 2014) and $17,778 per month for the nine months thereafter through to the end of her first year of service under the Agreement. Dr. Benlhassan will earn 2,000,000 Rule 144 restricted common shares of the Company on November 30, 2014 pursuant to the Agreement and May 30, 2014 Addendum Agreement.
Fair value of stock based compensation packages	$ 12,369,671							$ 4,000,000	$ 4,000,000			$ 4,000,000	$ 2,000,000	$ 2,000,000	$ 2,000,000	$ 2,000,000
Share price, per share								$ 2.00			$ 0.18	$ 2.00	$ 2.00		$ 2.00

Related Party Transactions (Details) (USD $)	12 Months Ended			0 Months Ended	12 Months Ended	0 Months Ended	12 Months Ended	0 Months Ended	12 Months Ended
Related Party Transactions (Details) (USD $)	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014 Dr. Dorothy Bray - CEO	Dec. 13, 2013 J. Scott Munro - Chief Financial Officer	Jan. 31, 2014 J. Scott Munro - Chief Financial Officer	Dec. 13, 2013 Chad S. Johnson - COO	Jan. 31, 2014 Chad S. Johnson - COO	Dec. 13, 2013 Raymond Dabney - Managing Consultant	Jan. 31, 2014 Raymond Dabney - Managing Consultant
Stock based compensation	$ 12,369,671		$ 4,000,000	$ 4,000,000	$ 4,000,000	$ 2,000,000	$ 2,000,000	$ 2,000,000	$ 2,000,000

Subsequent Events (Narrative) (Details) (USD $)	12 Months Ended							12 Months Ended	0 Months Ended									0 Months Ended
Subsequent Events (Narrative) (Details) (USD $)	Jan. 31, 2014	Jan. 31, 2013	Jun. 30, 2014	Dec. 13, 2013 Dr. Dorothy Bray - Director And CEO/President	Dec. 13, 2013 Chad S. Johnson - COO	Dec. 13, 2013 J. Scott Munro - Chief Financial Officer	Dec. 13, 2013 Raymond Dabney - Managing Consultant	Jan. 31, 2014 Common Stock	Jun. 30, 2014 Subsequent Event Dr. Dorothy Bray - Director And CEO/President	Jun. 30, 2014 Subsequent Event Chad S. Johnson - COO	Jun. 30, 2014 Subsequent Event Khadija Benlhassan - Director And Chief Scientific Officer	Jun. 30, 2014 Subsequent Event J. Scott Munro - Chief Financial Officer	Jun. 30, 2014 Subsequent Event Raymond Dabney - Managing Consultant	Mar. 20, 2014 Subsequent Event Common Stock	Apr. 23, 2014 Subsequent Event Rule144 Restricted Stock Consulting Agreement - Dr. Marco Kaiser	May 01, 2014 Subsequent Event Rule144 Restricted Stock Consulting Agreement - Railton Frith	May 01, 2014 Subsequent Event Rule144 Restricted Stock Consulting Agreement - Railton Frith	May 07, 2014 Subsequent Event Rule144 Restricted Stock Consulting Agreement - Professor Antony Bayer	May 27, 2014 Subsequent Event Rule144 Restricted Stock Consulting Agreement - Professor Jean Mariani	Jun. 04, 2014 Subsequent Event Rule144 Restricted Stock Consulting Agreement - Professor Iwona Wybranska	Jun. 21, 2014 Subsequent Event Rule144 Restricted Stock Consulting Agreement - Dr. Gundula Piechotta	Jun. 30, 2014 Subsequent Event Rule144 Restricted Stock Consulting Agreement - Dr. Heinz Ellerbrok	Jun. 30, 2014 Subsequent Event Intrinsic Venture Corp	Apr. 07, 2014 Subsequent Event Intrinsic Venture Corp	Mar. 10, 2014 Subsequent Event Intrinsic Venture Corp	Feb. 18, 2014 Subsequent Event Intrinsic Venture Corp	Feb. 07, 2014 Subsequent Event Intrinsic Venture Corp
Loan																							$ 240,000	$ 25,000	$ 15,000	$ 100,000	$ 10,000
Debt maturity description																							Due upon demand in 12 months
Debt instrument description																							Non-interest bearing promissory note
Cancellation of shares Prestige Performance Corp,shares								(5,000,000)						92,361
Shares issued for service, shares								6,000,000							10,000	10,000		10,000	10,000	10,000	10,000	10,000
Shares issued for service, value	12,000,000							6,000							42,500	37,500		37,500	50,000	56,000	56,000	56,000
Share price, per share				$ 2.00	$ 2.00	$ 2.00	$ 2.00								$ 4.25		$ 3.75	$ 3.75	$ 5.00	$ 5.60	$ 5.60	$ 5.60
Consulting agreement terms															On April 23, 2014, the Company signed a two-year management consulting agreement with Dr. Marco Kaiser to act as an advisor for molecular biology, genetics, infectious diseases, and DACTELLIGENCE™.	On May 1, 2014, the Company signed a two-year management consulting agreement with Railton Frith and his affiliates to act as advisors for DACTELLIGENCE™		On May 7, 2014, the Company signed a two-year management consulting agreement with Professor Antony Bayer and his affiliates to act as advisors for neurology and aging.	On May 27, 2014, the Company signed a two-year management consulting agreement with Professor Jean Mariani to act as an advisor for treatments targeting central nervous system diseases and aging.	On June 4, 2014, the Company signed a two-year management consulting agreement with Professor Iwona Wybrańska and her affiliates to act as advisors for nutrigenomics, metabolomics and functional food.	On June 21, 2014, the Company signed a two-year management consulting agreement with Dr. Gundula Piechotta and her affiliates to act as advisors for infectious diseases and DACTELLIGENCE™.	On June 30, 2014, the Company signed a two-year management consulting agreement with Dr. Heinz Ellerbrok and his affiliates to act as advisors for infectious diseases and DACTELLIGENCE™.
Shares issued for share based compensation									2,000,000	2,000,000	2,000,000	2,000,000	2,000,000
Stock options exercise price									$ 5.60	$ 5.60	$ 5.60	$ 5.60	$ 5.60
Fair market value of stock options granted			$ 15,809,499						$ 3,161,900	$ 3,161,900	$ 3,161,900	$ 3,161,900	$ 3,161,900
Option vesting period									1,000,000 options vest on each of November 1, 2014 and November 1, 2015	1,000,000 options vest on each of November 1, 2014 and November 1, 2015	1,000,000 options vest on each of November 1, 2014 and November 1, 2015	1,000,000 options vest on each of November 1, 2014 and November 1, 2015	1,000,000 options vest on each of November 1, 2014 and November 1, 2015
Expenses per option									$ 3.16	$ 3.16	$ 3.16	$ 3.16	$ 3.16

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended
Consolidated Statements Of Cash Flows (USD $)	Jan. 31, 2014	Jan. 31, 2013
Statement of Cash Flows [Abstract]
Net loss for the year	$ (12,980,317)	$ (68,438)
Adjustments to reconcile net loss to cash used in operating activities:
Amortization	206,534
Depreciation	1,611	2,396
Common stock issued for services	12,369,671
Expenses paid by related parties	20,555	39,000
Foreign exchange translation	(17,224)	(10,094)
Changes in operating assets and liabilities:
Accounts receivable	(20,090)	(117,715)
Other receivable	7,746
Accounts payable	(193,691)	312,005
Accrued expenses, primarily management fees	469,888	(236,584)
Net Cash Provided by (Used In) Operating Activities	(110,629)	156,000
Investing Activities
Purchase of property and equipment	6,590
Net Cash Used in Investing Activities	(6,590)
Financing Activities
Proceeds from the sale of common stock		12,550
Related party loans forgiven to share capital
Proceeds from related party notes payable	2,029	880
Repayments to related party loans		56,377
Net Cash Provided by Financing Activities	2,029	(42,947)
Change in Cash	(115,190)	113,053
Cash - Beginning of Year	167,146	54,093
Cash - End of Year	51,956	167,146
Supplemental Disclosures
Cancellation of common stock	5,000
Common stock issued for prepaid services	700,000
Common stock issued to acquire IML	20,000,000
Common stock issued to acquire patent	200,000
Common stock issued to extinguish debt	86,507	36,433
Interest paid
Income tax paid

Equipment (Narrative) (Details) (Computer)	12 Months Ended
Equipment (Narrative) (Details) (Computer)	Jan. 31, 2014
Computer
Estimated useful life	5 years